CODING FORMS FOR SRC INDEXING

Microfiche No.		
OTS0556254		
New Doc ID	Old Doc ID	
88-940000296	8EHQ-0694-13054	
Date Produced	Date Received	TSCA Section
05/31/94	06/03/94	8E
Submitting Organization		
RHONE-POULENC INC		
Contractor		
Document Title		
INITIAL SUBMISSION: LETTER FROM RHONE-POULENC INC TO USEPA REGARDING A CERIODAPHNIA DUBIA ACUTE/CHRONIC TOXICITY TEST OF CLARIFLOC C9470 DATED 053194		
Chemical Category		
CLARIFLOC C9470		

8EHQ-0694-13054 Contains No CBI

RHÔNE-POULENC

RECEIVED
OPPT CBIC
94 JUN -3 PM 2:36

RHÔNE-POULENC INC.

CN 5266, PRINCETON, NJ 08543-5266
TELEPHONE: (908) 297-0100 TELEX: 211056

May 31, 1994

8EHQ-94-13054
INIT 06/03/94

CERT. MAIL #P 378 286 226
RETURN RECEIPT REQUESTED

ORIGINAL

OPPT Document Processing Center (7408)
(ATTN: Section 8(e) Coordinator)
Office of Pollution Prevention and Toxics (OPPT)
U.S. Environmental Protection Agency
401 "M" Street, S.W.
Washington, DC 20460

88940000296

RE: TSCA §8(e) Notice

Dear Sir or Madam:

Rhône-Poulenc Inc. is providing this notice to the Agency in accordance with the provisions of Section 8(e) of the Toxic Substances Control Act (TSCA). We are submitting the results of a toxicity study on Clarifloc C9470 (inverse emulsion of high molecular weight cationic polyacrylamide).

A *Ceriodaphnia dubia* acute/chronic toxicity test was performed with Clarifloc C9470. The acute, 48-hr. LC50 determined in the study was 0.8 mg/L. A chronic reproduction NOEC of <10 μg/L and a LOEC of 10 μg/L was also determined.

These toxicities are in the same range as been reported for other hydrolytically stable, high molecular weight cationic polyacrylamides. Much of this data has been presented to the EPA by the Cationic Polymer Flocculants Association and in other submissions.

Cationic polymers are high affinity adsorbents that attach to any negatively charged surface or soluble polyanionic compound. Due to the high affinity for adsorption, cationic polymers are believed to have little effect on aquatic organisms in natural waters.

Rhône-Poulenc Inc. hereby asserts that none of the information contained herein is confidential business information (CBI). Should you have any questions, or require any further information, please call (609) 860-3586.

Very truly yours,

RHÔNE-POULENC INC.

James E. Blum

James E. Blum
Product Safety Compliance Manager

94-049L.EPA

CODING FORMS FOR SRC INDEXING

Microfiche No.		
OTS0556254		
New Doc ID	**Old Doc ID**	
89-950000107	8EHQ-0295-13054	
Date Produced	**Date Received**	**TSCA Section**
09/29/94	02/01/95	8E
Submitting Organization		
RHONE-POULENC INC		
Contractor		
BIO-RESEARCH LABS LTD		
Document Title		
SUPPORT: FINAL REPORT FOR A 90-DAY INHALATION NEUROTOXICITY AND TOXICITY STUDY BY EXPOSURE TO A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT WITH COVER LETTER DATED 013095		
Chemical Category		
CERIC OXIDE		

8EHQ-0295-13054

PDCN: 88940000296

RHÔNE-POULENC

RHÔNE-POULENC INC.
SPECIALTY CHEMICALS DIVISION
CN 7500, CRANBURY, NJ 08512-7500
TELEPHONE (609) 860-4000

8EHQ-94-13054
SP001 02/01/95

January 30, 1995

FEDERAL EXPRESS # 3665214066

Chemical Inventory Section (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 "M" Street, S.W.
Washington, DC 20460-0001

ORIGINAL

Contains No CBI

RE: 8EHQ-0694-13054

Dear Sir or Madam:

As requested in your followup to a TSCA Section 8(e) notice submitted by Rhone-Poulenc Inc., enclosed is the final report for a 90-day inhalation toxicity study on Ceric Oxide (CAS # 1306-38-3).

The chemical identity/composition of the test material are described in the report and the Certificate of Analysis (Appendix 17).

Should you have any questions, or require any further information, please call (609) 860-3586.

Very truly yours,

RHONE-POULENC, INC.

J. Blum

James E. Blum
Product Safety Compliance Manager

89950000107

RECEIVED
OPPT CBIC
95 FEB -1 AM 11:41

Enc.

JEB: 95-008L.DOC

TOXICOLOGY REPORT SUMMARY

PRODUCT:	Ceric Oxide
STUDY TITLE:	A 13-Week Inhalation Neurotoxicity and Toxicity Study by Nose-Only Exposure of a Dry Powder Aerosol of Ceric Oxide in the Albino Rat
AUTHOR:	A. Viau
STUDY DATE:	13 April 1994
LABORATORY:	Bio-Research Laboratories, Ltd.
REPORT REF:	Bio No 90831
SUMMARY AUTHOR:	J. Rieth
SIGNED:	J Rieth 26 September 94

Contains No CBI

Ceric oxide was tested via inhalation for 13 weeks (5 days/week, 6 hours/day) in groups of 15 male and female rats at dose levels of 0, 5, 50 and 500 mg/m^3. The CeO^2 test material was greater than 99% pure and had a mass median aerodynamic diameter of 2 microns. Animals were examined daily for signs of toxicity, and food consumption and body weights were measured weekly. The animals were examined monthly for potential neurotoxic effects via a functional observational battery and motor activity testing. Laboratory investigations included hematology, clinical biochemistry and urinalysis. Ophthalmoscopy was performed predose and at study termination. A gross pathological exam followed by a detailed histopathologic evaluation were conducted following treatment.

No deaths or clinical signs were recorded that were considered to be effects of treatment. There were no treatment related effects on food consumption, clinical biochemistry or urinalysis.

There were no behavioral effects observed which were associated with exposure to ceric oxide. Ophthalmology was not affected by treatment. The test material was not neurotoxic.

There were no apparent treatment related effects on liver or kidney function, or on reproductive organs.

Although not statistically significant, male body weights were lower in the high dose males than in the controls. This reduction in high dose male body weight gain may have been treatment related.

Statistically significantly higher lung weights were seen in the two highest dose levels in both sexes with apparent trends for higher lung weights encompassing all groups. The lungs in all dose groups were found to have pale areas macroscopically. The histopathological examination of the lung showed pigment accumulation at all dose levels with alveolar hyperplasia at the two highest levels in both sexes.

Treatment related pigment accumulation was observed in the nasal cavity (all treatment groups), bronchi and trachea (high and mid dose animals), and liver and spleen (high dose only).

Bronchial lymph nodes in both sexes were enlarged macroscopically at all dose levels in males and at the two highest dose levels in females. Microscopic findings in the bronchial and other lymph nodes included pigment accumulation and hyperplasia in both sexes at all dose levels. Pigment accumulation and metaplasia were observed in the larynx of animals in all treatment groups.

Higher segmented neutrophil counts were observed in all dose levels for females and the two highest dose levels for males.

The treatment related observations listed above are considered to be indications of varying levels of exposure to ceric oxide via inhalation. The findings are not considered to be evidence of direct toxicity, but rather demonstrate that the normal lung clearance mechanisms were overwhelmed by the high levels of exposure. Following ceric oxide deposition in the deep lung, the normal physiological responses of macrophage infiltration and lymphatic involvement were observed. A No-Observed-Effect-Level was not established in this study. It is probable that the observed findings would be reversible following an appropriate recovery period.

CUSTOMER: PLEASE REMOVE ONE OF THESE LABELS AND PLACE IT ABOVE THE AIRBILL ON YOUR PACKAGE.

3665214066 C

FEDERAL EXPRESS

USE THIS AIRBILL FOR SHIPMENTS WITHIN THE CONTINENTAL U.S., ALASKA AND HAWAII
USE THE INTERNATIONAL AIRBILL FOR SHIPMENTS TO PUERTO RICO AND ALL OTHER FEDERAL EXPRESS LOCATIONS
QUESTIONS? CALL 800-238-5355 TOLL FREE

AIRBILL PACKAGE TRACKING NUMBER 3665214066

2038N 3665214066

1 SENDER'S FEDERAL EXPRESS ACCOUNT NUMBER: 1484-3396-8 Date: 1/31/95

From (Your Name) Please Print: James E. Blum
Your Phone Number (Very Important): 609-395-4637
Company: RHONE-POULENC
Department/Floor No
Street Address: PROSPECT PLAINS RD
City: CRANBURY State: NJ ZIP Required: 08512

2 To (Recipient's Name) Please Print: TSCA Section 8(e) Coordinator
Recipient's Phone Number (Very Important)
Chemical Inventory Section (7407)
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Department/Floor No
Street Address: 401 M. Street, SW
City: Washington, DC State: ZIP Required: 20460-0001

YOUR INTERNAL BILLING REFERENCE INFORMATION (optional) (First 24 characters will appear on invoice): SA804

H If HOLD FOR PICK-UP, Print FEDEX Address Here
Street Address
City State ZIP Required

3 PAYMENT: 1 [X] Bill Sender 2 [ ] Bill Recipient's FedEx Acct No 3 [ ] Bill 3rd Party FedEx Acct No 4 [ ] Bill Credit Card 5 [ ] Cash/Check
Acct/Credit Card No Exp Date

4 SERVICES (Check only one box)

Priority Overnight: [X] 1 YOUR PACKAGING; 16 FEDEX LETTER *; 12 FEDEX PAK *; 13 FEDEX BOX; 14 FEDEX TUBE
Standard Overnight: 51 YOUR PACKAGING; 56 FEDEX LETTER *; 52 FEDEX PAK *; 53 FEDEX BOX; 54 FEDEX TUBE
Economy Two-Day: 30 ECONOMY
Government Overnight: 46 GOVT LETTER; 41 GOVT PACKAGE
Freight Service: 70 OVERNIGHT FREIGHT **; 80 TWO-DAY FREIGHT **
† Delivery commitment may be later in some areas
* Declared value limit $100
** Call for delivery schedule

5 DELIVERY AND SPECIAL HANDLING (Check services required)
1 [ ] HOLD FOR PICK-UP
2 [X] DELIVER WEEKDAY
3 DELIVER SATURDAY [ ]
4 DANGEROUS GOODS
5
6 DRY ICE lbs
7 OTHER SPECIAL SERVICE
8 ADDRESS CORRECTION
9 SATURDAY PICK-UP
10
11
12 HOLIDAY DELIVERY

6 PACKAGES / WEIGHT: 15
Total / Total: 15
DIM SHIPMENT (Chargeable Weight) lbs
X X =
Received At: [X] 1 Regular Stop; 2 [ ] On Call Stop; 3 [ ] Drop Box; 4 [ ] BSC; 5 [ ] Station

Emp No Date
[ ] Cash Received
[ ] Return Shipment
[ ] Third Party [ ] Chg To Del [ ] Chg To Hold
Street Address
City State Zip
Received By: X
Date/Time Received FedEx Employee Number

7 Release Signature: R. Coffey
FedEx Emp No Date/Time

Federal Express Use
Base Charges
Declared Value Charge
Other 1
Other 2
Total Charges

REVISION DATE 6/91
099
© 1990-91 FEC PRINTED IN USA

DESTINATION COPY

BIO-RESEARCH LABORATORIES LTD.

STUDY TITLE

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT

VOLUME I

SPONSOR

Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

DATA REQUIREMENTS

United States EPA/TSCA (40 CFR Part 792).
Japanese MHW GLP Regulations (Notification No. 313 and revised rule Notification No. 870)
OECD guidelines No. 413

AUTHOR

A. Viau, B.Sc.
Study Director

STUDY COMPLETED ON

September 29, 1994

PERFORMING LABORATORY

Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

LABORATORY PROJECT ID

90831

MONTREAL
87 Senneville Rd., Senneville, Quebec H9X 3R3, Canada
Tel: (514) 630-8200 Cable: BIOCAN Fax: (514) 457-3883

PROJECT NO. 90831

BIO-RESEARCH LABORATORIES LTD.

STATEMENT OF NO DATA CONFIDENTIALITY CLAIM

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of EPA/TSCA §10(d)(1)(A), (B) or (C), Japanese MHW Good Laboratory Practice Regulations (Notification No. 313 and subsequent revised rule Notification No. 870) and OECD guidelines (No. 413).

Company: _____

Company Agent: _____ Date: _____

Title: _____

Signature: _____

MONTRÉAL

87 Senneville Rd., Senneville, Quebec H9X 3R3, Canada
Tel: (514) 630-8200 Cable: BIOCAN Fax: (514) 457-3883

PROJECT NO. 90831

BIO-RESEARCH LABORATORIES LTD.

GOOD LABORATORY PRACTICE COMPLIANCE STATEMENT

This study complies with the Good Laboratory Practice Regulations of the United States EPA/TSCA (40 CFR Part 792), Japanese MHW Good Laboratory Practice Regulations (Notification No. 313 and subsequent revised rule Notification No. 870) and OECD guidelines (No. 413) with the following exceptions:

1. The diet used on this study, namely PMI Certified Rodent Chow 5002: PMI Feeds, Inc., is not analyzed in accordance with EPA/TSCA GLP Standards, but rather with FDA GMP Standards.

2. Analysis of the gravimetric samples performed by Rhône-Poulenc at their laboratories (ISO 9002 Certified) is not analyzed in accordance with EPA/TSCA GLP Standards.

Submitter: _____ Date: _____

Sponsor's Monitor: J Rieth Date: 30 September 94

Joseph P. Rieth, Ph.D., D.A.B.T.
Senior Toxicologist
Rhône-Poulenc
P.O. Box 12014, 2 T.W. Alexander Drive
Research Triangle Park, North Carolina
U.S.A. 27709

Study Director: A. Viau Date: September 29, 1994

A. Viau. B.Sc.
Study Director
Senior Research Scientist,
Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

MONTRÉAL
87 Senneville Rd., Senneville, Quebec H9X 3R3, Canada
Tel: (514) 630-8200 Cable: BIOCAN Fax: (514) 457-3883

PROJECT NO. 90831

BIO-RESEARCH LABORATORIES LTD.

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT

This research was conducted at Bio-Research Laboratories Ltd. in compliance with the Good Laboratory Practice Regulations of the United States EPA/TSCA (40 CFR Part 792), Japanese MHW Good Laboratory Practice Regulations (Notification No. 313 and subsequent revised rule Notification No. 870) and OECD guidelines (No. 413). The study was performed under the direction of:

A. Viau, B.Sc.
Study Director
Senior Research Scientist, Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

September 29, 1994
Date

With contributions from:

C.J. Perkin, B.Sc., D.A.B.T.
Director, Scientific Operations
Toxicology Division

Y. Deschamps, Ph.D.
Director, Clinical Laboratories

P. Blouin, D.V.M., Ph.D., Diplomate A.C.V.O.
Ophthalmologist

W. Evering, D.V.M., Ph. D.,
Diplomate A.C.V.P.
Staff Pathologist

C. Beaudry, D.V.M.
Clinical Veterinarian

PROJECT NO. 90831

BIO-RESEARCH LABORATORIES LTD.

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY
BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL
OF CERIC OXIDE IN THE ALBINO RAT

This report has been reviewed by:

C.M. Banks, B.Sc., D.A.B.T.
Scientific Director, Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

29 September 1994
Date

G.W. Lulham, M.Sc.
Director, Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

29 September, 1994
Date

MONTRÉAL
87 Senneville Rd., Senneville, Quebec H9X 3R3, Canada
Tel: (514) 630-8200 Cable: BIOCAN Fax: (514) 457-3883

TABLE OF CONTENTS

INDEX TO FIGURES
(40 - 48)

INDEX TO TABLES
(49 - 275)

INDEX TO APPENDICES
(276 - 1352)

SUMMARY

Four groups of Sprague-Dawley CD rats, each containing 15 males and 15 females, were exposed by nose-only inhalation to air (Group 1) or to a dry powder aerosol of Ceric Oxide (Groups 2, 3 and 4) for 6 hours a day, 5 days a week for 13 weeks.

The mean gravimetric chamber concentration, the mass median aerodynamic diameter and geometric standard deviation (MMAD ± GSD) and size below which there were 25% of the particles by mass for treated Groups 2, 3 and 4, were as follows:

Group/ Gravimetric conc.	MMAD ± GSD (µm)	25% Particle Size (µm)
2♂ 0.0050 mg/L	1.9 ± 1.9	1.3
2♀ 0.0050 mg/L	1.8 ± 1.9	1.2
3♂ 0.0505 mg/L	2.0 ± 1.9	1.3
3♀ 0.0505 mg/L	2.0 ± 1.9	1.3
4♂ 0.5082 mg/L	2.2 ± 1.8	1.5
4♀ 0.5068 mg/L	2.2 ± 1.8	1.5

All animals were examined twice daily for mortality and morbidity. Also, each animal was examined before, during and after exposure, for any overt signs of reaction to treatment. Body weight and food consumption were measured for each animal weekly, commencing on the day of randomization, and extending through the treatment period. In addition, each animal was weighed on days of behavioral testing and immediately before sacrifice at study termination. A Functional Observational Battery (FOB) was performed on all animals prior to commencement of treatment, on Day 1 (post-dosing) and once during each of Weeks 4, 8 and 13. Activity levels were tested prior to commencement of treatment, and during Weeks 4, 8 and 13. Laboratory investigations (hematology, clinical biochemistry and urinalysis) were performed in Week 6 and on all surviving animals at study termination. Ophthalmological examination was performed on all animals prior to commencement of treatment and on Groups 1 and 4 at study termination. A gross pathological examination was performed and selected tissues were weighed and retained for histopathological evaluation.

There was one death observed during the study. One high dose male was found dead at the end of treatment on Day 72 and was turned around in its restraining cone. The death was considered not to be treatment related but associated with the exposure procedure.

No clinical signs were recorded that were considered related to treatment with ceric oxide.

The overall body weight gain and food consumption of Group 4 was marginally inferior to that of the controls and was considered related to treatment with ceric oxide.

There were no intergroup differences suggestive of toxicity of ceric oxide on ophthalmology, clinical biochemistry or urinalysis.

Treatment related effects in hematology were observed as higher segmented neutrophil counts in Group 2 females and Groups 3 and 4 of both sexes at 6 and 13 weeks.

No behavioral changes following either acute or subchronic exposure and no significant differences for motor activity counts were observed in the treated groups.

A trend for higher lung weights of males and females from Groups 2, 3 and 4, and higher spleen weights of males from Group 4, were considered to be related to treatment with ceric oxide.

Macroscopically, pertinent changes were recorded in the lungs such as discoloration or pale areas (30 each in Groups 3 and 4), pale foci (4 animals in Group 2) and uncollapsed parenchyma (30 in Group 4 and 2 in Group 3). In addition, enlargement and/or pale discoloration of the bronchial lymph nodes (30 in Groups 3 and 4, and 28 in Group 2) and mediastinal (20 in Group 4, 18 in Group 3, 12 in Group 2 and 1 in Group 1) and pancreatic lymph nodes (3 in Group 1, 1 each in Groups 3 and 4) were primarily evident in animals treated with ceric oxide and considered to be induced by the test material. The above observations were considered to be effects of treatment with ceric oxide.

Histopathologically, pigment accumulation and/or alveolar epithelial/lymphoid hyperplasia in the lungs (30 each in Groups 2, 3 and 4), lymphoid hyperplasia of the bronchial (30 each in Groups 3 and 4, 24 in Group 2), mediastinal (18 each in Groups 3 and 4, 12 in Group 2) and pancreatic (1 in Group 3) lymph nodes, metaplasia and/or pigment accumulation in the larynx (22 in Group 4, 16 in Group 3 and 9 in Group 2), and pigment accumulation in the bronchial lymph node (30 each in Groups 3 and 4, and 27 in Group 2), nasal cavity (30 in Group 4, 26 in Group 3 and 15 in Group 2), bronchi (30 in Group 4, 9 in Group 3 and 1 in Group 2), trachea (28 in Group 4, 2 in Group 3), mediastinal lymph node (18 in Group 4, 17 in Group 3 and 12 in Group 2), liver (11 in Group 4), mandibular lymph node (12 in Group 4), spleen (9 in Group 4) and pancreatic lymph node (1 each in Groups 3 and 4) were considered to be induced by the test material.

In conclusion, nose-only inhalation exposure of Sprague-Dawley CD rats to ceric oxide dry powder aerosol was performed 6 hours daily, 5 days a week over 13 weeks at concentrations 0.0050, 0.0505 and 0.5075 mg/L. An overall no-effect level cannot be established based on marginally reduced body weight gains recorded in Group 4 animals, as well as other changes recorded in treated groups and including increased segmented neutrophil counts, higher lung and spleen weights, discoloration of the lungs and discoloration/enlargement of lymph nodes. Histopathologically, pigmented material accumulation in the lungs, bronchial, mandibular and mediastinal or pancreatic lymph nodes, trachea, bronchi, larynx, nasal cavity, liver and spleen, as well as alveolar epithelial hyperplasia (lungs), metaplasia (larynx) and lymphoid hyperplasia (bronchial and mediastinal or pancreatic lymph nodes, lungs) were seen in all treated groups. Systemic dissemination of the test article was evident in Group 4 animals.

INTRODUCTION

The purpose of this study was to investigate the potential toxicity of a powder aerosol of ceric oxide (CeO_2) during daily inhalation administration to the rat for a minimum of 13 consecutive weeks (5 days a week).

The rat was selected as the test system since it is an accepted rodent species for use in inhalation toxicity and neurotoxicity studies.

Inhalation was selected as the route of administration since it is a possible route of exposure in humans.

The dose levels were selected according to the potential human exposure (TLV of 5 mg/m^3 for respirable nuisance dusts) and existing toxicity data and by taking into consideration the limitations imposed by the exposure apparatus and procedure, as well as the stability of the experimental atmosphere.

This study was conducted at Bio-Research Laboratories Ltd., 87 Senneville Road, Senneville, Quebec, Canada, H9X 3R3, in accordance with the Good Laboratory Practice Regulations of the United States EPA/TSCA (40 CFR Part 792), Japanese MHW Good Laboratory Practice Regulations (Notification No. 313 and subsequent revised rule Notification No. 870) and OECD guidelines (No. 413). The study was initiated on August 6, 1993 (date the protocol was signed by the study director).

Dosing of animals took place on September 13 to December 10, 1993, for males and September 20 to December 17, 1993 for females and terminal necropsies were conducted on December 13 and 20, 1993 for males and females, respectively. The study was completed on the date appearing on the signature page.

A calendar of events documenting the major study events can be found in Table 1.

EXPERIMENTAL PROCEDURES

1. TEST SYSTEM

Eighty-four male and 85 female Sprague-Dawley CD (Crl:CD®(SD)BR) rats were received from Charles River Canada Inc., St. Constant, Quebec, Canada, on August 31, 1993.

Shortly after arrival, each animal was subjected to a general physical examination by a qualified member of the veterinary staff to ensure "normal" health status.

At the start of treatment, animals were approximately seven weeks of age with body weight ranges of 206 to 270 g for males and 135 to 179 g for females. Although the body weight range was slightly lower than specified in the protocol, this deviation was not considered to have influenced the outcome of the study.

All animals were uniquely identified by the AIMS tail tattoo system. Although the protocol states health screen animals will be identified by means of a standard system of ear notching, this deviation was not considered to have influenced the outcome of the study.

1.1 Assignment to Dosage Groups

An acclimation period of approximately 2 weeks (for males) and 3 weeks (for females) was allowed between animal receipt and the start of treatment in order to acclimate the rats to the laboratory environment. Although the females were acclimated for a longer period than specified in the protocol, this deviation was not considered to have influenced the outcome of the study. Treatment of males and females was staggered by one week for logisitical reasons.

Before the assignment of animals to treatment groups, 10 male and 10 female rats were selected from the total population using computer generated random numbers for the provision of blood samples, urine samples and gross pathology examination for health-screen purposes. The results of these investigations were available prior to the commencement of treatment.

Approximately one week before treatment of the males commenced, all animals were weighed and assigned to treatment groups using a computer-based randomization procedure which ensured homogeneity of group means and variances for body weight. Males and females were randomized separately. Rats in poor health or at the extremes of the body weight range were not assigned to treatment groups.

The animals were randomized into the following groups:

Group No./ Identification	Target Exposure Level (mg/L)	Animal Numbers Males	Females
1 Air control	0	1001-1015	1501-1515
2 Ceric oxide - Low dose	0.005	2001-2015	2501-2515
3 Ceric oxide - Intermediate dose	0.05	3001-3015	3501-3515
4 Ceric oxide - High dose	0.5	4001-4015	4501-4515

All remaining spare animals not assigned to a dose group were released from the study to Bio-Research's spare colony two weeks after the start of treatment for all animals.

1.2 Housing

Animals were individually housed in stainless-steel wire mesh-bottomed cages equipped with an automatic watering valve. All cages were clearly labeled with a color-coded card indicating project, group and animal numbers, sex and dosage level.

The animal room environment and photoperiod were controlled (targeted conditions: 12 to 15 air changes per hour, temperature 22 ± 3°C, humidity 50 ± 20%, 12 hours light, 12 hours dark). Although relative humidity was occasionally lower than the prescribed range, this deviation was of short duration and was considered not to have influenced the outcome of the study.

1.3 Diet and Water

All animals had access to a standard certified commercial laboratory diet (PMI Certified Rodent Chow 5002; PMI Feeds, Inc.) except during exposure, urinalysis, prior to bleeding and prior to necropsy. Animals were also provided with tap water ad libitum (except during exposure) which had been softened, purified by reverse osmosis and sterilized by ultraviolet light.

Maximum allowable concentrations of contaminants in the diet (e.g., heavy metals, aflatoxins, organophosphates, chlorinated hydrocarbons and PCBs) are controlled and routinely analyzed by the manufacturer (see Appendix 15).

Periodic analysis of the water was subcontracted to management authorized analytical laboratories which were audited by the Quality Assurance Department of Bio-Research Laboratories Ltd. The analytical results are retained in the archives of Bio-Research Laboratories Ltd. (see Appendix 16).

It was considered that there were no known contaminants in the dietary materials or water that could influence the toxicity of the test article.

2. TEST ARTICLE

2.1 Test Article Identification

Identity	Ceric oxide (CeO_2)
CAS Nos.	1306-38-3
Storage	Out of direct light, room temperature
Supplier	Rhône-Poulenc, Inc. 481 Doremus Avenue Newark, NJ 07105 U.S.A.

A shipment of 20 kg of test article was received on August 3, 1993. The test article was a white powder and was supplied in plastic drum. The container was labeled with project number, identity and lot number, expiration date, handling precautions and storage conditions.

A log book was maintained indicating where and when individual test article containers were used. Handling of the test article was performed while wearing a lab coat, gloves, dust mask and goggles or safety glasses with side shields.

A portion of this material was used on this study. With the exception of an archive sample, all test article remaining following completion of studies with CeO_2 has been returned to the Sponsor.

2.2 Test Article Analyses

The test article was characterized by the Sponsor. A test article Certificate of Analysis is presented in Appendix 17. Stability of the test compound over the duration of the study was demonstrated by the chemical analysis of the gravimetric filters performed by the Sponsor and is presented in Appendix 19. Although the samples sent before and after the treatment to the Sponsor were not used to assess the stability of the test article as specified in the protocol, this deviation was not considered to have influenced the outcome of the study.

3. INHALATION EXPOSURE EQUIPMENT

An illustration of the experimental apparatus is found in Figure 2.

Four standard stainless-steel cylindrical "flow-through" nose-only inhalation chambers (chamber volume approximately 80.6 L) were utilized in this experiment (Source: Mobec Inc., Montréal, Canada). The body of each chamber had 40 separate ports in two separate rows into which could be inserted the conical front section of a polycarbonate animal restraint cone (Source: M & M Tool Makers, Montréal, Canada). The top section of the inhalation chamber had an opening for inlet air into which the test article could be introduced. The bottom section of the chamber had a corresponding air extraction port and a drain valve for cleaning. The chamber was mounted on a transport cart such that the chamber could be easily rotated. The chambers were operated under slight negative pressure to prevent outward leakage of the test atmospheres.

The cones which served to restrain individual rats were custom-molded polycarbonate tubes of three different sizes which could accommodate weanling rats, young adults and adult rats. One end of the cone is tapered to approximately fit the shape of the rat's head and the diameter of the cylindrical portion of the cone is such that it is difficult for the rat to turn in the cone. The back portion of the cone is sealed with a plastic cap. The cone containing the rat is fastened to the inhalation chamber by means of a bracket with the nose portion of the cone protruding through a gasket into the chamber. This permits the rat to inhale the test or control atmospheres within the inhalation chamber without otherwise coming in contact with the atmosphere.

During the acclimation period, the rats were conditioned to the laboratory setting and restraint cones. The rats were acclimated to the restraint cones over a period of at least 3 days.

The flow rate through the inhalation chamber was set at a level determined in preliminary work to be adequate to maintain a chamber environment of 20-24°C, 30-70% relative humidity and at least 19% O_2 (prior to test article introduction) and at least 10 air changes/hour with the present animal load. A Sihi low-pressure vacuum pump (Source: Sihi Pumps Ltd., Ontario, Canada) was used to exhaust the inhalation chamber at the required flow rate and draw the contaminated air through a purifying system.

The inhalation chamber and test article generation system for the test groups were contained within separate ventilated walk-in fumehoods to prevent possible contamination of the room air with trace amounts of the test article.

3.1 Generation of Test Atmosphere

The test atmospheres were generated by a Venturi T-section. The Venturi T-sections were operated using predried compressed air obtained from the laboratory compressed air supply. Each Venturi T-section was placed in the inlet of the tangential top of the inhalation chamber such that the output from the T-section was into the chamber. A fixed powder feed nozzle, connected to the feed side of the T-section, was supplied with the test material via a linear powder feed track which contained the test material in a central channel. The powder feeding track was pulled past the aspiration nozzle by means of an electronic peristaltic pump. The rate at which the T-section was supplied with powder (and hence the concentration in the exposure chamber) was controlled by adjusting the rate which the track passed beneath the feed nozzle as well as the size of the central channel of the track. The generation device was custom-built at these laboratories.

3.2 Exposure Procedures

The rats were subjected to "nose-only" exposure for six hours a day, 5 days each week for a minimum of 13 weeks. For each test group, time zero, the time at which animals were placed on the chamber, was defined as that point in time at which approximately 95% of the desired concentration of test article has been established within the chamber. Flow rate through the chamber was calculated to yield a t_{95} (the time required to build up 95% of the target concentration) of no more than approximately 5 minutes. The t_{95} and t_{05} (the time to decay to 5% of the established concentration) were calculated and were equal to 2.4 minutes.

During exposure, aerosol was actively generated for at least 365 minutes (for at least the duration of the t_{95} plus 360 minutes). Following a minimum of 365 minutes of continuous operation, aerosol generation was stopped, and the chamber concentration allowed to decay for the calculated

t_{05}. The rats were removed from the exposure chamber when the generator was stopped and were returned to their home cages.

3.3 Absorption of the Test Article

It was not the intention of this study to investigate the absorption of the test article.

4. MONITORING OF EXPERIMENTAL ATMOSPHERES

4.1 Prestudy Chamber Atmosphere Validation

Prior to the start of treatment, calibration work using the test article was performed in an attempt to attain an exposure atmosphere with total gravimetric aerosol concentrations of 0.005, 0.05 and 0.5 mg/L. The particle size distribution with its mass median aerodynamic diameter and standard deviation (MMAD ± GSD) of the test article was used as received at the request of the Sponsor.

The homogeneity of chamber atmosphere distribution was evaluated for the low and high dose test article chambers. Three ports were sampled in sequence on the top and bottom animal levels of the chamber in duplicate. The overall mean and standard deviation was 0.0052 mg/L ± 0.00068 and 0.4982 ± 0.04330 for Groups 2 and 4, respectively. This represented a coefficient of variance of 13.08% and 8.69% for Groups 2 and 4, respectively, which was considered acceptable.

4.2 Chamber Concentrations

Gravimetric aerosol concentrations were measured hourly using vertically oriented open-faced glass fiber filters (Source: Gelman Sciences, Inc., Montréal, Canada). The sampling apparatus was placed slightly inside the chamber situated at the animal breathing zone, air was drawn accross the filter using an airflow ranging from 4 to 38 LPM. Weights of samples that varied by 20% or more from samples previously obtained on this study were repeated immediately. Each test atmosphere was continually monitored throughout the exposure period by a precalibrated real-time aerosol monitor (RAM-S, Source: MIE, Inc., Billerica, MA, U.S.A.) to provide instantaneous qualitative feedback on temporal atmosphere concentration stability. The RAM-S is a compact self-contained aerosol sensor. An air sample from the exposure chamber is continuously drawn through the sensing zone of the RAM-S in which particles are detected. The signal is then processed into a voltage output and recorded continuously on a stripchart. Filters from the second day of treatment, and monthly thereafter were forwarded to the Sponsor for chemical analysis. Raw data relevant to these analyses are retained by the Sponsor. The results of these analyses are provided in Appendix 19.

Nominal chamber concentrations of the test article in the exposure chamber were determined by dividing the amount of CeO_2 powder used by the total volume of air passing through the chamber during the generation period.

4.3 Particle Size Analysis

Particle size distribution analysis was performed weekly during treatment from each test chamber using an Andersen 1 ACFM cascade impactor (Andersen Samplers Incorporated, Atlanta, Georgia, U.S.A.) operated at a flow rate of 28.3 L/min. The method used consisted of a classification into a series of size ranges followed by gravimetric analysis.

The 5, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80 and 90% collections of mass with the estimated particle size were determined by means of a straight line of "best fit" connecting three particle size distribution points (the 16, 50 and 84% collections of mass generated by a computer program based on the Andersen Operating Manual TR# 76-900016 [January 1979 revision]) which had been plotted on log-probability paper with the particle size as the y-axis and the percent size by mass as the x-axis.

4.4 Chamber Conditions

Chamber airflow, temperature and relative humidity were recorded hourly during the exposure period.

5. OBSERVATIONS

Dated and signed records of activities relating to the day-to-day running and maintenance of the study within the animal room as well as the activities relating to the observations and examinations outlined in the protocol were recorded in a Room Maintenance Log and Project Log Book.

5.1 Clinical Examinations

All animals were examined within the cage twice daily for mortality and morbidity. Each animal was also examined outside of its cage before and after exposure for signs of reaction to treatment. Animals were examined hourly during exposure for any overt signs of reaction to treatment. A complete examination for clinical signs was performed weekly. Additional examinations were performed when required. Mortalities and observed clinical signs were individually recorded.

5.2 Body Weight

Body weights were measured for each animal weekly, commencing on the day of randomization and extending through the treatment period. In addition, each animal was weighed on days of behavioral testing and immediately before sacrifice at necropsy.

5.3 Food Consumption

Individual food consumption was measured weekly commencing the day of randomization and extending through the treatment period.

5.4 Functional Observational Battery (FOB)

All animals were tested prior to commencement of treatment, on Day 1 (post-dosing) and once during each of Weeks 4, 8 and 13. Testing of these time points allowed the FOB to be evaluated following acute and subchronic scenarios. Testing was performed by the same trained technicians, wherever possible, who were unaware of the animal's previous treatment and group assignment. This was possible by identifying individual rats by their arrival numbers only tattooed on the tail. In addition, cages were identified by arrival number only during the conduct of the FOB.

The functional observational battery was performed with equipment built for this purpose. The arena was a 2 feet square of plexiglass placed on a raised platform. The tests were conducted in the room housing the animals and temperature, humidity and photoperiod were monitored. Odors in the room were minimized by maintaining adequate air changes and cleaning of equipment, as necessary.

5.4.1 Qualitative

5.4.1.1 Observations in Home Cage

body position
tremors
twitches
convulsions
bizarre/stereotypic behavior

5.4.1.2 Removal from Home Cage

ease of removal
vocalization

5.4.1.3 Observations in Arena

rearing
ataxic
hypotonic and impaired gait
overall gait incapacity
bizarre/stereotypic behavior
palpebral closure
tremors
twitches,
convulsions
piloerection
respiratory rate/pattern
locomotor activity level
arousal
grooming
defecation
urination
olfactory response

5.4.1.4 Handling Observations

lacrimation
pupil size
salivation
urinary staining
diarrhea
body and abdominal tones
extensor thrust
corneal reflex
pinna reflex
toe and tail pinch
visual placing

5.4.1.5 On Surface

auricular startle
air righting reflex

5.4.1.6 On Top of Box

positional passivity

5.4.2 Quantitative

5.4.2.1 Grip Strength

Before the start of testing and following completion of testing on each day, the Chatillon strain gauges were checked using calibration weights and the readings recorded.

5.4.2.1.1 Forelimb

The dial on the gauge was set to "0". The rat was held by the body and/or tail and allowed to grip the mesh, and then was pulled slowly and steadily until it released its grip. Maximum strain was recorded two times, alternating with hindlimb grip testing.

5.4.2.1.2 Hindlimb

The dial on the gauge was set to "0". The rat was allowed to set its hindpaws against the mesh and was pulled backward by the base of the tail until it released its grip. The maximum strain was recorded two times alternating with forelimb grip testing.

5.4.2.2 Hindlimb Splay

Landing foot spread was measured by inking the hind feet of the rat. Hindlimb splay was recorded twice. The ink was wiped off the feet after testing using a paper towel dampened with water.

5.4.2.3 Body Temperature

The rectal probe was inserted and the reading was allowed to stabilize after which the temperature was recorded.

5.5 Motor Activity

Following the FOB assessments the animals were transferred to a testing room where activity levels were measured individually in figure 8 enclosures. Animals were tested prior to commencement of treatment, and during Weeks 4, 8 and 13. Animals from the control and treated groups were balanced across enclosures, where possible, using a preassigned distribution. The sessions were of 1-hour duration and activity counts were recorded by a microcomputer in 6 successive 10-minute intervals.

In the testing room, temperature and humidity were monitored and a background sound level of approximately 70 dBA and an illumination of approximately 1000-1200 Lux maintained throughout testing. Light levels in the testing room were measured before the start of testing and following completion of testing on each day. The sound level was recorded on a continuous basis throughout testing on each day.

In addition to the "diagnostic" function in the system, a check of each beam was made by manually "breaking" each beam a predetermined number of times and verifying that the "breaks" were properly recorded. These checks were made at least prior to the start of testing and at the completion of testing on each day.

5.6 Ophthalmology

Funduscopic (indirect ophthalmoscopy) and biomicroscopic (slit lamp) examinations were performed on all animals prior to commencement of treatment and during the last week of treatment on animals in the high dose and control groups. No changes in the eye were detected following treatment, therefore, animals in the low and intermediate groups were not examined.

5.7 Laboratory Investigations

Prior to commencement of treatment, laboratory investigations (hematology, clinical biochemistry and urinalysis) were performed on the 10 male and 10 female "health screen" animals.

Hematology and biochemistry were performed in Week 6 and on all surviving animals at study termination (at necropsy). Food was removed overnight from animals to be sampled for hematology and biochemistry. Blood samples were collected from the tail vein in Week 6 and from the abdominal aorta at necropsy.

Urine samples were collected in Weeks 6 and 13 (after the final FOB assessment) from individual animals placed in metabolism cages overnight (approximately 16-hour collection period) during which time they were deprived of food.

5.7.1 Hematology (using EDTA or Citrate * as anticoagulant)

Parameters examined:

red blood cell count
hemoglobin
hematocrit
erythrocyte indices (calculated: MCV, MCH, MCHC and RDW)
platelet count
mean platelet volume (MPV)
white blood cell count (total and differential)
prothrombin time (PT) *
blood cell morphology

5.7.2 Clinical Biochemistry (using no anticoagulant)

Parameters examined:

alkaline phosphatase (ALP)
alanine amino-transferase (ALT)
aspartate amino-transferase (AST)
total bilirubin
cholesterol
triglycerides
glucose
blood urea nitrogen (BUN)
creatinine
total protein
albumin
globulin (calculated)
A/G ratio (calculated)
sodium
chloride
potassium
calcium
inorganic phosphorus

5.7.3 Urinalysis

Parameters examined:

color and appearance
pH
glucose
ketones
blood (hemoglobin)
volume
specific gravity
bile pigment (bilirubin)
urobilinogen

protein
nitrite
microscopy of centrifuged deposit

6. TERMINAL PROCEDURES

6.1 Gross Pathology

Prior to commencement of treatment, 10 male and 10 female "health screen" animals were sacrificed by exsanguination from the abdominal aorta following anesthesia by intraperitoneal injection of sodium pentobarbital and blood sample collection. These animals were subjected to external and internal gross examination.

Animal No. 4001, found dead during the study, was subjected to necropsy and tissue samples were preserved.

All terminally sacrificed animals were killed by exsanguination from the abdominal aorta following induction of anesthesia by intraperitoneal injection of sodium pentobarbital. Animals were fasted overnight prior to scheduled kill and weighed before sacrifice. All males and females were killed on their respective necropsy day.

For all animals, necropsy consisted of an external examination, including identification of all clinically recorded lesions, as well as a detailed internal examination under the supervision of a pathologist.

6.2 Organ Weight Assessment

For all animals sacrificed at the scheduled termination of the study, the following organs were dissected free of fat and weighed:

adrenals
brain
heart
kidneys
liver
lungs
ovaries/testes
pituitary
prostate
spleen
thymus
thyroid lobes and parathyroids (lobes weighed together)
uterus

Paired organs were weighed together. Organ weights relative to both body and brain weights were calculated.

6.3 Tissue Preservation

On completion of the gross pathology examination the following tissues were retained and preserved, using neutral buffered 10% formalin unless otherwise indicated:

abnormalities
* animal identification
adrenals
aorta (thoracic)
** bone and marrow (sternum)
brain (3 levels)
bronchi
cecum
colon
duodenum
* epididymides
esophagus
* eyes
* femur
heart (including section of aorta)
ileum
jejunum
kidneys
larynx
liver (sample of 2 lobes)
++ lungs (all lobes)
lymph nodes (bronchial, mandibular and mesenteric)
\+ mammary gland (inguinal)
** nasal cavities and sinuses (4 levels)
*+ optic nerves
ovaries
pancreas
pharynx
pituitary
prostate
* rectum
salivary gland (submandibular)
sciatic nerve
seminal vesicles
skeletal muscle
skin (inguinal)
spinal cord (cervical)
spleen
stomach
* testes
thymus
\+ thyroid lobes (and parathyroids)
tongue

trachea
urinary bladder
uterus (and cervix)
vagina

* Fixed in Zenker's fluid (sacrificed animals only).
** Decalcified prior to sectioning.
\+ Examined histopathologically only if present in routine sections of eyes (optic nerves), thyroid lobes (parathyroids), or skin (mammary gland).
++ Lungs were infused with neutral buffered 10% formalin (sacrificed animals only).
▪ Retained but not processed.

For all sacrificed animals, three femoral bone marrow smears were prepared and stained with May-Grünwald-Giemsa but in the absence of hematological or pathological findings were not evaluated.

Additional tissue samples were taken at the discretion of the supervising pathologist to elucidate abnormal findings.

Femur samples were not retained for males and 9 females due to technical oversight. This is not considered to have interfered with the purpose of this study since femur samples were not intended to be evaluated on this study.

6.4 Histopathology

Tissues listed above from animals in Groups 1 and 4, animals that died prematurely, and respiratory tissues (lungs, larynx, pharynx, bronchi, trachea and nasal cavity and sinuses) and all gross lesions from animals in Groups 2 and 3 were prepared for histopathological examination by embedding in paraffin wax, sectioning and staining with hematoxylin and eosin and examined microscopically.

A peer review of the Study Pathologist's initial histopathology findings was conducted by Experimental Pathology Laboratories, Inc. (EPL). The technical approach which was followed during the review is summarized as follows: Reexamination of all slides from three of the animals of each sex in the control group and nine of the animals of each sex in the high dose group selected randomly. Reexamination of potential target organs tissues from all animals in all groups for specific toxicologic endpoints to verify the probable "no observed effect level". Potential target organs reviewed for males and females are listed below:

Lungs
Bronchus
Lymph nodes (bronchial, mediastinal, pancreatic and mandibular)
Nose
Larynx
Trachea
Spleen
Liver

Following the review of the microscopic changes initially reported by the Study Pathologist, the results were discussed and agreement was achieved on the appropriate terminology and diagnoses

to be used to describe the changes which were present. The diagnoses in the Study Pathologist's final report reflect the consensus diagnoses which were agreed upon by both the Study Pathologist and the Reviewing Pathologist.

7. STATISTICS

Numerical data obtained during the conduct of the study were subjected to calculation of group mean values with standard deviations. The data were analyzed for homogeneity of variance using Bartlett's test (FOB count data was transformed before analysis).

Homogeneous data were analyzed using Analysis of Variance and the significance of differences between the control and treated groups was assessed using Dunnett's 't' test. Heterogeneous data were analyzed using Kruskal-Wallis test and the significance of differences between the control and treated groups was assessed using Dunn's test.

Motor activity counts were analyzed using repeat measures analysis and graphical presentation of the data was made.

Where appropriate, frequency data, gross pathology and histopathology findings were analyzed by comparing the control group to the tested groups using Fisher's exact probability test.

8. QUALITY ASSURANCE

The Quality Assurance Department of Bio-Research Laboratories Ltd. undertook and documented inspections and audits of critical aspects of the study during its conduct at Bio-Research Laboratories Ltd., and audited the study report. Data audits were conducted according to MIL-STANDARD 105D, where appropriate.

The Quality Assurance Statement is presented on Pages 38 and 39.

9. ARCHIVES

All data (except for results of chemical analysis of gravimetric filters sent to the Sponsor), a sample of the test article, copies of the raw data from the chemical analysis of the gravimetric samples performed by the Sponsor, together with the original copy of the protocol, amendments and final report, have been retained in the scientific archives of Bio-Research Laboratories Ltd.

It is the responsibility of the Sponsor to archive all raw data generated during gravimetric sample analysis.

RESULTS AND DISCUSSION

1. Achieved Chamber Conditions (Table Nos. 2 to 5)

The mean achieved test article chamber concentration, mass median aerodynamic diameter and geometric standard deviation (MMAD ± GSD), the particle size below which there were 25% of the particles by mass and nominal concentration, were as follows:

Group No.	Concentration (mg/L) Target	Achieved	MMAD ± GSD (µm)	Particle Size for 25% of mass (µm)	Nominal (mg/L)
2♂	0.005	0.0050	1.9 ± 1.9	1.3	0.06
2♀	0.005	0.0050	1.8 ± 1.9	1.2	0.06
3♂	0.05	0.0505	2.0 ± 1.9	1.3	0.27
3♀	0.05	0.0505	2.0 ± 1.9	1.3	0.27
4♂	0.5	0.5082	2.2 ± 1.8	1.5	2.50
4♀	0.5	0.5068	2.2 ± 1.8	1.5	2.50

Gravimetric samples taken from the air control group (Group 1) revealed on a few occasions chamber concentrations ranging from 0.0001 mg/L to 0.0006 mg/L and on one sampling occasion 0.0014 mg/L. Based on the small amounts recorded and the low frequency of occurence, contamination was suspected to have occured during filter handling and processing and was considered not to have affected the outcome of the study.

During the 6-hour exposure period, chamber environmental conditions were as follows:

Group No.	Temperature (°C)	Relative Humidity (%)
1	21 - 25	30 - 70
2	21 - 26	38 - 62
3	21 - 25	40 - 53
4	21 - 27	37 - 57

The temperature occasionally exceeded the target range (20 to 24°C) during exposure of all groups. However, this is considered not to have had an adverse effect on the results of the study.

2. Clinical Signs and Mortality (Table No. 6, Appendix No. 1)

There were no deaths or clinical signs that were associated with the administration of ceric oxide.

There was one death observed during the study. Animal No. 4001 was found dead at the end of treatment on Day 72 after having turned around in its cone. No findings were observed on body weight, food consumption or clinical signs in this animal and the death was considered not to be treatment related but associated with the exposure restraint cone which had been changed to a larger size on that day. Gross pathological findings included thymus with multiple dark areas, lungs with multiple dark areas and discoloration (pale) and lymph nodes (mediastinal and bronchial) enlarged and discolored (pale).

Transient clinical signs observed after dosing in all groups consisted of reddish staining of the muzzle, cranial and periorbital regions. Generally, animals in all groups had one or more of these findings during treatment with muzzle and periorbital staining being the most prominent. The frequency of these observations were often similar to those seen in the controls and were therefore considered to be associated with the exposure procedure rather than treatment with ceric oxide.

Clinical signs observed to varying degrees in several animals of all groups during the treatment period included thin fur cover (except for Group 3), staining and/or scabs and/or lesions on the skin, eye partially closed, malocclusion or broken teeth.

Other incidental clinical signs included periorbital staining (animal no. 2009), fur staining (animal Nos. 3007, 1509, 1510, 3501, 3505, 4503, 4504, 4505, 4515 and 4516), swollen mouth or muzzle (animal Nos. 1009, 3007 and 3511), salivation and/or wet fur (animal Nos. 4012 and 1510), soft feces (animal No. 2009), redness of the skin (animal Nos. 2015, 1510 and 4511), presence of red liquid (animal Nos. 2015 and 1503), alopecia (animal No. 2015) and slight dehydration (animal No. 4504). These findings were not considered to be related to treatment with ceric oxide.

3. **Body Weight** (Table Nos. 7 and 8; Appendix No. 2)

Statistically significant lower mean body weight gains were recorded in high dose males when compared with the air controls (Group 1) in Weeks 2 and 8. The overall body weight gain of Group 4 was marginally inferior to that of the controls and although not statistically significant, was considered to be due to exposure to ceric oxide.

Statistically significant lower mean body weight gains were recorded in Group 2 females at Week 7 and Group 2, 3 and 4 females at Week 10 when compared with the air control animals. These observations were not considered to be treatment related.

4. **Food Consumption** (Table No. 9; Appendix No. 3)

Food consumption of high dose males was marginally lower and although not statistically different from controls could be considered to be related to exposure to ceric oxide.

5. **Ophthalmology** (Appendix No. 4)

The Ophthalmologist's Report is presented on page 33.

Treatment with ceric oxide did not produce any ocular changes. Minor observations recorded in isolated animals in most groups were considered incidental in origin.

6. **Functional Observational Battery (FOB)** (Table No. 10; Appendix No. 5)

No clear behavioral changes were observed between the control and treated groups for qualitative assessment at any of the time points measured. However, a significantly reduced forelimb grip strength was recorded in Group 4 females at Week 13.

7. **Motor Activity** (Table No. 11; Appendix No. 6; Figure No. 1)

No toxicologically significant differences for total motor activity counts for any occasion or either sex were recorded between the control and treated groups and the occasional transient changes seen in the patterns of activity were considered unlikely to be associated with treatment.

8. **Laboratory Investigations**

A legend of methods, symbols and units used in the laboratory investigations is presented in Appendix 7.

8.1 **Health Screen Examination** (Table Nos. 12 and 13; Appendix Nos. 8 to 10 and 14)

Results of the blood and urine analyses were reviewed and considered to be normal. Only a few rats showed abnormal gross pathological findings at necropsy, they were not considered to be unusual for animals of this strain and age. Consequently, the population of animals received was considered to be suitable for use on this study.

8.2 **Hematology** (Table No. 12; Appendix No. 8)

Treatment-related effects were observed in segmented neutrophil counts in Group 2 females and Groups 3 and 4 of both sexes.

Statistically significant elevated segmented neutrophil counts (when expressed as a percentage of WBC) in Group 2 and 3 females and Group 4 animals were recorded at Weeks 6 and/or 13 when compared to the air control group. When expressed in absolute terms, segmented neutrophil counts in Group 2 females as well as Group 3 and 4 males and females were elevated at Weeks 6 and 13 when compared to Group 1. These changes were considered related to treatment with ceric oxide.

Incidental increases not considered related to treatment were seen in white blood cell count and associated absolute lymphocyte and eosinophil counts of Group 3 males and hemoglobin in Group 4 females at Week 13.

8.3 **Clinical Biochemistry** (Table No. 13; Appendix No. 9)

Clinical biochemical parameters were considered unaffected by ceric oxide.

8.4 **Urinalysis** (Appendix No. 10)

Urinary parameters were considered to be unaffected by treatment with ceric oxide.

9. TERMINAL STUDIES

9.1 Organ Weights (Table Nos. 14 to 16; Appendix Nos. 11 to 13)

Treatment-related effects were seen in lung and spleen weights when expressed as absolute or relative to organ and brain weights.

Higher lung weights (absolute and relative to body weight and brain) were statistically significant in Groups 3 and 4 when compared with those of the air control Group 1. This change in weight, although not always statistically significant, was seen in all treated groups. In addition, higher spleen weights (relative to body weight) were statistically significant in Group 4 males when compared with the air control Group 1. The spleen weight when expressed as absolute weight and relative to brain weight in Group 4 males was also higher than the air control Group 1 but not statistically significant. Spleen and lung weight changes correlated with gross and/or microscopic findings and were considered to be related with treatment with ceric oxide.

Significantly higher thymus weight recorded in Group 3 males (absolute, relative to body weight and brain weight) when compared to the air control Group 1 was not considered to be related with treatment with ceric oxide.

9.2 Gross and Histopathological Examinations (Table Nos. 17 and 18, Appendix No. 14)

The Pathologist's Report is presented on Pages 34 to 37.

Macroscopically, pertinent changes were recorded in the lungs such as discoloration or pale areas (30 each in Groups 3 and 4) and pale foci (4 in Group 2) and uncollaspsed parenchyma (30 in Group 4, 2 in Group 3). Statistical analysis performed on the pale areas and pale foci in the lungs were significant in Group 3 males and females (pale area) and in Group 2 females (pale foci) when compared with the air control Group 1.

In addition, enlargement and/or pale discoloration of the bronchial (30 each in Groups 3 and 4, 28 in Group 2), mediastinal (20 in Group 4, 18 in Group 3, 12 in Group 2, 1 in Group 1) and pancreatic lymph nodes (3 in Group 1, 1 each in Groups 3 and 4)) were primarily evident in animals treated with ceric oxide and considered to be induced by the test material.

Histopathologically, the following findings were recorded and statistical evaluation was performed:

Tissue	No. of animals with finding / No. of animals examined							
	Gr1♂	Gr2♂	Gr3♂	Gr4♂	Gr1♀	Gr2♀	Gr3♀	Gr4♀
Bronchus								
- Pigment accumulation	0/15	1/15	5/15*	15/15*	0/15	0/15	4/15*	15/15*
Nasal Cavity								
- Hypertrophy and/or hyperplasia, Goblet cells	0/15	0/15	0/15	1/15	0/15	1/15	0/15	2/15
- Pigment accumulation	0/15	12/15*	15/15*	15/15*	0/15	3/15	11/15*	15/15*
Larynx								
- Metaplasia	0/15	3/15	9/15*	13/15*	0/15	3/15	6/15*	9/15*
- Pigment accumulation	0/15	6/15*	9/15*	12/15*	0/15	0/15	7/15*	9/15*
Liver								
- Pigment accumulation	0/15	0/9	0/7	6/15*	0/15	0/1	0/5	5/15*
Lung								
- Pigment accumulation	0/15	15/15*	15/15*	15/15*	0/15	15/15*	15/15*	15/15*
- Epithelial hyperplasia, Alveolar	0/15	1/15	11/15*	14/15*	0/15	0/15	5/15*	15/15*
- Hyperplasia, Lymphoid	0/15	0/15	0/15	12/15*	0/15	0/15	1/15	7/15*
Mandibular Lymph Node								
- Pigment accumulation	0/15	0/3	0/5	6/15*	0/15	0/5	0/3	6/15*
Spleen								
- Pigment accumulation	0/15	0/1	0/0	6/15*	0/15	0/0	0/0	3/15
Trachea								
- Pigment accumulation	0/15	0/15	1/15	14/15*	0/15	0/15	1/15	14/15*
Bronchial Lymph Node								
- Pigment accumulation	0/15	13/13*	15/15*	15/15*	0/15	14/15*	15/15*	15/15*
- Hyperplasia, Lymphoid	0/15	11/13*	15/15*	15/15*	0/15	13/15*	15/15*	15/15*
Mediastinal Lymph Node								
- Pigment accumulation	0/0	2/2	8/10	9/9	0/1	10/10	9/9	9/10
- Hyperplasia, Lymphoid	0/0	2/2	9/10	9/9	0/1	10/10	9/9	9/10
Pancreatic Lymph Node								
- Pigment accumulation	-	-	-	-	0/2	0/0	1/1	1/1
- Hyperplasia, Lymphoid	-	-	-	-	0/2	0/0	1/1	0/1

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: * - P < .05 (FISCHER'S)

All positive findings for a given dose level were considered to be induced by the test material, however, not all were statistically significant when compared with the air control Group 1. The

pigmented material present in the various organs was considered to be the test compound or a product thereof.

The presence of lymphoid hyperplasia in the lymph nodes and lungs is consistent with antigenic stimulation by the compound, and there was a correlation between the degree of hyperplasia and the volume of pigment in these tissues.

A no-effect level was not present in Groups 2, 3 and 4, and systemic dissemination of the test article was evident in Group 4 animals. A dose-related effect of the compound was clearly evident.

Remaining unmentioned lesions in various animals were deemed incidental.

CONCLUSION

Nose-only inhalation exposure of Sprague-Dawley CD rats to ceric oxide dry powder aerosol was performed 6 hours daily, 5 days a week over 13 weeks at concentrations of 0.0050, 0.0505 and 0.5075 mg/L. An overall no-effect level cannot be established based on marginally reduced body weight gains recorded in Group 4 animals, as well as other changes recorded in treated groups including increased segmented neutrophil counts, higher lung and spleen weights, discoloration of the lungs and discoloration/enlargement of lymph nodes. Histopathologically, pigmented material accumulation in the lungs, bronchial, mandibular and mediastinal or pancreatic lymph nodes, trachea, bronchi, larynx, nasal cavity, liver and spleen, as well as alveolar epithelial hyperplasia (lungs), metaplasia (larynx) and lymphoid hyperplasia (bronchial and mediastinal or pancreatic lymph nodes, lungs) were seen in all treated groups. Systemic dissemination of the test article was evident in Group 4 animals.

The following endpoints and the no observable effect level (NOEL) were obtained:

Endpoints	NOEL
Clinical signs and Mortality	0.0050 mg/L males and females
Body weight and food consumption	0.0505 mg/L males and females
Ophthalmology	0.0050 mg/L males and females
FOB	0.0050 mg/L males and females
Motor activity	0.0050 mg/L males and females
Laboratory investigations	0.0050 mg/L males and N.D. for females
Organ weights	0.0050 mg/L males and females
Gross and histopathological findings	N.D. for males and females

N.D. - Not Determined

OPHTHALMOLOGIST'S REPORT

A complete funduscopic (indirect ophthalmoscopy) and biomicroscopic (slit lamp) examination was performed on all animals during the pretreatment period and on animals in the high dose and control groups at Week 13.

There were no treatment-related ocular changes during the treatment phase. Minor findings were observed in a few animals. They were considered incidental in origin and unrelated to treatment since they have been routinely found in comparable populations. Since significant changes were not detected, animals in the low and intermediate dose groups were not examined.

P. Blouin, D.V.M., Ph.D., Diplomate A.C.V.O.
Ophthalmologist

Sept 28, 1994
Date

PATHOLOGIST'S REPORT

1. INTRODUCTION

This study was conducted to investigate the potential toxicity of a powder aerosol of ceric oxide (CeO_2) in rats when administered by nose-only inhalation. The animals were grouped as shown in the table below and the control animals and those exposed to the test article received filtered conditioned air and ceric oxide, respectively, for a minimum of 13 consecutive weeks for 5 days per week.

Group/ Identification	Target Exposure Level (mg/L)	No. of Animals Males	Females
1 Air control	0	15	15
2 Ceric oxide Low dose	0.005	15	15
3 Ceric oxide Intermediate dose	0.05	15	15
4 Ceric oxide High dose	0.5	15	15

A complete necropsy was performed on the animal(s) which died during or were sacrificed at termination of the study. Protocol-defined and any abnormal tissues were retained from all groups and microscopically evaluated in Groups 1 and 4. Additionally, selected tissues (nasal cavities and sinuses, larynx, pharynx, trachea, bronchi, lungs) and gross lesions from animals in Groups 2 and 3 were examined by light microscopy. One animal (4001) died on Day 72 of the study. The individual gross and histopathologic findings are presented in Appendix 14 and the incidence of these changes is shown in Tables 17 and 18.

2. RESULTS AND DISCUSSION

Gross Pathology:

Pertinent gross lesions which were considered to be effects of the test article were evident in the lungs as discoloration or pale areas, (30 each in Groups 3 and 4), pale foci (4 in Group 2) and uncollapsed parenchyma (30 in Group 4, 2 in Group 3). In addition, enlargement and/or pale discoloration of the bronchial (30 each in Groups 3 and 4, 28 in Group 2), mediastinal (20 in Group 4, 18 in Group 3, 12 in Group 2, 1 in Group 1) and pancreatic (3 in Group 1, 1 each in Groups 3 and 4) lymph nodes were primarily evident in the animals exposed to the test compound and were considered to be related to treatment in these rats. However, mandibular lymph node enlargement, which was present in control and test material-exposed animals, and dark discoloration of the lymph node (mediastinal) in one control female were not thought to

be effects of the test article. These and the remaining unmentioned gross lesions were deemed incidental.

Histopathology:

Salient light microscopic findings which were considered to be test material-induced were pigment accumulation and/or alveolar epithelial/lymphoid hyperplasia in the lungs (30 each in Groups 2, 3 and 4), lymphoid hyperplasia of the bronchial (30 each in Groups 3 and 4, 24 in Group 2), mediastinal (18 each in Groups 3 and 4, 12 in Group 2) and pancreatic (1 in Group 3) lymph nodes, metaplasia and/or pigment accumulation in the larynx (22 in Group 4, 16 in Group 3, 9 in Group 2), and pigment accumulation in the bronchial lymph node (30 each in Groups 3 and 4, 27 in Group 2), nasal cavity (30 in Group 4, 26 in Group 3, 15 in Group 2), bronchi (30 in Group 4, 9 in Group 3, 1 in Group 2), trachea (28 in Group 4, 2 in Group 3), mediastinal lymph node (18 in Group 4, 17 in Group 3, 12 in Group 2), liver (11 in Group 4), mandibular lymph node (12 in Group 4), spleen (9 in Group 4) and pancreatic lymph node (1 each in Groups 3 and 4).

The pigment was present both intra- and extracellularly within the respiratory system and presented histologically as distinctly round, granular, blackish green material. When apparent in such organs as the spleen, lymph nodes and liver, the material was evident with unchanged morphologic characteristics. These findings were consistent with systemic dissemination with minimal to inapparent light microscopic evidence of metabolization of the material.

The initial presence of the pigment almost exclusively within the cytoplasm of alveolar macrophages of the low dose group (2), with subsequent presence both intra- and extracellularly in the higher dose groups (3 and 4), suggested the attainment of a dose concentration which had superseded the rate of clearance of the compound from the alveolar space.

Lymphoid hyperplasia was considered to be reactive to the ceric oxide and was characterized by an increase in the number of lymphocytes, with expansion of the paracortices and cortices of the lymph nodes (1). The presence of lymphoid hyperplasia in the lymph nodes and lungs was consistent with antigenic stimulation by the compound. Antigenic stimulation is the immunologic process by which an immune response is induced (2). A correlation between the degree of lymphoid hyperplasia and the volume of pigment present in these tissues was evident. In addition, the pigment also was present within the pulmonary lymphoid follicles and was almost exclusively observed within the lymphoid follicles of the nasal cavity, larynx and spleen.

The pulmonary change was remarkable for the somewhat contained inflammatory response despite the copious amount of pigmented material present, particularly in the Group 4 animals. This finding, however, [illegible] compatible with the minimal clinical signs noted.

The laryngeal metaplasia was confined to the base of the epiglottis and was characterized by a loss of cilia and the distinct presence of flattened and squamous cells towards the surface of this site. This lesion was interpreted as being adaptive to the insult and can be reversible.

The base of the epiglottis in the larynx of rodents appears to have heightened sensitivity to inhaled materials (3). This is probably due to the airflow characteristics and the regional epithelial sensitiviety (4). Although humans possess similar epithelia in their larynx (5), their airflow pattern differs from that of rodents as air makes a 90° turn downwards to reach the larynx in humans (6). In rodents this angle is much less acute. Extrapolation to humans, therefore, should be made with caution due to the differing airflow patterns between the species.

The extensive thymic hemorrhage which was evident in animal No. 4001 which died, may be an indication of hypoxia due to respiratory compromise, an insult which likely contributed to the demise of this animal.

The remaining unmentioned lesions in the various animals were deemed incidental.

3. CONCLUSION

The pigmented material present in the various organs was considered to be the test compound or a product thereof. Pigment accumulation was considered to be due to the test article and was observed in multiple organs (lungs, trachea, bronchi, larynx, nasal cavity, liver, spleen and bronchial, mandibular, mediastinal, pancreatic lymph nodes). Additional test material-induced lesions such as alveolar epithelial hyperplasia (lungs), metaplasia (larynx) and lymphoid hyperplasia (bronchial, mediastinal and pancreatic lymph nodes, lungs) also were observed. A no-effect dose level was not present. Systemic dissemination of the test article was evident in Group 3 and 4 animals. A dose-related effect of the compound was clearly evident.

W. Evering, D.V.M., Ph.D., Diplomate, A.C.V.P.
Study Pathologist

25th September 1994
Date

References

1. Valli, V.E.O. (1985). The hematopoietic system. In: Pathology of Domestic Animals (K.V.F. Jubb, P.C. Kennedy, N. Palmer eds.) Vol. 3, pp. 83-236.

2. Tizard, I. (1982). General features of the immune response. In: Veterinary Immunology. 2nd edition. pp. 6-13.

3. Renne, R.A., Gideon, K.M., Miller, R.A., et al (1992). Histologic methods and interspecies variations in the laryngeal histology of F344/N rats and B6C3F1 mice. Toxicologic Pathology 20 (1): 44-51.

4. Gopinath, C., Prentice, D.E., and Lewis, D.J. (1987). The respiratory system. In: Atlas of Experimental Toxicologic Pathology. Current Histopathology (G.A. Gresham ed.) pp. 22-42.

5. Stell, P.M., Stell, I.M. and Watt, J. (1982). Age changes in the epithelial lining of the human larynx. Gerontology 28: 208-214.

6. Reznik, G.K. (1990). Comparative anatomy, physiology and function of the upper respiratory tract. Environmental Health Perspectives 85: 171-176.

QUALITY ASSURANCE
STATEMENT

In compliance with the Good Laboratory Practice Regulations, Study 90831 has been reviewed. The data presented in the final report accurately represent the data collected during the conduct of the study.

DATES OF INSPECTION	DATES OF REPORTS TO MANAGEMENT AND STUDY DIRECTOR
August 19, 1993	August 31, 1993
September 9, 1993	September 12, 1993
September 13,14, 1993	September 23, 1993
September 15, 1993	September 16, 1993
September 24, 1993	September 26, 1993
September 30, 1993	October 5, 1993
October 4, 1993	October 18, 1993
October 9, 1993	October 18, 1993
October 20, 1993	November 9, 1993
October 21, 1993	October 22, 1993
October 25, 1993	November 11, 1993
November 10, 1993	November 11, 1993
December 10, 15, 1993	December 21, 1993
December 17,20, 1993	January 4, 1994
December 30, 1993	January 4, 1994
January 4, 1994	January 5, 1994

(Continued)

QUALITY ASSURANCE
STATEMENT

DATES OF INSPECTION	DATES OF REPORTS TO MANAGEMENT AND STUDY DIRECTOR
March 16 - 29, 1994	April 4, 1994
March 21,22, 1994	April 2, 1994
March 21,24,25,28,29, 1994	April 4, 1994
March 21-April 6, 1994	May 17, 1994
March 22- April 4, 1994	May 17, 1994
March 17-April 6, 1994	June 17, 1994
May 26,27,30, 1994	June 12, 1994
August 26 -29, 1994	September 16, 1994
September 8, 1994	September 16, 1994
September 22, 1994	September 27, 1994

QUALITY ASSURANCE: A. Graham C.B. Moore DATE: 25.9.94 29.09.94

A. Gagné P. Sidney DATE: 1994-09-29 1994-09-29

FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
PRESTUDY, MALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
PRESTUDY, FEMALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
WEEK 4, MALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
WEEK 4, FEMALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
WEEK 8, MALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
WEEK 8, FEMALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
WEEK 13, MALES

PROJECT NO. 90831



FIGURE NO. 1

GROUP MEAN MOTOR ACTIVITY COUNTS
WEEK 13, FEMALES

PROJECT NO. 90831



Inhalation Chamber and Generator System



Legend

1 Powder feed nozzle (secured by clamp)
2 Linear powder feed track
3 Pump
4 Pulling chain
5 Venturi T-section (containing critical orifice)
6 Breathing port
7 Compressed air supply
8 Tangential chamber top
9 Cylindrical stainless-steel nose-only inhalation chamber
10 Restraint tube
11 Bracket
12 Chamber exhaust (to purifying system)

03-FIG-90763 © 1994-02-10 (mm)

TABLE NO. 1

CALENDAR OF EVENTS

PROJECT NO. 90831

MALES

DATE	STUDY DAYS	STUDY WEEKS	EVENT
August 31, 1993	-13	-2	Animal arrival, mortality check
September 2, 1993	-11	-2	Experimental atmosphere evaluation (begin), particle size analysis (begin)
September 3, 1993	-10	-2	Hematology/biochemistry (health screen), urinalysis (health screen), necropsy (health screen)
September 7, 1993	-6	-1	Randomization, acclimation, body weight (begin), food consumption (begin)
September 8, 9, 1993	-5, -4	-1	Acclimation
September 10, 1993	-3	-1	Ophthalmology
September 11, 1993	-2	-1	Functional observation battery, motor activity
September 13, 1993	1	1	Treatment begin, clinical sign (begin), functional observation battery
October 5, 8, 1993	23, 26	4	Animal spare released
October 9, 1993	27	4	Motor activity, functional observation battery
October 19-21, 1993	37-39	6	Hematology/biochemistry, urinalysis
November 6, 1993	55	8	Motor activity, functional observation battery
December 8, 1993	87	13	Ophthalmology
December 11, 1993	90	13	Motor activity, functional observation battery
December 13, 1993	92	14	Hematology/biochemistry, urinalysis, terminal necropsy

TABLE NO. 1

CALENDAR OF EVENTS

FEMALES

PROJECT NO. 90831

DATE	STUDY DAYS	STUDY WEEKS	EVENT
August 31, 1993	-20	-3	Animal arrival, mortality check
September 2, 1993	-18	-3	Experimental atmosphere evaluation (begin), particle size analysis (begin)
September 3, 1993	-17	-3	Hematology/biochemistry (health screen), urinalysis (health screen), necropsy (health screen)
September 7, 1993	-13	-2	Randomization, body weight (begin), food consumption (begin)
September 10, 1993	-10	-2	Ophthalmology
September 14-16, 1993	-6 to -4	-1	Acclimation
September 17, 1993	-3	-1	Motor activity, functional observation battery
September 20, 1993	1	1	Treatment begin, clinical sign (begin), functional observation battery
October 5, 8, 1993	16, 19	3	Animal spare released
October 16, 1993	27	4	Motor activity, functional observation battery
October 26-28, 1993	37-39	6	Hematology/biochemistry, urinalysis
November 13, 1993	55	8	Motor activity, functional observation battery
December 15, 1993	87	13	Ophthalmology
December 18, 1993	90	13	Motor activity, functional observation battery
December 20, 1993	92	14	Hematology/biochemistry, urinalysis, terminal necropsy

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 1 - AIR CONTROL

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
2	0.0006	0.0006	0.0014	0.0004	0.0006	0.0003	0.0007	0.00039
9	0.0000	0.0001	0.0000	0.0000	0.0000	0.0000	0.0000	0.00004
30	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.00000
31	0.0002	0.0003	0.0002	0.0000	0.0000	0.0003	0.0002	0.00014
51	0.0000	0.0001	0.0000	0.0000	0.0002	0.0001	0.0001	0.00008
86	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.0000	0.00000

MEAN+	0.0002
S.D.	0.00027
MEAN++	0.0001
S.D.	0.00009

\+ Overall mean for males (Day 1 to 89)
++ Overall mean for females (Day 8 to 96)

NOTE : Males were treated from Day 1 to 89 and
females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
1	0.0044	0.0052	0.0047	0.0054	0.0045* (0.0037) (0.0053)	0.0048	0.0048	0.00039
2	0.0063* (0.0100) (0.0025)	0.0065* (0.0064) (0.0066)	0.0037* (0.0022) (0.0038) (0.0052)	0.0050	0.0047	0.0062* (0.0104) (0.0046) (0.0037)	0.0054	0.00111
3	0.0048	0.0038	0.0044	0.0040	0.0049	0.0051* (0.0063) (0.0038)	0.0045	0.00052
4	0.0041	0.0040	0.0041* (0.0038) (0.0043)	0.0057* (0.0066) (0.0047)	0.0041	0.0049	0.0045	0.00068
5	0.0055	0.0049	0.0057	0.0053	0.0058	0.0055	0.0055	0.00032
8	0.0055* (0.0067) (0.0043)	0.0048	0.0036* (0.0031) (0.0040)	0.0045	0.0043	0.0034* (0.0037) (0.0031)	0.0044	0.00078
9	0.0043* (0.0051) (0.0035)	0.0045	0.0042	0.0034* (0.0036) (0.0031)	0.0041	0.0041	0.0041	0.00037
10	0.0045	0.0051	0.0040	0.0052* (0.0064) (0.0039)	0.0049	0.0046	0.0047	0.00044
11	0.0056	0.0050	0.0056	0.0047	0.0054	0.0050	0.0052	0.00037
12	0.0058* (0.0061) (0.0054)	0.0045	0.0049	0.0056	0.0045	0.0058	0.0052	0.00062
15	0.0059	0.0053	0.0041	0.0051	0.0055* (0.0067) (0.0042)	0.0044	0.0051	0.00068
16	0.0065* (0.0075) (0.0054)	0.0058	0.0046	0.0056	0.0055	0.0041	0.0054	0.00086
17	0.0059	0.0058	0.0049	0.0050	0.0055	0.0055	0.0054	0.00041
18	0.0060	0.0058	0.0050	0.0053	0.0054	0.0050	0.0054	0.00041
19	0.0057	0.0055	0.0061* (0.0061) (0.0061)	0.0043	0.0052* (0.0063) (0.0040)	0.0051	0.0053	0.00061

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
22	0.0044*	0.0053 (0.0066) (0.0040)	0.0047	0.0052	0.0050	0.0057	0.0051	0.00046
23	0.0061* (0.0077) (0.0060) (0.0046)	0.0036* (0.0029) (0.0042)	0.0066* (0.0066) (0.0065)	0.0046	0.0055	0.0047	0.0052	0.00110
24	0.0054	0.0040	0.0055	0.0058* (0.0065) (0.0050)	0.0052	0.0052	0.0052	0.00062
25	0.0052	0.0047	0.0054* (0.0073) (0.0034)	0.0054* (0.0074) (0.0034)	0.0043	0.0047	0.0050	0.00045
26	0.0056	0.0041	0.0045	0.0049	0.0057	0.0049	0.0050	0.00062
29	0.0050	0.0051	0.0052	0.0054* (0.0061) (0.0046)	0.0052	0.0055* (0.0064) (0.0045)	0.0052	0.00019
30	0.0080* (0.0108) (0.0052)	0.0048	0.0042	0.0056* (0.0064) (0.0048)	0.0040	0.0059	0.0054	0.00147
31	0.0045	0.0042* (0.0028) (0.0043)	0.0047	0.0048	0.0050* (0.0038) (0.0062)	0.0057	0.0048	0.00051
32	0.0057	0.0041	0.0053	0.0049	0.0059* (0.0067) (0.0051)	0.0054	0.0052	0.00065
33	0.0056* (0.0066) (0.0046)	0.0051	0.0057* (0.0077) (0.0036)	0.0057* (0.0063) (0.0050)	0.0055	0.0050	0.0054	0.00031
36	0.0054* (0.0071) (0.0037)	0.0054* (0.0066) (0.0041)	0.0041	0.0049	0.0046	0.0057	0.0050	0.00060
37	0.0062* (0.0068) (0.0056)	0.0051	0.0053* (0.0067) (0.0039)	0.0052	0.0058	0.0059	0.0056	0.00044
38	0.0048* (0.0065) (0.0031)	0.0055	0.0048	0.0047	0.0047	0.0058	0.0051	0.00048
39	0.0050	0.0042	0.0044	0.0060	0.0046	0.0049	0.0049	0.00064
40	0.0041	0.0043	0.0055	0.0044	0.0040	0.0041	0.0044	0.00056

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
43	0.0056* (0.0071) (0.0041)	0.0054* (0.0034) (0.0073)	0.0046* (0.0037) (0.0054)	0.0045	0.0046	0.0049	0.0049	0.00046
44	0.0034* (0.0032) (0.0037) (0.0032)	0.0050	0.0051	0.0053	0.0041	0.0047	0.0046	0.00072
45	0.0056	0.0043* (0.0035) (0.0050)	0.0042	0.0057	0.0042	0.0048	0.0048	0.00070
46	0.0057	0.0049	0.0057* (0.0077) (0.0037)	0.0044	0.0046	0.0040	0.0049	0.00070
47	0.0059	0.0043	0.0057	0.0051	0.0050	0.0044	0.0051	0.00065
50	0.0053* (0.0062) (0.0043)	0.0051	0.0046	0.0047* (0.0039) (0.0054)	0.0047	0.0058* (0.0061) (0.0055)	0.0050	0.00046
51	0.0055	0.0055	0.0046	0.0046	0.0053	0.0057	0.0052	0.00048
52	0.0042* (0.0035) (0.0048)	0.0043* (0.0038) (0.0048)	0.0049	0.0048	0.0051	0.0053	0.0048	0.00044
53	0.0046	0.0043	0.0051	0.0057	0.0050	0.0055	0.0050	0.00053
54	0.0050	0.0048* (0.0037) (0.0058)	0.0047	0.0053	0.0050	0.0042	0.0048	0.00037
57	0.0058	0.0049	0.0053	0.0056	0.0051	0.0054* (0.0078) (0.0029)	0.0054	0.00033
58	0.0050	0.0046	0.0047	0.0045	0.0050	0.0043	0.0047	0.00028
59	0.0056	0.0051	0.0054	0.0049	0.0048	0.0049	0.0051	0.00032
60	0.0048	0.0041	0.0046	0.0048	0.0045	0.0057	0.0048	0.00053
61	0.0059	0.0053* (0.0032) (0.0074)	0.0047	0.0047	0.0046	0.0053	0.0051	0.00051

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
64	0.0058	0.0040	0.0055	0.0055	0.0052	0.0051	0.0052	0.00063
65	0.0056	0.0045	0.0043	0.0045	0.0052	0.0042	0.0047	0.00056
66	0.0053*	0.0040*	0.0053	0.0064*	0.0058	0.0053*	0.0054	0.00079
	(0.0062)	(0.0038)		(0.0065)		(0.0069)		
	(0.0044)	(0.0041)		(0.0077)		(0.0037)		
				(0.0050)				
67	0.0042	0.0046	0.0047	0.0045	0.0046	0.0057*	0.0047	0.00051
						(0.0064)		
						(0.0050)		
68	0.0060*	0.0045	0.0054	0.0054	0.0058	0.0052*	0.0054	0.00052
	(0.0062)					(0.0071)		
	(0.0058)					(0.0033)		
71	0.0051	0.0047	0.0043*	0.0045	0.0043	0.0046	0.0046	0.00030
			(0.0034)					
			(0.0052)					
72	0.0053	0.0052	0.0048	0.0046	0.0050	0.0044	0.0049	0.00035
73	0.0060*	0.0046	0.0040	0.0054	0.0055	0.0053	0.0051	0.00071
	(0.0084)							
	(0.0054)							
	(0.0041)							
74	0.0051	0.0052	0.0057	0.0047	0.0060	0.0041	0.0051	0.00068
			(0.0070)	(0.0061)				
			(0.0044)	(0.0033)				
75	0.0050	0.0049	0.0049	0.0050	0.0052	0.0048	0.0050	0.00014
78	0.0043*	0.0041	0.0046	0.0047	0.0051	0.0048	0.0046	0.00036
	(0.0039)							
	(0.0046)							
79	0.0041	0.0056*	0.0057	0.0055*	0.0056	0.0058	0.0054	0.00064
		(0.0062)		(0.0080)				
		(0.0049)		(0.0043)				
				(0.0043)				
80	0.0046	0.0043	0.0051	0.0051*	0.0058	0.0053*	0.0050	0.00053
				(0.0062)		(0.0062)		
				(0.0039)		(0.0044)		
81	0.0049	0.0058	0.0053	0.0053	0.0054	0.0063*	0.0055	0.00049
						(0.0064)		
						(0.0062)		
82	0.0043	0.0056*	0.0051	0.0052*	0.0046	0.0053	0.0050	0.00048
		(0.0062)		(0.0038)				
		(0.0049)		(0.0066)				

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
85	0.0046	0.0042	0.0046	0.0040	0.0042	0.0045	0.0044	0.00025
86	0.0054* (0.0067) (0.0040)	0.0047	0.0050	0.0055	0.0055* (0.0079) (0.0050)	0.0048	0.0052	0.00036
87	0.0048	0.0050	0.0056	0.0052	0.0055	0.0054	0.0053	0.00031
88	0.0045	0.0043	0.0041* (0.0036) (0.0046)	0.0050	0.0042 (0.0037) (0.0046)	0.0056	0.0046	0.00058
89	0.0040	0.0042* (0.0035) (0.0049)	0.0048* (0.0067) (0.0028)	0.0046	0.0049	0.0057	0.0047	0.00060
92	0.0042	0.0041	0.0044* (0.0038) (0.0050)	0.0049	0.0046	0.0038* (0.0037) (0.0039)	0.0043	0.00039
93	0.0052	0.0048	0.0047	0.0049	0.0053	0.0055	0.0051	0.00031
94	0.0052	0.0045	0.0053	0.0048	0.0052	0.0045	0.0049	0.00037
95	0.0044* (0.0038) (0.0050)	0.0044* (0.0039) (0.0048)	0.0052	0.0058	0.0052	0.0050	0.0050	0.00054
96	0.0048	0.0044	0.0048	0.0047	0.0049	0.0045	0.0047	0.00019

MEAN+	0.0050
S.D.	0.00033
MEAN++	0.0050
S.D.	0.00032

\+ Overall mean for males (Day 1 to 89)
++ Overall mean for females (Day 8 to 96)
* Mean of samples obtained during the hour.

NOTE : Males were treated from Day 1 to 89 and
females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 2 PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
1	0.0428	0.0460	0.0760* (0.0615) (0.0905)	0.0553	0.0614* (0.0613) (0.0615)	0.0342* (0.0308) (0.0375)	0.0526	0.01490
2	0.0788* (0.0743) (0.0833)	0.0415	0.0488	0.0560	0.0453	0.0367* (0.0363) (0.0370)	0.0512	0.01503
3	0.0543	0.0455	0.0540	0.0420	0.0485	0.0573	0.0503	0.00590
4	0.0583	0.0503	0.0540	0.0575	0.0435	0.0505	0.0524	0.00549
5	0.0580	0.0563	0.0560	0.0520	0.0510	0.0498	0.0539	0.00334
8	0.0508	0.0598* (0.0725) (0.0470)	0.0493	0.0540	0.0495	0.0570	0.0534	0.00431
9	0.0533	0.0539* (0.0620) (0.0458)	0.0495	0.0495	0.0468	0.0463	0.0499	0.00318
10	0.0608* (0.0690) (0.0525)	0.0425* (0.0355) (0.0495)	0.0445	0.0515	0.0520	0.0528	0.0507	0.00655
11	0.0629* (0.0635) (0.0623)	0.0522* (0.0390) (0.0653)	0.0430	0.0478	0.0454	0.0418	0.0489	0.00782
12	0.0440	0.0553	0.0468	0.0525	0.0568	0.0525	0.0513	0.00495
15	0.0579* (0.0698) (0.0460)	0.0495	0.0470	0.0495	0.0573	0.0525	0.0523	0.00448
16	0.0573	0.0565	0.0528	0.0538	0.0440	0.0533	0.0530	0.00474
17	0.0674* (0.0988) (0.0360)	0.0440	0.0528	0.0525	0.0468	0.0523	0.0526	0.00808
18	0.0538	0.0440	0.0453	0.0575	0.0483	0.0498	0.0498	0.00513
19	0.0590	0.0473	0.0515	0.0543	0.0468	0.0538	0.0521	0.00462

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
22	0.0573	0.0488	0.0470	0.0535	0.0535	0.0553	0.0526	0.00392
23	0.0566* (0.0628) (0.0503)	0.0573	0.0453	0.0480	0.0455	0.0538	0.0511	0.00549
24	0.0578* (0.0658) (0.0498)	0.0490	0.0563* (0.0638) (0.0488)	0.0498	0.0518	0.0485	0.0522	0.00395
25	0.0523	0.0554* (0.0648) (0.0460)	0.0510	0.0525	0.0525	0.0505	0.0524	0.00171
26	0.0570	0.0498	0.0490	0.0528	0.0570	0.0560	0.0536	0.00361
29	0.0558	0.0420	0.0538	0.0500	0.0563	0.0458	0.0506	0.00578
30	0.0498	0.0490	0.0465	0.0538	0.0510	0.0508	0.0502	0.00242
31	0.0410	0.0423	0.0493	0.0408	0.0582	0.0518	0.0472	0.00707
32	0.0572* (0.0670) (0.0473)	0.0515	0.0540	0.0485	0.0480	0.0543	0.0523	0.00359
33	0.0448	0.0523	0.0493	0.0458	0.0533	0.0510	0.0494	0.00347
36	0.0555	0.0455	0.0575	0.0493	0.0515	0.0578	0.0529	0.00493
37	0.0550	0.0445	0.0370* (0.0345) (0.0395)	0.0545	0.0508	0.0535	0.0492	0.00712
38	0.0763* (0.0838) (0.0688)	0.0420	0.0580	0.0631* (0.0708) (0.0553)	0.0516* (0.0603) (0.0428)	0.0629* (0.0735) (0.0525)	0.0590	0.01163
39	0.0793* (0.0963) (0.0623)	0.0473	0.0490	0.0433	0.0475	0.0565	0.0538	0.01321
40	0.0533	0.0473	0.0578	0.0438	0.0565	0.0500	0.0515	0.00542

* Mean of samples obtained during the hour.

TABLE NO. 2 PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
43	0.0590* (0.0780) (0.0400)	0.0563	0.0448	0.0438	0.0515	0.0532* (0.0630) (0.0433)	0.0514	0.00610
44	0.0602* (0.0773) (0.0430)	0.0570	0.0485	0.0420	0.0500	0.0547* (0.0640) (0.0453)	0.0521	0.00657
45	0.0510	0.0428	0.0445	0.0423	0.0558	0.0459* (0.0670) (0.0248)	0.0471	0.00530
46	0.0508	0.0428	0.0435	0.0483	0.0458	0.0435	0.0458	0.00319
47	0.0555	0.0490	0.0463	0.0475	0.0483	0.0573	0.0507	0.00458
50	0.0561* (0.0663) (0.0458)	0.0515	0.0453	0.0465	0.0538	0.0601* (0.0668) (0.0673) (0.0463)	0.0522	0.00567
51	0.0553* (0.0733) (0.0373)	0.0403* (0.0353) (0.0453)	0.0508	0.0503	0.0600	0.0463	0.0505	0.00686
52	0.0548	0.0408	0.0535	0.0574* (0.0615) (0.0533)	0.0603	0.0545	0.0536	0.00671
53	0.0553	0.0468	0.0460	0.0483	0.0468	0.0473	0.0484	0.00346
54	0.0518	0.0480	0.0560	0.0603	0.0443	0.0535	0.0523	0.00569
57	0.0460	0.0448	0.0505	0.0513	0.0518	0.0533	0.0496	0.00341
58	0.0418	0.0593	0.0543	0.0575	0.0483	0.0580	0.0532	0.00684
59	0.0415	0.0400	0.0440	0.0485	0.0448	0.0490	0.0446	0.00363
60	0.0525	0.0403	0.0465	0.0495	0.0490	0.0547* (0.0643) (0.0450)	0.0488	0.00503
61	0.0500	0.0540	0.0430	0.0460	0.0498	0.0470	0.0483	0.00381

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
64	0.0483	0.0428* (0.0325) (0.0530)	0.0425	0.0498	0.0545	0.0470	0.0475	0.00452
65	0.0538	0.0505	0.0515	0.0453	0.0513	0.0393* (0.0373) (0.0413)	0.0486	0.00536
66	0.0500	0.0480	0.0450	0.0538	0.0550	0.0465	0.0497	0.00401
67	0.0558	0.0410	0.0480	0.0433	0.0575	0.0580	0.0506	0.00750
68	0.0569* (0.0748) (0.0390)	0.0593	0.0538	0.0503	0.0525	0.0523	0.0542	0.00332
71	0.0525	0.0518	0.0478	0.0565	0.0468	0.0535	0.0515	0.00363
72	0.0510	0.0453	0.0468	0.0445	0.0443	0.0573	0.0482	0.00510
73	0.0510	0.0488	0.0403* (0.0388) (0.0418)	0.0478	0.0445	0.0429* (0.0393) (0.0465)	0.0459	0.00401
74	0.0440	0.0573	0.0403* (0.0393) (0.0413)	0.0533	0.0445	0.0423	0.0470	0.00675
75	0.0513	0.0485	0.0508* (0.0398) (0.0618)	0.0553* (0.0625) (0.0480)	0.0560	0.0433	0.0509	0.00467
78	0.0488	0.0493	0.0455	0.0463* (0.0353) (0.0573)	0.0430	0.0405* (0.0365) (0.0445)	0.0456	0.00338
79	0.0513	0.0410	0.0463	0.0445	0.0530	0.0448	0.0468	0.00451
80	0.0472* (0.0393) (0.0550)	0.0450	0.0493	0.0430	0.0463	0.0518	0.0471	0.00312
81	0.0523	0.0538	0.0410* (0.0348) (0.0415) (0.0468)	0.0470	0.0569* (0.0623) (0.0515)	0.0523	0.0506	0.00567
82	0.0450	0.0578	0.0463	0.0581* (0.0623) (0.0538)	0.0595	0.0458	0.0521	0.00703

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
85	0.0503	0.0483	0.0475	0.0450	0.0505	0.0488	0.0484	0.00203
86	0.0438	0.0428	0.0508	0.0478	0.0495	0.0468	0.0469	0.00314
87	0.0590	0.0570	0.0438	0.0456	0.0443	0.0528	0.0504	0.00674
88	0.0575	0.0401*	0.0439*	0.0513	0.0533	0.0445	0.0484	0.00663
		(0.0388)	(0.0388)					
		(0.0413)	(0.0490)					
89	0.0530	0.0513	0.0433	0.0545	0.0590	0.0560	0.0529	0.00537
92	0.0619*	0.0597*	0.0503	0.0400	0.0528	0.0540	0.0531	0.00776
	(0.0768)	(0.0995)						
	(0.0470)	(0.0198						
93	0.0480	0.0403	0.0413	0.0453	0.0508	0.0510	0.0461	0.00463
94	0.0445	0.0538	0.0654*	0.0438	0.0525	0.0463	0.0511	0.00817
			(0.0743)					
			(0.0625)					
			(0.0595)					
95	0.0463	0.0554*	0.0543	0.0532*	0.0614*	0.0543	0.0542	0.00483
		(0.0668)		(0.0763)	(0.0673)			
		(0.0440)		(0.0300)	(0.0555)			
96	0.0597*	0.0593	0.0493	0.0643*	0.0544*	0.0553	0.0571	0.00519
	(0.0620)			(0.0718)	(0.0455)			
	(0.0573)			(0.0568)	(0.0633)			

MEAN +	0.0505
S.D.	0.00259
MEAN++	0.0505
S.D.	0.00278

+ Overall mean for males (Day 1 to 89)
++ Overall mean for females (Day 8 to 96)
* Mean of samples obtained during the hour.

NOTE : Males were treated from Day 1 to 89 and
females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
1	0.4375	0.5650	0.5325	0.5350	0.5675	0.4675	0.5175	0.05327
2	0.5300	0.4800	0.4525	0.5025	0.5625	0.5100	0.5063	0.03830
3	0.6225* (0.6950) (0.5500)	0.4700	0.4825	0.4975	0.6425* (0.6600) (0.6250)	0.4725	0.5313	0.07927
4	0.4100	0.5100	0.5225	0.4650	0.4450	0.5713* (0.6025) (0.5400)	0.4873	0.05843
5	0.4825	0.4850	0.4500	0.5450	0.6275* (0.7225) (0.7650) (0.4375) (0.5850)	0.5575	0.5246	0.06480
8	0.5100	0.5375	0.4900	0.4625	0.4950* (0.3525) (0.6375)	0.5950	0.5150	0.04629
9	0.4163* (0.3550) (0.4775)	0.3813* (0.3150) (0.4475)	0.6200* (0.6750) (0.5650)	0.5075	0.5175	0.4550	0.4829	0.08501
10	0.4600	0.4875	0.4125* (0.3675) (0.4575)	0.4250	0.4150	0.5450	0.4575	0.05187
11	0.5500	0.4200	0.4625	0.4200	0.3988* (0.3425) (0.4550)	0.4875	0.4565	0.05609
12	0.4425	0.4200* (0.3900) (0.4500)	0.4258* (0.3850) (0.2800) (0.6125)	0.4338* (0.3425) (0.5250)	0.4375	0.4575	0.4362	0.01320
15	0.6050* (0.7875) (0.4225)	0.6000	0.3713* (0.3900) (0.3525)	0.4825	0.5750	0.5575	0.5319	0.09025
16	0.4900	0.5350	0.4775	0.5550	0.5325	0.4200	0.5017	0.04959
17	0.5750* (0.6300) (0.5200)	0.4700	0.5450	0.6075* (0.7050) (0.5975) (0.5200)	0.5850* (0.6300) (0.5400)	0.5775	0.5600	0.04845
18	0.4600	0.4500	0.4475	0.4025	0.5700	0.5425	0.4788	0.06381
19	0.5650	0.5675	0.5550	0.4675	0.4675	0.5975	0.5367	0.05542

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
22	0.5438* (0.6125) (0.4750)	0.5650	0.5550	0.5200	0.4625	0.5538	0.5334	0.03794
23	0.5450* (0.4800) (0.6100)	0.4625	0.3813* (0.3600) (0.4025)	0.4700* (0.3825) (0.5575)	0.5538* (0.7325) (0.3750)	0.4675	0.4800	0.06321
24	0.5450	0.5500	0.4875	0.6163* (0.6350) (0.5975)	0.5563* (0.6775) (0.4350)	0.4775	0.5388	0.05073
25	0.5025	0.4825	0.4800	0.4300	0.5150	0.4100	0.4700	0.04132
26	0.5550	0.5150	0.4450	0.4750	0.5950	0.4325	0.5029	0.06392
29	0.4800	0.4950* (0.3875) (0.6025)	0.4750	0.5350	0.5275	0.5900	0.5171	0.04331
30	0.5650	0.4100	0.5175	0.5238* (0.6025) (0.4450)	0.5700	0.5700	0.5261	0.06152
31	0.5675	0.4150	0.5350* (0.6075) (0.4625)	0.6775	0.4550	0.6200* (0.8375) (0.6550) (0.3675)	0.5450	0.09878
32	0.5550	0.4775	0.4800	0.5488* (0.6650) (0.4325)	0.5513* (0.6450) (0.4575)	0.5725* (0.6125) (0.5325)	0.5309	0.04121
33	0.5888* (0.6025) (0.5750)	0.5863* (0.6375) (0.5350)	0.5575	0.5575	0.4075* (0.3773) (0.4375)	0.5825	0.5467	0.06962
36	0.5150	0.5950* (0.7400) (0.4500)	0.5375	0.4800	0.4700	0.5675	0.5275	0.04894
37	0.5500	0.5175	0.5250	0.6050	0.5163* (0.6500) (0.3825)	0.4625	0.5294	0.04679

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
38	0.5713* (0.6225) (0.5200)	0.4975	0.3575* (0.3125) (0.4025)	0.5725	0.5338* (0.6025) (0.4650)	0.4375* (0.3900) (0.4850)	0.4950	0.08432
39	0.6475* (0.7600) (0.8150)	0.5825	0.4200	0.4175* (0.3950) (0.4400)	0.4375	0.4100	0.4858	0.10254
40	0.4088* (0.3950) (0.4225)	0.4675	0.4950	0.4950	0.5700	0.4375	0.4790	0.05581
43	0.4350	0.4450	0.5700	0.5075	0.5038* (0.6200) (0.3875)	0.4625	0.4873	0.05032
44	0.4550	0.5500	0.5875	0.4250	0.4925	0.5475	0.5096	0.06256
45	0.4950	0.4125	0.5875* (0.7350) (0.4400)	0.4400	0.5600	0.5125	0.5013	0.06736
46	0.5700	0.4400	0.5000	0.4825	0.4850	0.4213* (0.3200) (0.5225)	0.4831	0.05200
47	0.4150	0.4625	0.4700	0.3688* (0.3225) (0.4150)	0.7113* (0.7975) (0.6250)	0.4225* (0.3825) (0.4625)	0.4750	0.12137
50	0.5275	0.4000* (0.3800) (0.4200)	0.4800	0.3950* (0.3775) (0.4125)	0.4325	0.4300	0.4442	0.05086
51	0.5375	0.5075* (0.3850) (0.6300)	0.4850	0.6088* (0.6500) (0.5675)	0.4150	0.4775	0.5052	0.06495
52	0.4200	0.5100	0.5925* (0.8700) (0.4525) (0.4550)	0.5575	0.5050	0.5225	0.5179	0.05825
53	0.4975	0.4725	0.4075* (0.3950) (0.4200)	0.5100	0.5475	0.5775	0.5021	0.05942
54	0.5925	0.4600	0.4800	0.4300	0.5625	0.4875	0.5021	0.06244

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
57	0.5225	0.5925	0.4475	0.4750	0.5500	0.5375	0.5208	0.05243
58	0.4275	0.4650	0.5050	0.5900	0.5150* (0.5575) (0.4725)	0.4313	0.4890	0.06135
59	0.4775	0.4650	0.5900	0.4700	0.5200	0.5050	0.5046	0.04697
60	0.4875	0.5375	0.4750	0.5875	0.5175	0.4900	0.5158	0.04182
61	0.5075	0.4925	0.4800	0.4850	0.5975	0.4900	0.5088	0.04446
64	0.6000	0.6588* (0.9025) (0.4150)	0.4338* (0.3925) (0.4750)	0.4000	0.4475	0.5263* (0.6300) (0.4225)	0.5111	0.10229
65	0.4875	0.4950	0.5525	0.5750* (0.6250) (0.5250)	0.5500* (0.6850) (0.4150)	0.5050	0.5275	0.03619
66	0.5625	0.5000	0.5525	0.4375	0.5675	0.5800	0.5333	0.05451
67	0.5500	0.5975	0.5250	0.5400	0.4950	0.5425	0.5417	0.03360
68	0.5100	0.5413* (0.6600) (0.4225)	0.5338* (0.6650) (0.4025)	0.4400	0.5750	0.6050	0.5342	0.05690
71	0.5800	0.4175	0.4250* (0.3875) (0.4625)	0.4975	0.4650	0.4875	0.4788	0.05918
72	0.4825	0.5325	0.4050* (0.3875) (0.4225)	0.5250	0.4400	0.5175	0.4838	0.05164
73	0.4925	0.4875	0.4375	0.5125	0.5400	0.6117* (0.6925) (0.6725) (0.4700)	0.5136	0.05872
74	0.5350	0.5300	0.5250	0.5100	0.4075	0.5300* (0.6225) (0.4375)	0.5063	0.04914
75	0.4750	0.4675	0.4700	0.4800	0.3825* (0.3650) (0.4000)	0.4800	0.4592	0.03790
78	0.5250	0.5538* (0.4875) (0.6200)	0.5400	0.5750* (0.5325) (0.6175)	0.5725* (0.4500) (0.6950)	0.5475	0.5523	0.01921

* Mean of samples obtained during the hour.

TABLE NO. 2

PROJECT NO. 90831

GRAVIMETRIC CHAMBER CONCENTRATIONS
(mg/L)
GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY DAY	SAMPLING TIME 0	1	2	3	4	5	MEAN	S.D.
79	0.5513* (0.6425) (0.4600)	0.5150	0.5450	0.6000	0.5575	0.4150	0.5306	0.06290
80	0.5363* (0.6125) (0.4600)	0.5775	0.4325* (0.2900) (0.4025) (0.6050)	0.4833* (0.3975) (0.3650) (0.6875)	0.4900	0.5788* (0.6900) (0.4675)	0.5164	0.05806
81	0.6113* (0.7325) (0.4900)	0.5938* (0.6200) (0.5675)	0.5175	0.5513* (0.6300) (0.4725)	0.4700	0.4625	0.5344	0.06218
82	0.5475	0.4200	0.5825* (0.3750) (0.7900)	0.4125	0.5250	0.4750	0.4938	0.06948
85	0.4850	0.5425	0.5950	0.4900	0.4900* (0.6050) (0.3750)	0.5325	0.5225	0.04307
86	0.5400	0.6300* (0.6050) (0.6550)	0.4438* (0.3750) (0.5125)	0.5225	0.5425	0.4975* (0.6050) (0.3900)	0.5294	0.06131
87	0.5525	0.5600	0.5050	0.5425	0.4775	0.5525	0.5317	0.03296
88	0.4350	0.6000	0.5350	0.4700	0.5350	0.5625	0.5229	0.06055
89	0.4575	0.4750	0.4725	0.4975	0.5700	0.6000	0.5121	0.05868
92	0.4000* (0.3375) (0.4625)	0.5025	0.4975	0.4725	0.4925	0.5075	0.4788	0.04043
93	0.4200	0.4575	0.5200* (0.6025) (0.4375)	0.4125	0.5625	0.5125	0.4808	0.06020
94	0.4525	0.5275	0.4725	0.5250	0.4325	0.5825	0.4988	0.05612
95	0.4425	0.5750	0.4875	0.5875	0.4575	0.5975	0.5246	0.06990
96	0.4900	0.4450	0.4575	0.4725	0.5600	0.5300	0.4925	0.04438

MEAN+	0.5082
S.D.	0.02681
MEAN++	0.5068
S.D.	0.02703

\+ Overall mean for males (Day 1 to 89)
++ Overall mean for females (Day 8 to 96)
* Mean of samples obtained during the hour.

NOTE : Males were treated from Day 1 to 89 and
females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 3

PROJECT NO. 90831

NOMINAL CONCENTRATION
(mg/L)

STUDY DAY	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE INTERMEDIATE DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	0.04	0.27	2.32
2	0.06	0.19	2.29
3	0.04	0.27	Nc
4	0.04	0.24	2.21
5	0.06	0.24	2.78
8	0.05	0.25	2.26
9	0.06	0.27	2.22
10	0.06	0.30	2.19
11	Nc	0.30	2.10
12	0.06	0.30	1.99
15	0.07	0.27	2.46
16	0.06	0.28	2.51
17	0.06	0.30	2.65
18	0.05	0.31	2.50
19	0.06	0.31	2.60
22	0.09	0.25	2.44
23	0.05	0.30	2.27
24	0.08	0.27	2.58
25	0.08	0.27	2.49
26	0.10	0.31	2.41
29	0.10	0.27	2.71
30	0.08	0.28	2.70
31	0.06	0.27	2.64
32	0.07	0.32	2.79
33	0.13	0.29	2.53
36	0.07	0.32	2.28
37	0.07	0.25	2.88
38	0.07	0.33	2.50
39	0.06	0.27	2.27
40	0.07	0.29	2.60
43	0.07	0.28	2.47
44	0.06	0.25	2.31
45	0.07	0.30	2.41
46	0.08	0.29	2.34
47	0.06	0.29	2.40
50	0.06	0.28	2.28
51	0.07	0.31	2.32
52	0.07	0.29	2.69
53	0.09	0.23	2.83
54	0.07	0.24	2.61

Nc Non calculable

TABLE NO. 3

PROJECT NO. 90831

NOMINAL CONCENTRATION
(mg/L)

STUDY DAY	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE INTERMEDIATE DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
57	0.06	0.22	2.54
58	0.07	0.27	2.79
59	0.07	0.21	2.41
60	0.06	0.26	2.82
61	0.05	0.28	2.47
64	0.07	0.26	2.64
65	0.06	0.21	2.70
66	0.06	0.19	2.44
67	0.06	0.22	2.56
68	0.06	0.31	2.51
71	0.06	0.27	2.63
72	0.07	0.22	2.40
73	0.05	0.20	2.39
74	0.07	0.23	2.75
75	0.05	0.25	2.86
78	0.06	0.21	2.60
79	0.05	0.24	2.21
80	0.04	0.21	3.42
81	0.08	0.21	2.41
82	0.05	0.30	2.48
85	0.07	0.29	2.26
86	0.07	0.24	2.36
87	T	0.30	2.37
88	0.05	0.30	2.32
89	0.05	0.27	2.56
92	0.05	0.30	2.47
93	0.05	0.28	2.36
94	0.05	0.30	2.40
95	0.05	0.31	2.51
96	0.04	0.26	2.40
MEAN: +	0.06	0.27	2.50
S.D.	0.015	0.035	0.230
MEAN: ++	0.06	0.27	2.50
S.D.	0.015	0.034	0.221

\+ Overall mean for males (Day 1 to 89)
++ Overall mean for females (Day 8 to 96)
T Technical error

NOTE: Males were treated from Day 1 to 89 and
females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 4

PROJECT NO. 90831

PARTICLE SIZE ANALYSIS
(MASS MEDIAN DIAMETER, (µm) AND GEOMETRIC STANDARD DEVIATION)

STUDY WEEK	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE INTERMEDIATE DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	2.1 ± 1.7	2.1 ± 1.9	2.2 ± 1.8
2	1.7 ± 2.0* (1.7 ± 2.1) (1.7 ± 1.9)	2.1 ± 2.0* (2.1 ± 2.1) (2.1 ± 1.8)	2.0 ± 2.2* (1.8 ± 2.4) (2.1 ± 1.9)
3	1.7 ± 1.9* (1.6 ± 2.1) (1.7 ± 1.6)	2.0 ± 1.8	2.1 ± 1.8
4	1.8 ± 1.7	2.3 ± 1.8	2.3 ± 1.8
5	1.8 ± 1.7	2.0 ± 1.6	2.4 ± 1.8
6	1.9 ± 2.0* (1.8 ± 2.3) (1.9 ± 1.6)	2.3 ± 2.0	2.2 ± 1.8
7	2.0 ± 2.0	2.1 ± 2.1* (2.0 ± 2.1) (2.2 ± 2.0)	2.3 ± 1.8
8	1.9 ± 1.7	1.8 ± 1.9	2.3 ± 1.8
9	1.6 ± 1.8	1.7 ± 2.2	2.0 ± 1.9
10	2.0 ± 2.0* (1.9 ± 2.1) (2.1 ± 1.8)	1.9 ± 1.7	2.3 ± 1.8* (2.2 ± 1.9) (2.3 ± 1.7)
11	1.9 ± 1.8* (1.9 ± 1.9) (1.9 ± 1.7)	1.9 ± 1.7	2.0 ± 1.9
12	1.8 ± 2.0* (1.7 ± 2.1) (1.9 ± 1.9)	2.2 ± 2.0	2.3 ± 1.6

TABLE NO. 4

PROJECT NO. 90831

PARTICLE SIZE ANALYSIS
(MASS MEDIAN DIAMETER, (µm) AND GEOMETRIC STANDARD DEVIATION)

STUDY WEEK	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE INTERMEDIATE DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
13	2.0 ± 2.1* (2.0 ± 2.0) (2.0 ± 2.1)	2.1 ± 2.0	2.5 ± 1.7
14	1.6 ± 2.1	2.2 ± 2.1* (2.0 ± 2.1) (2.3 ± 2.1)	2.4 ± 1.9
MEAN+ (MMAD ± GSD)	1.9 ± 1.9	2.0 ± 1.9	2.2 ± 1.8
MEAN++(MMAD ± GSD)	1.8 ± 1.9	2.0 ± 1.9	2.2 ± 1.8

\+ Overall mean for males (Week 1 to 13)
++ Overall mean for females (Week 2 to 14)
* Mean of samples taken during the same week.

NOTE: Males were treated from Day 1 to 89 and
females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 5

PROJECT NO. 90831

ESTIMATED PARTICLE SIZE (um)

GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY WEEK	MMAD ± GSD	% SIZE BY MASS 5	10	15	20	25	30	40	50	60	70	80	90
1	2.1 ± 1.7	0.94	1.1	1.3	1.4	1.5	1.6	1.8	2.1	2.4	2.7	3.2	3.9
2	1.7 ± 2.0 *	0.54*	0.70*	0.83*	0.95*	1.1 *	1.2 *	1.5 *	1.7 *	2.1 *	2.5 *	3.1 *	4.3 *
	(1.7 ± 2.1)	(0.49)	(0.64)	(0.78)	(0.90)	(1.0)	(1.1)	(1.4)	(1.7)	(2.1)	(2.5)	(3.2)	(4.5)
	(1.7 ± 1.9)	(0.59)	(0.76)	(0.88)	(1.0)	(1.1)	(1.2)	(1.5)	(1.7)	(2.0)	(2.4)	(3.0)	(4.0)
3	1.7 ± 1.9 *	0.63*	0.77*	0.88*	1.0 *	1.1 *	1.2 *	1.4 *	1.7 *	1.9 *	2.2 *	2.7 *	3.5 *
	(1.6 ± 2.1)	(0.52)	(0.66)	(0.78)	(0.90)	(1.0)	(1.1)	(1.3)	(1.6)	(1.9)	(2.3)	(2.9)	(3.9)
	(1.7 ± 1.6)	(0.74)	(0.88)	(0.98)	(1.1)	(1.2)	(1.3)	(1.5)	(1.7)	(1.9)	(2.1)	(2.5)	(3.1)
4	1.8 ± 1.7	0.70	0.86	0.98	1.1	1.2	1.3	1.5	1.8	2.1	2.4	2.9	3.7
5	1.8 ± 1.7	0.70	0.86	0.98	1.1	1.2	1.3	1.5	1.7	2.0	2.3	2.8	3.5
6	1.9 ± 2.0 *	0.64*	0.80*	0.94*	1.1 *	1.2 *	1.3 *	1.6 *	1.8 *	2.2 *	2.6 *	3.2 *	4.3 *
	(1.8 ± 2.3)	(0.48)	(0.64)	(0.78)	(0.92)	(1.1)	(1.2)	(1.5)	(1.8)	(2.2)	(2.7)	(3.6)	(5.1)
	(1.9 ± 1.6)	(0.80)	(0.96)	(1.1)	(1.2)	(1.3)	(1.4)	(1.6)	(1.8)	(2.1)	(2.4)	(2.8)	(3.5)
7	2.0 ± 2.0	0.64	0.82	0.98	1.1	1.3	1.4	1.7	2.0	2.4	2.9	3.6	4.9
8	1.9 ± 1.7	0.86	1.0	1.2	1.3	1.4	1.5	1.7	2.0	2.2	2.5	3.0	3.6
9	1.6 ± 1.8	0.64	0.78	0.88	1.0	1.1	1.2	1.4	1.6	1.8	2.1	2.6	3.3
10	2.0 ± 2.0 *	0.71*	0.87*	1.04*	1.2 *	1.4 *	1.5 *	1.7 *	2.0 *	2.4 *	2.9 *	3.5 *	4.7
	(1.9 ± 2.1)	(0.57)	(0.74)	(0.88)	(1.0)	(1.2)	(1.3)	(1.6)	(1.9)	(2.3)	(2.8)	(3.5)	(4.9)
	(2.1 ± 1.8)	(0.84)	(1.0)	(1.2)	(1.3)	(1.5)	(1.6)	(1.8)	(2.1)	(2.4)	(2.9)	(3.4)	(4.4)

TABLE NO. 5

PROJECT NO. 90831

ESTIMATED PARTICLE SIZE (um)

GROUP 2 - CERIC OXIDE - LOW DOSE

STUDY WEEK	MMAD ± GSD	% SIZE BY MASS 5	10	15	20	25	30	40	50	60	70	80	90
11	1.9 ± 1.8 *	0.72*	0.90*	1.04*	1.2 *	1.3 *	1.4 *	1.7 *	1.9 *	2.3 *	2.6 *	3.2 *	4.1 *
	(1.9 ± 1.9)	(0.66)	(0.84)	(0.98)	(1.1)	(1.3)	(1.4)	(1.6)	(1.9)	(2.3)	(2.7)	(3.3)	(4.4)
	(1.9 ± 1.7)	(0.78)	(0.96)	(1.1)	(1.2)	(1.3)	(1.4)	(1.7)	(1.9)	(2.2)	(2.5)	(3.0)	(3.8)
12	1.8 ± 2.0 *	0.59*	0.75*	0.88*	1.0 *	1.2	1.3 *	1.5 *	1.8 *	2.2 *	2.6 *	3.3 *	4.4 *
	(1.7 ± 2.1)	(0.50)	(0.66)	(0.78)	(0.92)	(1.1)	(1.2)	(1.4)	(1.7)	(2.1)	(2.6)	(3.3)	(4.6)
	(1.9 ± 1.9)	(0.68)	(0.84)	(0.98)	(1.1)	(1.2)	(1.3)	(1.6)	(1.9)	(2.2)	(2.6)	(3.2)	(4.2)
13	2.0 ± 2.1 *	0.60*	0.77*	0.93*	1.1 *	1.3	1.4 *	1.7 *	2.0 *	2.4 *	2.9 *	3.6 *	5.0 *
	(2.0 ± 2.0)	(0.64)	(0.82)	(0.98)	(1.1)	(1.3)	(1.4)	(1.7)	(2.0)	(2.4)	(2.8)	(3.5)	(4.7)
	(2.0 ± 2.1)	(0.56)	(0.72)	(0.88)	(1.0)	(1.2)	(1.3)	(1.6)	(2.0)	(2.4)	(2.9)	(3.7)	(5.2)
14	1.6 ± 2.1	0.52	0.66	0.78	0.90	1.0	1.1	1.4	1.6	2.0	2.4	2.9	4.0
MEAN +	1.9 ± 1.9	0.69	0.84	0.99	1.12	1.3	1.4	1.6	1.9	2.2	2.6	3.1	4.1
S.D.	0.14 ± 0.15	0.110	0.109	0.133	0.129	0.13	0.13	0.13	0.16	0.20	0.26	0.33	0.56
MEAN ++	1.8 ± 1.9	0.65	0.81	0.95	1.08	1.2	1.3	1.6	1.8	2.2	2.5	3.1	4.1
S.D.	0.14 ± 0.15	0.088	0.089	0.108	0.111	0.12	0.12	0.13	0.15	0.19	0.26	0.33	0.56

\+ Overall mean for males (Week 1 to 13)
++ Overall mean for females (Week 2 to 14)
* Mean of samples taken during the same week.

NOTE: Males were treated from Day 1 to 89 and females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 5

PROJECT NO. 90831

ESTIMATED PARTICLE SIZE (um)

GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY WEEK	MMAD ± GSD	% SIZE BY MASS 5	10	15	20	25	30	40	50	60	70	80	90
1	2.1 ± 1.9	0.72	0.90	1.1	1.2	1.4	1.5	1.8	2.1	2.5	3.0	3.7	4.9
2	2.1 ± 2.0 *	0.73*	0.91*	1.09*	1.2 *	1.3 *	1.5 *	1.8 *	2.1 *	2.5 *	3.0 *	3.7 *	4.9 *
	(2.1 ± 2.1)	(0.62)	(0.82)	(0.98)	(1.1)	(1.2)	(1.4)	(1.7)	(2.1)	(2.5)	(3.1)	(3.9)	(5.4)
	(2.1 ± 1.8)	(0.84)	(1.0)	(1.2)	(1.3)	(1.4)	(1.6)	(1.8)	(2.1)	(2.4)	(2.8)	(3.4)	(4.3)
3	2.0 ± 1.8	0.76	0.92	1.1	1.2	1.3	1.5	1.7	2.0	2.3	2.7	3.3	4.3
4	2.3 ± 1.8	0.86	1.1	1.2	1.4	1.5	1.7	2.0	2.4	2.7	3.2	3.9	5.0
5	2.0 ± 1.6	0.86	1.0	1.2	1.3	1.4	1.5	1.7	2.0	2.2	2.6	3.0	3.8
6	2.3 ± 2.0	0.78	0.98	1.2	1.3	1.5	1.6	2.0	2.3	2.8	3.3	4.0	5.4
7	2.1 ± 2.1*	0.62*	0.81*	0.99*	1.1 *	1.3 *	1.4 *	1.7 *	2.1 *	2.5 *	3.1 *	3.9 *	5.3 *
	(2.0 ± 2.1)	(0.55)	(0.74)	(0.88)	(1.0)	(1.2)	(1.3)	(1.6)	(2.0)	(2.4)	(2.9)	(3.8)	(5.2)
	(2.2 ± 2.0)	(0.68)	(0.88)	(1.1)	(1.2)	(1.4)	(1.5)	(1.8)	(2.2)	(2.6)	(3.2)	(4.0)	(5.4)
8	1.8 ± 1.9	0.68	0.84	0.98	1.1	1.2	1.3	1.6	1.8	2.1	2.5	3.0	4.0
9	1.7 ± 2.2	0.48	0.64	0.76	0.9	1.0	1.1	1.4	1.7	2.1	2.6	3.3	4.7
10	1.9 ± 1.7	0.76	0.94	1.1	1.2	1.3	1.4	1.7	1.9	2.2	2.6	3.1	4.0
11	1.9 ± 1.7	0.78	0.94	1.1	1.2	1.3	1.4	1.6	1.9	2.2	2.5	3.0	3.8
12	2.2 ± 2.0	0.72	0.92	1.1	1.2	1.4	1.5	1.8	2.2	2.6	3.1	3.8	5.2

TABLE NO. 5

PROJECT NO. 90831

ESTIMATED PARTICLE SIZE (um)

GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE

STUDY WEEK	MMAD	± GSD	% SIZE BY MASS 5	10	15	20	25	30	40	50	60	70	80	90
13	2.1	± 2.0	0.64	0.82	0.98	1.1	1.3	1.4	1.7	2.1	2.5	3.0	3.8	5.2
14	2.2	± 2.1 *	0.66*	0.85*	1.04*	1.2*	1.4 *	1.5 *	1.8 *	2.2 *	2.7 *	3.3 *	4.1 *	5.6 *
	(2.0	± 2.1)	(0.64)	(0.82)	(0.98)	(1.1)	(1.3)	(1.4)	(1.7)	(2.1)	(2.5)	(3.0)	(3.7)	(5.2)
	(2.3	± 2.1)	(0.68)	(0.88)	(1.1)	(1.2)	(1.4)	(1.6)	(1.9)	(2.3)	(2.8)	(3.5)	(4.4)	(6.0)
MEAN +	2.0	± 1.9	0.72	0.90	1.07	1.2	1.3	1.4	1.7	2.0	2.4	2.9	3.5	4.7
S.D.	0.18	± 0.17	0.102	0.110	0.121	0.12	0.13	0.15	0.16	0.19	0.23	0.28	0.39	0.60
MEAN ++	2.0	1.9	0.72	0.90	1.06	1.2	1.3	1.4	1.7	2.1	2.4	2.9	3.5	4.7
S.D.	0.19	0.18	0.104	0.111	0.120	0.12	0.13	0.15	0.16	0.20	0.24	0.31	0.42	0.65

\+ Overall mean for males (Week 1 to 13)
++ Overall mean for females (Week 2 to 14)
* Mean of samples taken during the same week.

NOTE: Males were treated from Day 1 to 89 and females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 5

PROJECT NO. 90831

ESTIMATED PARTICLE SIZE (um)

GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY WEEK	MMAD ± GSD	% SIZE BY MASS 5	10	15	20	25	30	40	50	60	70	80	90
1	2.2 ± 1.8	0.80	1.0	1.2	1.3	1.5	1.6	1.9	2.2	2.6	3.0	3.6	3.7
2	2.0 ± 2.2 *	0.58*	0.76*	0.94*	1.06*	1.2 *	1.4 *	1.7 *	2.0 *	2.4 *	3.0 *	3.8 *	5.3 *
	(1.8 ± 2.4)	(0.46)	(0.62)	(0.78)	(0.92)	(1.0)	(1.2)	(1.5)	(1.9)	(2.3)	(2.9)	(3.9)	(5.6)
	(2.1 ± 1.9)	(0.70)	(0.90)	(1.1)	(1.2)	(1.3)	(1.5)	(1.8)	(2.1)	(2.5)	(3.0)	(3.7)	(4.9)
3	2.1 ± 1.8	0.80	1.0	1.2	1.3	1.5	1.6	1.8	2.1	2.5	2.9	3.5	4.5
4	2.3 ± 1.8	0.88	1.1	1.3	1.4	1.6	1.7	2.0	2.3	2.7	3.1	3.8	4.9
5	2.4 ± 1.8	0.88	1.1	1.3	1.4	1.6	1.7	2.0	2.4	2.7	3.2	3.9	5.0
6	2.2 ± 1.8	0.82	1.0	1.2	1.3	1.5	1.6	1.9	2.2	2.5	3.0	3.6	4.7
7	2.3 ± 1.8	0.80	1.0	1.2	1.3	1.5	1.6	1.9	2.2	2.6	3.1	3.8	5.0
8	2.3 ± 1.8	0.88	1.1	1.3	1.4	1.6	1.7	2.0	2.3	2.7	3.2	3.8	4.9
9	2.0 ± 1.9	0.74	0.92	1.1	1.2	1.3	1.5	1.7	2.0	2.4	2.8	3.4	4.5
10	2.3 ± 1.8 *	0.80*	0.99*	1.2 *	1.3 *	1.5 *	1.6 *	2.0 *	2.3 *	2.7 *	3.2 *	3.9 *	5.0 *
	(2.2 ± 1.9)	(0.68)	(0.88)	(1.1)	(1.2)	(1.4)	(1.5)	(1.9)	(2.2)	(2.7)	(3.3)	(4.2)	(5.6)
	(2.3 ± 1.7)	(0.92)	(1.1)	(1.3)	(1.4)	(1.6)	(1.7)	(2.0)	(2.3)	(2.6)	(3.0)	(3.5)	(4.4)
11	2.0 ± 1.9	0.74	0.92	1.1	1.2	1.3	1.5	1.7	2.0	2.3	2.8	3.3	4.3
12	2.3 ± 1.6	1.1	1.3	1.5	1.6	1.7	1.9	2.0	2.3	2.6	2.9	3.4	4.3

TABLE NO. 5

PROJECT NO. 90831

ESTIMATED PARTICLE SIZE (um)

GROUP 4 - CERIC OXIDE - HIGH DOSE

STUDY WEEK	MMAD ± GSD	% SIZE BY MASS 5	10	15	20	25	30	40	50	60	70	80	90
13	2.5 ± 1.7	0.96	1.2	1.4	1.5	1.7	1.8	2.2	2.5	2.9	3.4	4.0	5.2
14	2.4 ± 1.9	0.78	1.00	1.2	1.3	1.5	1.7	2.0	2.4	2.8	3.4	4.2	5.5
MEAN +	2.2 ± 1.8	0.83	1.03	1.23	1.33	1.5	1.6	1.9	2.2	2.6	3.0	3.7	4.7
S.D.	0.16 ± 0.14	0.122	0.135	0.141	0.138	0.15	0.13	0.15	0.16	0.16	0.18	0.22	0.44
MEAN ++	2.2 ± 1.8	0.83	1.03	1.23	1.33	1.5	1.6	1.9	2.2	2.6	3.1	3.7	4.9
S.D.	0.17 ± 0.14	0.123	0.135	0.141	0.138	0.15	0.13	0.15	0.17	0.17	0.20	0.27	0.38

\+ Overall mean for males (Week 1 to 13)
++ Overall mean for females (Week 2 to 14)
* Mean of samples taken during the same week.

NOTE: Males were treated from Day 1 to 89 and females were treated from Day 8 to 96 due to staggered start.

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 1 PRE/POST RX/RX	2 PRE/POST RX/RX	3 PRE/POST RX/RX	4 PRE/POST RX/RX	5 PRE/POST RX/RX	8 PRE/POST RX/RX	9 PRE/POST RX/RX	10 PRE/POST RX/RX	11 PRE/POST RX/RX	12 PRE/POST RX/RX
Cranial Staining	1	0/1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/1	0/0
	2	0/0	0/1	0/0	0/0	0/0	0/0	0/0	0/1	0/0	0/0
	3	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	4	0/1	0/0	0/0	0/0	0/1	0/1	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/3	0/5	0/0	0/1	0/0	0/2	0/5	0/4	0/3	0/3
	2	0/7	0/5	0/0	0/5	0/6	0/1	1/0	0/6	1/6	0/4
	3	0/1	0/1	0/0	1/0	0/4	0/0	0/1	0/2	1/5	0/4
	4	0/0	0/1	0/0	0/0	0/3	0/1	3/0	0/3	1/6	1/1
Periorbital Staining	1	0/7	0/7	0/2	0/4	0/2	0/7	0/2	0/1	0/2	0/0
	2	0/4	0/4	0/1	0/3	0/2	0/3	0/1	0/1	0/2	0/2
	3	0/4	0/5	0/0	0/1	0/2	0/2	0/0	0/2	0/4	0/1
	4	0/4	0/6	0/2	0/3	0/4	0/5	0/0	0/1	0/0	0/1

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 15 PRE/POST RX/RX	16 PRE/POST RX/RX	17 PRE/POST RX/RX	18 PRE/POST RX/RX	19 PRE/POST RX/RX	22 PRE/POST RX/RX	23 PRE/POST RX/RX	24 PRE/POST RX/RX	25 PRE/POST RX/RX	26 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	2	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	3	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	4	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/1	0/1	0/9	0/0	0/1	0/2	0/1	0/6	0/7	0/1
	2	0/2	0/5	0/7	1/5	0/1	0/3	0/1	0/4	0/5	0/4
	3	0/1	0/7	0/8	0/6	0/2	0/0	0/3	0/4	0/4	0/1
	4	0/1	0/0	0/7	0/2	0/0	0/1	0/3	0/4	0/3	0/2
Periorbital Staining	1	0/1	0/2	0/2	1/1	0/0	0/3	0/2	0/0	0/0	0/0
	2	0/0	0/0	0/2	0/0	0/0	0/3	0/0	0/2	0/2	0/0
	3	0/0	0/0	0/1	0/0	0/0	0/1	0/1	1/2	0/2	0/1
	4	0/4	0/0	0/1	0/0	0/1	0/3	0/1	0/1	0/0	0/2

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 29 PRE/POST RX/RX	30 PRE/POST RX/RX	31 PRE/POST RX/RX	32 PRE/POST RX/RX	33 PRE/POST RX/RX	36 PRE/POST RX/RX	37 PRE/POST RX/RX	38 PRE/POST RX/RX	39 PRE/POST RX/RX	40 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/1	0/0	0/0	0/0	0/0	0/0	0/0
	2	0/0	0/0	0/0	0/0	0/0	0/0	1/1	0/0	0/0	0/2
	3	0/0	0/0	0/0	0/0	0/0	0/0	4/0	0/0	0/1	0/2
	4	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/1	0/3
Muzzle Staining	1	0/2	0/1	0/6	0/7	0/4	0/3	2/0	0/1	0/1	0/5
	2	0/3	0/4	0/7	0/7	0/5	0/4	1/1	0/2	0/3	0/4
	3	0/6	0/7	0/1	0/0	0/7	0/1	4/1	0/2	0/3	0/5
	4	0/0	0/4	0/3	0/6	0/2	0/2	0/3	0/1	0/3	0/4
Periorbital Staining	1	0/1	0/2	0/3	0/2	0/2	0/2	0/0	0/0	0/1	0/1
	2	0/1	0/2	0/2	0/3	0/0	0/0	0/1	0/1	0/2	0/2
	3	1/1	0/1	0/0	1/1	0/1	0/1	1/0	0/0	0/0	0/1
	4	0/1	0/1	0/0	0/2	0/1	0/3	0/2	0/1	0/3	0/2

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 43 PRE/POST RX/RX	44 PRE/POST RX/RX	45 PRE/POST RX/RX	46 PRE/POST RX/RX	47 PRE/POST RX/RX	50 PRE/POST RX/RX	51 PRE/POST RX/RX	52 PRE/POST RX/RX	53 PRE/POST RX/RX	54 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/1	0/0
	2	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	3	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	4	0/0	0/0	0/1	0/2	0/0	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/1	0/0	0/5	1/1	0/0	0/1	0/5	0/2	0/5	0/1
	2	0/3	0/1	0/3	0/3	0/0	0/0	0/5	0/1	0/0	0/4
	3	0/1	0/1	0/4	1/4	0/0	0/0	0/2	0/2	0/5	0/2
	4	0/0	0/1	2/6	1/7	0/0	0/2	0/6	0/1	0/4	0/1
Periorbital Staining	1	0/1	0/2	0/1	0/0	0/0	0/1	0/2	0/5	0/6	0/2
	2	0/0	0/1	0/0	0/0	0/0	0/1	0/1	0/0	0/0	0/2
	3	0/1	0/1	0/1	0/1	0/1	0/0	0/1	0/0	0/1	0/2
	4	0/4	0/1	0/2	0/3	0/1	0/0	0/3	0/1	0/2	0/3

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 57 PRE/POST RX/RX	58 PRE/POST RX/RX	59 PRE/POST RX/RX	60 PRE/POST RX/RX	61 PRE/POST RX/RX	64 PRE/POST RX/RX	65 PRE/POST RX/RX	66 PRE/POST RX/RX	67 PRE/POST RX/RX	68 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/1	0/0	0/0	0/2	0/0	0/0
	2	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/4	0/0	0/0
	3	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/2	0/0	0/0
	4	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/5	0/5	0/5	0/6	0/7	0/1	0/7	0/2	0/0	0/0
	2	0/5	0/5	0/8	0/8	0/1	0/4	0/9	0/2	0/1	0/0
	3	0/6	0/5	0/4	0/8	0/2	0/1	0/9	0/4	0/2	0/0
	4	0/6	0/3	0/4	0/3	0/1	0/2	0/5	0/3	0/0	0/1
Periorbital Staining	1	0/0	0/1	0/1	0/2	0/2	0/1	0/3	0/2	0/1	0/1
	2	0/1	0/2	0/0	0/1	0/0	0/0	0/2	0/0	0/0	0/0
	3	0/1	0/0	0/1	0/1	0/2	0/1	0/2	0/0	0/2	0/1
	4	0/2	0/4	0/3	0/1	0/3	0/1	0/2	0/6	0/2	0/1

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 71 PRE/POST RX/RX	72 PRE/POST RX/RX	73 PRE/POST RX/RX	74 PRE/POST RX/RX	75 PRE/POST RX/RX	78 PRE/POST RX/RX	79 PRE/POST RX/RX	80 PRE/POST RX/RX	81 PRE/POST RX/RX	82 PRE/POST RX/RX
Cranial Staining	1	0/0	0/1	0/0	0/0	0/2	0/0	0/1	0/0	0/0	0/0
	2	0/0	0/0	0/0	0/0	0/1	0/2	0/1	0/0	0/0	0/0
	3	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	4	0/0	0/1	0/0	0/0	0/2	0/2	0/2	0/0	0/0	0/0
Muzzle Staining	1	0/3	0/2	0/0	0/0	0/6	0/2	0/3	0/1	0/0	0/0
	2	0/3	0/3	0/0	0/3	0/8	0/1	0/5	0/0	0/3	0/2
	3	0/2	0/1	0/5	0/1	0/6	0/1	0/5	0/0	0/0	0/0
	4	0/1	0/3	0/2	0/0	0/8	0/5	0/8	0/0	0/2	0/1
Periorbital Staining	1	0/1	0/1	0/0	0/2	0/1	0/1	0/1	0/1	0/2	0/1
	2	0/0	0/0	0/1	0/2	0/0	0/3	1/2	1/2	1/1	1/2
	3	0/0	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/1	0/2
	4	0/2	0/2	0/2	0/2	0/1	0/1	0/3	0/0	0/2	0/1

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

MALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 85 PRE/POST RX/RX	86 PRE/POST RX/RX	87 PRE/POST RX/RX	88 PRE/POST RX/RX	89 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/0
	2	0/0	0/0	0/1	0/0	0/0
	3	0/0	0/0	0/0	0/0	0/0
	4	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/3	0/3	0/2	0/0	0/0
	2	0/7	0/9	0/10	0/0	0/0
	3	0/4	0/3	0/5	0/0	0/0
	4	0/4	0/0	0/5	0/1	0/1
Periorbital Staining	1	0/1	0/0	0/2	0/1	0/1
	2	0/1	0/5	0/3	1/3	1/2
	3	0/1	0/1	0/1	0/0	0/0
	4	0/1	0/1	0/1	0/2	0/1

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 1 PRE/POST RX/RX	2 PRE/POST RX/RX	3 PRE/POST RX/RX	4 PRE/POST RX/RX	5 PRE/POST RX/RX	8 PRE/POST RX/RX	9 PRE/POST RX/RX	10 PRE/POST RX/RX	11 PRE/POST RX/RX	12 PRE/POST RX/RX
Cranial Staining	1	0/0	0/1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	2	0/3	0/1	0/2	0/2	0/1	0/0	0/0	0/0	0/0	0/0
	3	0/1	0/1	0/1	0/1	0/1	0/1	0/0	0/0	0/1	0/0
	4	0/0	0/0	0/1	0/0	0/1	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/5	0/4	0/1	0/1	0/1	0/0	1/0	0/1	1/2	0/3
	2	0/3	0/0	0/0	0/2	0/3	0/0	0/0	0/3	0/1	0/3
	3	0/1	0/1	0/0	0/1	1/3	0/0	0/1	0/2	0/1	0/5
	4	0/2	0/0	0/2	0/2	0/4	0/0	0/0	0/6	1/0	0/3
Periorbital Staining	1	0/1	0/1	0/0	0/1	0/2	0/0	0/0	0/0	0/0	0/0
	2	0/1	0/4	0/3	0/2	0/8	0/1	0/1	0/1	0/5	0/3
	3	0/5	0/6	0/4	0/5	0/7	0/2	0/1	0/2	0/5	0/2
	4	0/3	0/2	0/3	0/5	0/5	0/0	0/0	0/2	0/0	0/2

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 15 PRE/POST RX/RX	16 PRE/POST RX/RX	17 PRE/POST RX/RX	18 PRE/POST RX/RX	19 PRE/POST RX/RX	22 PRE/POST RX/RX	23 PRE/POST RX/RX	24 PRE/POST RX/RX	25 PRE/POST RX/RX	26 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	2	0/1	0/0	0/0	0/1	0/1	0/0	0/0	0/1	0/0	0/2
	3	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
	4	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/3	0/3	0/2	0/3	0/3	0/4	0/5	0/0	0/3	0/1
	2	0/0	0/0	0/1	0/2	0/4	0/8	0/2	0/2	0/2	0/2
	3	0/3	0/1	0/4	0/0	0/1	0/5	0/7	0/1	0/5	0/0
	4	0/1	0/0	0/2	0/0	0/0	0/1	0/5	0/0	0/1	0/2
Periorbital Staining	1	1/1	0/1	0/1	0/1	0/3	0/1	1/1	1/0	1/1	0/4
	2	0/3	0/0	0/4	0/4	0/6	0/4	0/2	0/0	0/2	0/4
	3	1/3	0/2	0/3	0/3	0/2	1/3	1/4	1/2	0/1	0/4
	4	0/2	0/1	0/1	0/2	0/2	0/3	0/3	0/0	0/2	0/3

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 29 PRE/POST RX/RX	30 PRE/POST RX/RX	31 PRE/POST RX/RX	32 PRE/POST RX/RX	33 PRE/POST RX/RX	36 PRE/POST RX/RX	37 PRE/POST RX/RX	38 PRE/POST RX/RX	39 PRE/POST RX/RX	40 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/0	0/1	0/0
	2	0/0	0/1	0/3	0/0	0/0	0/3	0/0	0/1	1/4	0/0
	3	0/1	0/0	0/1	0/0	0/0	0/1	0/0	0/0	0/2	0/0
	4	0/0	0/0	0/0	0/0	0/0	0/1	0/0	0/0	0/1	0/0
Muzzle Staining	1	0/1	0/2	0/1	0/2	0/1	0/2	0/1	0/4	2/3	0/0
	2	0/1	0/0	0/0	0/0	0/1	0/1	0/0	0/2	2/3	0/0
	3	0/1	0/4	0/1	0/1	0/7	0/2	0/1	3/2	0/2	0/0
	4	0/3	0/0	0/1	0/0	0/4	0/2	0/0	1/2	0/1	0/0
Periorbital Staining	1	1/1	1/2	1/0	1/2	0/1	1/3	1/1	1/1	0/0	1/2
	2	0/2	0/5	0/2	0/1	0/1	0/2	0/0	0/1	0/2	0/0
	3	0/3	0/3	0/2	0/0	0/2	0/3	0/0	0/1	0/3	0/0
	4	0/2	0/5	0/4	0/0	0/1	0/1	0/0	0/3	0/3	0/3

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 43 PRE/POST RX/RX	44 PRE/POST RX/RX	45 PRE/POST RX/RX	46 PRE/POST RX/RX	47 PRE/POST RX/RX	50 PRE/POST RX/RX	51 PRE/POST RX/RX	52 PRE/POST RX/RX	53 PRE/POST RX/RX	54 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/0	0/0	0/2	0/2	0/0	0/0	0/2
	2	0/3	0/1	0/1	0/1	0/3	0/1	0/2	0/3	0/4	0/1
	3	0/0	0/1	0/0	0/0	0/0	0/2	0/2	0/2	0/1	0/2
	4	0/0	0/0	0/0	0/0	0/0	0/1	0/0	0/1	0/1	0/1
Muzzle Staining	1	1/0	0/4	0/3	0/0	0/7	0/5	0/6	0/2	0/3	0/4
	2	0/2	0/9	0/3	0/0	0/2	0/4	0/6	0/2	0/3	0/3
	3	0/1	0/4	0/5	0/4	0/5	0/4	0/2	0/7	0/8	0/7
	4	0/0	0/5	0/4	0/6	0/3	0/3	0/2	0/3	0/4	0/2
Periorbital Staining	1	1/1	0/2	0/2	0/4	0/1	1/4	1/8	1/2	1/4	0/3
	2	0/2	0/2	0/2	0/2	0/3	0/5	0/6	0/7	0/6	0/5
	3	0/0	0/3	0/2	0/4	0/3	1/4	1/7	1/5	1/5	0/5
	4	0/1	0/3	0/2	0/1	0/3	0/3	0/5	0/4	0/4	0/3

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 57 PRE/POST RX/RX	58 PRE/POST RX/RX	59 PRE/POST RX/RX	60 PRE/POST RX/RX	61 PRE/POST RX/RX	64 PRE/POST RX/RX	65 PRE/POST RX/RX	66 PRE/POST RX/RX	67 PRE/POST RX/RX	68 PRE/POST RX/RX
Cranial Staining	1	0/1	0/0	0/1	0/3	0/3	0/4	0/0	0/0	0/2	0/2
	2	0/2	0/2	0/4	0/4	0/6	0/1	0/0	0/2	0/3	0/2
	3	0/2	0/0	0/0	0/2	0/5	0/4	0/0	0/0	0/4	0/2
	4	0/1	0/0	0/0	0/0	0/0	0/1	0/2	0/0	0/0	0/4
Muzzle Staining	1	0/3	0/0	0/0	0/1	0/2	0/2	0/0	0/0	0/0	0/3
	2	0/3	0/0	0/0	0/2	0/3	0/3	0/0	0/1	0/4	0/6
	3	0/4	0/0	0/3	0/3	0/4	0/4	0/5	0/0	0/6	0/0
	4	0/0	0/0	0/2	0/0	0/1	0/0	0/3	0/0	0/0	0/7
Periorbital Staining	1	1/2	0/2	1/3	0/3	0/4	1/2	1/1	1/2	0/3	1/3
	2	0/5	0/2	0/6	0/7	0/7	0/3	0/1	0/2	0/4	0/3
	3	0/3	0/2	0/2	0/4	0/5	0/4	0/1	0/2	0/0	0/6
	4	0/1	0/2	0/2	0/2	0/3	0/3	0/1	0/1	0/3	0/2

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 71 PRE/POST RX/RX	72 PRE/POST RX/RX	73 PRE/POST RX/RX	74 PRE/POST RX/RX	75 PRE/POST RX/RX	78 PRE/POST RX/RX	79 PRE/POST RX/RX	80 PRE/POST RX/RX	81 PRE/POST RX/RX	82 PRE/POST RX/RX
Cranial Staining	1	0/0	0/1	0/0	0/0	0/0	0/0	0/0	0/2	0/0	0/0
	2	0/0	0/6	0/0	0/8	0/4	0/0	0/0	0/0	0/3	0/0
	3	0/0	0/1	0/0	0/3	0/1	0/0	0/0	0/3	0/2	0/0
	4	0/0	0/1	0/0	0/0	0/0	0/0	0/0	0/0	0/1	0/0
Muzzle Staining	1	0/0	0/10	0/0	0/6	0/0	0/1	0/0	0/2	0/4	0/4
	2	0/0	0/10	0/0	0/9	0/2	0/0	0/0	0/3	0/3	0/4
	3	0/0	0/0	0/0	0/5	0/1	0/0	0/0	0/3	0/5	0/4
	4	0/0	0/2	0/0	0/8	0/0	0/0	0/0	0/1	0/0	0/0
Periorbital Staining	1	0/2	1/3	1/4	1/2	1/3	0/3	0/4	0/4	1/7	1/3
	2	0/3	0/3	0/0	0/5	0/5	0/3	0/3	0/8	0/9	0/3
	3	0/2	0/2	0/0	0/1	0/1	0/2	0/1	0/7	0/5	0/1
	4	0/1	0/2	0/0	0/3	0/3	0/0	0/0	0/2	0/3	0/1

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO. 6

SUMMARY OF RECURRING CLINICAL SIGNS

PROJECT NO. 90831

FEMALES

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE - LOW DOSE
GROUP 3 - CERIC OXIDE - INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE - HIGH DOSE

OBSERVATION	GROUP NO.	STUDY DAY 85 PRE/POST RX/RX	86 PRE/POST RX/RX	87 PRE/POST RX/RX	88 PRE/POST RX/RX	89 PRE/POST RX/RX
Cranial Staining	1	0/0	0/0	0/0	0/1	0/0
	2	3/7	0/1	0/1	0/1	0/2
	3	0/4	0/1	0/0	0/0	0/1
	4	0/0	0/0	0/0	0/0	0/0
Muzzle Staining	1	0/0	0/4	0/3	0/0	0/0
	2	0/5	0/2	0/1	0/1	0/0
	3	0/0	0/2	0/3	0/6	0/4
	4	0/1	0/0	0/2	0/2	0/0
Periorbital Staining	1	1/3	1/3	1/2	1/3	1/1
	2	0/6	0/5	0/2	0/1	0/4
	3	0/4	0/4	0/1	0/3	0/2
	4	0/3	0/0	0/0	0/1	0/1

PRE RX : Pretreatment examination
POST RX : Post treatment examination

TABLE NO.: 7
PROJECT NO.: 90831

BODY WEIGHTS (G) - SUMMARY OF MEANS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX	MALES			
GROUP	1	2	3	4
DAY -6	187.6	187.2	187.1	187.8
DAY -2	225.3	222.7	225.7	223.6
DAY 1	236.3	233.5	237.5	234.0
DAY 8	281.6	278.2	282.4	274.5
DAY 15	328.9	323.2	327.0	313.7
DAY 22	358.8	354.3	357.4	344.7
DAY 27	380.3	374.0	380.2	364.1
DAY 29	391.1	384.9	389.3	372.4
DAY 36	418.9	411.0	417.8	399.6
DAY 43	428.5	423.3	425.9	409.2
DAY 50	450.6	443.2	448.9	429.8
DAY 55	460.7	455.1	458.3	433.3
DAY 57	472.4	466.7	470.1	448.6
DAY 64	494.0	485.4	492.0	466.8
DAY 71	504.6	500.8	503.1	479.7
DAY 78	515.3	503.7	513.9	487.9
DAY 85	523.9	515.8	525.5	497.0
DAY 90	519.0	511.4	524.5	496.2
DAY 91	510.0	503.4	515.1	487.9

TABLE NO.: 7
PROJECT NO.: 90831

BODY WEIGHTS (G) - SUMMARY OF MEANS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX	FEMALES			
GROUP	1	2	3	4
DAY-13	110.0	110.4	109.7	110.8
DAY -7	138.5	141.1	137.0	140.3
DAY -3	153.0	157.6	153.1	153.4
DAY 1	160.6	164.2	158.5	158.9
DAY 8	181.1	189.4	182.5	184.4
DAY 15	196.3	202.5	196.3	198.4
DAY 22	211.8	221.4	212.8	215.4
DAY 27	218.4	227.7	216.8	221.1
DAY 29	221.6	232.1	224.7	222.4
DAY 36	232.1	239.7	230.2	234.7
DAY 43	232.6	242.8	237.4	234.7
DAY 50	246.1	249.4	248.5	248.3
DAY 55	250.6	251.6	249.2	247.0
DAY 57	252.8	257.6	255.3	249.5
DAY 64	255.0	263.3	256.6	253.2
DAY 71	264.1	264.2	258.7	254.9
DAY 78	265.1	267.7	260.1	258.5
DAY 85	267.7	268.7	265.5	259.2
DAY 90	267.4	270.6	264.9	260.4
DAY 91	260.1	261.6	256.5	252.3

TABLE NO.: 8

PROJECT NO.: 90831

BODY WEIGHT GAINS (G) - SUMMARY OF MEANS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX	MALES			
GROUP	1	2	3	4
-6- -2	37.6	35.5	38.6	35.8
-2- 1	11.0	10.8	11.8	10.4
1- 8	45.4	44.7	44.9	40.5
8- 15	47.3	45.0	44.6	39.2 B
15- 22	29.9	31.1	30.4	30.9
22- 27	21.6	19.8	22.8	19.4
27- 29	10.8	10.9	9.1	8.3
29- 36	27.9	26.1	28.5	27.1
36- 43	9.6	12.3	8.1	9.6
43- 50	22.1	19.9	23.0	20.7
50- 55	10.0	11.9	9.3	3.5 B
55- 57	11.7	11.6	11.8	15.2
57- 64	21.6	18.7	21.9	18.2
64- 71	10.7	15.5	11.1	12.9
71- 78	10.6	2.8	10.8	7.7
78- 85	8.7	12.1	11.6	9.1
85- 90	-5.0	-4.4	-1.0	-.8
90- 91	-9.0	-8.0	-9.4	-8.4

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO.: 8 BODY WEIGHT GAINS (G) - SUMMARY OF MEANS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX	FEMALES			
GROUP	1	2	3	4
-13- -7	28.5	30.7	27.4	29.5
-7- -3	14.5	16.5	16.1	13.1
-3- 1	7.6	6.6	5.4	5.4
1- 8	20.5	25.2	24.0	25.5
8- 15	15.3	13.1	13.8	14.0
15- 22	15.5	18.9	16.6	17.0
22- 27	6.6	6.3	4.0	5.7
27- 29	3.2	4.4	7.9	1.3
29- 36	10.5	7.6	5.4	12.3
36- 43	.5	3.0	7.2	.0
43- 50	13.4	6.6 A	11.1	13.6
50- 55	4.6	2.2	.7	-1.3
55- 57	2.2	5.9	6.1	2.6
57- 64	2.2	5.8	1.2	3.7
64- 71	9.1	.9 B	2.2 A	1.7 B
71- 78	1.0	3.6	1.4	3.6
78- 85	2.6	.9	5.4	.8
85- 90	-.2	1.9	-.6	1.2
90- 91	-7.3	-9.0	-8.5	-8.1

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 B - P<.01 (DUNNETT'S)

TABLE NO.: 9 FOOD CONSUMPTION (GRAMS/ANIMAL), SUMMARY OF MEANS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX	MALES			
GROUP	1	2	3	4
1- 8	180.1	177.9	181.5	175.8
8- 15	191.1	189.3	190.3	177.6
15- 22	199.1	196.2	197.4	185.9
22- 29	200.5	194.2	200.8	190.6
29- 36	205.8	200.3	202.6	191.4
36- 43	181.7	178.4	181.5	174.9
43- 50	206.2	203.0	205.1	192.7
50- 57	215.3	212.9	213.2	196.9
57- 64	207.2	219.4	213.1	198.0
64- 71	209.4	210.9	213.7	200.7
71- 78	203.1	197.0	203.0	195.6
78- 85	199.7	203.5	207.7	197.5
85- 91	162.2	165.0	174.3	165.7

TABLE NO.: 9 FOOD CONSUMPTION (GRAMS/ANIMAL), SUMMARY OF MEANS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX	FEMALES			
GROUP	1	2	3	4
-7- 1	120.4	123.8	117.1	121.3
1- 8	123.5	130.8	120.5	123.5
8- 15	129.4	135.5	125.6	127.2
15- 22	130.8	139.3	129.8	131.7
22- 29	131.5	140.1	130.6	125.9
29- 36	134.6	139.9	129.7	134.5
36- 43	121.9	128.9	119.8	122.1
43- 50	148.5	146.7	144.4	149.4
50- 57	139.2	142.7	133.2	134.5
57- 64	136.4	144.5	133.9	134.8
64- 71	133.1	134.7	127.8	128.7
71- 78	133.5	135.7	128.9	133.0
78- 85	135.0	135.3	130.7	128.7
85- 91	112.6	114.5	109.6	110.5

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	4	26.7	5	33.3	6	40.0	5	33.3
	5	Sitting/standing	11	73.3	10	66.7	9	60.0	10	66.7
	6	Rearing	0	0.0	3	20.0	0	0.0	0	0.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	15	100.0	14	93.3	15	100.0	15	100.0
	2	Easy	0	0.0	1	6.7	0	0.0	0	0.0
VOCALIZATION	MEAN		0.3		0.1		0.2		0.1	
	S.D.		0.6		0.4		0.6		0.3	
ARENA										
REARING	MEAN		6.3		7.8		7.1		7.4	
	S.D.		1.7		2.7		3.0		2.5	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
LOCOMOTOR ACTIVITY LEVEL	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
AROUSAL	5	Normal	15	100.0	15	100.0	14	93.3	15	100.0
	6	Moderately increased	0	0.0	0	0.0	1	6.7	0	0.0
GROOMING	0	None	12	80.0	10	66.7	12	80.0	13	86.7
	2	Slight	3	20.0	5	33.3	3	20.0	2	13.3
DEFECATION	MEAN		2.7		1.9		1.8		1.7	
	S.D.		1.6		2.4		1.7		1.7	
URINATION	0	None	2	13.3	7	46.7	9	60.0	7	46.7
	2	Slight	13	86.7	8	53.3	6	40.0	8	53.3
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON SURFACE										
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	3	20.0	1	6.7	4	26.7	3	20.0
	5	Sitting/standing	12	80.0	14	93.3	11	73.3	12	80.0
	6	Rearing	2	13.3	3	20.0	4	26.7	4	26.7
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
REMOVAL FROM HOME CAGE EASE OF REMOVAL	0	Very easy	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
VOCALIZATION	MEAN		0.3		0.2		0.0		0.0	
	S.D.		1.0		0.8		0.0		0.0	
ARENA										
REARING	MEAN		10.9		11.7		12.6		11.3	
	S.D.		3.6		3.5		2.5		4.1	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
ARENA BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
LOCOMOTOR ACTIVITY LEVEL	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
AROUSAL	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
GROOMING	0	None	12	80.0	13	86.7	14	93.3	15	100.0
	2	Slight	3	20.0	2	13.3	1	6.7	0	0.0
DEFECATION	MEAN		0.1		0.2		0.3		0.1	
	S.D.		0.5		0.8		0.7		0.5	
URINATION	0	None	12	80.0	8	53.3	10	66.7	9	60.0
	2	Slight	3	20.0	7	46.7	5	33.3	6	40.0
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - PRESTUDY
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON SURFACE										
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	5	33.3	3	20.0	5	33.3	3	20.0
	5	Sitting/standing	10	66.7	12	80.0	10	66.7	12	80.0
	6	Rearing	0	0.0	1	6.7	3	20.0	3	20.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	15	100.0	15	100.0	15	100.0	14	93.3
	2	Easy	0	0.0	0	0.0	0	0.0	1	6.7
VOCALIZATION	MEAN		0.4		0.3		0.4		0.3	
	S.D.		1.1		0.6		1.1		1.0	
ARENA REARING	MEAN		7.1		9.0		7.7		6.7	
	S.D.		3.3		4.0		3.4		3.2	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON SURFACE										
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
COMMENT		Post treatment staining	5	33.3	1	6.7	2	13.3	1	6.7

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	5	33.3	3	20.0	3	20.0	5	33.3
	4	Moderate movement	10	66.7	11	73.3	11	73.3	10	66.7
	6	Vigorous movement	0	0.0	1	6.7	1	6.7	0	0.0
AROUSAL	4	Moderately decreased	2	13.3	1	6.7	2	13.3	4	26.7
	5	Normal	13	86.7	14	93.3	13	86.7	11	73.3
GROOMING	0	None	10	66.7	9	60.0	12	80.0	11	73.3
	2	Slight	5	33.3	6	40.0	3	20.0	3	20.0
	4	Moderate	0	0.0	0	0.0	0	0.0	1	6.7
DEFECATION	MEAN		2.1		0.9		1.5		1.3	
	S.D.		1.8		1.6		2.0		1.6	
URINATION	0	None	8	53.3	12	80.0	12	80.0	14	93.3
	2	Slight	7	46.7	3	20.0	3	20.0	1	6.7

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
	C	Chromodacryorrhea	5	33.3	2	13.3	2	13.3	2	13.3
	D	Deposit around eye(s)	5	33.3	2	13.3	2	13.3	2	13.3
PUPIL SIZE	0	Pinhead (Normal)	13	86.7	15	100.0	15	100.0	13	86.7
	4	Moderately dilated	2	13.3	0	0.0	0	0.0	2	13.3
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	14	93.3	14	93.3	15	100.0
	4	Present	0	0.0	1	6.7	1	6.7	0	0.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE										
BODY POSITION	4	Lying on side or curled up	5	33.3	5	33.3	3	20.0	2	13.3
	5	Sitting/standing	10	66.7	10	66.7	11	73.3	13	86.7
	6	Rearing	4	26.7	2	13.3	3	20.0	5	33.3
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	14	93.3	13	86.7	15	100.0	14	93.3
	2	Easy	1	6.7	2	13.3	0	0.0	1	6.7
VOCALIZATION	MEAN		0.5		0.3		0.6		0.1	
	S.D.		1.1		0.5		1.4		0.3	
ARENA										
REARING	MEAN		11.6		9.9		11.5		12.3	
	S.D.		4.4		3.7		5.7		3.1	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	0	0.0	1	6.7	2	13.3	0	0.0
	4	Moderate movement	12	80.0	13	86.7	10	66.7	13	86.7
	6	Vigorous movement	3	20.0	1	6.7	3	20.0	2	13.3
AROUSAL	4	Moderately decreased	0	0.0	1	6.7	1	13.3	0	0.0
	5	Normal	12	80.0	10	66.7	11	73.3	13	86.7
	6	Moderately increased	3	20.0	4	26.7	3	20.0	2	13.3
GROOMING	0	None	13	86.7	14	93.3	15	100.0	15	100.0
	2	Slight	2	13.3	1	6.7	0	0.0	0	0.0
DEFECATION	MEAN		0.5		0.1		0.1		0.0	
	S.D.		1.5		0.5		0.5		0.0	
URINATION	0	None	13	86.7	9	60.0	9	60.0	11	73.3
	2	Slight	2	13.3	6	40.0	6	40.0	4	26.7

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - DAY 1
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	14	93.3	15	100.0
	2	Slight delay	0	0.0	0	0.0	1	6.7	0	0.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
COMMENT		Rat dropped her pelvic area 7 to 8 times during arena observations	0	0.0	1	6.7	0	0.0	0	0.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	3	20.0	6	40.0	2	13.3	0	0.0
	5	Sitting/standing	12	80.0	9	60.0	13	86.7	15	100.0
	6	Rearing	1	6.7	1	6.7	1	6.7	1	6.7
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	15	100.0	15	100.0	12	80.0	15	100.0
	2	Easy	0	0.0	0	0.0	3	20.0	0	0.0
VOCALIZATION	MEAN		0.3		0.0		0.3		0.0	
	S.D.		1.0		0.0		0.7		0.0	
ARENA										
REARING	MEAN		4.2		4.6		5.1		5.2	
	S.D.		3.2		3.7		4.4		2.6	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	8	53.3	9	60.0	7	46.7	6	40.0
	4	Moderate movement	7	46.7	6	40.0	8	53.3	9	60.0
AROUSAL	2	Severely decreased	0	0.0	1	6.7	0	0.0	0	0.0
	4	Moderately decreased	2	13.3	2	13.3	3	20.0	0	0.0
	5	Normal	13	86.7	11	73.3	11	73.3	15	100.0
	6	Moderately increased	0	0.0	1	6.7	1	6.7	0	0.0
GROOMING	0	None	12	80.0	14	93.3	15	100.0	13	86.7
	2	Slight	3	20.0	1	6.7	0	0.0	2	13.3
DEFECATION	MEAN		1.6		0.7		0.7		0.7	
	S.D.		1.5		1.2		1.2		1.1	
URINATION	0	None	10	66.7	12	80.0	11	73.3	10	66.7
	2	Slight	5	33.3	3	20.0	4	26.7	5	33.3

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
	C	Chromodacryorrhea	0	0.0	0	0.0	1	6.7	0	0.0
	D	Deposit around eye(s)	0	0.0	0	0.0	1	6.7	0	0.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	0	0.0	2	13.3	2	13.3	1	6.7
	5	Sitting/standing	15	100.0	13	86.7	13	86.7	14	93.3
	6	Rearing	13	86.7	10	66.7	8	53.3	12	80.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	14	93.3	15	100.0	15	100.0	15	100.0
	6	Difficult	1	6.7	0	0.0	0	0.0	0	0.0
VOCALIZATION	MEAN		0.0		0.1		0.3		0.0	
	S.D.		0.0		0.5		0.7		0.0	
ARENA										
REARING	MEAN		11.7		8.8		10.1		11.3	
	S.D.		4.9		4.6		5.8		5.5	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	0	0.0	2	13.3	1	6.7	1	6.7
	4	Moderate movement	15	100.0	13	86.7	13	86.7	12	80.0
	6	Vigorous movement	0	0.0	0	0.0	1	6.7	2	13.3
AROUSAL	4	Moderately decreased	0	0.0	0	0.0	1	6.7	1	6.7
	5	Normal	8	53.3	11	73.3	9	60.0	8	53.3
	6	Moderately increased	7	46.7	4	26.7	5	33.3	6	40.0
GROOMING	0	None	14	93.3	14	93.3	11	73.3	14	93.3
	2	Slight	1	6.7	1	6.7	4	26.7	1	6.7
DEFECATION	MEAN		0.0		0.6		0.2		0.2	
	S.D.		0.0		1.2		0.8		0.8	
URINATION	0	None	14	93.3	8	53.3	12	80.0	13	86.7
	2	Slight	1	6.7	7	46.7	3	20.0	2	13.3

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OLFACTORY RESPONSE	0	Orients towards	14	93.3	15	100.0	15	100.0	15	100.0
	2	Does not orient towards	1	6.7	0	0.0	0	0.0	0	0.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
	C	Chromodacryorrhea	1	6.7	1	6.7	0	0.0	0	0.0
	D	Deposit around eye(s)	1	6.7	1	6.7	0	0.0	0	0.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 4
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	0	0.0	2	13.3	2	13.3	2	13.3
	5	Sitting/standing	15	100.0	13	86.7	13	86.7	13	86.7
	6	Rearing	2	13.3	2	13.3	2	13.3	3	20.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	10	66.7	14	93.3	14	93.3	13	86.7
	2	Easy	4	26.7	1	6.7	1	6.7	2	13.3
	6	Difficult	1	6.7	0	0.0	0	0.0	0	0.0
VOCALIZATION	MEAN		0.6		0.1		0.3		0.0	
	S.D.		1.2		0.4		1.0		0.0	
ARENA										
REARING	MEAN		3.5		4.5		4.7		4.3	
	S.D.		2.8		3.1		3.6		3.6	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	14	93.3
	4	1/2 closed	0	0.0	0	0.0	0	0.0	1	6.7
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	6	40.0	4	26.7	3	20.0	6	40.0
	4	Moderate movement	9	60.0	11	73.3	11	73.3	9	60.0
	6	Vigorous movement	0	0.0	0	0.0	1	6.7	0	0.0
AROUSAL	4	Moderately decreased	2	13.3	1	6.7	1	6.7	1	6.7
	5	Normal	13	86.7	14	93.3	11	73.3	12	80.0
	6	Moderately increased	0	0.0	0	0.0	3	20.0	2	13.3
GROOMING	0	None	12	80.0	13	86.7	15	100.0	13	86.7
	2	Slight	3	20.0	2	13.3	0	0.0	2	13.3
DEFECATION	MEAN		1.0		0.5		0.9		0.3	
	S.D.		1.6		1.4		1.8		1.0	

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE.

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
URINATION	0	None	11	73.3	13	86.7	13	86.7	12	80.0
	2	Slight	4	26.7	2	13.3	2	13.3	3	20.0
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
BODY TONE	5	Normal	15	100.0	15	100.0	14	93.3	15	100.0
	8	Resilient	0	0.0	0	0.0	1	6.7	0	0.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	14	93.3	15	100.0
	8	Resilient	0	0.0	0	0.0	1	6.7	0	0.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE										
BODY POSITION	4	Lying on side or curled up	3	20.0	2	13.3	0	0.0	1	6.7
	5	Sitting/standing	12	80.0	12	80.0	15	100.0	14	93.3
	6	Rearing	8	53.3	6	40.0	7	46.7	8	53.3
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	15	100.0	15	100.0	15	100.0	15	100.0
VOCALIZATION	MEAN		0.0		0.1		0.0		0.1	
	S.D.		0.0		0.3		0.0		0.4	
ARENA										
REARING	MEAN		10.7		10.3		9.4		13.2	
	S.D.		5.9		5.7		4.6		4.3	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	0	0.0	1	6.7	1	6.7	0	0.0
	4	Moderate movement	12	80.0	13	86.7	13	86.7	13	86.7
	6	Vigorous movement	3	20.0	1	6.7	1	6.7	2	13.3
AROUSAL	4	Moderately decreased	0	0.0	1	6.7	1	6.7	0	0.0
	5	Normal	9	60.0	8	53.3	9	60.0	9	60.0
	6	Moderately increased	6	40.0	6	40.0	5	33.3	6	40.0
GROOMING	0	None	12	80.0	13	86.7	11	73.3	14	93.3
	2	Slight	3	20.0	2	13.3	4	26.7	1	6.7
DEFECATION	MEAN		0.0		0.3		0.1		0.1	
	S.D.		0.0		1.0		0.3		0.3	
URINATION	0	None	13	86.7	11	73.3	13	86.7	14	93.3
	2	Slight	2	13.3	4	26.7	2	13.3	1	6.7

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
ARENA										
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 8
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	14	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	3	20.0	2	13.3	3	20.0	2	14.3
	5	Sitting/standing	12	80.0	13	86.7	12	80.0	12	85.7
	6	Rearing	0	0.0	4	26.7	4	26.7	1	7.1
TREMORS	0	None	15	100.0	15	100.0	15	100.0	14	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	14	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	14	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	14	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	14	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	13	86.7	13	86.7	13	86.7	13	92.9
	2	Easy	2	13.3	2	13.3	2	13.3	1	7.1
VOCALIZATION	MEAN		0.6		0.0 a		0.3		0.0 a	
	S.D.		1.4		0.0		1.3		0.0	
ARENA										
REARING	MEAN		1.7		2.5		3.4		2.7	
	S.D.		1.8		3.8		4.0		3.5	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	14	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	14	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	14	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: a $P < 0.05$ (WILCOXON'S)

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	14	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	14	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	14	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	14	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	14	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	14	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	14	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	14	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	14	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	14	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA LOCOMOTOR ACTIVITY LEVEL	0	None, resting	1	6.7	0	0.0	0	0.0	0	0.0
	2	Slight movement	6	40.0	6	40.0	6	40.0	8	57.1
	4	Moderate movement	8	53.3	8	53.3	8	53.3	6	42.9
	6	Vigorous movement	0	0.0	1	6.7	1	6.7	0	0.0
AROUSAL	4	Moderately decreased	1	6.7	3	20.0	2	13.3	1	7.1
	5	Normal	14	93.3	11	73.3	11	73.3	12	85.7
	6	Moderately increased	0	0.0	1	6.7	2	13.3	1	7.1
GROOMING	0	None	15	100.0	13	86.7	15	100.0	13	92.9
	2	Slight	0	0.0	2	13.3	0	0.0	1	7.1
DEFECATION	MEAN		1.1		0.9		1.3		0.4	
	S.D.		1.5		1.3		1.7		0.9	

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	14	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
URINATION	0	None	13	86.7	13	86.7	12	80.0	11	78.6
	2	Slight	2	13.3	2	13.3	3	20.0	3	21.4
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	14	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	14	100.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	14	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	14	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	14	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	14	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

PROJECT NO. 90831

NUMBER OF ANIMALS EXAMINED			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
CATEGORY	SCORE	DESCRIPTION	NO. 15	% 100.0	NO. 15	% 100.0	NO. 15	% 100.0	NO. 14	% 100.0
HANDLING										
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	14	100.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	14	100.0
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	14	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	14	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	14	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	14	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	14	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	14	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
MALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	14	100.0
CATEGORY	SCORE	DESCRIPTION								
ON TOP OF BOX										
POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	14	100.0
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	14	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	14	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HOME CAGE BODY POSITION	4	Lying on side or curled up	2	13.3	4	26.7	1	6.7	0	0.0
	5	Sitting/standing	13	86.7	11	73.3	14	93.3	15	100.0
	6	Rearing	11	73.3	8	53.3	7	46.7	12	80.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
REMOVAL FROM HOME CAGE										
EASE OF REMOVAL	0	Very easy	15	100.0	15	100.0	14	93.3	15	100.0
	2		0	0.0	0	0.0	1	6.7	0	0.0
VOCALIZATION	MEAN		0.0		0.2		0.1		0.0	
	S.D.		0.0		0.4		0.3		0.0	
ARENA										
REARING	MEAN		9.2		9.3		8.2		10.3	
	S.D.		5.9		5.3		5.5		3.9	
ATAXIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
HYPOTONIC GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
IMPAIRED GAIT	0	None	15	100.0	15	100.0	15	100.0	15	100.0
OVERALL GAIT INCAPACITY	0	None	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
ARENA										
BIZARRE/STEREOTYPIC BEHAVIOR	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PALPEBRAL CLOSURE	0	Eyes wide open	15	100.0	15	100.0	15	100.0	15	100.0
TREMORS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
TWITCHES	0	None	15	100.0	15	100.0	15	100.0	15	100.0
CONVULSIONS	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PILOERECTION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
RESPIRATORY RATE/PATTERN	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
			NO.	%	NO.	%	NO.	%	NO.	%
NUMBER OF ANIMALS EXAMINED			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ARENA										
LOCOMOTOR ACTIVITY LEVEL	2	Slight movement	2	13.3	0	0.0	2	13.3	0	0.0
	4	Moderate movement	12	80.0	14	93.3	12	80.0	12	80.0
	6	Vigorous movement	1	6.7	1	6.7	1	6.7	3	20.0
AROUSAL	4	Moderately decreased	0	0.0	0	0.0	1	6.7	0	0.0
	5	Normal	9	60.0	12	80.0	9	60.0	10	66.7
	6	Moderately increased	6	40.0	3	20.0	5	33.3	5	33.3
GROOMING	0	None	13	86.7	13	86.7	14	93.3	13	86.7
	2	Slight	2	13.3	2	13.3	1	6.7	2	13.3
DEFECATION	MEAN		0.0		0.1		0.0		0.0	
	S.D.		0.0		0.5		0.0		0.0	
URINATION	0	None	10	66.7	5	33.3	10	66.7	9	60.0
	2	Slight	5	33.3	10	66.7	5	33.3	6	40.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
CATEGORY	SCORE	DESCRIPTION	15	100.0	15	100.0	15	100.0	15	100.0
ARENA										
OLFACTORY RESPONSE	0	Orients towards	15	100.0	15	100.0	15	100.0	15	100.0
HANDLING										
LACRIMATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
PUPIL SIZE	0	Pinhead (Normal)	15	100.0	15	100.0	15	100.0	15	100.0
SALIVATION	0	None	15	100.0	15	100.0	15	100.0	15	100.0
URINARY STAINING	0	None	15	100.0	15	100.0	15	100.0	15	100.0
DIARRHEA	0	None	15	100.0	15	100.0	15	100.0	15	100.0
BODY TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ABDOMINAL TONE	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
HANDLING										
EXTENSOR THRUST	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0
CORNEAL REFLEX	4	Active single or double blink	15	100.0	15	100.0	15	100.0	15	100.0
PINNA REFLEX	4	Moderate brisk flick	15	100.0	15	100.0	15	100.0	15	100.0
TOE PINCH	4	Moderate withdrawal	15	100.0	15	100.0	15	100.0	15	100.0
TAIL PINCH	4	Moderate movement	15	100.0	15	100.0	15	100.0	15	100.0
VISUAL PLACING	5	Normal	15	100.0	15	100.0	15	100.0	15	100.0
ON TOP OF BOX POSITIONAL PASSIVITY	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
GROUP SUMMARY - WEEK 13
FEMALES

PROJECT NO. 90831

			GROUP 1 AIR CONTROL		GROUP 2 CERIC OXIDE LOW DOSE		GROUP 3 CERIC OXIDE INTERMEDIATE DOSE		GROUP 4 CERIC OXIDE HIGH DOSE	
NUMBER OF ANIMALS EXAMINED			NO.	%	NO.	%	NO.	%	NO.	%
			15	100.0	15	100.0	15	100.0	15	100.0
CATEGORY	SCORE	DESCRIPTION								
ON SURFACE										
AURICULAR STARTLE	4	Normal	15	100.0	15	100.0	15	100.0	15	100.0
AIR RIGHTING REFLEX	0	Normal	15	100.0	15	100.0	15	100.0	15	100.0

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

PRE-STUDY
MALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	793.0 102.03	433.3 104.00	7.8 1.72
GROUP 2 - CERIC OXIDE LOW DOSE	781.0 153.60	416.7 117.92	8.0 1.73
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	796.7 99.21	418.0 106.93	8.4 1.51
GROUP 4 - CERIC OXIDE HIGH DOSE	774.3 147.19	399.3 56.34	7.7 1.33

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

PRE-STUDY
FEMALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	670.7 117.61	386.3 92.78	7.8 1.14
GROUP 2 - CERIC OXIDE LOW DOSE	719.7 112.76	403.3 86.82	8.3 1.14
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	725.3 117.54	378.7 75.86	7.1 1.37
GROUP 4 - CERIC OXIDE HIGH DOSE	718.0 105.56	379.7 88.61	7.0 1.45

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

DAY 1
MALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	781.0 137.22	471.3 119.19	6.8 1.83
GROUP 2 - CERIC OXIDE LOW DOSE	785.3 128.47	491.0 123.10	6.5 1.52
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	807.7 129.34	453.7 102.08	7.2 1.31
GROUP 4 - CERIC OXIDE HIGH DOSE	753.0 137.28	461.3 102.44	6.7 1.46

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

PROJECT NO :90831

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

DAY 1
FEMALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	746.7 150.97	448.3 66.05	7.5 1.36
GROUP 2 - CERIC OXIDE LOW DOSE	774.3 111.61	438.7 81.16	6.9 .86
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	676.7 160.82	423.0 64.61	6.1 1.94
GROUP 4 - CERIC OXIDE HIGH DOSE	752.0 154.62	442.0 73.94	6.4 1.80

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

WEEK 4
MALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 -- AIR CONTROL	823.7 195.03	563.7 121.29	7.1 1.52
GROUP 2 - CERIC OXIDE LOW DOSE	751.0 115.92	577.3 106.32	7.4 1.96
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	809.7 201.55	574.3 145.01	8.0 1.82
GROUP 4 - CERIC OXIDE HIGH DOSE	764.7 147.29	595.7 142.04	7.6 2.27

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

WEEK 4
FEMALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	730.7 118.83	529.7 89.79	7.5 1.43
GROUP 2 - CERIC OXIDE LOW DOSE	734.7 115.77	477.7 66.25	7.5 1.34
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	709.3 135.51	455.0 125.47	7.4 1.80
GROUP 4 - CERIC OXIDE HIGH DOSE	742.3 139.67	448.3 91.92	7.0 1.49

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

WEEK 8
MALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	811.3 210.03	622.7 158.99	7.4 2.40
GROUP 2 - CERIC OXIDE LOW DOSE	717.0 195.73	606.7 105.20	8.1 2.04
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	733.3 156.71	645.0 155.37	8.2 1.53
GROUP 4 - CERIC OXIDE HIGH DOSE	696.3 190.44	663.7 124.49	7.6 1.97

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

WEEK 8
FEMALES

PROJECT NO :90831

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	806.7 150.93	586.7 112.72	7.6 1.42
GROUP 2 - CERIC OXIDE LOW DOSE	822.3 116.34	561.7 105.11	6.9 1.75
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	741.0 160.45	558.0 105.73	6.7 1.76
GROUP 4 - CERIC OXIDE HIGH DOSE	745.3 176.99	530.0 100.11	6.9 1.58

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

WEEK 13
MALES

PROJECT NO :90831

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	803.7 177.91	702.3 140.38	7.3 2.00
GROUP 2 - CERIC OXIDE LOW DOSE	849.3 138.38	734.7 90.88	7.6 1.65
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	808.0 156.07	713.7 165.11	7.7 2.00
GROUP 4 - CERIC OXIDE HIGH DOSE	815.7 179.75	707.9 181.40	7.6 1.87

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10

GROUP MEAN (S.D.) GRIP STRENGTH (G)
AND HINDLIMB SPLAY (CM)

PROJECT NO :90831

WEEK 13
FEMALES

	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	797.3 151.87	669.0 122.87	7.5 1.63
GROUP 2 - CERIC OXIDE LOW DOSE	840.0 122.88	659.3 128.45	7.4 1.27
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	774.3 122.98	610.3 103.88	7.1 2.28
GROUP 4 - CERIC OXIDE HIGH DOSE	660.7 A 162.58	602.0 124.30	7.1 2.23

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P <.05 (DUNNETT'S)

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (° C) PROJECT NO :90831

PRE-STUDY
MALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	37.6 .35
GROUP 2 - CERIC OXIDE LOW DOSE	37.7 .30
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	37.5 .35
GROUP 4 - CERIC OXIDE HIGH DOSE	37.6 .40

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

PRE-STUDY
FEMALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	37.9 .53
GROUP 2 - CERIC OXIDE LOW DOSE	37.8 .57
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	37.8 .32
GROUP 4 - CERIC OXIDE HIGH DOSE	37.8 .55

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

DAY 1
MALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	37.9 .32
GROUP 2 - CERIC OXIDE LOW DOSE	38.0 .44
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	37.8 .37
GROUP 4 - CERIC OXIDE HIGH DOSE	38.1 .33

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

DAY 1
FEMALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	38.1 .33
GROUP 2 - CERIC OXIDE LOW DOSE	38.0 .45
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	38.1 .40
GROUP 4 - CERIC OXIDE HIGH DOSE	38.1 .39

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 4
MALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	37.6 .47
GROUP 2 - CERIC OXIDE LOW DOSE	37.7 .51
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	38.0 .60
GROUP 4 - CERIC OXIDE HIGH DOSE	37.7 .46

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 4
FEMALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	38.4 .53
GROUP 2 - CERIC OXIDE LOW DOSE	38.2 .60
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	38.2 .39
GROUP 4 - CERIC OXIDE HIGH DOSE	38.4 .60

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 8
MALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	37.4 .58
GROUP 2 - CERIC OXIDE LOW DOSE	37.7 .59
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	37.7 .82
GROUP 4 - CERIC OXIDE HIGH DOSE	37.4 .45

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 8
FEMALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	38.2 .42
GROUP 2 - CERIC OXIDE LOW DOSE	38.2 .60
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	38.4 .51
GROUP 4 - CERIC OXIDE HIGH DOSE	38.3 .69

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
MALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	37.5 .59
GROUP 2 - CERIC OXIDE LOW DOSE	37.9 .58
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	37.6 .64
GROUP 4 - CERIC OXIDE HIGH DOSE	37.4 .36

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 10 GROUP MEAN (S.D.) BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
FEMALES

	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	38.3 .50
GROUP 2 - CERIC OXIDE LOW DOSE	38.1 .57
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	38.3 .71
GROUP 4 - CERIC OXIDE HIGH DOSE	38.4 .54

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS

MALES
PRE STUDY

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	104.5	111.0	110.4	104.7
	S.D.	34.90	31.94	19.95	22.50
	N	15	15	15	15
2	MEAN	72.1	81.5	83.9	76.8
	S.D.	29.57	30.43	22.16	25.38
	N	15	15	15	15
3	MEAN	51.1	38.5	58.5	41.7
	S.D.	36.44	38.13	35.30	36.45
	N	15	15	15	15
4	MEAN	20.3	16.7	22.0	20.1
	S.D.	30.38	25.06	23.62	30.99
	N	15	15	15	15
5	MEAN	11.5	2.0	11.3	14.3
	S.D.	23.21	4.16	21.19	27.85
	N	15	15	15	15
6	MEAN	1.8	5.9	3.9	8.0
	S.D.	3.86	16.49	8.94	21.62
	N	15	15	15	15
TOTAL	MEAN	261.3	255.5	289.9	265.6
	S.D.	128.48	117.82	88.59	135.33
	N	15	15	15	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	134.1	128.5	134.9	136.3
	S.D.	27.11	17.88	21.48	34.02
	N	15	15	14	15
2	MEAN	104.2	93.1	108.3	110.3
	S.D.	28.21	28.00	19.47	21.20
	N	15	15	14	15
3	MEAN	71.3	69.9	79.2	95.3
	S.D.	30.95	42.88	22.46	37.32
	N	15	15	14	15
4	MEAN	52.7	47.9	57.4	64.1
	S.D.	29.06	35.32	30.61	38.64
	N	15	15	14	15
5	MEAN	23.8	33.5	20.6	56.9
	S.D.	34.21	42.22	24.46	36.59
	N	15	15	14	15
6	MEAN	17.9	19.1	13.1	38.1
	S.D.	34.68	27.21	24.44	39.55
	N	15	15	14	15
TOTAL	MEAN	404.0	392.1	413.6	501.1
	S.D.	137.79	153.33	97.90	129.29
	N	15	15	14	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
MALES
WEEK 4

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	104.8	133.5	130.6	118.1
	S.D.	16.00	25.45	22.77	25.39
	N	15	15	15	15
2	MEAN	64.2	79.9	84.3	85.3
	S.D.	21.38	22.99	22.86	22.59
	N	15	15	15	15
3	MEAN	48.2	49.0	49.8	47.7
	S.D.	31.98	34.43	22.69	21.35
	N	15	15	15	15
4	MEAN	31.1	23.5	26.8	25.4
	S.D.	23.16	20.98	26.39	22.40
	N	15	15	15	15
5	MEAN	23.4	13.2	17.7	10.9
	S.D.	22.85	18.54	24.42	14.92
	N	15	15	15	15
6	MEAN	13.8	8.0	19.7	10.6
	S.D.	17.87	11.27	28.42	15.76
	N	15	15	15	15
TOTAL	MEAN	285.5	307.1 c	328.9 a	298.0 b
	S.D.	104.01	97.65	114.14	83.85
	N	15	15	15	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: a - P <.05 b - P <.01 c - P <.001 (T-TEST), LCV
SIGNIFICANT DOSE LEVEL CONTRASTS: NONE
LCV = Linear Constructed Variable

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	150.3	154.1	136.3	153.5
	S.D.	20.71	20.48	19.45	22.72
	N	15	15	15	15
2	MEAN	99.1	97.6	97.5	113.4
	S.D.	34.78	32.86	31.58	16.97
	N	15	15	15	15
3	MEAN	62.7	56.7	59.9	70.5
	S.D.	35.68	36.13	30.17	34.36
	N	15	15	15	15
4	MEAN	39.2	33.5	36.7	36.7
	S.D.	46.35	23.49	33.11	35.53
	N	15	15	15	15
5	MEAN	31.3	20.9	12.9	20.3
	S.D.	38.79	20.70	18.30	30.37
	N	15	15	15	15
6	MEAN	26.7	2.3	3.9	32.4
	S.D.	41.00	4.28	12.30	34.23
	N	15	15	15	15
TOTAL	MEAN	409.3	365.0 a	347.3	426.8
	S.D.	178.12	90.67	92.78	106.35
	N	15	15	15	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: a - P<.05 (T-TEST), LCV
SIGNIFICANT DOSE LEVELS CONTRASTS: NONE
LCV = Linear Constructed Variable

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
MALES
WEEK 8

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	108.3	120.1	107.8	128.8
	S.D.	25.22	21.72	33.21	27.69
	N	15	15	15	15
2	MEAN	74.4	80.6	71.0	75.7
	S.D.	24.45	18.48	28.81	20.05
	N	15	15	15	15
3	MEAN	47.2	50.1	57.7	46.1
	S.D.	18.50	30.78	28.94	20.61
	N	15	15	15	15
4	MEAN	26.7	39.0	31.4	30.9
	S.D.	20.48	25.36	14.73	19.15
	N	15	15	15	15
5	MEAN	8.1	27.5	17.9	13.3
	S.D.	11.58	25.31	18.43	19.22
	N	15	15	15	15
6	MEAN	15.7	10.9	16.7	10.1
	S.D.	17.87	10.94	22.67	13.43
	N	15	15	15	15
TOTAL	MEAN	280.4	328.2	302.5	304.9
	S.D.	78.17	85.01	104.29	80.26
	N	15	15	15	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	152.1	163.0	148.6	167.6
	S.D.	22.09	23.54	26.92	27.09
	N	15	15	15	15
2	MEAN	88.2	107.3	99.3	116.6
	S.D.	35.43	31.34	40.24	29.01
	N	15	15	15	15
3	MEAN	50.0	62.5	54.1	58.0
	S.D.	38.16	33.77	39.00	38.00
	N	15	15	15	15
4	MEAN	24.7	22.9	19.0	20.4
	S.D.	35.30	26.36	18.41	22.85
	N	15	15	15	15
5	MEAN	29.3	19.8	35.9	31.1
	S.D.	38.35	25.86	33.22	31.86
	N	15	15	15	15
6	MEAN	23.9	11.3	23.3	12.7
	S.D.	32.90	22.50	35.85	22.68
	N	15	15	15	15
TOTAL	MEAN	368.2	386.9 a	380.2	406.4 b
	S.D.	160.97	96.47	126.94	99.63
	N	15	15	15	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: a - P <.05 b - P <.01 (T-TEST), LCV
SIGNIFICANT DOSE LEVEL CONTRASTS: P <.05, Linear, LCV
LCV = Linear Constructed Variable

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
MALES
WEEK 13

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	96.0	110.7	113.9	108.1
	S.D.	28.83	28.80	22.75	25.29
	N	15	15	15	14
2	MEAN	63.7	64.5	60.6	74.1
	S.D.	33.08	27.10	20.42	19.96
	N	15	15	15	14
3	MEAN	32.3	35.4	35.9	43.9
	S.D.	21.35	23.31	25.39	19.68
	N	15	15	15	14
4	MEAN	15.6	19.0	17.8	24.3
	S.D.	11.10	18.60	19.18	17.24
	N	15	15	15	14
5	MEAN	17.1	14.6	24.9	16.6
	S.D.	18.83	20.81	23.41	16.96
	N	15	15	15	14
6	MEAN	8.8	10.7	17.3	12.0
	S.D.	15.30	12.19	19.75	14.07
	N	15	15	15	14
TOTAL	MEAN	233.4	254.9	270.4	279.0
	S.D.	86.23	83.40	95.99	55.27
	N	15	15	15	14

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: NONE

TABLE NO. 11

GROUP MEAN
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13

PROJECT NO.:90831

INTERVAL		GROUP 1 AIR CONTROL	GROUP 2 CERIC OXIDE LOW DOSE	GROUP 3 CERIC OXIDE MID DOSE	GROUP 4 CERIC OXIDE HIGH DOSE
1	MEAN	144.9	160.2	151.8	163.7
	S.D.	36.22	23.72	24.76	36.31
	N	15	15	15	15
2	MEAN	85.1	99.1	95.9	105.1
	S.D.	40.87	36.18	26.56	22.94
	N	15	15	15	15
3	MEAN	51.9	55.9	53.2	58.5
	S.D.	39.49	36.66	34.05	42.24
	N	15	15	15	15
4	MEAN	32.7	38.5	29.3	40.6
	S.D.	29.68	36.15	28.38	39.01
	N	15	15	15	15
5	MEAN	25.1	16.7	18.3	27.3
	S.D.	34.29	24.75	20.20	32.56
	N	15	15	15	15
6	MEAN	23.5	21.2	29.3	23.4
	S.D.	31.29	32.85	29.66	31.74
	N	15	15	15	15
TOTAL	MEAN	363.2	391.7 a	377.9	418.5 a
	S.D.	152.45	146.14	119.01	141.30
	N	15	15	15	15

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: a - P<.05 (T-TEST), LCV
SIGNIFICANT DOSE LEVEL CONTRASTS: NONE
LCV = Linear Constructed Variable

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - MALES

		WBC DIFFERENTIAL COUNT					
	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 5 - HEALTH SCREEN	5.8 1.87	17.2 6.75	0.0 0.00	81.4 6.65	.8 .79	.6 .70	0.0 0.00

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

HEALTH SCREEN - MALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT (ABSOLUTE)					
	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
GROUP 5 - HEALTH SCREEN	931.9	0.0	4741.3	41.5	35.3	0.0
	341.59	0.00	1814.56	41.33	43.41	0.00

TABLE NO. 12 GROUP MEAN (S.D.) HEMOGRAMS PROJECT NO :90831

HEALTH SCREEN - MALES

	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 5 - HEALTH SCREEN	6.12	12.7	36.9	60.3	20.8	34.5	13.4
	.231	.40	.81	1.47	.50	.74	.67

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - MALES

	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 5 - HEALTH SCREEN	969.6 88.46	8.3 .39	14.1 .38

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - FEMALES

		WBC DIFFERENTIAL COUNT					
	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 5 - HEALTH SCREEN	4.8	5.3	0.0	94.2	.3	.2	0.0
	1.97	2.54	0.00	2.30	.95	.42	0.00

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

HEALTH SCREEN - FEMALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT (ABSOLUTE)					
	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
GROUP 5 - HEALTH SCREEN	238.5 95.74	0.0 0.00	4554.9 1872.45	29.4 92.97	7.2 15.18	0.0 0.00

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - FEMALES

	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 5 - HEALTH SCREEN	5.28 .291	11.5 .44	33.2 1.49	63.0 2.53	21.8 .99	34.6 .43	15.6 1.30

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - FEMALES

	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 5 - HEALTH SCREEN	1012.6	8.4	13.8
	98.24	.33	.81

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 6 - MALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT						
	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	12.0 3.66	11.3 7.50	0.0 0.00	85.4 8.26	2.4 1.18	.9 2.05	0.0 0.00
GROUP 2 - CERIC OXI.E LOW DOSE	11.7 2.82	12.5 5.85	0.0 0.00	84.6 6.49	2.0 1.08	.9 1.19	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	14.6 2.08	17.7 5.57	0.0 0.00	79.0 5.66	2.8 1.92	.6 .73	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	13.9 4.35	22.8 B 6.76	0.0 0.00	73.7 B 6.93	2.8 1.81	.7 .95	0.0 0.00

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 6 - MALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT (ABSOLUTE)					
	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	1509.1 1697.34	0.0 0.00	10057.3 2454.69	298.3 179.70	122.0 299.36	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	1440.1 720.16	0.0 0.00	9891.2 2601.67	243.5 149.40	102.2 136.48	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	2560.3 881.45	0.0 0.00	11477.5 1944.38	429.4 268.07	82.9 124.52	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	3088.4 B 1162.05	0.0 0.00	10295.6 3669.81	386.5 300.38	109.5 175.05	0.0 0.00

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 6 - MALES

	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	7.76 .726	15.8 .47	42.3 3.92	54.5 1.65	20.5 2.29	37.6 4.24	12.6 .53
GROUP 2 - CERIC OXIDE LOW DOSE	7.87 .265	15.7 .83	43.3 2.14	54.9 1.66	20.0 .69	36.4 .94	12.3 .50
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	7.96 .242	15.8 .30	43.6 1.26	54.7 1.47	19.9 .66	36.4 .74	12.3 .42
GROUP 4 - CERIC OXIDE HIGH DOSE	7.88 .275	15.9 .34	43.4 1.10	55.1 1.74	20.2 .67	36.7 .43	12.5 .57

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 6 - MALES

	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	899.8 69.71	8.9 .47	14.4 .72
GROUP 2 - CERIC OXIDE LOW DOSE	913.3 111.39	9.1 .57	14.2 .79
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	870.8 72.13	9.0 .65	14.5 .70
GROUP 4 - CERIC OXIDE HIGH DOSE	834.6 144.93	8.9 .35	14.1 .85

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 6 - FEMALES

PROJECT NO :90831

	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	9.7 2.32	7.8 5.74	0.0 0.00	90.8 5.95	.8 .83	.7 1.00	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	9.0 2.54	13.0 6.32	0.0 0.00	84.5 6.72	1.7 1.60	.8 .60	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	10.0 1.72	17.0 B 6.41	0.0 0.00	80.1 B 7.51	2.0 1.41	.9 .83	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	10.5 3.82	13.3 4.31	0.0 0.00	84.9 4.46	1.1 1.00	.7 .89	0.0 0.00

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 6 - FEMALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT (ABSOLUTE)					
	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	723.9 493.52	0.0 0.00	8791.4 2355.39	65.6 66.68	74.7 119.35	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	1230.3 764.58	0.0 0.00	7537.3 2067.98	174.2 157.33	66.6 56.73	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	1679.6 A 650.53	0.0 0.00	8083.3 1737.40	194.6 146.15	92.5 87.74	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	1327.5 562.45	0.0 0.00	8915.7 3677.95	124.8 104.06	86.5 103.72	0.0 0.00

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	7.56 .342	14.7 1.58	41.3 1.75	54.7 2.21	19.5 2.29	35.6 3.27	11.7 .30
GROUP 2 - CERIC OXIDE LOW DOSE	7.58 .293	15.0 2.07	41.9 1.69	55.3 .87	19.8 2.38	35.8 4.30	11.7 .49
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	7.52 .270	15.2 .77	41.1 1.90	54.6 .85	20.2 .35	36.9 .39	11.6 .45
GROUP 4 - CERIC OXIDE HIGH DOSE	7.66 .368	15.4 .54	41.6 1.73	54.4 1.45	20.1 .67	37.0 .57	11.8 .45

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	824.8 230.02	9.0 .63	14.1 .55
GROUP 2 - CERIC OXIDE LOW DOSE	801.6 276.76	8.7 .37	13.9 .90
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	850.0 150.47	8.9 .40	14.2 .71
GROUP 4 - CERIC OXIDE HIGH DOSE	937.6 140.25	8.9 .52	14.2 .63

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 13 - MALES

PROJECT NO :90831

	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
				WBC DIFFERENTIAL COUNT			
GROUP 1 - AIR CONTROL	8.1 2.30	18.4 6.38	0.0 0.00	77.5 8.66	3.4 2.87	.7 1.03	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	8.2 1.66	20.1 6.91	.1 .26	76.1 7.87	2.8 2.11	1.0 .93	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	11.8 B 3.05	25.4 10.85	0.0 0.00	70.7 11.03	2.5 2.17	1.4 1.18	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	8.2 2.21	33.2B 9.45	0.0 0.00	62.7 B 11.00	3.1 2.96	.9 1.38	0.0 0.00

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 13 - MALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT (ABSOLUTE)					
	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	1541.1 908.78	0.0 0.00	6243.2 1574.71	267.5 197.31	61.5 93.81	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	1637.9 622.48	4.8 18.59	6253.5 1520.90	225.9 178.82	84.6 83.00	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	2844.1 B 1038.42	0.0 0.00	8480.7 A 3009.45	300.0 283.79	175.2 A 172.88	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	2698.0 B 1100.89	0.0 0.00	5238.2 1909.60	233.3 240.39	73.4 97.91	0.0 0.00

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 B - P<.01 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 13 - MALES

	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	8.42 .401	15.4 .61	43.4 2.26	51.5 1.50	18.3 .69	35.5 .90	12.6 .58
GROUP 2 - CERIC OXIDE LOW DOSE	8.41 .366	15.4 .53	43.8 1.90	52.1 1.48	18.3 .55	35.2 .76	12.4 .53
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	8.42 .360	15.5 .43	43.7 1.39	51.9 1.41	18.4 .73	35.5 .84	12.6 .51
GROUP 4 - CERIC OXIDE HIGH DOSE	8.51 .449	15.8 .53	44.6 2.23	52.5 1.47	18.6 .75	35.5 1.02	12.4 .63

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 13 - MALES

	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	908.7 103.22	8.7 .54	15.3 1.62
GROUP 2 - CERIC OXIDE LOW DOSE	960.3 117.14	8.8 .63	15.0 .81
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	936.9 79.39	8.9 .36	14.8 .84
GROUP 4 - CERIC OXIDE HIGH DOSE	901.6 78.02	8.9 .42	15.2 .98

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 13 - FEMALES

		WBC DIFFERENTIAL COUNT					
	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	4.2 1.50	8.3 4.24	0.0 0.00	85.7 5.48	4.7 2.55	1.3 1.75	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	5.1 1.67	19.1 B 10.02	0.0 0.00	75.3 B 10.67	4.4 2.64	1.3 1.03	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	4.9 1.34	19.1 B 7.82	0.0 0.00	76.9 A 8.49	3.2 3.61	.8 .86	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	5.0 1.46	21.9 B 6.32	0.0 0.00	73.9 B 7.10	3.5 2.61	.6 .74	.1 .26

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 B - P<.01 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

WEEK 13 - FEMALES

PROJECT NO :90831

	WBC DIFFERENTIAL COUNT (ABSOLUTE)					
	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	324.9 161.95	0.0 0.00	3623.7 1364.64	211.5 144.61	46.5 58.34	0.0 0.00
GROUP 2 - CERIC OXIDE LOW DOSE	1005.7 C 796.79	0.0 0.00	3793.7 1199.72	233.0 193.96	60.9 55.04	0.0 0.00
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	899.3 C 414.04	0.0 0.00	3802.4 1228.29	169.0 218.51	36.0 44.47	0.0 0.00
GROUP 4 - CERIC OXIDE HIGH DOSE	1080.7 C 398.80	0.0 0.00	3722.3 1137.35	188.1 175.35	31.5 41.50	4.1 15.75

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: C - P<.05 (DUNN'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90831

WEEK 13 - FEMALES

	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	7.83 .454	14.8 .49	42.0 1.81	53.7 1.55	19.0 .75	35.3 .78	11.5 .44
GROUP 2 - CERIC OXIDE LOW DOSE	7.72 .238	14.8 .55	41.7 1.44	54.0 1.30	19.1 .38	35.4 .66	11.7 .47
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	7.95 .425	15.0 .71	42.6 1.91	53.6 1.68	18.9 .44	35.3 .68	11.5 .45
GROUP 4 - CERIC OXIDE HIGH DOSE	8.09 .374	15.4 A .51	43.3 1.89	53.5 1.26	19.1 .56	35.7 .69	11.9 .33

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 (DUNNETT'S)

TABLE NO. 12

GROUP MEAN (S.D.) HEMOGRAMS

PROJECT NO :90931

WEEK 13 - FEMALES

	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	999.5 124.95	8.4 .52	14.0 .50
GROUP 2 - CERIC OXIDE LOW DOSE	957.9 120.77	8.4 .45	14.1 .44
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	901.2 70.63	8.4 .44	14.1 .50
GROUP 4 - CERIC OXIDE HIGH DOSE	953.2 79.12	8.5 .37	13.8 .45

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - MALES

	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 5 - HEALTH SCREEN	11.4 1.67	.5 .07	117.0 13.81	.09 .022	137.0 32.77	44.2 6.84

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - MALES

	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 5 - HEALTH SCREEN	239.8 67.96	10.0 .30	9.49 .584	78.2 13.71	38.8 6.53	5.2 .17

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - MALES

	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 5 - HEALTH SCREEN	2.8 .11	1.18 .057	2.4 .10	145.3 1.06	4.22 .210	103.0 .94

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - FEMALES

	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 5 - HEALTH SCREEN	15.3 3.74	.6 .09	132.0 20.31	.11 .023	120.2 12.50	30.5 7.29

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 5 - HEALTH SCREEN	211.9 31.43	10.1 .17	10.22 .589	89.5 10.31	28.4 7.18	5.2 .17

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90931

HEALTH SCREEN - FEMALES

	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 5 - HEALTH SCREEN	2.9 .11	1.26 .053	2.3 .10	145.6 1.08	4.38 .445	106.4 .52

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	17.3 2.50	.9 .15	103.6 12.49	.13 .027	149.9 23.28	42.7 4.92
GROUP 2 - CERIC OXIDE LOW DOSE	19.3 3.40	.9 .21	95.0 15.48	.14 .018	157.8 18.37	46.8 5.12
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	16.9 2.31	.8 .12	112.3 11.76	.15 .031	164.6 25.71	46.0 9.21
GROUP 4 - CERIC OXIDE HIGH DOSE	17.8 2.20	.8 .15	108.6 12.19	.14 .027	148.3 24.70	46.8 9.30

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	136.8 27.42	8.9 .34	7.42 .628	62.7 14.62	61.1 20.08	6.7 .32
GROUP 2 - CERIC OXIDE LOW DOSE	157.1 36.39	9.0 .24	7.20 .717	61.1 12.56	61.1 29.59	6.8 .26
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	156.3 30.15	9.1 .29	7.59 .842	61.2 13.86	68.3 26.87	6.6 .22
GROUP 4 - CERIC OXIDE HIGH DOSE	167.9 32.68	9.1 .25	7.33 .640	62.9 11.07	69.0 20.02	6.7 .28

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	3.4 .13	1.01 .080	3.4 .27	147.9 1.49	4.95 .630	104.3 1.22
GROUP 2 - CERIC OXIDE LOW DOSE	3.4 .11	1.00 .052	3.4 .20	147.7 2.09	5.05 .548	104.9 2.64
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3.3 .08	1.01 .049	3.3 .18	145.3 B 1.94	5.49 .659	102.6 2.29
GROUP 4 - CERIC OXIDE HIGH DOSE	3.3 .09	.94 .184	3.5 .40	146.5 1.69	5.06 .479	104.1 2.33

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	21.3 3.31	.9 .18	94.9 14.25	.14 .021	162.7 32.59	38.7 7.91
GROUP 2 - CERIC OXIDE LOW DOSE	22.5 2.56	.9 .13	96.4 9.08	.13 .029	159.4 26.75	37.4 5.47
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	22.1 3.42	.9 .13	102.2 12.09	.13 .029	139.5 19.63	42.3 6.64
GROUP 4 - CERIC OXIDE HIGH DOSE	22.2 4.14	1.0 .12	115.0 31.21	.15 .025	136.0 A 25.12	41.3 6.66

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 (DUNNETT'S)

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	118.0 25.76	9.7 .23	6.71 .945	74.6 15.78	44.8 9.00	6.8 .33
GROUP 2 - CERIC OXIDE LOW DOSE	122.8 40.20	9.7 .32	6.17 .553	78.0 16.22	42.2 6.50	7.0 .32
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	112.3 31.37	9.7 .36	6.14 .892	72.8 18.69	44.9 7.40	7.1 .20
GROUP 4 - CERIC OXIDE HIGH DOSE	115.5 22.56	9.9 .33	6.22 1.010	73.3 13.09	42.9 10.86	7.1 A .30

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 (DUNNETT'S)

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	3.5 .17	1.06 .072	3.3 .22	146.9 2.34	5.42 .601	106.8 2.86
GROUP 2 - CERIC OXIDE LOW DOSE	3.5 .10	1.03 .062	3.4 .25	146.5 2.18	5.37 .495	106.5 2.15
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3.6 .13	1.02 .046	3.5 A .12	145.4 2.41	5.40 .649	106.3 1.95
GROUP 4 - CERIC OXIDE HIGH DOSE	3.6 .15	1.03 .043	3.5 A .18	145.9 1.94	5.27 .759	106.9 1.53

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 (DUNNETT'S)

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	12.9 2.50	.6 .11	136.7 12.32	.10 .018	129.0 23.11	35.1 6.33
GROUP 2 - CERIC OXIDE LOW DOSE	13.7 2.06	.6 .13	138.9 15.32	.10 .018	133.2 31.32	39.1 7.42
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	13.9 2.06	.6 .11	150.9 15.38	.10 .028	129.7 15.56	34.9 5.57
GROUP 4 - CERIC OXIDE HIGH DOSE	14.5 2.79	.6 .12	137.1 22.45	.09 .019	139.1 27.31	42.1 18.29

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	69.6 17.93	9.5 .31	7.01 .720	52.3 17.31	68.4 27.58	6.1 .37
GROUP 2 - CERIC OXIDE LOW DOSE	75.8 22.89	9.3 .27	7.33 .496	50.7 11.10	60.2 39.97	6.0 .32
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	74.9 11.51	9.6 .38	7.26 .700	55.6 11.74	63.1 34.04	6.2 .41
GROUP 4 - CERIC OXIDE HIGH DOSE	82.3 17.66	9.4 .26	7.16 .583	50.1 11.59	55.4 21.95	6.0 .39

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	2.9 .12	.92 .067	3.2 .29	145.4 1.50	4.61 .210	101.6 1.72
GROUP 2 - CERIC OXIDE LOW DOSE	2.9 .13	.94 .064	3.1 .25	144.7 1.67	4.69 .289	101.3 1.87
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	2.9 .10	.91 .078	3.2 .35	144.5 1.13	4.98 .986	101.5 1.30
GROUP 4 - CERIC OXIDE HIGH DOSE	2.8 .15	.92 .111	3.1 .39	145.4 .74	4.63 .240	102.3 .99

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	15.1 2.34	.7 .14	135.3 17.10	.12 .026	119.5 25.60	34.2 6.94
GROUP 2 - CERIC OXIDE LOW DOSE	16.0 2.17	.6 .13	139.7 13.76	.11 .029	119.1 23.99	32.1 4.99
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	15.0 1.54	.6 .17	132.3 22.98	.11 .021	120.3 20.87	35.4 6.03
GROUP 4 - CERIC OXIDE HIGH DOSE	15.7 3.31	.6 .14	126.7 24.07	.11 .020	128.9 37.02	42.3 36.05

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	54.4 11.56	9.5 .40	6.78 .991	60.1 20.48	39.8 11.94	6.4 .39
GROUP 2 - CERIC OXIDE LOW DOSE	54.0 15.43	9.7 .44	6.87 .770	67.3 15.49	39.1 8.43	6.3 .32
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	53.9 12.04	9.7 .37	6.79 .700	56.9 15.40	31.9 10.15	6.5 .42
GROUP 4 - CERIC OXIDE HIGH DOSE	54.1 12.92	9.7 .43	6.67 .804	59.5 11.17	40.5 12.14	6.4 .32

TABLE NO. 13 GROUP MEAN (S.D.) CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	3.1 .16	.97 .075	3.2 .29	144.9 1.58	4.29 .248	103.4 1.55
GROUP 2 - CERIC OXIDE LOW DOSE	3.0 .18	.93 .082	3.3 .25	144.3 1.54	4.29 .348	103.3 1.44
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3.2 .18	.95 .094	3.4 .35	145.5 1.55	4.35 .306	103.9 1.44
GROUP 4 - CERIC OXIDE HIGH DOSE	3.2 .15	.97 .055	3.3 .21	145.1 1.58	4.36 .347	103.8 1.66

TABLE NO. 14 GROUP MEAN (S.D.) ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

MALES

	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	485.0 48.04	12.358 1.5845	.783 .1152	1.594 .1500	1.611 .1088
GROUP 2 - CERIC OXIDE LOW DOSE	476.2 43.08	12.239 1.9668	.805 .1457	1.579 .1668	1.760 .1398
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	488.4 20.80	12.948 1.0880	.866 .1202	1.569 .1046	2.574 E .3499
GROUP 4 - CERIC OXIDE HIGH DOSE	461.0 58.49	11.981 2.1479	.868 .1741	1.587 .3448	4.662 E .5161

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: E - P<.001 (DUNN'S)

TABLE NO. 14 GROUP MEAN (S.D.) ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

MALES

	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 1 - AIR CONTROL	.023 .0041	.062 .0079	2.987 .2970	3.543 .3093	1.283 .2452
GROUP 2 - CERIC OXIDE LOW DOSE	.021 .0020	.058 .0054	2.965 .2616	3.510 .2692	1.388 .3016
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	.021 .0032	.055 .0080	2.974 .1632	3.621 .2202	1.257 .2451
GROUP 4 - CERIC OXIDE HIGH DOSE	.022 .0044	.058 .0068	2.868 .3922	3.479 .3570	1.360 .3417

TABLE NO. 14 GROUP MEAN (S.D.) ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

MALES

	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	2.160 .0889	.015 .0027	.222 .0551
GROUP 2 - CERIC OXIDE LOW DOSE	2.133 .0537	.015 .0021	.235 .0509
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	2.118 .0782	.014 .0017	.287 B .0376
GROUP 4 - CERIC OXIDE HIGH DOSE	2.082 .1896	.015 .0021	.248 .0796

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 14 GROUP MEAN (S.D.) ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

FEMALES

	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIP CONTROL	240.8 18.96	6.425 .5200	.518 .0657	.950 .0768	1.145 .0871
GROUP 2 - CERIC OXIDE LOW DOSE	241.4 18.75	6.543 .7021	.584 .0795	.958 .1012	1.311 .1490
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	237.2 18.14	6.311 .6956	.534 .0966	.975 .1084	1.651 E .2900
GROUP 4 - CERIC OXIDE HIGH DOSE	234.1 15.30	6.343 .6212	.519 .0631	.957 .0634	3.173 E .3235

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: E - P<.001 (DUNN'S)

TABLE NO. 14 GROUP MEAN (S.D.) ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

FEMALES

	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 1 - AIR CONTROL	.015 .0024	.059 .0076	1.693 .1292	.083 .0178	.586 .1030
GROUP 2 - CERIC OXIDE LOW DOSE	.016 .0034	.061 .0125	1.681 .1090	.074 .0138	.546 .0822
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	.016 .0029	.062 .0095	1.643 .1487	.085 .0174	.564 .0771
GROUP 4 - CERIC OXIDE HIGH DOSE	.017 .0038	.062 .0102	1.620 .1719	.079 .0113	.554 .1028

TABLE NO. 14 GROUP MEAN (S.D.) ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

FEMALES

	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1.924 .0560	.017 .0028	.186 .0335
GROUP 2 - CERIC OXIDE LOW DOSE	1.965 .0803	.015 .0014	.173 .0635
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	1.943 .0783	.015 .0025	.204 .0386
GROUP 4 - CERIC OXIDE HIGH DOSE	1.931 .0467	.015 .0021	.165 .0426

TABLE NO. 15

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	485.0 48.04	2.545 .1534	.162 .0190	.330 .0318	.334 .0256
GROUP 2 - CERIC OXIDE LOW DOSE	476.2 43.08	2.560 .2395	.169 .0286	.332 .0230	.371 .0270
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	488.4 20.80	2.650 .1790	.178 .0266	.322 .0238	.528E .0775
GROUP 4 - CERIC OXIDE HIGH DOSE	461.0 58.49	2.586 .1803	.188A .0298	.344 .0474	1.024E .1621

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05(DUNNETT'S)
E - P<.001 (DUNN'S)

TABLE NO. 15

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 1 - AIR CONTROL	.005 .0007	.013 .0022	.619 .0686	.733 .0546	.264 .0476
GROUP 2 - CERIC OXIDE LOW DOSE	.005 .0005	.012 .0015	.624 .0399	.743 .0858	.292 .0673
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	.004 .0008	.011 .0017	.609 .0340	.743 .0663	.258 .0558
GROUP 4 - CERIC OXIDE HIGH DOSE	.005 .0010	.013 .0014	.622 .0310	.762 .0984	.294 .0511

TABLE NO. 15

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	.449 .0404	.003 .0005	.046 .0109
GROUP 2 - CERIC OXIDE LOW DOSE	.451 .0405	.003 .0005	.050 .0106
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	.434 .0237	.003 .0003	.059B .0074
GROUP 4 - CERIC OXIDE HIGH DOSE	.460 .0759	.003 .0003	.053 .0137

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: B - P<.01 (DUNNETT'S)

TABLE NO. 15

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	240.8 18.96	2.671 .1532	.216 .0281	.396 .0391	.477 .0443
GROUP 2 - CERIC OXIDE LOW DOSE	241.4 18.75	2.707 .1473	.242 .0259	.397 .0312	.544 .0557
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	237.2 18.14	2.660 .1992	.226 .0445	.412 .0395	.697E .1124
GROUP 4 - CERIC OXIDE HIGH DOSE	234.1 15.30	2.709 .1830	.222 .0252	.410 .0288	1.358E .1432

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: E - P<.001 (DUNN'S)

TABLE NO. 15

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 1 - AIR CONTROL	.006 .0011	.024 .0033	.705 .0560	.035 .0073	.249 .0599
GROUP 2 - CERIC OXIDE LOW DOSE	.007 .0012	.025 .0052	.698 .0417	.031 .0053	.227 .0400
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	.007 .0014	.026 .0043	.694 .0532	.036 .0071	.239 .0252
GROUP 4 - CERIC OXIDE HIGH DOSE	.007 .0017	.027 .0044	.692 .0628	.034 .0060	.237 .0497

TABLE NO. 15

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	.804 .0742	.007 .0012	.078 .0179
GROUP 2 - CERIC OXIDE LOW DOSE	.819 .0766	.006 .0007	.071 .0257
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	.823 .0578	.007 .0009	.086 .0168
GROUP 4 - CERIC OXIDE HIGH DOSE	.827 .0463	.007 .0008	.071 .0180

TABLE NO. 16

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (C%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 1 - AIR CONTROL	2.160 .0889	572.525 73.5889	36.255 5.0201	73.824 6.5727
GROUP 2 - CERIC OXIDE LOW DOSE	2.133 .0537	573.094 86.5667	37.656 6.3077	74.006 7.3564
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	2.118 .0782	611.995 54.9831	40.966 6.0432	74.136 5.0739
GROUP 4 - CERIC OXIDE HIGH DOSE	2.082 .1896	587.554 174.0101	42.378 11.6122	78.667 31.1347

TABLE NO. 16

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 1 - AIR CONTROL	74.610 4.0913	1.080 .1670	2.894 .3762	138.492 14.5001
GROUP 2 - CERIC OXIDE LOW DOSE	82.566 6.8553	1.004 .0923	2.735 .2878	138.965 11.3344
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	121.932 E 18.9617	.975 .1595	2.605 .3386	140.527 8.0447
GROUP 4 - CERIC OXIDE HIGH DOSE	225.991 E 35.2812	1.069 .2848	2.817 .5694	140.154 34.3996

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: E - P<.001 (DUNN'S)

TABLE NO. 16

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	GONADS	PRO-STATE	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	164.009 11.9466	59.259 10.4555	.690 .1149	10.237 2.3387
GROUP 2 - CERIC OXIDE LOW DOSE	164.702 14.0122	65.069 14.1198	.701 .1029	11.038 2.4431
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	171.105 11.0295	59.181 10.4695	.672 .0799	13.564A 1.8590
GROUP 4 - CERIC OXIDE HIGH DOSE	168.604 25.5096	67.140 26.1359	.714 .1917	12.182 4.7711

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: A - P<.05 (DUNNETT'S)

TABLE NO. 16

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 1 - AIR CONTROL	1.924 .0560	334.191 29.1008	26.950 3.5828	49.419 4.1965
GROUP 2 - CERIC OXIDE LOW DOSE	1.965 .0803	334.096 43.1074	29.779 4.2231	48.943 6.3919
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	1.943 .0783	324.656 30.6869	27.502 5.1799	50.242 5.6058
GROUP 4 - CERIC OXIDE HIGH DOSE	1.931 .0467	328.519 31.1325	26.909 3.3719	49.588 3.1272

TABLE NO. 16

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 1 - AIR CONTROL	59.521 4.6352	.781 .1197	3.044 .3765	88.100 7.6830
GROUP 2 - CERIC OXIDE LOW DOSE	66.866 8.3016	.806 .1753	3.112 .6755	85.751 7.5003
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	85.047 E 15.0128	.807 .1612	3.173 .5110	84.576 6.6131
GROUP 4 - CERIC OXIDE HIGH DOSE	164.322 E 16.1379	.857 .1911	3.211 .5157	83.867 8.5398

SIGNIFICANTLY DIFFERENT FROM CONTROL (GROUP 1) VALUE: E - P<.001 (DUNN'S)

TABLE NO. 16

GROUP MEAN (S.D.) RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	GONADS	UTERUS	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	4.310 .9285	30.476 5.2101	.869 .1540	9.661 1.7819
GROUP 2 - CERIC OXIDE LOW DOSE	3.789 .7421	28.193 4.6330	.779 .0944	8.827 3.2883
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	4.367 .8957	29.157 3.8670	.794 .1129	10.487 2.0096
GROUP 4 - CERIC OXIDE HIGH DOSE	4.084 .5944	28.761 5.3612	.802 .1028	8.565 2.2580

TABLE NO.: 17
PROJECT NO.: 90031

INCIDENCE OF GROSS PATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX :	--- MALE ---			
DOSE GROUP :	1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
NO. OF ANIMALS EXAMINED :	15	15	15	15
KIDNEY	0	2	1	3
-DILATATION	2	0	0	1
-AREA DEPRESSED	0	0	0	1
-FOCI DARK	0	1	0	0
-AREA PALE				
LIVER	2	9	7	2
-AREA PALE	2	0	1	0
-AREA RAISED	0	0	0	1
-MASS				
LUNG	0	0	0	15
-DISCOLORATION	0	0	1	1
-AREA DARK	0	0	15	0
-AREA PALE	0	0	2	15
-UNCOLLAPSED				
LYMPH NODE MANDIBULAR	4	2	5	4
-ENLARGEMENT	2	1	2	1
-AREA DARK	0	1	2	0
-FOCI DARK				
PITUITARY	0	1	0	1
-CYST				

TABLE NO.: 17
PROJECT NO.: 90831

INCIDENCE OF GROSS PATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX :	--- M A L E ---			
DOSE GROUP :	1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
NO. OF ANIMALS EXAMINED :	15	15	15	15
PROSTATE				
-AREA PALE	0	0	2	1
-AREA RAISED	0	0	0	1
SPLEEN				
-CYST	0	1	0	1
STOMACH				
-AREA DARK	0	0	1	0
THYMUS				
-AREA DARK	0	0	0	3
-SMALL	0	0	0	1
THYROID				
-SMALL	0	0	1	0
URINARY BLADDER				
-DILATATION	1	0	1	1
-THICKENING	0	0	1	0
-AREA DARK	0	0	1	0
LYMPH NODE BRONCHIAL				
-ENLARGEMENT	0	4	15	15
-DISCOLORATION	0	13	15	15

TABLE NO.: 17
PROJECT NO.: 90831

INCIDENCE OF GROSS PATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX :	--- M A L E ---			
DOSE GROUP :	1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
NO. OF ANIMALS EXAMINED :	15	15	15	15
LYMPH NODE MEDIASTINAL				
-ENLARGEMENT	0	2	9	9
-DISCOLORATION	0	2	9	10
-AREA DARK	0	0	1	0
LYMPH NODE PANCREATIC				
-ENLARGEMENT	1	0	0	0
-AREA DARK	0	0	1	0

TABLE NO.: 17
PROJECT NO.: 90831

INCIDENCE OF GROSS PATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

	--- FEMALE ---			
SEX :				
DOSE GROUP :	1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
NO. OF ANIMALS EXAMINED :	15	15	15	15
ADRENAL				
-ENLARGEMENT	0	1	0	0
KIDNEY				
-ADHESION	2	0	0	1
-CYST	0	1	1	0
-AREA DEPRESSED	0	1	1	1
-DILATATION	1	0	0	1
LIVER				
-AREA PALE	3	1	4	1
-AREA RAISED	1	1	1	0
LUNG				
-FOCI PALE	0	4	0	0
-AREA PALE	0	0	15	1
-DISCOLORATION	0	0	0	14
-UNCOLLAPSED	0	0	0	15
LYMPH NODE MANDIBULAR				
-AREA DARK	1	0	0	0
-ENLARGEMENT	2	4	3	1
-FOCI DARK	1	1	0	0

TABLE NO.: 17
PROJECT NO.: 90831

INCIDENCE OF GROSS PATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX :	--- FEMALE ---			
DOSE GROUP :	1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
NO. OF ANIMALS EXAMINED :	15	15	15	15
PITUITARY				
-ENLARGEMENT	1	0	0	0
THYMUS				
-SMALL	0	1	0	1
-AREA DARK	0	0	0	1
THYROID				
-ENLARGEMENT	1	0	0	0
LYMPH NODE BRONCHIAL				
-DISCOLORATION	0	15	15	15
-ENLARGEMENT	0	1	14	15
LYMPH NODE MEDIASTINAL				
-DISCOLORATION	1	10	9	10
-ENLARGEMENT	0	1	8	8
LYMPH NODE PANCREATIC				
-ENLARGEMENT	2	0	1	0
-DISCOLORATION	0	0	0	1

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- MALE ---			
SEX :					
DOSE GROUP :		1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :		15	15	15	15
ADRENAL	-TOTAL EXAMINED	15	0	0	15
-VACUOLATION, CORTICAL		8	0	0	6
AORTA	-TOTAL EXAMINED	15	0	0	15
BONE MARROW	-TOTAL EXAMINED	15	0	0	15
BONE STERNUM	-TOTAL EXAMINED	15	0	0	15
BRAIN	-TOTAL EXAMINED	15	0	0	15
BRONCHUS	-TOTAL EXAMINED	15	15	15	15
-PIGMENT ACCUMULATION		0	1	5	15
CAVITY NASAL	-TOTAL EXAMINED	15	15	15	15
-HYPERTROPHY AND/OR HYPERPLASIA, GOBLET CELL		0	0	0	1
-RHINITIS		0	1	0	0
-PIGMENT ACCUMULATION		0	12	15	15

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

SEX :	--- MALE ---			
DOSE GROUP :	1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
CECUM -TOTAL EXAMINED	15	0	0	15
COLON -TOTAL EXAMINED	15	0	0	15
-PARASITE	0	0	0	1
DUODENUM -TOTAL EXAMINED	15	0	0	15
EPIDIDYMIS -TOTAL EXAMINED	15	0	0	15
ESOPHAGUS -TOTAL EXAMINED	15	0	0	15
EYE -TOTAL EXAMINED	15	0	0	15
-FOLD/ROSETTE, RETINAL	1	0	0	0
-ATROPHY, RETINAL	1	0	0	0
HEART -TOTAL EXAMINED	15	0	0	15
-INFILTRATION, MONONUCLEAR CELL	8	0	0	2

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- MALE ---			
	SEX :				
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
ILEUM	-TOTAL EXAMINED	15	0	0	15
JEJUNUM	-TOTAL EXAMINED	15	0	0	15
KIDNEY	-TOTAL EXAMINED	15	3	1	15
	-FIBROPLASIA	2	0	0	0
	-CYST	1	0	0	1
	-DILATATION, PELVIS	0	1	1	3
	-DILATATION, TUBULAR	0	0	0	1
LARYNX	-TOTAL EXAMINED	15	15	15	15
	-METAPLASIA	0	3	9	13
	-PIGMENT ACCUMULATION	0	6	9	12
	-LARYNGITIS	0	0	0	1
LIVER	-TOTAL EXAMINED	15	9	7	15
	-VACUOLATION, HEPATOCELLULAR	2	7	5	1
	-NECROSIS	0	0	1	0
	-PIGMENT ACCUMULATION	0	0	0	6

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

	SEX :	--- M A L E ---			
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
LUNG	-TOTAL EXAMINED	15	15	15	15
-PIGMENT ACCUMULATION		0	15	15	15
-EPITHELIAL HYPERPLASIA, ALVEOLAR		0	1	11	14
-MINERALIZATION		0	1	0	0
-HYPERPLASIA, LYMPHOID		0	0	0	12
LYMPH NODE MANDIBULAR	-TOTAL EXAMINED	15	3	5	15
-PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY		4	2	5	4
-HEMORRHAGE		1	2	2	2
-PIGMENT ACCUMULATION		0	0	0	6
-HYPERPLASIA, LYMPHOID		0	0	0	2
LYMPH NODE MESENTERIC	-TOTAL EXAMINED	15	0	0	15
MAMMARY GLAND	-TOTAL EXAMINED	15	0	0	15
MUSCLE SKELETAL	-TOTAL EXAMINED	15	0	0	15
-INFILTRATION, MONONUCLEAR CELL		0	0	0	1

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- MALE ---			
SEX :					
DOSE GROUP :		1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :		15	15	15	15
NERVE OPTIC	-TOTAL EXAMINED	15	0	0	15
NERVE SCIATIC	-TOTAL EXAMINED	15	0	0	15
PANCREAS	-TOTAL EXAMINED	15	0	0	15
PARATHYROID	-TOTAL EXAMINED	13	0	0	10
PHARYNX	-TOTAL EXAMINED	15	15	15	15
PITUITARY	-TOTAL EXAMINED	15	1	0	15
-CYST		1	1	0	1
PROSTATE	-TOTAL EXAMINED	15	0	2	15
-PROSTATITIS		4	0	2	1

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

	SEX :	--- M A L E ---			
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
SALIVARY GLAND	-TOTAL EXAMINED	15	0	0	15
SEMINAL VESICLE	-TOTAL EXAMINED	15	0	0	15
SKIN	-TOTAL EXAMINED	15	0	0	15
SPINAL CORD CERVICAL	-TOTAL EXAMINED	14	0	0	15
SPLEEN	-TOTAL EXAMINED	15	1	0	15
-CYST, CAPSULAR		0	1	0	1
-PIGMENT ACCUMULATION		0	0	0	6
STOMACH	-TOTAL EXAMINED	15	0	1	15
TESTIS	-TOTAL EXAMINED	15	0	0	15

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- MALE ---			
	SEX :				
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
THYMUS	-TOTAL EXAMINED	15	0	0	15
-HEMORRHAGE		0	0	0	3
THYROID	-TOTAL EXAMINED	15	0	1	15
-CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS		5	0	0	9
TONGUE	-TOTAL EXAMINED	15	0	0	15
TRACHEA	-TOTAL EXAMINED	15	15	15	15
-PIGMENT ACCUMULATION		0	0	1	14
URINARY BLADDER	-TOTAL EXAMINED	15	0	2	15
-DILATATION		1	0	1	2
-HEMORRHAGE		0	0	1	0
LYMPH NODE BRONCHIAL	-TOTAL EXAMINED	15	13	15	15
-PIGMENT ACCUMULATION		0	13	15	15
-HYPERPLASIA, LYMPHOID		0	11	15	15

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- MALE ---			
	SEX :				
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
LYMPH NODE MEDIASTINAL	-TOTAL EXAMINED	0	2	10	9
-PIGMENT ACCUMULATION		0	2	8	9
-HYPERPLASIA, LYMPHOID		0	2	9	9
-HEMORRHAGE		0	0	1	0
LYMPH NODE PANCREATIC	-TOTAL EXAMINED	1	0	1	0
-HEMORRHAGE		0	0	1	0

TABLE NO.: 18
PROJECT NO.: 90031

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- FEMALE ---			
SEX :					
DOSE GROUP :		1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :		15	15	15	15
ADRENAL	-TOTAL EXAMINED	15	1	0	15
-FOCAL CORTICAL HYPERTROPHY		1	0	0	0
AORTA	-TOTAL EXAMINED	15	0	0	15
BONE MARROW	-TOTAL EXAMINED	15	0	0	15
BONE STERNUM	-TOTAL EXAMINED	15	0	0	15
BRAIN	-TOTAL EXAMINED	15	0	0	15
BRONCHUS	-TOTAL EXAMINED	15	15	15	15
-PIGMENT ACCUMULATION		0	0	4	15
CAVITY NASAL	-TOTAL EXAMINED	15	15	15	15
-ATROPHY, OLFACTORY EPITHELIUM		1	0	1	0
-HYPERTROPHY AND/OR HYPERPLASIA, GOBLET CELL		0	1	0	2
-PIGMENT ACCUMULATION		0	3	11	15

TABLE NO.: 18
PROJECT NO.: 90031

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- FEMALE ---			
	SEX :				
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
CECUM	-TOTAL EXAMINED	15	0	0	15
COLON	-TOTAL EXAMINED	15	0	0	15
DUODENUM	-TOTAL EXAMINED	15	0	0	15
ESOPHAGUS	-TOTAL EXAMINED	15	0	0	15
EYE	-TOTAL EXAMINED	15	0	0	15
-FOLD/ROSETTE, RETINAL		0	0	0	2
HEART	-TOTAL EXAMINED	15	0	0	15
ILEUM	-TOTAL EXAMINED	15	0	0	15
JEJUNUM	-TOTAL EXAMINED	15	0	0	15

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

	SEX :	--- FEMALE ---			
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
KIDNEY	-TOTAL EXAMINED	15	2	2	15
-DILATATION, PELVIS		1	0	0	1
-ADHESION, CAPSULAR		1	0	0	0
-CYST		0	0	1	1
-INFILTRATION, MONONUCLEAR CELL		0	0	1	0
LARYNX	-TOTAL EXAMINED	15	15	15	15
-METAPLASIA		0	3	6	9
-PIGMENT ACCUMULATION		0	0	7	9
-LARYNGITIS		0	0	1	0
LIVER	-TOTAL EXAMINED	15	1	5	15
-VACUOLATION, HEPATOCELLULAR		3	1	5	1
-ACCESSORY HEPATIC TISSUE		1	0	0	0
-PIGMENT ACCUMULATION		0	0	0	5
LUNG	-TOTAL EXAMINED	15	15	15	15
-PIGMENT ACCUMULATION		0	15	15	15
-EPITHELIAL HYPERPLASIA, ALVEOLAR		0	0	5	15
-HYPERPLASIA, LYMPHOID		0	0	1	7

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

	SEX :	--- F E M A L E ---			
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
LYMPH NODE MANDIBULAR	-TOTAL EXAMINED	15	5	3	15
-PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY		2	4	3	1
-HEMORRHAGE		3	1	0	0
-PIGMENT ACCUMULATION		0	0	0	6
LYMPH NODE MESENTERIC	-TOTAL EXAMINED	15	0	0	15
MAMMARY GLAND	-TOTAL EXAMINED	15	0	0	15
MUSCLE SKELETAL	-TOTAL EXAMINED	15	0	0	15
NERVE OPTIC	-TOTAL EXAMINED	15	0	0	15
NERVE SCIATIC	-TOTAL EXAMINED	15	0	0	15
OVARY	-TOTAL EXAMINED	15	0	0	15

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

	SEX :	--- FEMALE ---			
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
PANCREAS	-TOTAL EXAMINED	15	0	0	15
PARATHYROID	-TOTAL EXAMINED	11	0	0	9
PHARYNX	-TOTAL EXAMINED	15	15	15	15
PITUITARY	-TOTAL EXAMINED	15	0	0	15
SALIVARY GLAND	-TOTAL EXAMINED	15	0	0	15
SKIN	-TOTAL EXAMINED	15	0	0	15
SPINAL CORD CERVICAL	-TOTAL EXAMINED	15	0	0	15
SPLEEN	-TOTAL EXAMINED	15	0	0	15
-PIGMENT ACCUMULATION		0	0	0	3

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- FEMALE ---			
	SEX :				
	DOSE GROUP :	1	2	3	4
	NO. OF ANIMALS IN DOSE GROUP :	15	15	15	15
STOMACH	-TOTAL EXAMINED	15	0	0	15
THYMUS	-TOTAL EXAMINED	15	1	0	15
	-HEMORRHAGE	0	0	0	1
THYROID	-TOTAL EXAMINED	15	0	0	15
	-CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS	5	0	0	3
TONGUE	-TOTAL EXAMINED	15	0	0	15
TRACHEA	-TOTAL EXAMINED	15	15	15	15
	-PIGMENT ACCUMULATION	0	0	1	14
URINARY BLADDER	-TOTAL EXAMINED	15	0	0	15
UTERUS	-TOTAL EXAMINED	15	0	0	15

TABLE NO.: 18
PROJECT NO.: 90831

INCIDENCE OF HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
GROUP 2 CERIC OXIDE LOW DOSE
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 CERIC OXIDE HIGH DOSE

		--- FEMALE ---			
SEX :					
DOSE GROUP :		1	2	3	4
NO. OF ANIMALS IN DOSE GROUP :		15	15	15	15
VAGINA	-TOTAL EXAMINED	15	0	0	15
LYMPH NODE BRONCHIAL	-TOTAL EXAMINED	15	15	15	15
	-PIGMENT ACCUMULATION	0	14	15	15
	-HYPERPLASIA, LYMPHOID	0	13	15	15
	-HEMORRHAGE	0	1	0	0
LYMPH NODE MEDIASTINAL	-TOTAL EXAMINED	1	10	9	10
	-HEMORRHAGE	1	0	0	0
	-HYPERPLASIA, LYMPHOID	0	10	9	9
	-PIGMENT ACCUMULATION	0	10	9	9
LYMPH NODE PANCREATIC	-TOTAL EXAMINED	2	0	1	1
	-HYPERPLASIA, LYMPHOID	0	0	1	0
	-PIGMENT ACCUMULATION	0	0	1	1

BIO-RESEARCH LABORATORIES LTD.

STUDY TITLE

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT

VOLUME II

SPONSOR

Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

DATA REQUIREMENTS

United States EPA/TSCA (40 CFR Part 792).
Japanese MHW GLP Regulations (Notification No. 313 and revised rule Notification No. 870)
OECD guidelines No. 413

AUTHOR

A. Viau, B.Sc.
Study Director

STUDY COMPLETED ON

September 29, 1994

PERFORMING LABORATORY

Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

LABORATORY PROJECT ID

90831

MONTRÉAL
87 Senneville Rd., Senneville, Quebec H9X 3R3, Canada
Tel: (514) 630-8200 Cable: BIOCAN Fax: (514) 457-3883

INDEX TO VOLUME II
(276 - 670)

APPENDIX NO. 1

INDIVIDUAL CLINICAL OBSERVATIONS

PROJECT NO. 90831

MALES

GROUP 1 - VEHICLE CONTROL
GROUP 2 - CERIC OXIDE LOW DOSE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	OBSERVATION	DAY(S) OF OBSERVATION
1001	Mouth, incisor, broken	71-91
1009	Skin, lesion muzzle, general body condition, swollen muzzle	54-60
1013	Scab, right forelimb, left forelimb	32-47
	Lesion purulent, right forelimb	33-40
	Fur, thin cover, moderate, right forelimb	33-92
	Fur, thin cover, moderate, left forelimb	33-92
1017	Right eye partly closed	39-47
2009	Malocclusion of upper teeth	78-92
	Periorbital, staining, red, left eye	78-92
	Soft feces, liquid during dosing	78-89
	Staining in cage	78-89
2015	Alopecia, right scapular (region of lesion)	29-60
	Skin lesion, right scapular	29-81
	Redness, right scapular	29-89
	Scab, skin, right scapular, fur staining, red, right scapular	47-89
	Liquid, red, right scapular	47-60
3004	Left eye partly closed	18-24

APPENDIX NO. 1

INDIVIDUAL CLINICAL OBSERVATIONS

PROJECT NO. 90831

MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	OBSERVATION	DAY(S) OF OBSERVATION
3007	Right incisor, broken	16-92
	Fur, staining, red, muzzle	15-24
	Mouth swollen, moderate	15-24
4004	Scabs, multiple, left hindpaw	90-92
4006	Incisor, missing, top	10-16
	Incisors, broken, left, incisors, broken, right	16-24
4012	Salivation excessive, wet fur, muzzle, wet, lower jaw	58-60
4014	Scab, muzzle, left	10-16
4015	Left eye partly closed	18-24

APPENDIX NO. 1

INDIVIDUAL CLINICAL OBSERVATIONS

PROJECT NO. 90831

FEMALES

GROUP 1 - VEHICLE CONTROL

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	OBSERVATION	DAY(S) OF OBSERVATION
1503	Skin, lesion, muzzle	8-11
	Liquid, red, muzzle	8-12
	Staining, red, muzzle	8-12
	Scab, skin, muzzle	11-18
	Scab, skin, muzzle	40-46
1509	Fur, staining brown, left hindpaw	11-18
	Fur, thin cover, moderate, periorbital right	25-92
	Skin, redness, right periorbital	33-92
	Fur, staining, brown, dorsal thoracic	91-92
	Fur, staining, brown, ventral thoracic	91-92
1510	Skin, redness, right periorbital	25-33
	Fur, staining, red, right periorbital	25-33
	Fur, wet, right periorbital	25-33
1514	Scab, skin, muzzle	40-67
2506	Scab, skin, dry, red, mouth upper jaw, left	75-91
2507	Eyes partly closed, left	17-18
	Mouth, incisors, broken, teeth	73
2512	Fur, thin cover, slight lower jaw	18-25

APPENDIX NO. 1

INDIVIDUAL CLINICAL OBSERVATIONS

PROJECT NO. 90831

FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	OBSERVATION	DAY(S) OF OBSERVATION
3501	Fur, staining, brown, right pinna Fur, staining, brown, left hindlimb	11-18 11-18
3502	Incisor, not solid	27-40
3503	Incisors, broken	40-67
3505	Skin lesion, tip of tail Fur, staining, red, left periorbital	6-11 18-33
3511	General body condition, swollen muzzle, skin redness, muzzle	17-25
3516	Skin lesion, red, liquid, tip of tail General body condition: abnormality, tail, blood near tip Scab, skin, tip of tail	Pre Rx to 4 4-33 11-25
3517	Incisor, broken, left Scab, muzzle	40-67 67-89
4503	Fur, staining, reddish, dorsal cervical	11-18
4504	General body condition, dehydrated, slight Fur, staining, red, muzzle	11-12 18-25
4505	Fur, staining, red, muzzle	18-25

APPENDIX NO. 1

INDIVIDUAL CLINICAL OBSERVATIONS

PROJECT NO. 90831

FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	OBSERVATION	DAY(S) OF OBSERVATION
4509	Fur, thin cover, slight, muzzle	33-46
4511	Skin, redness, muzzle Fur, alopecia, moderate, muzzle	19-25 19-33
4515	Fur, staining, red, left forepaw, fur, staining, red, right forepaw	11-18
4516	Fur, staining, red, lower jaw, fur, thin cover, slight, lower jaw	18-25

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	-6	-2	1	8	15	22	27	29	36	43	50	55	57	64	71
MALES GROUP 1 AIR CONTROL															
1001	183	225	236	285	330	360	391	392	429	443	472	487	494	519	499
1002	180	211	223	265	313	341	362	377	405	422	453	468	478	507	526
1005	190	224	236	279	327	358	377	393	428	445	469	474	487	512	534
1006	186	223	233	269	316	338	356	369	389	394	412	419	434	455	469
1007	185	219	231	283	335	369	392	405	436	443	470	478	490	511	516
1008	180	211	217	259	305	324	345	353	375	377	389	395	408	422	435
1009	182	211	220	261	297	325	336	347	371	381	396	405	413	430	440
1010	188	227	233	280	326	360	380	390	419	431	457	466	479	498	515
1011	181	212	221	245	276	292	306	313	330	331	352	359	371	379	385
1012	194	232	243	292	348	389	411	419	457	462	488	502	514	538	548
1013	190	231	244	294	326	351	368	379	406	408	429	433	448	473	487
1014	195	236	252	308	374	411	439	453	485	490	507	522	540	559	564
1015	186	221	237	289	347	381	405	419	442	461	477	493	499	528	547
1016	199	252	263	314	365	401	436	447	477	491	516	526	541	562	571
1017	196	244	255	299	350	379	401	410	436	449	473	482	492	518	535
MEAN	187.6	225.3	236.3	281.6	328.9	358.8	380.3	391.1	418.9	428.5	450.6	460.7	472.4	494.0	504.6
S.D.	6.2	12.4	13.4	19.1	25.8	31.8	36.3	37.2	41.2	44.0	46.2	48.4	48.8	52.4	52.8
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	-6	-2	1	8	15	22	27	29	36	43	50	55	57	64	71
MALES GROUP 2 CERIC OXIDE LOW DOSE															
2001	192	224	237	284	323	351	371	383	412	423	444	458	466	490	505
2002	191	226	234	280	335	369	384	401	425	443	457	470	483	507	521
2003	189	228	247	297	358	398	426	436	468	483	513	525	548	563	576
2004	180	220	228	277	331	364	385	397	420	434	454	468	481	502	513
2005	188	209	223	269	316	344	365	373	403	409	433	442	458	481	494
2006	193	241	251	296	335	363	387	402	421	434	451	457	476	482	506
2007	185	220	227	274	319	348	367	371	398	414	425	438	440	462	483
2008	184	209	217	267	308	339	358	371	393	406	428	444	453	474	485
2009	179	210	219	259	295	329	346	359	378	388	410	423	433	445	459
2010	183	223	234	282	332	371	396	407	449	465	490	505	510	539	554
2011	188	221	236	267	307	335	350	358	379	380	397	408	419	435	446
2012	181	213	222	268	301	329	348	361	386	399	423	429	446	466	484
2013	178	211	221	263	309	331	353	361	383	394	401	413	425	435	448
2015	194	236	243	279	327	355	367	376	402	406	431	439	441	461	485
2016	203	250	265	310	352	386	407	419	449	472	493	507	521	536	555
MEAN	187.2	222.7	233.5	278.2	323.2	354.3	374.0	384.9	411.0	423.3	443.2	455.1	466.7	485.4	500.8
S.D.	6.9	12.1	13.6	14.1	18.0	20.8	23.3	24.1	27.6	31.2	33.9	34.8	37.1	38.4	38.3
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

MALES GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO. \ DAY	-6	-2	1	8	15	22	27	29	36	43	50	55	57	64	71
3001	188	227	241	283	333	368	394	403	429	442	472	492	495	514	529
3002	185	227	238	282	326	352	369	378	402	375	426	442	462	489	504
3003	192	232	244	296	335	370	391	400	430	445	458	462	483	504	513
3004	178	210	220	266	308	334	355	364	392	401	423	428	437	461	480
3005	192	222	230	275	318	348	369	379	407	415	442	450	465	489	500
3006	189	228	239	286	340	373	395	408	449	454	483	492	500	525	496
3007	194	233	244	284	329	337	363	371	399	416	433	443	450	470	481
3008	184	225	236	281	326	359	383	393	424	435	448	457	469	502	517
3009	185	223	236	286	328	358	379	386	414	426	449	457	469	488	502
3011	182	219	234	280	322	356	374	381	406	422	449	465	472	487	497
3012	193	234	250	289	335	367	388	401	427	434	444	446	460	476	493
3013	181	213	220	259	305	335	368	371	398	404	427	448	463	479	496
3014	181	219	231	278	325	357	382	388	418	429	448	456	459	477	493
3015	180	218	231	280	325	358	383	393	429	439	460	469	480	512	529
3016	204	257	270	312	351	389	410	424	443	452	470	467	488	506	516
MEAN	187.1	225.7	237.5	282.4	327.0	357.4	380.2	389.3	417.8	425.9	448.9	458.3	470.1	492.0	503.1
S.D.	6.9	11.0	12.2	12.1	11.5	15.1	14.3	16.3	16.9	21.3	17.7	17.4	16.9	18.0	15.1
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

MALES GROUP 4 CERIC OXIDE HIGH DOSE

ANIMAL NO. \ DAY	-6	-2	1	8	15	22	27	29	36	43	50	55	57	64	71
4001	180	216	229	267	313	341	356	361	393	408	433	430	446	467	473
4002	177	198	206	231	277	303	317	327	351	360	372	370	386	399	406
4003	187	230	242	294	344	377	403	418	458	466	489	491	516	534	550
4004	191	219	229	266	305	331	344	355	377	382	394	390	405	418	434
4005	191	233	243	284	316	350	363	377	399	412	430	435	451	469	486
4006	192	224	228	275	308	342	371	374	407	427	452	457	467	485	501
4007	184	212	221	250	286	320	334	342	354	357	381	383	398	418	418
4008	195	238	245	289	322	350	367	375	400	406	429	442	453	468	477
4009	190	219	225	264	298	321	340	341	366	377	387	396	404	417	438
4010	189	233	245	287	323	361	385	395	429	443	462	472	491	507	526
4011	187	231	240	287	330	371	393	404	429	437	463	469	483	512	517
4012	187	219	235	274	306	335	344	356	376	385	407	407	426	436	461
4014	185	218	229	268	315	336	350	360	381	382	400	393	407	429	441
4015	179	212	221	264	312	338	359	365	394	402	421	433	445	469	482
4016	203	253	270	318	351	396	433	436	480	494	526	531	553	574	586
MEAN	187.8	223.6	234.0	274.5	313.7	344.7	364.1	372.4	399.6	409.2	429.8	433.3	448.6	466.8	479.7
S.D.	6.5	13.1	14.6	20.3	19.5	24.0	29.8	29.9	36.8	38.7	42.9	45.1	47.3	49.5	50.1
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	78	85	90	91
MALES GROUP 1 AIR CONTROL				
1001	538	548	542	536
1002	542	554	553	538
1005	547	554	542	535
1006	469	480	464	462
1007	527	534	536	525
1008	447	451	449	441
1009	440	452	454	439
1010	524	536	538	531
1011	391	404	402	400
1012	558	558	554	549
1013	502	506	500	485
1014	570	576	566	551
1015	557	568	561	551
1016	570	580	581	567
1017	545	558	542	538
MEAN	515.3	523.9	519.0	510.0
S.D.	54.0	53.6	52.6	51.0
N	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	78	85	90	91
MALES	GROUP 2	CERIC OXIDE		LOW DOSE
2001	498	510	513	504
2002	528	544	546	529
2003	579	592	578	570
2004	524	539	527	516
2005	503	509	498	496
2006	511	523	504	504
2007	485	495	492	482
2008	490	501	500	489
2009	397	422	422	421
2010	562	578	576	568
2011	459	459	460	453
2012	496	507	504	494
2013	454	464	470	460
2015	502	519	506	496
2016	568	577	575	569
MEAN	503.7	515.8	511.4	503.4
S.D.	46.9	46.4	44.1	42.8
N	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	78	85	90	91
MALES GROUP 3 CERIC OXIDE				
3001	550	557	547	538
3002	506	512	514	506
3003	526	547	539	531
3004	487	501	495	486
3005	504	518	520	510
3006	525	546	547	535
3007	489	496	501	486
3008	534	550	556	546
3009	515	526	531	517
3011	504	520	521	511
3012	507	513	513	503
3013	507	504	496	490
3014	496	510	505	500
3015	538	547	543	534
3016	522	537	542	531
MEAN	513.9	525.5	524.5	515.1
S.D.	18.2	20.2	20.2	19.8
N	15	15	15	15

INTERMEDIATE DOSE

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	78	85	90	91
	MALES GROUP 4 CERIC OXIDE HIGH DOSE			
4002	409	414	407	401
4003	563	574	572	561
4004	440	425	421	424
4005	498	508	510	502
4006	514	531	533	517
4007	420	427	419	418
4008	484	498	494	488
4009	437	445	445	433
4010	537	549	553	541
4011	525	534	529	525
4012	469	479	468	467
4014	442	454	459	451
4015	493	500	506	487
4016	601	623	631	615
MEAN	487.9	497.0	496.2	487.9
S.D.	56.3	61.4	64.7	60.8
N	14	14	14	14

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	-13	-7	-3	1	8	15	22	27	29	36	43	50	55	57	64
FEMALES GROUP 1 AIR CONTROL															
1501	115	143	159	158	173	187	198	207	204	226	231	237	245	249	250
1502	110	138	150	164	191	202	223	226	244	253	257	267	264	273	275
1503	112	134	152	156	188	194	215	225	219	237	237	251	257	257	268
1504	110	134	152	165	189	205	216	227	240	240	240	254	260	263	265
1505	104	133	146	147	168	188	204	214	206	227	230	242	246	249	252
1506	109	147	160	168	192	202	223	234	222	240	230	247	255	260	247
1507	113	139	156	171	196	223	239	245	253	260	257	271	279	281	280
1508	118	153	172	177	193	210	235	239	236	256	243	265	269	267	274
1509	107	139	149	157	180	192	207	212	220	230	227	237	239	235	242
1510	106	132	144	155	168	184	199	202	215	231	226	238	243	244	248
1511	113	143	153	156	177	189	205	211	209	224	228	239	251	250	254
1512	111	134	151	157	172	184	190	189	201	208	213	229	228	231	225
1513	107	137	148	157	168	189	198	204	197	205	200	219	214	221	213
1514	106	134	152	160	178	194	209	215	224	224	220	235	238	243	245
1515	107	138	151	159	184	201	218	227	234	220	250	259	270	270	287
MEAN	110.0	138.5	153.0	160.6	181.1	196.3	211.8	218.4	221.6	232.1	232.6	246.1	250.6	252.8	255.0
S.D.	3.7	6.0	6.7	7.3	9.9	10.8	14.1	15.1	16.9	16.0	15.7	14.9	17.1	16.7	20.4
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

FEMALES GROUP 2 CERIC OXIDE LOW DOSE

ANIMAL NO. \ DAY	-13	-7	-3	1	8	15	22	27	29	36	43	50	55	57	64
2501	105	135	151	159	183	194	210	215	226	228	232	236	240	252	251
2502	108	132	147	153	169	186	197	214	226	225	236	225	229	239	241
2503	107	136	153	158	177	194	206	211	213	226	231	237	243	243	247
2504	110	136	150	159	183	198	217	225	224	242	246	260	256	261	271
2505	111	137	151	152	175	194	220	227	219	225	231	234	235	242	234
2506	114	140	156	153	195	206	224	233	244	229	248	245	256	269	275
2507	112	146	160	170	199	212	228	244	248	260	263	259	271	276	291
2508	108	144	162	172	199	220	253	251	252	281	274	291	286	301	304
2509	114	151	167	179	202	209	233	233	246	255	256	260	252	269	274
2510	117	156	177	179	216	233	251	254	256	269	274	284	282	281	292
2511	105	138	149	155	176	185	203	213	205	221	214	226	237	233	247
2512	113	142	166	176	200	214	227	236	239	238	246	250	254	255	263
2513	113	149	167	174	193	202	220	225	230	228	241	256	254	258	258
2514	109	129	148	153	177	186	204	211	213	222	211	230	230	233	242
2515	111	146	162	170	197	207	226	225	240	246	238	249	250	250	260
MEAN	110.4	141.1	157.6	164.2	189.4	202.5	221.4	227.7	232.1	239.7	242.8	249.4	251.6	257.6	263.3
S.D.	3.6	7.4	9.0	10.3	13.2	13.7	16.3	14.1	15.6	18.8	18.7	19.6	17.4	19.3	20.8
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

FEMALES GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO. \ DAY	-13	-7	-3	1	8	15	22	27	29	36	43	50	55	57	64
3501	110	139	155	162	190	204	219	227	233	246	256	262	258	270	281
3502	110	141	153	157	173	182	193	164	192	205	213	223	226	231	242
3503	106	141	159	165	194	210	232	241	245	251	250	270	277	271	279
3504	109	132	148	154	175	187	197	205	206	218	232	235	238	242	251
3505	108	139	156	160	175	196	203	217	226	217	238	233	242	252	242
3506	111	136	152	157	192	204	219	228	227	242	255	253	265	272	279
3507	106	135	149	155	187	180	220	207	217	213	230	241	233	244	226
3508	108	138	157	156	186	198	216	223	227	239	235	255	259	257	260
3509	105	132	145	150	182	193	223	227	231	230	254	264	259	270	276
3510	111	137	156	165	189	218	230	245	251	250	245	260	270	269	274
3511	110	132	147	161	161	183	201	198	211	206	218	230	223	232	214
3513	108	147	159	168	193	203	209	216	231	234	227	243	247	253	247
3514	120	140	163	173	192	213	227	241	253	253	268	295	282	299	299
3516	120	144	159	160	184	202	210	216	219	234	232	248	242	249	250
3517	103	121	137	135	165	173	194	197	201	213	208	217	216	219	228
MEAN	109.7	137.0	153.1	158.5	182.5	196.3	212.8	216.8	224.7	230.2	237.4	248.5	249.2	255.3	256.6
S.D.	4.7	6.1	6.7	8.8	10.4	13.1	12.8	20.9	17.6	16.8	17.0	20.4	20.0	20.5	24.2
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	-13	-7	-3	1	8	15	22	27	29	36	43	50	55	57	64
FEMALES GROUP 4 CERIC OXIDE HIGH DOSE															
4501	117	146	160	161	198	215	242	236	230	245	268	272	265	264	278
4502	115	133	147	152	176	181	216	213	219	234	222	251	240	240	241
4503	105	131	144	153	168	177	199	208	192	210	204	224	224	227	229
4504	107	138	156	155	176	191	198	205	207	213	223	228	230	233	235
4505	113	141	155	164	185	191	214	218	227	236	227	246	245	254	245
4506	111	141	155	165	193	212	224	231	239	245	244	254	254	257	266
4507	111	147	157	162	181	193	216	220	213	230	221	242	244	251	250
4508	118	152	171	177	203	209	225	228	237	239	238	254	253	256	266
4509	109	135	145	151	183	198	217	226	213	238	237	245	241	240	241
4510	107	134	145	151	178	196	203	214	215	209	228	232	237	240	250
4511	108	134	145	142	169	183	202	210	204	217	220	230	233	228	239
4513	114	152	163	177	201	208	226	227	235	246	246	259	263	263	270
4514	113	148	165	170	193	205	222	224	234	235	242	252	257	253	258
4515	112	144	156	165	198	228	234	253	259	274	270	281	272	284	281
4516	103	130	138	140	165	188	194	205	215	248	232	254	248	251	249
MEAN	110.8	140.3	153.4	158.9	184.4	198.4	215.4	221.1	222.4	234.7	234.7	248.3	247.0	249.5	253.2
S.D.	4.4	7.5	9.2	11.2	12.6	14.2	14.0	13.2	17.0	17.3	17.7	15.8	13.6	15.2	15.8
N	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	71	78	85	90	91
FEMALES GROUP 1 AIR CONTROL					
1501	265	261	272	277	272
1502	280	281	277	281	274
1503	265	270	274	276	273
1504	273	274	267	276	261
1505	257	260	260	260	248
1506	267	269	270	266	267
1507	298	290	296	293	285
1508	296	293	292	290	278
1509	2[illegible]	255	251	248	242
1510	257	264	261	266	260
1511	260	266	271	269	271
1512	229	236	234	233	226
1513	233	232	251	232	226
1514	251	239	246	250	240
1515	285	288	292	294	280
MEAN	264.1	265.1	267.7	267.4	260.1
S.D.	20.3	18.9	17.7	19.8	19.3
N	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	71	78	85	90	91
FEMALES	GROUP 2	CERIC OXIDE			LOW DOSE
2501	265	262	271	276	263
2502	234	244	252	248	240
2503	249	256	243	248	248
2504	282	279	282	269	261
2505	243	237	244	247	235
2506	267	278	277	281	271
2507	291	270	282	282	275
2508	312	312	318	321	314
2509	266	278	277	273	266
2510	294	301	301	292	285
2511	243	249	250	261	253
2512	260	265	261	273	252
2513	261	272	269	274	257
2514	233	248	245	245	240
2515	263	267	258	267	262
MEAN	264.2	267.7	268.7	270.6	261.6
S.D.	22.8	20.5	21.6	20.1	20.1
N	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	71	78	85	90	91
FEMALES	GROUP 3	CERIC OXIDE			INTERMEDIATE DOSE
3501	279	280	279	276	267
3502	243	247	253	249	245
3503	290	288	293	290	288
3504	242	248	258	253	244
3505	248	247	262	267	251
3506	273	274	283	277	272
3507	232	238	220	242	237
3508	265	268	277	276	267
3509	275	279	284	269	265
3510	277	275	278	281	266
3511	217	228	242	246	226
3513	260	260	267	266	259
3514	301	285	300	299	289
3516	249	255	257	257	251
3517	231	232	230	227	218
MEAN	258.7	260.1	265.5	264.9	256.5
S.D.	23.9	19.8	22.8	19.4	20.5
N	15	15	15	15	15

APPENDIX NO.: 2
PROJECT NO.: 90831

INDIVIDUAL BODY WEIGHTS (G)

ANIMAL NO. \ DAY	71	78	85	90	91
FEMALES	GROUP 4	CERIC OXIDE		HIGH DOSE	
4501	273	275	283	293	289
4502	248	247	263	259	252
4503	221	232	237	241	227
4504	232	236	241	240	232
4505	255	258	255	260	250
4506	265	266	269	260	258
4507	256	261	255	251	247
4508	267	275	268	268	257
4509	251	248	246	238	241
4510	249	244	250	254	243
4511	242	248	241	256	246
4513	273	278	278	280	270
4514	260	269	267	280	262
4515	283	295	289	284	271
4516	245	245	245	242	239
MEAN	254.9	258.5	259.2	260.4	252.3
S.D.	16.4	17.7	16.1	17.3	16.2
N	15	15	15	15	15

APPENDIX NO. 3 PROJECT NO. 90831

INDIVIDUAL FOOD CONSUMPTION (G)
MALES AND FEMALES

The following footnotes have been used throughout the appendix:

Pf	Powdered food
T	Technical error

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

MALES GROUP 1 AIR CONTROL

ANIMAL NO. \ DAY	8	15	22	29	36	43	50	57	64	71	78	85	91
1001	186	200	209	207	219	195	233	226	231	207	214	233	160
1002	161	179	181	191	200	179	213	221	213	199	208	210	166
1005	174	189	200	203	216	198	218	225	227	230	226	205	166
1006	162	179	181	182	167	155	172	175	184	191	177	176	144
1007	182	191	T	216	224	195	218	228	232	224	216	220	187
1008	156	154	177	173	163	151	167	177	207	172	162	162	133
1009	148	162	163	160	165	148	167	169	171	169	160	162	140
1010	180	194	205	206	212	185	212	220	221	221	215	216	183
1011	152	160	162	161	167	139	161	172	163	175	163	159	134
1012	183	207	213	213	227	193	220	241	234	217	219	196	159
1013	189	179	183	179	193	170	202	203	186	202	207	193	167
1014	204	223	237	232	244	205	227	248	248	233	229	224	172
1015	201	214	224	220	221	204	222	234	244	234	226	214	164
1016	222	227	240	247	253	222	251	261	119	246	219	224	201
1017	202	208	214	216	215	187	209	229	230	221	205	202	158
MEAN	180.1	191.1	199.1	200.5	205.8	181.7	206.2	215.3	207.2	209.4	203.1	199.7	162.2
S.D.	21.5	22.5	25.3	25.5	29.0	24.2	27.2	29.3	35.9	24.3	24.7	24.7	19.2
N	15	15	14	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

MALES GROUP 2 CERIC OXIDE LOW DOSE

ANIMAL NO. \ DAY	8	15	22	29	36	43	50	57	64	71	78	85	91
2001	180	183	188	182	192	165	194	206	204	216	187	191	171
2002	185	207	211	203	206	181	208	223	224	226	215	213	172
2003	197	228	237	240	232	207	253	272	264	226	231	226	182
2004	191	206	208	205	202	176	215	226	226	218	211	216	171
2005	178	186	197	192	201	160	211	223	225	218	212	204	165
2006	183	187	188	195	196	180	203	207	193	199	198	195	154
2007	176	193	198	186	203	181	191	199	206	209	188	199	156
2008	178	185	197	190	197	179	201	209	189	207	198	207	171
2009	168	174	184	182	189	169	193	203	200	203	111	Pf	127
2010	199	210	224	227	249	226	244	252	265	264	245	250	200
2011	153	161	175	169	169	143	166	173	171	173	174	165	150
2012	161	166	172	171	178	166	184	196	192	190	193	192	162
2013	156	166	173	176	175	158	164	187	312	185	172	175	157
2015	175	191	188	187	T	184	204	192	200	207	207	216	168
2016	188	196	204	208	215	200	214	224	219	223	211	201	166
MEAN	177.9	189.3	196.2	194.2	200.3	178.4	203.0	212.9	219.4	210.9	197.0	203.5	165.0
S.D.	13.6	18.5	18.4	19.8	21.5	20.7	24.1	25.1	36.6	21.2	30.9	21.2	16.0
N	15	15	15	15	14	15	15	15	15	15	15	14	15

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

MALES GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO. \ DAY	8	15	22	29	36	43	50	57	64	71	78	85	91
3001	194	204	217	217	214	188	224	238	236	235	229	214	171
3002	182	189	189	198	194	132	225	233	228	219	200	204	178
3003	195	191	196	200	203	188	195	208	217	216	209	216	183
3004	164	175	181	182	177	158	176	186	193	197	185	192	158
3005	169	177	188	196	190	180	199	201	202	204	201	203	180
3006	180	205	203	202	218	196	223	218	229	214	174	227	186
3007	179	202	Pf	191	206	201	211	219	218	217	202	205	168
3008	187	193	210	209	206	188	208	208	224	227	220	228	191
3009	178	183	188	195	193	174	197	211	195	200	199	207	170
3011	186	187	205	193	201	183	223	220	206	214	207	208	169
3012	198	205	216	220	224	196	193	205	214	217	211	207	173
3013	174	184	188	207	199	177	207	226	208	210	200	198	160
3014	178	190	197	196	202	184	201	215	205	208	200	201	178
3015	169	183	193	203	211	186	206	210	218	221	207	203	173
3016	189	186	194	205	199	189	190	200	207	206	201	202	176
MEAN	181.5	190.3	197.4	200.8	202.6	181.5	205.1	213.2	213.1	213.7	203.0	207.7	174.3
S.D.	10.0	10.0	11.1	9.8	11.7	17.1	14.4	13.2	12.6	10.0	12.9	9.9	9.1
N	15	15	14	15	15	15	15	15	15	15	15	15	15

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

MALES GROUP 4 CERIC OXIDE HIGH DOSE

ANIMAL NO. \ DAY	8	15	22	29	36	43	50	57	64	71	78	85	91
4001	164	177	184	176	188	159	186	188	187	180	DEAD		
4002	136	158	166	167	167	156	162	168	161	159	154	157	135
4003	188	197	187	217	220	204	217	223	223	227	216	222	175
4004	161	172	174	171	174	162	165	167	167	174	175	158	136
4005	195	190	196	196	195	181	203	205	213	218	215	210	179
4006	170	Pf	188	198	210	192	199	202	206	210	211	210	173
4007	147	156	170	174	162	145	171	184	178	166	163	164	139
4008	196	176	185	188	186	174	198	201	197	197	198	202	174
4009	166	168	170	171	170	165	165	175	179	187	171	175	151
4010	187	188	202	211	219	197	216	226	232	238	223	225	185
4011	184	197	207	213	201	181	203	213	223	221	213	217	180
4012	175	168	183	180	178	158	185	186	176	202	191	196	160
4014	166	174	175	183	180	161	185	171	187	186	173	190	167
4015	192	183	186	188	188	173	194	197	199	208	206	203	170
4016	211	184	216	225	235	215	242	247	243	237	229	237	196
MEAN	175.8	177.6	185.9	190.6	191.4	174.9	192.7	196.9	198.0	200.7	195.6	197.5	165.7
S.D.	20.2	12.8	14.4	18.7	21.5	19.9	22.2	23.4	24.7	24.9	24.4	25.7	18.9
N	15	14	15	15	15	15	15	15	15	15	14	14	14

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

ANIMAL NO. \ DAY	1	8	15	22	29	36	43	50	57	64	71	78	85	91
FEMALES GROUP 1 AIR CONTROL														
1501	126	124	128	123	124	141	123	141	139	134	132	132	130	113
1502	120	127	137	147	144	150	139	158	143	148	140	140	140	117
1503	114	131	121	135	132	149	135	156	149	149	T	133	144	117
1504	120	126	128	132	137	136	121	144	140	135	138	131	131	106
1505	117	128	135	132	127	144	130	163	152	152	134	142	146	122
1506	120	127	127	138	131	133	127	140	143	127	136	144	141	118
1507	131	139	142	144	144	137	124	153	144	139	150	139	138	114
1508	130	126	136	138	136	145	114	158	141	134	144	149	130	119
1509	117	120	123	131	134	136	127	142	124	130	125	131	123	103
1510	117	113	127	126	139	144	114	148	141	143	134	138	131	122
1511	113	121	120	121	123	127	111	140	140	131	124	132	137	112
1512	120	120	130	125	121	122	115	156	129	126	116	112	123	88
1513	116	115	125	119	112	110	103	128	114	116	120	113	134	99
1514	121	115	126	124	126	116	109	132	126	120	119	T	117	103
1515	122	120	136	128	140	128	138	167	165	163	151	T	160	135
MEAN	120.4	123.5	129.4	130.8	131.5	134.6	121.9	148.5	139.2	136.4	133.1	133.5	135.0	112.6
S.D.	5.4	6.8	6.4	8.2	9.1	11.9	10.9	11.6	12.3	12.8	11.2	10.8	10.6	11.3
N	15	15	15	15	15	15	15	15	15	15	14	13	15	15

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

FEMALES GROUP 2 CERIC OXIDE LOW DOSE

ANIMAL NO. \ DAY	1	8	15	22	29	36	43	50	57	64	71	78	85	91
2501	124	131	135	134	139	140	118	145	147	144	138	136	139	121
2502	117	121	130	124	140	133	118	127	140	131	118	124	125	100
2503	119	125	133	135	132	145	135	146	140	142	136	139	129	117
2504	118	129	135	138	144	152	134	161	153	157	155	148	154	121
2505	113	115	125	127	132	120	113	132	121	120	113	113	116	100
2506	119	145	146	144	155	141	143	156	162	169	151	147	151	134
2507	123	129	131	141	140	138	123	143	135	147	133	T	123	96
2508	124	134	140	155	138	159	141	162	153	153	149	147	139	120
2509	134	139	148	156	146	149	130	145	155	147	109	142	133	105
2510	143	157	166	164	167	165	155	185	156	168	167	T	165	132
2511	116	119	120	131	124	133	118	143	135	141	127	T	137	118
2512	134	136	132	142	139	134	128	151	133	138	132	129	129	110
2513	124	124	129	132	140	130	131	152	144	143	138	136	133	119
2514	120	121	125	124	128	126	117	136	130	133	122	131	126	104
2515	129	136	137	142	137	135	129	118	137	136	134	136	130	120
MEAN	123.8	130.8	135.5	139.3	140.1	139.9	128.9	146.7	142.7	144.5	134.7	135.7	135.3	114.5
S.D.	8.2	11.0	11.3	11.9	10.4	12.0	11.6	16.0	11.4	13.3	16.0	10.3	13.0	11.4
N	15	15	15	15	15	15	15	15	15	15	15	12	15	15

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

FEMALES GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO. \ DAY	1	8	15	22	29	36	43	50	57	64	71	78	85	91
3501	118	123	133	132	136	141	134	155	144	161	135	149	138	116
3502	119	108	114	113	Pf	110	97	T	108	114	111	109	113	95
3503	134	137	146	144	146	134	120	161	153	144	147	144	137	120
3504	108	106	115	114	108	117	115	126	117	124	113	124	122	99
3505	114	114	126	120	130	119	118	127	128	122	113	127	132	106
3506	112	122	122	124	122	128	127	132	133	146	118	129	130	106
3507	112	120	113	135	120	125	122	138	130	121	123	122	122	112
3508	118	126	125	132	130	135	113	143	132	129	129	130	131	106
3509	111	122	123	143	134	135	135	157	143	152	138	143	147	109
3510	130	138	148	146	149	151	129	155	146	142	152	135	142	124
3511	114	103	114	122	118	115	115	144	123	115	109	119	133	104
3513	126	129	132	130	140	136	113	141	142	133	133	133	132	111
3514	129	134	134	150	154	153	145	192	163	150	161	134	150	134
3516	109	115	122	120	119	124	107	137	116	124	109	113	114	98
3517	103	110	117	122	122	122	109	113	120	133	125	122	118	104
MEAN	117.1	120.5	125.6	129.8	130.6	129.7	119.8	144.4	133.2	133.9	127.8	128.9	130.7	109.6
S.D.	9.1	11.0	11.1	11.8	13.3	12.7	12.3	19.4	15.2	14.4	16.5	11.2	11.3	10.4
N	15	15	15	15	14	15	15	14	15	15	15	15	15	15

APPENDIX NO.: 3
PROJECT NO.: 90831

INDIVIDUAL FOOD CONSUMPTION (GRAMS/ANIMAL)

FEMALES GROUP 4 CERIC OXIDE HIGH DOSE

ANIMAL NO. \ DAY	1	8	15	22	29	36	43	50	57	64	71	78	85	91
4501	T	133	139	140	120	128	141	161	133	140	139	137	136	129
4502	117	118	126	135	129	127	115	156	129	128	129	131	132	121
4503	117	112	115	127	117	137	110	154	131	127	118	135	120	106
4504	140	125	128	127	126	126	123	139	125	126	125	121	118	101
4505	112	113	114	126	122	130	109	142	129	130	124	130	125	111
4506	135	141	141	139	139	140	123	152	130	140	124	131	127	103
4507	127	121	131	140	125	142	122	169	143	144	140	152	140	111
4508	132	139	T	131	129	133	132	155	144	143	139	139	138	116
4509	114	126	134	131	125	145	127	142	130	128	125	127	120	103
4510	117	124	124	118	118	122	122	142	135	139	131	128	136	110
4511	105	111	119	119	111	111	103	131	120	123	113	116	115	103
4513	126	124	120	133	123	137	126	140	147	143	133	140	135	122
4514	128	130	134	143	139	148	133	162	152	145	143	142	140	118
4515	122	129	138	135	146	149	131	154	142	141	136	143	132	109
4516	105	107	117	T	118	144	114	140	130	125	112	121	117	95
MEAN	121.3	123.5	127.2	131.7	125.9	134.5	122.1	149.4	134.5	134.8	128.7	133.0	128.7	110.5
S.D.	10.7	10.3	9.3	7.8	9.3	10.7	10.4	10.8	9.0	8.1	9.8	9.6	9.1	9.2
N	14	15	14	14	15	15	15	15	15	15	15	15	15	15

APPENDIX NO. 4

INDIVIDUAL OPHTHALMOSCOPY
EXAMINATION
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE LOW DOSE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE
GROUP 4 - CERIC OXIDE HIGH DOSE

GROUP NO.	ANIMAL NO.	PRETREATMENT	WEEK 13
1	1007	Focal nuclear opacity, left eye	
		All other animals appear normal	
	1010	-	Reddish discharge, left eye
	1017	-	Focal chorioretinal atrophy, right eye
			All other animals appear normal
2	2015	Focal nuclear opacity, both eyes	
		All other animals appear normal	
3	3013	Vitreous hemorrhage, right eye	
		All other animals appear normal	
4	4006	Vitreous hemorrhage, left eye	All animals appear normal
	4007	Focal nuclear opacity, left eye	
		All other animals appear normal	

APPENDIX NO. 4

INDIVIDUAL OPHTHALMOSCOPY
EXAMINATION
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL
GROUP 2 - CERIC OXIDE LOW DOSE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

GROUP NO.	ANIMAL NO.	PRETREATMENT	WEEK 13
1	1510	Vitreous hemorrhage, right eye	
		All other animals appear normal	
	1512	-	Focal nuclear opacity, left eye
			All other animals appear normal
2	2511	Vitreous hemorrhage, left eye	
	2514	Focal nuclear opacity, right eye	
		All other animals appear normal	
3	3502	Focal nuclear opacity, right eye	
	3506	Vitreous hemorrhage, left eye	
	3507	Vitreous hemorrhage, left eye	
		All other animals appear normal	

APPENDIX NO. 4

INDIVIDUAL OPHTHALMOSCOPY
EXAMINATION
FEMALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

GROUP NO.	ANIMAL NO.	PRETREATMENT	WEEK 13
4	4505	Focal nuclear opacity, right eye	
	4506	Focal nuclear opacity, right eye	Focal nuclear opacity, right eye
		All other animals appear normal	
	4507		Focal chorioretinal atrophy, right eye
			All other animals appear normal

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HOME CAGE															
BODY POSITION	5	5	5	5	4	5	5	5	4	4	5	5	4	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	2	0	0	0	0	0	0	0	0	0	1	1	0	0
ARENA															
REARING	9	3	6	7	7	5	7	8	7	8	5	3	7	6	7
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	0	2	0	0	0	2	2	0	0	0	0	0
DEFECATION	3	0	1	4	4	5	4	0	2	3	3	4	2	1	4
URINATION	0	2	2	2	2	2	2	2	0	2	2	2	2	2	2
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HOME CAGE															
BODY POSITION	5,6	5	4	4	5	4	5	4	5,6	5	5,6	5	5	5	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
VOCALIZATION	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0
ARENA															
REARING	4	6	6	7	11	9	7	9	14	12	6	7	6	7	6
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	2	0	0	2	0	0	0	0	0	2	2	2	0	0
DEFECATION	1	1	5	0	7	2	4	0	2	6	0	0	0	1	0
URINATION	0	2	2	2	2	2	2	0	0	2	0	0	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HANDLING															
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HOME CAGE															
BODY POSITION	5	4	4	5	4	4	5	5	5	5	5	5	4	5	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0
ARENA															
REARING	8	7	9	4	8	5	4	15	3	6	7	11	6	8	6
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO. 3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	6	5	5	5	5	5	5	5
GROOMING	2	0	0	0	0	0	2	0	2	0	0	0	0	0	0
DEFECATION	0	4	3	0	3	4	0	0	2	0	2	3	0	2	4
URINATION	0	2	2	0	0	2	0	2	2	0	0	0	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO. 4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HOME CAGE															
BODY POSITION	5	5	5	5	5	5	4	5	5	4	5	5	4	4	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
ARENA															
REARING	5	13	8	7	7	6	5	7	11	5	7	11	7	8	4
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	0	0	0	2	2	0	0	0	0	0	0	0
DEFECATION	3	1	4	0	3	2	3	4	0	4	0	1	0	0	0
URINATION	2	2	2	0	2	2	0	2	0	2	0	0	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HOME CAGE															
BODY POSITION	5	5,6	5	5,6	5	4	5	5	5	4	5	5	5	5	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	1	0	0	0	0	0	0	0	4	0	0	0	0
ARENA															
REARING	11	14	12	15	4	10	7	8	13	9	17	8	16	10	10
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	2	0	0	0	0	0	0	2	0	2	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
URINATION	0	0	0	0	0	0	0	0	0	0	2	0	2	0	2
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HOME CAGE															
BODY POSITION	5,6	5	5	5,6	5	5	5	5	5	5	4	5	5	5,6	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	3	0
ARENA															
REARING	16	13	12	8	7	6	14	14	10	13	10	9	10	19	14
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	0	0	0	0	2	0	0	0	2	0	0	0
DEFECATION	0	0	0	0	0	3	0	0	0	0	0	0	0	0	0
URINATION	0	0	0	0	2	2	2	2	2	0	0	2	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HOME CAGE															
BODY POSITION	5	4	4	5	5	5,6	5,6	5,6	5	5	5	5,6	4	4	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOLTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	10	9	12	14	10	12	11	11	11	16	15	16	15	11	16
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
DEFECATION	2	0	0	0	0	0	0	0	0	0	0	0	2	0	0
URINATION	0	0	2	0	0	0	0	0	2	2	0	2	2	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO. 4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HOME CAGE															
BODY POSITION	5,6	5	5,6	5,6	5	5	5,6	5	4	4	4	5	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	9	8	16	14	12	12	21	12	11	6	4	13	10	9	13
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	2	0	2	0	2	2	2	0	2	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
PRESTUDY
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECTS NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HOME CAGE															
BODY POSITION	5	5	5	5	4	5	4	5	5	4	4	5	4	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	1	0	0	0	0	0	0	0	0	0	4	1	0	0
ARENA															
REARING	10	10	7	8	2	5	12	13	7	8	5	3	2	8	7
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

PROJECTS NO. 90831

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	2	4	4	4	2	4	2	4	2	4	2
AROUSAL	5	5	5	5	4	5	5	5	5	5	5	5	4	5	5
GROOMING	0	0	2	2	0	0	0	2	2	0	0	2	0	0	0
DEFECATION	0	0	0	5	3	3	2	0	3	5	2	4	2	0	2
URINATION	0	0	0	0	2	2	0	2	0	2	0	2	2	0	2
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0,DC	0,DC	0,DC	0	0	0	0	0	0	0	0,DC	0	0	0	0,DC
PUPIL SIZE	4	4	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECTS NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMMENTS	b	b	-	-	-	-	-	-	-	-	b	-	-	b	b

b Post treatment staining

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HOME CAGE															
BODY POSITION	5	5,6	5	5	5	5	5	4	5	5	4	5	5	5	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	2	0	0	0	0	1	0	0	0	0	1	0	0	0	0
ARENA															
REARING	11	10	8	14	14	15	2	9	13	10	9	5	3	6	6
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	6	4	4	2	4	4	4	4	2	2	4	4
AROUSAL	5	5	5	5	5	5	4	5	5	5	5	5	5	5	5
GROOMING	0	0	2	0	0	2	2	2	2	2	0	0	0	0	0
DEFECATION	0	5	0	0	0	0	0	0	0	0	3	2	0	3	0
URINATION	0	2	0	0	2	0	0	0	2	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0,DC	0,DC	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMMENTS	-	-	b	-	-	-	-	-	-	-	-	-	-	-	-

b Post treatment staining

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HOME CAGE															
BODY POSITION	5	5,6	4	5	4	4	5	5	5	5	5	5,6	4	5,6	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	4	0	0	0	0	0	2	0	0	0	0	0	0	0	0
ARENA															
REARING	8	11	8	3	9	4	7	14	2	5	5	11	9	11	9
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	6	4	2	4	4	4	4	2	2	4	4	4	4	4
AROUSAL	5	5	5	4	5	5	5	5	4	5	5	5	5	5	5
GROOMING	0	0	0	0	0	0	0	2	0	0	2	0	0	0	2
DEFECATION	0	3	3	0	3	3	0	0	0	0	0	6	0	4	0
URINATION	0	2	0	0	0	0	0	0	2	0	0	0	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0,DC	0	0	0,DC	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMMENTS	-	-	-	b	-	-	-	-	-	-	b	-	-	-	-

b Post treatment staining

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HOME CAGE															
BODY POSITION	5,6	5	5	5	5	5	5	5	5	4	5,6	4	4	5	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	4	0	0	0	0	1	0	0	0
ARENA															
REARING	9	12	4	8	2	1	7	11	7	7	8	3	7	9	5
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	2	4	2	2	4	4	4	2	4	2	4	4	4
AROUSAL	5	5	4	5	4	4	5	5	5	5	5	4	5	5	5
GROOMING	0	0	2	0	4	0	0	0	0	0	0	2	2	0	0
DEFECATION	0	3	3	0	1	0	0	0	2	0	3	0	2	0	5
URINATION	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0,DC	0	0	0	0	0	0	0	0	0	0	0,DC	0
PUPIL SIZE	0	0	0	0	0	4	0	0	0	0	4	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMMENTS	-	-	-	-	-	-	-	-	-	-	b	-	-	-	-

b Post treatment staining

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HOME CAGE															
BODY POSITION	5,6	4	5	4	5,6	4	4	4	5	5	5,6	5	5,6	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
VOCALIZATION	3	0	0	0	1	0	0	0	0	0	3	0	0	0	0
ARENA															
REARING	20	16	9	17	7	12	8	9	5	9	13	10	18	12	9
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	6	4	4	4	4	4	4	4	4	6	4	6	4	4
AROUSAL	6	6	5	5	6	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	0	2	0	0	0	0	0	0	0	0	2	0	0
DEFECATION	0	0	0	0	0	0	0	3	0	0	0	0	0	0	5
URINATION	0	0	0	0	2	0	0	2	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HOME CAGE															
BODY POSITION	5	5	5	4	5,6	5	4	5	4	4	5	5	4	5	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	2	0	0	0	0	0	2	0	0	0
VOCALIZATION	0	0	1	0	1	0	0	0	0	0	0	1	0	1	0
ARENA															
REARING	11	16	11	12	6	9	7	6	10	10	7	8	10	19	6
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	6	4	4	4	4	4	2	4	4	4
AROUSAL	5	6	5	6	5	6	5	5	5	5	5	4	5	6	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
DEFECATION	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
URINATION	0	0	0	0	0	2	0	2	2	0	2	2	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
COMMENTS	-	-	-	-	-	-	-	-	a	-	-	-	-	-	-

a Rat dropped her pelvic area 7 to 8 times during arena observations

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HOME CAGE															
BODY POSITION	5	5	5	5	5	4	6	5	4	5,6	4	5	5,6	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	4	0	0	1	0	0	0	0	0	0	0	4	0	0
ARENA															
REARING	14	11	14	14	2	10	8	8	8	13	13	15	5	10	27
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO. 3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	2	4	4	4	4	4	6	6	4	2	6
AROUSAL	6	5	5	5	4	5	5	5	5	6	5	6	5	5	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
URINATION	0	0	2	2	2	0	0	0	2	0	0	2	2	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HOME CAGE															
BODY POSITION	5	5	5	5,6	4	5,6	5,6	5	5	4	5	5	5	5,6	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
ARENA															
REARING	14	6	12	16	16	11	14	12	12	12	12	10	11	8	18
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	6	4	4	4	4	4	4	4	6
AROUSAL	5	5	5	5	6	5	5	5	5	5	5	5	5	5	6
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	0	2	0	0	0	0	2	0	2	2	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
DAY 1
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HOME CAGE															
BODY POSITION	5	5	5	5	5	4	4	4	5,6	5	5	5	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	4	0	0
ARENA															
REARING	9	9	0	6	8	2	3	3	6	2	7	0	0	4	4
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	2	4	4	4	2	2	4	4	2	2	2	2	2
AROUSAL	5	5	4	5	5	5	5	5	5	5	5	5	4	5	5
GROOMING	0	0	0	2	2	0	2	0	0	0	0	0	0	0	0
DEFECATION	4	0	0	2	3	2	0	0	3	0	2	2	2	4	0
URINATION	2	0	0	0	2	2	0	0	2	0	0	2	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HANDLING															
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HOME CAGE															
BODY POSITION	5	5	4	4	5	5,6	5	4	5	4	5	4	4	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	3	6	5	4	13	4	0	1	10	9	0	4	5	2	3
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	2	4	4	4	4	2	2	2	4	4	2	2	2	2	2
AROUSAL	5	5	5	5	6	5	2	5	5	5	4	5	5	4	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
DEFECATION	4	2	0	0	0	2	0	0	0	0	0	2	0	0	0
URINATION	0	0	0	0	2	2	0	0	0	2	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HOME CAGE															
BODY POSITION	5	5	5	5	5,6	5	5	5	5	5	5	4	5	5	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	2	0	0	0	2	2	0	0	0	0	0	0	0	0
VOCALIZATION	0	2	0	0	0	0	1	0	0	2	0	0	0	0	0
ARENA															
REARING	2	16	10	3	9	2	4	8	4	0	2	1	6	8	1
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	2	4	4	4	4	2	2	4	2	2	4	2	4	4	2
AROUSAL	4	6	5	5	5	5	5	5	5	4	5	5	5	5	4
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	0	3	0	0	0	0	1	0	2	0	3	2
URINATION	0	2	0	0	2	0	0	0	0	2	0	0	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0,DC	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HOME CAGE															
BODY POSITION	5	5	5	5	5	5	5	5	5	5	5	5,6	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	12	4	6	4	4	6	4	6	6	3	1	6	6	2	8
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO. 4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	2	2	4	2	4	4	2	2	2	4	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	2	0	0	0	0	0	0	0	0	0	0	2	0	0
DEFECATION	0	2	2	0	0	0	0	2	0	3	0	0	0	0	2
URINATION	0	2	2	0	2	0	0	2	2	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5,6	5,6	5,6	5	5,6	5,6	5	5,6	5,6	5,6	5,6	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	6	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	16	20	8	15	7	11	4	11	14	11	13	9	21	11	5
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	6	6	5	6	6	5	5	5	6	5	6	6	5	5	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0,DC	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HANDLING															
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5,6	5,6	5,6	5	5,6	5	5,6	5	4	5,6	4	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	13	18	14	4	2	7	5	9	8	12	11	2	7	7	13
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	2	4	4	4	4	4	4	2	4	4	4
AROUSAL	6	5	5	5	5	6	5	6	5	5	5	5	5	5	6
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0
DEFECATION	0	0	0	0	0	0	0	0	3	0	0	3	0	3	0
URINATION	2	0	0	0	2	2	0	0	2	0	0	2	2	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0,DC	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HANDLING															
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5,6	5,6	5,6	4	5,6	4	5	5	5	5,6	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	2	0	0	0	2	0	0	0	0	0	0	0	0	0
ARENA															
REARING	16	7	10	15	7	16	3	4	8	2	5	21	13	8	16
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	2	4	6	4	4	4
AROUSAL	5	5	5	6	5	6	5	6	5	4	5	6	5	5	6
GROOMING	2	0	0	0	0	0	0	0	2	2	0	0	0	0	2
DEFECATION	0	0	3	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	2	0	0	0	0	0	2	0	0	2	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HOME CAGE															
BODY POSITION	5,6	5,6	5	5,6	5,6	5,6	5,6	5,6	5,6	5,6	4	5,6	5,6	5	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	11	3	10	10	9	15	13	14	15	13	1	11	19	5	21
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	4	4	4	2	4	6	4	6
AROUSAL	6	5	5	5	5	6	5	6	5	5	4	6	6	5	6
GROOMING	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
DEFECATION	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	2	0	0	0	0	2	0	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 4
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HANDLING															
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HOME CAGE															
BODY POSITION	5,6	5	5	5,6	5	5	5	5	5	5	5	5	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	2	0	6	0	2	0	0	0	0	0	0	2	2	0	0
VOCALIZATION	0	0	4	0	0	0	0	0	0	0	0	1	2	0	2
ARENA															
REARING	7	6	1	5	4	5	2	3	7	0	7	0	0	0	5
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	2	4	4	4	2	2	4	2	4	2	2	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	4	4	5	5
GROOMING	0	0	0	2	0	0	0	2	2	0	0	0	0	0	0
DEFECATION	0	0	0	1	3	0	3	0	0	0	4	4	0	0	0
URINATION	0	0	0	0	2	2	0	0	0	0	2	2	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HOME CAGE															
BODY POSITION	5	5	4	5	5,6	5	5	5	5	5	4	5,6	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
ARENA															
REARING	4	6	6	6	13	5	2	3	7	3	0	5	2	3	2
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	2	4	4	4	4	4	4	4	4	4	2	4	4	2	2
AROUSAL	5	5	5	5	5	5	5	5	5	5	4	5	5	5	5
GROOMING	0	0	0	0	0	2	0	0	2	0	0	0	0	0	0
DEFECATION	5	2	0	0	0	0	1	0	0	0	0	0	0	0	0
URINATION	0	0	0	0	2	2	0	0	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO.														
	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO. 3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HOME CAGE															
BODY POSITION	5	5	5,6	5	5,6	4	5	5	5	5	4	5	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
VOCALIZATION	1	4	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	4	11	5	3	11	2	2	7	1	5	1	3	10	5	0
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO. 3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	6	4	4	4	2	2	4	4	4	4	4	4	4	2
AROUSAL	5	6	5	5	6	5	5	6	5	5	5	5	5	5	4
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	1	0	3	0	3	6
URINATION	2	0	0	0	2	0	0	0	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	8	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	8	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

CATEGORY	ANIMAL NO.														
	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TA[illegible] INCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO. 4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HOME CAGE															
BODY POSITION	5	5	5	5,6	4	5	4	5	5	5	5	5,6	5	5,6	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	2	0	2	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	10	9	10	2	0	3	0	6	3	0	3	9	4	4	2
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	4	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	2	2	4	2	4	4	2	2	4	4	4	2
AROUSAL	5	5	6	5	4	5	5	5	5	5	5	6	5	5	5
GROOMING	0	2	0	0	0	0	0	0	0	0	2	0	0	0	0
DEFECATION	0	0	1	0	4	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	2	0	0	0	0	2	0	0	0	0	2	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4001	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5	5	5	4	4	5,6	5	5,6	5,6	5,6	5,6	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	20	19	10	16	5	9	7	9	8	7	8	4	21	14	3
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	6	6	4	4	4	4	4	4	4	4	4	4	6	4	4
AROUSAL	6	6	5	5	5	5	6	5	6	5	5	5	6	6	5
GROOMING	0	0	0	0	0	0	0	0	2	2	0	0	2	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	0	0	0	0	0	0	0	0	0	2	2	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HOME CAGE															
BODY POSITION	5,6	5,6	6	4	5	5	5	5	5	4	5	5	5,6	5,6	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
ARENA															
REARING	18	21	17	2	8	3	8	8	15	14	8	4	12	7	9
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	6	4	2	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	6	6	6	4	6	5	5	6	5	5	5	5	6	5	5
GROOMING	0	0	2	0	0	0	0	0	0	0	0	0	0	2	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	4	0
URINATION	0	0	0	0	0	0	2	2	2	0	0	0	0	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HOME CAGE															
BODY POSITION	5	5	5	5,6	5,6	5	5,6	5,6	5	5	5,6	5	5	5,6	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	9	18	9	12	4	12	6	2	5	7	11	14	9	6	17
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	2	4	4	4	4	6	4	4
AROUSAL	5	6	5	6	5	5	5	4	5	5	6	5	5	6	6
GROOMING	2	0	0	0	0	0	0	0	0	2	0	2	0	0	2
DEFECATION	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	2	2	0	0	0	0	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HOME CAGE															
BODY POSITION	5	5,6	5,6	5	5,6	5,6	5	5	5,6	5	4	5,6	5,6	5	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0
ARENA															
REARING	18	10	12	12	14	20	18	14	16	10	5	11	9	10	19
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
ARENA															
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	6	4	4	4	4	4	4	4	4	6
AROUSAL	5	5	5	5	6	5	5	5	6	5	5	6	6	6	6
GROOMING	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 8
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.														
	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HANDLING															
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HOME CAGE															
BODY POSITION	5	5	5	4	4	5	5	5	5	5	4	5	5	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	2	0	0	2	0	0
VOCALIZATION	0	0	1	0	0	0	0	0	0	1	0	0	5	0	2
ARENA															
REARING	6	2	0	0	0	4	2	1	2	1	3	0	0	4	1
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	2	2	4	2	4	2	2	4	4	2	0	4	4
AROUSAL	5	5	5	5	5	5	5	5	5	5	5	5	4	5	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	4	2	2	3	0	2	0	3	2	0	0	0
URINATION	0	0	0	0	0	0	0	0	0	0	2	2	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO.														
	1001	1002	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HOME CAGE															
BODY POSITION	5	5	4	5	5,6	5,6	5	5	5	5	4	5,6	5,6	5	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	2	0	0	0	0	0	0	0	2	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	1	4	5	0	15	3	2	0	0	0	0	3	2	0	3
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	6	4	4	2	2	2	2	4	4	2	2
AROUSAL	5	5	5	5	6	5	5	5	4	5	4	5	5	4	5
GROOMING	0	0	2	0	0	2	0	0	0	0	0	0	0	0	0
DEFECATION	3	3	0	0	0	2	1	0	3	0	1	0	0	0	0
URINATION	0	0	0	0	2	0	0	0	2	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2015	2016
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HOME CAGE															
BODY POSITION	5	5	5,6	5	5,6	4	4	5	4	5,6	5	5	5	5,6	5
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	2	0	0	2	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	5	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	0	11	3	1	7	2	0	2	0	3	0	2	12	7	1
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	2	6	2	4	4	4	2	4	2	2	4	4	4	4	2
AROUSAL	4	6	5	5	6	5	5	5	4	5	5	5	5	5	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	4	0	4	0	1	0	0	5	0	1	0	2	1	0	2
URINATION	2	2	0	0	2	0	0	0	0	0	0	0	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3001	3002	3003	3004	3005	3006	3007	3008	3009	3011	3012	3013	3014	3015	3016
HANDLING															
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.													
	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HOME CAGE														
BODY POSITION	5	5	5	4	5	5	5	5	5	5	5	5,6	5	4
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE														
EASE OF REMOVAL	0	0	0	0	0	2	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA														
REARING	11	1	0	0	2	0	6	0	1	0	6	6	0	5
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.													
CATEGORY	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
ARENA														
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	2	2	2	2	4	2	2	2	4	4	2	4
AROUSAL	5	5	5	5	5	5	6	5	5	5	5	5	4	5
GROOMING	2	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	3	0	0	0	0	0	1	1	0	0	0	0	1
URINATION	0	0	0	0	0	0	2	0	0	0	0	2	0	2
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING														
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
MALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO.													
	4002	4003	4004	4005	4006	4007	4008	4009	4010	4011	4012	4014	4015	4016
HANDLING														
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX														
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE														
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5,6	5,6	4	5,6	4	5,6	5	5	5,6	5,6	5,6	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	14	17	15	14	3	11	11	2	11	0	0	7	12	16	5
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	6	4	4	4	4	4	2	4	2	4	4	4	4	4
AROUSAL	6	6	6	6	5	5	5	5	5	5	5	6	5	6	5
GROOMING	0	0	0	0	0	0	0	0	0	0	0	0	2	2	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	0	0	0	0	0	2	2	0	0	2	2	2	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

CATEGORY	ANIMAL NO. 1501	1502	1503	1504	1505	1506	1507	1508	1509	1510	1511	1512	1513	1514	1515
HANDLING															
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5	5,6	5,6	5	4	5,6	4	4	5	5,6	4	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	1	0	0	1	0	0	0	1	0	0	0
ARENA															
REARING	19	16	19	2	8	7	7	6	13	12	5	5	9	6	6
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

CATEGORY	ANIMAL NO. 2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	6	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AROUSAL	6	6	6	5	5	5	5	5	5	5	5	5	5	5	5
GROOMING	0	0	2	0	0	0	0	0	0	0	0	0	0	2	0
DEFECATION	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0
URINATION	2	0	0	0	2	0	2	2	2	2	0	2	2	2	2
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

	ANIMAL NO.														
CATEGORY	2501	2502	2503	2504	2505	2506	2507	2508	2509	2510	2511	2512	2513	2514	2515
HANDLING															
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HOME CAGE															
BODY POSITION	5,6	5,6	5,6	5,6	5,6	5	4	5	5	5	5	5	5,6	5	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	7	19	12	11	3	4	4	1	3	6	14	8	10	4	17
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	4	2	4	4	6	4	4	2	4
AROUSAL	6	6	5	6	5	5	5	4	5	5	6	5	5	5	6
GROOMING	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	2	2	2	2	0	0	0	0	0	0	2	0	0	0
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	ANIMAL NO.														
CATEGORY	3501	3502	3503	3504	3505	3506	3507	3508	3509	3510	3511	3513	3514	3516	3517
HANDLING															
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HOME CAGE															
BODY POSITION	5	5,6	5,6	5,6	5,6	5	5,6	5,6	5,6	5,6	5	5,6	5,6	5,6	5,6
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
REMOVAL FROM HOME CAGE															
EASE OF REMOVAL	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
VOCALIZATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ARENA															
REARING	6	11	8	11	10	7	16	12	13	19	5	8	12	10	6
ATAXIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HYPOTONIC GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IMPAIRED GAIT	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
OVERALL GAIT INCAPACITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BIZARRE/STEREOTYPIC BEHAVIOR	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5

PROJECT NO. 90831

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

CATEGORY	ANIMAL NO. 4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
ARENA															
PALPEBRAL CLOSURE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TREMORS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TWITCHES	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CONVULSIONS	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
RESPIRATORY RATE/PATTERN	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
LOCOMOTOR ACTIVITY LEVEL	4	4	4	4	4	4	6	4	6	4	4	4	4	4	6
AROUSAL	5	6	5	5	5	5	5	6	5	6	5	5	6	6	5
GROOMING	0	0	0	0	0	0	0	2	0	0	0	0	0	0	2
DEFECATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINATION	0	0	0	2	2	0	2	0	0	2	0	0	0	2	2
OLFACTORY RESPONSE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HANDLING															
LACRIMATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PUPIL SIZE	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SALIVATION	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
URINARY STAINING	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
DIARRHEA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
BODY TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5

APPENDIX NO. 5

FUNCTIONAL OBSERVATIONAL BATTERY
QUALITATIVE ASSESSMENTS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	ANIMAL NO.														
CATEGORY	4501	4502	4503	4504	4505	4506	4507	4508	4509	4510	4511	4513	4514	4515	4516
HANDLING															
ABDOMINAL TONE	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
EXTENSOR THRUST	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
PINNA REFLEX	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TOE PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
TAIL PINCH	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
VISUAL PLACING	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
ON TOP OF BOX															
POSITIONAL PASSIVITY	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
ON SURFACE															
AURICULAR STARTLE	4	4	4	4	4	4	4	4	4	4	4	4	4	4	4
AIR RIGHTING REFLEX	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	795.0	340.0	6.4
	1002	650.0	380.0	9.0
	1005	685.0	610.0	9.0
	1006	900.0	550.0	6.9
	1007	770.0	340.0	6.3
	1008	790.0	340.0	3.9
	1009	805.0	335.0	9.4
	1010	655.0	570.0	7.7
	1011	915.0	460.0	9.3
	1012	780.0	390.0	6.6
	1013	970.0	510.0	8.7
	1014	690.0	395.0	9.5
	1015	915.0	430.0	6.4
	1016	715.0	285.0	7.1
	1017	860.0	565.0	10.2

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	700.0	355.0	7.9
	2002	875.0	445.0	9.7
	2003	805.0	450.0	9.6
	2004	640.0	425.0	9.5
	2005	960.0	380.0	9.9
	2006	815.0	555.0	8.9
	2007	640.0	465.0	8.6
	2008	870.0	280.0	3.7
	2009	650.0	415.0	8.5
	2010	620.0	215.0	7.9
	2011	895.0	385.0	9.5
	2012	565.0	475.0	6.9
	2013	670.0	230.0	5.5
	2015	910.0	520.0	7.6
	2016	1100.0	655.0	7.2

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	655.0	320.0	6.6
	3002	835.0	530.0	9.9
	3003	835.0	410.0	7.9
	3004	880.0	455.0	10.0
	3005	790.0	485.0	8.8
	3006	900.0	410.0	10.3
	3007	685.0	350.0	9.3
	3008	665.0	360.0	7.4
	3009	885.0	660.0	9.1
	3011	855.0	445.0	9.5
	3012	865.0	245.0	8.9
	3013	805.0	400.0	6.5
	3014	595.0	260.0	4.9
	3015	800.0	425.0	8.3
	3016	900.0	515.0	8.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	825.0	455.0	6.4
	4002	855.0	445.0	9.6
	4003	630.0	335.0	6.6
	4004	625.0	395.0	6.1
	4005	710.0	380.0	7.5
	4006	1025.0	460.0	9.3
	4007	985.0	485.0	9.8
	4008	695.0	410.0	6.4
	4009	855.0	445.0	8.5
	4010	805.0	300.0	6.8
	4011	735.0	345.0	8.5
	4012	450.0	335.0	6.6
	4014	875.0	430.0	6.6
	4015	705.0	425.0	7.1
	4016	840.0	345.0	9.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	490.0	300.0	9.0
	1502	775.0	335.0	6.3
	1503	660.0	260.0	8.1
	1504	550.0	295.0	6.8
	1505	630.0	245.0	9.0
	1506	695.0	475.0	8.4
	1507	755.0	385.0	8.9
	1508	720.0	505.0	8.4
	1509	695.0	420.0	9.1
	1510	505.0	305.0	8.4
	1511	815.0	380.0	8.0
	1512	715.0	450.0	7.5
	1513	495.0	480.0	5.1
	1514	875.0	425.0	7.4
	1515	685.0	535.0	7.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	630.0	245.0	5.0
	2502	590.0	300.0	7.7
	2503	765.0	515.0	8.6
	2504	455.0	420.0	7.9
	2505	560.0	300.0	8.6
	2506	785.0	380.0	9.3
	2507	775.0	555.0	9.5
	2508	695.0	410.0	8.3
	2509	830.0	415.0	9.1
	2510	765.0	450.0	7.6
	2511	815.0	340.0	8.7
	2512	820.0	450.0	7.6
	2513	815.0	510.0	9.5
	2514	790.0	350.0	9.2
	2515	705.0	410.0	8.2

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	805.0	475.0	6.3
	3502	845.0	370.0	9.0
	3503	815.0	490.0	8.2
	3504	645.0	290.0	7.3
	3505	775.0	295.0	7.9
	3506	765.0	330.0	6.7
	3507	650.0	520.0	7.8
	3508	645.0	350.0	8.7
	3509	760.0	390.0	8.0
	3510	815.0	465.0	7.8
	3511	710.0	390.0	7.4
	3513	550.0	360.0	6.0
	3514	935.0	290.0	6.8
	3516	675.0	350.0	6.0
	3517	490.0	315.0	3.5

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	540.0	390.0	7.2
	4502	685.0	560.0	9.3
	4503	640.0	560.0	7.1
	4504	855.0	655.0	8.2
	4505	815.0	545.0	6.7
	4506	1095.0	615.0	9.1
	4507	800.0	435.0	9.1
	4508	1075.0	680.0	7.1
	4509	545.0	460.0	5.3
	4510	615.0	460.0	6.8
	4511	880.0	470.0	7.8
	4513	780.0	685.0	5.2
	4514	575.0	585.0	5.5
	4515	680.0	455.0	4.4
	4516	600.0	395.0	5.2

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	755.0	460.0	4.9
	4502	840.0	450.0	8.7
	4503	680.0	335.0	9.4
	4504	715.0	290.0	7.2
	4505	715.0	345.0	5.4
	4506	575.0	245.0	8.4
	4507	755.0	330.0	7.1
	4508	875.0	510.0	6.8
	4509	625.0	260.0	5.0
	4510	575.0	360.0	7.2
	4511	705.0	445.0	8.8
	4513	750.0	370.0	5.6
	4514	930.0	550.0	7.9
	4515	595.0	345.0	7.0
	4516	680.0	400.0	5.7

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	1030.0	460.0	5.3
	1002	575.0	280.0	5.2
	1005	905.0	480.0	8.2
	1006	810.0	505.0	6.8
	1007	535.0	300.0	5.0
	1008	820.0	445.0	4.3
	1009	955.0	555.0	5.8
	1010	805.0	545.0	7.7
	1011	740.0	590.0	9.4
	1012	655.0	575.0	7.4
	1013	845.0	515.0	8.1
	1014	740.0	630.0	9.1
	1015	840.0	475.0	8.4
	1016	635.0	215.0	3.5
	1017	825.0	500.0	7.6

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	845.0	325.0	7.1
	2002	770.0	585.0	6.6
	2003	820.0	420.0	7.6
	2004	695.0	505.0	6.2
	2005	825.0	565.0	7.6
	2006	1025.0	555.0	6.9
	2007	825.0	635.0	7.0
	2008	830.0	565.0	4.4
	2009	690.0	570.0	4.4
	2010	530.0	265.0	7.3
	2011	930.0	525.0	9.2
	2012	575.0	350.0	5.7
	2013	755.0	330.0	4.0
	2015	905.0	505.0	8.5
	2016	760.0	665.0	5.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	685.0	330.0	4.4
	3002	1090.0	565.0	6.9
	3003	825.0	580.0	7.2
	3004	875.0	540.0	8.9
	3005	755.0	300.0	6.7
	3006	645.0	465.0	8.1
	3007	860.0	540.0	8.4
	3008	685.0	455.0	4.9
	3009	960.0	550.0	7.8
	3011	795.0	370.0	7.7
	3012	815.0	460.0	8.4
	3013	845.0	310.0	7.4
	3014	570.0	330.0	5.9
	3015	825.0	560.0	8.7
	3016	885.0	450.0	6.8

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	700.0	510.0	6.2
	4002	930.0	585.0	8.1
	4003	650.0	545.0	7.5
	4004	430.0	245.0	8.1
	4005	635.0	275.0	6.7
	4006	890.0	425.0	6.8
	4007	905.0	520.0	9.4
	4008	740.0	360.0	4.9
	4009	715.0	535.0	5.2
	4010	655.0	505.0	5.2
	4011	740.0	490.0	8.6
	4012	780.0	395.0	5.4
	4014	965.0	510.0	5.6
	4015	795.0	455.0	5.1
	4016	765.0	565.0	7.3

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	760.0	430.0	8.3
	1502	580.0	380.0	8.2
	1503	580.0	450.0	9.1
	1504	835.0	375.0	5.9
	1505	515.0	395.0	9.2
	1506	900.0	560.0	8.5
	1507	860.0	520.0	8.1
	1508	915.0	435.0	7.6
	1509	570.0	570.0	8.0
	1510	655.0	380.0	8.1
	1511	835.0	430.0	6.4
	1512	840.0	480.0	6.5
	1513	565.0	365.0	4.6
	1514	850.0	495.0	5.6
	1515	940.0	460.0	8.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	585.0	315.0	7.1
	2502	790.0	365.0	6.7
	2503	685.0	400.0	7.1
	2504	805.0	500.0	5.5
	2505	770.0	450.0	6.6
	2506	815.0	480.0	7.2
	2507	905.0	580.0	8.0
	2508	515.0	370.0	6.4
	2509	720.0	545.0	7.4
	2510	780.0	395.0	6.0
	2511	860.0	345.0	5.4
	2512	840.0	450.0	7.0
	2513	760.0	565.0	6.6
	2514	875.0	410.0	8.3
	2515	910.0	410.0	8.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	650.0	545.0	4.6
	3502	565.0	370.0	9.1
	3503	925.0	390.0	7.5
	3504	780.0	360.0	5.8
	3505	655.0	495.0	8.2
	3506	685.0	475.0	7.2
	3507	535.0	500.0	6.7
	3508	740.0	375.0	8.2
	3509	975.0	445.0	8.1
	3510	720.0	375.0	6.3
	3511	730.0	500.0	4.2
	3513	510.0	335.0	4.4
	3514	800.0	410.0	4.2
	3516	400.0	380.0	4.4
	3517	480.0	390.0	2.7

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	575.0	515.0	4.9
	4502	955.0	375.0	7.7
	4503	550.0	450.0	9.1
	4504	895.0	470.0	9.6
	4505	880.0	265.0	6.6
	4506	725.0	500.0	7.1
	4507	770.0	435.0	8.6
	4508	1015.0	465.0	4.7
	4509	515.0	480.0	4.4
	4510	690.0	410.0	5.9
	4511	725.0	365.0	6.8
	4513	725.0	510.0	4.7
	4514	915.0	460.0	7.3
	4515	590.0	375.0	4.4
	4516	755.0	555.0	4.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	790.0	380.0	5.1
	1002	735.0	465.0	6.4
	1005	865.0	470.0	8.2
	1006	615.0	555.0	8.0
	1007	840.0	545.0	9.0
	1008	800.0	440.0	6.6
	1009	1165.0	540.0	7.1
	1010	855.0	705.0	5.7
	1011	620.0	550.0	7.5
	1012	995.0	760.0	5.2
	1013	890.0	695.0	9.3
	1014	955.0	580.0	8.6
	1015	1150.0	735.0	7.1
	1016	545.0	400.0	4.3
	1017	535.0	635.0	8.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	735.0	750.0	6.7
	2002	775.0	690.0	7.1
	2003	965.0	435.0	10.1
	2004	720.0	615.0	8.9
	2005	600.0	525.0	9.4
	2006	660.0	620.0	9.7
	2007	790.0	655.0	9.7
	2008	520.0	685.0	4.8
	2009	900.0	465.0	6.2
	2010	650.0	565.0	9.0
	2011	760.0	600.0	4.6
	2012	750.0	410.0	6.6
	2013	855.0	485.0	4.4
	2015	730.0	685.0	6.9
	2016	855.0	475.0	7.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	975.0	515.0	5.4
	3002	725.0	910.0	9.8
	3003	675.0	685.0	9.0
	3004	600.0	515.0	9.0
	3005	1075.0	525.0	9.5
	3006	855.0	465.0	10.1
	3007	655.0	625.0	9.6
	3008	550.0	545.0	6.3
	3009	860.0	575.0	10.0
	3011	575.0	560.0	5.7
	3012	765.0	345.0	7.6
	3013	870.0	555.0	6.4
	3014	790.0	360.0	4.9
	3015	1300.0	670.0	8.9
	3016	875.0	765.0	8.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	955.0	675.0	6.4
	4002	805.0	820.0	10.2
	4003	800.0	860.0	9.7
	4004	720.0	680.0	11.7
	4005	725.0	550.0	6.7
	4006	710.0	575.0	8.3
	4007	610.0	510.0	11.6
	4008	675.0	505.0	6.8
	4009	900.0	595.0	7.7
	4010	355.0	395.0	5.4
	4011	820.0	635.0	5.5
	4012	890.0	445.0	5.2
	4014	800.0	390.0	8.1
	4015	805.0	555.0	5.3
	4016	900.0	745.0	5.7

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	800.0	500.0	7.8
	1502	830.0	690.0	6.8
	1503	625.0	605.0	9.1
	1504	840.0	515.0	6.1
	1505	725.0	510.0	6.7
	1506	855.0	595.0	9.3
	1507	615.0	520.0	8.1
	1508	890.0	555.0	8.6
	1509	705.0	550.0	5.8
	1510	760.0	490.0	10.1
	1511	520.0	465.0	6.5
	1512	845.0	635.0	6.0
	1513	555.0	305.0	6.7
	1514	780.0	560.0	5.8
	1515	615.0	450.0	8.9

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	700.0	395.0	7.0
	2502	690.0	475.0	8.2
	2503	705.0	530.0	7.1
	2504	840.0	500.0	4.4
	2505	650.0	475.0	7.6
	2506	575.0	590.0	6.9
	2507	950.0	440.0	8.0
	2508	575.0	475.0	6.6
	2509	645.0	435.0	8.0
	2510	845.0	470.0	5.9
	2511	805.0	545.0	8.1
	2512	850.0	495.0	7.0
	2513	840.0	560.0	9.6
	2514	750.0	325.0	9.5
	2515	600.0	455.0	8.9

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	730.0	535.0	6.1
	3502	570.0	345.0	7.6
	3503	780.0	560.0	8.6
	3504	640.0	395.0	4.8
	3505	805.0	370.0	8.6
	3506	760.0	445.0	8.4
	3507	715.0	640.0	9.9
	3508	735.0	440.0	9.3
	3509	970.0	375.0	9.4
	3510	800.0	780.0	9.1
	3511	775.0	370.0	7.1
	3513	530.0	415.0	5.9
	3514	790.0	310.0	6.9
	3516	410.0	395.0	5.8
	3517	630.0	450.0	4.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	735.0	535.0	4.8
	4502	840.0	520.0	8.8
	4503	500.0	515.0	9.1
	4504	850.0	435.0	8.0
	4505	845.0	460.0	6.6
	4506	885.0	535.0	9.2
	4507	860.0	340.0	9.4
	4508	910.0	435.0	6.6
	4509	490.0	285.0	5.7
	4510	665.0	475.0	6.8
	4511	695.0	290.0	6.8
	4513	880.0	585.0	5.8
	4514	590.0	395.0	6.1
	4515	725.0	400.0	6.3
	4516	665.0	520.0	5.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	880.0	520.0	6.2
	1002	535.0	575.0	5.9
	1005	925.0	510.0	3.6
	1006	995.0	670.0	7.9
	1007	1150.0	555.0	9.9
	1008	775.0	430.0	8.2
	1009	840.0	630.0	8.9
	1010	820.0	870.0	5.8
	1011	525.0	635.0	10.1
	1012	815.0	830.0	3.9
	1013	855.0	670.0	8.4
	1014	1190.0	930.0	10.4
	1015	780.0	670.0	8.1
	1016	535.0	445.0	3.6
	1017	550.0	400.0	9.7

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	425.0	625.0	9.0
	2002	775.0	710.0	6.4
	2003	710.0	640.0	10.2
	2004	300.0	635.0	10.3
	2005	555.0	535.0	7.5
	2006	700.0	670.0	5.9
	2007	1050.0	770.0	8.5
	2008	650.0	675.0	5.8
	2009	910.0	515.0	7.1
	2010	820.0	750.0	11.3
	2011	870.0	435.0	9.8
	2012	825.0	450.0	6.1
	2013	555.0	530.0	4.7
	2015	745.0	505.0	10.3
	2016	865.0	655.0	8.5

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	670.0	350.0	4.6
	3002	770.0	935.0	10.1
	3003	880.0	655.0	8.5
	3004	850.0	685.0	8.3
	3005	775.0	745.0	7.9
	3006	630.0	745.0	8.6
	3007	815.0	760.0	8.7
	3008	700.0	640.0	10.6
	3009	1140.0	800.0	7.8
	3011	500.0	475.0	6.5
	3012	730.0	685.0	9.2
	3013	595.0	530.0	6.9
	3014	530.0	410.0	7.0
	3015	680.0	695.0	9.1
	3016	735.0	565.0	9.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	825.0	760.0	5.1
	4002	810.0	950.0	10.0
	4003	605.0	805.0	9.5
	4004	735.0	580.0	10.0
	4005	585.0	560.0	4.4
	4006	765.0	635.0	8.4
	4007	875.0	595.0	10.3
	4008	545.0	735.0	8.8
	4009	215.0	590.0	4.9
	4010	460.0	480.0	5.5
	4011	900.0	740.0	7.8
	4012	930.0	565.0	6.2
	4014	800.0	640.0	7.6
	4015	730.0	555.0	7.6
	4016	665.0	765.0	8.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	625.0	650.0	7.8
	1502	705.0	545.0	8.9
	1503	685.0	590.0	8.9
	1504	735.0	630.0	6.6
	1505	890.0	560.0	7.4
	1506	1180.0	610.0	7.5
	1507	745.0	625.0	7.7
	1508	870.0	575.0	6.9
	1509	770.0	565.0	6.0
	1510	680.0	580.0	10.3
	1511	825.0	390.0	8.1
	1512	740.0	590.0	6.5
	1513	845.0	385.0	5.6
	1514	1075.0	880.0	5.9
	1515	730.0	625.0	9.9

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	700.0	440.0	6.9
	2502	800.0	620.0	9.5
	2503	845.0	510.0	8.5
	2504	745.0	575.0	5.9
	2505	715.0	405.0	5.6
	2506	850.0	745.0	6.4
	2507	1030.0	510.0	5.9
	2508	735.0	535.0	5.4
	2509	835.0	495.0	8.3
	2510	915.0	545.0	4.5
	2511	765.0	460.0	6.2
	2512	1100.0	530.0	4.1
	2513	710.0	625.0	8.1
	2514	770.0	665.0	9.8
	2515	820.0	765.0	8.3

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	600.0	555.0	6.9
	3502	835.0	605.0	8.5
	3503	725.0	525.0	8.4
	3504	650.0	525.0	5.9
	3505	1115.0	465.0	6.9
	3506	545.0	640.0	6.8
	3507	920.0	735.0	9.8
	3508	615.0	415.0	6.2
	3509	950.0	785.0	9.0
	3510	725.0	555.0	7.1
	3511	715.0	570.0	3.7
	3513	580.0	475.0	5.5
	3514	645.0	420.0	4.6
	3516	655.0	490.0	7.2
	3517	840.0	610.0	4.1

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	790.0	795.0	5.4
	1002	455.0	490.0	5.6
	1005	875.0	545.0	7.4
	1006	795.0	715.0	7.7
	1007	835.0	930.0	7.4
	1008	800.0	640.0	5.4
	1009	1220.0	870.0	7.6
	1010	940.0	850.0	6.1
	1011	595.0	555.0	9.3
	1012	895.0	720.0	5.1
	1013	775.0	660.0	8.9
	1014	845.0	705.0	10.2
	1015	870.0	860.0	7.9
	1016	550.0	495.0	4.4
	1017	815.0	705.0	11.3

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	970.0	775.0	9.1
	2002	845.0	745.0	4.8
	2003	1090.0	770.0	8.2
	2004	815.0	725.0	8.4
	2005	645.0	585.0	8.1
	2006	885.0	800.0	6.8
	2007	820.0	825.0	10.5
	2008	840.0	620.0	7.8
	2009	990.0	900.0	4.7
	2010	710.0	790.0	8.3
	2011	730.0	625.0	8.2
	2012	680.0	795.0	7.1
	2013	710.0	625.0	5.9
	2015	1020.0	775.0	9.5
	2016	990.0	665.0	6.3

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	800.0	665.0	5.9
	3002	930.0	1000.0	11.4
	3003	965.0	675.0	9.0
	3004	950.0	780.0	4.4
	3005	1065.0	550.0	6.3
	3006	930.0	850.0	8.8
	3007	780.0	940.0	9.4
	3008	775.0	830.0	9.7
	3009	660.0	805.0	8.5
	3011	475.0	535.0	6.1
	3012	735.0	710.0	8.3
	3013	765.0	745.0	5.7
	3014	680.0	410.0	5.1
	3015	950.0	495.0	9.3
	3016	660.0	715.0	7.6

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	970.0	1000.0	11.5
	4003	945.0	1105.0	9.0
	4004	630.0	635.0	9.6
	4005	700.0	660.0	5.4
	4006	1095.0	595.0	8.0
	4007	690.0	540.0	9.3
	4008	640.0	740.0	8.0
	4009	670.0	600.0	5.3
	4010	600.0	775.0	7.8
	4011	930.0	665.0	6.8
	4012	880.0	690.0	5.7
	4014	1030.0	570.0	5.9
	4015	625.0	450.0	5.9
	4016	1015.0	885.0	8.3

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	645.0	560.0	7.6
	1502	680.0	805.0	7.1
	1503	930.0	710.0	9.1
	1504	690.0	640.0	7.1
	1505	850.0	530.0	6.0
	1506	1050.0	885.0	7.4
	1507	890.0	735.0	9.0
	1508	890.0	820.0	9.1
	1509	1050.0	820.0	7.7
	1510	605.0	715.0	9.4
	1511	740.0	555.0	7.5
	1512	550.0	585.0	8.3
	1513	830.0	560.0	3.3
	1514	835.0	600.0	5.4
	1515	725.0	515.0	8.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	885.0	875.0	6.9
	2502	1015.0	730.0	10.0
	2503	855.0	530.0	7.0
	2504	685.0	700.0	5.7
	2505	790.0	675.0	8.0
	2506	680.0	720.0	8.7
	2507	875.0	575.0	7.9
	2508	735.0	520.0	7.5
	2509	945.0	915.0	9.4
	2510	870.0	640.0	5.8
	2511	660.0	425.0	6.9
	2512	1030.0	725.0	6.0
	2513	870.0	615.0	6.9
	2514	980.0	645.0	7.5
	2515	725.0	600.0	6.4

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	725.0	780.0	6.4
	3502	625.0	540.0	8.2
	3503	855.0	560.0	9.3
	3504	650.0	605.0	6.2
	3505	975.0	640.0	9.0
	3506	1025.0	605.0	7.6
	3507	825.0	845.0	10.3
	3508	790.0	620.0	8.3
	3509	875.0	560.0	9.0
	3510	800.0	700.0	8.6
	3511	620.0	600.0	7.0
	3513	705.0	510.0	4.5
	3514	720.0	490.0	4.2
	3516	645.0	640.0	6.6
	3517	780.0	460.0	1.8

APPENDIX NO. 5 INDIVIDUAL GRIP STRENGTH (G) AND HINDLIMB SPLAY (CM) PROJECT NO :90831

MEAN OF TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	FORELIMB GRIP STRENGTH	HINDLIMB GRIP STRENGTH	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	535.0	475.0	6.1
	4502	685.0	765.0	7.5
	4503	480.0	655.0	7.6
	4504	915.0	705.0	9.2
	4505	905.0	600.0	8.3
	4506	775.0	710.0	9.9
	4507	775.0	740.0	9.5
	4508	530.0	590.0	7.9
	4509	535.0	725.0	5.3
	4510	895.0	605.0	8.5
	4511	685.0	530.0	9.7
	4513	560.0	420.0	3.8
	4514	605.0	470.0	3.1
	4515	630.0	370.0	4.2
	4516	400.0	670.0	6.3

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1001	01	700.0	320.0
	1001	02	890.0	360.0
	1002	01	580.0	390.0
	1002	02	720.0	370.0
	1005	01	730.0	600.0
	1005	02	640.0	620.0
	1006	01	920.0	550.0
	1006	02	880.0	550.0
	1007	01	790.0	240.0
	1007	02	750.0	440.0
	1008	01	700.0	260.0
	1008	02	880.0	420.0
	1009	01	790.0	310.0
	1009	02	820.0	360.0
	1010	01	610.0	530.0
	1010	02	700.0	610.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1011	01	920.0	440.0
	1011	02	910.0	480.0
	1012	01	680.0	310.0
	1012	02	880.0	470.0
	1013	01	950.0	480.0
	1013	02	990.0	540.0
	1014	01	650.0	470.0
	1014	02	730.0	320.0
	1015	01	860.0	380.0
	1015	02	970.0	480.0
	1016	01	700.0	280.0
	1016	02	730.0	290.0
	1017	01	900.0	610.0
	1017	02	820.0	520.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	690.0	310.0
	2001	02	710.0	400.0
	2002	01	900.0	420.0
	2002	02	850.0	470.0
	2003	01	790.0	440.0
	2003	02	820.0	460.0
	2004	01	680.0	410.0
	2004	02	600.0	440.0
	2005	01	990.0	400.0
	2005	02	930.0	360.0
	2006	01	730.0	470.0
	2006	02	900.0	640.0
	2007	01	680.0	400.0
	2007	02	600.0	530.0
	2008	01	930.0	300.0
	2008	02	810.0	260.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	660.0	410.0
	2009	02	640.0	420.0
	2010	01	570.0	210.0
	2010	02	670.0	220.0
	2011	01	930.0	320.0
	2011	02	860.0	450.0
	2012	01	500.0	540.0
	2012	02	630.0	410.0
	2013	01	710.0	280.0
	2013	02	630.0	180.0
	2015	01	940.0	580.0
	2015	02	880.0	460.0
	2016	01	1200.0	670.0
	2016	02	1000.0	640.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	650.0	330.0
	3001	02	660.0	310.0
	3002	01	720.0	580.0
	3002	02	950.0	480.0
	3003	01	880.0	400.0
	3003	02	790.0	420.0
	3004	01	830.0	410.0
	3004	02	930.0	500.0
	3005	01	850.0	440.0
	3005	02	730.0	530.0
	3006	01	860.0	480.0
	3006	02	940.0	340.0
	3007	01	660.0	370.0
	3007	02	710.0	330.0
	3008	01	660.0	310.0
	3008	02	670.0	410.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	860.0	750.0
	3009	02	910.0	570.0
	3011	01	890.0	530.0
	3011	02	820.0	360.0
	3012	01	830.0	290.0
	3012	02	900.0	200.0
	3013	01	790.0	450.0
	3013	02	820.0	350.0
	3014	01	640.0	290.0
	3014	02	550.0	230.0
	3015	01	720.0	520.0
	3015	02	880.0	330.0
	3016	01	860.0	480.0
	3016	02	940.0	550.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	750.0	480.0
	4001	02	900.0	430.0
	4002	01	800.0	430.0
	4002	02	910.0	460.0
	4003	01	500.0	350.0
	4003	02	760.0	320.0
	4004	01	690.0	410.0
	4004	02	560.0	380.0
	4005	01	620.0	410.0
	4005	02	800.0	350.0
	4006	01	980.0	450.0
	4006	02	1070.0	470.0
	4007	01	990.0	460.0
	4007	02	980.0	510.0
	4008	01	730.0	410.0
	4008	02	660.0	410.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	940.0	480.0
	4009	02	770.0	410.0
	4010	01	800.0	400.0
	4010	02	810.0	200.0
	4011	01	600.0	430.0
	4011	02	870.0	260.0
	4012	01	510.0	310.0
	4012	02	390.0	360.0
	4014	01	880.0	490.0
	4014	02	870.0	370.0
	4015	01	720.0	420.0
	4015	02	690.0	430.0
	4016	01	840.0	240.0
	4016	02	840.0	450.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1501	01	500.0	330.0
	1501	02	480.0	270.0
	1502	01	710.0	370.0
	1502	02	840.0	300.0
	1503	01	670.0	280.0
	1503	02	650.0	240.0
	1504	01	520.0	210.0
	1504	02	580.0	380.0
	1505	01	660.0	240.0
	1505	02	600.0	250.0
	1506	01	630.0	420.0
	1506	02	760.0	530.0
	1507	01	600.0	390.0
	1507	02	910.0	380.0
	1508	01	610.0	500.0
	1508	02	830.0	510.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1509	01	600.0	430.0
	1509	02	790.0	410.0
	1510	01	500.0	300.0
	1510	02	510.0	310.0
	1511	01	730.0	340.0
	1511	02	900.0	420.0
	1512	01	660.0	500.0
	1512	02	770.0	400.0
	1513	01	540.0	510.0
	1513	02	450.0	450.0
	1514	01	890.0	420.0
	1514	02	860.0	430.0
	1515	01	700.0	560.0
	1515	02	670.0	510.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	700.0	230.0
	2501	02	560.0	260.0
	2502	01	590.0	330.0
	2502	02	590.0	270.0
	2503	01	770.0	490.0
	2503	02	760.0	540.0
	2504	01	500.0	420.0
	2504	02	410.0	420.0
	2505	01	570.0	280.0
	2505	02	550.0	320.0
	2506	01	760.0	350.0
	2506	02	810.0	410.0
	2507	01	720.0	550.0
	2507	02	830.0	560.0
	2508	01	600.0	360.0
	2508	02	790.0	460.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	830.0	380.0
	2509	02	830.0	450.0
	2510	01	680.0	460.0
	2510	02	850.0	440.0
	2511	01	770.0	320.0
	2511	02	860.0	360.0
	2512	01	900.0	420.0
	2512	02	740.0	480.0
	2513	01	840.0	510.0
	2513	02	790.0	510.0
	2514	01	720.0	360.0
	2514	02	860.0	340.0
	2515	01	790.0	400.0
	2515	02	620.0	420.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	930.0	440.0
	3501	02	680.0	510.0
	3502	01	760.0	290.0
	3502	02	930.0	450.0
	3503	01	800.0	560.0
	3503	02	830.0	420.0
	3504	01	690.0	310.0
	3504	02	600.0	270.0
	3505	01	700.0	300.0
	3505	02	850.0	290.0
	3506	01	780.0	340.0
	3506	02	750.0	320.0
	3507	01	600.0	530.0
	3507	02	700.0	510.0
	3508	01	630.0	340.0
	3508	02	660.0	360.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	710.0	450.0
	3509	02	810.0	330.0
	3510	01	720.0	490.0
	3510	02	910.0	440.0
	3511	01	730.0	400.0
	3511	02	690.0	380.0
	3513	01	500.0	400.0
	3513	02	600.0	320.0
	3514	01	900.0	200.0
	3514	02	970.0	380.0
	3516	01	650.0	340.0
	3516	02	700.0	360.0
	3517	01	480.0	280.0
	3517	02	500.0	350.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	780.0	470.0
	4501	02	730.0	450.0
	4502	01	950.0	450.0
	4502	02	730.0	450.0
	4503	01	790.0	270.0
	4503	02	570.0	400.0
	4504	01	680.0	250.0
	4504	02	750.0	330.0
	4505	01	710.0	310.0
	4505	02	720.0	380.0
	4506	01	620.0	280.0
	4506	02	530.0	210.0
	4507	01	740.0	280.0
	4507	02	770.0	380.0
	4508	01	850.0	420.0
	4508	02	900.0	600.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	570.0	240.0
	4509	02	680.0	280.0
	4510	01	640.0	340.0
	4510	02	510.0	380.0
	4511	01	730.0	490.0
	4511	02	680.0	400.0
	4513	01	750.0	350.0
	4513	02	750.0	390.0
	4514	01	980.0	540.0
	4514	02	880.0	560.0
	4515	01	690.0	370.0
	4515	02	500.0	320.0
	4516	01	770.0	450.0
	4516	02	590.0	350.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1001	01	1100.0	410.0
	1001	02	960.0	510.0
	1002	01	520.0	240.0
	1002	02	630.0	320.0
	1005	01	910.0	520.0
	1005	02	900.0	440.0
	1006	01	890.0	520.0
	1006	02	730.0	490.0
	1007	01	620.0	360.0
	1007	02	450.0	240.0
	1008	01	790.0	410.0
	1008	02	850.0	480.0
	1009	01	950.0	580.0
	1009	02	960.0	530.0
	1010	01	720.0	520.0
	1010	02	890.0	570.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90931

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1011	01	780.0	500.0
	1011	02	700.0	680.0
	1012	01	640.0	630.0
	1012	02	670.0	520.0
	1013	01	770.0	530.0
	1013	02	920.0	500.0
	1014	01	710.0	700.0
	1014	02	770.0	560.0
	1015	01	900.0	450.0
	1015	02	780.0	500.0
	1016	01	650.0	220.0
	1016	02	620.0	210.0
	1017	01	770.0	440.0
	1017	02	880.0	560.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	850.0	340.0
	2001	02	840.0	310.0
	2002	01	670.0	570.0
	2002	02	870.0	600.0
	2003	01	880.0	410.0
	2003	02	760.0	430.0
	2004	01	790.0	500.0
	2004	02	600.0	510.0
	2005	01	720.0	630.0
	2005	02	930.0	500.0
	2006	01	990.0	520.0
	2006	02	1060.0	590.0
	2007	01	870.0	660.0
	2007	02	780.0	610.0
	2008	01	730.0	550.0
	2008	02	930.0	580.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	770.0	580.0
	2009	02	610.0	560.0
	2010	01	550.0	260.0
	2010	02	510.0	270.0
	2011	01	880.0	530.0
	2011	02	980.0	520.0
	2012	01	530.0	390.0
	2012	02	620.0	310.0
	2013	01	780.0	360.0
	2013	02	730.0	300.0
	2015	01	850.0	550.0
	2015	02	960.0	460.0
	2016	01	770.0	630.0
	2016	02	750.0	700.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	750.0	380.0
	3001	02	620.0	280.0
	3002	01	1070.0	570.0
	3002	02	1110.0	560.0
	3003	01	900.0	590.0
	3003	02	750.0	570.0
	3004	01	900.0	520.0
	3004	02	850.0	560.0
	3005	01	700.0	240.0
	3005	02	810.0	360.0
	3006	01	670.0	520.0
	3006	02	620.0	410.0
	3007	01	850.0	610.0
	3007	02	870.0	470.0
	3008	01	670.0	530.0
	3008	02	700.0	380.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	930.0	550.0
	3009	02	990.0	550.0
	3011	01	840.0	350.0
	3011	02	750.0	390.0
	3012	01	920.0	460.0
	3012	02	710.0	460.0
	3013	01	900.0	310.0
	3013	02	790.0	310.0
	3014	01	580.0	360.0
	3014	02	560.0	300.0
	3015	01	890.0	560.0
	3015	02	760.0	560.0
	3016	01	860.0	460.0
	3016	02	910.0	440.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	770.0	550.0
	4001	02	630.0	470.0
	4002	01	1040.0	590.0
	4002	02	820.0	580.0
	4003	01	640.0	530.0
	4003	02	660.0	560.0
	4004	01	500.0	270.0
	4004	02	360.0	220.0
	4005	01	750.0	270.0
	4005	02	520.0	280.0
	4006	01	870.0	430.0
	4006	02	910.0	420.0
	4007	01	910.0	600.0
	4007	02	900.0	440.0
	4008	01	750.0	420.0
	4008	02	730.0	300.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	670.0	510.0
	4009	02	760.0	560.0
	4010	01	680.0	410.0
	4010	02	630.0	600.0
	4011	01	630.0	520.0
	4011	02	850.0	460.0
	4012	01	720.0	470.0
	4012	02	840.0	320.0
	4014	01	900.0	510.0
	4014	02	1030.0	510.0
	4015	01	750.0	390.0
	4015	02	840.0	520.0
	4016	01	800.0	600.0
	4016	02	730.0	530.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1501	01	680.0	380.0
	1501	02	840.0	480.0
	1502	01	630.0	380.0
	1502	02	530.0	380.0
	1503	01	710.0	530.0
	1503	02	450.0	370.0
	1504	01	800.0	420.0
	1504	02	870.0	330.0
	1505	01	580.0	380.0
	1505	02	450.0	410.0
	1506	01	940.0	500.0
	1506	02	860.0	620.0
	1507	01	870.0	520.0
	1507	02	850.0	520.0
	1508	01	980.0	400.0
	1508	02	850.0	470.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1509	01	690.0	590.0
	1509	02	450.0	550.0
	1510	01	650.0	420.0
	1510	02	660.0	340.0
	1511	01	840.0	410.0
	1511	02	830.0	450.0
	1512	01	930.0	460.0
	1512	02	750.0	500.0
	1513	01	600.0	350.0
	1513	02	530.0	380.0
	1514	01	820.0	520.0
	1514	02	880.0	470.0
	1515	01	910.0	460.0
	1515	02	970.0	460.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	560.0	320.0
	2501	02	610.0	310.0
	2502	01	710.0	360.0
	2502	02	870.0	370.0
	2503	01	750.0	330.0
	2503	02	620.0	470.0
	2504	01	850.0	500.0
	2504	02	760.0	500.0
	2505	01	720.0	440.0
	2505	02	820.0	460.0
	2506	01	810.0	470.0
	2506	02	820.0	490.0
	2507	01	940.0	600.0
	2507	02	870.0	560.0
	2508	01	540.0	380.0
	2508	02	490.0	360.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	790.0	580.0
	2509	02	650.0	510.0
	2510	01	680.0	310.0
	2510	02	880.0	480.0
	2511	01	900.0	310.0
	2511	02	820.0	380.0
	2512	01	740.0	460.0
	2512	02	940.0	440.0
	2513	01	880.0	550.0
	2513	02	640.0	580.0
	2514	01	980.0	440.0
	2514	02	770.0	380.0
	2515	01	880.0	420.0
	2515	02	940.0	400.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	590.0	600.0
	3501	02	710.0	490.0
	3502	01	630.0	380.0
	3502	02	500.0	360.0
	3503	01	900.0	370.0
	3503	02	950.0	410.0
	3504	01	760.0	280.0
	3504	02	800.0	440.0
	3505	01	620.0	460.0
	3505	02	690.0	530.0
	3506	01	580.0	450.0
	3506	02	790.0	500.0
	3507	01	550.0	480.0
	3507	02	520.0	520.0
	3508	01	840.0	360.0
	3508	02	640.0	390.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	960.0	390.0
	3509	02	990.0	500.0
	3510	01	830.0	440.0
	3510	02	610.0	310.0
	3511	01	780.0	480.0
	3511	02	680.0	520.0
	3513	01	490.0	390.0
	3513	02	530.0	280.0
	3514	01	720.0	390.0
	3514	02	880.0	430.0
	3516	01	450.0	380.0
	3516	02	350.0	380.0
	3517	01	530.0	400.0
	3517	02	430.0	380.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	610.0	490.0
	4501	02	540.0	540.0
	4502	01	910.0	300.0
	4502	02	1000.0	450.0
	4503	01	650.0	440.0
	4503	02	450.0	460.0
	4504	01	820.0	400.0
	4504	02	970.0	540.0
	4505	01	820.0	280.0
	4505	02	940.0	250.0
	4506	01	800.0	580.0
	4506	02	650.0	420.0
	4507	01	710.0	450.0
	4507	02	830.0	420.0
	4508	01	1000.0	490.0
	4508	02	1030.0	440.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	530.0	490.0
	4509	02	500.0	470.0
	4510	01	740.0	410.0
	4510	02	640.0	410.0
	4511	01	760.0	360.0
	4511	02	690.0	370.0
	4513	01	750.0	480.0
	4513	02	700.0	540.0
	4514	01	830.0	480.0
	4514	02	1000.0	440.0
	4515	01	590.0	360.0
	4515	02	590.0	390.0
	4516	01	800.0	520.0
	4516	02	710.0	590.0

APPENDIX NO: 5

PROJECT NO : 90831

INDIVIDUAL GRIP STRENGTH (G)

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1001	01	870.0	270.0
	1001	02	710.0	490.0
	1002	01	810.0	440.0
	1002	02	660.0	490.0
	1005	01	930.0	440.0
	1005	02	800.0	500.0
	1006	01	620.0	580.0
	1006	02	610.0	530.0
	1007	01	930.0	540.0
	1007	02	750.0	550.0
	1008	01	730.0	480.0
	1008	02	870.0	400.0
	1009	01	1300.0	600.0
	1009	02	1030.0	480.0
	1010	01	780.0	870.0
	1010	02	930.0	540.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1011	01	680.0	620.0
	1011	02	560.0	480.0
	1012	01	960.0	750.0
	1012	02	1030.0	770.0
	1013	01	980.0	710.0
	1013	02	800.0	680.0
	1014	01	1020.0	510.0
	1014	02	890.0	650.0
	1015	01	1100.0	600.0
	1015	02	1200.0	870.0
	1016	01	530.0	380.0
	1016	02	560.0	420.0
	1017	01	540.0	610.0
	1017	02	530.0	660.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	740.0	740.0
	2001	02	730.0	760.0
	2002	01	850.0	670.0
	2002	02	700.0	710.0
	2003	01	1000.0	350.0
	2003	02	930.0	520.0
	2004	01	740.0	680.0
	2004	02	700.0	550.0
	2005	01	740.0	670.0
	2005	02	460.0	380.0
	2006	01	710.0	440.0
	2006	02	610.0	800.0
	2007	01	730.0	580.0
	2007	02	850.0	730.0
	2008	01	500.0	630.0
	2008	02	540.0	740.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	930.0	370.0
	2009	02	870.0	560.0
	2010	01	690.0	580.0
	2010	02	610.0	550.0
	2011	01	860.0	620.0
	2011	02	660.0	580.0
	2012	01	850.0	440.0
	2012	02	650.0	380.0
	2013	01	970.0	480.0
	2013	02	740.0	490.0
	2015	01	710.0	760.0
	2015	02	750.0	610.0
	2016	01	890.0	520.0
	2016	02	820.0	430.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	1000.0	610.0
	3001	02	950.0	420.0
	3002	01	680.0	930.0
	3002	02	770.0	890.0
	3003	01	600.0	730.0
	3003	02	750.0	640.0
	3004	01	650.0	440.0
	3004	02	550.0	590.0
	3005	01	1060.0	530.0
	3005	02	1090.0	520.0
	3006	01	980.0	570.0
	3006	02	730.0	360.0
	3007	01	700.0	670.0
	3007	02	610.0	580.0
	3008	01	520.0	690.0
	3008	02	580.0	400.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	740.0	460.0
	3009	02	980.0	690.0
	3011	01	580.0	520.0
	3011	02	570.0	600.0
	3012	01	730.0	360.0
	3012	02	800.0	330.0
	3013	01	970.0	640.0
	3013	02	770.0	470.0
	3014	01	700.0	350.0
	3014	02	880.0	370.0
	3015	01	1300.0	530.0
	3015	02	1300.0	810.0
	3016	01	810.0	740.0
	3016	02	940.0	790.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	1050.0	590.0
	4001	02	860.0	760.0
	4002	01	830.0	820.0
	4002	02	780.0	820.0
	4003	01	800.0	880.0
	4003	02	800.0	840.0
	4004	01	750.0	830.0
	4004	02	690.0	530.0
	4005	01	880.0	510.0
	4005	02	570.0	590.0
	4006	01	740.0	520.0
	4006	02	680.0	630.0
	4007	01	630.0	520.0
	4007	02	590.0	500.0
	4008	01	770.0	540.0
	4008	02	580.0	470.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	930.0	650.0
	4009	02	870.0	540.0
	4010	01	300.0	400.0
	4010	02	410.0	390.0
	4011	01	770.0	620.0
	4011	02	870.0	650.0
	4012	01	810.0	460.0
	4012	02	970.0	430.0
	4014	01	790.0	300.0
	4014	02	810.0	480.0
	4015	01	870.0	500.0
	4015	02	740.0	610.0
	4016	01	880.0	790.0
	4016	02	920.0	700.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1501	01	840.0	560.0
	1501	02	760.0	440.0
	1502	01	710.0	700.0
	1502	02	950.0	680.0
	1503	01	630.0	590.0
	1503	02	620.0	620.0
	1504	01	850.0	510.0
	1504	02	830.0	520.0
	1505	01	850.0	440.0
	1505	02	600.0	580.0
	1506	01	960.0	540.0
	1506	02	750.0	650.0
	1507	01	690.0	570.0
	1507	02	540.0	470.0
	1508	01	990.0	650.0
	1508	02	790.0	460.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1509	01	660.0	570.0
	1509	02	750.0	530.0
	1510	01	810.0	430.0
	1510	02	710.0	550.0
	1511	01	600.0	490.0
	1511	02	440.0	440.0
	1512	01	870.0	610.0
	1512	02	820.0	660.0
	1513	01	600.0	210.0
	1513	02	510.0	400.0
	1514	01	810.0	520.0
	1514	02	750.0	600.0
	1515	01	630.0	570.0
	1515	02	600.0	330.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	730.0	300.0
	2501	02	670.0	490.0
	2502	01	600.0	440.0
	2502	02	780.0	510.0
	2503	01	750.0	600.0
	2503	02	660.0	460.0
	2504	01	980.0	420.0
	2504	02	700.0	580.0
	2505	01	720.0	420.0
	2505	02	580.0	530.0
	2506	01	590.0	630.0
	2506	02	560.0	550.0
	2507	01	930.0	370.0
	2507	02	970.0	510.0
	2508	01	600.0	470.0
	2508	02	550.0	480.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	650.0	450.0
	2509	02	640.0	420.0
	2510	01	710.0	420.0
	2510	02	980.0	520.0
	2511	01	750.0	560.0
	2511	02	860.0	530.0
	2512	01	800.0	510.0
	2512	02	900.0	480.0
	2513	01	980.0	500.0
	2513	02	700.0	620.0
	2514	01	800.0	400.0
	2514	02	700.0	250.0
	2515	01	550.0	440.0
	2515	02	650.0	470.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	730.0	530.0
	3501	02	730.0	540.0
	3502	01	530.0	280.0
	3502	02	610.0	410.0
	3503	01	760.0	600.0
	3503	02	800.0	520.0
	3504	01	600.0	400.0
	3504	02	680.0	390.0
	3505	01	890.0	350.0
	3505	02	720.0	390.0
	3506	01	810.0	410.0
	3506	02	710.0	480.0
	3507	01	730.0	620.0
	3507	02	700.0	660.0
	3508	01	730.0	490.0
	3508	02	740.0	390.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	950.0	390.0
	3509	02	990.0	360.0
	3510	01	1000.0	730.0
	3510	02	600.0	830.0
	3511	01	800.0	380.0
	3511	02	750.0	360.0
	3513	01	600.0	410.0
	3513	02	460.0	420.0
	3514	01	730.0	280.0
	3514	02	850.0	340.0
	3516	01	500.0	500.0
	3516	02	320.0	290.0
	3517	01	560.0	420.0
	3517	02	700.0	480.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	860.0	540.0
	4501	02	610.0	530.0
	4502	01	800.0	540.0
	4502	02	880.0	500.0
	4503	01	520.0	540.0
	4503	02	480.0	490.0
	4504	01	970.0	420.0
	4504	02	730.0	450.0
	4505	01	870.0	510.0
	4505	02	820.0	410.0
	4506	01	790.0	490.0
	4506	02	980.0	580.0
	4507	01	910.0	300.0
	4507	02	810.0	380.0
	4508	01	940.0	380.0
	4508	02	880.0	490.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	520.0	310.0
	4509	02	460.0	260.0
	4510	01	750.0	350.0
	4510	02	580.0	600.0
	4511	01	680.0	340.0
	4511	02	710.0	240.0
	4513	01	960.0	510.0
	4513	02	800.0	660.0
	4514	01	630.0	430.0
	4514	02	550.0	360.0
	4515	01	810.0	460.0
	4515	02	640.0	340.0
	4516	01	640.0	430.0
	4516	02	690.0	610.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1001	01	950.0	530.0
	1001	02	810.0	510.0
	1002	01	570.0	700.0
	1002	02	500.0	450.0
	1005	01	1000.0	520.0
	1005	02	850.0	500.0
	1006	01	1000.0	640.0
	1006	02	990.0	700.0
	1007	01	1150.0	610.0
	1007	02	1150.0	500.0
	1008	01	800.0	510.0
	1008	02	750.0	350.0
	1009	01	820.0	690.0
	1009	02	860.0	570.0
	1010	01	800.0	890.0
	1010	02	840.0	850.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1011	01	460.0	520.0
	1011	02	590.0	750.0
	1012	01	880.0	820.0
	1012	02	750.0	840.0
	1013	01	860.0	700.0
	1013	02	850.0	640.0
	1014	01	1200.0	860.0
	1014	02	1180.0	1000.0
	1015	01	730.0	570.0
	1015	02	830.0	770.0
	1016	01	570.0	510.0
	1016	02	500.0	380.0
	1017	01	550.0	420.0
	1017	02	550.0	380.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	450.0	650.0
	2001	02	400.0	600.0
	2002	01	800.0	810.0
	2002	02	750.0	610.0
	2003	01	700.0	760.0
	2003	02	720.0	520.0
	2004	01	280.0	610.0
	2004	02	320.0	660.0
	2005	01	510.0	550.0
	2005	02	600.0	520.0
	2006	01	730.0	730.0
	2006	02	670.0	610.0
	2007	01	1050.0	760.0
	2007	02	1050.0	780.0
	2008	01	600.0	700.0
	2008	02	700.0	650.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	950.0	500.0
	2009	02	870.0	530.0
	2010	01	790.0	850.0
	2010	02	850.0	650.0
	2011	01	800.0	360.0
	2011	02	940.0	510.0
	2012	01	740.0	360.0
	2012	02	910.0	540.0
	2013	01	490.0	470.0
	2013	02	620.0	590.0
	2015	01	690.0	540.0
	2015	02	800.0	470.0
	2016	01	800.0	670.0
	2016	02	930.0	640.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	730.0	250.0
	3001	02	610.0	450.0
	3002	01	620.0	870.0
	3002	02	920.0	1000.0
	3003	01	960.0	600.0
	3003	02	800.0	710.0
	3004	01	780.0	690.0
	3004	02	920.0	680.0
	3005	01	830.0	790.0
	3005	02	720.0	700.0
	3006	01	560.0	690.0
	3006	02	700.0	800.0
	3007	01	780.0	740.0
	3007	02	850.0	780.0
	3008	01	590.0	630.0
	3008	02	810.0	650.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	1150.0	740.0
	3009	02	1130.0	860.0
	3011	01	410.0	390.0
	3011	02	590.0	560.0
	3012	01	690.0	750.0
	3012	02	770.0	620.0
	3013	01	690.0	520.0
	3013	02	500.0	540.0
	3014	01	610.0	380.0
	3014	02	450.0	440.0
	3015	01	810.0	810.0
	3015	02	550.0	580.0
	3016	01	870.0	650.0
	3016	02	600.0	480.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	830.0	820.0
	4001	02	820.0	700.0
	4002	01	770.0	900.0
	4002	02	850.0	1000.0
	4003	01	610.0	820.0
	4003	02	600.0	790.0
	4004	01	780.0	550.0
	4004	02	690.0	610.0
	4005	01	600.0	440.0
	4005	02	570.0	680.0
	4006	01	760.0	560.0
	4006	02	770.0	710.0
	4007	01	950.0	610.0
	4007	02	800.0	580.0
	4008	01	590.0	710.0
	4008	02	500.0	760.0

APPENDIX NO: 5

PROJECT NO : 90831

INDIVIDUAL GRIP STRENGTH (G)

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	200.0	670.0
	4009	02	230.0	510.0
	4010	01	450.0	500.0
	4010	02	470.0	460.0
	4011	01	1000.0	720.0
	4011	02	800.0	760.0
	4012	01	920.0	580.0
	4012	02	940.0	550.0
	4014	01	710.0	620.0
	4014	02	890.0	660.0
	4015	01	850.0	440.0
	4015	02	610.0	670.0
	4016	01	650.0	730.0
	4016	02	680.0	800.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1501	01	660.0	610.0
	1501	02	590.0	690.0
	1502	01	720.0	690.0
	1502	02	690.0	400.0
	1503	01	680.0	530.0
	1503	02	690.0	650.0
	1504	01	680.0	620.0
	1504	02	790.0	640.0
	1505	01	780.0	650.0
	1505	02	1000.0	470.0
	1506	01	1180.0	580.0
	1506	02	1180.0	640.0
	1507	01	770.0	640.0
	1507	02	720.0	610.0
	1508	01	930.0	680.0
	1508	02	810.0	470.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1509	01	760.0	580.0
	1509	02	780.0	550.0
	1510	01	610.0	540.0
	1510	02	750.0	620.0
	1511	01	860.0	410.0
	1511	02	790.0	370.0
	1512	01	710.0	510.0
	1512	02	770.0	670.0
	1513	01	880.0	470.0
	1513	02	810.0	300.0
	1514	01	1150.0	840.0
	1514	02	1000.0	920.0
	1515	01	760.0	640.0
	1515	02	700.0	610.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	710.0	470.0
	2501	02	690.0	410.0
	2502	01	810.0	630.0
	2502	02	790.0	610.0
	2503	01	950.0	540.0
	2503	02	740.0	480.0
	2504	01	810.0	650.0
	2504	02	680.0	500.0
	2505	01	700.0	380.0
	2505	02	730.0	430.0
	2506	01	870.0	750.0
	2506	02	830.0	740.0
	2507	01	960.0	460.0
	2507	02	1100.0	560.0
	2508	01	650.0	520.0
	2508	02	820.0	550.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	930.0	400.0
	2509	02	740.0	590.0
	2510	01	1030.0	610.0
	2510	02	800.0	480.0
	2511	01	700.0	400.0
	2511	02	830.0	520.0
	2512	01	1000.0	500.0
	2512	02	1200.0	560.0
	2513	01	740.0	720.0
	2513	02	680.0	530.0
	2514	01	840.0	650.0
	2514	02	700.0	680.0
	2515	01	790.0	730.0
	2515	02	850.0	800.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	660.0	560.0
	3501	02	540.0	550.0
	3502	01	800.0	540.0
	3502	02	870.0	670.0
	3503	01	730.0	520.0
	3503	02	720.0	530.0
	3504	01	690.0	530.0
	3504	02	610.0	520.0
	3505	01	1060.0	410.0
	3505	02	1170.0	520.0
	3506	01	520.0	520.0
	3506	02	570.0	760.0
	3507	01	1030.0	820.0
	3507	02	810.0	650.0
	3508	01	720.0	370.0
	3508	02	510.0	460.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	940.0	850.0
	3509	02	960.0	720.0
	3510	01	740.0	400.0
	3510	02	710.0	710.0
	3511	01	830.0	550.0
	3511	02	600.0	590.0
	3513	01	600.0	470.0
	3513	02	560.0	480.0
	3514	01	740.0	430.0
	3514	02	550.0	410.0
	3516	01	710.0	510.0
	3516	02	600.0	470.0
	3517	01	850.0	600.0
	3517	02	830.0	620.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	560.0	300.0
	4501	02	520.0	480.0
	4502	01	730.0	630.0
	4502	02	640.0	490.0
	4503	01	740.0	460.0
	4503	02	540.0	660.0
	4504	01	790.0	600.0
	4504	02	920.0	710.0
	4505	01	700.0	570.0
	4505	02	930.0	520.0
	4506	01	1220.0	710.0
	4506	02	970.0	520.0
	4507	01	850.0	330.0
	4507	02	750.0	540.0
	4508	01	1090.0	570.0
	4508	02	1060.0	790.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	590.0	510.0
	4509	02	500.0	410.0
	4510	01	530.0	450.0
	4510	02	700.0	470.0
	4511	01	800.0	460.0
	4511	02	960.0	480.0
	4513	01	840.0	620.0
	4513	02	720.0	750.0
	4514	01	580.0	530.0
	4514	02	570.0	640.0
	4515	01	680.0	450.0
	4515	02	680.0	460.0
	4516	01	570.0	320.0
	4516	02	630.0	470.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1001	01	780.0	850.0
	1001	02	800.0	740.0
	1002	01	450.0	490.0
	1002	02	460.0	490.0
	1005	01	890.0	620.0
	1005	02	860.0	470.0
	1006	01	700.0	700.0
	1006	02	890.0	730.0
	1007	01	900.0	1100.0
	1007	02	770.0	760.0
	1008	01	870.0	520.0
	1008	02	730.0	760.0
	1009	01	1310.0	920.0
	1009	02	1130.0	820.0
	1010	01	890.0	850.0
	1010	02	990.0	850.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1011	01	570.0	690.0
	1011	02	620.0	420.0
	1012	01	850.0	720.0
	1012	02	940.0	720.0
	1013	01	850.0	730.0
	1013	02	700.0	590.0
	1014	01	760.0	650.0
	1014	02	930.0	760.0
	1015	01	800.0	950.0
	1015	02	940.0	770.0
	1016	01	560.0	480.0
	1016	02	540.0	510.0
	1017	01	810.0	760.0
	1017	02	820.0	650.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	980.0	680.0
	2001	02	960.0	870.0
	2002	01	870.0	740.0
	2002	02	820.0	750.0
	2003	01	1190.0	650.0
	2003	02	990.0	890.0
	2004	01	850.0	740.0
	2004	02	780.0	710.0
	2005	01	730.0	560.0
	2005	02	560.0	610.0
	2006	01	920.0	860.0
	2006	02	850.0	740.0
	2007	01	790.0	910.0
	2007	02	850.0	740.0
	2008	01	970.0	720.0
	2008	02	710.0	520.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	1030.0	930.0
	2009	02	950.0	870.0
	2010	01	750.0	700.0
	2010	02	670.0	880.0
	2011	01	670.0	730.0
	2011	02	790.0	520.0
	2012	01	700.0	890.0
	2012	02	660.0	700.0
	2013	01	820.0	600.0
	2013	02	600.0	650.0
	2015	01	1110.0	900.0
	2015	02	930.0	650.0
	2016	01	1000.0	660.0
	2016	02	980.0	670.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	1050.0	810.0
	3001	02	550.0	520.0
	3002	01	930.0	1080.0
	3002	02	930.0	920.0
	3003	01	1100.0	670.0
	3003	02	830.0	680.0
	3004	01	910.0	790.0
	3004	02	990.0	770.0
	3005	01	1300.0	700.0
	3005	02	830.0	400.0
	3006	01	1030.0	850.0
	3006	02	830.0	850.0
	3007	01	870.0	930.0
	3007	02	690.0	950.0
	3008	01	800.0	900.0
	3008	02	750.0	760.0

APPENDIX NO: 5 INDIVIDUAL GRIP STRENGTH (G) PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	660.0	810.0
	3009	02	660.0	800.0
	3011	01	450.0	430.0
	3011	02	500.0	640.0
	3012	01	740.0	630.0
	3012	02	730.0	790.0
	3013	01	780.0	660.0
	3013	02	750.0	830.0
	3014	01	650.0	460.0
	3014	02	710.0	360.0
	3015	01	900.0	480.0
	3015	02	1000.0	510.0
	3016	01	690.0	630.0
	3016	02	630.0	800.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	01	1080.0	1000.0
	4002	02	860.0	1000.0
	4003	01	1090.0	1100.0
	4003	02	800.0	1110.0
	4004	01	740.0	770.0
	4004	02	520.0	500.0
	4005	01	600.0	630.0
	4005	02	800.0	690.0
	4006	01	1080.0	630.0
	4006	02	1110.0	560.0
	4007	01	780.0	550.0
	4007	02	600.0	530.0
	4008	01	720.0	830.0
	4008	02	560.0	650.0
	4009	01	640.0	690.0
	4009	02	700.0	510.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4010	01	530.0	870.0
	4010	02	670.0	680.0
	4011	01	860.0	640.0
	4011	02	1000.0	690.0
	4012	01	890.0	760.0
	4012	02	870.0	620.0
	4014	01	910.0	600.0
	4014	02	1150.0	540.0
	4015	01	650.0	430.0
	4015	02	600.0	470.0
	4016	01	730.0	850.0
	4016	02	1300.0	920.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1501	01	740.0	660.0
	1501	02	550.0	460.0
	1502	01	760.0	710.0
	1502	02	600.0	900.0
	1503	01	1060.0	600.0
	1503	02	800.0	820.0
	1504	01	630.0	750.0
	1504	02	750.0	530.0
	1505	01	850.0	510.0
	1505	02	850.0	550.0
	1506	01	1000.0	840.0
	1506	02	1100.0	930.0
	1507	01	840.0	780.0
	1507	02	940.0	690.0
	1508	01	980.0	760.0
	1508	02	800.0	880.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 1 - AIR CONTROL	1509	01	1000.0	900.0
	1509	02	1100.0	740.0
	1510	01	620.0	820.0
	1510	02	590.0	610.0
	1511	01	680.0	540.0
	1511	02	800.0	570.0
	1512	01	540.0	550.0
	1512	02	560.0	620.0
	1513	01	880.0	620.0
	1513	02	780.0	500.0
	1514	01	1000.0	640.0
	1514	02	670.0	560.0
	1515	01	670.0	540.0
	1515	02	780.0	490.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	770.0	750.0
	2501	02	1000.0	1000.0
	2502	01	830.0	680.0
	2502	02	1200.0	780.0
	2503	01	730.0	400.0
	2503	02	980.0	660.0
	2504	01	650.0	690.0
	2504	02	720.0	710.0
	2505	01	840.0	600.0
	2505	02	740.0	750.0
	2506	01	760.0	800.0
	2506	02	600.0	640.0
	2507	01	970.0	460.0
	2507	02	780.0	690.0
	2508	01	680.0	510.0
	2508	02	790.0	530.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	1010.0	930.0
	2509	02	880.0	900.0
	2510	01	850.0	680.0
	2510	02	890.0	600.0
	2511	01	620.0	450.0
	2511	02	700.0	400.0
	2512	01	810.0	700.0
	2512	02	1250.0	750.0
	2513	01	840.0	620.0
	2513	02	900.0	610.0
	2514	01	980.0	590.0
	2514	02	980.0	700.0
	2515	01	770.0	600.0
	2515	02	680.0	600.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	610.0	830.0
	3501	02	840.0	730.0
	3502	01	700.0	540.0
	3502	02	550.0	540.0
	3503	01	770.0	590.0
	3503	02	940.0	530.0
	3504	01	800.0	580.0
	3504	02	500.0	630.0
	3505	01	1000.0	760.0
	3505	02	950.0	520.0
	3506	01	970.0	630.0
	3506	02	1080.0	580.0
	3507	01	860.0	850.0
	3507	02	790.0	840.0
	3508	01	940.0	700.0
	3508	02	640.0	540.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	880.0	500.0
	3509	02	870.0	620.0
	3510	01	950.0	750.0
	3510	02	650.0	650.0
	3511	01	580.0	660.0
	3511	02	660.0	540.0
	3513	01	770.0	450.0
	3513	02	640.0	570.0
	3514	01	690.0	440.0
	3514	02	750.0	540.0
	3516	01	750.0	700.0
	3516	02	540.0	580.0
	3517	01	880.0	460.0
	3517	02	680.0	460.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	670.0	380.0
	4501	02	400.0	570.0
	4502	01	690.0	680.0
	4502	02	680.0	850.0
	4503	01	400.0	630.0
	4503	02	560.0	680.0
	4504	01	950.0	700.0
	4504	02	880.0	710.0
	4505	01	1020.0	690.0
	4505	02	790.0	510.0
	4506	01	700.0	770.0
	4506	02	850.0	650.0
	4507	01	730.0	820.0
	4507	02	820.0	660.0
	4508	01	500.0	640.0
	4508	02	560.0	540.0

APPENDIX NO: 5

INDIVIDUAL GRIP STRENGTH (G)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	FORELIMB	HINDLIMB
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	600.0	830.0
	4509	02	470.0	620.0
	4510	01	900.0	690.0
	4510	02	890.0	520.0
	4511	01	730.0	660.0
	4511	02	640.0	400.0
	4513	01	600.0	460.0
	4513	02	520.0	380.0
	4514	01	560.0	500.0
	4514	02	650.0	440.0
	4515	01	700.0	420.0
	4515	02	560.0	320.0
	4516	01	450.0	790.0
	4516	02	350.0	550.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	01	6.6
	1001	02	6.2
	1002	01	9.3
	1002	02	8.7
	1005	01	9.5
	1005	02	8.4
	1006	01	7.2
	1006	02	6.6
	1007	01	8.1
	1007	02	4.5
	1008	01	3.9
	1008	02	3.8
	1009	01	9.5
	1009	02	9.3
	1010	01	8.1
	1010	02	7.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1011	01	9.5
	1011	02	9.1
	1012	01	6.1
	1012	02	7.0
	1013	01	8.5
	1013	02	8.9
	1014	01	9.8
	1014	02	9.2
	1015	01	7.2
	1015	02	5.7
	1016	01	7.5
	1016	02	6.7
	1017	01	10.7
	1017	02	9.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	8.1
	2001	02	7.7
	2002	01	9.6
	2002	02	9.7
	2003	01	10.0
	2003	02	9.2
	2004	01	9.6
	2004	02	9.4
	2005	01	9.6
	2005	02	10.2
	2006	01	9.6
	2006	02	8.2
	2007	01	8.9
	2007	02	8.3
	2008	01	3.9
	2008	02	3.4

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	8.5
	2009	02	8.4
	2010	01	7.4
	2010	02	8.5
	2011	01	9.4
	2011	02	9.6
	2012	01	7.7
	2012	02	6.1
	2013	01	6.1
	2013	02	4.9
	2015	01	8.1
	2015	02	7.1
	2016	01	6.5
	2016	02	7.8

APPENDIX NO: 5 INDIVIDUAL HINDLIMB SPLAY (CM) PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	7.5
	3001	02	5.7
	3002	01	10.5
	3002	02	9.3
	3003	01	9.0
	3003	02	6.7
	3004	01	10.3
	3004	02	9.6
	3005	01	9.6
	3005	02	8.0
	3006	01	10.8
	3006	02	9.8
	3007	01	9.2
	3007	02	9.4
	3008	01	8.6
	3008	02	6.1

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	8.3
	3009	02	10.0
	3011	01	9.7
	3011	02	9.3
	3012	01	8.4
	3012	02	9.3
	3013	01	7.6
	3013	02	5.4
	3014	01	4.4
	3014	02	5.3
	3015	01	8.2
	3015	02	8.4
	3016	01	8.2
	3016	02	8.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	7.2
	4001	02	5.7
	4002	01	9.9
	4002	02	9.3
	4003	01	7.3
	4003	02	5.9
	4004	01	5.4
	4004	02	6.8
	4005	01	8.2
	4005	02	6.8
	4006	01	9.4
	4006	02	9.1
	4007	01	9.1
	4007	02	10.5
	4008	01	6.8
	4008	02	6.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	9.1
	4009	02	7.8
	4010	01	7.0
	4010	02	6.5
	4011	01	8.3
	4011	02	8.8
	4012	01	7.1
	4012	02	6.0
	4014	01	6.9
	4014	02	6.3
	4015	01	7.7
	4015	02	6.5
	4016	01	9.4
	4016	02	8.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	01	8.8
	1501	02	9.3
	1502	01	6.2
	1502	02	6.3
	1503	01	7.5
	1503	02	8.8
	1504	01	6.8
	1504	02	6.7
	1505	01	9.3
	1505	02	8.7
	1506	01	8.7
	1506	02	8.1
	1507	01	8.8
	1507	02	8.9
	1508	01	7.8
	1508	02	9.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1509	01	9.6
	1509	02	8.5
	1510	01	8.8
	1510	02	7.9
	1511	01	9.2
	1511	02	6.8
	1512	01	7.8
	1512	02	7.2
	1513	01	5.1
	1513	02	5.1
	1514	01	7.4
	1514	02	7.4
	1515	01	7.2
	1515	02	7.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	4.4
	2501	02	5.6
	2502	01	7.2
	2502	02	8.1
	2503	01	8.5
	2503	02	8.7
	2504	01	9.0
	2504	02	6.8
	2505	01	8.4
	2505	02	8.7
	2506	01	9.1
	2506	02	9.5
	2507	01	9.5
	2507	02	9.5
	2508	01	8.6
	2508	02	8.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	9.2
	2509	02	9.0
	2510	01	8.2
	2510	02	7.0
	2511	01	8.6
	2511	02	8.8
	2512	01	7.5
	2512	02	7.6
	2513	01	9.2
	2513	02	9.7
	2514	01	9.0
	2514	02	9.4
	2515	01	8.8
	2515	02	7.6

APPENDIX NO: 5 INDIVIDUAL HINDLIMB SPLAY (CM) PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	4.1
	3501	02	8.5
	3502	01	9.3
	3502	02	8.8
	3503	01	8.1
	3503	02	8.2
	3504	01	7.9
	3504	02	6.6
	3505	01	8.3
	3505	02	7.5
	3506	01	5.5
	3506	02	7.9
	3507	01	8.3
	3507	02	7.4
	3508	01	8.8
	3508	02	8.6

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	8.2
	3509	02	7.7
	3510	01	7.9
	3510	02	7.7
	3511	01	8.0
	3511	02	6.8
	3513	01	6.8
	3513	02	5.2
	3514	01	6.9
	3514	02	6.6
	3516	01	5.1
	3516	02	6.8
	3517	01	3.8
	3517	02	3.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	4.6
	4501	02	5.2
	4502	01	10.2
	4502	02	7.1
	4503	01	9.3
	4503	02	9.5
	4504	01	5.9
	4504	02	8.5
	4505	01	5.0
	4505	02	5.9
	4506	01	8.3
	4506	02	8.5
	4507	01	8.8
	4507	02	5.4
	4508	01	7.3
	4508	02	6.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - PRE-STUDY
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	5.0
	4509	02	5.0
	4510	01	7.5
	4510	02	6.9
	4511	01	9.0
	4511	02	8.6
	4513	01	5.2
	4513	02	6.0
	4514	01	7.4
	4514	02	8.5
	4515	01	7.3
	4515	02	6.6
	4516	01	6.5
	4516	02	4.8

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	01	6.3
	1001	02	4.2
	1002	01	6.4
	1002	02	4.0
	1005	01	9.2
	1005	02	7.1
	1006	01	6.0
	1006	02	7.5
	1007	01	6.2
	1007	02	3.8
	1008	01	4.8
	1008	02	3.7
	1009	01	5.3
	1009	02	6.2
	1010	01	7.3
	1010	02	8.1

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1011	01	9.7
	1011	02	9.1
	1012	01	7.6
	1012	02	7.2
	1013	01	7.6
	1013	02	8.6
	1014	01	8.6
	1014	02	9.6
	1015	01	8.7
	1015	02	8.1
	1016	01	4.1
	1016	02	2.9
	1017	01	8.3
	1017	02	7.0

APPENDIX NO: 5 INDIVIDUAL HINDLIMB SPLAY (CM) PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	8.1
	2001	02	6.0
	2002	01	6.0
	2002	02	7.1
	2003	01	7.1
	2003	02	8.0
	2004	01	6.7
	2004	02	5.6
	2005	01	8.8
	2005	02	6.3
	2006	01	7.6
	2006	02	6.2
	2007	01	7.2
	2007	02	6.8
	2008	01	4.3
	2008	02	4.4

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	5.1
	2009	02	3.6
	2010	01	7.3
	2010	02	7.3
	2011	01	9.4
	2011	02	9.0
	2012	01	5.4
	2012	02	6.0
	2013	01	4.0
	2013	02	3.9
	2015	01	8.5
	2015	02	8.4
	2016	01	5.2
	2016	02	5.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	4.7
	3001	02	4.2
	3002	01	7.6
	3002	02	6.2
	3003	01	8.0
	3003	02	6.4
	3004	01	9.1
	3004	02	8.6
	3005	01	7.1
	3005	02	6.3
	3006	01	8.8
	3006	02	7.5
	3007	01	9.4
	3007	02	7.3
	3008	01	4.2
	3008	02	5.6

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	9.1
	3009	02	6.4
	3011	01	6.6
	3011	02	8.8
	3012	01	8.8
	3012	02	7.9
	3013	01	7.6
	3013	02	7.2
	3014	01	6.6
	3014	02	5.2
	3015	01	7.6
	3015	02	9.8
	3016	01	6.5
	3016	02	7.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	7.3
	4001	02	5.1
	4002	01	9.1
	4002	02	7.2
	4003	01	8.8
	4003	02	6.2
	4004	01	8.3
	4004	02	7.9
	4005	01	7.4
	4005	02	6.0
	4006	01	7.2
	4006	02	6.3
	4007	01	9.9
	4007	02	8.9
	4008	01	4.5
	4008	02	5.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	6.1
	4009	02	4.3
	4010	01	5.3
	4010	02	5.1
	4011	01	9.6
	4011	02	7.5
	4012	01	4.9
	4012	02	5.9
	4014	01	6.5
	4014	02	4.6
	4015	01	5.6
	4015	02	4.5
	4016	01	7.1
	4016	02	7.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	01	8.2
	1501	02	8.4
	1502	01	7.9
	1502	02	8.5
	1503	01	9.6
	1503	02	8.5
	1504	01	6.9
	1504	02	4.9
	1505	01	9.6
	1505	02	8.7
	1506	01	8.5
	1506	02	8.4
	1507	01	8.0
	1507	02	8.1
	1508	01	8.4
	1508	02	6.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1509	01	9.2
	1509	02	6.7
	1510	01	8.6
	1510	02	7.6
	1511	01	7.3
	1511	02	5.5
	1512	01	7.5
	1512	02	5.5
	1513	01	4.9
	1513	02	4.2
	1514	01	6.5
	1514	02	4.6
	1515	01	8.0
	1515	02	8.3

APPENDIX NO: 5 INDIVIDUAL HINDLIMB SPLAY (CM) PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	7.1
	2501	02	7.0
	2502	01	7.2
	2502	02	6.2
	2503	01	7.6
	2503	02	6.5
	2504	01	6.0
	2504	02	5.0
	2505	01	7.8
	2505	02	5.4
	2506	01	7.0
	2506	02	7.3
	2507	01	8.1
	2507	02	7.8
	2508	01	6.9
	2508	02	6.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	7.4
	2509	02	7.4
	2510	01	6.8
	2510	02	5.1
	2511	01	5.9
	2511	02	4.8
	2512	01	7.4
	2512	02	6.6
	2513	01	8.3
	2513	02	5.0
	2514	01	8.9
	2514	02	7.7
	2515	01	8.2
	2515	02	7.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	3.7
	3501	02	5.5
	3502	01	9.1
	3502	02	9.1
	3503	01	7.3
	3503	02	7.7
	3504	01	6.4
	3504	02	5.2
	3505	01	8.0
	3505	02	8.4
	3506	01	7.8
	3506	02	6.6
	3507	01	7.6
	3507	02	5.8
	3508	01	8.9
	3508	02	7.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	8.7
	3509	02	7.5
	3510	01	6.7
	3510	02	5.8
	3511	01	4.1
	3511	02	4.3
	3513	01	4.5
	3513	02	4.3
	3514	01	4.0
	3514	02	4.3
	3516	01	3.8
	3516	02	5.0
	3517	01	2.9
	3517	02	2.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	4.9
	4501	02	4.9
	4502	01	7.9
	4502	02	7.5
	4503	01	9.7
	4503	02	8.4
	4504	01	9.4
	4504	02	9.8
	4505	01	6.9
	4505	02	6.2
	4506	01	6.8
	4506	02	7.3
	4507	01	9.0
	4507	02	8.3
	4508	01	5.0
	4508	02	4.4

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - DAY 1
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	4.5
	4509	02	4.4
	4510	01	6.3
	4510	02	5.5
	4511	01	7.4
	4511	02	6.1
	4513	01	4.3
	4513	02	5.0
	4514	01	6.9
	4514	02	7.6
	4515	01	5.4
	4515	02	3.3
	4516	01	4.2
	4516	02	4.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	01	5.8
	1001	02	4.4
	1002	01	6.4
	1002	02	6.5
	1005	01	9.2
	1005	02	7.1
	1006	01	8.3
	1006	02	7.7
	1007	01	10.0
	1007	02	8.0
	1008	01	5.3
	1008	02	7.8
	1009	01	7.3
	1009	02	6.8
	1010	01	5.6
	1010	02	5.8

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1011	01	7.9
	1011	02	7.1
	1012	01	4.2
	1012	02	6.1
	1013	01	9.8
	1013	02	8.8
	1014	01	9.3
	1014	02	8.0
	1015	01	8.4
	1015	02	5.7
	1016	01	4.1
	1016	02	4.4
	1017	01	8.9
	1017	02	7.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	7.8
	2001	02	5.5
	2002	01	7.9
	2002	02	6.4
	2003	01	10.4
	2003	02	9.9
	2004	01	10.0
	2004	02	7.8
	2005	01	10.0
	2005	02	8.8
	2006	01	10.3
	2006	02	9.1
	2007	01	9.6
	2007	02	9.8
	2008	01	5.0
	2008	02	4.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	7.1
	2009	02	5.2
	2010	01	9.1
	2010	02	8.8
	2011	01	4.3
	2011	02	4.8
	2012	01	6.8
	2012	02	6.4
	2013	01	4.4
	2013	02	4.5
	2015	01	6.4
	2015	02	7.3
	2016	01	7.9
	2016	02	6.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	5.6
	3001	02	5.2
	3002	01	10.3
	3002	02	9.3
	3003	01	10.5
	3003	02	7.5
	3004	01	11.1
	3004	02	6.8
	3005	01	9.0
	3005	02	9.9
	3006	01	10.6
	3006	02	9.5
	3007	01	10.7
	3007	02	8.5
	3008	01	5.8
	3008	02	6.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	9.9
	3009	02	10.0
	3011	01	5.0
	3011	02	6.3
	3012	01	7.1
	3012	02	8.1
	3013	01	6.0
	3013	02	6.8
	3014	01	4.0
	3014	02	5.8
	3015	01	9.5
	3015	02	8.2
	3016	01	9.4
	3016	02	7.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	7.2
	4001	02	5.6
	4002	01	11.1
	4002	02	9.3
	4003	01	10.3
	4003	02	9.1
	4004	01	11.5
	4004	02	11.9
	4005	01	6.7
	4005	02	6.7
	4006	01	8.7
	4006	02	7.8
	4007	01	11.9
	4007	02	11.4
	4008	01	6.2
	4008	02	7.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	9.0
	4009	02	6.4
	4010	01	6.1
	4010	02	4.6
	4011	01	7.2
	4011	02	3.8
	4012	01	5.3
	4012	02	5.0
	4014	01	8.0
	4014	02	8.1
	4015	01	4.6
	4015	02	6.0
	4016	01	6.5
	4016	02	4.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	01	7.1
	1501	02	8.4
	1502	01	7.5
	1502	02	6.0
	1503	01	9.3
	1503	02	8.9
	1504	01	6.8
	1504	02	5.4
	1505	01	7.0
	1505	02	6.4
	1506	01	9.0
	1506	02	9.6
	1507	01	7.6
	1507	02	8.5
	1508	01	8.2
	1508	02	8.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1509	01	6.2
	1509	02	5.4
	1510	01	10.1
	1510	02	10.0
	1511	01	5.5
	1511	02	7.5
	1512	01	6.4
	1512	02	5.6
	1513	01	6.8
	1513	02	6.6
	1514	01	6.6
	1514	02	4.9
	1515	01	8.7
	1515	02	9.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	6.6
	2501	02	7.3
	2502	01	8.7
	2502	02	7.7
	2503	01	7.7
	2503	02	6.5
	2504	01	3.7
	2504	02	5.2
	2505	01	8.1
	2505	02	7.1
	2506	01	5.9
	2506	02	8.0
	2507	01	7.6
	2507	02	8.4
	2508	01	7.3
	2508	02	5.8

APPENDIX NO: 5

PROJECT NO : 90831

INDIVIDUAL HINDLIMB SPLAY (CM)

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	9.0
	2509	02	7.0
	2510	01	5.9
	2510	02	6.0
	2511	01	8.6
	2511	02	7.6
	2512	01	7.4
	2512	02	6.6
	2513	01	8.9
	2513	02	10.2
	2514	01	9.4
	2514	02	9.6
	2515	01	8.9
	2515	02	

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	7.7
	3501	02	4.5
	3502	01	7.9
	3502	02	7.3
	3503	01	9.1
	3503	02	8.1
	3504	01	4.4
	3504	02	5.1
	3505	01	8.6
	3505	02	8.5
	3506	01	8.6
	3506	02	8.2
	3507	01	9.9
	3507	02	9.8
	3508	01	9.4
	3508	02	9.1

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	9.5
	3509	02	9.3
	3510	01	8.1
	3510	02	10.1
	3511	01	6.0
	3511	02	8.3
	3513	01	6.2
	3513	02	5.5
	3514	01	6.9
	3514	02	6.8
	3516	01	4.7
	3516	02	6.8
	3517	01	4.0
	3517	02	4.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	4.3
	4501	02	5.3
	4502	01	8.5
	4502	02	9.1
	4503	01	9.5
	4503	02	8.6
	4504	01	8.5
	4504	02	7.5
	4505	01	7.5
	4505	02	5.6
	4506	01	9.5
	4506	02	8.9
	4507	01	9.5
	4507	02	9.2
	4508	01	7.2
	4508	02	6.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 4
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	6.6
	4509	02	4.8
	4510	01	8.0
	4510	02	5.5
	4511	01	8.9
	4511	02	4.6
	4513	01	5.2
	4513	02	6.4
	4514	01	7.5
	4514	02	4.7
	4515	01	6.8
	4515	02	5.8
	4516	01	5.6
	4516	02	5.1

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	01	6.3
	1001	02	6.1
	1002	01	7.0
	1002	02	4.8
	1005	01	4.1
	1005	02	3.0
	1006	01	8.4
	1006	02	7.5
	1007	01	9.6
	1007	02	10.2
	1008	01	8.6
	1008	02	7.8
	1009	01	8.6
	1009	02	9.1
	1010	01	5.6
	1010	02	5.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1011	01	10.3
	1011	02	10.0
	1012	01	3.3
	1012	02	4.5
	1013	01	9.0
	1013	02	7.8
	1014	01	9.9
	1014	02	10.9
	1015	01	8.7
	1015	02	7.4
	1016	01	3.0
	1016	02	4.1
	1017	01	9.6
	1017	02	9.8

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	9.7
	2001	02	8.3
	2002	01	6.2
	2002	02	6.6
	2003	01	10.0
	2003	02	10.4
	2004	01	10.9
	2004	02	9.7
	2005	01	7.3
	2005	02	7.7
	2006	01	6.2
	2006	02	5.6
	2007	01	8.5
	2007	02	8.5
	2008	01	5.4
	2008	02	6.1

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	8.7
	2009	02	5.5
	2010	01	12.3
	2010	02	10.2
	2011	01	9.3
	2011	02	10.3
	2012	01	5.1
	2012	02	7.0
	2013	01	4.4
	2013	02	5.0
	2015	01	10.1
	2015	02	10.5
	2016	01	9.4
	2016	02	7.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	4.4
	3001	02	4.7
	3002	01	10.4
	3002	02	9.7
	3003	01	9.5
	3003	02	7.4
	3004	01	9.8
	3004	02	6.7
	3005	01	9.1
	3005	02	6.7
	3006	01	9.4
	3006	02	7.9
	3007	01	8.6
	3007	02	8.7
	3008	01	12.5
	3008	02	8.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	8.3
	3009	02	7.4
	3011	01	6.1
	3011	02	6.8
	3012	01	11.2
	3012	02	7.2
	3013	01	6.5
	3013	02	7.2
	3014	01	8.8
	3014	02	5.2
	3015	01	9.9
	3015	02	8.2
	3016	01	9.4
	3016	02	9.4

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	01	5.4
	4001	02	4.9
	4002	01	9.9
	4002	02	10.1
	4003	01	10.1
	4003	02	8.8
	4004	01	10.1
	4004	02	9.8
	4005	01	4.6
	4005	02	4.2
	4006	01	7.8
	4006	02	9.0
	4007	01	10.7
	4007	02	9.9
	4008	01	8.8
	4008	02	8.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4009	01	4.9
	4009	02	4.8
	4010	01	7.1
	4010	02	3.8
	4011	01	7.2
	4011	02	8.4
	4012	01	6.3
	4012	02	6.1
	4014	01	8.0
	4014	02	7.2
	4015	01	8.3
	4015	02	6.8
	4016	01	8.7
	4016	02	7.4

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	01	8.8
	1501	02	6.8
	1502	01	8.8
	1502	02	9.0
	1503	01	9.9
	1503	02	7.9
	1504	01	7.5
	1504	02	5.7
	1505	01	6.9
	1505	02	7.8
	1506	01	7.1
	1506	02	7.9
	1507	01	7.3
	1507	02	8.0
	1508	01	6.7
	1508	02	7.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1509	01	6.0
	1509	02	6.0
	1510	01	10.2
	1510	02	10.3
	1511	01	8.5
	1511	02	7.8
	1512	01	6.6
	1512	02	6.4
	1513	01	4.9
	1513	02	6.3
	1514	01	5.5
	1514	02	6.3
	1515	01	9.9
	1515	02	9.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	6.7
	2501	02	7.1
	2502	01	9.4
	2502	02	9.6
	2503	01	8.5
	2503	02	8.5
	2504	01	6.0
	2504	02	5.8
	2505	01	6.9
	2505	02	4.4
	2506	01	6.0
	2506	02	6.9
	2507	01	6.4
	2507	02	5.5
	2508	01	5.7
	2508	02	5.1

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	8.5
	2509	02	8.0
	2510	01	4.1
	2510	02	4.8
	2511	01	6.3
	2511	02	6.1
	2512	01	3.4
	2512	02	4.8
	2513	01	8.4
	2513	02	7.9
	2514	01	9.9
	2514	02	9.6
	2515	01	8.6
	2515	02	7.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	6.7
	3501	02	7.2
	3502	01	8.8
	3502	02	8.1
	3503	01	8.4
	3503	02	8.3
	3504	01	5.7
	3504	02	6.2
	3505	01	8.1
	3505	02	5.6
	3506	01	6.9
	3506	02	6.6
	3507	01	10.1
	3507	02	9.4
	3508	01	6.5
	3508	02	5.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	9.4
	3509	02	8.6
	3510	01	7.0
	3510	02	7.1
	3511	01	3.3
	3511	02	4.1
	3513	01	5.2
	3513	02	5.8
	3514	01	4.2
	3514	02	5.0
	3516	01	7.6
	3516	02	6.7
	3517	01	3.7
	3517	02	4.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	6.7
	4501	02	7.6
	4502	01	9.5
	4502	02	9.0
	4503	01	7.3
	4503	02	6.8
	4504	01	8.5
	4504	02	7.9
	4505	01	7.5
	4505	02	5.9
	4506	01	9.4
	4506	02	8.8
	4507	01	8.9
	4507	02	9.3
	4508	01	7.4
	4508	02	6.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 8
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	5.1
	4509	02	5.5
	4510	01	6.4
	4510	02	7.1
	4511	01	6.8
	4511	02	8.7
	4513	01	5.3
	4513	02	5.0
	4514	01	5.6
	4514	02	5.3
	4515	01	4.6
	4515	02	4.1
	4516	01	5.6
	4516	02	4.8

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1001	01	6.0
	1001	02	4.7
	1002	01	6.3
	1002	02	4.8
	1005	01	8.0
	1005	02	6.8
	1006	01	9.0
	1006	02	6.4
	1007	01	7.5
	1007	02	7.4
	1008	01	4.4
	1008	02	6.3
	1009	01	8.5
	1009	02	6.6
	1010	01	5.9
	1010	02	6.3

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1011	01	9.5
	1011	02	9.1
	1012	01	4.1
	1012	02	6.1
	1013	01	8.4
	1013	02	9.3
	1014	01	10.1
	1014	02	10.3
	1015	01	8.6
	1015	02	7.2
	1016	01	4.2
	1016	02	4.7
	1017	01	11.9
	1017	02	10.6

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2001	01	10.8
	2001	02	7.4
	2002	01	5.0
	2002	02	4.6
	2003	01	8.1
	2003	02	8.3
	2004	01	9.1
	2004	02	7.7
	2005	01	9.1
	2005	02	7.2
	2006	01	6.3
	2006	02	7.2
	2007	01	11.0
	2007	02	10.0
	2008	01	10.1
	2008	02	5.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2009	01	5.6
	2009	02	3.7
	2010	01	10.0
	2010	02	6.5
	2011	01	6.7
	2011	02	9.7
	2012	01	6.7
	2012	02	7.5
	2013	01	7.2
	2013	02	4.6
	2015	01	9.3
	2015	02	9.6
	2016	01	7.2
	2016	02	5.4

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	01	5.3
	3001	02	6.5
	3002	01	11.5
	3002	02	11.2
	3003	01	10.2
	3003	02	7.8
	3004	01	4.9
	3004	02	4.0
	3005	01	6.0
	3005	02	6.5
	3006	01	9.2
	3006	02	8.3
	3007	01	9.8
	3007	02	9.0
	3008	01	10.7
	3008	02	8.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3009	01	6.1
	3009	02	8.8
	3011	01	4.9
	3011	02	7.2
	3012	01	7.8
	3012	02	8.7
	3013	01	5.2
	3013	02	6.2
	3014	01	4.4
	3014	02	5.7
	3015	01	9.1
	3015	02	9.4
	3016	01	8.7
	3016	02	6.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	01	12.8
	4002	02	10.2
	4003	01	8.9
	4003	02	9.0
	4004	01	10.2
	4004	02	9.0
	4005	01	5.3
	4005	02	5.5
	4006	01	9.4
	4006	02	6.6
	4007	01	7.3
	4007	02	11.2
	4008	01	7.3
	4008	02	8.7
	4009	01	5.3
	4009	02	5.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
MALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4010	01	7.0
	4010	02	8.5
	4011	01	6.7
	4011	02	6.9
	4012	01	5.7
	4012	02	5.6
	4014	01	5.7
	4014	02	6.0
	4015	01	5.7
	4015	02	6.0
	4016	01	8.7
	4016	02	7.8

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1501	01	7.8
	1501	02	7.3
	1502	01	6.2
	1502	02	7.9
	1503	01	9.4
	1503	02	8.8
	1504	01	7.0
	1504	02	7.2
	1505	01	5.4
	1505	02	6.6
	1506	01	7.7
	1506	02	7.2
	1507	01	8.9
	1507	02	9.1
	1508	01	9.2
	1508	02	8.9

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

TRIALS 1 AND 2 - WEEK 13
FEMALES

PROJECT NO : 90831

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 1 - AIR CONTROL	1509	01	7.3
	1509	02	8.1
	1510	01	8.9
	1510	02	9.9
	1511	01	9.0
	1511	02	6.0
	1512	01	8.3
	1512	02	8.3
	1513	01	2.9
	1513	02	3.6
	1514	01	5.1
	1514	02	5.7
	1515	01	9.5
	1515	02	7.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2501	01	6.5
	2501	02	7.4
	2502	01	10.1
	2502	02	9.9
	2503	01	7.4
	2503	02	6.6
	2504	01	6.6
	2504	02	4.7
	2505	01	7.6
	2505	02	8.4
	2506	01	9.2
	2506	02	8.1
	2507	01	8.2
	2507	02	7.6
	2508	01	7.0
	2508	02	8.0

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 2 - CERIC OXIDE LOW DOSE	2509	01	9.6
	2509	02	9.2
	2510	01	5.7
	2510	02	5.8
	2511	01	6.7
	2511	02	7.0
	2512	01	5.1
	2512	02	6.9
	2513	01	6.9
	2513	02	7.0
	2514	01	7.8
	2514	02	7.1
	2515	01	6.7
	2515	02	6.2

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	01	6.7
	3501	02	6.1
	3502	01	9.2
	3502	02	7.2
	3503	01	10.0
	3503	02	8.6
	3504	01	6.9
	3504	02	5.5
	3505	01	9.2
	3505	02	8.8
	3506	01	7.9
	3506	02	7.2
	3507	01	10.0
	3507	02	10.5
	3508	01	7.9
	3508	02	8.6

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3509	01	8.9
	3509	02	9.0
	3510	01	9.0
	3510	02	8.2
	3511	01	7.4
	3511	02	6.6
	3513	01	4.1
	3513	02	4.8
	3514	01	4.1
	3514	02	4.2
	3516	01	6.9
	3516	02	6.3
	3517	01	1.8
	3517	02	1.7

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	01	6.1
	4501	02	6.0
	4502	01	8.2
	4502	02	6.7
	4503	01	7.9
	4503	02	7.3
	4504	01	8.7
	4504	02	9.6
	4505	01	7.8
	4505	02	8.8
	4506	01	10.5
	4506	02	9.3
	4507	01	10.1
	4507	02	8.9
	4508	01	8.3
	4508	02	7.5

APPENDIX NO: 5

INDIVIDUAL HINDLIMB SPLAY (CM)

PROJECT NO : 90831

TRIALS 1 AND 2 - WEEK 13
FEMALES

	ANIMAL NO.	TRIAL	HINDLIMB SPLAY
GROUP 4 - CERIC OXIDE HIGH DOSE	4509	01	6.0
	4509	02	4.5
	4510	01	9.0
	4510	02	8.0
	4511	01	9.4
	4511	02	10.0
	4513	01	4.6
	4513	02	3.0
	4514	01	3.6
	4514	02	2.6
	4515	01	4.6
	4515	02	3.8
	4516	01	6.1
	4516	02	6.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (℃)

PROJECT NO :90831

PRE-STUDY
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1001	38.6
	1002	37.8
	1005	37.7
	1006	38.0
	1007	37.5
	1008	37.4
	1009	37.4
	1010	37.5
	1011	37.6
	1012	37.2
	1013	37.5
	1014	37.3
	1015	37.6
	1016	38.0
	1017	37.6

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

PRE-STUDY
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	38.3
	2002	38.2
	2003	37.7
	2004	37.7
	2005	38.1
	2006	37.5
	2007	37.7
	2008	37.7
	2009	38.1
	2010	37.5
	2011	37.6
	2012	37.6
	2013	37.4
	2015	37.7
	2016	37.3

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

PRE-STUDY
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	37.5
	3002	38.1
	3003	37.7
	3004	37.7
	3005	37.6
	3006	37.6
	3007	37.8
	3008	37.6
	3009	36.9
	3011	38.1
	3012	37.5
	3013	37.2
	3014	37.6
	3015	37.3
	3016	36.9

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

PRE-STUDY
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	37.2
	4002	38.3
	4003	38.0
	4004	37.2
	4005	38.0
	4006	38.1
	4007	37.5
	4008	37.7
	4009	38.3
	4010	37.4
	4011	37.5
	4012	37.2
	4014	37.5
	4015	37.6
	4016	37.2

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

PRE-STUDY
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1501	37.6
	1502	39.1
	1503	38.6
	1504	37.9
	1505	38.4
	1506	37.8
	1507	38.1
	1508	37.5
	1509	37.7
	1510	37.6
	1511	37.6
	1512	38.1
	1513	37.0
	1514	37.3
	1515	37.6

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

PRE-STUDY
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2501	38.5
	2502	38.4
	2503	37.8
	2504	38.5
	2505	37.7
	2506	38.6
	2507	37.9
	2508	36.6
	2509	37.0
	2510	37.5
	2511	37.5
	2512	37.4
	2513	37.9
	2514	38.0
	2515	37.9

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

PRE-STUDY
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	37.9
	3502	37.7
	3503	37.4
	3504	37.7
	3505	37.5
	3506	38.4
	3507	38.0
	3508	37.8
	3509	37.8
	3510	38.2
	3511	37.5
	3513	37.9
	3514	37.7
	3516	37.1
	3517	38.0

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

PRE-STUDY
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	38.5
	4502	37.3
	4503	38.0
	4504	38.8
	4505	37.9
	4506	38.2
	4507	38.4
	4508	37.8
	4509	37.3
	4510	37.7
	4511	36.8
	4513	37.6
	4514	37.9
	4515	37.6
	4516	37.0

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1001	38.9
	1002	38.2
	1005	37.9
	1006	38.0
	1007	37.7
	1008	37.8
	1009	37.7
	1010	38.1
	1011	37.6
	1012	37.8
	1013	37.9
	1014	37.7
	1015	37.6
	1016	37.9
	1017	37.8

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	38.7
	2002	38.9
	2003	38.2
	2004	38.3
	2005	38.0
	2006	37.3
	2007	37.7
	2008	38.0
	2009	38.0
	2010	38.0
	2011	37.7
	2012	37.9
	2013	37.6
	2015	37.9
	2016	37.3

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	38.0
	3002	38.3
	3003	37.7
	3004	37.9
	3005	37.5
	3006	38.2
	3007	37.8
	3008	38.2
	3009	37.0
	3011	38.3
	3012	37.4
	3013	38.0
	3014	37.8
	3015	37.7
	3016	37.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	38.2
	4002	38.9
	4003	37.7
	4004	37.9
	4005	38.0
	4006	37.7
	4007	37.9
	4008	38.0
	4009	38.2
	4010	37.7
	4011	38.6
	4012	37.9
	4014	38.2
	4015	38.0
	4016	38.1

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1501	38.4
	1502	37.7
	1503	37.6
	1504	38.0
	1505	38.7
	1506	38.0
	1507	38.0
	1508	37.6
	1509	37.8
	1510	38.4
	1511	38.5
	1512	38.2
	1513	38.0
	1514	38.3
	1515	37.9

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2501	37.8
	2502	37.9
	2503	38.8
	2504	38.5
	2505	38.2
	2506	38.1
	2507	37.5
	2508	37.6
	2509	37.4
	2510	37.3
	2511	37.6
	2512	38.1
	2513	37.8
	2514	38.3
	2515	38.6

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	38.2
	3502	37.8
	3503	38.3
	3504	38.4
	3505	37.7
	3506	37.5
	3507	38.5
	3508	37.5
	3509	37.9
	3510	38.8
	3511	37.9
	3513	37.6
	3514	38.3
	3516	38.3
	3517	38.4

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

DAY 1
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	38.7
	4502	37.9
	4503	37.9
	4504	38.6
	4505	37.8
	4506	38.5
	4507	38.2
	4508	37.9
	4509	37.9
	4510	38.1
	4511	37.8
	4513	37.8
	4514	38.7
	4515	37.4
	4516	38.4

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1001	38.5
	1002	38.1
	1005	37.3
	1006	37.6
	1007	38.0
	1008	37.3
	1009	37.1
	1010	37.2
	1011	38.1
	1012	37.2
	1013	37.0
	1014	37.2
	1015	38.2
	1016	37.5
	1017	37.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	38.0
	2002	38.6
	2003	37.3
	2004	37.4
	2005	38.6
	2006	38.2
	2007	37.1
	2008	37.6
	2009	37.9
	2010	37.6
	2011	37.4
	2012	37.3
	2013	37.4
	2015	37.5
	2016	36.9

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	38.0
	3002	38.9
	3003	38.2
	3004	38.2
	3005	38.7
	3006	38.0
	3007	37.9
	3008	37.6
	3009	37.5
	3011	39.2
	3012	38.3
	3013	37.2
	3014	37.6
	3015	37.6
	3016	37.1

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (℃)

PROJECT NO :90831

WEEK 4
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	38.1
	4002	38.3
	4003	37.9
	4004	37.1
	4005	37.4
	4006	37.3
	4007	38.3
	4008	37.4
	4009	37.9
	4010	37.1
	4011	37.0
	4012	38.3
	4014	37.4
	4015	37.9
	4016	37.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1501	38.5
	1502	38.7
	1503	38.4
	1504	38.6
	1505	39.4
	1506	38.9
	1507	37.7
	1508	37.9
	1509	38.9
	1510	37.3
	1511	38.7
	1512	38.7
	1513	38.1
	1514	38.2
	1515	38.2

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2501	38.9
	2502	39.0
	2503	39.0
	2504	39.1
	2505	38.0
	2506	38.4
	2507	37.6
	2508	38.1
	2509	37.6
	2510	37.7
	2511	38.2
	2512	37.4
	2513	38.2
	2514	37.5
	2515	38.7

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	38.6
	3502	38.1
	3503	38.0
	3504	38.6
	3505	38.2
	3506	38.6
	3507	37.9
	3508	38.1
	3509	37.6
	3510	37.5
	3511	37.8
	3513	37.8
	3514	38.6
	3516	38.6
	3517	38.4

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 4
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	39.1
	4502	38.7
	4503	38.6
	4504	38.6
	4505	38.8
	4506	39.2
	4507	37.9
	4508	37.4
	4509	38.6
	4510	37.8
	4511	37.2
	4513	38.5
	4514	38.8
	4515	38.1
	4516	38.9

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 8
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1001	38.4
	1002	37.3
	1005	37.8
	1006	38.1
	1007	38.4
	1008	37.2
	1009	36.7
	1010	36.8
	1011	37.1
	1012	36.9
	1013	37.8
	1014	37.7
	1015	36.8
	1016	37.0
	1017	37.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 8
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	37.9
	2002	38.4
	2003	36.5
	2004	37.1
	2005	38.2
	2006	37.8
	2007	38.2
	2008	37.4
	2009	37.0
	2010	37.2
	2011	37.0
	2012	37.7
	2013	38.1
	2015	38.5
	2016	37.8

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 8
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	37.6
	3002	38.6
	3003	37.8
	3004	36.6
	3005	38.1
	3006	37.0
	3007	36.7
	3008	38.0
	3009	36.9
	3011	39.7
	3012	37.2
	3013	38.1
	3014	38.4
	3015	37.6
	3016	37.3

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 8
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	37.4
	4002	38.3
	4003	38.1
	4004	37.6
	4005	37.2
	4006	36.7
	4007	37.2
	4008	37.0
	4009	36.9
	4010	37.2
	4011	37.1
	4012	38.0
	4014	37.4
	4015	37.6
	4016	37.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 8
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1501	38.9
	1502	38.7
	1503	38.5
	1504	38.1
	1505	38.2
	1506	38.3
	1507	37.9
	1508	37.4
	1509	38.2
	1510	37.6
	1511	38.6
	1512	38.3
	1513	38.5
	1514	38.3
	1515	37.7

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (℃)

PROJECT NO :90831

WEEK 8
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2501	39.0
	2502	38.8
	2503	39.1
	2504	37.9
	2505	38.5
	2506	37.1
	2507	37.9
	2508	37.5
	2509	38.1
	2510	37.3
	2511	38.1
	2512	37.7
	2513	38.6
	2514	38.3
	2515	38.4

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 8
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	38.9
	3502	38.7
	3503	38.6
	3504	38.8
	3505	38.3
	3506	38.4
	3507	38.8
	3508	38.3
	3509	37.5
	3510	38.0
	3511	38.7
	3513	37.1
	3514	38.4
	3516	38.8
	3517	38.4

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 8
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	39.4
	4502	38.7
	4503	38.8
	4504	38.0
	4505	38.6
	4506	38.7
	4507	37.5
	4508	37.8
	4509	38.0
	4510	37.1
	4511	37.0
	4513	38.6
	4514	38.9
	4515	38.4
	4516	38.7

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1001	38.8
	1002	38.9
	1005	37.5
	1006	37.7
	1007	37.3
	1008	37.5
	1009	37.2
	1010	37.1
	1011	37.2
	1012	37.6
	1013	37.2
	1014	37.4
	1015	37.0
	1016	36.9
	1017	37.9

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	38.1
	2002	38.8
	2003	37.4
	2004	37.0
	2005	38.4
	2006	38.0
	2007	38.6
	2008	37.7
	2009	37.9
	2010	37.2
	2011	37.4
	2012	37.9
	2013	38.7
	2015	37.2
	2016	38.3

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (℃) PROJECT NO :90831

WEEK 13
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	38.3
	3002	38.5
	3003	38.5
	3004	37.4
	3005	38.3
	3006	37.5
	3007	37.3
	3008	37.1
	3009	36.6
	3011	38.3
	3012	37.1
	3013	37.6
	3014	38.1
	3015	36.9
	3016	37.0

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 13
MALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	38.0
	4003	37.9
	4004	36.9
	4005	37.2
	4006	37.0
	4007	37.4
	4008	37.1
	4009	37.4
	4010	37.3
	4011	36.8
	4012	37.8
	4014	37.4
	4015	37.3
	4016	37.5

APPENDIX NO. 5

INDIVIDUAL BODY TEMPERATURE (°C)

PROJECT NO :90831

WEEK 13
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 1 - AIR CONTROL	1501	38.9
	1502	38.7
	1503	38.9
	1504	38.4
	1505	38.8
	1506	37.9
	1507	38.4
	1508	37.6
	1509	38.5
	1510	37.7
	1511	37.4
	1512	38.1
	1513	38.7
	1514	38.2
	1515	37.7

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 2 - CERIC OXIDE LOW DOSE	2501	38.8
	2502	38.9
	2503	39.0
	2504	37.7
	2505	38.3
	2506	37.9
	2507	38.2
	2508	37.5
	2509	37.8
	2510	37.0
	2511	37.9
	2512	38.1
	2513	38.2
	2514	37.7
	2515	38.8

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	39.0
	3502	38.9
	3503	38.5
	3504	38.9
	3505	38.0
	3506	37.4
	3507	38.3
	3508	37.9
	3509	37.5
	3510	38.5
	3511	39.0
	3513	36.8
	3514	38.3
	3516	37.6
	3517	39.2

APPENDIX NO. 5 INDIVIDUAL BODY TEMPERATURE (°C) PROJECT NO :90831

WEEK 13
FEMALES

	ANIMAL NO.	BODY TEMPERATURE
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	39.1
	4502	38.8
	4503	38.9
	4504	38.7
	4505	38.8
	4506	37.7
	4507	38.6
	4508	39.0
	4509	38.4
	4510	38.1
	4511	37.1
	4513	38.0
	4514	38.5
	4515	38.3
	4516	38.6

CER-TP-94-1000 A.V.

BIO-RESEARCH LABORATORIES LTD.

STUDY TITLE

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT

VOLUME III

SPONSOR

Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

DATA REQUIREMENTS

United States EPA/TSCA (40 CFR Part 792).
Japanese MHW GLP Regulations (Notification No. 313 and revised rule Notification No. 870)
OECD guidelines No. 413

AUTHOR

A. Viau, B.Sc.
Study Director

STUDY COMPLETED ON

September 29, 1994

PERFORMING LABORATORY

Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

LABORATORY PROJECT ID

90831

PAGE 671 OF 1352 PAGES

INDEX TO VOLUME III
(671 - 995)

APPENDIX NO. 6 PROJECT NO. 90831

INDIVIDUAL MOTOR ACTIVITY COUNTS
MALES AND FEMALES

The following footnotes have been used throughout the appendix:

Dead	Animal dead
T	Technical error

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1001	1	11	26	14	15	9	21	25	17	138	
	2	3	21	10	7	11	15	16	11	94	
	3	10	14	16	17	5	13	15	9	99	
	4	9	7	14	11	7	2	5	5	60	
	5	10	12	14	3	3	1	1	1	45	
	6	0	2	0	0	0	0	0	0	2	
	TOTAL										438
1002	1	4	11	23	21	8	22	26	14	129	
	2	2	12	17	11	5	18	15	14	94	
	3	7	5	15	23	5	14	14	13	96	
	4	4	6	12	13	2	8	12	9	66	
	5	13	13	11	15	6	1	1	9	69	
	6	0	1	12	0	0	0	0	0	13	
	TOTAL										467
1005	1	13	21	25	22	9	31	23	21	165	
	2	10	18	14	10	7	22	17	13	111	
	3	6	16	12	13	13	18	18	16	112	
	4	9	13	8	8	3	23	18	14	96	
	5	0	0	0	0	0	5	0	0	5	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										489
1006	1	2	8	15	15	12	13	21	13	99	
	2	2	2	1	3	3	6	16	4	37	
	3	3	3	5	6	13	8	9	5	52	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	1	0	1	
	TOTAL										189

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1007	1	4	7	18	20	7	15	18	10	99	
	2	16	1	14	16	6	12	9	5	79	
	3	4	1	6	12	3	4	5	2	37	
	4	0	0	3	8	0	4	8	0	23	
	5	0	0	1	0	0	0	0	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										239
1008	1	9	23	20	12	16	18	23	18	139	
	2	4	11	12	17	7	14	25	6	96	
	3	6	1	2	4	14	14	7	2	50	
	4	0	0	0	0	0	0	0	0	0	
	5	3	6	5	7	10	8	7	6	52	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										337
1009	1	9	13	19	18	10	12	11	13	105	
	2	7	11	17	4	6	18	19	12	94	
	3	2	6	6	7	5	1	1	1	29	
	4	1	2	6	1	0	4	4	8	26	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										255
1010	1	7	16	17	13	6	B	11	14	92	
	2	7	12	10	13	10	15	14	15	96	
	3	6	1	4	16	2	6	1	2	38	
	4	0	0	0	2	0	0	0	0	2	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										228

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1011	1	10	12	16	16	7	15	19	7	102	
	2	3	8	12	7	4	13	7	0	54	
	3	1	3	2	0	1	0	6	2	15	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										171
1012	1	9	12	12	11	8	16	13	11	92	
	2	6	11	10	8	7	8	9	8	67	
	3	3	2	0	1	8	1	7	1	23	
	4	0	0	0	0	0	0	1	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										183
1013	1	0	0	2	4	0	0	0	0	6	
	2	0	0	2	0	0	0	0	0	2	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	1	3	1	1	2	1	9	
	TOTAL										17
1014	1	3	10	56	10	3	11	7	7	107	
	2	1	0	6	16	1	3	15	6	48	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										155

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1015	1	1	12	14	13	7	14	19	5	85	
	2	2	3	4	1	6	11	9	8	44	
	3	3	4	10	8	4	9	10	3	51	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										180
1016	1	4	22	19	14	6	14	15	13	107	
	2	9	14	17	8	4	8	8	12	80	
	3	5	8	10	17	11	16	15	15	97	
	4	0	1	0	0	0	0	0	3	4	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										288
1017	1	8	11	20	13	6	15	19	11	103	
	2	7	13	13	12	6	9	15	10	85	
	3	3	8	13	9	6	9	11	9	68	
	4	1	3	2	4	3	11	2	1	27	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	1	0	0	1	
	TOTAL										284

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2001	1	7	14	28	16	6	17	11	6	105	
	2	1	2	14	10	1	10	7	5	50	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										155
2002	1	8	19	20	22	18	16	19	17	139	
	2	11	4	14	9	2	9	16	9	74	
	3	2	2	8	8	2	7	12	4	45	
	4	0	2	1	1	0	2	6	8	20	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										278
2003	1	6	14	19	18	10	21	24	9	121	
	2	9	18	23	16	5	20	9	16	116	
	3	4	12	14	21	3	18	16	19	107	
	4	4	16	5	9	7	9	12	23	85	
	5	0	0	0	0	0	0	0	0	0	
	6	2	9	8	5	2	8	6	23	63	
	TOTAL										492
2004	1	10	10	15	10	11	17	27	15	115	
	2	9	17	13	11	21	11	17	6	105	
	3	4	10	5	0	17	3	15	6	60	
	4	0	0	0	0	39	0	0	0	39	
	5	0	0	0	0	7	1	4	0	12	
	6	0	1	1	1	0	1	1	1	6	
	TOTAL										337

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2005	1	7	11	10	11	19	23	22	19	122	
	2	3	2	7	5	39	9	9	11	85	
	3	0	0	0	0	69	1	4	5	79	
	4	0	0	0	0	42	0	0	0	42	
	5	0	0	0	0	11	0	0	0	11	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										339
2006	1	4	13	24	16	7	25	22	17	128	
	2	2	8	23	9	4	17	20	20	103	
	3	8	11	26	16	4	12	10	13	100	
	4	2	5	6	1	0	3	3	6	26	
	5	0	0	1	0	0	0	0	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										358
2007	1	8	11	27	14	11	8	10	6	95	
	2	2	5	18	7	4	7	10	7	60	
	3	1	3	4	8	0	8	8	5	37	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	2	0	0	0	0	0	2	
	TOTAL										194
2008	1	6	12	28	29	15	20	24	22	156	
	2	8	12	24	15	17	19	18	8	121	
	3	2	5	18	12	10	7	1	2	57	
	4	3	5	12	5	4	2	1	5	37	
	5	0	0	1	3	0	2	0	0	6	
	6	0	1	10	4	3	0	0	0	18	
	TOTAL										395

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2009	1	11	18	31	13	9	21	24	13	140	
	2	8	17	30	9	9	5	21	4	103	
	3	0	0	0	0	0	0	9	0	9	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										252
2010	1	9	13	15	13	10	17	21	13	111	
	2	4	7	10	6	7	6	9	5	54	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										165
2011	1	9	14	11	15	5	21	28	18	121	
	2	5	14	10	17	12	19	16	16	109	
	3	3	12	1	1	6	11	22	10	66	
	4	0	0	0	0	0	1	0	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										297
2012	1	0	2	1	6	4	11	13	4	41	
	2	1	4	6	1	1	6	10	1	30	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										71

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2013	1	6	12	17	11	21	12	10	9	98	
	2	3	2	10	8	6	10	7	5	51	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										149
2015	1	10	13	19	16	12	18	25	15	128	
	2	11	23	11	9	13	18	17	11	113	
	3	0	0	2	2	0	5	4	0	13	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										254
2016	1	6	3	5	5	5	5	9	7	45	
	2	2	4	9	6	2	3	16	6	48	
	3	0	0	0	1	0	3	0	0	4	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										97

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3001	1	2	6	16	11	2	11	17	10	75	
	2	10	14	18	21	14	14	18	12	121	
	3	5	12	16	12	8	21	21	19	114	
	4	0	4	8	3	0	2	4	3	24	
	5	0	0	2	2	0	1	1	0	6	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										340
3002	1	7	19	27	16	12	12	24	24	141	
	2	5	13	17	7	5	5	21	6	79	
	3	6	12	8	16	10	7	14	19	92	
	4	4	16	5	8	3	15	10	15	76	
	5	2	11	8	5	5	16	15	7	69	
	6	1	3	2	0	0	2	1	1	10	
	TOTAL										467
3003	1	3	11	17	22	5	12	17	19	106	
	2	10	10	7	11	9	9	11	10	77	
	3	5	15	9	9	12	4	9	11	74	
	4	3	6	5	6	10	8	9	9	56	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										313
3004	1	9	12	21	25	8	16	14	18	123	
	2	3	11	13	13	2	18	17	7	84	
	3	2	6	30	9	3	11	4	1	66	
	4	0	0	7	0	0	0	0	0	7	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										280

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3005	1	6	14	18	16	8	24	18	13	117	
	2	6	22	40	16	4	11	11	13	123	
	3	9	10	18	14	4	18	20	8	101	
	4	1	4	11	15	3	3	13	6	56	
	5	1	6	1	1	2	3	3	4	21	
	6	2	1	3	5	0	4	0	0	15	
	TOTAL										433
3006	1	8	13	30	18	8	23	22	11	133	
	2	3	17	13	7	6	15	16	12	89	
	3	6	5	3	2	2	4	1	1	24	
	4	0	0	2	0	0	0	0	0	2	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										248
3007	1	6	11	20	22	6	18	13	11	107	
	2	6	10	10	19	13	15	12	10	95	
	3	7	11	11	13	5	10	6	10	73	
	4	6	7	7	8	1	4	1	2	36	
	5	0	0	0	4	2	2	0	1	9	
	6	0	0	0	1	0	0	0	0	1	
	TOTAL										321
3008	1	10	29	22	19	11	16	19	13	139	
	2	9	8	13	17	3	17	17	12	96	
	3	5	11	19	16	4	17	5	3	80	
	4	0	0	0	0	0	0	1	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	6	3	4	3	3	1	7	5	32	
	TOTAL										348

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3009	1	5	11	14	12	9	15	19	12	97	
	2	3	6	6	9	4	6	11	11	56	
	3	1	2	3	5	2	0	0	0	13	
	4	0	0	4	0	0	0	0	0	4	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										170
3011	1	8	11	13	16	13	18	18	13	110	
	2	7	13	11	4	41	13	10	8	107	
	3	1	1	2	1	71	1	1	1	79	
	4	0	0	0	0	7	0	0	0	7	
	5	0	0	0	0	5	0	0	0	5	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										308
3012	1	2	14	19	11	10	13	18	14	101	
	2	0	7	13	9	9	12	10	5	65	
	3	0	3	11	8	2	7	10	3	44	
	4	0	2	8	1	3	3	4	3	24	
	5	6	5	9	3	7	15	5	3	53	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										288
3013	1	9	11	11	18	9	21	24	11	114	
	2	6	4	6	6	5	22	23	8	80	
	3	0	0	0	0	0	4	0	0	4	
	4	0	0	0	0	0	0	2	0	2	
	5	0	0	0	0	0	4	2	0	6	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										206

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3014	1	9	18	13	20	7	25	16	16	124	
	2	6	15	14	10	3	16	6	7	77	
	3	2	13	4	11	2	16	13	7	68	
	4	0	0	0	0	0	0	9	0	9	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										278
3015	1	4	10	15	12	5	7	20	14	87	
	2	1	1	9	2	0	7	22	4	46	
	3	1	5	11	2	4	1	13	7	44	
	4	0	0	0	0	0	0	7	2	9	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										186
3016	1	7	9	12	6	9	15	15	9	82	
	2	4	7	7	8	5	9	13	10	63	
	3	0	0	0	0	0	1	0	0	1	
	4	0	1	3	4	0	5	4	0	17	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										163

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4001	1	4	26	16	16	13	25	21	18	139	
	2	11	19	18	9	6	12	17	25	117	
	3	3	6	4	9	5	13	16	21	77	
	4	3	8	4	3	3	1	1	13	36	
	5	0	0	0	0	0	0	1	1	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										371
4002	1	5	15	19	16	7	23	30	21	136	
	2	5	6	7	9	35	4	25	13	104	
	3	0	0	3	3	12	3	7	3	31	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										271
4003	1	1	5	13	10	3	19	17	7	75	
	2	4	11	13	12	10	4	3	7	64	
	3	0	0	12	2	1	1	0	0	16	
	4	0	3	0	0	2	5	7	2	19	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										174
4004	1	8	13	24	19	4	14	10	17	109	
	2	15	11	15	17	8	16	7	12	101	
	3	21	13	13	13	13	15	11	11	110	
	4	11	6	5	15	14	19	15	7	92	
	5	8	5	5	8	6	10	6	5	53	
	6	10	14	9	13	8	8	8	11	81	
	TOTAL										546

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4005	1	8	22	22	15	7	16	19	12	121	
	2	7	7	10	8	3	18	18	3	74	
	3	1	3	2	3	0	3	5	2	19	
	4	0	0	0	0	0	0	1	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										215
4006	1	6	9	10	8	6	11	19	21	90	
	2	4	15	16	14	5	13	17	10	94	
	3	4	5	8	13	2	13	22	12	79	
	4	0	0	0	0	0	0	8	3	11	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										274
4007	1	12	15	30	19	12	16	23	10	137	
	2	15	14	15	4	7	17	17	5	94	
	3	8	9	7	4	4	13	17	11	73	
	4	15	6	9	7	2	7	15	17	78	
	5	14	8	7	2	12	6	21	20	90	
	6	4	3	3	1	2	5	5	7	30	
	TOTAL										502
4008	1	6	11	17	10	4	15	22	8	93	
	2	7	8	12	8	4	8	17	6	70	
	3	2	4	3	2	0	2	2	2	17	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										180

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4009	1	5	12	17	14	5	9	22	18	102	
	2	2	11	12	13	6	6	11	13	74	
	3	3	5	6	10	9	11	12	8	64	
	4	0	1	1	1	1	2	2	0	8	
	5	1	1	2	4	1	6	3	0	18	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										266
4010	1	12	16	18	18	11	17	13	10	115	
	2	4	7	13	14	6	16	9	10	79	
	3	3	3	8	7	1	4	6	2	34	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										228
4011	1	10	21	20	16	5	8	12	21	113	
	2	12	15	13	11	2	22	13	15	103	
	3	12	14	10	15	8	10	9	10	88	
	4	6	6	8	11	0	13	4	8	56	
	5	4	16	10	5	3	3	5	6	52	
	6	1	2	0	0	0	0	0	0	3	
	TOTAL										415
4012	1	4	8	13	8	7	8	13	8	69	
	2	4	7	4	7	3	8	9	9	51	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										120

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
PRE STUDY

PROJECT NO.:90831

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4014	1	4	3	24	13	10	10	15	10	89	
	2	0	4	3	1	21	2	5	2	38	
	3	0	0	0	0	4	0	0	0	4	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	6	0	0	0	6	
	TOTAL										137
4015	1	4	17	10	14	10	17	19	12	103	
	2	2	7	13	9	1	6	11	8	57	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										160
4016	1	4	9	5	9	9	10	24	9	79	
	2	1	4	3	4	0	9	6	5	32	
	3	1	2	0	0	2	5	2	1	13	
	4	0	0	0	0	0	1	0	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										125

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1001	1	9	15	13	16	15	11	10	15	104	
	2	8	11	8	7	13	15	13	10	85	
	3	16	5	15	13	4	17	9	6	85	
	4	4	3	4	6	11	11	11	5	55	
	5	2	6	6	12	1	3	12	7	49	
	6	4	6	1	2	5	13	5	2	38	
	TOTAL										416
1002	1	8	17	21	16	11	17	17	18	125	
	2	4	2	8	7	4	9	21	9	64	
	3	10	14	9	9	3	9	22	12	88	
	4	2	4	5	6	0	1	6	9	33	
	5	0	0	3	3	3	7	5	2	23	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										333
1005	1	10	13	13	18	14	18	11	14	111	
	2	7	8	6	10	3	10	10	7	61	
	3	7	12	7	7	7	12	8	4	64	
	4	4	8	11	12	2	4	15	6	62	
	5	8	7	6	9	7	10	16	11	74	
	6	5	8	6	6	2	12	9	4	52	
	TOTAL										424
1006	1	5	18	14	11	4	24	15	10	101	
	2	3	9	8	11	3	23	16	15	88	
	3	2	3	4	11	2	18	13	8	61	
	4	1	1	3	11	4	4	2	6	32	
	5	2	1	6	7	2	7	3	3	31	
	6	1	2	0	6	0	2	0	1	12	
	TOTAL										325

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1007	1	4	12	17	14	7	13	8	10	85	
	2	2	7	4	11	2	1	2	13	42	
	3	3	3	1	1	1	0	0	0	9	
	4	0	0	5	4	0	1	1	2	13	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										149
1008	1	8	20	19	19	17	16	8	13	120	
	2	6	12	11	12	9	10	9	19	88	
	3	5	13	2	4	12	6	5	7	54	
	4	0	2	0	0	0	0	0	0	2	
	5	0	3	0	0	0	0	0	0	3	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										267
1009	1	9	21	15	10	8	13	10	17	103	
	2	5	9	6	9	3	7	6	16	61	
	3	6	14	15	9	10	10	14	14	92	
	4	0	21	13	6	2	3	5	19	69	
	5	5	5	0	0	4	5	9	7	35	
	6	2	5	4	6	0	3	3	8	31	
	TOTAL										391
1010	1	6	14	14	13	7	12	14	26	106	
	2	3	13	10	12	2	2	2	3	47	
	3	0	2	2	4	0	1	1	2	12	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	2	0	0	0	0	2	
	TOTAL										167

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1011	1	6	11	21	6	7	13	20	7	91	
	2	2	9	16	7	8	5	3	3	53	
	3	1	1	3	0	0	0	0	0	5	
	4	0	0	0	3	0	4	5	0	12	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										161
1012	1	7	16	12	9	6	18	14	11	93	
	2	6	15	15	15	3	5	4	5	68	
	3	6	13	5	4	6	9	9	3	55	
	4	1	4	14	3	6	4	3	4	39	
	5	0	7	0	0	2	1	2	1	13	
	6	3	11	5	2	1	4	5	5	36	
	TOTAL										304
1013	1	4	11	9	15	6	8	9	13	75	
	2	1	0	0	0	1	1	1	6	10	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										85
1014	1	3	13	21	28	3	16	24	21	129	
	2	3	4	8	11	0	13	17	5	61	
	3	0	0	0	0	0	1	19	0	20	
	4	4	2	6	4	0	0	17	4	37	
	5	0	2	3	3	7	3	15	0	33	
	6	5	2	0	0	1	4	8	6	26	
	TOTAL										306

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1015	1	6	12	13	14	6	15	17	8	91	
	2	2	8	19	12	1	9	12	14	77	
	3	1	5	7	10	4	8	16	8	59	
	4	1	8	7	5	3	6	8	10	48	
	5	0	0	3	2	0	1	4	1	11	
	6	0	1	8	1	0	0	0	0	10	
	TOTAL										296
1016	1	12	15	14	25	9	18	18	15	126	
	2	4	14	11	8	1	6	10	12	66	
	3	2	5	4	7	1	10	9	2	40	
	4	1	2	6	4	1	0	0	0	14	
	5	0	4	7	0	0	8	4	2	25	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										271
1017	1	9	14	16	12	11	19	15	16	112	
	2	5	14	15	16	6	11	13	12	92	
	3	3	10	14	16	7	9	8	12	79	
	4	3	5	9	6	3	4	8	13	51	
	5	3	6	6	5	2	7	12	13	54	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										388

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2001	1	4	8	18	11	4	11	15	15	86	
	2	2	2	3	15	3	3	1	8	37	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										123
2002	1	14	16	15	17	10	18	24	14	128	
	2	5	15	21	20	5	13	5	10	94	
	3	5	17	23	11	2	12	7	10	87	
	4	4	8	7	6	5	9	12	9	60	
	5	0	0	0	0	0	2	6	5	13	
	6	1	2	6	0	4	0	0	4	17	
	TOTAL										399
2003	1	3	17	16	21	6	20	15	10	108	
	2	4	12	16	11	5	12	8	8	76	
	3	6	14	8	8	5	11	10	10	72	
	4	2	3	2	1	0	3	6	3	20	
	5	0	5	6	4	0	4	7	2	28	
	6	0	6	5	3	2	1	5	9	31	
	TOTAL										335
2004	1	6	19	23	15	7	19	18	14	121	
	2	3	14	14	9	7	12	11	6	76	
	3	2	12	5	8	6	14	16	10	73	
	4	0	0	12	1	0	0	0	0	13	
	5	0	0	2	0	0	0	0	0	2	
	6	0	1	3	0	0	0	0	0	4	
	TOTAL										289

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2005	1	18	13	11	7	22	21	19	14	125	
	2	8	3	14	10	17	9	7	12	80	
	3	5	9	9	8	28	7	10	16	92	
	4	5	2	1	2	38	2	3	3	56	
	5	3	0	4	2	20	2	2	2	35	
	6	3	1	0	0	0	6	3	6	19	
	TOTAL										407
2006	1	8	18	19	11	12	26	20	18	132	
	2	4	11	17	4	1	10	14	8	69	
	3	5	13	6	3	1	7	13	12	60	
	4	0	3	12	3	0	2	3	2	25	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										286
2007	1	6	14	19	17	8	25	30	23	142	
	2	4	9	15	12	9	20	28	15	112	
	3	0	3	3	4	0	13	6	6	35	
	4	0	1	1	2	0	8	7	6	25	
	5	0	0	0	0	0	3	3	0	6	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										320
2008	1	9	19	18	14	6	40	37	22	165	
	2	4	6	5	11	5	21	18	6	76	
	3	4	6	8	7	3	21	4	1	54	
	4	7	4	3	4	2	19	6	6	51	
	5	3	10	4	8	0	26	2	6	59	
	6	3	0	0	2	0	5	1	0	11	
	TOTAL										416

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2009	1	7	27	21	23	9	34	26	19	166	
	2	3	7	12	5	3	4	11	10	55	
	3	0	0	1	0	0	0	0	0	1	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										222
2010	1	17	26	18	23	8	18	17	22	149	
	2	10	12	13	12	6	11	13	16	93	
	3	3	4	7	6	4	5	6	8	43	
	4	3	1	3	3	2	0	5	3	20	
	5	6	3	10	6	3	1	1	10	40	
	6	0	3	2	5	1	2	5	13	31	
	TOTAL										376
2011	1	7	22	22	28	13	28	31	28	179	
	2	12	18	13	17	10	14	30	21	135	
	3	4	15	9	13	3	27	17	12	100	
	4	0	8	2	3	1	20	8	6	48	
	5	0	0	0	0	0	2	2	1	5	
	6	0	0	0	0	0	2	2	1	5	
	TOTAL										472
2012	1	6	16	27	13	7	17	18	11	115	
	2	4	7	11	18	7	6	6	5	64	
	3	4	4	2	10	2	0	0	4	26	
	4	0	0	0	1	0	0	0	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										206

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2013	1	7	14	15	13	11	18	18	10	106	
	2	3	7	11	12	5	15	11	12	76	
	3	1	5	2	6	1	1	0	2	18	
	4	0	2	2	1	0	3	3	2	13	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	2	0	0	0	0	0	2	
	TOTAL										215
2015	1	9	29	18	15	10	18	29	24	152	
	2	2	11	13	11	12	3	11	9	72	
	3	5	9	12	9	5	13	12	9	74	
	4	0	4	4	4	0	2	4	3	21	
	5	0	7	3	0	0	0	0	0	10	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										329
2016	1	11	16	16	16	9	8	26	26	128	
	2	7	11	13	15	4	10	9	14	83	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										211

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3001	1	3	4	14	17	9	8	15	20	90	
	2	5	10	3	8	2	12	21	14	75	
	3	0	0	0	0	0	0	9	2	11	
	4	0	0	0	0	0	0	3	0	3	
	5	0	0	0	0	0	0	1	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										180
3002	1	14	15	18	22	13	23	21	22	148	
	2	3	14	12	15	3	23	19	22	111	
	3	4	17	5	11	4	16	10	11	78	
	4	3	7	7	12	7	17	11	5	69	
	5	0	0	0	0	0	0	0	0	0	
	6	0	2	1	1	0	3	0	0	7	
	TOTAL										413
3003	1	4	19	12	19	6	18	21	21	120	
	2	3	4	7	16	8	11	13	17	79	
	3	0	10	6	5	2	5	3	14	45	
	4	2	2	4	7	5	7	7	12	46	
	5	0	0	3	5	0	0	0	1	9	
	6	0	4	5	11	2	1	1	2	26	
	TOTAL										325
3004	1	4	11	14	15	5	12	18	8	87	
	2	5	9	13	18	3	11	12	11	82	
	3	2	0	4	10	1	14	9	1	41	
	4	0	0	0	0	0	2	0	0	2	
	5	0	4	0	3	0	7	2	1	17	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										229

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES

WEEK 4

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3005	1	13	13	18	21	6	15	18	23	127	
	2	3	3	7	6	5	5	6	11	46	
	3	18	5	5	6	2	7	9	9	61	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										234
3006	1	16	28	26	21	10	25	17	26	169	
	2	4	21	11	13	3	24	18	21	115	
	3	1	9	4	6	1	18	7	11	57	
	4	0	15	1	0	1	8	1	0	26	
	5	0	8	2	2	0	10	3	1	26	
	6	0	2	0	0	0	0	0	0	2	
	TOTAL										395
3007	1	5	22	20	44	8	17	8	15	139	
	2	3	7	8	12	10	7	4	3	54	
	3	0	0	1	4	0	0	0	0	5	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										198
3008	1	21	15	21	21	14	12	17	21	142	
	2	17	13	22	14	14	13	9	7	109	
	3	20	5	8	10	10	1	8	4	66	
	4	3	4	5	3	0	3	1	14	33	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										350

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3009	1	5	21	14	20	4	17	23	25	129	
	2	3	12	14	8	5	6	16	20	84	
	3	2	18	2	7	2	4	16	7	58	
	4	3	10	2	2	0	12	4	2	35	
	5	0	0	0	0	0	0	0	0	0	
	6	2	2	2	5	0	5	3	3	22	
	TOTAL										328
3011	1	9	17	16	17	44	21	13	15	152	
	2	0	3	2	2	52	2	2	1	64	
	3	2	3	5	2	20	1	1	1	35	
	4	0	0	0	0	14	0	0	0	14	
	5	2	5	3	3	7	1	1	1	23	
	6	1	0	1	4	15	0	0	0	21	
	TOTAL										309
3012	1	5	18	21	23	3	19	18	18	125	
	2	4	15	17	14	5	19	13	10	97	
	3	5	11	10	7	3	5	11	12	64	
	4	1	9	14	6	1	3	4	4	42	
	5	1	10	13	9	1	14	7	11	66	
	6	0	7	5	4	0	7	5	6	34	
	TOTAL										428
3013	1	8	18	15	14	6	25	51	23	160	
	2	6	6	8	7	1	26	30	23	107	
	3	8	10	4	5	2	25	23	9	86	
	4	2	1	2	1	0	31	31	14	82	
	5	4	1	2	4	1	24	20	13	69	
	6	4	7	7	12	2	31	20	21	104	
	TOTAL										608

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3014	1	10	16	19	12	8	15	20	18	118	
	2	4	12	12	9	1	23	22	11	94	
	3	2	12	5	5	2	10	16	6	58	
	4	2	7	3	6	2	13	6	5	44	
	5	0	8	9	5	0	3	8	15	48	
	6	5	4	8	6	3	6	2	19	53	
	TOTAL										415
3015	1	5	22	25	28	5	15	17	15	132	
	2	4	12	19	26	4	14	9	10	98	
	3	1	6	8	15	5	6	8	5	54	
	4	0	0	3	2	0	0	0	0	5	
	5	0	0	3	3	0	0	0	0	6	
	6	1	2	6	9	1	2	2	3	26	
	TOTAL										321
3016	1	5	17	23	15	10	12	18	21	121	
	2	1	10	9	3	2	9	11	5	50	
	3	1	6	10	5	0	4	2	0	28	
	4	0	0	1	0	0	0	0	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										200

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4001	1	3	26	19	16	9	18	10	17	118	
	2	3	26	5	5	5	3	4	11	62	
	3	0	9	8	13	0	0	0	0	30	
	4	1	8	10	1	0	3	2	1	26	
	5	0	0	0	0	0	0	0	0	0	
	6	0	4	4	0	0	0	0	0	8	
	TOTAL										244
4002	1	6	16	12	11	21	13	8	11	98	
	2	4	6	6	4	45	1	8	6	80	
	3	0	7	1	1	18	0	0	0	27	
	4	0	0	0	0	14	0	0	0	14	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										219
4003	1	13	14	23	14	14	13	15	9	115	
	2	4	7	13	10	14	9	15	9	81	
	3	2	12	9	3	3	6	9	4	48	
	4	0	1	0	0	0	0	0	0	1	
	5	1	4	3	2	0	2	7	0	19	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										264
4004	1	13	28	14	26	16	17	19	17	150	
	2	11	12	14	31	8	10	20	14	120	
	3	6	4	6	18	7	9	6	10	66	
	4	3	9	5	32	4	10	5	15	83	
	5	1	2	1	16	1	3	2	1	27	
	6	0	1	1	7	0	0	0	0	9	
	TOTAL										455

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4005	1	8	16	18	10	5	14	10	14	95	
	2	8	11	12	18	8	12	9	13	91	
	3	7	8	8	5	1	6	7	13	55	
	4	2	1	1	3	2	1	1	8	19	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										260
4006	1	3	28	23	25	6	42	25	25	177	
	2	1	10	6	19	0	33	17	39	125	
	3	0	5	2	5	3	31	9	8	63	
	4	0	1	1	1	0	13	0	0	16	
	5	2	1	2	5	1	15	8	2	36	
	6	1	6	4	4	0	10	8	5	38	
	TOTAL										455
4007	1	8	16	21	9	10	11	16	15	106	
	2	7	6	9	13	4	21	17	8	85	
	3	0	3	2	8	5	5	3	5	31	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	1	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										223
4008	1	4	13	19	18	5	13	28	18	118	
	2	5	13	14	13	4	18	25	16	108	
	3	0	5	5	7	4	10	17	14	62	
	4	2	4	6	7	0	8	18	7	52	
	5	0	0	0	0	0	0	1	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										341

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4009	1	9	12	16	16	7	18	13	15	106	
	2	4	9	9	9	4	6	10	13	64	
	3	1	3	6	2	3	8	7	6	36	
	4	1	3	3	2	1	1	5	6	22	
	5	0	0	1	0	0	0	0	0	1	
	6	3	7	6	6	2	8	3	5	40	
	TOTAL										269
4010	1	8	16	21	20	8	20	19	13	125	
	2	2	8	9	7	5	7	6	4	48	
	3	2	3	3	4	1	7	2	3	25	
	4	0	1	1	3	2	2	1	1	11	
	5	0	0	0	1	0	0	0	0	1	
	6	0	0	0	2	0	2	0	0	4	
	TOTAL										214
4011	1	12	14	8	28	6	24	14	17	123	
	2	4	11	3	10	1	16	4	14	63	
	3	2	5	1	11	2	15	8	14	58	
	4	0	1	0	6	0	7	2	5	21	
	5	0	5	0	3	0	3	0	0	11	
	6	0	1	0	4	0	2	0	0	7	
	TOTAL										283
4012	1	9	19	17	23	9	25	34	18	154	
	2	1	20	17	13	2	16	16	23	108	
	3	0	21	16	8	0	7	5	5	62	
	4	0	6	0	0	0	0	0	0	6	
	5	0	13	9	3	1	7	6	4	43	
	6	0	3	0	0	0	0	0	0	3	
	TOTAL										376

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

MALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4014	1	9	10	19	13	9	19	13	10	102	
	2	7	15	9	12	10	14	7	13	87	
	3	2	2	6	6	5	3	4	3	31	
	4	1	0	2	3	11	2	5	3	27	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										247
4015	1	3	20	8	12	3	11	6	16	79	
	2	3	20	12	8	3	20	14	11	91	
	3	6	12	12	8	3	15	13	30	99	
	4	0	9	1	0	0	7	17	21	55	
	5	1	3	0	0	0	2	5	12	23	
	6	0	13	0	1	0	7	6	16	43	
	TOTAL										390
4016	1	6	18	19	12	10	13	13	15	106	
	2	3	14	9	8	10	11	4	8	67	
	3	2	12	1	3	2	0	0	2	22	
	4	3	15	1	2	4	1	1	1	28	
	5	0	0	0	0	0	0	0	0	0	
	6	2	3	0	0	2	0	0	0	7	
	TOTAL										230

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1001	1	9	22	12	13	8	18	13	15	110	
	2	11	13	8	4	11	11	9	12	79	
	3	10	6	6	7	3	13	9	7	61	
	4	3	1	1	1	0	18	4	2	30	
	5	5	3	1	3	1	3	3	3	22	
	6	12	6	4	3	7	10	5	3	50	
	TOTAL										352
1002	1	8	18	13	13	7	21	10	26	116	
	2	4	13	12	11	3	8	9	12	72	
	3	2	6	0	2	1	16	9	12	48	
	4	5	6	7	7	1	3	4	4	37	
	5	5	5	2	0	0	0	0	5	17	
	6	3	0	0	0	0	0	0	0	3	
	TOTAL										293
1005	1	4	9	8	14	2	8	6	13	64	
	2	2	8	10	16	3	6	8	8	61	
	3	4	7	2	10	0	9	4	9	45	
	4	3	9	15	11	4	7	12	9	70	
	5	4	5	3	5	9	4	3	5	38	
	6	0	0	7	9	0	5	2	5	28	
	TOTAL										306
1006	1	6	15	16	14	5	16	19	15	106	
	2	0	13	14	10	1	18	13	9	78	
	3	2	9	5	7	4	12	6	4	49	
	4	2	3	8	4	2	0	0	0	19	
	5	0	2	3	2	0	2	1	1	11	
	6	1	5	4	7	1	6	3	1	28	
	TOTAL										291

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1007	1	3	8	25	10	3	17	10	4	80	
	2	0	5	9	9	2	16	6	4	51	
	3	0	3	3	2	0	6	6	6	26	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	1	13	3	2	3	1	1	2	26	
	TOTAL										183
1008	1	9	10	6	11	21	22	30	22	131	
	2	3	3	3	4	23	13	23	25	97	
	3	0	2	1	3	22	11	9	19	67	
	4	1	0	0	0	5	6	8	9	29	
	5	0	0	0	0	0	0	1	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										325
1009	1	4	14	15	14	6	16	13	19	101	
	2	3	6	17	6	2	15	4	12	65	
	3	2	4	16	9	0	8	6	10	55	
	4	0	9	6	2	0	0	0	0	17	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	2	0	0	0	0	0	2	
	TOTAL										240
1010	1	7	12	11	10	8	8	8	12	76	
	2	4	12	6	16	2	12	11	10	73	
	3	1	7	2	3	0	7	2	1	23	
	4	0	0	1	4	0	6	0	2	13	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										185

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1011	1	8	15	9	11	12	16	16	12	99	
	2	10	7	9	4	0	1	17	19	67	
	3	1	3	3	3	0	7	4	0	21	
	4	0	0	0	0	0	0	1	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										188
1012	1	6	24	14	24	5	24	15	21	133	
	2	4	12	5	8	4	13	9	7	62	
	3	3	9	12	12	0	11	6	7	60	
	4	1	7	7	30	1	11	6	2	65	
	5	0	2	1	8	0	2	0	0	13	
	6	0	2	5	13	1	1	0	1	23	
	TOTAL										356
1013	1	6	6	7	5	8	19	22	9	82	
	2	0	0	2	2	5	7	0	0	16	
	3	0	4	2	2	2	13	0	0	23	
	4	0	0	0	0	0	12	0	0	12	
	5	0	0	0	4	1	9	3	2	19	
	6	0	0	0	0	0	1	0	0	1	
	TOTAL										153
1014	1	8	19	18	27	9	24	34	17	156	
	2	6	11	18	14	10	21	15	13	108	
	3	6	6	7	7	4	17	19	12	78	
	4	8	2	3	5	3	11	6	4	42	
	5	0	0	0	0	0	0	0	0	0	
	6	5	7	12	8	4	5	3	1	45	
	TOTAL										429

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1015	1	3	25	29	23	2	18	15	13	128	
	2	6	7	11	18	4	3	5	19	73	
	3	0	13	8	4	1	5	4	5	40	
	4	0	6	7	2	0	1	1	1	18	
	5	0	0	1	0	0	0	0	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										260
1016	1	6	26	13	18	9	14	12	18	116	
	2	0	21	16	19	1	33	13	12	115	
	3	0	0	21	11	2	2	3	1	40	
	4	0	3	5	5	0	11	3	5	32	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										303
1017	1	7	21	18	21	14	24	10	12	127	
	2	3	11	15	16	9	14	16	15	99	
	3	6	9	14	11	4	11	10	7	72	
	4	0	0	5	7	0	3	0	0	15	
	5	0	0	0	0	0	0	0	0	0	
	6	1	4	7	5	3	3	3	3	29	
	TOTAL										342

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2001	1	4	7	12	35	7	10	6	7	88	
	2	0	3	10	15	1	5	10	13	57	
	3	2	3	0	6	2	1	0	0	14	
	4	0	0	4	0	0	0	0	0	4	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										163
2002	1	13	32	20	21	11	14	9	12	132	
	2	5	16	9	2	2	22	14	24	94	
	3	4	8	3	3	2	17	16	30	83	
	4	3	1	2	4	1	4	6	19	40	
	5	0	2	5	0	0	0	1	4	12	
	6	0	1	0	0	0	2	0	11	14	
	TOTAL										375
2003	1	4	12	16	15	3	16	16	13	95	
	2	5	11	7	11	2	9	11	11	67	
	3	4	20	13	16	0	20	9	14	96	
	4	0	7	9	7	0	3	3	6	35	
	5	0	4	7	20	1	9	5	14	60	
	6	4	1	1	4	2	5	6	9	32	
	TOTAL										385
2004	1	4	34	27	27	8	15	17	13	145	
	2	1	16	10	11	5	23	13	12	91	
	3	0	7	4	4	12	10	12	11	60	
	4	2	3	3	8	6	21	24	11	78	
	5	0	0	0	0	0	2	3	1	6	
	6	0	0	0	0	0	8	0	0	8	
	TOTAL										388

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2005	1	11	16	16	22	14	22	19	25	145	
	2	8	9	16	13	15	16	10	11	98	
	3	2	2	1	2	17	5	8	6	43	
	4	1	3	1	5	23	8	6	5	52	
	5	0	2	3	2	4	2	8	5	26	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										364
2006	1	8	20	18	15	7	22	25	24	139	
	2	2	8	16	14	3	15	9	19	86	
	3	1	10	4	1	5	4	12	22	59	
	4	0	0	3	0	0	0	0	0	3	
	5	0	2	5	4	0	7	1	0	19	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										307
2007	1	4	31	20	29	2	25	17	28	156	
	2	3	38	18	22	2	14	12	15	124	
	3	0	7	5	18	1	0	0	2	33	
	4	2	20	8	18	0	13	8	11	80	
	5	0	6	5	14	0	29	5	10	69	
	6	0	5	0	7	0	3	0	0	15	
	TOTAL										477
2008	1	5	19	9	12	8	29	15	19	116	
	2	5	14	11	11	6	19	13	17	96	
	3	2	2	0	0	1	30	16	24	75	
	4	0	2	1	3	0	28	9	4	47	
	5	2	2	0	0	0	21	8	5	38	
	6	0	3	0	0	0	12	7	5	27	
	TOTAL										399

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2009	1	4	24	25	26	5	17	17	16	134	
	2	0	16	27	11	0	4	3	0	61	
	3	0	0	1	4	0	0	0	0	5	
	4	0	0	2	3	0	0	0	0	5	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	5	0	0	0	0	5	
	TOTAL										210
2010	1	8	13	16	18	12	15	17	15	114	
	2	4	6	11	5	12	12	8	12	70	
	3	0	5	5	11	2	8	12	9	52	
	4	0	8	5	5	2	15	8	4	47	
	5	2	9	10	8	2	2	5	4	42	
	6	0	0	0	0	0	2	0	0	2	
	TOTAL										327
2011	1	9	21	20	20	6	18	14	17	125	
	2	3	17	22	16	2	19	6	5	90	
	3	3	15	14	19	4	17	15	14	101	
	4	1	4	5	6	0	1	3	2	22	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										338
2012	1	9	15	17	31	5	11	19	14	121	
	2	5	6	6	11	2	11	18	12	71	
	3	1	0	2	7	0	2	2	2	16	
	4	0	2	1	14	0	9	2	3	31	
	5	2	0	4	15	0	9	7	10	47	
	6	0	0	0	5	0	2	2	3	12	
	TOTAL										298

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2013	1	5	15	18	15	8	12	14	11	98	
	2	5	5	12	11	5	15	8	6	67	
	3	1	1	12	12	0	20	9	3	58	
	4	0	5	2	12	1	24	11	5	60	
	5	0	0	0	2	0	5	0	0	7	
	6	0	1	2	4	0	8	1	0	16	
	TOTAL										306
2015	1	7	15	16	12	12	10	14	15	101	
	2	2	12	14	13	2	13	10	11	77	
	3	4	6	5	12	2	6	5	8	48	
	4	1	11	7	21	1	9	6	7	63	
	5	2	14	13	31	1	5	2	3	71	
	6	0	10	7	5	0	3	1	2	28	
	TOTAL										388
2016	1	11	11	11	12	6	7	11	23	92	
	2	5	4	4	3	2	5	18	19	60	
	3	0	0	0	2	1	0	2	3	8	
	4	2	0	0	1	0	2	6	7	18	
	5	0	0	0	0	0	0	13	3	16	
	6	0	0	0	0	0	0	4	0	4	
	TOTAL										198

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

MALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3001	1	7	10	13	10	11	14	14	10	89	
	2	6	8	14	13	19	15	10	16	101	
	3	2	7	8	14	10	28	18	23	110	
	4	0	2	4	3	1	5	10	9	34	
	5	0	1	2	1	0	4	6	1	15	
	6	0	5	7	2	0	6	0	0	20	
	TOTAL										369
3002	1	7	11	15	18	11	16	23	17	118	
	2	5	14	7	18	5	16	17	6	88	
	3	2	6	9	22	4	11	4	6	64	
	4	1	6	7	7	1	4	2	7	35	
	5	0	0	0	0	0	0	0	0	0	
	6	1	0	5	5	1	4	3	3	22	
	TOTAL										327
3003	1	5	20	17	19	4	16	18	18	117	
	2	0	6	9	17	1	1	2	3	39	
	3	2	6	6	13	2	5	3	7	44	
	4	0	3	2	11	0	3	2	5	26	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										226
3004	1	7	18	12	8	7	33	13	21	119	
	2	4	15	4	11	2	30	10	6	82	
	3	0	4	0	2	0	38	5	7	56	
	4	0	5	2	4	0	30	3	6	50	
	5	0	1	0	1	0	19	0	0	21	
	6	0	0	0	0	0	5	0	0	5	
	TOTAL										333

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

MALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3005	1	10	20	21	11	8	19	15	18	122	
	2	10	9	7	12	6	21	15	11	91	
	3	7	7	6	10	5	6	10	22	73	
	4	1	4	1	6	1	3	4	3	23	
	5	0	2	2	2	0	2	1	3	12	
	6	0	0	0	0	0	0	1	0	1	
	TOTAL										322
3006	1	5	13	14	15	5	32	15	17	116	
	2	0	2	1	2	2	28	2	1	38	
	3	0	0	0	0	0	11	8	4	23	
	4	0	0	0	0	0	4	12	8	24	
	5	0	3	3	3	0	17	11	2	39	
	6	0	0	0	3	0	4	5	3	15	
	TOTAL										255
3007	1	3	5	15	26	7	14	4	7	81	
	2	2	6	10	22	6	9	5	7	67	
	3	0	6	13	28	1	1	2	2	53	
	4	0	5	25	10	0	1	1	2	44	
	5	0	0	6	1	0	0	0	0	7	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										252
3008	1	11	18	19	34	4	15	18	34	153	
	2	18	9	7	7	10	16	16	13	96	
	3	26	5	6	3	1	15	9	11	76	
	4	1	1	0	0	0	25	2	2	31	
	5	2	0	0	0	3	30	5	3	43	
	6	0	0	0	0	0	5	0	0	5	
	TOTAL										404

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3009	1	6	14	18	18	5	17	12	13	103	
	2	3	14	9	6	4	15	10	8	69	
	3	1	8	13	7	1	3	5	6	44	
	4	1	7	8	5	0	3	4	5	33	
	5	0	1	5	4	1	4	2	1	18	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										267
3011	1	0	0	0	4	4	0	0	0	8	
	2	0	0	0	0	0	0	0	0	0	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	4	0	0	0	4	
	5	0	0	0	0	0	0	0	0	0	
	6	3	3	3	3	1	5	9	8	35	
	TOTAL										47
3012	1	7	17	18	21	6	27	21	20	137	
	2	2	7	6	3	2	16	24	13	73	
	3	0	5	3	6	0	25	13	17	69	
	4	0	2	3	3	0	25	14	9	56	
	5	1	10	8	5	1	14	10	9	58	
	6	1	5	2	2	0	3	7	7	27	
	TOTAL										420
3013	1	2	10	7	15	9	34	19	14	110	
	2	1	2	2	4	0	58	18	16	101	
	3	2	6	3	4	3	26	17	1	62	
	4	0	0	0	1	0	27	14	5	47	
	5	0	0	0	0	0	24	9	5	38	
	6	0	0	0	0	0	12	12	2	26	
	TOTAL										384

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3014	1	4	15	18	32	2	21	18	27	137	
	2	1	17	15	10	1	18	20	18	100	
	3	1	16	19	29	1	17	14	12	109	
	4	0	9	7	7	0	4	4	5	36	
	5	0	0	0	0	0	0	0	0	0	
	6	2	14	15	12	8	14	8	14	87	
	TOTAL										469
3015	1	5	14	10	27	5	17	11	17	106	
	2	3	9	4	10	2	17	12	11	68	
	3	0	2	3	10	0	7	7	4	33	
	4	0	0	0	0	0	4	2	0	6	
	5	0	0	0	0	0	4	0	0	4	
	6	0	0	0	0	0	5	0	0	5	
	TOTAL										222
3016	1	3	29	16	14	7	17	10	5	101	
	2	0	32	17	2	0	1	0	0	52	
	3	0	19	20	4	0	3	2	2	50	
	4	0	10	8	0	0	1	2	1	22	
	5	0	10	3	0	0	0	0	0	13	
	6	0	3	0	0	0	0	0	0	3	
	TOTAL										241

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4001	1	3	23	20	17	8	12	9	6	98	
	2	1	16	5	3	1	9	3	8	46	
	3	0	11	2	0	0	1	0	0	14	
	4	0	9	1	0	0	0	1	1	12	
	5	0	1	4	0	0	0	0	0	5	
	6	0	2	0	0	0	0	0	0	2	
	TOTAL										177
4002	1	20	12	9	8	21	11	19	14	114	
	2	3	6	6	6	45	2	4	12	84	
	3	2	6	6	8	16	9	7	8	62	
	4	0	0	0	0	40	0	0	0	40	
	5	0	0	0	0	1	0	0	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										301
4003	1	7	19	23	19	8	20	13	16	127	
	2	3	15	8	9	1	7	12	7	62	
	3	0	2	3	10	0	10	42	7	74	
	4	0	0	0	0	0	4	12	1	17	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										280
4004	1	11	17	19	30	11	19	22	21	150	
	2	5	18	13	13	9	16	16	19	109	
	3	7	6	12	18	6	8	7	17	81	
	4	0	7	6	23	0	12	5	11	64	
	5	1	2	2	9	1	7	4	5	31	
	6	0	0	0	6	0	0	0	0	6	
	TOTAL										441

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4005	1	7	18	15	15	11	29	22	28	145	
	2	8	15	3	8	1	18	10	22	85	
	3	0	3	4	5	1	16	13	21	63	
	4	0	2	0	1	2	7	13	4	29	
	5	0	0	0	0	0	0	0	2	2	
	6	1	2	1	1	0	16	11	6	38	
	TOTAL										362
4006	1	8	31	25	36	2	27	13	35	177	
	2	1	13	6	14	2	5	0	2	43	
	3	1	17	8	26	0	4	0	1	57	
	4	0	2	10	28	0	0	0	0	40	
	5	0	0	9	13	0	0	0	0	22	
	6	0	0	0	4	0	0	0	0	4	
	TOTAL										343
4007	1	8	13	17	19	12	16	20	10	115	
	2	5	3	15	12	4	13	14	8	74	
	3	0	1	1	6	1	10	6	3	28	
	4	0	1	2	5	3	5	4	5	25	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										242
4008	1	4	16	31	26	6	16	17	13	129	
	2	6	6	18	16	2	8	10	21	87	
	3	1	7	23	11	1	8	3	4	58	
	4	0	0	0	7	0	1	2	4	14	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										288

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4009	1	12	15	17	16	8	10	15	11	104	
	2	16	7	13	10	4	7	13	13	83	
	3	1	7	7	5	0	4	3	5	32	
	4	0	1	2	4	0	13	6	6	32	
	5	1	0	2	3	0	5	1	1	13	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										264
4010	1	3	13	7	10	3	47	12	17	112	
	2	1	13	10	24	2	31	3	5	89	
	3	0	0	0	2	0	30	4	4	40	
	4	0	1	0	1	0	26	5	2	35	
	5	0	0	0	0	0	9	0	0	9	
	6	0	0	0	0	0	11	1	0	12	
	TOTAL										297
4011	1	7	20	9	11	3	25	12	21	108	
	2	2	12	9	12	3	6	4	7	55	
	3	1	5	6	14	1	0	0	0	27	
	4	1	9	5	8	1	9	2	2	37	
	5	2	13	7	35	2	1	1	4	65	
	6	2	2	0	12	1	2	1	6	26	
	TOTAL										318
4012	1	6	39	34	49	5	32	10	12	187	
	2	1	20	16	25	0	17	4	9	92	
	3	0	6	11	30	0	11	0	0	58	
	4	0	7	6	36	0	16	3	2	70	
	5	0	2	11	13	0	6	5	6	43	
	6	0	6	8	14	0	1	1	2	32	
	TOTAL										482

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4014	1	9	12	17	19	12	15	9	18	111	
	2	2	12	14	13	11	8	12	12	84	
	3	4	3	10	8	8	7	1	6	47	
	4	2	7	7	4	1	7	8	3	39	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										281
4015	1	6	23	20	18	6	28	23	29	153	
	2	0	9	5	4	0	51	18	7	94	
	3	0	0	0	0	0	11	5	0	16	
	4	0	0	0	0	0	5	2	0	7	
	5	0	0	0	0	0	4	1	0	5	
	6	0	0	0	0	0	17	9	0	26	
	TOTAL										301
4016	1	6	16	14	19	12	11	11	13	102	
	2	1	26	6	3	3	1	3	5	48	
	3	1	15	3	3	8	2	1	1	34	
	4	0	0	0	0	3	0	0	0	3	
	5	0	0	0	0	4	0	0	0	4	
	6	0	0	0	0	5	0	0	0	5	
	TOTAL										196

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 1 AIR CONTROL

PROJECT NO.:90B31

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1001	1	6	18	9	17	5	20	9	17	101	
	2	11	13	9	11	15	6	6	13	84	
	3	1	4	3	1	2	6	4	8	29	
	4	0	0	0	0	0	4	3	3	10	
	5	0	0	0	0	0	2	0	0	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										226
1002	1	12	12	11	14	7	11	14	18	99	
	2	7	10	10	15	2	16	5	16	81	
	3	6	1	0	1	6	6	4	0	24	
	4	6	2	2	3	3	4	0	1	21	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										225
1005	1	6	16	9	11	4	8	7	11	72	
	2	5	14	6	10	5	7	6	6	59	
	3	6	12	4	8	3	7	9	5	54	
	4	2	11	7	6	3	2	2	5	38	
	5	0	4	1	3	0	2	3	3	16	
	6	0	3	0	0	0	1	0	0	4	
	TOTAL										243
1006	1	3	5	8	11	2	5	7	8	49	
	2	1	6	6	11	1	3	6	7	41	
	3	1	1	2	10	1	1	2	1	19	
	4	0	0	0	1	0	0	0	0	1	
	5	0	3	3	6	0	0	0	0	12	
	6	0	9	0	6	1	4	5	4	29	
	TOTAL										151

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1007	1	4	9	21	13	1	7	6	5	66	
	2	5	1	10	6	0	7	1	1	31	
	3	0	3	3	3	0	1	1	2	13	
	4	0	4	6	7	0	0	0	0	17	
	5	0	0	5	0	0	0	0	0	5	
	6	0	1	1	2	2	0	0	0	6	
	TOTAL										138
1008	1	8	11	14	16	14	19	12	6	100	
	2	1	5	3	3	12	16	11	5	56	
	3	0	0	0	0	4	11	14	2	31	
	4	0	0	0	1	2	14	2	1	20	
	5	1	3	6	4	3	8	3	4	32	
	6	0	0	0	0	2	9	2	2	15	
	TOTAL										254
1009	1	3	22	12	14	7	7	7	12	84	
	2	3	20	9	10	0	4	2	7	55	
	3	0	16	3	1	3	6	7	10	46	
	4	0	12	2	5	0	4	0	2	25	
	5	2	14	4	3	4	8	13	16	64	
	6	0	3	4	6	0	14	12	16	55	
	TOTAL										329
1010	1	7	10	15	14	6	6	8	14	80	
	2	0	0	4	1	0	0	0	0	5	
	3	0	0	7	1	0	0	0	0	8	
	4	0	0	1	0	0	0	0	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										95

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1011	1	17	11	15	6	8	11	8	13	89	
	2	5	16	10	12	5	3	5	11	67	
	3	6	12	3	1	4	9	8	5	48	
	4	2	5	4	6	1	1	0	3	22	
	5	1	5	2	1	0	1	1	2	13	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										239
1012	1	7	15	14	18	6	18	11	23	112	
	2	1	20	8	12	2	7	6	5	61	
	3	1	8	9	12	1	3	1	1	36	
	4	0	10	4	3	0	3	0	0	20	
	5	0	7	4	5	1	1	2	4	24	
	6	3	3	3	6	1	0	0	1	17	
	TOTAL										270
1013	1	5	15	6	6	7	12	12	12	75	
	2	1	6	5	8	5	8	2	11	46	
	3	2	2	0	0	0	1	7	2	14	
	4	1	2	2	2	4	2	7	8	28	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	2	0	2	
	TOTAL										165
1014	1	14	17	14	23	9	34	27	25	163	
	2	11	18	19	17	14	19	26	33	157	
	3	3	8	10	9	8	22	15	17	92	
	4	0	0	0	0	0	2	0	0	2	
	5	1	4	5	8	1	18	9	2	48	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										462

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1015	1	5	20	28	26	4	21	11	20	135	
	2	0	22	15	8	1	3	3	6	58	
	3	0	7	8	1	0	0	0	0	16	
	4	0	2	8	2	0	0	0	0	12	
	5	0	9	1	1	0	3	1	2	17	
	6	0	1	0	0	0	0	0	0	1	
	TOTAL										239
1016	1	5	22	8	10	4	9	14	20	92	
	2	2	23	5	4	0	14	10	18	76	
	3	0	10	7	3	0	2	1	1	24	
	4	0	11	0	0	0	3	1	1	16	
	5	0	2	0	0	0	0	0	0	2	
	6	0	1	0	0	0	0	0	0	1	
	TOTAL										211
1017	1	9	13	14	21	12	14	19	21	123	
	2	4	8	7	8	9	7	14	21	78	
	3	0	2	3	5	1	3	5	11	30	
	4	0	0	0	0	0	0	1	0	1	
	5	1	1	2	2	3	4	6	2	21	
	6	0	0	0	0	0	0	0	1	1	
	TOTAL										254

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

MALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2001	1	6	13	16	25	6	9	11	14	100	
	2	3	9	25	11	2	5	8	5	68	
	3	0	1	42	6	0	1	0	0	50	
	4	0	0	8	0	0	0	0	0	8	
	5	0	0	3	0	0	0	0	0	3	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										229
2002	1	10	16	16	17	4	18	9	24	114	
	2	4	14	12	22	4	15	3	11	85	
	3	6	13	8	14	2	8	5	13	69	
	4	0	3	2	0	0	0	0	11	16	
	5	1	11	11	6	1	5	3	5	43	
	6	0	0	0	1	0	4	0	7	12	
	TOTAL										339
2003	1	8	21	15	9	3	20	8	12	96	
	2	0	11	8	14	1	15	16	17	82	
	3	3	5	10	5	0	3	3	2	31	
	4	2	1	2	7	2	2	2	3	21	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										230
2004	1	6	17	21	22	10	15	12	19	122	
	2	3	21	22	16	2	19	13	17	113	
	3	3	22	16	9	2	9	7	10	78	
	4	2	9	18	2	1	6	5	0	43	
	5	0	0	1	0	0	0	0	0	1	
	6	0	0	0	2	0	0	0	0	2	
	TOTAL										359

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2005	1	8	23	10	14	19	15	16	17	122	
	2	5	9	13	7	20	9	6	5	74	
	3	0	4	0	4	3	3	2	5	21	
	4	0	0	2	2	1	7	1	0	13	
	5	0	7	1	0	0	1	5	3	17	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										247
2006	1	5	22	29	14	8	17	22	17	134	
	2	1	7	19	7	0	15	13	11	73	
	3	0	0	14	1	0	5	0	0	20	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										227
2007	1	8	17	17	26	13	22	21	16	140	
	2	8	8	5	18	1	10	6	11	67	
	3	0	0	0	6	0	4	0	0	10	
	4	0	0	0	2	0	0	0	0	2	
	5	0	0	0	1	0	1	0	0	2	
	6	0	0	0	7	0	5	2	6	20	
	TOTAL										241
2008	1	10	18	13	20	6	12	13	15	107	
	2	4	9	1	2	3	4	2	9	34	
	3	0	7	3	6	0	7	0	0	23	
	4	0	4	3	4	0	30	4	3	48	
	5	0	5	0	3	2	11	4	2	27	
	6	0	2	1	1	0	13	2	2	21	
	TOTAL										260

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2009	1	4	27	14	5	1	2	2	3	58	
	2	0	0	2	0	0	0	0	0	2	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	1	0	0	0	0	0	1	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										61
2010	1	8	24	22	17	18	11	8	22	130	
	2	4	8	12	7	9	6	6	19	71	
	3	5	9	9	6	2	4	6	11	52	
	4	2	2	3	2	2	1	2	9	23	
	5	6	7	6	5	3	10	10	15	62	
	6	1	1	3	1	0	6	4	13	29	
	TOTAL										367
2011	1	5	33	24	27	6	15	18	24	152	
	2	7	24	10	16	7	1	7	9	81	
	3	2	16	9	9	2	8	9	5	60	
	4	0	0	3	0	0	0	0	0	3	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										296
2012	1	7	10	9	15	2	10	9	7	69	
	2	0	6	2	16	1	5	3	3	36	
	3	1	2	3	11	7	4	0	0	28	
	4	0	1	0	17	0	3	2	2	25	
	5	0	0	0	4	0	0	0	0	4	
	6	0	0	0	12	0	0	0	0	12	
	TOTAL										174

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

MALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2013	1	5	28	21	40	5	23	12	15	149	
	2	0	12	11	46	0	11	1	5	86	
	3	0	2	8	25	0	1	0	0	36	
	4	0	13	16	29	0	1	0	0	59	
	5	0	0	6	5	0	0	0	0	11	
	6	0	2	7	19	0	0	0	0	28	
	TOTAL										369
2015	1	9	14	11	14	4	10	7	9	78	
	2	3	5	10	8	0	5	6	6	43	
	3	1	12	9	11	3	4	4	3	47	
	4	0	18	2	0	0	1	1	1	23	
	5	4	15	5	5	5	9	3	3	49	
	6	0	4	0	0	0	0	0	1	5	
	TOTAL										245
2016	1	10	12	6	6	6	14	17	18	89	
	2	7	8	5	10	1	6	7	9	53	
	3	0	0	0	0	0	0	6	0	6	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	3	3	2	2	2	0	13	7	32	
	TOTAL										180

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3001	1	7	8	9	12	8	10	19	16	89	
	2	2	2	5	6	4	11	10	6	46	
	3	0	0	0	0	7	0	3	5	15	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										150
3002	1	9	17	17	25	9	15	16	18	126	
	2	5	16	12	13	6	8	7	5	72	
	3	3	12	7	5	0	5	2	5	39	
	4	4	13	10	14	3	5	3	6	58	
	5	0	3	6	4	1	1	1	1	17	
	6	2	5	5	2	0	0	1	3	18	
	TOTAL										330
3003	1	3	19	15	21	5	20	8	9	100	
	2	2	9	9	15	3	8	3	4	53	
	3	0	4	3	4	1	7	4	5	28	
	4	0	0	4	10	0	2	1	5	22	
	5	0	0	0	11	0	1	0	0	12	
	6	0	0	1	9	0	3	0	2	15	
	TOTAL										230
3004	1	10	21	6	16	7	26	11	15	112	
	2	0	1	1	2	0	7	4	4	19	
	3	0	0	0	0	0	0	1	0	1	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	1	0	0	1	
	6	0	0	0	0	0	0	1	0	1	
	TOTAL										134

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3005	1	16	13	15	9	9	15	12	13	102	
	2	20	7	5	6	4	7	12	17	78	
	3	2	2	0	1	0	4	4	2	15	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	2	1	3	2	5	4	0	17	
	TOTAL										212
3006	1	1	34	17	21	3	14	12	12	114	
	2	0	19	2	2	0	1	0	0	24	
	3	0	12	8	1	0	2	3	3	29	
	4	0	3	0	0	0	0	0	0	3	
	5	0	6	3	2	0	1	0	0	12	
	6	0	4	5	2	2	1	1	3	18	
	TOTAL										200
3007	1	6	22	15	46	4	14	12	20	139	
	2	2	6	2	18	4	12	7	6	57	
	3	0	6	4	19	0	2	3	12	46	
	4	0	3	1	2	0	2	0	2	10	
	5	0	2	5	22	0	3	1	1	34	
	6	0	4	1	5	0	1	0	0	11	
	TOTAL										297
3008	1	9	22	12	22	8	20	18	35	146	
	2	8	7	9	8	10	11	14	9	76	
	3	7	6	5	4	4	7	5	6	44	
	4	3	1	0	1	2	4	4	11	26	
	5	1	10	5	7	0	6	6	17	52	
	6	2	10	2	4	1	4	1	8	32	
	TOTAL										376

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3009	1	3	16	14	12	5	14	18	14	96	
	2	1	10	5	11	2	3	7	6	45	
	3	0	4	4	1	0	5	3	1	18	
	4	0	0	0	0	0	0	0	0	0	
	5	0	5	5	1	3	2	1	0	17	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										176
3011	1	2	10	7	11	18	26	20	19	113	
	2	0	3	1	1	1	36	11	4	57	
	3	0	5	1	2	2	37	12	1	60	
	4	1	0	0	0	0	15	5	0	21	
	5	1	4	6	8	3	23	15	23	83	
	6	0	0	0	0	1	21	2	0	24	
	TOTAL										358
3012	1	1	19	6	13	1	42	38	18	138	
	2	0	3	2	9	0	36	19	13	82	
	3	4	2	1	3	1	41	4	4	60	
	4	0	0	0	1	0	27	5	3	36	
	5	0	0	0	0	0	23	15	0	38	
	6	0	8	4	4	0	14	7	6	43	
	TOTAL										397
3013	1	4	23	26	12	2	9	13	14	103	
	2	2	10	16	29	2	8	5	5	77	
	3	0	0	15	8	0	0	0	0	23	
	4	0	1	14	4	0	0	0	0	19	
	5	0	3	6	4	0	0	0	0	13	
	6	1	4	9	29	3	15	5	6	72	
	TOTAL										307

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3014	1	3	20	17	16	4	23	20	17	120	
	2	2	26	11	8	3	17	12	7	86	
	3	2	18	5	5	2	8	10	8	58	
	4	1	10	7	7	3	6	4	15	53	
	5	2	4	8	4	2	10	7	9	46	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										363
3015	1	5	8	8	9	2	15	7	11	65	
	2	3	13	11	15	3	6	5	7	63	
	3	0	2	0	1	1	2	0	0	6	
	4	0	0	0	0	0	0	0	0	0	
	5	3	1	0	2	2	0	0	1	9	
	6	0	0	0	1	0	1	0	0	2	
	TOTAL										145
3016	1	2	20	54	30	1	11	17	11	146	
	2	0	5	9	6	1	7	34	12	74	
	3	4	11	21	21	5	12	6	16	96	
	4	0	2	6	3	0	1	3	4	19	
	5	0	3	5	14	1	2	2	12	39	
	6	0	0	5	2	0	0	0	0	7	
	TOTAL										381

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4001 DEAD	1										
	2										
	3										
	4										
	5										
	6										
	TOTAL										
4002	1	6	12	12	12	10	18	13	14	97	
	2	7	14	11	7	14	10	14	14	91	
	3	1	2	3	1	39	7	4	5	62	
	4	0	2	1	2	26	4	2	1	38	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										288
4003	1	2	18	12	25	2	17	15	19	110	
	2	2	17	17	12	0	5	7	13	73	
	3	1	9	11	5	0	2	2	3	33	
	4	0	17	3	2	0	4	6	7	39	
	5	1	15	10	5	0	6	7	4	48	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										303
4004	1	13	21	25	26	12	20	18	20	155	
	2	10	13	15	27	4	6	12	20	107	
	3	0	9	16	21	1	8	6	8	69	
	4	0	1	2	2	0	0	0	0	5	
	5	0	0	0	3	0	0	0	0	3	
	6	0	4	7	7	1	5	4	4	32	
	TOTAL										371

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

MALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4005	1	8	22	19	15	8	16	9	18	115	
	2	4	7	10	8	2	12	9	7	59	
	3	2	18	5	4	0	2	6	14	51	
	4	2	13	3	0	0	2	3	2	25	
	5	1	7	4	4	1	0	2	12	31	
	6	0	0	0	0	0	0	0	4	4	
	TOTAL										285
4006	1	4	13	6	14	7	37	11	19	111	
	2	2	7	5	7	1	37	9	7	75	
	3	0	0	0	0	0	21	0	0	21	
	4	0	0	0	0	0	8	1	0	9	
	5	0	0	0	0	0	5	5	0	10	
	6	0	0	0	0	0	13	0	0	13	
	TOTAL										239
4007	1	8	10	23	14	10	14	20	16	115	
	2	5	6	12	9	9	13	5	12	71	
	3	6	2	4	4	2	0	1	6	25	
	4	0	0	0	5	0	1	3	4	13	
	5	0	0	0	0	0	0	0	0	0	
	6	0	3	2	2	1	2	6	4	20	
	TOTAL										244
4008	1	3	29	29	16	5	13	19	16	130	
	2	6	22	9	12	4	15	16	17	101	
	3	7	11	17	8	2	9	3	3	60	
	4	0	6	11	8	1	7	7	5	45	
	5	0	1	2	0	0	0	0	0	3	
	6	0	7	10	2	0	4	4	6	33	
	TOTAL										372

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4009	1	7	8	11	12	3	5	8	9	63	
	2	7	7	4	17	1	5	5	7	53	
	3	5	4	6	16	0	2	1	5	39	
	4	0	1	1	10	1	4	2	4	23	
	5	7	3	4	7	0	2	0	0	23	
	6	0	5	7	16	0	4	3	5	40	
	TOTAL										241
4010	1	3	2	2	9	3	25	14	6	64	
	2	7	8	3	3	3	20	9	13	66	
	3	1	0	0	0	1	22	8	1	33	
	4	0	0	0	0	0	17	5	0	22	
	5	0	1	0	0	0	12	1	2	16	
	6	0	0	0	0	0	4	0	0	4	
	TOTAL										205
4011	1	4	11	5	8	2	22	14	19	85	
	2	2	6	3	8	3	15	3	7	47	
	3	3	10	11	19	5	11	14	10	83	
	4	3	12	4	9	1	19	10	8	66	
	5	2	5	3	4	3	21	5	4	47	
	6	0	0	0	1	2	0	0	1	4	
	TOTAL										332
4012	1	8	41	17	16	3	17	11	19	132	
	2	0	40	14	17	0	7	5	7	90	
	3	0	16	7	8	0	1	3	3	38	
	4	0	7	2	1	0	4	1	1	16	
	5	0	9	0	0	0	0	0	0	9	
	6	0	12	1	0	0	2	0	1	16	
	TOTAL										301

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
MALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4014	1	7	18	13	13	17	22	14	19	123	
	2	1	14	1	7	18	13	7	2	63	
	3	5	4	6	9	6	12	7	7	56	
	4	0	0	0	2	1	2	0	0	5	
	5	0	3	4	2	7	5	9	2	32	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										279
4015	1	3	17	8	22	2	36	15	11	114	
	2	2	16	8	8	0	50	5	6	95	
	3	0	0	0	0	1	20	1	1	23	
	4	0	0	0	0	0	16	0	0	16	
	5	0	0	0	0	0	8	2	0	10	
	6	0	0	0	0	0	1	0	0	1	
	TOTAL										259
4016	1	8	14	26	18	6	8	9	11	100	
	2	1	7	20	8	3	2	2	3	46	
	3	0	3	5	6	1	1	2	4	22	
	4	1	2	6	4	0	1	2	2	18	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	1	0	0	0	0	1	
	TOTAL										187

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1501	1	11	30	19	21	10	14	26	29	160	
	2	7	29	26	21	13	28	31	22	177	
	3	8	18	14	19	12	21	14	16	122	
	4	5	19	21	11	9	12	13	11	101	
	5	8	16	9	21	11	12	13	13	103	
	6	7	22	18	12	5	8	14	14	100	
	TOTAL										763
1502	1	13	29	26	31	9	14	17	25	164	
	2	11	20	9	17	9	18	11	17	112	
	3	10	6	4	8	8	9	5	14	64	
	4	12	8	3	5	25	7	3	7	70	
	5	0	0	0	0	11	0	0	0	11	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										421
1503	1	3	30	23	7	3	14	23	16	119	
	2	7	18	16	8	8	12	17	17	103	
	3	2	11	9	6	6	16	20	20	90	
	4	0	15	17	10	3	6	11	8	70	
	5	2	11	13	10	2	19	21	11	89	
	6	10	20	10	7	9	9	16	17	98	
	TOTAL										569
1504	1	14	19	18	18	11	16	18	20	134	
	2	12	11	7	15	5	14	13	10	87	
	3	8	8	7	9	22	9	5	7	75	
	4	2	3	4	4	8	1	4	2	28	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										324

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1505	1	12	23	24	21	5	19	24	18	146	
	2	8	10	9	11	3	20	16	21	98	
	3	4	7	10	13	3	15	20	15	87	
	4	2	7	6	11	0	10	17	11	64	
	5	0	0	0	0	0	0	3	0	3	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										398
1506	1	7	19	24	25	9	33	26	16	159	
	2	6	15	18	21	9	15	18	13	115	
	3	7	11	16	9	10	16	13	7	89	
	4	4	9	9	8	6	10	8	4	58	
	5	7	6	3	2	6	8	6	7	45	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										467
1507	1	5	13	19	15	11	14	16	8	101	
	2	4	7	7	13	5	13	7	3	59	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	2	5	3	4	3	8	4	4	33	
	TOTAL										193
1508	1	10	18	24	12	14	15	16	13	122	
	2	5	8	13	13	13	18	16	17	103	
	3	3	6	7	9	7	9	5	6	52	
	4	0	2	1	1	1	2	0	0	7	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										284

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1509	1	8	24	27	28	14	20	23	31	175	
	2	8	18	15	25	13	14	13	10	116	
	3	9	18	14	14	9	16	23	11	114	
	4	10	13	19	10	2	14	7	6	81	
	5	0	2	0	0	0	0	0	0	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										488
1510	1	12	17	16	16	14	11	8	12	106	
	2	16	6	10	8	13	5	5	6	69	
	3	8	4	4	5	14	4	0	6	45	
	4	1	2	1	3	33	1	2	1	44	
	5	0	0	0	0	23	0	0	0	23	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										287
1511	1	11	22	20	28	20	24	19	15	159	
	2	7	17	20	17	27	16	18	17	139	
	3	5	17	20	14	4	15	15	12	102	
	4	3	6	7	7	3	8	9	6	49	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										449
1512	1	8	11	13	13	8	16	10	14	93	
	2	9	12	8	4	4	17	14	11	79	
	3	9	5	9	8	6	11	9	3	60	
	4	10	8	2	2	7	8	6	12	55	
	5	2	5	1	7	1	2	1	1	20	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										307

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1513	1	9	19	13	12	11	22	16	18	120	
	2	11	11	11	13	17	17	15	11	106	
	3	5	9	3	7	11	14	6	5	60	
	4	4	13	7	7	7	14	10	22	84	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										370
1514	1	9	13	12	11	14	12	14	15	100	
	2	22	13	13	12	18	11	7	7	103	
	3	6	5	10	10	8	7	7	11	64	
	4	5	4	5	10	15	9	6	9	63	
	5	9	3	6	4	17	5	7	6	57	
	6	1	1	0	3	13	8	3	1	30	
	TOTAL										417
1515	1	8	15	31	25	8	17	21	28	153	
	2	4	8	16	10	8	14	25	12	97	
	3	8	4	11	4	1	3	9	6	46	
	4	17	0	0	0	0	0	0	0	17	
	5	4	0	0	0	0	0	0	0	4	
	6	6	0	0	0	0	0	0	0	6	
	TOTAL										323

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2501	1	4	17	25	26	14	14	11	13	124	
	2	7	10	9	21	14	10	7	8	86	
	3	4	7	11	14	5	9	7	9	66	
	4	16	3	3	16	6	7	5	12	68	
	5	2	7	3	6	3	4	2	8	35	
	6	18	2	3	3	2	1	4	5	38	
	TOTAL										417
2502	1	25	19	23	27	19	22	17	16	168	
	2	46	16	18	14	21	10	11	8	144	
	3	21	10	14	18	15	10	11	7	106	
	4	59	8	7	7	10	5	5	5	106	
	5	59	7	4	8	2	12	15	27	134	
	6	45	0	1	1	2	9	7	20	85	
	TOTAL										743
2503	1	8	21	17	14	9	23	16	11	119	
	2	9	13	9	15	12	8	10	10	86	
	3	13	3	7	3	15	11	5	9	66	
	4	6	7	10	6	26	8	2	4	69	
	5	5	7	4	6	12	29	6	2	71	
	6	0	1	2	3	28	5	0	1	40	
	TOTAL										451
2504	1	6	8	17	24	11	12	17	24	119	
	2	6	10	11	10	12	8	17	13	87	
	3	9	3	10	11	16	6	7	12	74	
	4	6	11	7	14	6	19	17	10	90	
	5	6	7	4	11	15	12	19	10	84	
	6	9	13	5	4	6	7	7	6	57	
	TOTAL										511

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2505	1	8	12	21	14	12	11	15	17	110	
	2	7	13	6	7	20	8	9	10	80	
	3	4	4	2	6	22	5	2	4	49	
	4	1	1	1	1	34	8	1	2	49	
	5	0	0	0	0	3	0	0	0	3	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										291
2506	1	7	13	18	14	12	14	25	22	125	
	2	10	19	14	13	8	18	27	18	127	
	3	20	27	27	20	6	23	30	26	179	
	4	0	5	10	4	0	5	7	5	36	
	5	0	0	2	0	0	0	0	0	2	
	6	0	4	6	0	0	0	0	0	10	
	TOTAL										479
2507	1	5	14	18	18	7	15	20	18	115	
	2	2	5	14	12	8	14	8	6	69	
	3	7	10	8	16	6	20	11	8	86	
	4	1	0	2	2	28	3	1	1	38	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										308
2508	1	13	29	29	19	19	16	18	20	163	
	2	13	19	14	13	10	16	10	12	107	
	3	8	10	11	10	4	12	6	13	74	
	4	14	19	12	12	6	14	11	14	102	
	5	17	8	11	15	6	10	5	12	84	
	6	37	2	0	0	0	6	0	1	46	
	TOTAL										576

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2509	1	8	12	21	18	12	20	23	19	133	
	2	7	11	19	11	9	22	17	15	111	
	3	4	8	7	11	7	23	9	12	81	
	4	10	5	2	4	2	7	1	14	45	
	5	6	3	3	5	4	2	11	12	46	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										416
2510	1	12	18	19	23	6	26	18	18	140	
	2	1	7	7	10	1	16	7	8	57	
	3	0	0	0	0	0	2	0	0	2	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										199
2511	1	7	19	9	9	10	18	22	17	111	
	2	5	5	10	6	2	10	8	8	54	
	3	7	3	4	1	3	9	4	5	36	
	4	1	2	4	2	0	2	2	0	13	
	5	0	0	0	0	0	0	0	0	0	
	6	3	2	1	1	0	1	1	2	11	
	TOTAL										225
2512	1	8	15	14	9	15	12	18	16	107	
	2	6	7	7	10	9	6	5	6	56	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										163

APPENDIX NO.6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2513	1	4	21	14	19	12	24	16	17	127	
	2	9	20	29	27	9	14	11	13	132	
	3	11	6	7	13	26	12	11	11	97	
	4	1	0	0	0	28	3	3	2	37	
	5	0	0	0	0	8	0	0	0	8	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										401
2514	1	7	15	18	20	12	29	16	14	131	
	2	11	21	12	8	10	23	11	7	103	
	3	5	10	7	13	12	16	11	3	77	
	4	10	6	8	7	5	8	11	9	64	
	5	2	2	3	6	7	7	2	7	36	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										411
2515	1	10	20	17	21	7	22	19	20	136	
	2	7	15	11	18	6	17	12	11	97	
	3	5	9	4	8	4	10	9	6	55	
	4	0	0	0	0	0	0	2	0	2	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										290

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3501	1	15	13	20	30	5	15	16	18	132	
	2	15	10	21	17	5	10	19	10	107	
	3	8	10	16	16	7	16	14	9	96	
	4	1	3	7	11	6	6	16	2	52	
	5	3	0	0	2	0	3	3	0	11	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										398
3502	1	7	25	24	20	5	24	28	23	156	
	2	7	12	18	13	6	28	24	6	114	
	3	10	10	4	5	3	15	15	7	69	
	4	4	14	12	15	6	13	6	15	85	
	5	1	3	2	1	0	1	2	3	13	
	6	4	7	1	3	1	8	20	6	50	
	TOTAL										487
3503	1	7	21	24	14	5	15	25	20	131	
	2	15	20	16	14	8	25	18	16	132	
	3	7	13	14	15	10	19	19	15	112	
	4	6	9	10	17	5	15	21	10	93	
	5	2	9	11	20	8	13	12	8	83	
	6	2	3	2	7	3	9	3	6	35	
	TOTAL										586
3504	1	10	20	24	20	13	20	16	18	141	
	2	9	16	8	14	10	18	12	8	95	
	3	9	18	11	11	3	11	7	7	77	
	4	4	4	5	10	3	4	5	5	40	
	5	0	4	4	7	1	7	2	4	29	
	6	12	11	14	12	3	13	8	6	79	
	TOTAL										461

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3505	1	8	14	27	21	13	11	18	6	118	
	2	5	11	20	16	12	22	16	12	114	
	3	6	8	9	6	8	7	6	13	63	
	4	1	8	10	7	3	5	6	3	43	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										338
3506	1	0	4	28	30	6	22	21	15	126	
	2	4	13	12	14	7	9	17	7	83	
	3	7	4	6	6	4	3	6	5	41	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										250
3507	1	6	11	14	21	15	12	13	13	105	
	2	8	9	9	9	20	13	13	11	92	
	3	8	12	10	10	27	16	10	10	103	
	4	6	5	3	6	49	3	4	3	79	
	5	0	1	2	2	20	0	1	1	27	
	6	0	0	0	0	13	0	0	0	13	
	TOTAL										419
3508	1	9	17	19	23	14	23	35	17	157	
	2	13	11	11	10	7	20	8	15	95	
	3	5	16	11	4	9	14	3	10	72	
	4	9	6	6	6	7	13	9	6	62	
	5	1	1	2	1	0	1	1	1	8	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										394

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3509	1	9	34	25	20	6	33	22	17	166	
	2	12	22	18	14	16	21	15	10	128	
	3	10	13	15	26	6	16	19	11	116	
	4	9	22	14	10	4	16	11	20	106	
	5	1	4	2	2	1	2	1	1	14	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										530
3510	1	3	22	20	14	4	14	34	24	135	
	2	7	9	18	8	5	11	39	18	115	
	3	3	8	19	13	7	6	19	6	81	
	4	5	2	3	0	0	1	18	3	32	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										363
3511	1	10	27	21	33	12	24	19	27	173	
	2	6	19	19	33	10	11	10	16	124	
	3	3	8	5	12	32	17	3	3	83	
	4	8	6	6	9	33	8	8	11	89	
	5	6	6	7	10	12	8	7	6	62	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										531
3513	1	12	20	15	18	11	17	14	22	129	
	2	7	10	12	12	17	39	10	11	118	
	3	5	7	12	9	9	8	3	5	58	
	4	13	6	4	9	15	10	4	5	66	
	5	1	3	4	1	9	5	0	0	23	
	6	0	0	0	0	7	0	0	0	7	
	TOTAL										401

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO. 190831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3514	1	8	10	12	14	6	14	20	21	105	
	2	10	9	2	3	6	11	13	13	67	
	3	5	5	5	6	5	12	5	7	50	
	4	3	3	4	2	7	2	3	1	25	
	5	2	1	4	3	2	2	0	5	19	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										266
3516 T	1										
	2										
	3										
	4										
	5										
	6										
	TOTAL										
3517	1	8	22	12	15	11	20	15	12	115	
	2	9	26	18	20	10	16	15	18	132	
	3	11	10	15	14	6	11	14	7	88	
	4	4	4	4	1	7	6	4	1	31	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										366

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4501	1	5	33	15	23	7	10	15	17	125	
	2	9	24	13	9	13	17	18	18	121	
	3	9	21	17	19	7	18	17	15	123	
	4	4	12	12	13	16	17	18	5	97	
	5	13	19	10	18	7	15	14	14	110	
	6	5	41	6	8	11	18	11	16	116	
	TOTAL										692
4502	1	12	12	12	19	21	20	16	16	128	
	2	9	9	14	13	32	12	6	11	106	
	3	8	7	3	9	57	6	7	6	103	
	4	15	7	9	9	12	11	17	6	86	
	5	21	9	7	5	20	12	12	12	98	
	6	6	5	7	14	20	10	7	8	77	
	TOTAL										598
4503	1	5	22	35	29	6	20	17	24	160	
	2	3	22	17	11	7	17	11	8	96	
	3	6	20	14	15	3	33	29	12	132	
	4	2	16	15	13	5	13	12	21	97	
	5	4	15	13	14	5	3	9	17	80	
	6	6	11	4	8	3	2	1	13	48	
	TOTAL										613
4504	1	14	16	19	25	12	21	16	22	145	
	2	16	18	14	23	13	22	9	20	135	
	3	15	15	10	11	12	27	12	19	121	
	4	17	11	9	15	19	15	3	14	103	
	5	52	5	6	5	4	5	4	7	88	
	6	43	6	4	11	3	7	5	6	85	
	TOTAL										677

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4505	1	18	23	36	18	6	17	28	20	166	
	2	10	10	11	11	14	18	14	9	97	
	3	13	13	18	18	9	16	12	16	115	
	4	6	12	11	18	7	13	8	5	80	
	5	5	14	12	18	0	8	14	5	76	
	6	5	3	4	7	31	5	9	3	67	
	TOTAL										601
4506	1	9	15	21	20	17	14	31	19	146	
	2	7	7	8	6	14	3	12	12	69	
	3	3	15	8	5	7	11	13	10	72	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										287
4507	1	16	19	21	18	15	12	17	13	131	
	2	11	9	11	12	15	13	9	15	95	
	3	7	2	6	9	12	5	3	8	52	
	4	4	3	4	4	5	5	7	7	39	
	5	8	3	3	6	1	10	8	6	45	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										362
4508	1	10	25	23	24	8	26	28	27	171	
	2	10	22	17	19	5	27	26	16	142	
	3	11	30	19	20	10	28	27	17	162	
	4	7	16	19	21	4	16	10	11	104	
	5	2	2	1	1	1	10	2	1	20	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										599

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4509	1	9	32	12	21	13	29	18	18	152	
	2	9	21	15	13	13	15	19	16	121	
	3	7	14	12	6	5	10	7	7	68	
	4	0	0	7	0	0	0	0	0	7	
	5	11	9	9	14	9	17	11	8	88	
	6	0	4	4	6	7	8	4	3	36	
	TOTAL										472
4510	1	15	24	17	21	7	24	21	20	149	
	2	8	20	19	18	8	19	13	16	121	
	3	1	7	6	11	5	9	8	5	52	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										322
4511	1	0	0	0	0	25	0	0	0	25	
	2	3	15	11	13	3	18	44	22	129	
	3	12	23	34	21	5	20	23	9	147	
	4	10	13	21	11	2	12	26	12	107	
	5	5	8	5	3	0	4	7	8	40	
	6	4	4	4	9	5	10	25	3	64	
	TOTAL										512
4513	1	13	21	13	23	7	20	13	14	124	
	2	14	18	16	11	8	10	9	12	98	
	3	8	12	9	11	18	10	17	17	102	
	4	5	9	5	2	7	1	5	3	37	
	5	3	5	7	0	4	3	9	3	34	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										395

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
PRE STUDY

PROJECT NO.:90831

GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4514	1	8	21	21	25	6	23	20	16	140	
	2	8	14	9	9	6	15	10	16	87	
	3	2	2	5	6	10	10	8	10	53	
	4	6	7	6	3	14	7	10	5	58	
	5	4	9	17	10	13	11	14	15	93	
	6	3	2	0	0	0	0	3	1	9	
	TOTAL										440
4515	1	7	26	21	17	8	14	18	22	133	
	2	8	15	13	14	6	17	18	8	99	
	3	5	14	9	6	4	9	22	6	75	
	4	4	12	7	9	5	6	20	10	73	
	5	0	2	2	2	1	1	9	4	21	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										401
4516	1	16	21	18	24	11	19	18	23	150	
	2	8	21	14	23	12	25	10	26	139	
	3	11	10	5	5	7	3	3	8	52	
	4	8	4	8	16	8	12	7	11	74	
	5	1	13	3	8	4	12	10	10	61	
	6	21	15	15	4	1	3	5	5	69	
	TOTAL										545

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1501	1	12	22	21	29	22	37	20	21	184	
	2	14	23	12	18	11	33	15	15	141	
	3	16	11	13	25	15	21	16	10	127	
	4	18	14	23	18	27	17	15	13	145	
	5	13	8	5	18	36	21	11	15	127	
	6	16	18	14	21	27	11	9	12	128	
	TOTAL										852
1502	1	24	22	13	11	16	20	20	28	154	
	2	9	9	4	7	18	14	10	16	87	
	3	18	11	8	7	4	9	9	16	82	
	4	3	3	0	2	2	3	1	8	22	
	5	11	3	1	1	6	5	2	4	33	
	6	3	0	0	0	0	0	0	0	3	
	TOTAL										381
1503	1	4	28	16	19	1	34	26	17	145	
	2	9	15	17	18	4	27	22	24	136	
	3	3	7	14	10	4	17	15	18	88	
	4	1	10	7	21	9	10	24	15	97	
	5	5	17	8	30	11	12	9	9	101	
	6	4	27	9	27	17	13	10	7	114	
	TOTAL										681
1504	1	12	25	22	16	18	15	26	19	153	
	2	10	20	14	12	11	21	7	31	126	
	3	30	7	3	3	19	12	5	11	90	
	4	3	0	0	0	0	0	0	0	3	
	5	18	8	6	4	1	2	9	8	56	
	6	4	0	0	0	0	0	0	0	4	
	TOTAL										432

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1505	1	12	14	18	18	7	22	21	22	134	
	2	11	14	19	19	7	11	12	12	105	
	3	4	12	11	4	6	19	7	6	69	
	4	4	4	1	2	1	2	3	0	17	
	5	2	2	3	1	1	4	0	0	13	
	6	2	6	14	6	5	8	4	9	54	
	TOTAL										392
1506	1	12	17	12	21	13	32	19	14	140	
	2	10	11	15	23	10	6	11	9	95	
	3	0	4	11	4	1	2	1	1	24	
	4	1	9	6	2	1	3	4	2	28	
	5	0	0	0	0	0	0	0	0	0	
	6	2	4	5	3	2	3	2	2	23	
	TOTAL										310
1507	1	8	18	24	23	10	17	25	16	141	
	2	2	6	13	9	2	2	6	5	45	
	3	0	0	0	8	1	3	9	6	27	
	4	1	5	6	10	2	1	2	3	30	
	5	1	2	5	1	0	2	3	1	15	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										258
1508	1	12	26	21	16	32	21	14	14	156	
	2	3	8	12	15	23	11	11	4	87	
	3	10	8	5	3	25	5	8	6	70	
	4	0	2	3	5	17	2	1	3	33	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	10	0	0	0	10	
	TOTAL										356

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.190831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1509	1	11	34	28	21	18	35	20	25	192	
	2	9	31	23	28	20	14	15	26	166	
	3	13	13	8	7	8	17	23	20	109	
	4	7	15	12	15	11	29	17	16	122	
	5	0	5	19	6	0	2	5	10	47	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										636
1510	1	6	20	18	15	12	16	18	16	121	
	2	6	4	9	8	19	11	13	10	80	
	3	9	9	9	7	13	15	6	8	76	
	4	0	0	0	0	53	0	0	0	53	
	5	0	0	0	0	11	0	0	0	11	
	6	0	0	0	0	21	0	0	0	21	
	TOTAL										362
1511	1	14	14	27	21	15	20	26	20	157	
	2	4	16	19	15	7	8	14	15	98	
	3	4	3	2	9	1	6	14	4	43	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	1	0	0	0	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										299
1512	1	13	36	19	32	15	22	16	17	170	
	2	10	11	23	19	14	12	9	16	114	
	3	4	13	8	4	14	2	3	1	49	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	1	5	4	3	1	6	1	1	22	
	TOTAL										355

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1513	1	18	21	17	17	22	23	17	15	150	
	2	7	22	9	6	13	12	12	13	94	
	3	0	1	1	3	1	3	4	3	16	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	1	1	
	TOTAL										261
1514	1	18	10	12	14	13	21	11	16	115	
	2	11	14	11	11	9	12	5	7	80	
	3	4	6	7	10	20	9	6	8	70	
	4	0	0	0	0	38	0	0	0	38	
	5	4	3	1	2	26	3	3	4	46	
	6	0	0	0	0	18	0	0	0	18	
	TOTAL										367
1515	1	11	34	19	11	8	18	15	27	143	
	2	0	4	8	2	0	2	10	7	33	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	1	1	8	2	1	1	3	3	20	
	6	0	0	0	0	0	0	2	0	2	
	TOTAL										198

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2501	1	14	16	16	17	13	20	16	25	137	
	2	9	20	9	9	9	12	15	9	92	
	3	8	17	6	5	7	7	6	12	68	
	4	7	12	9	5	4	5	7	10	59	
	5	3	5	11	7	0	4	5	10	45	
	6	1	2	2	0	0	0	0	2	7	
	TOTAL										408
2502	1	30	21	20	19	11	34	21	17	173	
	2	51	14	6	15	15	24	15	12	152	
	3	34	17	10	15	16	13	8	10	123	
	4	24	8	6	5	7	6	7	13	76	
	5	10	2	1	2	2	1	2	8	28	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										552
2503	1	11	18	14	20	13	21	14	23	134	
	2	9	10	16	8	8	11	10	10	82	
	3	3	9	4	16	22	17	9	8	88	
	4	3	2	0	4	22	3	0	0	34	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										338
2504	1	12	31	28	15	14	26	22	17	165	
	2	4	7	11	15	5	9	8	6	65	
	3	0	4	2	2	4	0	0	1	13	
	4	0	0	0	0	0	0	0	0	0	
	5	1	3	2	7	1	2	2	2	20	
	6	0	2	2	3	3	2	2	1	15	
	TOTAL										278

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2505	1	12	12	16	18	13	18	13	12	114	
	2	7	9	6	5	13	9	5	8	62	
	3	7	16	7	10	22	2	3	4	71	
	4	1	6	1	1	29	2	1	1	42	
	5	3	1	1	1	6	1	3	1	17	
	6	0	0	0	0	1	0	0	0	1	
	TOTAL										307
2506	1	9	22	25	25	10	23	19	14	147	
	2	3	14	15	11	8	13	17	16	97	
	3	5	5	8	9	3	13	13	3	59	
	4	1	5	7	1	3	8	15	4	44	
	5	0	0	0	0	0	1	6	0	7	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										354
2507	1	6	22	39	35	15	21	19	22	179	
	2	12	18	12	14	20	22	16	18	132	
	3	0	2	3	4	41	7	2	4	63	
	4	0	0	0	0	6	0	0	0	6	
	5	0	1	3	3	16	2	1	1	27	
	6	0	0	0	0	7	0	0	0	7	
	TOTAL										414
2508	1	28	22	14	16	14	25	17	23	159	
	2	23	13	6	12	8	8	10	18	98	
	3	9	10	22	9	15	5	9	11	90	
	4	8	1	2	6	10	9	3	13	52	
	5	3	5	0	0	0	0	7	1	16	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										415

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2509	1	15	18	13	26	21	21	24	26	164	
	2	18	18	9	8	20	12	15	19	119	
	3	7	5	0	0	5	1	1	3	22	
	4	0	0	0	0	0	0	0	0	0	
	5	7	6	5	3	7	7	4	1	40	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										346
2510	1	14	31	23	20	12	29	30	29	188	
	2	11	13	24	12	8	15	19	11	113	
	3	4	5	8	2	16	2	9	12	58	
	4	0	0	41	2	0	0	0	0	43	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										402
2511	1	13	33	23	20	8	25	21	12	155	
	2	5	12	18	12	5	10	13	25	100	
	3	8	14	7	6	3	4	3	6	51	
	4	3	5	3	2	2	5	5	4	29	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										335
2512	1	6	16	27	18	5	28	17	22	139	
	2	0	2	9	2	0	1	1	2	17	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										156

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2513	1	14	25	23	27	21	20	21	26	177	
	2	10	9	11	11	38	17	18	14	128	
	3	11	14	11	10	25	14	7	9	101	
	4	6	6	3	2	23	7	5	3	55	
	5	0	0	0	0	3	0	0	0	3	
	6	0	0	0	0	3	0	0	0	3	
	TOTAL										467
2514	1	14	18	26	12	17	13	29	15	144	
	2	8	17	23	9	22	10	12	12	113	
	3	6	5	4	3	9	4	5	3	39	
	4	3	4	3	1	6	2	9	7	35	
	5	14	7	7	6	11	12	8	3	68	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										399
2515	1	8	22	19	23	8	20	22	15	137	
	2	8	15	10	17	8	12	16	8	94	
	3	1	1	1	1	0	0	0	0	4	
	4	1	3	6	6	1	2	4	4	27	
	5	3	7	4	4	4	8	10	2	42	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										304

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3501	1	8	17	27	15	9	22	21	22	141	
	2	7	15	24	8	9	14	13	12	102	
	3	2	11	20	15	10	12	12	6	88	
	4	1	7	21	6	3	7	4	4	53	
	5	0	0	15	2	0	2	1	2	22	
	6	0	0	2	0	0	0	0	0	2	
	TOTAL										408
3502	1	7	16	11	12	8	18	16	12	100	
	2	0	0	0	0	0	0	0	0	0	
	3	3	0	0	0	1	6	0	0	10	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										110
3503	1	10	15	16	20	17	14	16	14	122	
	2	9	6	10	13	7	17	10	20	92	
	3	3	8	6	11	5	4	9	9	55	
	4	5	7	9	27	5	14	6	9	82	
	5	4	4	6	30	0	3	3	10	60	
	6	2	5	4	7	1	6	7	16	48	
	TOTAL										459
3504	1	12	21	18	26	18	20	26	16	157	
	2	3	16	15	17	24	15	14	9	118	
	3	24	7	4	10	18	18	8	10	99	
	4	1	7	6	10	12	6	5	5	52	
	5	0	0	0	0	27	0	0	0	27	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										453

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3505	1	13	13	21	25	12	15	29	23	151	
	2	11	11	16	14	4	17	20	15	108	
	3	2	5	6	4	4	11	11	8	51	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										310
3506	1	10	14	18	21	10	26	27	20	146	
	2	8	10	16	15	11	13	32	18	123	
	3	3	0	0	0	2	0	4	3	12	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										281
3507	1	13	12	13	14	8	21	14	14	109	
	2	4	8	11	13	8	23	7	9	83	
	3	2	3	3	3	62	5	1	7	86	
	4	3	1	4	3	14	4	4	1	34	
	5	0	0	0	0	8	0	0	0	8	
	6	0	0	0	0	2	0	0	0	2	
	TOTAL										322
3508	1	11	20	21	20	14	24	22	12	144	
	2	5	11	19	10	9	12	11	14	91	
	3	1	0	0	0	29	2	0	0	32	
	4	3	2	4	3	5	4	9	1	31	
	5	0	2	5	3	11	3	0	0	24	
	6	0	0	0	0	1	0	0	0	1	
	TOTAL										323

APPENDIX NO.6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3509	1	14	22	21	17	12	28	23	30	167	
	2	9	16	15	24	10	28	16	17	135	
	3	3	12	12	13	5	28	12	7	92	
	4	1	7	5	5	0	21	4	4	47	
	5	0	0	0	0	0	1	1	0	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										443
3510	1	6	23	23	24	7	19	18	17	137	
	2	4	16	8	20	4	15	24	17	108	
	3	15	21	15	15	2	6	6	5	85	
	4	2	20	13	10	8	12	17	6	88	
	5	3	7	7	4	2	1	2	15	41	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										459
3511	1	8	16	21	28	21	26	20	22	162	
	2	11	11	10	16	23	22	9	8	110	
	3	0	0	0	0	52	0	0	0	52	
	4	0	0	0	0	25	0	0	0	25	
	5	0	0	0	0	3	0	0	0	3	
	6	0	0	0	0	6	0	0	0	6	
	TOTAL										358
3513	1	13	18	20	16	15	13	16	10	121	
	2	15	7	16	9	12	8	17	4	88	
	3	3	0	0	0	40	0	5	1	49	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										258

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3514	1	11	13	18	23	16	26	13	11	131	
	2	11	12	16	3	4	11	20	21	98	
	3	3	4	0	0	0	2	11	5	25	
	4	5	15	18	12	6	11	11	14	92	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										346
3516	1	9	21	22	10	12	16	19	30	139	
	2	7	11	25	12	7	11	13	41	127	
	3	5	4	7	16	4	10	5	24	75	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										341
3517	1	6	21	20	21	15	10	12	13	118	
	2	6	13	6	13	12	13	10	6	79	
	3	8	11	11	7	10	12	11	18	88	
	4	6	4	3	5	4	4	13	7	46	
	5	0	0	0	0	0	5	2	0	7	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										338

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4501	1	10	27	20	22	15	19	13	15	141	
	2	8	13	15	15	14	14	15	12	106	
	3	4	7	10	10	17	8	5	10	71	
	4	3	6	5	7	13	6	5	9	54	
	5	2	7	4	24	18	5	4	8	72	
	6	7	10	6	11	11	11	9	12	77	
	TOTAL										521
4502	1	15	20	15	24	16	13	11	12	126	
	2	6	22	5	7	27	12	5	19	103	
	3	11	18	18	7	25	5	3	5	92	
	4	13	8	12	18	38	12	9	10	120	
	5	7	12	5	7	15	9	7	3	65	
	6	1	0	3	3	14	3	2	4	30	
	TOTAL										536
4503	1	9	33	22	29	6	28	15	27	169	
	2	11	30	9	4	7	19	9	28	117	
	3	5	23	4	21	6	6	6	37	108	
	4	4	19	3	3	0	8	7	35	79	
	5	8	10	12	19	7	8	3	13	80	
	6	2	11	12	10	3	11	14	16	79	
	TOTAL										632
4504	1	17	27	21	24	15	20	22	30	176	
	2	17	17	7	9	11	21	14	17	113	
	3	18	16	12	13	39	6	5	15	124	
	4	1	5	1	3	40	0	0	0	50	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	7	0	0	0	7	
	TOTAL										470

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4505	1	18	27	25	25	10	28	24	25	182	
	2	12	20	18	13	23	10	15	16	127	
	3	13	10	11	11	16	6	13	18	98	
	4	7	6	9	8	6	5	9	4	54	
	5	1	1	1	0	0	2	5	1	11	
	6	5	9	4	9	4	2	9	7	49	
	TOTAL										521
4506	1	16	21	19	19	12	17	24	26	154	
	2	14	20	6	24	9	27	13	10	123	
	3	3	0	0	0	0	3	1	0	7	
	4	7	2	3	8	4	7	5	3	39	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										323
4507	1	12	14	17	19	13	21	17	13	126	
	2	6	14	12	8	21	9	12	10	92	
	3	4	5	6	2	16	6	8	5	52	
	4	0	0	0	0	0	0	0	0	0	
	5	2	6	4	3	20	4	4	8	51	
	6	0	0	0	0	6	0	0	0	6	
	TOTAL										327
4508	1	13	28	30	22	10	34	18	20	175	
	2	6	26	23	17	7	23	16	12	130	
	3	6	13	13	14	6	22	14	16	104	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	8	7	7	6	2	11	5	3	49	
	TOTAL										458

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4509	1	12	36	26	24	11	31	25	22	187	
	2	6	20	17	14	8	21	21	15	122	
	3	3	21	13	11	2	15	9	10	84	
	4	3	8	6	5	1	7	4	2	36	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										429
4510	1	9	23	26	24	14	26	17	20	159	
	2	5	20	17	15	20	19	24	23	143	
	3	0	8	2	9	12	9	8	8	56	
	4	0	0	0	0	0	0	0	0	0	
	5	1	4	3	3	3	3	3	4	24	
	6	7	15	8	9	14	12	22	15	102	
	TOTAL										484
4511	1	9	16	25	15	8	21	32	17	143	
	2	2	15	25	11	2	25	23	19	122	
	3	1	8	12	3	0	7	26	5	62	
	4	0	0	4	2	0	3	32	1	42	
	5	0	0	0	0	0	0	0	0	0	
	6	1	8	5	9	1	6	11	4	45	
	TOTAL										414
4513	1	9	13	11	24	16	16	17	13	119	
	2	4	10	11	3	3	12	17	11	71	
	3	4	9	8	13	9	7	10	5	65	
	4	0	0	5	0	0	0	0	0	5	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										260

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 4
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4514	1	9	14	12	16	28	18	17	24	138	
	2	15	15	10	7	15	10	23	16	111	
	3	11	10	3	2	8	11	6	11	62	
	4	6	0	0	0	0	0	0	0	6	
	5	2	0	0	0	0	0	0	0	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										319
4515	1	10	22	14	12	5	18	19	33	133	
	2	3	16	12	4	2	14	18	41	110	
	3	4	4	3	7	5	11	18	21	73	
	4	2	6	5	4	1	5	21	21	65	
	5	0	0	0	0	0	0	0	0	0	
	6	1	3	4	1	5	10	6	12	42	
	TOTAL										423
4516	1	16	22	21	24	9	22	21	39	174	
	2	6	11	14	18	21	13	15	13	111	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										285

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1501	1	18	24	24	20	22	34	23	17	182	
	2	18	14	16	18	26	13	14	10	129	
	3	19	22	10	9	19	15	22	10	126	
	4	7	14	9	12	16	17	17	18	110	
	5	5	20	11	14	16	9	17	14	106	
	6	9	9	12	19	14	14	9	15	101	
	TOTAL										754
1502	1	20	15	11	14	19	16	21	24	140	
	2	24	17	7	10	11	6	3	13	91	
	3	30	9	5	8	7	6	4	6	75	
	4	15	16	4	14	3	6	5	8	71	
	5	29	19	10	10	12	6	4	13	103	
	6	29	3	4	7	6	3	0	11	63	
	TOTAL										543
1503	1	6	27	29	23	5	21	23	25	159	
	2	3	13	8	10	5	19	11	5	74	
	3	4	13	8	20	1	13	9	14	82	
	4	0	4	3	4	6	8	5	0	30	
	5	2	14	11	7	1	5	11	8	59	
	6	2	10	6	6	1	3	10	5	43	
	TOTAL										447
1504	1	10	20	21	20	10	18	13	30	142	
	2	11	10	9	11	11	10	10	12	84	
	3	7	9	8	8	8	3	1	1	45	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	2	0	0	0	2	
	6	17	1	4	2	1	6	9	1	41	
	TOTAL										314

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1505	1	11	24	28	23	5	17	11	16	135	
	2	5	13	17	6	1	8	5	5	60	
	3	0	0	0	0	0	0	0	0	0	
	4	0	4	4	1	0	2	1	1	13	
	5	0	0	0	0	0	0	0	0	0	
	6	1	10	19	12	2	4	3	9	60	
	TOTAL										268
1506	1	7	26	16	22	10	35	31	22	169	
	2	4	10	9	5	5	10	16	4	63	
	3	0	0	0	0	0	0	0	0	0	
	4	0	1	4	0	0	0	0	0	5	
	5	0	8	7	5	4	5	8	1	38	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										275
1507	1	6	22	19	13	10	16	20	12	118	
	2	1	1	5	3	5	4	4	1	24	
	3	0	2	4	1	0	0	5	2	14	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	1	0	0	0	0	0	0	1	
	TOTAL										157
1508	1	11	18	19	17	23	23	23	17	151	
	2	6	8	7	9	26	15	10	4	85	
	3	4	5	7	6	21	11	14	11	79	
	4	0	0	0	0	12	0	0	0	12	
	5	0	0	0	0	10	0	0	0	10	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										337

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1509	1	9	31	24	27	15	41	31	29	207	
	2	7	38	17	27	32	21	19	18	179	
	3	4	18	8	13	12	7	14	7	83	
	4	2	4	10	9	8	5	6	7	51	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										520
1510	1	14	23	23	17	18	22	23	16	156	
	2	3	9	8	9	32	11	11	10	93	
	3	0	0	0	0	6	0	0	0	6	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										255
1511	1	8	22	19	18	7	13	28	15	130	
	2	9	8	11	6	11	12	10	10	77	
	3	2	11	5	2	1	5	13	8	47	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										254
1512	1	7	21	26	26	16	18	23	13	150	
	2	1	14	20	15	5	13	11	11	90	
	3	1	4	8	8	1	0	6	5	33	
	4	0	2	2	0	0	0	0	0	4	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										277

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 8
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1513	1	9	19	13	18	14	42	15	20	150	
	2	6	10	13	10	13	27	15	10	104	
	3	3	6	3	3	2	4	1	2	24	
	4	0	0	0	0	0	0	0	0	0	
	5	2	6	2	3	3	16	3	4	39	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										317
1514	1	13	28	25	17	13	24	19	20	159	
	2	21	12	16	9	18	18	9	9	112	
	3	9	9	9	11	26	14	7	7	92	
	4	13	6	3	2	30	3	8	10	75	
	5	24	7	7	4	10	8	3	7	70	
	6	32	3	3	3	5	1	1	1	49	
	TOTAL										557
1515	1	10	17	17	23	9	26	15	17	134	
	2	7	4	2	13	4	13	6	9	58	
	3	2	4	3	3	24	3	2	3	44	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	12	0	0	0	12	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										248

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2501	1	7	17	23	24	14	22	13	17	137	
	2	6	14	18	17	5	5	8	13	86	
	3	3	10	17	8	2	10	18	13	81	
	4	2	3	2	0	0	1	1	3	12	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	1	0	0	0	0	0	1	
	TOTAL										317
2502	1	45	33	15	23	18	26	18	31	209	
	2	45	10	7	15	11	7	13	15	123	
	3	43	11	8	18	1	11	5	15	112	
	4	28	4	2	4	10	11	6	9	74	
	5	36	3	3	6	7	4	1	11	71	
	6	10	0	0	0	0	0	0	1	11	
	TOTAL										600
2503	1	10	28	12	21	6	16	18	36	147	
	2	10	18	7	12	5	4	4	8	68	
	3	8	17	10	9	7	16	9	14	90	
	4	10	2	1	2	4	10	1	2	32	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										337
2504	1	13	27	14	16	15	20	29	20	154	
	2	7	16	13	21	28	11	24	14	134	
	3	3	8	6	8	25	11	4	3	68	
	4	0	0	0	0	0	0	0	0	0	
	5	1	4	2	4	3	6	8	1	29	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										385

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2505	1	19	14	9	25	28	18	16	14	143	
	2	13	13	8	14	23	14	6	14	105	
	3	9	12	4	5	52	6	3	8	99	
	4	0	0	0	0	10	0	0	0	10	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	6	0	0	0	6	
	TOTAL										363
2506	1	9	17	31	21	11	26	30	26	171	
	2	5	24	18	30	7	19	11	19	133	
	3	0	9	2	3	0	0	0	1	15	
	4	0	2	5	5	0	10	4	1	27	
	5	0	0	1	1	0	1	0	0	3	
	6	3	11	15	9	7	13	14	16	88	
	TOTAL										437
2507	1	11	20	20	22	18	24	25	17	157	
	2	8	7	9	10	34	24	8	6	106	
	3	2	7	6	3	37	4	2	2	63	
	4	0	0	0	0	7	0	0	0	7	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										333
2508	1	11	11	11	8	15	26	15	29	126	
	2	14	7	3	2	9	14	15	8	72	
	3	10	3	4	9	31	11	3	9	80	
	4	12	4	2	1	3	0	0	0	22	
	5	2	2	3	2	3	5	2	1	20	
	6	1	4	0	0	1	1	0	0	7	
	TOTAL										327

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2509	1	18	30	17	21	18	26	21	15	166	
	2	16	8	8	12	50	11	11	15	131	
	3	31	0	0	0	0	0	0	0	31	
	4	0	0	0	0	0	0	0	0	0	
	5	1	0	0	0	0	0	0	0	1	
	6	9	5	4	4	1	1	0	2	26	
	TOTAL										355
2510	1	13	22	18	24	27	24	25	26	179	
	2	18	9	7	2	21	5	9	15	86	
	3	7	3	2	8	19	6	7	9	61	
	4	1	3	3	1	0	2	2	3	15	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										341
2511	1	13	37	33	26	6	26	34	21	196	
	2	11	16	17	19	4	16	11	17	111	
	3	0	5	4	2	0	2	1	3	17	
	4	0	0	0	0	0	0	0	0	0	
	5	3	11	4	9	1	8	9	11	56	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										380
2512	1	7	16	26	23	7	17	22	26	144	
	2	0	3	13	15	10	4	0	0	45	
	3	0	0	3	1	0	0	0	0	4	
	4	0	0	6	0	0	0	0	0	6	
	5	0	0	0	0	0	0	0	0	0	
	6	0	2	2	1	0	0	0	3	8	
	TOTAL										207

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2513	1	26	22	22	30	13	19	17	23	172	
	2	12	16	20	23	20	12	14	15	132	
	3	1	10	8	6	48	6	9	10	98	
	4	3	6	9	2	51	1	3	3	78	
	5	0	1	1	2	21	6	4	4	39	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										519
2514	1	18	16	23	35	12	26	26	36	192	
	2	28	29	20	12	7	23	16	30	165	
	3	6	11	12	10	5	11	18	5	78	
	4	0	0	0	0	0	0	4	0	4	
	5	8	15	4	6	1	7	14	9	64	
	6	2	1	0	0	0	0	1	2	6	
	TOTAL										509
2515	1	12	25	27	24	11	13	19	21	152	
	2	5	26	23	20	11	11	12	5	113	
	3	4	5	3	17	1	4	1	5	40	
	4	3	10	7	13	2	6	10	6	57	
	5	2	2	2	5	0	1	1	1	14	
	6	1	1	4	6	1	1	2	1	17	
	TOTAL										393

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3501	1	7	18	19	8	2	16	16	12	98	
	2	2	3	4	1	0	1	4	8	23	
	3	7	1	1	5	7	5	5	3	34	
	4	1	4	5	3	1	2	2	5	23	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	1	0	1	
	TOTAL										179
3502	1	13	25	20	16	12	42	33	27	188	
	2	7	15	13	19	10	13	11	14	102	
	3	10	4	5	16	4	18	15	10	82	
	4	8	10	7	5	2	4	3	3	42	
	5	7	9	11	10	4	24	7	22	94	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										508
3503	1	13	21	19	11	9	20	22	10	125	
	2	6	9	10	31	4	18	25	15	118	
	3	3	12	7	11	3	7	15	12	70	
	4	1	5	5	15	0	11	12	6	55	
	5	1	6	7	5	2	14	6	9	50	
	6	5	22	8	6	6	10	11	16	84	
	TOTAL										502
3504	1	14	20	20	18	9	16	16	22	135	
	2	5	20	12	12	15	19	18	11	112	
	3	5	3	1	0	4	0	2	1	16	
	4	0	0	0	0	0	4	0	0	4	
	5	0	8	5	4	32	2	10	19	80	
	6	0	0	0	0	1	0	0	0	1	
	TOTAL										348

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

FEMALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3505	1	15	22	14	16	14	26	19	13	139	
	2	0	0	0	0	0	0	2	4	6	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										145
3506	1	12	18	24	23	16	29	30	24	176	
	2	7	13	19	19	6	25	18	13	120	
	3	1	7	9	13	18	7	7	4	66	
	4	0	0	2	0	0	0	0	0	2	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										364
3507	1	11	14	15	12	21	19	19	22	133	
	2	9	7	8	9	37	2	6	18	96	
	3	0	12	0	2	20	2	0	8	44	
	4	0	0	0	0	7	0	0	0	7	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										280
3508	1	17	12	18	12	7	12	28	18	124	
	2	10	12	12	14	4	8	12	21	93	
	3	2	0	0	0	0	7	4	1	14	
	4	0	0	0	0	0	0	0	0	0	
	5	0	2	0	0	0	3	5	2	12	
	6	5	3	5	3	2	3	1	10	32	
	TOTAL										275

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3509	1	8	30	25	33	8	32	24	24	184	
	2	2	33	20	21	2	18	11	9	116	
	3	0	42	18	21	3	12	4	7	107	
	4	0	13	6	4	0	0	0	0	23	
	5	1	17	15	15	1	11	2	4	66	
	6	0	11	8	10	0	1	0	0	30	
	TOTAL										526
3510	1	10	34	19	16	9	11	14	16	129	
	2	8	23	14	16	8	15	13	12	109	
	3	0	9	8	3	1	2	7	12	42	
	4	1	4	4	2	4	1	2	2	20	
	5	0	8	1	1	0	3	5	8	26	
	6	0	1	1	1	0	0	0	4	7	
	TOTAL										333
3511	1	19	25	16	22	28	16	23	26	175	
	2	18	15	7	20	28	27	15	16	146	
	3	8	6	3	8	63	4	4	11	107	
	4	0	0	0	0	3	0	0	0	3	
	5	0	0	0	0	31	0	0	0	31	
	6	14	12	8	10	46	9	11	12	122	
	TOTAL										584
3513	1	8	18	14	16	21	20	16	19	132	
	2	12	6	3	12	8	11	13	10	75	
	3	9	4	4	4	18	10	7	6	62	
	4	1	2	4	0	21	0	0	0	28	
	5	8	2	4	3	6	11	8	11	53	
	6	0	0	0	0	8	2	1	0	11	
	TOTAL										361

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

FEMALES
WEEK 8
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3514	1	12	26	24	24	9	18	21	23	157	
	2	10	43	16	14	5	11	11	29	139	
	3	0	7	4	0	0	2	1	2	16	
	4	0	0	0	0	0	0	0	0	0	
	5	2	15	14	8	1	7	6	18	71	
	6	1	11	10	9	1	3	2	4	41	
	TOTAL										424
3516	1	5	24	18	23	13	30	25	18	156	
	2	8	23	31	16	9	23	23	14	147	
	3	5	17	15	12	14	35	19	11	128	
	4	2	5	8	3	1	9	10	3	41	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										472
3517	1	12	39	27	34	15	20	15	16	178	
	2	5	24	23	12	6	4	5	8	87	
	3	1	9	2	4	1	3	3	1	24	
	4	1	5	8	6	7	5	3	2	37	
	5	5	13	11	7	8	5	4	2	55	
	6	2	7	6	4	0	2	0	0	21	
	TOTAL										402

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4501	1	17	29	20	15	18	18	17	16	150	
	2	7	15	15	13	13	3	9	12	87	
	3	6	12	4	4	11	7	7	11	62	
	4	4	7	9	9	12	2	7	8	58	
	5	5	4	11	19	22	4	8	9	82	
	6	2	1	3	5	13	5	5	3	37	
	TOTAL										476
4502	1	14	23	9	29	28	14	12	20	149	
	2	10	9	8	8	53	10	6	15	119	
	3	9	9	7	15	21	6	3	5	75	
	4	28	2	3	5	7	1	5	5	56	
	5	16	3	3	1	3	5	4	2	37	
	6	1	0	0	0	0	0	0	0	1	
	TOTAL										437
4503	1	5	17	29	31	8	34	30	18	172	
	2	22	20	17	9	2	22	13	39	144	
	3	6	7	15	11	0	10	9	19	77	
	4	0	0	1	0	0	0	0	0	1	
	5	0	1	7	2	0	8	6	6	30	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										424
4504	1	23	31	19	16	17	22	19	19	166	
	2	10	17	11	9	13	40	21	15	136	
	3	4	0	0	0	25	7	7	9	52	
	4	0	0	0	0	3	0	0	0	3	
	5	0	0	0	0	11	0	0	0	11	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										368

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4505	1	30	23	18	23	18	23	23	21	179	
	2	9	18	14	12	31	13	14	16	127	
	3	23	16	18	13	7	10	11	17	115	
	4	29	0	0	0	0	0	0	0	29	
	5	13	0	0	0	0	0	0	0	13	
	6	1	0	0	0	0	0	0	0	1	
	TOTAL										464
4506	1	16	29	22	31	9	22	28	30	187	
	2	18	16	14	19	15	18	26	28	154	
	3	3	11	10	10	1	5	7	4	51	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										392
4507	1	13	23	15	11	25	19	16	23	145	
	2	6	2	4	1	56	5	7	4	85	
	3	0	0	0	0	3	0	0	0	3	
	4	0	0	0	0	5	0	0	0	5	
	5	0	0	0	0	3	0	0	0	3	
	6	0	0	0	0	1	0	0	0	1	
	TOTAL										242
4508	1	19	39	37	31	9	31	21	22	209	
	2	13	39	31	20	3	16	16	19	157	
	3	10	24	20	17	4	16	13	16	120	
	4	26	5	6	5	0	1	0	1	44	
	5	14	4	3	4	0	2	3	3	33	
	6	0	1	0	0	0	1	1	1	4	
	TOTAL										567

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

FEMALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4509	1	12	36	31	41	11	44	23	22	220	
	2	3	16	15	22	4	18	19	22	119	
	3	3	9	13	27	4	16	15	10	97	
	4	0	4	9	8	1	1	1	1	25	
	5	0	0	0	0	0	0	0	0	0	
	6	1	3	7	4	1	4	3	3	26	
	TOTAL										487
4510	1	9	21	22	23	26	32	21	19	173	
	2	7	23	26	21	8	21	19	14	139	
	3	0	0	0	0	0	2	0	0	2	
	4	0	0	0	0	0	0	3	2	5	
	5	3	8	8	9	18	15	9	9	79	
	6	0	0	0	0	3	0	0	0	3	
	TOTAL										401
4511	1	7	18	23	22	12	22	21	17	142	
	2	8	7	11	7	12	11	32	19	107	
	3	3	3	13	9	4	10	13	6	61	
	4	0	4	5	6	1	3	4	3	26	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										336
4513	1	5	16	19	18	6	18	27	15	124	
	2	5	16	5	6	3	10	18	15	78	
	3	2	7	5	2	2	3	2	1	24	
	4	0	0	0	0	0	0	0	0	0	
	5	1	5	6	4	1	4	7	7	35	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										261

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

FEMALES
WEEK 8
GROUP 4 CERIC OXIDE HIGH DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4514	1	17	16	14	24	16	16	15	22	140	
	2	7	11	10	13	34	12	5	11	103	
	3	4	2	1	8	51	6	2	12	86	
	4	2	3	3	5	38	1	1	1	54	
	5	6	6	2	10	18	5	2	5	54	
	6	7	7	4	8	37	5	5	10	83	
	TOTAL										520
4515	1	10	33	28	19	15	26	38	26	195	
	2	7	21	27	17	7	16	20	18	133	
	3	3	3	2	2	0	18	2	3	33	
	4	0	0	0	0	0	0	0	0	0	
	5	12	13	13	8	5	17	17	4	89	
	6	23	0	0	0	0	0	0	0	23	
	TOTAL										473
4516	1	8	29	26	22	11	19	25	23	163	
	2	5	6	7	12	1	5	12	13	61	
	3	2	0	0	4	1	0	4	1	12	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	2	2	1	0	4	2	1	12	
	TOTAL										248

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 13
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1501	1	21	42	22	17	25	23	26	28	204	
	2	4	17	16	13	29	16	19	25	139	
	3	11	23	10	11	13	14	9	21	112	
	4	14	21	11	10	16	8	8	19	107	
	5	12	8	9	13	9	7	2	19	79	
	6	42	5	5	8	19	11	6	9	105	
	TOTAL										746
1502	1	13	21	17	15	12	24	27	31	160	
	2	7	5	3	11	20	7	10	20	83	
	3	28	4	3	3	5	4	4	6	57	
	4	5	0	0	0	0	0	0	0	5	
	5	6	0	0	0	0	0	0	0	6	
	6	26	5	6	3	6	8	9	5	68	
	TOTAL										379
1503	1	7	29	30	31	2	23	17	26	165	
	2	4	24	9	7	3	11	12	16	86	
	3	2	9	6	9	2	11	6	12	57	
	4	4	9	7	3	14	4	10	13	64	
	5	6	3	3	5	5	8	6	30	66	
	6	2	8	3	6	1	14	4	9	47	
	TOTAL										485
1504	1	15	19	20	19	10	13	23	20	139	
	2	10	11	11	19	12	7	10	13	93	
	3	8	0	0	0	4	3	1	1	17	
	4	20	0	0	0	0	0	0	0	20	
	5	0	0	0	0	0	0	0	0	0	
	6	10	5	5	3	4	1	7	5	40	
	TOTAL										309

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 13
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1505	1	14	28	25	18	10	29	21	27	172	
	2	7	14	17	22	3	17	26	20	126	
	3	10	19	15	11	9	18	11	15	108	
	4	0	1	3	3	2	5	2	1	17	
	5	0	0	0	0	0	0	0	0	0	
	6	0	9	3	3	2	5	5	4	31	
	TOTAL										454
1506	1	6	28	26	17	11	38	36	19	181	
	2	0	0	4	0	0	0	0	0	4	
	3	0	0	0	0	0	0	0	0	0	
	4	0	2	3	0	0	1	1	1	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										193
1507	1	4	24	17	13	7	20	16	12	113	
	2	2	2	2	3	3	6	9	6	33	
	3	0	0	0	0	0	0	0	0	0	
	4	0	11	3	2	3	3	2	7	31	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										177
1508	1	11	19	26	21	30	24	12	14	157	
	2	7	12	16	12	20	17	19	14	117	
	3	1	10	4	4	14	2	2	1	38	
	4	0	0	1	2	6	0	0	0	9	
	5	7	15	8	8	11	13	18	19	99	
	6	0	1	0	0	1	1	2	0	5	
	TOTAL										425

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

PROJECT NO.:90831

FEMALES
WEEK 13
GROUP 1 AIR CONTROL

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1509	1	13	26	31	32	15	22	20	28	187	
	2	10	23	18	17	10	20	25	18	141	
	3	9	24	4	6	14	22	7	14	100	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										428
1510	1	8	16	14	13	26	17	12	9	115	
	2	3	5	7	2	16	10	9	5	57	
	3	0	0	0	0	31	0	0	0	31	
	4	0	0	0	0	18	0	0	0	18	
	5	0	0	0	1	3	1	2	5	12	
	6	0	0	0	0	2	0	0	0	2	
	TOTAL										235
1511	1	16	16	16	20	16	18	20	17	139	
	2	12	12	12	18	17	13	13	9	106	
	3	0	0	0	0	9	0	0	0	9	
	4	0	0	0	0	20	0	0	0	20	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										274
1512	1	8	26	16	23	13	18	18	19	141	
	2	4	9	12	9	9	18	17	22	100	
	3	5	20	14	13	4	7	9	12	84	
	4	3	5	5	3	11	10	11	12	60	
	5	2	8	2	4	17	4	4	11	52	
	6	0	5	0	0	9	2	2	1	19	
	TOTAL										456

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 13
GROUP 1 AIR CONTROL

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
1513	1	6	6	7	6	2	10	16	10	63	
	2	2	5	2	1	8	8	20	2	48	
	3	2	11	6	7	8	19	14	8	75	
	4	4	2	4	3	8	9	32	1	63	
	5	0	0	0	0	0	0	2	0	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										251
1514	1	17	13	16	15	14	10	21	24	130	
	2	11	7	9	8	9	16	24	20	104	
	3	5	8	6	9	17	8	10	14	77	
	4	5	12	11	2	7	4	4	3	48	
	5	7	3	4	6	24	1	1	4	50	
	6	16	5	0	0	1	2	5	5	34	
	TOTAL										443
1515	1	4	13	17	11	10	13	16	24	108	
	2	4	4	4	2	0	7	8	10	39	
	3	0	2	3	3	0	2	2	2	14	
	4	0	2	10	0	1	0	0	8	21	
	5	0	0	0	0	5	2	3	0	10	
	6	0	0	0	0	0	0	0	1	1	
	TOTAL										193

APPENDIX NO.6

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2501	1	6	16	17	29	6	26	19	18	137	
	2	6	16	39	21	6	6	14	15	123	
	3	4	8	13	16	5	6	11	5	68	
	4	0	0	2	0	0	0	0	0	2	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										330
2502	1	17	19	21	26	17	26	39	33	198	
	2	31	9	2	11	12	37	25	12	139	
	3	40	9	11	11	12	6	11	11	111	
	4	28	2	6	10	24	10	19	5	104	
	5	12	2	0	3	28	1	0	3	49	
	6	32	7	3	6	5	6	9	9	77	
	TOTAL										678
2503	1	18	19	21	23	14	25	18	25	163	
	2	12	9	9	6	37	2	4	3	82	
	3	5	4	2	3	15	7	0	7	43	
	4	0	0	0	0	5	0	0	0	5	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										293
2504	1	13	27	21	34	19	27	23	23	187	
	2	6	27	11	22	15	15	17	20	133	
	3	7	18	5	4	19	5	14	6	78	
	4	0	0	0	0	14	0	0	0	14	
	5	0	0	0	0	5	0	0	0	5	
	6	1	6	10	8	5	7	6	8	51	
	TOTAL										468

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2505	1	12	20	13	16	21	11	19	13	125	
	2	18	9	13	16	16	11	16	9	108	
	3	0	0	0	1	28	1	1	5	36	
	4	0	0	0	0	10	0	0	0	10	
	5	0	0	0	0	6	0	0	0	6	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										285
2506	1	8	36	26	23	18	23	15	18	167	
	2	15	20	20	18	14	13	22	7	129	
	3	9	6	3	1	2	16	7	6	50	
	4	6	3	3	1	0	11	1	2	27	
	5	3	4	6	5	3	10	3	0	34	
	6	3	3	7	3	0	5	4	1	26	
	TOTAL										433
2507	1	12	23	18	18	26	31	29	26	183	
	2	8	7	7	6	10	4	14	17	73	
	3	1	7	9	9	15	10	8	5	64	
	4	0	0	0	0	7	0	0	0	7	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	7	0	0	0	7	
	TOTAL										334
2508	1	13	17	12	11	11	19	16	15	114	
	2	15	16	5	5	8	7	3	5	64	
	3	15	4	2	1	4	3	5	2	36	
	4	7	11	0	2	7	3	2	7	39	
	5	2	4	0	0	0	1	0	0	7	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										260

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS

FEMALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2509	1	17	23	23	19	17	23	20	17	159	
	2	17	14	7	8	16	16	10	22	110	
	3	13	14	4	2	5	1	3	15	57	
	4	1	3	2	1	3	5	7	8	30	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	1	1	
	TOTAL										357
2510	1	23	13	22	27	14	22	26	25	172	
	2	8	7	6	17	30	9	4	8	89	
	3	0	0	0	0	6	0	0	0	6	
	4	10	4	6	11	12	7	10	4	64	
	5	0	0	0	0	25	0	0	0	25	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										356
2511	1	5	26	26	21	6	24	13	32	153	
	2	5	11	11	10	3	11	12	17	80	
	3	1	0	0	2	1	3	0	0	7	
	4	0	2	1	0	0	1	3	1	8	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										248
2512	1	7	44	29	28	13	18	27	22	188	
	2	0	5	6	5	0	7	5	6	34	
	3	0	0	2	0	0	0	0	0	2	
	4	4	7	10	14	2	6	14	11	68	
	5	0	0	2	0	0	0	0	0	2	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										294

APPENDIX NO.6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 2 CERIC OXIDE LOW DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
2513	1	11	30	33	18	9	11	14	21	147	
	2	10	12	16	13	17	10	14	9	101	
	3	5	5	14	6	8	7	8	4	57	
	4	2	0	0	0	37	0	0	0	39	
	5	0	0	0	0	5	2	2	0	9	
	6	2	2	2	1	5	1	0	1	14	
	TOTAL										367
2514	1	15	23	24	23	15	21	21	18	160	
	2	15	16	14	16	47	18	18	25	169	
	3	12	16	12	6	36	4	8	17	111	
	4	10	11	11	6	55	4	6	16	119	
	5	7	11	10	12	16	5	11	16	88	
	6	9	10	12	11	31	10	9	13	105	
	TOTAL										752
2515	1	9	19	23	16	19	20	26	18	150	
	2	2	12	7	9	1	6	6	10	53	
	3	2	16	12	12	5	20	21	25	113	
	4	2	4	4	9	0	7	7	9	42	
	5	0	6	3	6	0	1	2	7	25	
	6	2	8	3	3	2	6	10	3	37	
	TOTAL										420

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3501	1	8	18	18	18	10	14	24	15	125	
	2	9	4	4	6	4	7	11	6	51	
	3	2	9	3	5	10	14	8	9	60	
	4	0	5	5	2	3	5	7	5	32	
	5	5	5	2	2	3	2	8	4	31	
	6	0	1	2	1	0	3	2	4	13	
	TOTAL										312
3502	1	14	31	23	34	11	15	22	25	175	
	2	24	22	17	8	8	13	14	11	117	
	3	2	13	4	15	13	5	2	0	54	
	4	1	1	3	2	4	5	2	7	25	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										371
3503	1	8	22	18	16	10	28	16	22	140	
	2	6	15	12	14	1	14	9	11	82	
	3	2	10	7	7	1	7	5	11	50	
	4	5	15	4	5	2	8	7	8	54	
	5	3	5	1	4	1	8	7	4	33	
	6	0	0	0	0	0	2	0	0	2	
	TOTAL										361
3504	1	12	20	18	16	13	31	31	19	160	
	2	13	16	14	16	19	17	17	15	127	
	3	7	8	7	11	28	13	20	12	106	
	4	2	2	9	3	14	4	5	2	41	
	5	19	1	4	7	1	2	19	1	54	
	6	23	9	2	3	0	4	3	8	52	
	TOTAL										540

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3505	1	8	19	20	12	10	16	15	18	118	
	2	7	18	4	6	8	9	6	5	63	
	3	0	7	0	0	0	0	0	0	7	
	4	0	1	0	0	1	1	3	1	7	
	5	0	0	5	2	0	0	0	0	7	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										202
3506	1	15	21	21	26	18	27	28	33	189	
	2	2	5	10	13	1	9	12	17	69	
	3	0	3	10	8	3	8	20	5	57	
	4	5	0	2	2	0	0	0	1	10	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										325
3507	1	13	21	20	16	14	15	27	17	143	
	2	1	18	11	4	17	6	9	11	77	
	3	1	7	0	0	41	2	3	5	59	
	4	0	5	4	3	14	8	3	3	40	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	2	0	0	0	2	
	TOTAL										321
3508	1	10	13	15	12	24	9	7	10	100	
	2	7	5	2	5	15	4	6	25	69	
	3	4	2	1	1	14	1	2	1	26	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	9	9	4	3	14	6	5	5	55	
	TOTAL										250

APPENDIX NO. 6

PROJECT NO.:90831

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3509	1	11	26	20	21	7	26	28	23	162	
	2	6	13	8	9	4	19	28	11	98	
	3	1	4	3	4	0	4	2	7	25	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	1	3	4	8	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										293
3510	1	9	35	20	25	15	17	24	24	169	
	2	10	19	8	14	11	13	19	14	108	
	3	9	10	8	7	27	19	17	14	111	
	4	3	24	7	12	6	8	8	11	79	
	5	1	1	0	2	1	1	1	7	14	
	6	3	9	9	6	10	6	5	25	73	
	TOTAL										554
3511	1	15	27	11	16	23	26	19	18	155	
	2	13	12	12	18	28	13	11	13	120	
	3	8	13	7	10	34	7	12	2	93	
	4	7	6	4	14	20	11	9	13	84	
	5	4	7	1	2	9	4	3	4	34	
	6	3	5	8	6	31	7	12	3	75	
	TOTAL										561
3513	1	14	13	23	23	19	12	14	15	133	
	2	7	7	5	9	20	9	12	18	87	
	3	5	3	6	2	19	4	2	3	44	
	4	0	1	2	2	12	0	0	0	17	
	5	0	0	0	0	5	0	0	0	5	
	6	2	1	2	3	4	2	0	1	15	
	TOTAL										301

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 3 CERIC OXIDE INTERMEDIATE DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
3514	1	17	19	27	22	12	29	24	27	177	
	2	6	35	18	24	8	15	8	21	135	
	3	4	23	9	9	4	11	14	11	85	
	4	3	7	3	9	2	5	13	9	51	
	5	0	16	12	6	13	4	4	3	58	
	6	1	11	8	13	0	9	5	12	59	
	TOTAL										565
3516	1	12	22	19	20	16	30	23	29	171	
	2	7	29	14	12	5	24	15	17	123	
	3	0	3	2	1	0	4	0	0	10	
	4	0	0	0	0	0	0	0	0	0	
	5	0	6	2	2	1	10	4	5	30	
	6	3	4	1	2	0	20	2	4	36	
	TOTAL										370
3517	1	16	24	16	16	15	23	19	31	160	
	2	7	19	13	15	8	18	15	18	113	
	3	0	3	0	0	0	4	2	2	11	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	2	20	7	5	2	8	6	8	58	
	TOTAL										342

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4501	1	8	18	17	10	15	31	18	23	140	
	2	2	11	12	14	4	12	15	17	87	
	3	3	4	4	8	6	7	7	11	50	
	4	6	19	15	16	16	9	9	8	98	
	5	6	15	8	14	7	9	3	3	65	
	6	9	6	5	4	9	5	5	11	54	
	TOTAL										494
4502	1	13	27	12	18	20	15	14	20	139	
	2	7	8	4	23	16	13	2	14	87	
	3	14	6	5	9	43	19	5	5	106	
	4	2	6	4	3	18	21	5	5	64	
	5	7	5	6	4	24	5	4	5	60	
	6	1	2	0	1	13	4	2	4	27	
	TOTAL										483
4503	1	12	42	22	21	6	28	27	34	192	
	2	10	17	27	7	3	16	13	18	111	
	3	0	18	14	7	0	10	9	9	67	
	4	0	11	3	2	0	1	6	4	27	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										397
4504	1	20	29	40	27	20	20	31	35	222	
	2	11	12	30	11	14	16	23	11	128	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	1	0	0	0	0	0	1	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										351

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4505	1	27	25	29	29	13	18	24	22	187	
	2	35	22	8	6	16	10	10	14	121	
	3	45	16	14	10	6	14	8	9	122	
	4	45	13	12	11	10	5	16	3	115	
	5	60	4	5	3	6	5	3	6	92	
	6	39	5	13	7	6	2	7	7	86	
	TOTAL										723
4506	1	8	29	17	24	11	32	36	26	183	
	2	23	21	16	17	11	9	14	24	135	
	3	30	18	10	14	8	12	10	20	122	
	4	27	14	5	8	6	13	7	8	88	
	5	2	6	16	4	20	6	5	5	64	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										592
4507	1	10	17	15	12	12	18	20	24	128	
	2	17	14	7	3	16	4	4	6	71	
	3	1	0	0	1	1	2	2	2	9	
	4	18	2	0	0	0	0	0	0	20	
	5	2	0	0	0	0	0	0	0	2	
	6	12	0	0	0	3	0	0	0	15	
	TOTAL										245
4508	1	17	31	25	27	10	28	18	24	180	
	2	6	16	16	20	4	15	20	15	112	
	3	4	5	3	2	0	0	6	12	32	
	4	0	0	0	0	0	0	0	0	0	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										324

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4509	1	14	27	27	41	11	42	25	34	221	
	2	3	16	12	14	7	15	22	19	108	
	3	0	0	0	0	0	0	0	0	0	
	4	0	0	0	0	0	0	0	0	0	
	5	1	3	7	5	1	5	6	5	33	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										362
4510	1	10	28	38	31	20	25	24	26	202	
	2	7	21	25	19	14	18	17	15	136	
	3	2	9	13	8	24	14	10	15	95	
	4	0	0	0	0	3	0	0	0	3	
	5	0	0	0	0	21	0	0	0	21	
	6	1	2	2	2	35	10	11	11	74	
	TOTAL										531
4511	1	9	15	26	11	6	10	28	20	125	
	2	1	20	14	5	0	3	3	8	54	
	3	0	2	14	2	1	3	12	3	37	
	4	1	2	7	2	0	6	8	1	27	
	5	0	0	0	0	0	0	0	0	0	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										243
4513	1	7	12	15	16	14	18	20	13	115	
	2	3	12	15	15	5	14	24	18	106	
	3	3	6	10	2	5	8	14	9	57	
	4	0	5	2	1	1	5	2	1	17	
	5	0	1	0	0	0	0	0	2	3	
	6	0	0	0	0	0	0	0	0	0	
	TOTAL										298

APPENDIX NO. 6

INDIVIDUAL
MOTOR ACTIVITY COUNTS
FEMALES
WEEK 13
GROUP 4 CERIC OXIDE HIGH DOSE

PROJECT NO.:90831

NO. OF BREAKS PER BEAM

ANIMAL NO.	INTERVAL	BEAM NO. 1	2	3	4	5	6	7	8	INTERVAL TOTAL	SESSION TOTAL
4514	1	9	24	16	23	16	17	19	32	156	
	2	18	19	11	15	16	5	8	26	118	
	3	7	8	10	11	15	6	14	16	87	
	4	5	11	8	10	26	3	8	6	77	
	5	6	8	13	10	15	3	0	9	64	
	6	11	3	2	2	10	4	9	30	71	
	TOTAL										573
4515	1	6	20	22	16	9	12	18	30	133	
	2	2	22	11	7	7	16	13	20	98	
	3	4	14	10	11	3	22	7	4	75	
	4	0	13	7	2	9	11	9	3	54	
	5	0	0	0	0	5	0	0	0	5	
	6	0	0	0	0	1	0	0	0	1	
	TOTAL										366
4516	1	10	16	14	16	17	16	21	22	132	
	2	22	10	14	7	9	12	12	18	104	
	3	8	0	0	0	0	1	5	4	18	
	4	1	0	0	0	1	1	15	1	19	
	5	0	0	0	0	0	0	0	0	0	
	6	2	1	2	2	4	3	5	4	23	
	TOTAL										296

APPENDIX NO. 7 METHODS, SYMBOLS AND UNITS USED IN LABORATORY INVESTIGATIONS PROJECT NO. 90831

1. HEMATOLOGY LABORATORY

Red Blood Cell Count RBC

Coulter S-Plus-IV. Electrical resistance.
Unit: x $10^6/mm^3$.
Reference: Coulter operating manual, Oct. 1983.

Hemoglobin Hb

Coulter S-Plus-IV. Photometric method.
Unit: g/dL.
Reference: Coulter Operating Manual, Nov. 1983.

Hematocrit Ht

Coulter S-Plus-IV. Calculated.
Unit: %.
Reference: Coulter operating manual, Nov. 1983.

Erythrocyte Indices

Coulter S-Plus-IV. Calculated.
Reference: Coulter operating manual, Oct. 1983 and Nov. 1983.

Mean Corpuscular Volume MCV Unit: um^3.

Mean Corpuscular Hemoglobin MCH Unit: pg.

Mean Corpuscular Hemoglobin Concentration MCHC Unit: g/dL.

Red Cell Size Distribution Width RDW Unit: %.

Platelet Count PLT

Coulter S-Plus-IV. Electrical resistance.
Unit: x $10^3/mm^3$.
Reference: Coulter operating manual, Oct. 1983.

Mean Platelet Volume MPV

Unit: um^3.

White Blood Cell Count WBC

Coulter S-Plus-IV. Electrical resistance.
Unit: x $10^3/mm^3$.
Reference: Coulter operating manual, Oct. 1983.

1. HEMATOLOGY LABORATORY (CONT'D)

WBC Differential Stain

Hematek II automatic slide stainer. Modified Wright's stain.
Reference: Ames Hematek II stainer operating manual, 1978.

WBC Differential Count

Microscopic enumeration (100 white cells).
Unit: % OR Number (n/mm^3) (absolute value)
References: Blood morphology of lab. animal, S. Schermer, 1967.
Veterinary Hematology, 4th edition. Schalm 1986.

WBC Differential Reported as Number or %

Segmented Neutrophils NEUT SEG
Band NEUT NSEG
Lymphocytes LYMPH
Monocytes MONO
Eosinophils EOSIN
Basophils BASO

Immature cells IMMC

- Atypical Lymphocyte ALYMP
- Metamyelocyte MMYEL
- Myelocyte MYEL
- Promyelocyte PMYEL
- Blast BLAST
- Promonocyte PMONO
- Plasma Cell PCELL
- Band Eosinophils BEOS

OTHERS - Reported as Number But Not Included in WBC Differential

Nucleated Red Blood Cells NRBC
Proerythroblast PROER
Basophilic Erythroblast BASER
Polychromatic Erythroblast POLER
Orthochromatic Erythroblast ORTER

1. HEMATOLOGY LABORATORY (CONT'D)

Cell Morphology

Microscopic examination. Evaluated simultaneously with the WBC differential count.

The following observations are reported as:

1+ (slight), 2+ (moderate), 3+ (moderate to marked) or 4+ (marked).

Polychromasia POLY
Crenation CREN
Anisocytosis ANIS
Hypochromia HYPO
Hyperchromia HYPR
Microcytosis MICR
Macrocytosis MACR
Poikilocytosis POIK
Rouleau Formation ROUL
Agglutination AGGL
Acanthocyte (spur cell) ACAN
Codocyte (target cell) CODO
Dacryocyte (tear cell) DACR

Drepanocyte (sickle cell) DREP
Elliptocyte (ovalocyte) ELLP
Keratocyte (horn cell) KERA
Leptocyte (thin cell) LEPT
Schizocyte (helmet cell) SCHZ
Spherostomatocyte (spherocyte) SPHR
Stomatocyte (mouth cell) STOM
Cabot Rings CABT
Howell Jolly Bodies HJB
Basophilic Stippling BSTIP

Hypersegmentation HYSG
Toxic Granulations TOXG
Vacuoles VAC
Döhle Bodies DOHL

Azurophilic Granulations AZUR
Giant Neutrophils GNEU
Pelger Huet Anomaly PHA

References:

- Morphology of canine and feline blood cells, Rich, 1976.
- Atlas of cell morphology, Barbara, 1984.
- Blood morphology, S. Schermer, 1967.
- Vet. Hematology, Schalm's, 1986.

Reported as Presence of

Heinz Bodies HEINZB
Plasmodium (Trophozoite Stage) PLST
Plasmodium (Schizont Stage) PLSS
Megakaryocytes MEGA
Giant Platelet GPLT
Degenerated Cell DGENC

1. HEMATOLOGY LABORATORY (CONT'D)

Megakaryocyte MEGAK
Kurloff Cell KURL
Monocyte with Erythrophagocytosis EPHAG
Cellular Anaplasia CANAP

Prothrombin Time PT

MLA Electra 750. Photometric method of endpoint detection.
Unit: seconds.
Reference: MLA operator's manual, 1977.

Bone Marrow Stain

Manual. May-Grünwald-Giemsa stain.
or Hematek II stainer. Modified Wright's stain.
References: Medical lab. Tech-Lynch, 1967, page 644. Ames Hematek II stainer operating manual, 1978.

2. CLINICAL CHEMISTRY LABORATORY

Alanine Aminotransferase/ALT: Adapted for H-717.
Units: U/L. IFCC/SFBC method.
Reference: BMC, package insert, Hico ALT, Dec. 1987.

Aspartate Aminotransferase/AST/GOT: Adapted for H-717.
Units: U/L. IFCC/SFBC method.
Reference: BMC, package insert, Hico AST, Dec. 1987.

Albumin/ALB: Adapted for H-717.
Units: g/dL. Bromcresol-green method.
Reference; BMC, package insert, Albumin, Nov. 1987.

Albumin/globulin or A/G Ratio: Calculated.

Alkaline Phosphatase/ALP: Adapted for H-717.
Units: U/L. PNPP - AMP buffer method.
Reference: BMC, package insert, Alkaline Phosphatase, AMP Buffer, Oct. 1988.

Alkaline Phosphatase isoenzymes: Electrophoresis.
Units: % and U/L
Reference: Beckman Isopal, package insert, February 1991.

Calcium/CA: Adapted for H-717.
Units: mg/dL.
Ca-cresolphthalein complexone.
Reference: BMC, package insert, Calcium Gaba, 1989.

Cholesterol/CHOL: Adapted for H-717.
Units: mg/dL. CHOD-PAP enzymatic colorimetric method.
Reference: BMC, package insert, Cholesterol Chod - PAP method, June 1987.

Creatinine/CREAT (Serum): Adapted for H-717.
Units: mg/dL. Jaffe kinetic method.
Reference: BMC, package insert, Hico creatinine, Dec. 1987.

Globulin/Cl/GLOB: Calculated. Total serum protein - serum albumin = serum globulin.
Units: g/dL.

Glucose/GLU: Adapted for H-717.
Units: mg/dL. Hexokinase method.
Reference: BMC, package insert, Gluco - Quant Glucose, March 1988.

Phosphorus/PHOS (serum or urine): Adapted for H-717.
Units: mg/dL. Phosphomolybdate complex measured at 340 nm.
Reference: BMC, package insert, Inorganic Phosphorous, Oct. 1987.

2. CLINICAL CHEMISTRY LABORATORY (CONT'D)

Sodium/Na, Potassium/K, Chloride/Cl: (Serum) Ion selective electrode module of H-717. Indirect measurement.
Units: mEq/L.
Reference: Operator's manual, March 1988.

Total Bilirubin/T. BIL: Adapted for H-717.
Units: mg/dL. DPD method.
Reference: BMC, package insert, Hico Bilirubin, Aug. 1988.

Total Protein/TP: Adapted for H-717.
Units: g/dL. Biuret method.
Reference: BMC package insert, Hico Total protein, Dec. 1987.

Triglycerides/TRIG: Adapted for H-717.
Units: mg/dL. GPO-PAP
enzymatic colorimetric method.
Reference: BMC, package insert, Triglycerides GPO-PAP, Dec. 1987.

Urea Nitrogen/BUN: Adapted for H-717. Urease method. Results reported as mg/dL of blood urea nitrogen.
Reference: BMC, package insert, Urea, Dec. 1987.

3. URINALYSIS

3.1 Test for pH, Protein, Glucose, Bilirubin, Ketone, Blood, Nitrite, Urobilinogen and Specific Gravity in Urine

N-Multistix S.G. reagent strip system using CLINITEK 200 Urine Chemistry Analyzer. Reflectance spectrophotometer. References: Clinitek operating manual, 1985. Ames, package insert, Ames reagent strips, AD0021.

Test values measured and reported (S.I. Units)

Protein PROT

Reported as:
- negative (-)
- trace (±) (0.15 g/L approximate)
- 0.3 g/L
- 1.0 g/L
- ≥ 3.0 g/L

Glucose GLU

Reported as:
- negative (-)
- 5.5 mmol/L
- 14.0 mmol/L
- 28.0 mmol/L
- ≥ 55.0 mmol/L

Ketone KET

Reported as:
- negative (-)
- trace (±) (0.5 mmol/L approximate)
- 1.5 mmol/L
- 3.9 mmol/L
- 7.8 mmol/L

Bilirubin BIL

Reported as:
- negative (-)
- trace (±)
- small (+)
- moderate (++)
- large (+++)

Blood

Reported as:
- negative (-)
- trace (±)
- small (+)
- moderate (++)
- large (+++)

3. URINALYSIS (CONT'D)

pH

Reported as: 5.0
5.5
6.0
6.5
7.0
7.5
8.0
8.5
≥ 9.0

Nitrite NIT

Reported as: negative (-)
positive (+)

Urobilinogen UBG

Reported as: 3.2 umol/L
16.0 umol/L
33.0 umol/L
66.0 umol/L
131.0 umol/L

Specific Gravity

Reported as: ≤ 1.005*
1.010
1.015
1.020
1.025
≥ 1.030*

3.2 Urinalysis - Gross Analysis (Manual, Visual Method)

Color

Y = Yellow
Br = Brown
Gr = Green
R = Red
A = Amber

Lt = Light
D = Dark
Co = Colorless

Volume

Manual. Unit: mL.

---

* ≤ 1.005 or ≥ 1.030 will be determined by using the Refractometer.

3. URINALYSIS (CONT'D)

Appearance APPEAR

C = Clear
Cl = Cloudy
T = Turbid

3.3 Urinalysis - Sediment Microscopy (Microscopic Examination)

3.3.1 Organized Sediments - Cells

White Blood Cell WBC

Reported in number/HPF (high power field).

Red Blood Cell RBC

Reported in number/HPF (high power field).

Epithelial Cell EPC

Reported in number/HPF (high power field)

3.3.2 Organized Sediments - Mucous

Reported as:	negative	(-)/High power field (HPF)
	slight or few	(+)
	moderate	(++)
	large	(+++)
	very large	(++++)

3.3.3 Organized Sediments - Bacteria

Reported as:	negative	(-)/High power field (HPF)
	slight or few	(+)
	moderate	(++)
	large	(+++)
	very large	(++++)

3.3.4 Organized Sediments - Misc.

Reported as:	negative	(-)/High power field (HPF)
	slight or few	(+) (1-10/HPF)
	moderate	(++) (11-30/HPF)
	large	(+++) (31-50/HPF)
	very large	(++++) (+51/HPF)

S = Spermatozoa
Y = Yeast
Pr = Protozoa
PO = Parasite Ova

3. URINALYSIS (CONT'D)

The following are reported as presence:

P = Pus

The following are reported in number (high power field):

Tr = Trichomonas
FB = Fat Bodies

Casts - The following are reported in number/LPF (low power field)

H:	Hyaline	Er:	Erythrocyte
G:	Granular	Wa:	Waxy
Ep:	Epithelial	Fa:	Fatty
L:	Leukocyte	Ce:	Cellular

3.3.5 Unorganized Sediments - Crystals

Reported as:	negative	(-)/High power field (HPF)
	slight or few	(+) (1-10/HPF)
	moderate	(++) (11-30/HPF)
	large	(+++) (31-50/HPF)
	very large	(++++) (+51/HPF)

Phosphate PHOS

TP = Triple phosphate
AP = Amorphous phosphate

Urate

AU = Amorphous urate
AmU = Ammonium urate

Oxalate

CO = Calcium oxalate

Other Crystals

CC = Calcium carbonate
CS = Calcium sulphate
TC = Tyrosine crystal
HA = Hippuric acid
LC = Leucine crystal
BC = Bilirubin crystal
CyC = Cystine crystal

Uric Acid

UA = Uric acid

3. URINALYSIS (CONT'D)

Unidentified Crystals

1C = Irregular crystals
2C = Rectangular crystals
3C = Irregular crystals covered with spicules
4C = Rosette and needle-like crystals
5C = Sharp needles polarizing crystals

APPENDIX NO. 8 PROJECT NO. 90831

INDIVIDUAL HEMOGRAMS
MALES AND FEMALES

The following footnotes have been used throughout the appendix:

Ct	Clotted
Ns	No sample
NSQ	Not sufficient quantity

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - MALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 5 - HEALTH SCREEN	5001	5.5	18.0	0.0	80.0	1.0	1.0	0.0
	5002	7.4	20.0	0.0	80.0	0.0	0.0	0.0
	5003	3.2	18.0	0.0	80.0	2.0	0.0	0.0
	5004	5.2	18.0	0.0	81.0	0.0	1.0	0.0
	5005	8.9	7.0	0.0	92.0	0.0	1.0	0.0
	5006	6.0	14.0	0.0	82.0	2.0	2.0	0.0
	5007	3.7	18.0	0.0	81.0	0.0	1.0	0.0
	5008	4.6	33.0	0.0	66.0	1.0	0.0	0.0
	5009	4.9	13.0	0.0	86.0	1.0	0.0	0.0
	5010	8.1	13.0	0.0	86.0	1.0	0.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

HEALTH SCREEN - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 5 - HEALTH SCREEN	5001	990.0	0.0	4400.0	55.0	55.0	0.0
	5002	1480.0	0.0	5920.0	0.0	0.0	0.0
	5003	576.0	0.0	2560.0	64.0	0.0	0.0
	5004	936.0	0.0	4212.0	0.0	52.0	0.0
	5005	623.0	0.0	8188.0	0.0	89.0	0.0
	5006	840.0	0.0	4920.0	120.0	120.0	0.0
	5007	666.0	0.0	2997.0	0.0	37.0	0.0
	5008	1518.0	0.0	3036.0	46.0	0.0	0.0
	5009	637.0	0.0	4214.0	49.0	0.0	0.0
	5010	1053.0	0.0	6966.0	81.0	0.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

HEALTH SCREEN - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 5 - HEALTH SCREEN	5001	6.31	12.5	37.0	58.7	19.8	33.7	12.8
	5002	5.86	12.2	35.8	61.1	20.8	34.1	13.5
	5003	6.03	12.5	36.8	61.0	20.7	34.0	12.9
	5004	6.28	12.9	37.7	60.1	20.5	34.2	13.2
	5005	6.12	12.8	37.7	61.6	20.9	34.0	14.2
	5006	5.72	12.1	35.5	62.0	21.2	34.1	13.2
	5007	6.53	13.3	37.4	57.3	20.4	35.5	12.5
	5008	6.22	13.1	37.3	60.0	21.1	35.1	14.2
	5009	6.06	13.0	36.2	59.8	21.5	35.9	14.5
	5010	6.10	13.0	37.6	61.6	21.3	34.6	13.1

HEALTH SCREEN - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 5 - HEALTH SCREEN	5001	1037.0	8.5	13.9
	5002	1059.0	8.5	14.0
	5003	1031.0	7.9	13.5
	5004	1130.0	8.5	14.3
	5005	885.0	8.2	14.6
	5006	942.0	8.8	14.2
	5007	925.0	8.0	14.1
	5008	891.0	8.2	14.2
	5009	930.0	8.9	13.6
	5010	866.0	7.7	14.7

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
HEALTH SCREEN
MALES

PROJECT NO. 90831

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
5001	-	1+	-	-	-	-	-	-	-
5002	-	1+	-	1+	-	-	-	-	-
5003	-	1+	-	1+	-	-	-	-	-
5004	-	1+	-	1+	-	-	-	-	-
5005	-	1+	-	-	-	-	-	-	-
5006	-	1+	-	1+	-	-	-	-	-
5007	1+	1+	-	-	-	-	-	-	-
5008	1+	1+	-	-	-	-	-	-	-
5009	-	2+	-	1+	-	-	-	-	-
5010	1+	1+	-	-	-	-	-	-	-

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 5 - HEALTH SCREEN	5501	4.0	11.0	0.0	89.0	0.0	0.0	0.0
	5502	4.2	5.0	0.0	95.0	0.0	0.0	0.0
	5503	4.5	6.0	0.0	94.0	0.0	0.0	0.0
	5504	3.6	5.0	0.0	94.0	0.0	1.0	0.0
	5505	4.4	3.0	0.0	97.0	0.0	0.0	0.0
	5506	6.7	4.0	0.0	96.0	0.0	0.0	0.0
	5507	3.9	5.0	0.0	95.0	0.0	0.0	0.0
	5508	9.8	3.0	0.0	94.0	3.0	0.0	0.0
	5509	3.6	3.0	0.0	96.0	0.0	1.0	0.0
	5510	3.6	8.0	0.0	92.0	0.0	0.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 5 - HEALTH SCREEN	5501	440.0	0.0	3560.0	0.0	0.0	0.0
	5502	210.0	0.0	3990.0	0.0	0.0	0.0
	5503	270.0	0.0	4230.0	0.0	0.0	0.0
	5504	180.0	0.0	3384.0	0.0	36.0	0.0
	5505	132.0	0.0	4268.0	0.0	0.0	0.0
	5506	268.0	0.0	6432.0	0.0	0.0	0.0
	5507	195.0	0.0	3705.0	0.0	0.0	0.0
	5508	294.0	0.0	9212.0	294.0	0.0	0.0
	5509	108.0	0.0	3456.0	0.0	36.0	0.0
	5510	288.0	0.0	3312.0	0.0	0.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 5 - HEALTH SCREEN	5501	4.77	10.7	30.1	63.2	22.4	35.5	15.0
	5502	5.63	11.3	33.0	58.6	20.1	34.3	16.1
	5503	5.28	11.0	31.8	60.3	20.8	34.5	17.1
	5504	5.55	11.5	33.4	60.2	20.7	34.4	16.2
	5505	5.22	11.7	34.0	65.2	22.4	34.4	17.3
	5506	5.19	11.8	33.8	65.2	22.7	34.9	13.7
	5507	4.88	11.3	32.2	65.9	23.2	35.1	13.3
	5508	5.28	11.7	34.3	65.0	22.2	34.1	16.1
	5509	5.63	12.2	35.1	62.4	21.7	34.7	15.7
	5510	5.39	11.8	34.4	63.9	21.9	34.3	15.6

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 5 - HEALTH SCREEN	5501	1186.0	7.8	13.7
	5502	865.0	8.3	14.1
	5503	976.0	8.3	12.9
	5504	1134.0	8.4	14.3
	5505	925.0	8.7	13.4
	5506	1038.0	8.6	15.3
	5507	1011.0	8.1	14.4
	5508	1042.0	8.6	12.4
	5509	1033.0	8.9	13.9
	5510	916.0	8.7	13.8

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
HEALTH SCREEN
FEMALES

PROJECT NO. 90831

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
5501	1+	1+	-	1+	-	-	-	-	-
5502	-	2+	-	1+	-	-	-	-	-
5503	1+	2+	-	-	-	-	-	-	-
5504	-	2+	-	1+	-	-	-	-	-
5505	1+	2+	-	-	-	-	-	-	-
5506	1+	2+	-	-	-	-	-	-	-
5507	1+	2+	-	-	-	-	-	-	-
5508	1+	2+	-	-	-	-	-	-	-
5509	-	2+	-	-	-	-	-	-	NRBC 2
5510	-	2+	-	1+	-	-	-	-	-

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - MALES

			WBC DIFFERENTIAL COUNT					
	ANIMAL NO.	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	1001	8.1	10.0	0.0	90.0	0.0	0.0	0.0
	1002	11.2	10.0	0.0	88.0	2.0	0.0	0.0
	1005	13.7	11.0	0.0	85.0	3.0	1.0	0.0
	1006	10.1	7.0	0.0	92.0	1.0	0.0	0.0
	1007	17.4	4.0	0.0	93.0	3.0	0.0	0.0
	1008	10.8	7.0	0.0	92.0	1.0	0.0	0.0
	1009	12.3	8.0	0.0	89.0	2.0	1.0	0.0
	1010	21.3	34.0	0.0	63.0	3.0	0.0	0.0
	1011	9.2	8.0	0.0	87.0	4.0	1.0	0.0
	1012	9.2	9.0	0.0	87.0	3.0	1.0	0.0
	1013	12.2	9.0	0.0	87.0	4.0	0.0	0.0
	1014	7.2	10.0	0.0	87.0	3.0	0.0	0.0
	1015	10.5	5.0	0.0	90.0	3.0	2.0	0.0
	1016	11.9	19.0	0.0	80.0	1.0	0.0	0.0
	1017	14.7	18.0	0.0	71.0	3.0	8.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	LYMPH	MONO	EOSIN	BASO
		WBC DIFFERENTIAL COUNT (ABSOLUTE)					
GROUP 1 - AIR CONTROL	1001	810.0	0.0	7290.0	0.0	0.0	0.0
	1002	1120.0	0.0	9856.0	224.0	0.0	0.0
	1005	1507.0	0.0	11645.0	411.0	137.0	0.0
	1006	707.0	0.0	9292.0	101.0	0.0	0.0
	1007	696.0	0.0	16182.0	522.0	0.0	0.0
	1008	756.0	0.0	9936.0	108.0	0.0	0.0
	1009	984.0	0.0	10947.0	246.0	123.0	0.0
	1010	7242.0	0.0	13419.0	639.0	0.0	0.0
	1011	736.0	0.0	8004.0	368.0	92.0	0.0
	1012	828.0	0.0	8004.0	276.0	92.0	0.0
	1013	1098.0	0.0	10614.0	488.0	0.0	0.0
	1014	720.0	0.0	6264.0	216.0	0.0	0.0
	1015	525.0	0.0	9450.0	315.0	210.0	0.0
	1016	2261.0	0.0	9520.0	119.0	0.0	0.0
	1017	2646.0	0.0	10437.0	441.0	1176.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	1001	8.55	16.1	47.0	55.0	18.8	34.2	12.1
	1002	7.90	15.4	42.5	53.8	19.5	36.2	11.9
	1005	7.62	16.0	43.0	56.4	21.0	37.2	12.2
	1006	7.91	15.7	42.0	53.1	19.8	37.4	13.1
	1007	7.92	15.8	43.8	55.3	19.9	36.1	12.2
	1008	5.48	15.4	29.3	53.4	28.1	52.6	11.8
	1009	7.81	15.2	41.7	53.4	19.5	36.4	13.0
	1010	7.28	14.9	40.1	55.1	20.5	37.1	13.1
	1011	8.23	15.1	42.2	51.3	18.3	35.8	12.0
	1012	7.77	15.6	43.2	55.6	20.1	36.1	13.2
	1013	7.72	16.3	43.8	56.7	21.1	37.2	12.6
	1014	8.64	16.2	45.2	52.3	18.8	35.9	13.0
	1015	7.48	16.1	42.8	57.2	21.5	37.6	13.2
	1016	7.94	16.2	43.4	54.6	20.4	37.4	12.8
	1017	8.11	16.4	44.1	54.4	20.2	37.2	13.1

WEEK 6 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	1001	892.0	8.4	14.0
	1002	710.0	8.4	14.4
	1005	914.0	8.6	13.5
	1006	916.0	9.1	15.5
	1007	811.0	9.0	13.8
	1008	1001.0	8.9	14.2
	1009	988.0	10.0	16.1
	1010	941.0	9.6	Ct
	1011	903.0	8.8	14.0
	1012	913.0	9.2	14.7
	1013	866.0	8.2	13.9
	1014	883.0	8.8	14.9
	1015	936.0	9.1	13.8
	1016	930.0	8.6	14.7
	1017	893.0	8.6	14.0

APPENDIX NO. 8

PROJECT NO. 90831

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
MALES

GROUP 1 - AIR CONTROL

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
1001	2+	1+	-	-	-	-	-	-	NRBC 4
1002	4+	1+	-	-	-	-	-	-	-
1005	4+	1+	-	1+	-	-	-	-	NRBC 2
1006	4+	1+	-	1+	-	-	-	-	NRBC 1
1007	3+	1+	-	-	-	-	-	-	-
1008	4+	1+	-	1+	-	-	-	-	NRBC 2
1009	4+	1+	-	1+	-	-	-	-	NRBC 1
1010	4+	1+	-	1+	-	-	-	-	-
1011	3+	1+	-	-	-	-	-	-	NRBC 1
1012	3+	1+	-	1+	-	-	-	-	-
1013	4+	1+	-	1+	-	-	-	-	-
1014	3+	1+	-	1+	-	-	-	-	-
1015	3+	1+	-	1+	-	-	-	-	-
1016	4+	2+	-	1+	-	-	-	-	NRBC 1
1017	4+	1+	-	1+	-	-	-	-	-

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 2 - CERIC OXIDE LOW DOSE	2001	16.0	14.0	0.0	83.0	2.0	1.0	0.0
	2002	16.9	6.0	0.0	92.0	2.0	0.0	0.0
	2003 Ct							
	2004 Ns							
	2005	9.3	8.0	0.0	88.0	1.0	3.0	0.0
	2006	10.7	11.0	0.0	87.0	2.0	0.0	0.0
	2007	14.6	12.0	0.0	86.0	2.0	0.0	0.0
	2008	9.4	11.0	0.0	89.0	0.0	0.0	0.0
	2009	11.7	8.0	0.0	88.0	2.0	2.0	0.0
	2010	8.8	11.0	0.0	87.0	1.0	1.0	0.0
	2011	7.8	14.0	0.0	82.0	2.0	2.0	0.0
	2012	11.0	5.0	0.0	93.0	2.0	0.0	0.0
	2013	10.7	21.0	0.0	77.0	2.0	0.0	0.0
	2015	11.2	26.0	0.0	70.0	4.0	0.0	0.0
	2016	13.7	15.0	0.0	78.0	4.0	3.0	0.0

WEEK 6 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 2 - CERIC OXIDE LOW DOSE	2001	2240.0	0.0	13280.0	320.0	160.0	0.0
	2002	1014.0	0.0	15548.0	338.0	0.0	0.0
	2003 Ct						
	2004 Ns						
	2005	744.0	0.0	8184.0	93.0	279.0	0.0
	2006	1177.0	0.0	9309.0	214.0	0.0	0.0
	2007	1752.0	0.0	12556.0	292.0	0.0	0.0
	2008	1034.0	0.0	8366.0	0.0	0.0	0.0
	2009	936.0	0.0	10296.0	234.0	234.0	0.0
	2010	968.0	0.0	7656.0	88.0	88.0	0.0
	2011	1092.0	0.0	6396.0	156.0	156.0	0.0
	2012	550.0	0.0	10230.0	220.0	0.0	0.0
	2013	2247.0	0.0	8239.0	214.0	0.0	0.0
	2015	2912.0	0.0	7840.0	448.0	0.0	0.0
	2016	2055.0	0.0	10686.0	548.0	411.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 2 - CERIC OXIDE LOW DOSE	2001	8.05	16.4	44.9	55.8	20.4	36.5	12.1
	2002	8.14	16.3	43.8	53.8	20.0	37.2	13.3
	2003Ct							
	2004Ns							
	2005	8.39	16.9	48.0	57.2	20.1	35.2	11.9
	2006	7.60	14.2	42.0	55.2	18.7	33.8	11.6
	2007	7.54	16.0	43.6	57.8	21.2	36.7	11.8
	2008	8.02	16.5	44.8	55.9	20.6	36.8	12.0
	2009	7.74	15.4	41.5	53.6	19.9	37.1	12.9
	2010	7.51	14.6	40.1	53.4	19.4	36.4	12.6
	2011	8.01	16.3	44.5	55.6	20.3	36.6	11.9
	2012	7.63	15.5	42.1	55.2	20.3	36.8	12.8
	2013	8.02	15.9	42.6	53.1	19.8	37.3	12.3
	2015	7.75	14.6	40.4	52.1	18.8	36.2	12.5
	2016	7.94	16.1	44.1	55.6	20.3	36.5	12.5

WEEK 6 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 2 - CERIC OXIDE LOW DOSE	2001	949.0	9.2	13.9
	2002	988.0	9.2	13.5
	2003Ct			12.9
	2004Ns			15.3
	2005	816.0	9.3	14.4
	2006	858.0	10.3	14.2
	2007	973.0	8.1	14.0
	2008	898.0	8.9	15.1
	2009	985.0	9.7	Ct
	2010	875.0	9.6	13.3
	2011	775.0	8.9	15.6
	2012	1187.0	8.4	14.3
	2013	896.0	8.6	14.5
	2015	917.0	9.1	13.7
	2016	756.0	9.0	Ct

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
2001	3+	1+	-	-	-	-	-	-	NRBC 3
2002	4+	1+	-	-	-	-	-	-	NRBC 1
2003 Ct									
2004 Ns									
2005	1+	1+	-	-	-	-	-	-	NRBC 6
2006	4+	1+	-	1+	-	-	-	-	-
2007	3+	1+	-	1+	-	-	-	-	NRBC 4
2008	4+	1+	-	-	-	-	-	-	NRBC 3
2009	4+	1+	-	1+	-	-	-	-	NRBC 1
2010	4+	1+	-	1+	-	-	-	-	NRBC 1
2011	3+	1+	-	1+	-	-	-	-	-
2012	3+	1+	-	1+	-	-	-	-	-
2013	3+	1+	-	-	-	-	-	-	NRBC 1
2015	3+	1+	-	1+	-	-	-	-	-
2016	3+	1+	-	-	-	-	-	-	NRBC 1

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	WBC X10 3	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	15.4	18.0	0.0	77.0	4.0	1.0	0.0
	3002 Ct							
	3003	12.2	8.0	0.0	87.0	5.0	0.0	0.0
	3004	18.3.	11.0	0.0	86.0	2.0	1.0	0.0
	3005 Ct							
	3006 Ct							
	3007 Ct							
	3008	13.0	26.0	0.0	72.0	2.0	0.0	0.0
	3009 Ct							
	3011 NSQ		18.0	0.0	80.0	1.0	1.0	0.0
	3012	14.7	21.0	0.0	73.0	6.0	0.0	0.0
	3013 Ct							
	3014	16.3	23.0	0.0	73.0	2.0	2.0	0.0
	3015	14.0	17.0	0.0	83.0	0.0	0.0	0.0
	3016	12.5	17.0	0.0	80.0	3.0	0.0	0.0

WEEK 6 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	2772.0	0.0	11858.0	616.0	154.0	0.0
	3002Ct						
	3003	976.0	0.0	10614.0	610.0	0.0	0.0
	3004	2013.0	0.0	15738.0	366.0	183.0	0.0
	3005Ct						
	3006Ct						
	3007Ct						
	3008	3380.0	0.0	9360.0	260.0	0.0	0.0
	3009Ct						
	3011NSQ						
	3012	3087.0	0.0	10731.0	882.0	0.0	0.0
	3013Ct						
	3014	3749.0	0.0	11899.0	326.0	326.0	0.0
	3015	2380.0	0.0	11620.0	0.0	0.0	0.0
	3016	2125.0	0.0	10000.0	375.0	0.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	7.97	15.7	43.0	53.9	19.7	36.5	12.0
	3002Ct							
	3003	7.54	15.8	42.8	56.7	21.0	37.0	11.7
	3004	8.21	16.3	46.2	56.3	19.9	35.3	12.4
	3005Ct							
	3006Ct							
	3007Ct							
	3008	8.12	15.6	42.3	52.1	19.2	36.9	12.4
	3009Ct							
	3011NSQ							
	3012	8.09	15.8	44.0	54.4	19.5	35.9	12.2
	3013Ct							
	3014	8.19	15.9	44.3	54.1	19.4	35.9	12.9
	3015	7.79	15.3	42.8	54.9	19.6	35.8	11.9
	3016	7.74	16.1	43.0	55.5	20.8	37.5	12.8

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	876.0	8.8	14.7
	3002 Ct			14.2
	3003	791.0	9.0	13.9
	3004	761.0	8.5	NSQ
	3005 Ct			16.1
	3006 Ct			14.0
	3007 Ct			
	3008	871.0	9.1	14.0
	3009 Ct			13.9
	3011 NSQ			
	3012	964.0	8.5	14.0
	3013 Ct			
	3014	870.0	8.8	Ct
	3015	967.0	8.7	14.9
	3016	866.0	10.5	14.8

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
3001	3+	1+	-	-	-	-	-	-	NRBC 1
3002 Ct									
3003	4+	1+	-	1+	-	-	-	-	-
3004	2+	1+	-	-	1+	1+	-	-	NRBC 1
3005 Ct									
3006Ct									
3007 Ct									
3008	3+	1+	-	1+	-	-	-	-	NRBC 1
3009 Ct									
3011	4+	1+	-	1+	-	-	-	-	NRBC 2
3012	3+	1+	-	-	-	-	-	-	-
3013 Ct									
3014	3+	1+	-	-	-	-	-	-	-
3015	3+	1+	-	-	-	-	-	-	-
3016	4+	1+	-	1+	-	-	-	-	-

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 4 - CERIC OXIDE HIGH DOSE	4001 Ct							
	4002	9.3	20.0	0.0	77.0	2.0	1.0	0.0
	4003	12.2	26.0	0.0	70.0	4.0	0.0	0.0
	4004 Ct							
	4005 Ct							
	4006	6.7	22.0	0.0	73.0	5.0	0.0	0.0
	4007	14.7	17.0	0.0	80.0	3.0	0.0	0.0
	4008	17.8	31.0	0.0	63.0	5.0	1.0	0.0
	4009	13.1	19.0	0.0	79.0	2.0	0.0	0.0
	4010	10.8	35.0	0.0	64.0	0.0	1.0	0.0
	4011	20.4	14.0	0.0	82.0	4.0	0.0	0.0
	4012 Ct							
	4014 Ns							
	4015	14.9	27.0	0.0	69.0	3.0	1.0	0.0
	4016	18.9	17.0	0.0	80.0	0.0	3.0	0.0

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 4 - CERIC OXIDE HIGH DOSE	4001 Ct						
	4002	1860.0	0.0	7161.0	186.0	93.0	0.0
	4003	3172.0	0.0	8540.0	488.0	0.0	0.0
	4004 Ct						
	4005 Ct						
	4006	1474.0	0.0	4891.0	335.0	0.0	0.0
	4007	2499.0	0.0	11760.0	441.0	0.0	0.0
	4008	5518.0	0.0	11214.0	890.0	178.0	0.0
	4009	2489.0	0.0	10349.0	262.0	0.0	0.0
	4010	3780.0	0.0	6912.0	0.0	108.0	0.0
	4011	2856.0	0.0	16728.0	816.0	0.0	0.0
	4012 Ct						
	4014 Ns						
	4015	4023.0	0.0	10281.0	447.0	149.0	0.0
	4016	3213.0	0.0	15120.0	0.0	567.0	0.0

WEEK 6 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 4 - CERIC OXIDE HIGH DOSE	4001 Ct							
	4002	7.72	16.3	44.0	57.0	21.1	37.0	11.9
	4003	7.45	15.6	42.2	56.7	20.9	36.9	11.5
	4004 Ct							
	4005 Ct							
	4006	7.79	15.5	42.2	54.2	19.9	36.7	13.1
	4007	7.92	16.2	43.7	55.2	20.5	37.1	12.8
	4008	7.69	15.5	42.5	55.3	20.2	36.4	12.6
	4009	8.44	16.0	43.9	52.0	19.0	36.5	12.1
	4010	8.10	15.6	42.4	52.4	19.3	36.8	13.0
	4011	8.06	16.3	45.7	56.7	20.2	35.7	12.4
	4012 Ct							
	4014 Ns							
	4015	7.95	16.2	43.9	55.2	20.4	36.9	12.0
	4016	7.72	16.0	43.2	55.9	20.7	37.1	13.2

WEEK 6 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 4 - CERIC OXIDE HIGH DOSE	4001 Ct			14.3
	4002	549.0	9.0	NSQ
	4003	897.0	8.7	Ct
	4004 Ct			14.1
	4005 Ct			14.0
	4006	713.0	9.5	Ct
	4007	888.0	9.0	16.2
	4008	745.0	9.2	13.7
	4009	850.0	8.3	Ct
	4010	1099.0	9.1	14.1
	4011	824.0	9.1	14.2
	4012 Ct			14.2
	4014 Ns			
	4015	864.0	8.5	12.8
	4016	917.0	8.9	13.7

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
4001 Ct									
4002	4+	1+	-	1+	-	-	-	-	NRBC 2
4003	4+	2+	-	1+	-	-	-	-	NRBC 2
4004 Ct									
4005 Ct									
4006	3+	1+	-	-	-	-	-	-	-
4007	3+	1+	-	-	-	-	-	-	NRBC 3
4008	4+	1+	-	1+	-	-	-	-	-
4009	4+	1+	-	-	-	-	-	-	NRBC 1
4010	4+	1+	-	1+	-	-	-	-	-
4011	3+	1+	-	-	-	-	-	-	-
4012 Ct									
4014 Ns									
4015	2+	1+	-	1+	-	-	-	-	-
4016	3+	1+	-	-		-	-	-	NRBC 1

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	1501	8.9	8.0	0.0	91.0	0.0	1.0	0.0
	1502	8.5	14.0	0.0	86.0	0.0	0.0	0.0
	1503 Ct							
	1504 Ct							
	1505	8.2	9.0	0.0	88.0	2.0	1.0	0.0
	1506	14.1	4.0	0.0	95.0	0.0	1.0	0.0
	1507 Ct							
	1508 Ct							
	1509	8.3	18.0	0.0	81.0	1.0	0.0	0.0
	1510 Ct							
	1511	11.4	1.0	0.0	99.0	0.0	0.0	0.0
	1512 Ns							
	1513	12.0	10.0	0.0	86.0	1.0	3.0	0.0
	1514	8.7	5.0	0.0	94.0	1.0	0.0	0.0
	1515	6.8	1.0	0.0	97.0	2.0	0.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	1501	712.0	0.0	8099.0	0.0	89.0	0.0
	1502	1190.0	0.0	7310.0	0.0	0.0	0.0
	1503Ct						
	1504Ct						
	1505	738.0	0.0	7216.0	164.0	82.0	0.0
	1506	564.0	0.0	13395.0	0.0	141.0	0.0
	1507Ct						
	1508Ct						
	1509	1494.0	0.0	6723.0	83.0	0.0	0.0
	1510Ct						
	1511	114.0	0.0	11286.0	0.0	0.0	0.0
	1512Ns						
	1513	1200.0	0.0	10320.0	120.0	360.0	0.0
	1514	435.0	0.0	8178.0	87.0	0.0	0.0
	1515	68.0	0.0	6596.0	136.0	0.0	0.0

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	1501	7.65	14.6	43.0	56.2	19.1	34.0	11.6
	1502	6.88	15.0	39.3	57.1	21.8	38.2	11.4
	1503Ct							
	1504Ct							
	1505	7.22	15.4	41.7	57.7	21.3	37.0	12.0
	1506	7.83	15.5	42.4	54.1	19.8	36.6	11.8
	1507Ct							
	1508Ct							
	1509	7.72	15.6	42.5	55.0	20.2	36.7	11.4
	1510Ct							
	1511	7.72	10.7	38.9	50.4	13.9	27.5	12.0
	1512Ns							
	1513	7.57	14.5	40.3	53.2	19.2	36.0	12.1
	1514	8.01	16.0	43.7	54.5	20.0	36.7	11.3
	1515	7.40	15.1	39.8	53.8	20.4	37.9	11.7

WEEK 6 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	1501	507.0	9.0	Ct
	1502	1000.0	9.5	14.4
	1503Ct			
	1504Ct			
	1505	808.0	8.1	12.9
	1506	1025.0	8.4	14.4
	1507Ct			
	1508Ct			
	1509	1041.0	8.7	Ct
	1510Ct			
	1511	881.0	9.7	14.5
	1512	Ns	Ns	14.3
	1513	461.0	10.0	14.0
	1514	1034.0	8.9	14.5
	1515	666.0	8.6	13.8

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
1501	4+	1+	-	1+	-	-	-	-	-
1502	4+	2+	-	1+	-	-	-	-	-
1503 Ct									
1504 Ct									
1505	2+	2+	-	1+	-	-	-	-	-
1506	3+	1+	-	-	-	-	-	-	-
1507 Ct									
1508 Ct									
1509	4+	1+	-	-	-	-	-	-	-
1510 Ct									
1511	4+	1+	-	1+	-	-	-	-	-
1512 Ns									
1513	4+	1+	-	-	-	-	-	-	-
1514	4+	1+	-	-	-	-	-	-	-
1515	4+	1+	-	1+	-	-	-	-	-

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
			WBC DIFFERENTIAL COUNT					
GROUP 2 - CERIC OXIDE LOW DOSE	2501	NSO	12.0	0.0	87.0	0.0	1.0	0.0
	2502	7.0	9.0	0.0	89.0	1.0	1.0	0.0
	2503 Ct							
	2504	9.6	25.0	0.0	72.0	3.0	0.0	0.0
	2505	8.4	10.0	0.0	87.0	2.0	1.0	0.0
	2506	10.1	11.0	0.0	85.0	3.0	1.0	0.0
	2507	10.0	24.0	0.0	72.0	3.0	1.0	0.0
	2508	10.4	22.0	0.0	78.0	0.0	0.0	0.0
	2509	7.4	10.0	0.0	83.0	5.0	2.0	0.0
	2510	10.8	12.0	0.0	87.0	0.0	1.0	0.0
	2511	4.3	9.0	0.0	90.0	0.0	1.0	0.0
	2512	14.5	11.0	0.0	85.0	3.0	1.0	0.0
	2513	7.0	8.0	0.0	91.0	1.0	0.0	0.0
	2514	8.6	6.0	0.0	93.0	1.0	0.0	0.0
	2515 Ns							

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 2 - CERIC OXIDE LOW DOSE	2501 NSQ						
	2502	630.0	0.0	6230.0	70.0	70.0	0.0
	2503 Ct						
	2504	2400.0	0.0	6912.0	288.0	0.0	0.0
	2505	840.0	0.0	7308.0	168.0	84.0	0.0
	2506	1111.0	0.0	8585.0	303.0	101.0	0.0
	2507	2400.0	0.0	7200.0	300.0	100.0	0.0
	2508	2288.0	0.0	8112.0	0.0	0.0	0.0
	2509	740.0	0.0	6142.0	370.0	148.0	0.0
	2510	1296.0	0.0	9396.0	0.0	108.0	0.0
	2511	387.0	0.0	3870.0	0.0	43.0	0.0
	2512	1595.0	0.0	12325.0	435.0	145.0	0.0
	2513	560.0	0.0	6370.0	70.0	0.0	0.0
	2514	516.0	0.0	7998.0	86.0	0.0	0.0
	2515 Ns						

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 2 - CERIC OXIDE LOW DOSE	2501 NSQ							
	2502	7.91	15.7	42.9	54.2	19.8	36.6	11.5
	2503 Ct							
	2504	7.41	15.6	41.6	56.1	21.1	37.5	12.6
	2505	7.65	15.8	42.8	56.0	20.7	36.9	11.7
	2506	7.47	15.2	41.1	55.0	20.3	37.0	12.4
	2507	7.59	15.6	42.4	55.9	20.6	36.8	11.4
	2508	7.39	14.5	39.5	53.5	19.6	36.7	11.0
	2509	7.61	15.9	42.8	56.3	20.9	37.1	11.2
	2510	8.00	15.9	43.8	54.8	19.9	36.3	11.5
	2511	6.91	8.6	38.5	55.7	12.4	22.3	11.3
	2512	7.47	15.7	40.9	54.7	21.0	38.4	11.6
	2513	7.59	15.8	41.7	55.0	20.8	37.8	11.9
	2514	7.92	16.1	44.3	55.9	20.3	36.4	12.2
	2515 Ns							

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 2 - CERIC OXIDE LOW DOSE	2501NSQ			
	2502	724.0	8.3	14.6
	2503Ct			16.0
	2504	666.0	8.8	Ct
	2505	854.0	8.5	13.9
	2506	928.0	9.1	14.1
	2507	545.0	8.4	Ct
	2508	961.0	8.3	14.0
	2509	1196.0	8.5	14.1
	2510	971.0	8.7	12.9
	2511	114.0	8.8	12.7
	2512	771.0	8.7	13.5
	2513	1013.0	8.5	13.3
	2514	876.0	9.6	13.4
	2515Ns			

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
2501	3+	1+	-	1+	-	-	-	-	NRBC 1
2502	4+	1+	-	1+	-	-	-	-	-
2503 Ct									
2504	3+	1+	-	-	-	-	-	-	NRBC 1
2505	4+	1+	-	1+	-	-	-	-	-
2506	2+	1+	-	-	-	-	-	-	-
2507	3+	1+	-	1+	-	-	-	-	NRBC 1
2508	3+	1+	-	1+	-	-	-	-	-
2509	3+	1+	-	-	-	-	-	-	-
2510	3+	1+	-	-	-	-	-	-	-
2511	4+	1+	-	1+	-	-	-	-	-
2512	4+	1+	-	-	-	-	-	-	-
2513	4+	1+	-	1+	-	-	-	-	-
2514	4+	1+	-	-	-	-	-	-	-
2515 Ns									

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	WBC $\times 10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501 Ns							
	3502 Ct							
	3503	8.2	19.0	0.0	78.0	3.0	0.0	0.0
	3504 Ct							
	3505	8.1	16.0	0.0	81.0	3.0	0.0	0.0
	3506 Ct							
	3507 Ct							
	3508	12.3	22.0	0.0	74.0	3.0	1.0	0.0
	3509	8.8	22.0	0.0	74.0	3.0	1.0	0.0
	3510	11.5	13.0	0.0	82.0	3.0	2.0	0.0
	3511 Ns							
	3513 Ct							
	3514	9.0	25.0	0.0	72.0	1.0	2.0	0.0
	3516	10.6	5.0	0.0	95.0	0.0	0.0	0.0
	3517	11.9	14.0	0.0	85.0	0.0	1.0	0.0

WEEK 6 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501 Ns						
	3502 Ct						
	3503	1558.0	0.0	6396.0	246.0	0.0	0.0
	3504 Ct						
	3505	1296.0	0.0	6561.0	243.0	0.0	0.0
	3506 Ct						
	3507 Ct						
	3508	2706.0	0.0	9102.0	369.0	123.0	0.0
	3509	1936.0	0.0	6512.0	264.0	88.0	0.0
	3510	1495.0	0.0	9430.0	345.0	230.0	0.0
	3511 Ns						
	3513 Ct						
	3514	2250.0	0.0	6480.0	90.0	180.0	0.0
	3516	530.0	0.0	10070.0	0.0	0.0	0.0
	3517	1666.0	0.0	10115.0	0.0	119.0	0.0

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501 Ns							
	3502 Ct							
	3503	7.83	16.1	44.0	56.2	20.6	36.6	11.4
	3504 Ct							
	3505	7.16	14.4	39.3	54.9	20.1	36.6	10.7
	3506 Ct							
	3507 Ct							
	3508	7.67	15.4	41.5	54.1	20.1	37.1	11.9
	3509	7.27	14.6	39.3	54.1	20.1	37.1	12.1
	3510	7.72	15.9	42.7	55.3	20.6	37.2	11.4
	3511 Ns							
	3513 Ct							
	3514	7.83	16.0	42.7	54.5	20.4	37.5	11.9
	3516	7.37	14.5	39.9	54.2	19.7	36.3	11.9
	3517	7.32	14.4	39.2	53.5	19.7	36.8	11.7

WEEK 6 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501 Ns			14.9
	3502 Ct			
	3503	940.0	9.0	13.8
	3504 Ct			15.5
	3505	1021.0	8.6	Ct
	3506 Ct			
	3507 Ct			14.1
	3508	831.0	8.8	14.1
	3509	843.0	8.9	14.3
	3510	671.0	8.5	14.4
	3511 Ns			
	3513 Ct			
	3514	929.0	8.8	13.7
	3516	974.0	8.7	14.6
	3517	591.0	9.8	12.9

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
3501 Ns									
3502 Ct									
3503	4+	1+	-	1+	-	-	-	-	NRBC 2
3504 Ct									
3505	4+	1+	-	1+	-	-	-	-	-
3506Ct									
3507 Ct									
3508	2+	1+	-	-	-	-	-	-	-
3509	2+	1+	-	-	-	-	-	-	-
3510	3+	1+	-	-	-	-	-	-	-
3511 Ns									
3513 Ct									
3514	4+	1+	-	-	-	-	-	-	-
3516	4+	1+	-	-	-	-	-	-	-
3517	4+	1+	-	-	-	-	-	-	-

WEEK 6 - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	9.2	16.0	0.0	83.0	1.0	0.0	0.0
	4502	NSQ	13.0	0.0	87.0	0.0	0.0	0.0
	4503	5.5	17.0	0.0	83.0	0.0	0.0	0.0
	4504	20.2	4.0	0.0	94.0	1.0	1.0	0.0
	4505 Ct							
	4506	11.4	18.0	0.0	80.0	2.0	0.0	0.0
	4507	8.2	12.0	0.0	86.0	2.0	0.0	0.0
	4508	12.1	17.0	0.0	82.0	0.0	1.0	0.0
	4509	12.3	19.0	0.0	77.0	2.0	2.0	0.0
	4510	7.7	10.0	0.0	89.0	1.0	0.0	0.0
	4511	8.5	13.0	0.0	84.0	1.0	2.0	0.0
	4513	9.3	11.0	0.0	86.0	3.0	0.0	0.0
	4514 Ct							
	4515	10.6	10.0	0.0	88.0	0.0	2.0	0.0
	4516 Ns							

WEEK 6 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	1472.0	0.0	7636.0	92.0	0.0	0.0
	4502 NSQ						
	4503	935.0	0.0	4565.0	0.0	0.0	0.0
	4504	808.0	0.0	18988.0	202.0	202.0	0.0
	4505 Ct						
	4506	2052.0	0.0	9120.0	228.0	0.0	0.0
	4507	984.0	0.0	7052.0	164.0	0.0	0.0
	4508	2057.0	0.0	9922.0	0.0	121.0	0.0
	4509	2337.0	0.0	9471.0	246.0	246.0	0.0
	4510	770.0	0.0	6853.0	77.0	0.0	0.0
	4511	1105.0	0.0	7140.0	85.0	170.0	0.0
	4513	1023.0	0.0	7998.0	279.0	0.0	0.0
	4514 Ct						
	4515	1060.0	0.0	9328.0	0.0	212.0	0.0
	4516 Ns						

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	7.80	15.9	42.7	54.8	20.4	37.2	11.9
	4502NSQ							
	4503	7.18	14.5	38.9	54.2	20.2	37.3	12.1
	4504	7.94	15.7	42.2	53.2	19.8	37.2	12.2
	4505Ct							
	4506	7.75	15.5	41.7	53.8	20.0	37.2	11.9
	4507	7.89	16.0	42.8	54.2	20.3	37.4	12.4
	4508	7.32	15.1	40.3	55.0	20.6	37.5	11.6
	4509	7.29	15.6	41.7	57.2	21.4	37.4	11.3
	4510	7.50	15.2	40.9	54.5	20.3	37.2	12.2
	4511	7.38	14.4	38.8	52.6	19.5	37.1	10.9
	4513	7.72	15.6	43.4	56.2	20.2	36.0	11.5
	4514Ct							
	4515	8.44	15.8	44.1	52.3	18.7	35.8	11.7
	4516Ns							

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	961.0	8.8	14.8
	4502 NSQ			15.0
	4503	942.0	9.1	14.8
	4504	865.0	9.2	14.1
	4505 Ct			
	4506	1109.0	8.4	13.9
	4507	918.0	8.8	13.4
	4508	984.0	9.0	14.4
	4509	913.0	8.5	13.8
	4510	1167.0	7.7	14.4
	4511	891.0	9.0	14.3
	4513	948.0	9.2	14.4
	4514 Ct			14.8
	4515	616.0	9.7	13.3
	4516 Ns			12.9

APPENDIX NO. 8

PROJECT NO. 90831

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 6
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
4501	2+	1+	-	1+	-	-	-	-	-
4502	2+	1+	-	1+	-	-	-	-	-
4503	3+	1+	-	1+	-	-	-	-	-
4504	3+	1+	-	1+	-	-	-	-	-
4505 Ct									
4506	2+	1+	-	1+	1+	-	-	-	-
4507	2+	1+	-	-	-	-	-	-	NRBC 1
4508	2+	1+	-	1+	-	-	-	-	-
4509	2+	1+	-	1+	-	-	-	-	NRBC 1
4510	2+	1+	-	-	-	-	-	-	-
4511	4+	1+	-	-	-	-	-	-	-
4513	2+	1+	-	-	-	-	-	-	-
4514 Ct									
4515	3+	1+	-	-	-	-	-	-	NRBC 2
4516Ns									

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	1001	8.3	28.0	0.0	71.0	1.0	0.0	0.0
	1002	8.2	18.0	0.0	79.0	2.0	1.0	0.0
	1005	15.3	29.0	0.0	66.0	3.0	2.0	0.0
	1006	6.9	16.0	0.0	82.0	2.0	0.0	0.0
	1007	9.3	17.0	0.0	80.0	3.0	0.0	0.0
	1008	7.7	17.0	0.0	80.0	3.0	0.0	0.0
	1009	9.5	15.0	0.0	83.0	2.0	0.0	0.0
	1010	9.7	14.0	0.0	81.0	5.0	0.0	0.0
	1011	6.6	11.0	0.0	86.0	3.0	0.0	0.0
	1012	6.9	13.0	0.0	84.0	3.0	0.0	0.0
	1013	7.3	18.0	0.0	75.0	5.0	2.0	0.0
	1014	6.4	32.0	0.0	55.0	12.0	1.0	0.0
	1015	6.3	21.0	0.0	70.0	6.0	3.0	0.0
	1016	6.5	14.0	0.0	86.0	0.0	0.0	0.0
	1017	6.8	13.0	0.0	84.0	1.0	2.0	0.0

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	1001	2324.0	0.0	5893.0	83.0	0.0	0.0
	1002	1476.0	0.0	6478.0	164.0	82.0	0.0
	1005	4437.0	0.0	10098.0	459.0	306.0	0.0
	1006	1104.0	0.0	5658.0	138.0	0.0	0.0
	1007	1581.0	0.0	7440.0	279.0	0.0	0.0
	1008	1309.0	0.0	6160.0	231.0	0.0	0.0
	1009	1425.0	0.0	7885.0	190.0	0.0	0.0
	1010	1358.0	0.0	7857.0	485.0	0.0	0.0
	1011	726.0	0.0	5676.0	198.0	0.0	0.0
	1012	897.0	0.0	5796.0	207.0	0.0	0.0
	1013	1314.0	0.0	5475.0	365.0	146.0	0.0
	1014	2048.0	0.0	3520.0	768.0	64.0	0.0
	1015	1323.0	0.0	4410.0	378.0	189.0	0.0
	1016	910.0	0.0	5590.0	0.0	0.0	0.0
	1017	884.0	0.0	5712.0	68.0	136.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	1001	8.20	14.9	41.9	51.1	18.2	35.6	13.4
	1002	8.77	16.1	45.2	51.5	18.4	35.6	12.6
	1005	7.85	15.2	41.4	52.7	19.4	36.7	12.1
	1006	8.14	15.1	40.7	50.0	18.6	37.1	13.0
	1007	8.34	15.0	43.5	52.1	18.0	34.5	12.0
	1008	8.40	15.4	42.7	50.8	18.3	36.1	13.2
	1009	7.90	14.4	40.5	51.3	18.2	35.5	12.9
	1010	8.70	15.9	45.4	52.2	18.3	35.0	12.4
	1011	8.72	15.1	44.2	50.7	17.3	34.2	12.3
	1012	8.89	15.8	45.6	51.3	17.8	34.6	13.7
	1013	8.90	16.7	47.9	53.8	18.8	34.9	12.0
	1014	9.13	15.3	44.4	48.6	16.8	34.5	12.9
	1015	8.25	16.1	45.2	54.8	19.5	35.6	12.2
	1016	8.05	15.0	40.9	50.8	18.6	36.7	11.7
	1017	8.08	14.9	41.1	50.9	18.4	36.2	12.4

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	1001	1055.0	8.2	14.9
	1002	878.0	8.1	14.6
	1005	866.0	8.6	14.8
	1006	876.0	8.6	15.1
	1007	757.0	8.7	14.6
	1008	1061.0	7.7	15.2
	1009	905.0	9.3	19.4
	1010	1069.0	9.9	14.8
	1011	1042.0	9.1	14.5
	1012	916.0	9.2	14.4
	1013	856.0	8.8	14.8
	1014	846.0	9.0	14.7
	1015	753.0	8.9	14.1
	1016	853.0	8.4	19.1
	1017	898.0	8.5	14.6

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
1001	1+	1+	-	1+	-	-	-	-	-
1002	1+	1+	-	1+	-	-	-	-	-
1005	1+	1+	-	1+	-	-	-	-	-
1006	2+	1+	-	1+	-	-	-	-	-
1007	1+	-	-	1+	-	-	-	-	-
1008	1+	1+	-	1+	-	-	-	-	-
1009	1+	1+	-	1+	-	-	-	-	-
1010	1+	-	-	1+	-	-	-	-	-
1011	1+	-	-	1+	-	-	-	-	-
1012	1+	1+	-	1+	-	-	-	-	-
1013	2+	1+	-	1+	-	-	-	-	-
1014	2+	1+	-	1+	-	-	-	-	-
1015	3+	1+	-	1+	-	-	-	-	-
1016	2+	-	-	1+	-	-	-	-	-
1017	1+	1+	-	-	-	-	-	-	-

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 2 - CERIC OXIDE LOW DOSE	2001	10.5	28.0	0.0	70.0	1.0	1.0	0.0
	2002	11.8	13.0	0.0	85.0	0.0	2.0	0.0
	2003	7.0	19.0	0.0	79.0	1.0	1.0	0.0
	2004	7.2	20.0	1.0	72.0	5.0	2.0	0.0
	2005	7.4	31.0	0.0	65.0	4.0	0.0	0.0
	2006	8.4	12.0	0.0	81.0	7.0	0.0	0.0
	2007	8.7	30.0	0.0	61.0	6.0	3.0	0.0
	2008	10.6	15.0	0.0	81.0	3.0	1.0	0.0
	2009	7.7	19.0	0.0	79.0	1.0	1.0	0.0
	2010	8.1	21.0	0.0	73.0	5.0	1.0	0.0
	2011	6.2	25.0	0.0	71.0	2.0	2.0	0.0
	2012	9.0	17.0	0.0	81.0	2.0	0.0	0.0
	2013	6.6	11.0	0.0	88.0	1.0	0.0	0.0
	2015	6.5	12.0	0.0	85.0	2.0	1.0	0.0
	2016	7.4	28.0	0.0	70.0	2.0	0.0	0.0

WEEK 13 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 2 - CERIC OXIDE LOW DOSE	2001	2940.0	0.0	7350.0	105.0	105.0	0.0
	2002	1534.0	0.0	10030.0	0.0	236.0	0.0
	2003	1330.0	0.0	5530.0	70.0	70.0	0.0
	2004	1440.0	72.0	5184.0	360.0	144.0	0.0
	2005	2294.0	0.0	4810.0	296.0	0.0	0.0
	2006	1008.0	0.0	6804.0	588.0	0.0	0.0
	2007	2610.0	0.0	5307.0	522.0	261.0	0.0
	2008	1590.0	0.0	8586.0	318.0	106.0	0.0
	2009	1463.0	0.0	6083.0	77.0	77.0	0.0
	2010	1701.0	0.0	5913.0	405.0	81.0	0.0
	2011	1550.0	0.0	4402.0	124.0	124.0	0.0
	2012	1530.0	0.0	7290.0	180.0	0.0	0.0
	2013	726.0	0.0	5808.0	66.0	0.0	0.0
	2015	780.0	0.0	5525.0	130.0	65.0	0.0
	2016	2072.0	0.0	5180.0	148.0	0.0	0.0

WEEK 13 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 2 - CERIC OXIDE LOW DOSE	2001	8.31	15.6	43.4	52.2	18.8	36.0	12.4
	2002	8.21	15.1	41.3	50.3	18.4	36.6	13.4
	2003	8.40	15.4	42.8	50.9	18.3	36.0	12.8
	2004	8.60	15.6	43.2	50.2	18.1	36.1	12.7
	2005	8.28	15.6	44.3	53.5	18.8	35.2	11.8
	2006	8.18	15.4	43.1	52.7	18.8	35.7	11.9
	2007	7.85	14.9	42.7	54.4	19.0	34.9	12.1
	2008	8.78	16.5	46.7	53.2	18.8	35.3	11.6
	2009	7.69	14.1	39.4	51.3	18.3	35.7	13.2
	2010	9.08	15.5	45.5	50.1	17.1	34.1	12.8
	2011	8.51	15.7	45.7	53.7	18.4	34.4	12.1
	2012	8.24	15.3	44.0	53.4	18.6	34.8	12.2
	2013	8.46	15.4	44.3	52.4	18.2	34.7	12.3
	2015	8.82	15.2	44.3	50.2	17.2	34.3	13.0
	2016	8.71	16.0	46.3	53.1	18.4	34.6	12.1

WEEK 13 - MALES

	ANIMAL NO.	PLT $\times 10^3$	MPV UM^3	PT SEC.
GROUP 2 - CERIC OXIDE LOW DOSE	2001	955.0	9.1	14.8
	2002	930.0	9.2	16.8
	2003	1029.0	8.2	14.8
	2004	1012.0	8.7	15.7
	2005	786.0	8.8	15.4
	2006	827.0	9.4	14.3
	2007	902.0	7.6	NSQ
	2008	1179.0	8.2	15.6
	2009	899.0	8.4	14.4
	2010	1022.0	10.2	14.4
	2011	967.0	8.7	16.2
	2012	1115.0	8.8	14.5
	2013	1095.0	8.4	14.3
	2015	783.0	9.4	15.0
	2016	903.0	9.2	14.1

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
2001	1+	1+	-	1+	-	-	-	-	-
2002	1+	-	-	-	-	-	-	-	SPHR 1+
2003	1+	-	-	1+	-	-	-	-	-
2004	2+	1+	-	1+	-	-	-	-	NRBC 2
2005	2+	1+	-	1+	-	-	-	-	NRBC 1
2006	2+	1+	-	1+	-	-	-	-	-
2007	1+	1+	-	-	-	-	-	-	-
2008	2+	-	-	1+	-	-	-	-	-
2009	1+	1+	-	1+	-	-	-	-	-
2010	3+	1+	-	1+	1+	-	-	-	-
2011	2+	1+	-	1+	-	-	-	-	-
2012	2+	-	-	1+	-	-	-	-	-
2013	2+	1+	-	1+	-	-	-	-	-
2015	1+	-	-	1+	1+	1+	-	-	-
2016	1+	-	-	-	-	-	-	-	-

WEEK 13 - MALES

			WBC DIFFERENTIAL COUNT					
	ANIMAL NO.	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	9.0	21.0	0.0	77.0	0.0	2.0	0.0
	3002	9.5	49.0	0.0	50.0	1.0	0.0	0.0
	3003	16.1	23.0	0.0	71.0	2.0	4.0	0.0
	3004	12.1	21.0	0.0	78.0	0.0	1.0	0.0
	3005	13.7	14.0	0.0	84.0	1.0	1.0	0.0
	3006	17.6	15.0	0.0	78.0	5.0	2.0	0.0
	3007	14.4	20.0	0.0	80.0	0.0	0.0	0.0
	3008	11.7	31.0	0.0	66.0	0.0	3.0	0.0
	3009	14.9	10.0	0.0	84.0	5.0	1.0	0.0
	3011	8.4	42.0	0.0	52.0	6.0	0.0	0.0
	3012	8.6	29.0	0.0	67.0	2.0	2.0	0.0
	3013	9.0	21.0	0.0	75.0	4.0	0.0	0.0
	3014	12.3	39.0	0.0	54.0	5.0	2.0	0.0
	3015	11.8	25.0	0.0	71.0	3.0	1.0	0.0
	3016	7.9	21.0	0.0	73.0	4.0	2.0	0.0

WEEK 13 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	1890.0	0.0	6930.0	0.0	180.0	0.0
	3002	4655.0	0.0	4750.0	95.0	0.0	0.0
	3003	3703.0	0.0	11431.0	322.0	644.0	0.0
	3004	2541.0	0.0	9438.0	0.0	121.0	0.0
	3005	1918.0	0.0	11508.0	137.0	137.0	0.0
	3006	2640.0	0.0	13728.0	880.0	352.0	0.0
	3007	2880.0	0.0	11520.0	0.0	0.0	0.0
	3008	3627.0	0.0	7722.0	0.0	351.0	0.0
	3009	1490.0	0.0	12516.0	745.0	149.0	0.0
	3011	3528.0	0.0	4368.0	504.0	0.0	0.0
	3012	2494.0	0.0	5762.0	172.0	172.0	0.0
	3013	1890.0	0.0	6750.0	360.0	0.0	0.0
	3014	4797.0	0.0	6642.0	615.0	246.0	0.0
	3015	2950.0	0.0	8378.0	354.0	118.0	0.0
	3016	1659.0	0.0	5767.0	316.0	158.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	8.52	15.4	42.6	50.0	18.1	36.2	12.1
	3002	8.00	15.2	42.5	53.1	19.0	35.8	12.0
	3003	7.96	15.4	42.1	52.9	19.3	36.6	12.1
	3004	8.61	16.2	44.7	51.9	18.8	36.3	12.5
	3005	8.03	15.4	42.2	52.5	19.2	36.5	13.3
	3006	8.28	15.6	42.5	51.3	18.8	36.7	13.1
	3007	8.56	16.4	46.5	54.3	19.2	35.3	12.2
	3008	9.17	15.9	45.6	49.7	17.3	34.9	13.0
	3009	8.24	15.8	44.4	53.9	19.2	35.6	11.9
	3011	8.32	14.8	42.7	51.3	17.8	34.7	12.6
	3012	8.64	15.4	44.0	50.9	17.8	35.0	13.4
	3013	8.57	15.3	44.7	52.2	17.9	34.2	12.8
	3014	9.05	15.6	45.2	49.9	17.2	34.5	13.1
	3015	8.32	15.0	43.4	52.2	18.0	34.5	12.1
	3016	8.10	15.2	42.8	52.8	18.8	35.5	12.5

WEEK 13 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	916.0	8.8	16.4
	3002	833.0	8.5	16.6
	3003	788.0	8.9	14.3
	3004	1065.0	8.3	14.5
	3005	1079.0	8.4	NSQ
	3006	857.0	8.6	15.3
	3007	969.0	9.3	14.8
	3008	987.0	8.9	13.8
	3009	913.0	8.8	13.8
	3011	945.0	9.1	14.1
	3012	916.0	8.6	14.6
	3013	942.0	9.5	14.9
	3014	1013.0	9.1	14.5
	3015	930.0	9.1	15.0
	3016	900.0	9.4	14.5

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
3001	1+	1+	-	-	-	-	-	-	-
3002	1+	-	-	1+	-	-	-	-	NRBC 1
3003	2+	1+	-	1+	-	-	-	-	-
3004	2+	1+	-	-	-	-	-	-	-
3005	1+	1+	-	1+	-	-	-	-	-
3006	2+	1+	-	1+	-	-	-	-	-
3007	2+	1+	-	-	-	-	-	-	-
3008	1+	1+	-	1+	-	-	-	-	-
3009	2+	1+	-	1+	-	-	-	-	-
3011	2+	1+	-	-	-	-	-	-	-
3012	2+	1+	-	1+	-	-	-	-	-
3013	1+	1+	-	1+	-	-	-	-	-
3014	2+	1+	-	1+	-	-	-	-	-
3015	1+	1+	-	-	-	-	-	-	-
3016	2+	1+	-	1+	-	-	-	-	-

WEEK 13 - MALES

	ANIMAL NO.	WBC $X10^3$	NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	6.9	33.0	0.0	67.0	0.0	0.0	0.0
	4003	9.1	28.0	0.0	68.0	2.0	2.0	0.0
	4004	8.9	45.0	0.0	52.0	3.0	0.0	0.0
	4005	6.1	34.0	0.0	59.0	7.0	0.0	0.0
	4006	5.4	44.0	0.0	46.0	8.0	2.0	0.0
	4007	7.3	27.0	0.0	71.0	2.0	0.0	0.0
	4008	11.9	44.0	0.0	55.0	0.0	1.0	0.0
	4009	9.6	15.0	0.0	83.0	2.0	0.0	0.0
	4010	8.9	37.0	0.0	63.0	0.0	0.0	0.0
	4011	11.5	16.0	0.0	83.0	0.0	1.0	0.0
	4012	5.7	37.0	0.0	56.0	6.0	1.0	0.0
	4014	6.3	37.0	0.0	60.0	3.0	0.0	0.0
	4015	6.7	29.0	0.0	63.0	3.0	5.0	0.0
	4016	11.1	39.0	0.0	52.0	8.0	1.0	0.0

WEEK 13 - MALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	2277.0	0.0	4623.0	0.0	0.0	0.0
	4003	2548.0	0.0	6188.0	182.0	182.0	0.0
	4004	4005.0	0.0	4628.0	267.0	0.0	0.0
	4005	2074.0	0.0	3599.0	427.0	0.0	0.0
	4006	2376.0	0.0	2484.0	432.0	108.0	0.0
	4007	1971.0	0.0	5183.0	146.0	0.0	0.0
	4008	5236.0	0.0	6545.0	0.0	119.0	0.0
	4009	1440.0	0.0	7968.0	192.0	0.0	0.0
	4010	3293.0	0.0	5607.0	0.0	0.0	0.0
	4011	1840.0	0.0	9545.0	0.0	115.0	0.0
	4012	2109.0	0.0	3192.0	342.0	57.0	0.0
	4014	2331.0	0.0	3780.0	189.0	0.0	0.0
	4015	1943.0	0.0	4221.0	201.0	335.0	0.0
	4016	4329.0	0.0	5772.0	888.0	111.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	7.86	15.7	43.1	54.8	20.0	36.4	11.8
	4003	7.94	15.8	42.2	53.1	19.9	37.5	12.1
	4004	8.26	15.7	42.7	51.7	19.0	36.8	12.6
	4005	8.39	15.5	42.6	50.8	18.5	36.4	12.8
	4006	8.87	16.6	45.9	51.8	18.7	36.1	13.4
	4007	7.99	15.0	42.3	53.0	18.8	35.4	12.6
	4008	8.71	16.2	46.4	53.3	18.6	34.9	11.2
	4009	9.00	16.4	47.3	52.6	18.2	34.6	13.1
	4010	9.05	15.4	44.4	49.1	17.0	34.7	12.8
	4011	8.65	16.1	47.1	54.5	18.6	34.2	12.6
	4012	9.09	16.2	47.1	51.8	17.8	34.4	11.6
	4014	8.86	16.3	47.1	53.2	18.4	34.6	12.1
	4015	8.59	16.1	45.7	53.2	18.7	35.2	11.6
	4016	7.93	14.8	41.2	51.9	18.7	36.0	12.6

WEEK 13 - MALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	848.0	8.9	14.8
	4003	852.0	8.8	15.3
	4004	920.0	8.7	15.5
	4005	971.0	8.7	14.6
	4006	879.0	9.1	16.9
	4007	969.0	8.5	15.3
	4008	791.0	9.0	15.6
	4009	870.0	8.2	17.3
	4010	1040.0	9.6	14.2
	4011	852.0	9.6	15.1
	4012	838.0	9.2	15.5
	4014	879.0	8.7	14.6
	4015	1052.0	8.5	14.4
	4016	862.0	9.4	13.7

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
4002	1+	1+	-	1+	-	-	-	-	-
4003	1+	1+	-	1+	-	-	-	-	-
4004	2+	1+	-	1+	-	-	-	-	-
4005	2+	1+	-	1+	-	-	-	-	NRBC 1
4006	2+	1+	-	1+	-	-	-	-	NRBC 1
4007	1+	1+	-	1+	-	-	-	-	-
4008	1+	1+	-	1+	-	-	-	-	-
4009	1+	-	-	-	-	-	-	-	-
4010	2+	1+	-	1+	-	-	-	-	-
4011	1+	1+	-	1+	-	-	-	-	-
4012	1+	1+	-	1+	-	-	-	-	-
4014	1+	1+	-	-	-	-	-	-	NRBC 1
4015	2+	1+	-	1+	-	-	-	-	-
4016	2+	1+	-	1+	-	-	-	-	-

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 1 - AIR CONTROL	1501	5.6	10.0	0.0	86.0	4.0	0.0	0.0
	1502	3.4	10.0	0.0	84.0	5.0	1.0	0.0
	1503	4.4	10.0	0.0	84.0	5.0	1.0	0.0
	1504	4.5	12.0	0.0	80.0	6.0	2.0	0.0
	1505	3.2	13.0	0.0	78.0	3.0	6.0	0.0
	1506	3.8	10.0	0.0	87.0	1.0	2.0	0.0
	1507	2.6	4.0	0.0	92.0	4.0	0.0	0.0
	1508	2.9	15.0	0.0	76.0	5.0	4.0	0.0
	1509	3.9	8.0	0.0	81.0	11.0	0.0	0.0
	1510	5.3	5.0	0.0	90.0	5.0	0.0	0.0
	1511	4.7	0.0	0.0	97.0	3.0	0.0	0.0
	1512	7.9	6.0	0.0	87.0	7.0	0.0	0.0
	1513	5.3	3.0	0.0	89.0	6.0	2.0	0.0
	1514	1.6	13.0	0.0	87.0	0.0	0.0	0.0
	1515	4.0	6.0	0.0	88.0	5.0	1.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 1 - AIR CONTROL	1501	560.0	0.0	4816.0	224.0	0.0	0.0
	1502	340.0	0.0	2856.0	170.0	34.0	0.0
	1503	440.0	0.0	3696.0	220.0	44.0	0.0
	1504	540.0	0.0	3600.0	270.0	90.0	0.0
	1505	416.0	0.0	2496.0	96.0	192.0	0.0
	1506	380.0	0.0	3306.0	38.0	76.0	0.0
	1507	104.0	0.0	2392.0	104.0	0.0	0.0
	1508	435.0	0.0	2204.0	145.0	116.0	0.0
	1509	312.0	0.0	3159.0	429.0	0.0	0.0
	1510	265.0	0.0	4770.0	265.0	0.0	0.0
	1511	0.0	0.0	4559.0	141.0	0.0	0.0
	1512	474.0	0.0	6873.0	553.0	0.0	0.0
	1513	159.0	0.0	4717.0	318.0	106.0	0.0
	1514	208.0	0.0	1392.0	0.0	0.0	0.0
	1515	240.0	0.0	3520.0	200.0	40.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 1 - AIR CONTROL	1501	7.56	15.1	41.8	55.3	20.0	36.1	10.8
	1502	7.47	14.4	41.0	54.9	19.3	35.1	11.0
	1503	7.59	14.8	41.0	54.0	19.5	36.1	10.9
	1504	7.58	14.6	40.2	53.1	19.3	36.3	11.8
	1505	6.99	14.0	39.9	57.1	20.0	35.1	11.1
	1506	8.32	15.2	44.2	53.1	18.3	34.4	11.8
	1507	7.49	14.5	40.4	53.9	19.4	35.9	11.7
	1508	7.41	14.8	40.8	55.1	20.0	36.2	12.0
	1509	7.97	14.9	41.4	52.0	18.7	36.0	11.9
	1510	8.11	15.2	42.8	52.8	18.7	35.5	11.8
	1511	8.46	14.8	42.9	50.7	17.5	34.5	12.2
	1512	8.27	15.2	43.2	52.2	18.4	35.2	11.6
	1513	8.23	15.1	44.4	53.9	18.3	34.0	11.1
	1514	7.55	13.9	40.3	53.4	18.4	34.5	11.6
	1515	8.46	15.8	45.9	54.2	18.7	34.5	11.3

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 1 - AIR CONTROL	1501	952.0	8.8	13.2
	1502	989.0	9.0	13.8
	1503	998.0	7.7	14.2
	1504	1154.0	8.1	13.3
	1505	670.0	8.0	13.7
	1506	1078.0	7.8	14.0
	1507	951.0	8.2	13.8
	1508	995.0	8.1	13.5
	1509	1205.0	8.0	14.5
	1510	853.0	9.1	14.1
	1511	1006.0	8.8	14.1
	1512	1000.0	8.4	14.9
	1513	1029.0	9.5	14.7
	1514	1011.0	8.6	14.6
	1515	1102.0	8.5	13.8

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	ILJB	BSTIP	COMMENTS
1501	1+	1+	-	1+	-	-	-	-	-
1502	1+	1+	-	1+	-	-	-	-	NRBC 1
1503	1+	1+	-	1+	-	-	-	-	-
1504	1+	-	-	1+	-	-	-	-	-
1505	-	-	-	1+	-	-	-	-	-
1506	-	-	-	1+	1+	-	-	-	-
1507	1+	-	-	1+	-	-	-	-	-
1508	1+	-	-	1+	-	-	-	-	NRBC 1
1509	2+	-	-	1+	-	-	-	-	-
1510	-	1+	-	1+	1+	-	-	-	-
1511	-	1+	-	1+	1+	-	-	-	-
1512	-	-	-	1+	-	-	-	-	-
1513	-	-	-	1+	-	-	-	-	-
1514	1+	-	-	1+	-	-	-	-	-
1515	1+	-	-	1+	-	-	-	-	-

WEEK 13 - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 2 - CERIC OXIDE LOW DOSE	2501	2.7	30.0	0.0	67.0	1.0	2.0	0.0
	2502	4.2	40.0	0.0	54.0	4.0	2.0	0.0
	2503	4.1	13.0	0.0	82.0	5.0	0.0	0.0
	2504	4.8	15.0	0.0	76.0	8.0	1.0	0.0
	2505	5.0	12.0	0.0	80.0	7.0	1.0	0.0
	2506	5.7	14.0	0.0	81.0	5.0	0.0	0.0
	2507	4.3	14.0	0.0	80.0	3.0	3.0	0.0
	2508	8.6	41.0	0.0	48.0	9.0	2.0	0.0
	2509	5.3	9.0	0.0	83.0	8.0	0.0	0.0
	2510	7.5	22.0	0.0	78.0	0.0	0.0	0.0
	2511	4.1	12.0	0.0	84.0	3.0	1.0	0.0
	2512	7.6	14.0	0.0	81.0	3.0	2.0	0.0
	2513	2.9	14.0	0.0	79.0	4.0	3.0	0.0
	2514	4.5	18.0	0.0	77.0	4.0	1.0	0.0
	2515	5.1	18.0	0.0	79.0	2.0	1.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 2 - CERIC OXIDE LOW DOSE	2501	810.0	0.0	1809.0	27.0	54.0	0.0
	2502	1680.0	0.0	2268.0	168.0	84.0	0.0
	2503	533.0	0.0	3362.0	205.0	0.0	0.0
	2504	720.0	0.0	3648.0	384.0	48.0	0.0
	2505	600.0	0.0	4000.0	350.0	50.0	0.0
	2506	798.0	0.0	4617.0	285.0	0.0	0.0
	2507	602.0	0.0	3440.0	129.0	129.0	0.0
	2508	3526.0	0.0	4128.0	774.0	172.0	0.0
	2509	477.0	0.0	4399.0	424.0	0.0	0.0
	2510	1650.0	0.0	5850.0	0.0	0.0	0.0
	2511	492.0	0.0	3444.0	123.0	41.0	0.0
	2512	1064.0	0.0	6156.0	228.0	152.0	0.0
	2513	406.0	0.0	2291.0	116.0	87.0	0.0
	2514	810.0	0.0	3465.0	180.0	45.0	0.0
	2515	918.0	0.0	4029.0	102.0	51.0	0.0

WEEK 13 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 2 - CERIC OXIDE LOW DOSE	2501	7.01	13.7	39.0	55.7	19.5	35.1	11.5
	2502	7.84	14.5	41.1	52.4	18.5	35.3	11.9
	2503	7.54	14.1	41.4	54.9	18.7	34.1	11.5
	2504	7.83	15.2	42.1	53.8	19.4	36.1	12.6
	2505	7.92	15.4	42.1	53.2	19.4	36.5	12.4
	2506	7.95	15.3	43.5	54.7	19.2	35.2	11.9
	2507	7.54	14.4	40.1	53.2	19.1	35.9	11.9
	2508	7.65	14.1	39.2	51.2	18.4	36.0	12.0
	2509	7.98	15.5	43.3	54.3	19.4	35.8	11.1
	2510	7.77	14.5	40.8	52.5	18.7	35.5	12.1
	2511	7.79	15.1	42.6	54.7	19.4	35.4	10.9
	2512	7.78	15.2	42.2	54.2	19.5	36.0	11.7
	2513	7.86	15.2	43.6	55.5	19.3	34.8	11.6
	2514	7.66	14.7	42.6	55.6	19.2	34.5	11.4
	2515	7.75	14.6	41.8	54.0	18.8	34.9	11.2

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 2 - CERIC OXIDE LOW DOSE	2501	983.0	8.7	13.6
	2502	795.0	8.0	14.6
	2503	915.0	8.8	14.4
	2504	1046.0	8.4	14.4
	2505	898.0	8.5	13.5
	2506	883.0	8.7	13.3
	2507	1009.0	8.3	14.2
	2508	921.0	7.7	14.1
	2509	1260.0	8.1	13.7
	2510	1014.0	8.6	13.5
	2511	861.0	7.8	14.7
	2512	1089.0	7.9	14.4
	2513	1014.0	8.3	14.3
	2514	806.0	9.4	14.3
	2515	874.0	8.2	14.1

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
2501	1+	1+	-	1+	-	-	-	-	-
2502	-	-	-	1+	1+	-	-	-	-
2503	-	-	-	1+	-	-	-	-	-
2504	1+	-	-	1+	-	-	-	-	-
2505	2+	-	-	1+	-	-	-	-	-
2506	-	-	-	1+	-	-	-	-	-
2507	1+	-	-	1+	-	-	-	-	NRBC 1
2508	2+	1+	-	1+	-	-	-	-	-
2509	-	-	-	1+	-	-	-	-	NRBC 1
2510	1+	-	-	-	-	-	-	-	-
2511	1+	1+	-	-	-	-	-	-	-
2512	1+	1+	-	-	-	-	-	-	-
2513	-	-	-	1+	1+	-	-	-	-
2514	-	-	-	1+	-	-	-	-	-
2515	-	-	-	2+	-	-	-	-	-

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	3.4	31.0	0.0	66.0	2.0	1.0	0.0
	3502	2.7	22.0	0.0	74.0	3.0	1.0	0.0
	3503	5.1	13.0	0.0	84.0	2.0	1.0	0.0
	3504	6.3	21.0	0.0	68.0	10.0	1.0	0.0
	3505	6.5	31.0	0.0	63.0	6.0	0.0	0.0
	3506	5.6	6.0	0.0	79.0	12.0	3.0	0.0
	3507	3.6	27.0	0.0	72.0	0.0	1.0	0.0
	3508	3.6	18.0	0.0	79.0	1.0	2.0	0.0
	3509	7.1	14.0	0.0	85.0	1.0	0.0	0.0
	3510	5.0	17.0	0.0	83.0	0.0	0.0	0.0
	3511	5.8	18.0	0.0	80.0	2.0	0.0	0.0
	3513	3.7	24.0	0.0	72.0	4.0	0.0	0.0
	3514	4.5	14.0	0.0	84.0	1.0	1.0	0.0
	3516	6.3	6.0	0.0	94.0	0.0	0.0	0.0
	3517	4.4	25.0	0.0	70.0	4.0	1.0	0.0

WEEK 13 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	1054.0	0.0	2244.0	68.0	34.0	0.0
	3502	594.0	0.0	1998.0	81.0	27.0	0.0
	3503	663.0	0.0	4284.0	102.0	51.0	0.0
	3504	1323.0	0.0	4284.0	630.0	63.0	0.0
	3505	2015.0	0.0	4095.0	390.0	0.0	0.0
	3506	336.0	0.0	4424.0	672.0	168.0	0.0
	3507	972.0	0.0	2592.0	0.0	36.0	0.0
	3508	648.0	0.0	2844.0	36.0	72.0	0.0
	3509	994.0	0.0	6035.0	71.0	0.0	0.0
	3510	850.0	0.0	4150.0	0.0	0.0	0.0
	3511	1044.0	0.0	4640.0	116.0	0.0	0.0
	3513	888.0	0.0	2664.0	148.0	0.0	0.0
	3514	630.0	0.0	3780.0	45.0	45.0	0.0
	3516	378.0	0.0	5922.0	0.0	0.0	0.0
	3517	1100.0	0.0	3080.0	176.0	44.0	0.0

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	7.61	14.7	41.9	55.1	19.3	35.1	11.2
	3502	7.83	14.4	40.9	52.2	18.4	35.2	10.8
	3503	7.95	15.2	42.7	53.7	19.1	35.6	11.4
	3504	7.26	13.8	37.6	51.8	19.0	36.7	11.8
	3505	8.13	15.1	42.4	52.1	18.6	35.6	12.4
	3506	8.78	16.5	45.2	51.5	18.8	36.5	12.2
	3507	7.75	14.4	41.3	53.3	18.6	34.9	11.5
	3508	8.27	15.5	44.0	53.2	18.7	35.2	11.3
	3509	8.34	16.2	45.0	53.9	19.4	36.0	11.2
	3510	7.92	14.9	42.6	53.8	18.8	35.0	10.7
	3511	7.20	14.5	42.0	58.4	20.1	34.5	11.2
	3513	8.45	15.7	44.8	53.0	18.6	35.1	11.6
	3514	7.75	14.7	42.3	54.6	19.0	34.7	11.7
	3516	7.86	15.0	42.8	54.4	19.1	35.1	11.5
	3517	8.15	15.0	43.7	53.6	18.4	34.3	11.5

WEEK 13 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	947.0	8.2	14.0
	3502	838.0	8.4	14.7
	3503	898.0	8.7	13.1
	3504	949.0	7.8	13.5
	3505	951.0	8.4	13.9
	3506	1059.0	7.9	13.4
	3507	957.0	8.0	14.2
	3508	870.0	8.6	13.8
	3509	842.0	8.0	14.6
	3510	795.0	8.4	14.1
	3511	837.0	8.6	14.9
	3513	939.0	9.2	13.8
	3514	932.0	8.7	14.3
	3516	896.0	8.2	14.0
	3517	808.0	9.3	14.5

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
3501	-	-	-	-	1+	-	-	-	-
3502	-	-	-	1+	-	-	-	-	-
3503	-	-	-	1+	-	-	-	-	-
3504	1+	-	-	1+	-	-	-	-	-
3505	1+	-	-	1+	-	-	-	-	-
3506	1+	1+	-	1+	-	-	-	-	-
3507	1+	1+	-	1+	-	-	-	-	-
3508	1+	1+	-	-	-	-	-	-	-
3509	2+	-	-	-	-	-	-	-	-
3510	-	1+	-	1+	-	-	-	-	-
3511	-	-	-	-	-	-	-	-	-
3513	-	-	-	-	-	-	-	-	-
3514	-	-	-	1+	1+	-	-	-	-
3516	1+	-	-	1+	-	-	-	-	-
3517	-	-	-	1+	-	-	-	-	-

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	WBC $X10^3$	WBC DIFFERENTIAL COUNT NEUT SEG %	NEUT NSEG %	LYMPH %	MONO %	EOSIN %	BASO %
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	3.0	28.0	0.0	68.0	3.0	1.0	0.0
	4502	4.6	27.0	0.0	71.0	2.0	0.0	0.0
	4503	4.0	25.0	0.0	69.0	6.0	0.0	0.0
	4504	6.1	25.0	0.0	66.0	6.0	2.0	1.0
	4505	3.6	34.0	0.0	64.0	2.0	0.0	0.0
	4506	6.2	11.0	0.0	84.0	5.0	0.0	0.0
	4507	3.4	20.0	0.0	77.0	2.0	1.0	0.0
	4508	4.7	25.0	0.0	69.0	4.0	2.0	0.0
	4509	6.9	24.0	0.0	65.0	10.0	1.0	0.0
	4510	4.2	18.0	0.0	81.0	0.0	1.0	0.0
	4511	5.1	17.0	0.0	80.0	3.0	0.0	0.0
	4513	6.2	24.0	0.0	74.0	2.0	0.0	0.0
	4514	3.9	19.0	0.0	81.0	0.0	0.0	0.0
	4515	5.3	10.0	0.0	85.0	5.0	0.0	0.0
	4516	8.2	22.0	0.0	75.0	2.0	1.0	0.0

WEEK 13 - FEMALES

	ANIMAL NO.	NEUT SEG	NEUT NSEG	WBC DIFFERENTIAL COUNT (ABSOLUTE) LYMPH	MONO	EOSIN	BASO
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	840.0	0.0	2040.0	90.0	30.0	0.0
	4502	1242.0	0.0	3266.0	92.0	0.0	0.0
	4503	1000.0	0.0	2760.0	240.0	0.0	0.0
	4504	1525.0	0.0	4026.0	366.0	122.0	61.0
	4505	1224.0	0.0	2304.0	72.0	0.0	0.0
	4506	682.0	0.0	5208.0	310.0	0.0	0.0
	4507	680.0	0.0	2618.0	68.0	34.0	0.0
	4508	1175.0	0.0	3243.0	188.0	94.0	0.0
	4509	1656.0	0.0	4485.0	690.0	69.0	0.0
	4510	756.0	0.0	3402.0	0.0	42.0	0.0
	4511	867.0	0.0	4080.0	153.0	0.0	0.0
	4513	1488.0	0.0	4588.0	124.0	0.0	0.0
	4514	741.0	0.0	3159.0	0.0	0.0	0.0
	4515	530.0	0.0	4505.0	265.0	0.0	0.0
	4516	1804.0	0.0	6150.0	164.0	82.0	0.0

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS

PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	RBC $X10^6$	Hb G/DL	Ht %	MCV UM^3	MCH PG	MCHC G/DL	RDW %
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	8.01	15.7	43.8	54.7	19.6	35.8	11.9
	4502	8.30	16.2	44.5	53.6	19.5	36.4	12.0
	4503	7.62	14.6	39.9	52.3	19.2	36.6	12.1
	4504	8.37	15.5	43.7	52.2	18.5	35.5	12.5
	4505	8.09	14.9	43.0	53.2	18.4	34.6	11.1
	4506	8.53	15.9	44.4	52.1	18.6	35.8	12.1
	4507	7.89	15.1	41.7	52.8	19.1	36.2	12.0
	4508	7.63	15.1	41.6	54.5	19.8	36.3	11.7
	4509	7.77	15.4	43.0	55.4	19.8	35.8	11.5
	4510	7.56	14.6	40.0	52.9	19.3	36.5	12.0
	4511	8.84	16.2	46.7	52.8	18.3	34.7	12.0
	4513	7.96	15.6	44.0	55.3	19.6	35.4	11.5
	4514	8.32	15.9	45.9	55.2	19.1	34.6	11.9
	4515	8.46	15.4	43.7	51.7	18.2	35.2	11.7
	4516	7.98	15.6	43.0	53.9	19.5	36.3	11.8

APPENDIX NO. 8 INDIVIDUAL HEMOGRAMS PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	PLT $X10^3$	MPV UM^3	PT SEC.
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	918.0	8.4	13.3
	4502	788.0	8.3	13.8
	4503	891.0	8.6	13.8
	4504	911.0	9.0	13.2
	4505	958.0	9.0	13.7
	4506	1018.0	8.4	13.8
	4507	964.0	8.4	13.8
	4508	939.0	8.6	13.6
	4509	1020.0	8.3	13.6
	4510	1083.0	7.7	13.8
	4511	998.0	8.5	14.2
	4513	1007.0	8.5	14.1
	4514	830.0	8.8	14.8
	4515	935.0	9.2	13.3
	4516	1038.0	8.2	14.6

APPENDIX NO. 8

INDIVIDUAL HEMOGRAMS
BLOOD CELL MORPHOLOGY
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CREN	POLY	HYPO	ANIS	POIK	CODO	HJB	BSTIP	COMMENTS
4501	1+	1+	-	1+	-	-	-	-	-
4502	1+	-	-	1+	-	-	-	-	-
4503	1+	-	-	-	-	-	-	-	-
4504	1+	1+	-	1+	-	-	-	-	-
4505	-	-	-	1+	-	-	-	-	ROUL 1+
4506	1+	-	-	1+	-	-	-	-	-
4507	2+	1+	-	1+	-	-	-	-	-
4508	2+	1+	-	-	-	-	-	-	-
4509	1+	1+	-	1+	-	-	-	-	-
4510	1+	-	-	1+	-	-	-	-	-
4511	1+	1+	-	1+	-	-	-	-	-
4513	-	-	-	1+	-	-	-	-	NRBC 1
4514	1+	1+	-	1+	-	-	-	-	-
4515	-	-	-	1+	-	-	-	-	-
4516	-	1+	-	1+	-	-	-	-	-

APPENDIX NO. 9 PROJECT NO. 90831

INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES
MALES AND FEMALES

The following footnotes have been used throughout the appendix:

Ns	No sample
NSQ	Not sufficient quantity

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 5 - HEALTH SCREEN	5001	13.9	.5	132.0	.09	210.0	57.0
	5002	11.5	.4	119.0	.07	173.0	49.0
	5003	11.1	.5	132.0	.05	121.0	45.0
	5004	11.5	.5	133.0	.08	114.0	34.0
	5005	12.5	.6	123.0	.13	135.0	44.0
	5006	13.0	.5	123.0	.07	126.0	38.0
	5007	8.4	.4	100.0	.08	106.0	39.0
	5008	10.1	.5	100.0	.11	105.0	40.0
	5009	12.6	.6	107.0	.08	132.0	45.0
	5010	9.7	.5	101.0	.09	148.0	51.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 5 - HEALTH SCREEN	5001	157.0	10.2	9.00	77.0	29.0	5.4
	5002	287.0	9.6	9.31	100.0	49.0	5.1
	5003	206.0	9.9	8.69	68.0	40.0	5.4
	5004	188.0	9.8	9.61	68.0	33.0	5.2
	5005	207.0	9.9	8.82	70.0	47.0	4.9
	5006	292.0	9.7	9.78	83.0	32.0	5.4
	5007	198.0	9.8	9.12	83.0	37.0	5.0
	5008	184.0	10.4	10.23	64.0	40.0	5.2
	5009	332.0	10.4	10.12	102.0	37.0	5.3
	5010	347.0	10.3	10.22	67.0	44.0	5.2

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 5 - HEALTH SCREEN	5001	3.0	1.25	2.4	147.0	4.40	103.0
	5002	2.7	1.12	2.4	145.0	4.24	103.0
	5003	2.9	1.16	2.5	146.0	3.80	103.0
	5004	2.9	1.26	2.3	144.0	4.25	104.0
	5005	2.7	1.23	2.2	144.0	4.17	103.0
	5006	2.9	1.16	2.5	146.0	4.25	104.0
	5007	2.7	1.17	2.3	145.0	4.08	102.0
	5008	2.8	1.17	2.4	146.0	4.09	103.0
	5009	2.9	1.21	2.4	146.0	4.40	104.0
	5010	2.7	1.08	2.5	144.0	4.56	101.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 5 - HEALTH SCREEN	5501	15.7	.4	149.0	.10	117.0	28.0
	5502	18.9	.6	165.0	.11	131.0	27.0
	5503	11.2	.6	122.0	.08	104.0	18.0
	5504	17.5	.6	127.0	.13	149.0	30.0
	5505	16.4	.5	117.0	.15	115.0	31.0
	5506	14.6	.6	128.0	.10	113.0	45.0
	5507	12.6	.6	109.0	.09	121.0	35.0
	5508	11.2	.7	106.0	.08	122.0	36.0
	5509	22.7	.7	159.0	.13	120.0	31.0
	5510	12.0	.5	138.0	.11	110.0	24.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

HEALTH SCREEN - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 5 - HEALTH SCREEN	5501	197.0	10.3	10.46	89.0	44.0	5.0
	5502	277.0	10.1	9.56	73.0	22.0	5.4
	5503	196.0	10.1	10.53	101.0	29.0	5.2
	5504	218.0	9.9	10.17	100.0	35.0	5.2
	5505	188.0	10.0	9.83	94.0	22.0	5.4
	5506	229.0	9.9	9.70	89.0	27.0	5.4
	5507	227.0	10.1	9.73	75.0	30.0	4.9
	5508	159.0	10.4	10.34	101.0	29.0	5.3
	5509	225.0	10.3	11.58	92.0	19.0	5.1
	5510	203.0	10.0	10.27	81.0	27.0	5.2

HEALTH SCREEN - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 5 - HEALTH SCREEN	5501	2.8	1.27	2.2	146.0	4.18	106.0
	5502	3.0	1.25	2.4	147.0	4.04	107.0
	5503	2.8	1.17	2.4	146.0	4.05	106.0
	5504	3.0	1.36	2.2	144.0	4.72	106.0
	5505	3.0	1.25	2.4	145.0	4.13	106.0
	5506	3.0	1.25	2.4	145.0	4.11	106.0
	5507	2.7	1.23	2.2	146.0	4.04	106.0
	5508	2.9	1.21	2.4	144.0	5.38	107.0
	5509	2.9	1.32	2.2	147.0	4.77	107.0
	5510	2.9	1.26	2.3	146.0	4.37	107.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	1001	21.1	1.1	91.0	.13	142.0	52.0
	1002	17.4	.9	103.0	.12	178.0	47.0
	1005	21.1	1.0	121.0	.15	135.0	46.0
	1006	15.0	.6	93.0	.11	165.0	38.0
	1007	13.6	.8	120.0	.10	133.0	39.0
	1008	15.2	.9	89.0	.13	200.0	40.0
	1009	17.5	1.0	81.0	.14	146.0	46.0
	1010	16.0	1.0	99.0	.12	162.0	52.0
	1011	22.4	1.2	113.0	.17	156.0	39.0
	1012	15.4	1.0	106.0	.13	161.0	40.0
	1013	16.7	.9	90.0	.15	163.0	43.0
	1014	16.4	.7	117.0	.12	117.0	42.0
	1015	18.6	.9	110.0	.17	108.0	36.0
	1016	16.4	.9	111.0	.07	142.0	41.0
	1017	17.2	.9	110.0	.10	140.0	39.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	1001	176.0	8.9	6.05	58.0	32.0	6.6
	1002	193.0	8.9	7.74	84.0	58.0	6.2
	1005	128.0	9.3	8.60	79.0	48.0	6.9
	1006	142.0	9.4	7.76	53.0	87.0	7.1
	1007	116.0	8.0	7.56	65.0	108.0	6.7
	1008	142.0	8.8	7.46	45.0	72.0	6.8
	1009	119.0	8.9	6.89	62.0	64.0	6.6
	1010	159.0	9.1	8.16	64.0	74.0	7.4
	1011	110.0	9.0	6.74	54.0	66.0	6.6
	1012	95.0	8.7	7.33	65.0	54.0	6.5
	1013	145.0	8.8	7.76	48.0	39.0	6.4
	1014	159.0	9.0	6.98	42.0	38.0	7.1
	1015	105.0	9.2	6.95	96.0	44.0	6.9
	1016	145.0	8.8	7.53	62.0	65.0	6.4
	1017	118.0	9.3	7.83	63.0	68.0	6.7

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	1001	3.4	1.06	3.2	149.0	4.33	106.0
	1002	3.1	1.00	3.1	146.0	4.62	105.0
	1005	3.4	.97	3.5	147.0	4.85	105.0
	1006	3.5	.97	3.6	146.0	5.20	103.0
	1007	3.3	.97	3.4	147.0	6.80	102.0
	1008	3.5	1.06	3.3	149.0	5.22	104.0
	1009	3.4	1.06	3.2	151.0	4.56	105.0
	1010	3.3	.80	4.1	148.0	5.44	104.0
	1011	3.5	1.13	3.1	147.0	5.31	104.0
	1012	3.4	1.10	3.1	149.0	4.81	104.0
	1013	3.3	1.06	3.1	149.0	4.52	105.0
	1014	3.5	.97	3.6	149.0	4.40	105.0
	1015	3.5	1.03	3.4	149.0	4.41	106.0
	1016	3.1	.94	3.3	147.0	4.61	102.0
	1017	3.3	.97	3.4	146.0	5.20	104.0

WEEK 6 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 2 - CERIC OXIDE LOW DOSE	2001	18.5	1.0	107.0	.15	162.0	45.0
	2002	19.3	1.0	124.0	.15	141.0	40.0
	2003	21.9	1.1	87.0	.11	143.0	51.0
	2004	27.6	1.2	89.0	.12	125.0	39.0
	2005	24.8	1.5	60.0	.11	160.0	49.0
	2006	18.4	.9	94.0	.12	156.0	39.0
	2007	17.8	.8	98.0	.16	191.0	48.0
	2008	16.4	.8	74.0	.12	148.0	52.0
	2009	16.3	.8	110.0	.12	157.0	42.0
	2010	13.7	.7	98.0	.14	143.0	48.0
	2011	19.2	.8	90.0	.14	148.0	53.0
	2012	18.2	.8	87.0	.15	172.0	54.0
	2013	18.2	.8	105.0	.13	191.0	50.0
	2015	18.7	.8	94.0	.16	175.0	43.0
	2016	19.8	.8	108.0	.16	155.0	49.0

WEEK 6 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 2 - CERIC OXIDE LOW DOSE	2001	150.0	8.8	7.90	62.0	39.0	6.9
	2002	121.0	8.9	8.40	77.0	105.0	6.8
	2003	194.0	9.4	6.86	84.0	33.0	6.9
	2004	96.0	9.4	6.53	52.0	40.0	7.4
	2005	132.0	8.8	5.20	44.0	33.0	6.5
	2006	245.0	9.1	7.44	56.0	79.0	6.9
	2007	144.0	8.9	7.01	51.0	49.0	6.8
	2008	146.0	9.0	7.12	79.0	73.0	6.9
	2009	170.0	9.2	7.74	71.0	102.0	6.6
	2010	166.0	9.5	7.72	70.0	125.0	6.8
	2011	145.0	8.9	7.32	46.0	37.0	7.0
	2012	152.0	9.0	7.28	51.0	41.0	6.5
	2013	149.0	9.0	7.17	64.0	42.0	7.0
	2015	208.0	8.7	7.29	56.0	52.0	6.4
	2016	138.0	9.0	7.07	53.0	66.0	6.5

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 2 - CERIC OXIDE LOW DOSE	2001	3.4	.97	3.5	148.0	4.22	105.0
	2002	3.3	.94	3.5	148.0	4.76	104.0
	2003	3.5	1.03	3.4	149.0	4.67	107.0
	2004	3.5	.90	3.9	150.0	4.12	107.0
	2005	3.3	1.03	3.2	149.0	5.87	110.0
	2006	3.5	1.03	3.4	149.0	4.97	102.0
	2007	3.5	1.06	3.3	149.0	4.86	106.0
	2008	3.4	.97	3.5	149.0	5.74	106.0
	2009	3.4	1.06	3.2	144.0	5.60	102.0
	2010	3.3	.94	3.5	147.0	5.23	101.0
	2011	3.6	1.06	3.4	149.0	5.77	108.0
	2012	3.3	1.03	3.2	148.0	4.62	105.0
	2013	3.4	.94	3.6	149.0	4.96	106.0
	2015	3.2	1.00	3.2	145.0	4.94	102.0
	2016	3.3	1.03	3.2	143.0	5.47	102.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	18.9	.5	112.0	.13	124.0	31.0
	3002	22.3	.9	108.0	.16	212.0	48.0
	3003	14.2	.8	133.0	.16	207.0	56.0
	3004	17.8	1.0	122.0	.17	177.0	49.0
	3005	17.7	.8	107.0	.16	145.0	46.0
	3006	17.6	.9	131.0	.22	163.0	49.0
	3007	13.8	.7	95.0	.10	184.0	41.0
	3008	16.0	.9	104.0	.11	197.0	69.0
	3009	18.2	1.0	102.0	.16	160.0	50.0
	3011	18.4	.8	109.0	.17	154.0	38.0
	3012	15.8	.8	101.0	.10	147.0	50.0
	3013	13.4	.9	124.0	.14	137.0	33.0
	3014	17.4	.9	114.0	.15	152.0	44.0
	3015	14.9	.8	123.0	.16	160.0	43.0
	3016	17.4	.9	100.0	.16	150.0	43.0

WEEK 6 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	127.0	9.1	8.32	57.0	55.0	6.3
	3002	175.0	9.0	7.95	65.0	55.0	6.7
	3003	123.0	9.2	6.91	82.0	70.0	6.8
	3004	128.0	NSQ	6.60	NSQ	NSQ	NSQ
	3005	231.0	9.3	8.21	80.0	81.0	6.7
	3006	145.0	9.5	9.46	72.0	89.0	6.5
	3007	172.0	8.7	7.42	53.0	55.0	6.5
	3008	140.0	9.3	7.11	70.0	152.0	7.0
	3009	188.0	9.5	7.13	82.0	64.0	6.6
	3011	150.0	9.0	6.94	47.0	51.0	6.8
	3012	129.0	9.0	6.60	41.0	65.0	6.5
	3013	187.0	8.6	8.33	56.0	48.0	6.9
	3014	146.0	9.2	8.59	49.0	50.0	6.6
	3015	168.0	8.7	6.89	54.0	66.0	6.5
	3016	136.0	8.8	7.43	49.0	55.0	6.2

WEEK 6 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	3.2	1.03	3.1	142.0	4.93	98.0
	3002	3.3	.97	3.4	144.0	6.14	106.0
	3003	3.3	.94	3.5	143.0	5.13	104.0
	3004	NSQ	NSQ	NSQ	147.0	7.04	106.0
	3005	3.4	1.03	3.3	146.0	5.01	102.0
	3006	3.2	.97	3.3	145.0	6.13	100.0
	3007	3.3	1.03	3.2	147.0	5.06	102.0
	3008	3.4	.94	3.6	149.0	5.14	106.0
	3009	3.4	1.06	3.2	147.0	4.71	102.0
	3011	3.4	1.00	3.4	144.0	5.60	103.0
	3012	3.3	1.03	3.2	143.0	5.36	100.0
	3013	3.3	.92	3.6	145.0	6.31	102.0
	3014	3.4	1.06	3.2	146.0	5.79	103.0
	3015	3.3	1.03	3.2	144.0	4.89	103.0
	3016	3.2	1.07	3.0	147.0	5.17	102.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	14.9	.6	113.0	.16	142.0	45.0
	4002	17.1	.9	125.0	.10	121.0	42.0
	4003	18.0	.8	120.0	.20	150.0	54.0
	4004	13.0	.5	103.0	.15	125.0	49.0
	4005	21.1	.9	119.0	.12	117.0	35.0
	4006	18.0	.9	97.0	.17	152.0	44.0
	4007	18.7	.9	96.0	.13	180.0	53.0
	4008	17.9	.8	95.0	.12	188.0	50.0
	4009	16.7	.9	112.0	.12	137.0	50.0
	4010	18.1	.7	101.0	.14	173.0	41.0
	4011	19.1	.9	95.0	.14	154.0	35.0
	4012	16.5	.9	91.0	.19	182.0	71.0
	4014	20.6	1.0	119.0	.13	152.0	54.0
	4015	16.5	.7	117.0	.15	107.0	41.0
	4016	20.9	1.1	126.0	.15	145.0	38.0

WEEK 6 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	176.0	9.1	7.26	72.0	112.0	6.4
	4002	135.0	9.4	6.41	65.0	74.0	6.7
	4003	135.0	9.1	7.99	85.0	77.0	6.4
	4004	168.0	9.6	7.04	66.0	48.0	6.7
	4005	187.0	9.1	8.78	48.0	57.0	6.7
	4006	150.0	9.4	7.02	60.0	94.0	6.9
	4007	201.0	9.3	6.36	NSQ	NSQ	6.2
	4008	158.0	8.9	7.40	67.0	43.0	6.9
	4009	149.0	9.4	6.56	54.0	89.0	6.4
	4010	167.0	9.0	7.68	53.0	67.0	6.7
	4011	138.0	8.6	7.42	52.0	69.0	6.7
	4012	217.0	9.1	7.67	50.0	40.0	6.5
	4014	244.0	9.0	7.51	59.0	58.0	6.9
	4015	163.0	9.2	7.02	72.0	66.0	7.0
	4016	131.0	9.0	7.83	77.0	72.0	7.3

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4001	3.3	1.06	3.1	145.0	4.65	103.0
	4002	3.4	1.03	3.3	148.0	4.35	107.0
	4003	3.3	1.06	3.1	144.0	5.16	103.0
	4004	3.4	1.03	3.3	145.0	5.36	104.0
	4005	3.3	.97	3.4	147.0	6.26	108.0
	4006	3.5	1.03	3.4	149.0	4.95	105.0
	4007	NSQ	.32	4.7	150.0	5.48	109.0
	4008	3.2	.86	3.7	146.0	5.20	105.0
	4009	3.3	1.06	3.1	148.0	4.75	104.0
	4010	3.3	.97	3.4	145.0	5.35	101.0
	4011	3.3	.97	3.4	145.0	5.23	102.0
	4012	3.3	1.03	3.2	147.0	5.06	104.0
	4014	3.4	.97	3.5	146.0	5.08	103.0
	4015	3.3	.89	3.7	146.0	4.68	102.0
	4016	3.5	.92	3.8	146.0	4.40	102.0

APPENDIX NO. 9

INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	1501	15.9	.8	76.0	.12	141.0	41.0
	1502	22.4	.7	88.0	.14	176.0	36.0
	1503	19.8	.9	99.0	.14	206.0	42.0
	1504	26.9	1.5	81.0	.16	172.0	46.0
	1505	24.0	.9	82.0	.11	171.0	42.0
	1506	20.8	.8	112.0	.14	141.0	50.0
	1507	20.8	1.0	107.0	.13	138.0	31.0
	1508	18.2	.9	97.0	.15	171.0	42.0
	1509	28.4	1.0	81.0	.15	215.0	54.0
	1510	19.7	1.1	105.0	.10	210.0	40.0
	1511	18.1	.9	96.0	.13	154.0	34.0
	1512	21.4	.9	97.0	.17	181.0	26.0
	1513	22.5	.8	80.0	.13	136.0	27.0
	1514	18.8	.9	95.0	.12	124.0	37.0
	1515	22.5	1.0	128.0	.17	104.0	33.0

WEEK 6 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	1501	157.0	9.8	5.05	91.0	55.0	7.0
	1502	90.0	9.3	7.00	89.0	33.0	6.6
	1503	123.0	9.3	6.63	74.0	35.0	6.7
	1504	159.0	9.6	7.15	89.0	42.0	6.9
	1505	116.0	9.6	5.31	60.0	58.0	6.7
	1506	131.0	9.9	6.01	56.0	44.0	6.6
	1507	123.0	9.5	6.82	60.0	45.0	6.2
	1508	97.0	9.9	6.06	91.0	52.0	7.4
	1509	131.0	9.5	7.65	71.0	37.0	6.5
	1510	128.0	9.7	7.40	90.0	47.0	7.3
	1511	113.0	9.9	7.38	64.0	54.0	6.6
	1512	94.0	10.0	8.73	72.0	44.0	6.5
	1513	58.0	9.7	6.19	82.0	49.0	7.2
	1514	131.0	10.0	6.20	41.0	26.0	7.0
	1515	119.0	9.8	7.10	89.0	51.0	6.8

APPENDIX NO. 9

INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES

PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	1501	3.7	1.12	3.3	150.0	4.08	108.0
	1502	3.5	1.13	3.1	145.0	5.17	105.0
	1503	3.4	1.03	3.3	144.0	5.68	104.0
	1504	3.5	1.03	3.4	148.0	6.21	110.0
	1505	3.4	1.03	3.3	151.0	5.38	113.0
	1506	3.7	1.28	2.9	143.0	5.43	103.0
	1507	3.2	1.07	3.0	145.0	5.50	108.0
	1508	3.7	1.00	3.7	147.0	5.55	107.0
	1509	3.3	1.03	3.2	147.0	5.92	109.0
	1510	3.8	1.09	3.5	145.0	6.37	105.0
	1511	3.4	1.06	3.2	146.0	5.73	103.0
	1512	3.3	1.03	3.2	147.0	5.59	106.0
	1513	3.6	1.00	3.6	147.0	4.89	106.0
	1514	3.5	1.00	3.5	149.0	4.47	105.0
	1515	3.5	1.06	3.3	150.0	5.27	110.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 2 - CERIC OXIDE LOW DOSE	2501	23.2	1.0	83.0	.12	146.0	37.0
	2502	20.6	1.0	99.0	.09	198.0	34.0
	2503	21.4	.9	97.0	.10	167.0	37.0
	2504	24.7	.9	105.0	.12	211.0	43.0
	2505	19.8	.9	85.0	.11	144.0	29.0
	2506	19.6	.7	91.0	.19	176.0	34.0
	2507	27.8	1.0	99.0	.17	127.0	41.0
	2508	19.3	1.1	98.0	.14	162.0	31.0
	2509	21.8	.7	93.0	.16	150.0	44.0
	2510	22.5	.8	95.0	.11	185.0	44.0
	2511	22.1	.7	116.0	.12	143.0	45.0
	2512 Ns						
	2513	23.1	.9	105.0	.12	137.0	32.0
	2514	26.2	1.0	87.0	.12	126.0	35.0
	2515 Ns						

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 2 - CERIC OXIDE LOW DOSE	2501	104.0	10.1	6.05	85.0	43.0	7.6
	2502	112.0	9.4	6.56	85.0	45.0	7.2
	2503	168.0	9.1	5.36	71.0	37.0	6.4
	2504	109.0	9.4	6.07	82.0	38.0	7.1
	2505	92.0	9.7	5.44	78.0	38.0	7.0
	2506	98.0	10.0	7.12	88.0	50.0	7.1
	2507	121.0	9.6	5.83	110.0	55.0	7.0
	2508	134.0	9.9	6.29	79.0	45.0	7.1
	2509	111.0	10.1	5.50	87.0	48.0	7.3
	2510	66.0	9.9	6.55	81.0	41.0	6.8
	2511	163.0	9.6	5.97	67.0	30.0	6.8
	2512Ns						
	2513	99.0	9.3	6.55	59.0	38.0	6.5
	2514	220.0	9.8	6.87	42.0	41.0	6.9
	2515Ns						

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 2 - CERIC OXIDE LOW DOSE	2501	3.6	.90	4.0	146.0	5.23	107.0
	2502	3.6	1.00	3.6	144.0	5.49	103.0
	2503	3.4	1.13	3.0	144.0	5.19	106.0
	2504	3.6	1.03	3.5	146.0	5.40	108.0
	2505	3.6	1.06	3.4	145.0	5.43	105.0
	2506	3.7	1.09	3.4	145.0	5.57	103.0
	2507	3.5	1.00	3.5	145.0	6.83	106.0
	2508	3.5	.97	3.6	147.0	4.81	107.0
	2509	3.6	.97	3.7	148.0	5.01	106.0
	2510	3.5	1.06	3.3	145.0	5.30	106.0
	2511	3.5	1.06	3.3	149.0	5.14	108.0
	2512 Ns						
	2513	3.3	1.03	3.2	149.0	4.94	108.0
	2514	3.6	1.09	3.3	151.0	5.49	111.0
	2515 Ns						

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	27.3	1.1	108.0	.17	178.0	49.0
	3502	21.6	1.0	82.0	.11	157.0	41.0
	3503	20.1	.8	109.0	.09	152.0	41.0
	3504	29.7	1.0	83.0	.18	132.0	33.0
	3505	19.8	.8	89.0	.08	176.0	38.0
	3506	24.6	1.0	119.0	.14	114.0	40.0
	3507	22.9	1.0	118.0	.11	133.0	38.0
	3508	19.6	.7	98.0	.11	126.0	44.0
	3509	21.0	.7	104.0	.14	133.0	34.0
	3510	23.0	.9	94.0	.14	120.0	44.0
	3511	19.3	.8	113.0	.12	127.0	43.0
	3513	18.3	1.1	118.0	.11	152.0	34.0
	3514	20.1	.8	98.0	.13	139.0	55.0
	3516	18.4	.9	101.0	.17	119.0	51.0
	3517	25.9	.9	99.0	.14	134.0	50.0

WEEK 6 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	136.0	9.8	5.77	57.0	42.0	7.1
	3502	155.0	9.7	8.29	NSQ	NSQ	NSQ
	3503	124.0	9.4	5.32	103.0	45.0	7.0
	3504	157.0	10.1	5.63	83.0	51.0	7.1
	3505	99.0	9.4	6.53	104.0	44.0	7.0
	3506	127.0	9.4	5.80	71.0	40.0	7.0
	3507	73.0	9.5	5.14	52.0	41.0	6.8
	3508	88.0	10.0	5.53	84.0	43.0	7.5
	3509	77.0	9.7	6.78	52.0	37.0	6.7
	3510	115.0	9.6	7.55	60.0	38.0	6.9
	3511	119.0	9.6	5.56	55.0	38.0	7.0
	3513	102.0	10.0	5.51	NSQ	NSQ	7.3
	3514	81.0	10.1	6.69	86.0	63.0	7.2
	3516	69.0	8.7	5.62	58.0	49.0	7.0
	3517	162.0	9.9	6.45	82.0	53.0	7.1

WEEK 6 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	3.6	1.03	3.5	147.0	5.18	107.0
	3502	NSQ	NSQ	NSQ	148.0	5.33	108.0
	3503	3.5	1.00	3.5	144.0	4.57	105.0
	3504	3.7	1.09	3.4	146.0	5.94	107.0
	3505	3.5	1.00	3.5	146.0	5.75	109.0
	3506	3.6	1.06	3.4	142.0	5.83	103.0
	3507	3.4	1.00	3.4	141.0	4.84	105.0
	3508	3.7	.97	3.8	146.0	4.49	106.0
	3509	3.4	1.03	3.3	144.0	5.03	104.0
	3510	3.3	.92	3.6	142.0	6.72	104.0
	3511	3.6	1.06	3.4	146.0	4.88	108.0
	3513	3.8	1.09	3.5	150.0	5.94	110.0
	3514	3.6	1.00	3.6	147.0	4.73	106.0
	3516	3.5	1.00	3.5	146.0	5.94	107.0
	3517	3.6	1.03	3.5	146.0	5.88	106.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	27.2	1.1	162.0	.15	124.0	45.0
	4502	21.2	1.1	189.0	.14	170.0	41.0
	4503	29.3	1.1	105.0	.16	167.0	37.0
	4504	17.7	.8	159.0	.12	128.0	40.0
	4505	19.3	.9	95.0	.17	119.0	33.0
	4506	19.0	.8	92.0	.15	144.0	36.0
	4507	28.1	1.2	73.0	.16	124.0	52.0
	4508	21.4	1.0	97.0	.19	194.0	52.0
	4509	24.0	1.0	103.0	.14	122.0	40.0
	4510	26.4	.9	111.0	.13	117.0	50.0
	4511	18.7	.9	101.0	.17	124.0	43.0
	4513	21.1	.9	114.0	.18	111.0	45.0
	4514	24.6	.9	106.0	.12	139.0	41.0
	4515	16.8	.8	123.0	.14	104.0	35.0
	4516	17.7	1.0	95.0	.10	153.0	30.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 6 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	115.0	10.2	6.13	78.0	33.0	7.0
	4502	147.0	9.6	5.96	52.0	40.0	7.0
	4503	102.0	9.6	8.22	89.0	38.0	6.9
	4504	153.0	9.7	5.41	68.0	48.0	7.2
	4505	112.0	9.5	7.05	98.0	53.0	6.8
	4506	106.0	9.9	7.16	70.0	30.0	7.4
	4507	100.0	9.8	6.29	82.0	53.0	7.4
	4508	91.0	9.6	7.44	60.0	49.0	7.0
	4509	75.0	10.5	5.10	86.0	39.0	7.4
	4510	94.0	10.4	4.55	63.0	34.0	7.4
	4511	141.0	9.9	6.31	76.0	66.0	6.8
	4513	126.0	10.1	5.51	66.0	38.0	7.4
	4514	142.0	9.8	5.04	56.0	41.0	7.0
	4515	110.0	10.4	6.14	85.0	26.0	7.3
	4516	118.0	9.7	6.94	70.0	55.0	6.4

WEEK 6 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	3.5	1.00	3.5	146.0	7.02	108.0
	4502	3.6	1.06	3.4	142.0	5.97	107.0
	4503	3.5	1.03	3.4	146.0	6.07	110.0
	4504	3.7	1.06	3.5	145.0	5.28	105.0
	4505	3.4	1.00	3.4	147.0	4.76	107.0
	4506	3.8	1.06	3.6	143.0	5.10	105.0
	4507	3.6	.95	3.8	149.0	4.91	108.0
	4508	3.5	1.00	3.5	145.0	6.03	106.0
	4509	3.9	1.11	3.5	145.0	4.37	106.0
	4510	3.7	1.00	3.7	146.0	4.36	108.0
	4511	3.5	1.06	3.3	145.0	5.08	105.0
	4513	3.7	1.00	3.7	148.0	5.19	108.0
	4514	3.6	1.06	3.4	149.0	4.43	109.0
	4515	3.6	.97	3.7	147.0	4.74	106.0
	4516	3.3	1.06	3.1	146.0	5.73	106.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	1001	13.3	.7	114.0	.13	152.0	41.0
	1002	15.2	.7	132.0	.11	182.0	40.0
	1005	11.6	.6	117.0	.11	115.0	33.0
	1006	18.4	.7	128.0	.10	149.0	35.0
	1007	11.7	.8	147.0	.10	128.0	36.0
	1008	11.0	.4	148.0	.12	96.0	33.0
	1009	14.3	.5	129.0	.10	118.0	44.0
	1010	12.4	.7	132.0	.07	151.0	49.0
	1011	11.9	.6	150.0	.10	126.0	31.0
	1012	8.7	.5	148.0	.09	130.0	36.0
	1013	13.3	.6	142.0	.11	125.0	31.0
	1014	11.4	.6	152.0	.08	92.0	32.0
	1015	10.7	.5	150.0	.09	119.0	23.0
	1016	17.0	.6	131.0	.06	139.0	30.0
	1017	12.6	.7	131.0	.11	113.0	33.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	1001	84.0	9.2	6.06	54.0	57.0	6.3
	1002	106.0	9.1	5.95	64.0	47.0	6.0
	1005	58.0	9.9	7.08	69.0	102.0	6.8
	1006	97.0	9.5	5.78	41.0	54.0	6.8
	1007	51.0	9.5	6.85	50.0	79.0	6.0
	1008	67.0	9.2	7.90	30.0	36.0	5.8
	1009	71.0	9.9	7.34	50.0	37.0	5.9
	1010	80.0	9.3	7.45	54.0	74.0	6.2
	1011	66.0	9.5	8.21	43.0	42.0	5.6
	1012	49.0	9.7	6.47	62.0	55.0	6.3
	1013	63.0	9.0	7.77	33.0	54.0	5.8
	1014	70.0	9.5	7.42	31.0	68.0	6.0
	1015	46.0	10.0	7.06	98.0	83.0	6.6
	1016	85.0	9.1	6.68	57.0	111.0	5.8
	1017	51.0	9.4	7.06	48.0	127.0	5.9

WEEK 13 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	1001	2.9	.85	3.4	143.0	4.54	98.0
	1002	2.9	.94	3.1	144.0	4.52	100.0
	1005	3.0	.79	3.8	145.0	4.79	102.0
	1006	3.2	.89	3.6	147.0	4.29	102.0
	1007	2.9	.94	3.1	145.0	4.56	101.0
	1008	2.9	1.00	2.9	145.0	4.62	102.0
	1009	2.9	.97	3.0	148.0	4.58	103.0
	1010	2.8	.82	3.4	144.0	4.99	101.0
	1011	2.8	1.00	2.8	145.0	4.75	101.0
	1012	3.1	.97	3.2	147.0	4.91	103.0
	1013	2.9	1.00	2.9	147.0	4.76	103.0
	1014	2.8	.87	3.2	146.0	4.30	103.0
	1015	3.1	.89	3.5	147.0	4.66	105.0
	1016	2.8	.93	3.0	144.0	4.51	100.0
	1017	2.9	.97	3.0	144.0	4.32	100.0

WEEK 13 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 2 - CERIC OXIDE LOW DOSE	2001	18.6	.9	135.0	.10	155.0	38.0
	2002	16.1	.5	132.0	.08	160.0	33.0
	2003	11.4	.5	118.0	.08	132.0	35.0
	2004	14.3	.6	145.0	.10	120.0	30.0
	2005	12.0	.7	132.0	.11	96.0	38.0
	2006	13.8	.6	129.0	.07	107.0	43.0
	2007	14.6	.8	144.0	.08	112.0	40.0
	2008	12.5	.8	110.0	.11	208.0	58.0
	2009	14.0	.6	162.0	.09	108.0	41.0
	2010	12.0	.6	151.0	.12	139.0	37.0
	2011	11.1	.6	143.0	.13	108.0	48.0
	2012	13.5	.5	138.0	.11	117.0	43.0
	2013	16.0	.5	171.0	.08	184.0	41.0
	2015	11.8	.5	137.0	.08	125.0	32.0
	2016	13.6	.6	136.0	.11	127.0	29.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 2 - CERIC OXIDE LOW DOSE	2001	78.0	8.9	6.76	53.0	67.0	6.3
	2002	74.0	8.9	6.61	59.0	127.0	6.0
	2003	99.0	9.5	6.62	74.0	143.0	6.1
	2004	41.0	9.7	7.73	51.0	104.0	6.2
	2005	63.0	9.3	7.31	33.0	33.0	5.6
	2006	136.0	9.6	6.72	40.0	59.0	6.4
	2007	62.0	8.9	7.14	42.0	30.0	6.3
	2008	67.0	9.7	8.04	68.0	40.0	6.5
	2009	89.0	9.5	7.52	54.0	48.0	5.6
	2010	72.0	9.4	7.69	57.0	104.0	6.2
	2011	67.0	9.4	7.75	39.0	23.0	5.7
	2012	64.0	9.3	7.39	43.0	27.0	5.4
	2013	69.0	9.3	7.47	54.0	26.0	6.0
	2015	101.0	9.2	8.10	49.0	28.0	5.9
	2016	55.0	9.5	7.07	44.0	44.0	6.1

WEEK 13 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 2 - CERIC OXIDE LOW DOSE	2001	3.0	.91	3.3	141.0	5.09	99.0
	2002	2.9	.94	3.1	144.0	4.48	98.0
	2003	3.0	.97	3.1	144.0	4.71	100.0
	2004	2.9	.88	3.3	145.0	4.82	102.0
	2005	2.7	.93	2.9	144.0	4.24	101.0
	2006	3.2	1.00	3.2	147.0	4.56	103.0
	2007	2.8	.80	3.5	145.0	4.20	103.0
	2008	3.0	.86	3.5	146.0	5.23	99.0
	2009	2.8	1.00	2.8	146.0	4.77	102.0
	2010	2.9	.88	3.3	142.0	5.03	100.0
	2011	2.9	1.04	2.8	146.0	4.71	102.0
	2012	2.7	1.00	2.7	145.0	4.50	104.0
	2013	2.9	.94	3.1	144.0	4.54	100.0
	2015	2.9	.97	3.0	147.0	4.62	104.0
	2016	2.9	.91	3.2	145.0	4.79	102.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	14.4	.6	121.0	.09	125.0	33.0
	3002	19.0	.7	126.0	.06	136.0	36.0
	3003	16.4	.6	131.0	.10	142.0	41.0
	3004	14.1	.7	152.0	.13	118.0	45.0
	3005	13.2	.6	175.0	.11	118.0	32.0
	3006	12.8	.6	173.0	.15	104.0	35.0
	3007	13.6	.7	152.0	.10	150.0	30.0
	3008	12.1	.5	147.0	.08	140.0	47.0
	3009	16.0	.6	162.0	.14	124.0	35.0
	3011	11.5	.4	156.0	.07	125.0	30.0
	3012	14.4	.4	152.0	.09	130.0	34.0
	3013	11.2	.7	163.0	.12	112.0	27.0
	3014	14.4	.7	154.0	.09	124.0	34.0
	3015	12.7	.7	152.0	.08	132.0	35.0
	3016	12.3	.5	148.0	.06	166.0	30.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	60.0	9.2	6.41	55.0	81.0	6.0
	3002	80.0	9.1	7.09	57.0	88.0	6.0
	3003	83.0	10.0	6.63	77.0	111.0	7.3
	3004	66.0	9.7	7.60	63.0	85.0	6.2
	3005	89.0	10.3	9.13	65.0	58.0	5.6
	3006	56.0	10.0	7.53	66.0	61.0	6.2
	3007	84.0	9.5	6.55	47.0	41.0	6.3
	3008	70.0	9.4	7.21	62.0	150.0	6.0
	3009	98.0	9.9	7.43	72.0	28.0	6.3
	3011	72.0	9.1	6.66	40.0	35.0	6.5
	3012	79.0	9.7	6.97	41.0	47.0	6.1
	3013	79.0	9.7	8.22	54.0	46.0	6.1
	3014	68.0	9.3	6.90	42.0	37.0	6.0
	3015	78.0	9.6	7.32	50.0	36.0	6.3
	3016	62.0	9.0	7.23	43.0	42.0	5.5

WEEK 13 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	2.9	.94	3.1	143.0	4.65	100.0
	3002	2.8	.87	3.2	144.0	4.48	101.0
	3003	3.1	.74	4.2	145.0	4.44	102.0
	3004	2.9	.88	3.3	144.0	4.70	100.0
	3005	2.8	1.00	2.8	143.0	8.47	101.0
	3006	2.9	.88	3.3	145.0	4.54	103.0
	3007	3.0	.91	3.3	143.0	5.06	99.0
	3008	2.9	.94	3.1	145.0	4.68	101.0
	3009	3.1	.97	3.2	146.0	4.73	102.0
	3011	2.8	.76	3.7	143.0	5.14	103.0
	3012	2.9	.91	3.2	144.0	4.93	102.0
	3013	2.9	.91	3.2	146.0	4.73	102.0
	3014	2.9	.94	3.1	145.0	4.58	103.0
	3015	3.0	.91	3.3	146.0	4.70	103.0
	3016	2.8	1.04	2.7	145.0	4.74	100.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	14.8	.5	107.0	.09	151.0	36.0
	4003	13.9	.6	123.0	.14	169.0	48.0
	4004	12.3	.7	115.0	.10	205.0	98.0
	4005	17.2	.6	117.0	.09	141.0	48.0
	4006	13.2	.5	104.0	.10	130.0	34.0
	4007	16.2	.9	157.0	.08	116.0	39.0
	4008	17.3	.6	158.0	.08	109.0	43.0
	4009	16.4	.5	161.0	.09	107.0	35.0
	4010	11.1	.6	134.0	.10	157.0	32.0
	4011	11.5	.5	118.0	.07	147.0	26.0
	4012	14.3	.8	163.0	.09	142.0	47.0
	4014	12.0	.7	156.0	.07	140.0	51.0
	4015	12.1	.7	161.0	.11	103.0	28.0
	4016	20.8	.6	146.0	.07	131.0	24.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	82.0	9.1	7.08	50.0	49.0	5.7
	4003	56.0	9.2	6.24	69.0	81.0	6.0
	4004	80.0	9.4	6.19	54.0	43.0	6.2
	4005	90.0	9.3	7.86	39.0	79.0	5.9
	4006	75.0	9.7	6.49	57.0	91.0	6.3
	4007	93.0	9.4	7.20	45.0	23.0	5.4
	4008	90.0	9.6	7.53	49.0	29.0	5.8
	4009	83.0	9.5	7.84	36.0	36.0	5.8
	4010	78.0	9.3	7.03	41.0	81.0	6.2
	4011	72.0	8.9	6.70	40.0	46.0	5.7
	4012	103.0	9.2	7.13	42.0	46.0	5.6
	4014	124.0	9.2	7.89	44.0	38.0	6.0
	4015	67.0	9.9	7.62	63.0	60.0	6.4
	4016	59.0	9.2	7.50	73.0	73.0	6.9

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - MALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	2.9	1.04	2.8	145.0	4.11	100.0
	4003	2.9	.94	3.1	146.0	4.34	102.0
	4004	3.0	.94	3.2	145.0	4.40	103.0
	4005	2.8	.90	3.1	146.0	4.80	101.0
	4006	3.1	.97	3.2	145.0	4.60	103.0
	4007	2.7	1.00	2.7	144.0	4.70	104.0
	4008	2.6	.81	3.2	145.0	4.39	102.0
	4009	2.9	1.00	2.9	146.0	4.63	103.0
	4010	3.0	.94	3.2	146.0	4.86	102.0
	4011	2.8	.97	2.9	145.0	4.95	102.0
	4012	2.8	1.00	2.8	146.0	4.78	103.0
	4014	2.8	.87	3.2	146.0	4.70	102.0
	4015	3.0	.88	3.4	146.0	4.83	102.0
	4016	2.6	.60	4.3	144.0	4.79	103.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 1 - AIR CONTROL	1501	12.0	.9	98.0	.14	129.0	34.0
	1502	20.1	.5	120.0	.12	107.0	29.0
	1503	18.7	.8	119.0	.14	120.0	32.0
	1504	15.1	.7	125.0	.08	96.0	36.0
	1505	16.6	.5	144.0	.07	114.0	53.0
	1506	15.7	.8	140.0	.10	114.0	38.0
	1507	13.8	.6	151.0	.12	114.0	27.0
	1508	11.8	.5	132.0	.11	99.0	39.0
	1509	18.0	.7	130.0	.13	109.0	33.0
	1510	13.7	.6	165.0	.10	182.0	29.0
	1511	14.5	.7	143.0	.12	114.0	31.0
	1512	14.0	.5	122.0	.15	175.0	29.0
	1513	14.7	.7	140.0	.13	106.0	27.0
	1514	14.3	.8	143.0	.09	117.0	33.0
	1515	14.1	.5	158.0	.16	96.0	43.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 1 - AIR CONTROL	1501	72.0	9.3	5.84	73.0	35.0	7.0
	1502	38.0	9.3	5.33	78.0	57.0	6.5
	1503	60.0	9.1	5.62	52.0	46.0	6.4
	1504	64.0	9.3	6.54	82.0	53.0	6.1
	1505	42.0	9.0	5.61	54.0	32.0	6.0
	1506	64.0	9.5	7.34	35.0	29.0	6.1
	1507	49.0	9.4	7.38	42.0	35.0	6.0
	1508	45.0	9.7	6.85	82.0	43.0	6.4
	1509	48.0	9.8	9.04	55.0	30.0	5.8
	1510	64.0	9.1	6.30	59.0	53.0	6.4
	1511	62.0	10.1	7.61	53.0	58.0	6.4
	1512	63.0	10.1	7.81	38.0	29.0	6.4
	1513	35.0	9.4	7.16	56.0	34.0	6.8
	1514	64.0	9.8	6.48	36.0	18.0	6.1
	1515	46.0	10.3	6.81	107.0	45.0	7.2

WEEK 13 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 1 - AIR CONTROL	1501	3.2	.84	3.8	143.0	4.47	101.0
	1502	3.2	.97	3.3	147.0	4.27	104.0
	1503	3.2	1.00	3.2	145.0	4.04	100.0
	1504	3.1	1.03	3.0	145.0	3.87	102.0
	1505	3.0	1.00	3.0	143.0	3.73	102.0
	1506	3.2	1.10	2.9	146.0	4.54	105.0
	1507	3.0	1.00	3.0	144.0	4.28	104.0
	1508	3.1	.94	3.3	146.0	4.44	103.0
	1509	2.8	.93	3.0	145.0	4.54	105.0
	1510	3.2	1.00	3.2	143.0	4.23	103.0
	1511	3.2	1.00	3.2	148.0	4.38	104.0
	1512	3.2	1.00	3.2	146.0	4.27	104.0
	1513	3.0	.79	3.8	143.0	4.54	105.0
	1514	3.0	.97	3.1	146.0	4.19	105.0
	1515	3.5	.95	3.7	144.0	4.50	104.0

WEEK 13 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 2 - CERIC OXIDE LOW DOSE	2501	17.0	.9	137.0	.10	90.0	37.0
	2502	18.9	.6	151.0	.09	171.0	39.0
	2503	21.0	.6	130.0	.08	108.0	34.0
	2504	13.3	.6	123.0	.09	143.0	30.0
	2505	14.3	.9	121.0	.10	146.0	36.0
	2506	15.3	.6	157.0	.14	130.0	29.0
	2507	14.8	.6	131.0	.10	87.0	31.0
	2508	15.1	.6	145.0	.10	107.0	29.0
	2509	18.7	.6	172.0	.20	126.0	40.0
	2510	16.0	.7	131.0	.10	142.0	32.0
	2511	14.2	.7	141.0	.10	117.0	31.0
	2512	15.6	.5	138.0	.09	99.0	26.0
	2513	17.2	.7	146.0	.11	101.0	23.0
	2514	15.2	.7	126.0	.11	122.0	37.0
	2515	13.6	.4	146.0	.10	97.0	27.0

WEEK 13 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 2 - CERIC OXIDE LOW DOSE	2501	37.0	9.4	5.25	77.0	45.0	6.4
	2502	63.0	9.1	6.04	49.0	31.0	6.3
	2503	65.0	9.7	6.93	56.0	27.0	6.0
	2504	42.0	9.1	7.60	60.0	38.0	5.8
	2505	46.0	9.6	6.13	75.0	43.0	6.5
	2506	53.0	10.0	7.34	91.0	44.0	6.7
	2507	45.0	9.9	6.95	93.0	60.0	6.1
	2508	51.0	10.1	6.35	55.0	43.0	6.5
	2509	59.0	10.5	8.02	73.0	46.0	6.5
	2510	28.0	9.4	6.77	66.0	41.0	6.1
	2511	78.0	9.3	6.86	47.0	29.0	5.7
	2512	49.0	10.4	8.12	78.0	40.0	6.5
	2513	50.0	9.4	7.19	51.0	33.0	5.9
	2514	89.0	10.0	7.17	54.0	33.0	6.2
	2515	55.0	9.7	6.31	85.0	34.0	6.7

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 2 - CERIC OXIDE LOW DOSE	2501	3.2	1.00	3.2	144.0	4.02	102.0
	2502	3.1	.97	3.2	145.0	3.65	103.0
	2503	3.1	1.07	2.9	144.0	3.97	101.0
	2504	2.8	.93	3.0	143.0	4.32	103.0
	2505	3.2	.97	3.3	144.0	4.94	104.0
	2506	3.3	.97	3.4	142.0	3.99	101.0
	2507	3.0	.97	3.1	145.0	4.30	103.0
	2508	2.8	.76	3.7	143.0	4.20	103.0
	2509	3.1	.91	3.4	144.0	4.65	102.0
	2510	2.8	.85	3.3	142.0	4.33	103.0
	2511	2.8	.97	2.9	147.0	4.26	105.0
	2512	2.9	.81	3.6	144.0	4.56	104.0
	2513	2.8	.90	3.1	146.0	4.43	105.0
	2514	3.1	1.00	3.1	147.0	4.80	106.0
	2515	3.1	.86	3.6	145.0	3.97	104.0

WEEK 13 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	16.2	.5	145.0	.08	115.0	37.0
	3502	16.8	.6	131.0	.08	119.0	33.0
	3503	15.6	.3	141.0	.12	119.0	36.0
	3504	13.6	.8	126.0	.10	107.0	34.0
	3505	15.5	.3	134.0	.09	130.0	34.0
	3506	15.1	.7	148.0	.12	105.0	37.0
	3507	16.5	.6	92.0	.12	160.0	32.0
	3508	16.4	.6	120.0	.12	112.0	30.0
	3509	15.1	.7	76.0	.12	144.0	37.0
	3510	13.4	.7	147.0	.14	117.0	39.0
	3511	17.4	.8	126.0	.10	165.0	38.0
	3513	12.7	.7	167.0	.09	109.0	23.0
	3514	12.4	.3	149.0	.15	94.0	35.0
	3516	14.0	.5	137.0	.13	108.0	34.0
	3517	14.5	.6	145.0	.10	101.0	52.0

APPENDIX NO. 9 INDIVIDUAL CLINICAL BIOCHEMICAL ANALYSES PROJECT NO :90831

WEEK 13 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	45.0	9.3	5.73	53.0	41.0	6.5
	3502	61.0	9.3	6.83	37.0	45.0	6.1
	3503	67.0	9.6	6.30	78.0	43.0	6.5
	3504	53.0	9.5	6.76	62.0	27.0	7.1
	3505	75.0	9.7	6.17	85.0	35.0	7.0
	3506	73.0	9.6	7.73	43.0	27.0	6.1
	3507	44.0	9.4	6.59	50.0	13.0	6.8
	3508	43.0	10.1	5.96	78.0	21.0	7.3
	3509	43.0	9.8	7.65	42.0	22.0	6.5
	3510	63.0	9.5	6.55	40.0	45.0	6.3
	3511	49.0	9.3	6.42	59.0	20.0	6.0
	3513	58.0	9.9	7.26	49.0	42.0	5.9
	3514	46.0	9.9	6.31	64.0	33.0	6.8
	3516	34.0	9.8	7.56	44.0	29.0	6.2
	3517	55.0	10.7	8.02	70.0	35.0	6.5

WEEK 13 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	3.2	.97	3.3	145.0	3.64	102.0
	3502	3.0	.97	3.1	147.0	4.47	106.0
	3503	3.2	.97	3.3	144.0	4.15	101.0
	3504	2.9	.69	4.2	142.0	3.93	103.0
	3505	3.4	.94	3.6	146.0	4.83	105.0
	3506	3.0	.97	3.1	146.0	4.31	103.0
	3507	3.3	.94	3.5	146.0	4.66	104.0
	3508	3.6	.97	3.7	147.0	4.60	105.0
	3509	3.1	.91	3.4	148.0	4.61	105.0
	3510	3.0	.91	3.3	144.0	4.21	104.0
	3511	3.1	1.07	2.9	147.0	4.20	105.0
	3513	3.1	1.11	2.8	145.0	4.57	104.0
	3514	3.3	.94	3.5	144.0	4.30	102.0
	3516	3.1	1.00	3.1	146.0	4.49	105.0
	3517	3.0	.86	3.5	146.0	4.30	105.0

WEEK 13 - FEMALES

	ANIMAL NO.	B.U.N. MG/DL	CREAT-ININE MG/DL	GLUCOSE MG/DL	TOTAL BILI-RUBIN MG/DL	AST U/L	ALT U/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	16.9	.8	133.0	.11	136.0	36.0
	4502	19.8	.7	154.0	.09	142.0	35.0
	4503	22.5	.7	138.0	.13	245.0	172.0
	4504	14.3	.4	80.0	.10	140.0	32.0
	4505	17.2	.7	103.0	.08	91.0	36.0
	4506	19.1	.5	83.0	.11	138.0	30.0
	4507	12.4	.6	151.0	.12	103.0	39.0
	4508	11.7	.6	140.0	.14	118.0	38.0
	4509	16.7	.6	114.0	.14	103.0	33.0
	4510	16.2	.8	129.0	.10	91.0	33.0
	4511	12.1	.7	129.0	.14	150.0	31.0
	4513	10.2	.4	144.0	.12	114.0	35.0
	4514	15.3	.6	130.0	.10	117.0	28.0
	4515	14.5	.4	160.0	.10	129.0	26.0
	4516	16.0	.4	113.0	.09	117.0	31.0

WEEK 13 - FEMALES

	ANIMAL NO.	ALKALINE PHOS-PHATASE U/L	CA MG/DL	PHOS-PHORUS MG/DL	CHOLES-TEROL MG/DL	TRIGLY-CERIDES MG/DL	TOTAL PROTEIN G/DL
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	54.0	9.1	5.38	66.0	45.0	6.0
	4502	63.0	9.2	5.60	36.0	69.0	6.3
	4503	60.0	9.4	7.75	63.0	35.0	6.3
	4504	62.0	9.4	7.66	53.0	29.0	6.9
	4505	56.0	9.5	7.30	65.0	23.0	6.5
	4506	49.0	9.7	6.00	64.0	28.0	6.9
	4507	40.0	9.4	5.67	84.0	43.0	6.7
	4508	48.0	10.0	6.90	57.0	56.0	6.5
	4509	32.0	10.8	7.63	69.0	46.0	6.6
	4510	54.0	9.4	6.47	48.0	46.0	6.0
	4511	80.0	9.9	6.18	60.0	32.0	6.6
	4513	53.0	9.9	6.46	54.0	45.0	6.5
	4514	74.0	9.5	7.42	47.0	29.0	5.9
	4515	36.0	10.0	6.41	61.0	35.0	6.6
	4516	51.0	10.0	7.23	65.0	47.0	6.1

WEEK 13 - FEMALES

	ANIMAL NO.	ALBUMIN G/DL	A/G RATIO	GLOBULIN G/DL	NA MEQ/L	K MEQ/L	CL MEQ/L
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	3.0	1.00	3.0	143.0	4.33	102.0
	4502	3.1	.97	3.2	142.0	4.26	103.0
	4503	3.2	1.03	3.1	145.0	4.03	103.0
	4504	3.2	.86	3.7	146.0	4.74	102.0
	4505	3.1	.91	3.4	147.0	4.75	107.0
	4506	3.5	1.03	3.4	147.0	4.49	103.0
	4507	3.2	.91	3.5	144.0	3.42	101.0
	4508	3.2	.97	3.3	146.0	4.25	104.0
	4509	3.4	1.06	3.2	145.0	4.42	104.0
	4510	2.9	.94	3.1	144.0	4.08	103.0
	4511	3.2	.94	3.4	147.0	4.78	106.0
	4513	3.2	.97	3.3	143.0	4.62	104.0
	4514	3.0	1.03	2.9	146.0	4.34	106.0
	4515	3.2	.94	3.4	146.0	4.54	104.0
	4516	3.0	.97	3.1	145.0	4.36	105.0

APPENDIX NO. 10 PROJECT NO. 90831

INDIVIDUAL URINALYSIS
MALES AND FEMALES

The following footnotes have been used throughout the appendix:

Ns	No sample
NSQ	Not sufficient quantity

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
HEALTH SCREEN
MALES

PROJECT NO. 90831

	CHEMICAL ANALYSIS								GROSS ANALYSIS			
ANIMAL NO.	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
5001	6.5	-	-	±	-	-	3.2	-	1.015	Y	C	12.5
5002	7.0	-	-	±	-	-	3.2	-	1.015	Y	C	8.0
5003	7.0	-	-	-	-	-	3.2	-	1.010	LY	C	14.0
5004	6.5	-	-	±	-	0.3	16.0	-	1.030	Y	C	2.5
5005	7.0	-	-	≥7.8	-	0.3	16.0	-	1.025	Y	C	3.0
5006	7.5	-	-	-	-	-	3.2	-	1.015	LY	C	10.0
5007	6.5	-	-	±	-	±	16.0	-	1.025	Y	C	3.0
5008	7.0	-	-	-	-	-	3.2	-	1.015	LY	C	9.0
5009	7.0	-	-	-	-	-	3.2	-	1.015	LY	C	9.0
5010	6.5	-	-	1.5	-	±	3.2	+	1.025	Y	C	6.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
HEALTH SCREEN
MALES

PROJECT NO. 90831

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
5001	0-1	-	-	-	+++	-	+TP	+AU	-	-	-
5002	0-1	-	-	-	+++	-	+TP	-	-	-	+CS
5003	0-1	-	-	-	+++	-	++TP	-	-	-	-
5004	-	-	-	-	++++	-	+TP	-	-	-	+CS
5005	0-1	-	0-2	-	++++	-	+TP	-	-	-	-
5006	-	-	-	-	+	-	+TP	-	-	-	-
5007	0-1	-	-	-	+	-	+TP	-	-	-	-
5008	0-1	-	-	-	+++	-	+AP+TP	-	-	-	-
5009	0-1	-	0-1	-	+++	-	+TP	-	-	-	-
5010	0-1	-	0-2	-	++++	-	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
HEALTH SCREEN
FEMALES

PROJECT NO. 90831

	CHEMICAL ANALYSIS								GROSS ANALYSIS			
ANIMAL NO.	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
5501	7.0	-	-	-	-	-	3.2	-	1.010	LY	C	10.0
5502	7.5	-	-	-	-	-	3.2	-	1.010	LY	C	7.0
5503	7.0	-	-	1.5	-	-	3.2	-	1.020	Y	C	2.0
5504	7.0	-	-	-	-	-	3.2	-	1.015	Y	C	2.5
5505	7.0	-	-	3.9	-	-	3.2	-	1.020	Y	C	4.0
5506	7.0	-	-	±	-	-	3.2	-	1.015	Y	C	2.5
5507	6.5	-	-	1.5	-	±	16.0	-	1.025	Y	C	2.0
5508	7.5	-	-	±	-	±	3.2	-	1.015	Y	C	3.5
5509	6.5	-	-	-	-	-	3.2	-	1.020	Y	C	4.0
5510	7.0	-	-	-	-	±	16.0	-	1.015	Y	C	3.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
HEALTH SCREEN
FEMALES

PROJECT NO. 90831

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
5501	–	–	0-2	–	+++	–	+TP	–	–	–	+CS
5502	0-1	–	–	–	++	–	+TP	–	–	–	+CS
5503	–	–	0-1	–	+++	–	+TP	–	–	–	–
5504	0-1	–	0-1	–	+++	–	+TP	–	–	–	–
5505	0-1	0-2	–	–	+++	–	+TP	–	–	–	–
5506	0-1	–	–	–	+++	–	+TP	–	–	–	–
5507	0-1	–	–	–	++	–	+TP	–	–	–	+CS
5508	0-1	–	–	–	+++	–	+TP	–	–	–	–
5509	0-1	–	0-1	–	+	–	+TP	–	–	–	+CS
5510	0-1	–	0-2	–	+++	–	+TP	–	–	–	–

APPENDIX NO. 10

PROJECT NO. 90831

INDIVIDUAL URINALYSIS
WEEK 6
MALES

GROUP 1 - AIR CONTROL

ANIMAL NO.	CHEMICAL ANALYSIS								GROSS ANALYSIS			
	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
1001	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	C	7.5
1002	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	C	8.0
1005	6.0	-	+	1.5	-	1.0	16.0	+	1.060	Y	C	1.5
1006	6.5	-	-	±	-	1.0	16.0	+	1.025	Y	C	7.0
1007	6.5	-	-	±	-	0.3	16.0	-	1.025	Y	C	10.0
1008	6.5	-	-	-	-	±	3.2	-	1.010	LtY	C	20.0
1009	5.0	-	+	±	-	≥3.0	16.0	+	1.124	Y	C	1.0
1010	7.0	-	-	-	-	0.3	3.2	-	1.015	LtY	C	10.5
1011 Ns												
1012	7.5	-	-	±	-	0.3	16.0	-	1.020	Y	C	13.0
1013	6.5	-	-	±	-	-	3.2	-	1.015	Y	C	20.0
1014	7.5	-	-	±	-	±	3.2	-	1.015	Y	C	13.5
1015	6.5	-	-	-	-	0.3	16.0	-	1.036	Y	C	6.0
1016	6.5	-	-	±	-	±	3.2	-	1.025	Y	C	15.0
1017	7.0	-	-	1.5	-	0.3	3.2	-	1.025	Y	C	7.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
1001	0-1	0-1	0-1	-	++	-	+TP	-	-	-	-
1002	0-1	-	0-1	-	++	-	-	-	-	-	+CC
1005	0-1	0-1	0-1	-	+	-	-	-	-	-	-
1006	2-3	-	-	-	++	+S	+TP	-	-	-	-
1007	0-2	3-5	0-2	-	+	-	+TP	-	-	-	-
1008	2-3	-	0-1	-	++	+S	-	-	-	-	-
1009	-	-	-	-	+	+S	+TP	-	-	-	+CS
1010	0-1	0-1	0-1	-	+	-	+TP	-	-	-	-
1011 Ns											
1012	0-1	0-1	1-2	++	++	-	+TP	-	-	-	+CC
1013	0-1	-	1-2	-	+	-	+TP	-	-	-	+CC
1014	0-1	1-2	0-1	-	-	-	+TP	-	-	-	-
1015	0-1	0-1	1-2	-	+	-	+TP	-	-	-	+CC
1016	2-3	0-1	1-2	-	+	-	-	-	-	-	+CS+CC
1017	0-1	0-1	0-1	-	+	+S	+TP	-	-	-	+CC

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	CHEMICAL ANALYSIS								GROSS ANALYSIS			
ANIMAL NO.	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
2001	6.0	-	-	-	-	0.3	16.0	-	1.032	Y	C	3.5
2002	6.0	-	+	1.5	-	1.0	16.0	-	1.044	Y	Cl	4.0
2003	7.0	-	-	±	-	0.3	3.2	-	1.025	Y	Cl	15.0
2004	6.5	-	+	±	-	1.0	16.0	-	1.048	Y	C	5.0
2005	6.0	-	+	±	-	1.0	16.0	-	1.050	Y	Cl	4.5
2006	6.5	-	-	-	-	0.3	3.2	+	1.038	Y	C	2.5
2007	6.0	-	-	±	-	0.3	16.0	-	1.048	Y	C	5.0
2008	6.5	-	-	-	-	±	3.2	-	1.020	LtY	C	13.0
2009	6.0	-	+	±	-	≥3.0	16.0	+	1.084	Y	C	1.0
2010	6.0	-	-	±	-	±	3.2	+	1.015	LtY	C	13.0
2011	7.0	-	+	±	-	0.3	16.0	+	1.025	Y	C	2.5
2012	6.0	-	-	-	-	-	3.2	-	1.010	LtY	C	21.0
2013	7.5	-	-	-	-	±	3.2	-	1.010	LtY	C	30.0
2015	6.5	-	+	1.5	-	1.0	16.0	+	1.025	Y	C	2.0
2016	6.5	-	+	1.5	-	≥3.0	16.0	+	1.064	Y	C	4.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
2001	0-1	-	0-1	-	+	-	-	-	-	-	+CC
2002	1-2	0-1	15-20	++	++	+S	+TP	-	-	-	-
2003	0-1	-	1-2	+	++	+S	+TP	-	-	-	-
2004	1-2	2-3	1-2	+	+	+S	+TP	-	-	-	-
2005	1-2	-	15-20	+	+	-	-	-	-	-	-
2006	0-1	-	-	-	++	-	-	-	-	-	+CS
2007	0-1	-	-	-	+	+S	-	-	-	-	+CS
2008	0-1	-	0-1	-	++	+S	+TP	-	-	-	-
2009	-	-	0-1	-	-	-	+TP	-	-	-	+CS
2010	0-1	-	0-1	-	-	+S	+TP	-	-	-	-
2011	-	-	0-1	-	+	-	+TP	-	-	-	+CS+CC
2012	1-2	-	1-2	-	+	+S	+TP	-	-	-	-
2013	0-1	-	1-2	-	+	+S	+TP	-	-	-	+CC
2015	0-1	-	0-1	-	+	+S	+TP	-	-	-	+CS
2016	0-1	-	1-2	-	+	-	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	CHEMICAL ANALYSIS								GROSS ANALYSIS			
ANIMAL NO.	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
3001	6.0	-	-	1.5	-	0.3	16.0	-	1.042	Y	C	2.5
3002	7.0	-	-	1.5	-	0.3	3.2	+	1.025	Y	Cl	7.0
3003	6.5	-	-	±	-	0.3	3.2	-	1.040	Y	C	6.0
3004	6.0	-	+	-	-	0.3	16.0	-	1.048	Y	C	4.5
3005	7.0	-	-	±	-	1.0	16.0	-	1.040	Y	Cl	7.0
3006	7.0	-	-	±	-	0.3	3.2	-	1.025	Y	C	9.5
3007	7.5	-	-	-	-	±	3.2	-	1.015	LtY	C	18.0
3008	7.0	-	-	±	-	0.3	3.2	-	1.025	LtY	C	9.5
3009	6.5	-	+	±	-	≥3.0	16.0	+	1.080	Y	C	1.5
3011	7.0	-	+	1.5	++	≥3.0	16.0	+	1.056	Y	C	2.5
3012	7.0	-	-	±	-	±	3.2	-	1.015	Y	C	14.0
3013	7.0	-	-	±	±	0.3	3.2	+	1.020	Y	C	5.0
3014	7.0	-	-	±	-	0.3	16.0	-	1.020	Y	C	10.5
3015	7.5	-	-	-	-	-	3.2	-	1.015	LtY	C	22.0
3016	7.0	-	-	±	±	0.3	3.2	-	1.020	LtY	C	7.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
3001	0-1	-	1-2	-	++	+S	-	-	-	-	+CS
3002	0-1	-	1-2	-	+	+S	+TP	-	-	-	+CC+CS
3003	0-1	-	2-3	-	+	+S	+TP	-	-	-	-
3004	0-1	1-2	1-2	-	+	+S	-	-	-	-	-
3005	0-1	-	2-3	-	+	+S	+TP	-	-	-	-
3006	0-1	0-1	-	-	+	-	+TP	-	-	-	+CS
3007	-	-	0-1	-	+	+S	+TP	-	-	-	-
3008	0-1	-	0-1	-	+	+S	+TP	-	-	-	-
3009	-	-	-	-	+	-	+TP	-	-	-	+CS
3011	1-2	25-30	1-2	-	+	-	-	-	-	-	-
3012	0-1	-	0-1	-	-	-	+TP	-	-	-	-
3013	0-1	0-1	0-1	-	+	-	+TP	-	-	-	+CS
3014	0-1	-	0-1	+	-	-	+TP	-	-	-	-
3015	0-1	-	0-1	-	+	+S	-	-	-	-	+CS
3016	0-1	-	1-3	-	++	+S	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
4001	6.5	-	-	±	-	0.3	16.0	-	1.025	Y	C	6.0
4002	6.5	-	+	±	-	≥3.0	16.0	+	1.056	Y	C	2.5
4003	6.5	-	-	±	-	0.3	3.2	-	1.020	Y	Cl	10.0
4004	6.5	-	-	1.5	-	0.3	3.2	+	1.025	Y	C	5.0
4005	7.5	-	-	1.5	-	0.3	16.0	+	1.025	Y	C	6.0
4006	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	C	8.0
4007	7.0	-	-	-	-	±	3.2	-	1.015	LtY	C	10.0
4008	6.5	-	-	±	-	0.3	16.0	-	1.025	Y	C	4.0
4009	6.5	-	-	-	-	±	3.2	-	1.015	LtY	C	13.0
4010	5.0	-	+	±	-	1.0	16.0	+	1.060	Y	C	1.0
4011	6.5	-	-	-	-	-	3.2	-	1.007	LtY	C	35.0
4012	7.0	-	-	-	-	-	3.2	-	1.020	Y	C	5.5
4014	6.0	-	+	±	-	≥3.0	16.0	+	1.078	Y	C	1.0
4015	7.0	-	-	±	-	0.3	3.2	-	1.020	Y	C	11.0
4016	6.5	-	+	±	-	1.0	16.0	+	1.046	Y	C	3.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
4001	0-1	0-1	0-1	-	+	+S	+TP	-	-	-	+CC
4002	1-2	1-2	0-1	-	+	+S	+TP	-	-	-	+CC
4003	0-1	-	0-1	-	+++	+S	+TP	-	-	-	-
4004	0-1	-	0-1	-	+	-	-	-	-	-	-
4005	0-1	-	1-2	-	+	-	+TP	-	-	-	-
4006	0-1	-	0-1	-	++	-	+TP	-	-	-	+CS
4007	1-2	-	0-1	-	+++	-	+TP	-	-	-	+CS
4008	0-1	-	0-1	-	+	+S	-	-	-	-	+CS
4009	-	-	0-1	-	++	+S	-	-	-	-	-
4010	-	-	0-1	-	+	-	+TP	-	-	-	+CS
4011	0-1	-	1-2	-	-	-	-	-	-	-	-
4012	0-1	-	1-2	-	+	+S	+TP	-	-	-	+CC
4014	1-2	0-1	0-1	-	+	+S	+TP	-	-	-	-
4015	0-1	-	3-4	-	+	+S	+TP	-	-	-	+CC
4016	0-1	-	1-2	+	+	-	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
1501 Ns												
1502	5.5	-	-	-	-	-	3.2	+	1.015	LtY	C	12.0
1503	7.0	-	-	-	-	0.3	16.0	-	1.025	Y	C	4.0
1504	6.0	-	+	-	-	1.0	16.0	-	1.066	Y	C	2.5
1505	6.0	-	-	-	-	0.3	3.2	+	1.040	Y	C	4.0
1506	7.0	-	-	±	-	±	16.0	-	1.025	Y	C	3.0
1507	7.0	-	+	-	-	1.0	16.0	+	1.075	DY	C	1.0
1508	7.5	-	-	-	-	-	3.2	-	1.010	LtY	C	16.0
1509	8.0	-	-	-	-	-	3.2	-	1.015	LtY	Cl	9.0
1510	6.5	-	-	-	-	-	3.2	-	1.020	LtY	C	5.0
1511	6.5	-	-	-	-	0.3	16.0	+	1.036	Y	C	1.0
1512	6.0	-	-	-	-	-	3.2	+	1.026	Y	C	2.5
1513 Ns												
1514	7.0	-	-	-	-	-	16.0	+	1.010	LtY	C	6.0
1515	8.5	-	-	-	-	-	3.2	+	1.015	LtY	C	7.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

SEDIMENT MICROSCOPY

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
1501 Ns											
1502	8-10	-	3-4	+	++	-	+TP	-	-	-	+CS
1503	3-4	-	0-2	-	+	-	+TP	-	-	-	+CS
1504	2-3	-	0-1	+	++	-	+TP	+AU	-	-	-
1505	0-2	-	2-3	+	+++	-	-	+AU	-	-	-
1506	0-1	0-1	-	-	-	-	+AP	-	-	-	-
1507	4-6	-	0-2	-	+	-	+TP	++AU	-	-	+CS
1508	0-2	-	0-1	-	+	-	+AP	-	-	-	-
1509	3-4	0-1	0-2	-	++	-	+AP+TP	-	-	-	-
1510	0-2	-	0-2	-	++	-	+TP	-	-	-	-
1511	0-1	-	0-1	-	+	-	-	-	-	-	-
1512	0-1	-	0-1	-	+	-	-	-	-	-	+CS
1513 Ns											
1514	0-1	-	1-2	-	+	-	-	-	-	-	+CC+CS
1515	0-1	-	0-1	-	+++	-	-	-	-	-	+CC

APPENDIX NO. 10

PROJECT NO. 90831

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NITT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
2501	7.0	-	-	-	-	-	3.2	-	1.020	LtY	C	8.0
2502	6.5	-	-	-	-	0.3	3.2	+	1.044	LtY	C	0.5
2503	7.0	-	-	-	-	-	3.2	-	1.015	LtY	C	13.5
2504	6.5	-	-	-	-	-	3.2	-	1.020	LtY	C	11.5
2505	6.0	-	-	-	-	0.3	3.2	+	1.048	Y	C	2.0
2506	5.5	-	-	-	-	-	3.2	-	1.015	Y	C	8.0
2507	7.5	-	-	-	-	-	3.2	-	1.020	Y	C	4.0
2508	7.0	-	-	-	-	-	3.2	-	1.015	LtY	C	14.0
2509	7.0	-	-	-	-	-	3.2	-	1.015	LtY	C	8.0
2510	6.5	-	-	-	-	-	3.2	-	1.025	Y	C	6.5
2511	7.5	-	-	-	-	0.3	16.0	+	1.025	Y	C	1.5
2512	6.0	-	-	-	-	0.3	16.0	+	1.044	Y	C	1.0
2513	6.5	-	-	-	-	0.3	16.0	+	1.048	Y	C	1.0
2514	6.5	-	-	-	-	-	3.2	+	1.015	LtY	C	6.0
2515	7.0	-	-	-	-	0.3	16.0	-	1.025	Y	C	4.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

SEDIMENT MICROSCOPY

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
2501	0-2	-	1-2	-	++	-	-	+AU	-	-	-
2502	0-1	-	0-2	-	+	-	-	+AU	-	-	-
2503	2-3	-	0-1	-	+	-	+TP	-	-	-	-
2504	3-4	-	0-2	-	+++	-	++TP	-	-	-	+CS
2505	3-4	-	0-2	-	+	-	+TP	-	-	-	-
2506	2-3	-	0-1	+	+	-	+++TP	-	-	-	-
2507	2-3	0-2	0-1	-	+	-	+TP	-	-	-	+CS
2508	3-4	-	0-2	-	+++	-	+TP	+AU	-	-	-
2509	2-3	-	0-1	-	+++	-	+TP	-	-	-	-
2510	2-3	-	1-2	-	+	-	+TP	-	-	-	-
2511	0-1	-	1-2	-	+	-	+TP	-	-	-	-
2512	0-1	-	0-1	-	+	-	-	-	-	-	-
2513	0-1	-	0-1	-	+	-	-	-	-	-	-
2514	0-1	0-1	1-2	-	+	-	-	-	-	-	+CS
2515	0-1	0-1	0-1	-	+	-	-	-	-	-	+CC+CS

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CHEMICAL ANALYSIS								GROSS ANALYSIS			
	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
3501	6.0	-	+	-	-	0.3	16.0	+	1.060	LtY	C	0.5
3502	7.0	-	-	-	-	±	3.2	+	1.020	Y	C	3.0
3503	7.0	-	-	-	-	-	3.2	-	1.010	LtY	C	14.0
3504	7.0	-	-	-	-	-	16.0	+	1.015	LtY	C	7.5
3505	6.0	-	-	-	-	-	3.2	-	1.010	Co	C	12.0
3506	6.5	-	-	-	-	±	3.2	+	1.025	Y	C	3.0
3507	5.5	-	-	-	-	-	3.2	-	1.015	Y	C	5.0
3508	7.0	-	-	-	-	-	3.2	-	1.015	LtY	C	16.5
3509	6.0	-	-	-	-	-	3.2	-	1.020	Y	C	3.5
3510	7.0	-	-	-	-	-	3.2	-	1.010	LtY	C	8.0
3511	7.0	-	-	-	-	-	3.2	+	1.015	LtY	C	6.0
3513 Ns												
3514	7.0	-	-	-	-	-	3.2	+	1.015	LtY	C	7.0
3516	7.5	-	-	-	-	-	3.2	-	1.010	LtY	C	13.5
3517	6.0	-	+	-	-	1.0	16.0	+	1.044	Y	C	0.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

SEDIMENT MICROSCOPY

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
3501	0-2	-	0-1	-	+	-	+TP	+AU	-	-	+CS
3502	0-2	-	-	-	++++	-	+TP	-	-	-	-
3503	0-2	-	0-1	+	++	-	+TP	-	-	-	+CS
3504	0-2	-	1-2	-	++	-	+TP	-	-	-	+CS
3505	0-2	-	1-2	-	+	-	+TP	-	-	-	+CS
3506	3-4	-	2-3	-	+++	-	-	+AU	-	-	+CS
3507	2-3	-	-	-	+	-	-	+AU	-	-	-
3508	2-3	-	0-2	-	+++	-	+AP	-	-	-	-
3509	1-2	-	0-2	-	+	-	+TP	-	-	-	-
3510	0-2	-	1-2	-	+	-	+TP	-	-	-	-
3511	0-1	-	0-1	-	+	-	+TP	-	-	-	-
3513 Ns											
3514	2-3	-	0-1	-	+++	-	-	+AU	-	-	-
3516	0-2	-	0-1	-	+	-	+TP	-	-	-	+CS
3517	2-3	-	0-1	-	+	-	-	+AU	-	-	+CS

APPENDIX NO. 10

PROJECT NO. 90831

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
4501	6.5	-	-	-	-	-	3.2	+	1.015	LtY	C	4.0
4502	7.0	-	-	-	-	-	3.2	+	1.015	Y	C	7.5
4503	6.0	-	+	-	-	0.3	16.0	+	1.062	Y	C	0.5
4504	6.5	-	-	-	-	±	3.2	-	1.025	Y	C	3.0
4505	6.5	-	-	-	-	0.3	16.0	+	1.056	Y	C	1.0
4506	5.5	-	-	-	-	-	3.2	-	1.009	LtY	C	19.5
4507	6.0	-	-	-	-	-	3.2	-	1.025	DY	C	0.5
4508	6.0	-	-	-	-	-	3.2	+	1.020	Y	C	2.5
4509	5.5	-	-	-	-	-	3.2	-	1.036	DY	C	5.0
4510	6.5	-	-	-	-	-	3.2	-	1.006	Co	Cl	22.5
4511	7.0	-	-	-	-	0.3	16.0	-	1.040	Y	C	2.0
4513	6.0	-	+	-	-	0.3	16.0	+	1.064	Y	C	2.0
4514	7.0	-	-	-	-	-	3.2	-	1.020	LtY	C	9.0
4515	6.5	-	-	-	-	-	3.2	-	1.015	LtY	C	8.5
4516	6.5	-	-	-	-	-	3.2	-	1.020	LtY	C	4.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 6
FEMALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
4501	0-2	-	0-1	-	++	-	-	+AU	-	-	-
4502	2-3	-	0-1	-	+++	-	+TP	-	-	-	+CS
4503	2-3	-	0-1	-	+	-	-	+AU	-	-	+CS
4504	0-2	0-1	3-4	+	+++	-	+TP	+AU	-	-	-
4505	1-2	0-1	1-2	-	+	-	+TP	-	-	-	-
4506	1-2	-	0-2	-	++	-	-	+AU	-	-	-
4507	0-1	-	0-2	-	-	-	-	+AU	-	-	+CS
4508	2-3	-	0-1	-	+	-	+TP	-	-	-	+CS
4509	2-4	-	0-1	-	+	-	+TP	+AU	-	-	-
4510	0-2	-	3-4	-	+	-	-	+AU	-	-	+CS
4511	0-1	-	0-2	-	+	-	-	+AU	-	-	-
4513	0-1	-	0-2	-	++	-	+TP	+AU	-	-	+CS
4514	3-4	-	0-1	-	+	-	-	+AU	-	-	+CS
4515	0-2	-	1-2	-	+++	-	-	+AU	-	-	+CS
4516	2-3	-	0-2	-	+	-	-	+AU	-	-	+CS

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
1001	7.0	-	-	-	-	-	3.2	-	1.015	Y	C	21.0
1002	6.0	-	-	±	-	0.3	16.0	-	1.038	Y	C	2.0
1005	6.5	-	-	±	-	0.3	3.2	-	1.025	Y	C	4.5
1006 NSQ												
1007	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	C	4.5
1008	8.5	-	-	±	-	±	3.2	-	1.015	Y	C	10.0
1009 Ns												
1010	6.5	-	-	±	-	0.3	3.2	-	1.025	Y	Cl	3.0
1011	6.5	-	-	±	-	±	3.2	-	1.020	Y	C	4.5
1012	7.0	-	-	-	-	±	3.2	-	1.010	LtY	C	27.0
1013	6.0	-	+	±	-	1.0	3.2	-	1.075	Y	C	1.0
1014	6.5	-	-	±	-	0.3	3.2	-	1.020	Y	C	9.0
1015	7.0	-	-	-	-	0.3	3.2	-	1.015	Y	C	27.0
1016	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	C	7.5
1017	7.0	-	+	1.5	-	0.3	16.0	-	1.025	Y	C	1.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
1001	3-5	-	2-3	-	+	+S	-	-	-	-	-
1002	1-2	-	1-2	-	+	-	-	-	-	-	-
1005	1-2	-	1-2	-	++	-	-	-	-	-	-
1006 NSQ											
1007	0-1	-	1-2	-	++	-	+TP	-	-	-	+CC
1008	1-2	-	1-2	-	+	-	+TP	-	-	-	+CC
1009 Ns											
1010	3-5	-	1-2	-	++	-	+TP	-	-	-	-
1011	0-1	-	1-2	-	++	-	-	-	-	-	-
1012	0-1	-	1-2	-	++	-	-	-	-	-	-
1013	0-1	-	1-2	+	-	++S	+TP	-	-	-	-
1014	0-1	-	1-2	-	+	+S	-	-	-	-	-
1015	0-1	-	2-3	-	++	+S	+AP+TP	-	-	-	-
1016	1-2	-	1-2	-	+	-	+TP	-	-	-	-
1017	1-2	-	1-2	-	+	-	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	CHEMICAL ANALYSIS								GROSS ANALYSIS			
ANIMAL NO.	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
2001	5.5	-	+	±	-	≥3.0	16.0	+	1.099	Y	Cl	0.5
2002	6.5	-	-	1.5	-	1.0	16.0	-	1.045	Y	C	6.5
2003	6.5	-	-	-	-	±	3.2	-	1.020	Y	C	17.0
2004	6.5	-	-	-	-	-	3.2	-	1.010	LtY	C	24.0
2005	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	Cl	5.5
2006	6.5	-	-	±	-	1.0	16.0	-	1.051	Y	C	1.0
2007	6.5	-	-	±	-	0.3	16.0	-	1.025	Y	C	5.5
2008	6.0	-	-	±	-	1.0	3.2	+	1.060	Y	C	1.0
2009 Ns												
2010	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	C	9.0
2011	7.0	-	-	±	-	1.0	16.0	-	1.025	Y	C	2.5
2012	7.0	-	-	-	-	-	3.2	-	1.010	LtY	C	31.0
2013	7.0	-	-	-	-	±	3.2	-	1.015	Y	C	13.0
2015	6.5	-	-	±	-	0.3	3.2	-	1.020	Y	C	13.0
2016	7.5	-	-	±	-	0.3	3.2	-	1.015	Y	C	8.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
	SEDIMENT MICROSCOPY										
2001	0-1	-	0-1	-	+	++S	+TP	-	-	-	-
2002	0-1	-	3-4	+	+	-	-	-	-	-	-
2003	0-1	-	1-2	-	-	+S	-	-	-	-	-
2004	0-1	-	2-3	-	++	+S	-	-	-	-	+CS
2005	0-1	-	4-6	-	+	-	+TP	-	-	-	-
2006	0-1	-	0-1	+	+	-	+TP	+AU	-	-	-
2007	1-2	-	1-2	-	+	-	-	-	-	-	-
2008	0-1	-	0-1	-	+	-	-	-	-	-	-
2009 Ns											
2010	1-2	-	3-4	-	+	+S	+TP	-	-	-	-
2011	0-1	-	0-1	-	+	-	+TP	-	-	-	-
2012	1-2	-	1-2	-	++	+S	-	-	-	-	-
2013	0-1	-	0-1	-	+	+S	-	-	-	-	-
2015	-	-	0-2	-	+++	+S	+TP	-	-	-	-
2016	0-1	-	4-6	+	+	++S	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
3001	6.0	-	-	1.5	-	0.3	16.0	-	1.025	Y	C	2.0
3002	6.0	-	+	±	-	1.0	16.0	-	1.069	Y	Cl	1.0
3003	7.0	-	-	±	-	0.3	3.2	-	1.025	Y	Cl	4.5
3004	6.0	-	-	-	-	±	3.2	-	1.015	Y	C	11.0
3005	6.5	-	-	±	++	0.3	3.2	-	1.025	Y	C	10.5
3006	6.5	-	-	1.5	-	1.0	3.2	-	1.048	Y	C	4.0
3007	7.0	-	-	-	-	0.3	3.2	-	1.020	Y	C	8.0
3008	7.0	-	-	-	-	±	3.2	-	1.020	Y	C	14.0
3009	7.0	-	-	-	-	±	3.2	-	1.010	Y	C	16.0
3011	6.5	-	+	±	-	1.0	16.0	-	1.063	Y	Cl	2.5
3012	7.0	-	-	1.5	-	0.3	3.2	-	1.025	Y	Cl	4.0
3013	6.5	-	+	1.5	-	1.0	16.0	-	1.025	Y	Cl	2.5
3014	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	Cl	7.0
3015	7.5	-	-	±	-	0.3	16.0	-	1.015	Y	Cl	9.0
3016	6.0	-	+	1.5	-	≥3.0	16.0	+	1.084	DY	C	0.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
3001	-	-	0-1	-	++	-	+TP	-	-	-	-
3002	0-1	-	0-2	-	+	++S	++TP	-	-	-	-
3003	0-1	-	-	-	++++	++S	+TP	-	-	-	+CS
3004	-	-	0-2	-	+	+S	+TP	-	-	-	-
3005	-	2-4	0-2	-	++	+S	+TP	-	-	-	-
3006	0-1	-	0-2	-	++	-	+TP	-	-	-	++CS
3007	-	-	0-1	-	+++	-	+TP	-	-	-	+CS
3008	-	-	0-1	-	++	+S	++TP	-	-	-	-
3009	-	-	0-1	-	+	+S	+AP+TP	-	-	-	-
3011	-	-	0-2	-	+	-	+TP	-	-	-	++CS
3012	0-1	-	0-2	-	+	-	++TP	-	-	-	-
3013	2-4	-	-	-	+	-	++TP	-	-	-	++CS
3014	-	-	0-2	-	++	-	++TP	-	-	-	-
3015	0-3	-	0-2	-	+++	-	++TP	-	-	-	-
3016	-	-	0-2	-	+	-	+TP	-	-	-	++CS

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CHEMICAL ANALYSIS								GROSS ANALYSIS			
	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
4002	6.5	-	+	±	++	≥3.0	16.0	+	1.063	Y	C	1.0
4003 Ns												
4004	7.0	-	-	±	-	0.3	16.0	-	1.025	Y	Cl	4.0
4005 Ns												
4006	7.0	-	-	±	+	0.3	16.0	-	1.025	Y	Cl	7.5
4007	6.5	-	+	±	-	0.3	16.0	-	1.048	Y	Cl	3.5
4008 NSQ												
4009 Ns												
4010	7.0	-	-	1.5	±	0.3	3.2	-	1.025	Y	C	9.0
4011	7.0	-	-	1.5	-	0.3	3.2	-	1.025	Y	Cl	11.0
4012	7.0	-	+	±	-	≥3.0	16.0	+	1.063	DY	Cl	1.5
4014	6.5	-	-	-	±	±	3.2	-	1.020	Y	Cl	10.0
4015	7.0	-	-	-	±	0.3	3.2	-	1.020	Y	C	12.0
4016	6.5	-	-	±	+++	1.0	3.2	-	1.020	Y	Cl	18.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
MALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
4002	2-4	>50	0-2	-	+	-	+TP	-	-	-	+CS
4003 Ns											
4004	0-2	-	0-3	-	++	-	++TP	-	-	-	+CS
4005 Ns											
4006	0-2	2-4	0-3	-	+++	-	++AP++TP	-	-	-	-
4007	0-1	-	-	-	+	-	++TP	-	-	-	-
4008 NSQ											
4009 Ns											
4010	0-2	2-4	-	-	+++	+S	++TP	-	-	-	-
4011	0-2	-	6-8	-	+++	+S	++TP	-	-	-	++CS
4012	0-3	-	0-2	-	+	+S	-	-	-	-	++CS
4014	2-4	0-2	-	-	+++	-	++TP	+AU	-	-	-
4015	0-1	0-2	-	-	+++	-	++TP	-	-	-	-
4016	12-15	>50	-	-	++	++S	+TP	-	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
1501	≥9.0	-	-	-	+	0.3	3.2	-	1.015	DY	Cl	6.0
1502	6.5	-	-	-	-	-	3.2	+	1.025	Y	C	4.0
1503	6.5	-	-	-	-	0.3	3.2	-	1.025	Y	C	3.5
1504	6.5	-	-	-	-	±	3.2	-	1.020	Y	C	5.0
1505	6.0	-	+	-	-	1.0	16.0	+	1.068	Y	C	0.5
1506	7.0	-	-	-	-	±	3.2	-	1.025	Y	C	3.0
1507	7.0	-	-	-	-	±	3.2	-	1.020	LtY	C	7.0
1508	6.0	-	-	-	-	-	3.2	-	1.025	Y	C	4.0
1509	6.5	-	-	-	-	±	3.2	-	1.025	Y	C	3.5
1510 Ns												
1511	6.5	-	-	-	-	-	3.2	-	1.008	LtY	C	16.0
1512	6.5	-	-	±	-	0.3	16.0	+	1.048	Y	C	0.5
1513	6.5	-	-	-	-	-	3.2	-	1.015	Y	C	6.0
1514	7.0	-	-	-	-	±	3.2	+	1.025	Y	C	3.0
1515	6.5	-	-	-	-	0.3	3.2	-	1.025	Y	C	3.0

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 1 - AIR CONTROL

SEDIMENT MICROSCOPY

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
1501	2-3	0-1	0-2	-	+++	-	+TP	-	-	-	++CS
1502	0-1	-	0-1	-	++	-	+TP	-	-	-	+CS
1503	0-1	0-1	1-2	-	++	-	-	+AU	-	-	-
1504	2-3	0-1	0-2	+	++	-	-	+AU	-	-	-
1505	2-3	-	0-2	+	+	-	+TP	+AU	-	-	+CS
1506	3-4	-	0-2	+	++	-	++TP	+AU	-	-	-
1507	2-3	0-1	3-4	-	++	-	-	+AU	-	-	+CS
1508	3-4	0-1	2-3	+	++	-	-	+AU	-	-	-
1509	4-6	-	0-2	-	+++	-	+TP	+AU	-	-	+CS
1510 Ns											
1511	0-2	-	0-1	+	+++	-	-	+AU	-	-	-
1512	0-1	-	0-2	-	+	-	-	+AU	-	-	-
1513	0-2	-	2-3	+	+++	-	-	+AU	-	-	-
1514	4-6	-	2-3	-	++	-	-	+AU	-	-	+CS
1515	0-2	-	2-3	-	+	-	+TP	+AU	-	-	-

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

ANIMAL NO.	CHEMICAL ANALYSIS pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	GROSS ANALYSIS SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
2501	6.0	-	-	-	-	±	3.2	-	1.025	Y	C	3.0
2502	7.5	-	-	-	-	-	3.2	-	1.010	LtY	C	14.0
2503	6.5	-	-	-	-	-	3.2	-	1.015	LtY	C	6.0
2504	7.0	-	-	-	-	-	3.2	+	1.010	Y	C	15.0
2505	7.0	-	-	-	-	-	3.2	-	1.015	Y	C	7.0
2506	6.5	-	-	-	-	±	3.2	+	1.025	Y	C	2.5
2507	5.5	-	-	-	-	-	3.2	-	1.015	Y	C	11.5
2508	6.5	-	-	-	-	-	3.2	-	1.015	Y	C	7.0
2509	7.0	-	-	-	-	0.3	3.2	-	1.025	Y	Cl	4.0
2510	6.5	-	-	-	-	±	3.2	-	1.025	Y	Cl	6.0
2511	7.0	-	-	-	-	0.3	3.2	+	1.025	Y	C	1.0
2512	6.5	-	-	-	-	-	3.2	+	1.015	Y	C	6.0
2513	6.5	-	-	-	-	0.3	3.2	+	1.025	Y	C	1.0
2514	6.0	-	-	-	-	0.3	16.0	-	1.042	Y	C	2.0
2515	6.5	-	-	±	-	±	3.2	-	1.025	Y	C	5.5

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 2 - CERIC OXIDE LOW DOSE

	SEDIMENT MICROSCOPY										
ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
2501	0-2	-	0-1	-	++++	-	-	+AU	-	-	-
2502	0-2	-	1-2	-	+++	-	+TP	-	-	-	-
2503	0-1	-	0-2	-	++++	-	-	+AU	-	-	-
2504	2-3	-	0-1	-	++++	-	+TP	-	-	-	+CS
2505	2-3	-	0-1	-	+++	-	-	+AU	-	-	+CS
2506	0-2	-	0-1	-	++++	-	-	+AU	-	-	-
2507	2-3	-	0-1	-	++++	-	-	+AU	-	-	+CS
2508	3-4	-	0-1	-	+++	-	-	+AU	-	-	+CS
2509	0-1	-	0-1	-	+	-	+TP	-	-	-	+CS
2510	-	-	0-2	-	++	-	+TP	+AU	-	-	-
2511	0-1	-	0-1	-	++	-	+TP	-	-	-	+CS
2512	-	-	0-1	-	+++	-	-	+AU	-	-	-
2513	0-1	-	0-1	-	+	-	-	+AU	-	-	+CS
2514	-	-	0-1	-	+	-	+TP	+AU	-	-	+CS
2515	-	-	0-2	-	+++	-	-	+AU	-	-	+CS

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

ANIMAL NO.	CHEMICAL ANALYSIS								GROSS ANALYSIS			
	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
3501 Ns												
3502	6.0	-	-	-	-	±	3.2	-	1.025	Y	C	3.0
3503	6.5	-	-	-	-	-	3.2	-	1.007	LtY	C	31.5
3504	7.0	-	-	-	±	-	3.2	+	1.015	Y	C	4.0
3505	6.0	-	-	-	-	0.3	16.0	+	1.046	Y	C	1.0
3506	6.0	-	-	-	-	-	3.2	+	1.036	Y	C	5.0
3507	6.5	-	-	-	-	±	3.2	-	1.025	Y	C	3.0
3508	6.5	-	-	-	-	-	3.2	-	1.020	LtY	C	9.0
3509	6.0	-	-	±	-	0.3	16.0	+	1.048	Y	C	0.5
3510	8.0	-	-	-	-	-	3.2	+	1.010	LtY	C	1.0
3511	5.5	-	+	±	-	0.3	16.0	+	1.052	DY	C	1.0
3513	6.5	-	-	-	-	-	3.2	-	1.015	LtY	C	8.0
3514	6.5	-	-	-	-	-	3.2	-	1.025	Y	C	6.0
3516	6.5	-	-	-	-	-	3.2	-	1.010	LtY	C	10.0
3517 Ns												

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE

SEDIMENT MICROSCOPY

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
3501 Ns											
3502	–	–	0–1	–	++	–	+TP	+AU	–	–	+CS
3503	–	–	0–1	–	+++	–	–	+AU	–	–	–
3504	–	0–1	0–2	–	+	–	++TP	–	–	–	+CS
3505	–	–	0–1	–	+	–	–	+AU	–	–	+CS
3506	0–1	–	0–2	–	+++	–	+TP	–	–	–	+CS
3507	0–1	–	0–1	–	+	–	–	–	–	–	+CS
3508	–	–	0–1	–	++	–	–	+AU	–	–	+CS
3509	0–1	–	0–1	–	+	–	+TP	–	–	–	+CS
3510	–	–	0–1	–	+++	–	+TP	–	–	–	+CS
3511	0–1	–	–	–	++	–	–	+AU	–	–	+CS
3513	–	–	0–2	–	+++	–	–	+AU	–	–	–
3514	–	–	0–2	–	++++	–	+TP	+AU	–	–	–
3516	0–1	–	0–2	–	++	–	–	+AU	–	–	–
3517 Ns											

APPENDIX NO. 10

PROJECT NO. 90831

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

GROUP 4 - CERIC OXIDE HIGH DOSE

ANIMAL NO.	CHEMICAL ANALYSIS								GROSS ANALYSIS			
	pH	GLU. mmol/L	BIL.	KET. mmol/L	BLOOD	PROT. g/L	UBG umol/L	NIT.	SPECIFIC GRAVITY	COLOR	APPEAR	VOLUME mL
4501	6.5	-	-	-	-	0.3	3.2	-	1.025	Y	C	4.5
4502	≥9.0	-	+	±	-	0.3	16.0	+	1.015	Y	C	0.5
4503	5.5	-	+	±	-	1.0	16.0	+	1.066	DY	C	0.5
4504	6.0	-	-	-	-	-	3.2	-	1.025	Y	C	4.0
4505	6.0	-	-	-	-	0.3	16.0	-	1.042	Y	C	1.0
4506	6.0	-	-	-	-	-	3.2	+	1.015	Y	C	7.0
4507	6.0	-	-	-	-	0.3	16.0	+	1.044	Y	C	2.0
4508 Ns												
4509	5.5	-	+	±	-	0.3	16.0	+	1.048	Y	C	1.0
4510 Ns												
4511	6.0	-	-	-	-	±	16.0	-	1.040	Y	C	3.0
4513	6.5	-	-	-	-	0.3	16.0	+	1.025	Y	C	1.0
4514	7.0	-	-	-	-	-	3.2	-	1.015	Y	C	14.0
4515	7.0	-	-	-	-	-	3.2	-	1.015	Y	C	5.0
4516 Ns												

APPENDIX NO. 10

INDIVIDUAL URINALYSIS
WEEK 13
FEMALES

PROJECT NO. 90831

GROUP 4 - CERIC OXIDE HIGH DOSE

SEDIMENT MICROSCOPY

ANIMAL NO.	WBC n/HPF	RBC n/HPF	EPC n/HPF	MUCOUS	BACTERIA	MISC.	PHOS.	URATE	OXALATE	URIC ACID	OTHER CRYSTALS
4501	0-1	-	-	-	+++	-	+TP	-	-	-	-
4502	-	-	0-1	-	+	-	+TP	-	-	-	+CS
4503	-	-	0-1	-	+	-	-	-	-	-	+CS
4504	-	-	0-1	-	++	-	+TP	-	-	-	-
4505	0-1	-	0-1	-	+	-	-	-	-	-	+CS
4506	0-1	-	-	-	+++	-	-	+AU	-	-	-
4507	0-1	-	0-1	-	+++	-	-	+AU	-	-	+CS
4508 Ns											
4509	0-1	-	-	-	+	-	+TP	-	-	-	+CS
4510 Ns											
4511	0-1	-	-	-	++	-	+TP	++AU	-	-	-
4513	0-1	-	0-1	-	+++	-	+TP	-	-	-	-
4514	0-1	-	0-1	-	++	-	++AP	-	-	-	-
4515	0-2	-	0-1	-	+++	-	+TP	-	-	-	-
4516 Ns											

BIO-RESEARCH LABORATORIES LTD.

STUDY TITLE

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT

VOLUME IV

SPONSOR

Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

DATA REQUIREMENTS

United States EPA/TSCA (40 CFR Part 792).
Japanese MHW GLP Regulations (Notification No. 313 and revised rule Notification No. 870)
OECD guidelines No. 413

AUTHOR

A. Viau, B.Sc.
Study Director

STUDY COMPLETED ON

September 29, 1994

PERFORMING LABORATORY

Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

LABORATORY PROJECT ID

90831

MONTRÉAL
87 Senneville Rd., Senneville, Québec H9X 3R3, Canada
Tel: (514) 630-8200 . Cable: BIOCAN Fax: (514) 457-3883

INDEX TO VOLUME IV
(996 - 1352)

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	1001	513.3	12.924	1.018	1.842	1.733
	1002	512.3	11.904	.839	1.703	1.840
	1005	511.3	12.735	.788	1.580	1.745
	1006	439.0	11.668	.651	1.379	1.532
	1007	500.7	14.176	.816	1.583	1.571
	1008	416.9	10.354	.698	1.385	1.568
	1009	421.6	10.466	.631	1.642	1.464
	1010	501.2	11.957	.698	1.402	1.515
	1011	382.6	9.621	.753	1.526	1.458
	1012	523.9	13.073	.776	1.667	1.637
	1013	460.6	10.679	.693	1.411	1.576
	1014	519.7	14.314	.864	1.791	1.636
	1015	518.6	13.738	.713	1.584	1.658
	1016	540.2	14.816	1.008	1.756	1.694
	1017	513.6	12.948	.801	1.653	1.540

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 1 - AIR CONTROL	1001	.027	.076	3.285	3.860	1.383
	1002	.031	.056	3.005	3.722	1.201
	1005	.026	.064	2.618	3.807	1.200
	1006	.021	.066	3.330	3.581	.952
	1007	.020	.058	3.020	3.390	1.210
	1008	.016	.059	3.043	2.977	1.210
	1009	.026	.060	2.689	3.182	1.361
	1010	.023	.050	2.565	3.308	1.608
	1011	.020	.069	2.565	3.192	.680
	1012	.021	.047	3.128	3.672	1.323
	1013	.020	.062	2.807	3.399	1.682
	1014	.027	.068	3.345	3.835	1.360
	1015	.019	.068	3.051	4.115	1.271
	1016	.025	.070	3.482	3.426	1.280
	1017	.028	.065	2.871	3.683	1.519

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1001	2.293	.020	.297
	1002	2.278	.016	.347
	1005	2.199	.020	.210
	1006	2.132	.016	.170
	1007	2.033	.013	.194
	1008	2.015	.013	.165
	1009	2.094	.015	.172
	1010	2.271	.011	.180
	1011	2.047	.010	.248
	1012	2.151	.015	.191
	1013	2.238	.014	.239
	1014	2.212	.016	.218
	1015	2.162	.014	.166
	1016	2.137	.013	.291
	1017	2.133	.017	.238

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 2 - CERIC OXIDE LOW DOSE	2001	481.8	12.790	.834	1.505	1.714
	2002	506.8	14.938	1.074	1.669	1.593
	2003	543.3	14.500	.815	2.001	2.061
	2004	490.2	14.058	.715	1.638	1.869
	2005	468.3	11.153	.923	1.541	1.743
	2006	480.4	12.108	.806	1.538	1.646
	2007	458.5	11.858	1.051	1.665	1.759
	2008	460.5	12.204	.617	1.400	1.754
	2009	399.1	9.887	.683	1.358	1.509
	2010	538.8	15.715	.964	1.813	1.897
	2011	425.9	9.491	.728	1.400	1.702
	2012	462.9	9.770	.604	1.458	1.658
	2013	420.2	10.686	.703	1.554	1.823
	2015	467.2	10.964	.838	1.591	1.746
	2016	538.6	13.465	.715	1.554	1.928

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	.023	.064	3.085	3.791	1.672
	2002	.023	.052	3.326	3.489	1.350
	2003	.020	.060	3.057	3.774	1.641
	2004	.024	.054	3.145	3.479	1.216
	2005	.022	.057	2.672	3.140	1.545
	2006	.020	.055	2.957	3.594	1.008
	2007	.023	.061	3.051	3.229	1.754
	2008	.024	.062	2.815	3.916	1.217
	2009	.016	.049	2.650	3.341	.759
	2010	.020	.056	3.554	3.342	1.655
	2011	.021	.056	2.764	3.461	1.394
	2012	.022	.071	2.604	3.793	1.300
	2013	.021	.063	2.786	3.771	1.869
	2015	.023	.057	2.955	2.992	1.197
	2016	.019	.060	3.054	3.541	1.236

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 2 - CERIC OXIDE LOW DOSE	2001	2.188	.016	.177
	2002	2.184	.012	.211
	2003	2.171	.012	.321
	2004	2.187	.015	.173
	2005	2.148	.014	.164
	2006	2.121	.014	.258
	2007	2.222	.017	.262
	2008	2.106	.015	.334
	2009	2.176	.013	.183
	2010	2.126	.015	.259
	2011	2.082	.013	.271
	2012	2.059	.017	.225
	2013	2.052	.016	.219
	2015	2.069	.014	.227
	2016	2.106	.020	.242

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	515.4	13.710	.738	1.684	2.209
	3002	484.2	13.113	.819	1.685	2.606
	3003	505.8	13.833	.780	1.444	2.329
	3004	464.5	11.667	.621	1.491	2.241
	3005	484.6	14.498	.868	1.615	2.584
	3006	509.7	13.874	.888	1.478	2.969
	3007	458.0	11.403	.953	1.485	2.758
	3008	515.0	14.912	1.093	1.649	2.772
	3009	488.6	11.944	.829	1.737	2.235
	3011	483.8	13.080	.880	1.626	1.982
	3012	478.9	11.607	1.051	1.381	2.869
	3013	452.9	13.099	.948	1.550	2.764
	3014	471.6	11.988	.926	1.661	3.033
	3015	506.3	13.057	.823	1.499	3.065
	3016	507.4	12.442	.773	1.552	2.201

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	.022	.048	3.064	3.688	1.506
	3002	.022	.059	2.754	3.562	.936
	3003	.017	.058	2.980	3.773	1.075
	3004	.020	.042	2.831	3.463	1.266
	3005	.024	.065	3.328	3.643	1.353
	3006	.019	.048	3.093	3.598	1.158
	3007	.028	.052	2.963	3.727	1.417
	3008	.019	.065	3.249	3.595	.997
	3009	.021	.061	2.801	3.496	1.471
	3011	.022	.048	2.886	3.245	1.046
	3012	.019	.044	2.931	3.597	1.008
	3013	.019	.066	3.002	4.082	1.761
	3014	.022	.055	2.798	4.008	1.265
	3015	.015	.055	2.898	3.484	1.048
	3016	.017	.062	3.036	3.354	1.541

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	2.171	.016	.238
	3002	1.995	.013	.318
	3003	2.195	.014	.332
	3004	2.124	.011	.271
	3005	2.182	.013	.348
	3006	1.951	.015	.281
	3007	2.088	.015	.279
	3008	2.171	.014	.320
	3009	2.194	.018	.206
	3011	2.055	.012	.302
	3012	2.066	.015	.272
	3013	2.162	.013	.259
	3014	2.135	.015	.262
	3015	2.070	.015	.310
	3016	2.213	.014	.304

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	386.6	9.102	.788	1.361	4.038
	4003	537.6	12.936	.976	1.604	5.407
	4004	393.9	9.358	.673	1.417	5.270
	4005	472.8	12.883	1.266	1.502	4.932
	4006	493.9	13.013	.719	1.552	5.000
	4007	395.3	9.740	.784	1.567	5.349
	4008	456.6	11.318	.840	1.573	4.332
	4009	409.8	10.097	.774	1.393	3.784
	4010	508.2	14.842	1.083	1.538	4.489
	4011	494.6	12.801	.880	1.588	4.599
	4012	440.1	11.077	.733	1.595	4.918
	4014	418.3	11.068	.840	1.486	4.517
	4015	463.2	12.853	.704	1.306	3.963
	4016	582.5	16.643	1.088	2.739	4.677

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	.018	.059	2.338	3.294	1.187
	4003	.017	.070	2.977	3.263	1.202
	4004	.024	.055	2.351	3.322	1.196
	4005	.027	.051	3.171	3.877	1.449
	4006	.023	.062	3.129	3.912	1.391
	4007	.016	.059	2.423	2.458	1.141
	4008	.027	.060	2.748	3.560	1.622
	4009	.030	.049	2.660	3.739	1.069
	4010	.021	.066	3.274	3.641	1.536
	4011	.023	.057	3.187	3.484	1.814
	4012	.018	.056	2.577	3.357	1.126
	4014	.017	.045	2.708	3.635	1.202
	4015	.020	.055	2.932	3.613	.905
	4016	.027	.065	3.670	3.555	2.198

APPENDIX NO. 11 ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	2.016	.013	.185
	4003	2.090	.014	.222
	4004	2.161	.013	.169
	4005	2.255	.015	.263
	4006	2.268	.014	.215
	4007	2.059	.014	.219
	4008	2.172	.015	.209
	4009	2.145	.014	.220
	4010	2.099	.018	.305
	4011	2.069	.016	.468
	4012	2.183	.012	.213
	4014	2.090	.013	.171
	4015	2.069	.013	.283
	4016	1.475	.020	.332

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	1501	252.0	6.540	.530	.942	1.179
	1502	254.5	6.682	.505	1.006	1.055
	1503	253.7	6.665	.497	1.048	1.149
	1504	247.0	6.835	.565	.956	1.190
	1505	232.9	6.381	.639	.958	1.119
	1506	244.8	5.842	.435	.900	1.072
	1507	265.1	6.980	.661	.938	1.375
	1508	262.4	7.084	.471	1.040	1.195
	1509	221.4	5.733	.507	.857	1.105
	1510	237.4	6.727	.510	1.049	1.147
	1511	249.4	6.226	.567	.836	1.108
	1512	207.6	6.273	.490	.902	1.085
	1513	205.4	5.221	.463	1.012	1.088
	1514	222.8	6.236	.491	.812	1.261
	1515	256.2	6.953	.439	.998	1.044

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 1 - AIR CONTROL	1501	.016	.057	1.907	.102	.617
	1502	.019	.055	1.575	.105	.969
	1503	.012	.051	1.647	.078	.635
	1504	.014	.064	1.817	.081	.413
	1505	.012	.070	1.765	.065	.509
	1506	.017	.071	1.606	.103	.541
	1507	.014	.066	1.853	.111	.502
	1508	.013	.063	1.857	.071	.485
	1509	.014	.053	1.505	.073	.558
	1510	.018	.056	1.699	.070	.719
	1511	.014	.056	1.760	.084	.833
	1512	.013	.054	1.710	.086	.626
	1513	.015	.046	1.565	.076	.805
	1514	.018	.067	1.528	.095	.611
	1515	.018	.050	1.607	.045	.594

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1501	1.816	.019	.227
	1502	1.929	.016	.174
	1503	1.873	.018	.186
	1504	1.938	.017	.194
	1505	1.908	.017	.149
	1506	1.977	.019	.193
	1507	1.929	.016	.136
	1508	1.937	.015	.189
	1509	1.827	.013	.157
	1510	2.007	.014	.224
	1511	1.948	.014	.182
	1512	1.910	.014	.259
	1513	1.966	.019	.203
	1514	2.005	.016	.146
	1515	1.896	.024	.167

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	242.3	6.380	.504	.986	1.182
	2502	219.5	6.005	.484	.818	1.194
	2503	232.3	5.633	.596	.929	1.207
	2504	243.7	6.898	.613	1.097	1.386
	2505	216.8	5.873	.476	.880	1.165
	2506	249.0	7.320	.562	.876	1.260
	2507	256.6	6.825	.615	.901	1.537
	2508	289.2	7.983	.681	1.104	1.271
	2509	245.4	6.318	.550	.994	1.276
	2510	263.8	7.713	.745	1.141	1.695
	2511	230.9	6.092	.682	.862	1.304
	2512	236.8	5.906	.632	.912	1.176
	2513	236.1	6.274	.591	1.071	1.415
	2514	219.1	6.070	.534	.893	1.371
	2515	240.1	6.859	.500	.910	1.233

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	.012	.060	1.653	.068	.515
	2502	.012	.069	1.500	.056	.632
	2503	.011	.046	1.561	.077	.541
	2504	.016	.083	1.787	.078	.598
	2505	.011	.063	1.656	.079	.540
	2506	.018	.058	1.832	.053	1.441
	2507	.017	.053	1.660	.084	.577
	2508	.020	.074	1.759	.084	.381
	2509	.013	.047	1.605	.060	.684
	2510	.021	.069	1.912	.105	.588
	2511	.019	.067	1.587	.093	.942
	2512	.020	.051	1.691	.065	.506
	2513	.017	.081	1.735	.069	1.533
	2514	.015	.049	1.603	.071	.434
	2515	.015	.046	1.670	.071	.555

APPENDIX NO. 11 ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	1.890	.016	.163
	2502	1.938	.015	.126
	2503	1.954	.013	.327
	2504	1.837	.017	.132
	2505	1.962	.017	.130
	2506	2.014	.015	.225
	2507	2.037	.016	.125
	2508	1.941	.016	.223
	2509	1.948	.015	.112
	2510	1.866	.015	.232
	2511	2.089	.014	.207
	2512	2.008	.013	.197
	2513	2.062	.014	.130
	2514	2.067	.014	.081
	2515	1.855	.017	.182

APPENDIX NO. 11 ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	243.6	7.126	.522	1.069	1.838
	3502	228.0	5.842	.577	.836	1.473
	3503	269.1	7.003	.568	1.109	1.496
	3504	229.5	6.774	.751	1.008	1.471
	3505	233.4	6.763	.429	.984	1.381
	3506	250.2	6.056	.559	.934	1.785
	3507	216.6	5.672	.593	1.091	1.695
	3508	250.5	6.199	.410	.885	1.500
	3509	246.9	5.842	.427	1.080	2.535
	3510	244.3	6.910	.605	1.113	1.788
	3511	214.2	5.484	.561	.875	1.619
	3513	237.2	5.942	.494	.889	1.583
	3514	263.4	7.761	.543	1.070	1.779
	3516	228.4	5.894	.596	.884	1.436
	3517	202.8	5.399	.369	.804	1.386

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	.014	.074	1.816	.056	.656
	3502	.018	.058	1.738	.093	.557
	3503	.013	.046	1.684	.088	.645
	3504	.013	.065	1.655	.100	.482
	3505	.013	.050	1.442	.066	.602
	3506	.016	.073	1.573	.112	.589
	3507	.022	.072	1.452	.097	1.099
	3508	.015	.051	1.620	.057	1.054
	3509	.018	.075	1.563	.098	.456
	3510	.016	.059	1.857	.098	.660
	3511	.013	.061	1.455	.071	.486
	3513	.016	.058	1.711	.092	.610
	3514	.013	.066	1.924	.099	.867
	3516	.020	.064	1.642	.076	.578
	3517	.013	.051	1.519	.070	.453

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	1.928	.020	.171
	3502	1.959	.013	.150
	3503	1.977	.015	.229
	3504	1.885	.017	.243
	3505	1.957	.017	.163
	3506	1.897	.014	.213
	3507	1.869	.015	.256
	3508	1.863	.015	.209
	3509	1.936	.015	.187
	3510	1.913	.014	.199
	3511	1.973	.013	.202
	3513	1.985	.016	.284
	3514	2.186	.021	.220
	3516	1.932	.015	.162
	3517	1.881	.011	.165

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	270.1	7.045	.497	.996	3.481
	4502	232.7	6.405	.571	.946	3.388
	4503	214.6	5.801	.448	.967	3.177
	4504	214.4	6.031	.503	.964	3.651
	4505	230.9	5.869	.479	1.012	2.760
	4506	241.6	6.031	.575	.970	3.030
	4507	230.0	6.221	.557	.956	2.707
	4508	242.2	7.147	.521	.960	3.070
	4509	223.5	6.103	.503	.896	3.195
	4510	225.9	6.523	.566	.990	3.080
	4511	224.5	5.503	.352	.826	2.750
	4513	250.5	7.520	.610	1.113	3.426
	4514	241.9	5.838	.555	.927	3.724
	4515	249.7	7.264	.549	.942	3.304
	4516	219.4	5.845	.501	.895	2.850

APPENDIX NO. 11

ABSOLUTE ORGAN WEIGHTS (G)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	.017	.057	1.720	.076	.415
	4502	.014	.079	1.631	.092	.439
	4503	.010	.056	1.398	.087	.496
	4504	.021	.067	1.758	.095	.742
	4505	.020	.070	1.465	.089	.682
	4506	.014	.046	1.465	.070	.615
	4507	.021	.070	1.737	.053	1.464
	4508	.014	.077	1.777	.075	.525
	4509	.016	.049	1.563	.090	.499
	4510	.021	.058	1.546	.083	.580
	4511	.012	.053	1.396	.064	.884
	4513	.023	.071	1.974	.076	.695
	4514	.014	.062	1.580	.078	.550
	4515	.014	.064	1.818	.074	.498
	4516	.016	.053	1.465	.079	.465

APPENDIX NO. 11 ABSOLUTE ORGAN WEIGHTS (G) PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	2.063	.017	.121
	4502	1.965	.016	.115
	4503	1.905	.015	.163
	4504	1.940	.015	.142
	4505	1.944	.015	.162
	4506	1.883	.017	.185
	4507	1.942	.018	.222
	4508	1.890	.016	.173
	4509	1.888	.013	.159
	4510	1.908	.016	.175
	4511	1.957	.013	.172
	4513	1.966	.020	.154
	4514	1.920	.012	.269
	4515	1.901	.015	.173
	4516	1.890	.015	.091

APPENDIX NO. 12

PROJECT NO :90831

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	1001	513.3	2.519	.198	.359	.338
	1002	512.3	2.324	.164	.332	.359
	1005	511.3	2.491	.154	.309	.341
	1006	439.0	2.658	.148	.314	.349
	1007	500.7	2.831	.163	.316	.314
	1008	416.9	2.484	.167	.332	.376
	1009	421.6	2.482	.150	.389	.347
	1010	501.2	2.386	.139	.280	.302
	1011	382.6	2.515	.197	.399	.381
	1012	523.9	2.495	.148	.318	.312
	1013	460.6	2.318	.150	.306	.342
	1014	519.7	2.754	.166	.345	.315
	1015	518.6	2.649	.137	.305	.320
	1016	540.2	2.743	.187	.325	.314
	1017	513.6	2.521	.156	.322	.300

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 1 - AIR CONTROL	1001	.005	.015	.640	.752	.269
	1002	.006	.011	.587	.727	.234
	1005	.005	.012	.512	.745	.235
	1006	.005	.015	.759	.816	.217
	1007	.004	.012	.603	.677	.242
	1008	.004	.014	.730	.714	.290
	1009	.006	.014	.638	.755	.323
	1010	.005	.010	.512	.660	.321
	1011	.005	.018	.670	.834	.178
	1012	.004	.009	.597	.701	.253
	1013	.004	.013	.609	.738	.365
	1014	.005	.013	.644	.738	.262
	1015	.004	.013	.588	.793	.245
	1016	.005	.013	.645	.634	.237
	1017	.006	.013	.559	.717	.296

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

MALES

PROJECT NO :90831

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1001	.447	.004	.058
	1002	.445	.003	.068
	1005	.430	.004	.041
	1006	.486	.004	.039
	1007	.406	.003	.039
	1008	.483	.003	.040
	1009	.497	.004	.041
	1010	.453	.002	.036
	1011	.535	.003	.065
	1012	.411	.003	.036
	1013	.486	.003	.052
	1014	.426	.003	.042
	1015	.417	.003	.032
	1016	.396	.002	.054
	1017	.415	.003	.046

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 2 - CERIC OXIDE LOW DOSE	2001	481.8	2.655	.173	.312	.356
	2002	506.8	2.948	.212	.329	.314
	2003	543.3	2.669	.150	.368	.379
	2004	490.2	2.868	.146	.334	.381
	2005	468.3	2.382	.197	.329	.372
	2006	480.4	2.520	.168	.320	.343
	2007	458.5	2.586	.229	.363	.384
	2008	460.5	2.650	.134	.304	.381
	2009	399.1	2.477	.171	.340	.378
	2010	538.8	2.917	.179	.336	.352
	2011	425.9	2.228	.171	.329	.400
	2012	462.9	2.111	.130	.315	.358
	2013	420.2	2.543	.167	.370	.434
	2015	467.2	2.347	.179	.341	.374
	2016	538.6	2.500	.133	.289	.358

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 2 - CERIC OXIDE LOW DOSE	2001	.005	.013	.640	.787	.347
	2002	.005	.010	.656	.688	.266
	2003	.004	.011	.563	.695	.302
	2004	.005	.011	.642	.710	.248
	2005	.005	.012	.571	.671	.330
	2006	.004	.011	.616	.748	.210
	2007	.005	.013	.665	.704	.383
	2008	.005	.013	.611	.850	.264
	2009	.004	.012	.664	.837	.190
	2010	.004	.010	.660	.620	.307
	2011	.005	.013	.649	.813	.327
	2012	.005	.015	.563	.819	.281
	2013	.005	.015	.663	.897	.445
	2015	.005	.012	.632	.640	.256
	2016	.004	.011	.567	.657	.229

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 2 - CERIC OXIDE LOW DOSE	2001	.454	.003	.037
	2002	.431	.002	.042
	2003	.400	.002	.059
	2004	.446	.003	.035
	2005	.459	.003	.035
	2006	.442	.003	.054
	2007	.485	.004	.057
	2008	.457	.003	.073
	2009	.545	.003	.046
	2010	.395	.003	.048
	2011	.489	.003	.064
	2012	.445	.004	.049
	2013	.488	.004	.052
	2015	.443	.003	.049
	2016	.391	.004	.045

APPENDIX NO. 12

PROJECT NO :90831

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	515.4	2.660	.143	.327	.429
	3002	484.2	2.708	.169	.348	.538
	3003	505.8	2.735	.154	.285	.460
	3004	464.5	2.512	.134	.321	.482
	3005	484.6	2.992	.179	.333	.533
	3006	509.7	2.722	.174	.290	.582
	3007	458.0	2.490	.208	.324	.602
	3008	515.0	2.896	.212	.320	.538
	3009	488.6	2.445	.170	.356	.457
	3011	483.8	2.704	.182	.336	.410
	3012	478.9	2.424	.219	.288	.599
	3013	452.9	2.892	.209	.342	.610
	3014	471.6	2.542	.196	.352	.643
	3015	506.3	2.579	.163	.296	.605
	3016	507.4	2.452	.152	.306	.434

APPENDIX NO. 12

PROJECT NO :90831

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	.004	.009	.594	.716	.292
	3002	.004	.012	.569	.736	.193
	3003	.003	.012	.589	.746	.213
	3004	.004	.009	.609	.746	.273
	3005	.005	.013	.687	.752	.279
	3006	.004	.009	.607	.706	.227
	3007	.006	.011	.647	.814	.309
	3008	.004	.013	.631	.698	.194
	3009	.004	.013	.573	.716	.301
	3011	.005	.010	.597	.671	.216
	3012	.004	.009	.612	.751	.210
	3013	.004	.015	.663	.901	.389
	3014	.005	.012	.593	.850	.268
	3015	.003	.011	.572	.688	.207
	3016	.003	.012	.598	.661	.304

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	.421	.003	.046
	3002	.412	.003	.066
	3003	.434	.003	.066
	3004	.457	.002	.058
	3005	.450	.003	.072
	3006	.383	.003	.055
	3007	.456	.003	.061
	3008	.422	.003	.062
	3009	.449	.004	.042
	3011	.425	.003	.062
	3012	.431	.003	.057
	3013	.477	.003	.057
	3014	.453	.003	.056
	3015	.409	.003	.061
	3016	.436	.003	.060

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	386.6	2.354	.204	.352	1.044
	4003	537.6	2.406	.182	.298	1.006
	4004	393.9	2.376	.171	.360	1.338
	4005	472.8	2.725	.268	.318	1.043
	4006	493.9	2.635	.146	.314	1.012
	4007	395.3	2.464	.198	.396	1.353
	4008	456.6	2.479	.184	.345	.949
	4009	409.8	2.464	.189	.340	.923
	4010	508.2	2.921	.213	.303	.883
	4011	494.6	2.588	.178	.321	.930
	4012	440.1	2.517	.167	.362	1.117
	4014	418.3	2.646	.201	.355	1.080
	4015	463.2	2.775	.152	.282	.856
	4016	582.5	2.857	.187	.470	.803

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	PRO-STATE
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	.005	.015	.605	.852	.307
	4003	.003	.013	.554	.607	.224
	4004	.006	.014	.597	.843	.304
	4005	.006	.011	.671	.820	.306
	4006	.005	.013	.634	.792	.282
	4007	.004	.015	.613	.622	.289
	4008	.006	.013	.602	.780	.355
	4009	.007	.012	.649	.912	.261
	4010	.004	.013	.644	.716	.302
	4011	.005	.012	.644	.704	.367
	4012	.004	.013	.586	.763	.256
	4014	.004	.011	.647	.869	.287
	4015	.004	.012	.633	.780	.195
	4016	.005	.011	.630	.610	.377

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	.521	.003	.048
	4003	.389	.003	.041
	4004	.549	.003	.043
	4005	.477	.003	.056
	4006	.459	.003	.044
	4007	.521	.004	.055
	4008	.476	.003	.046
	4009	.523	.003	.054
	4010	.413	.003	.060
	4011	.418	.003	.095
	4012	.496	.003	.048
	4014	.500	.003	.041
	4015	.447	.003	.061
	4016	.253	.003	.057

APPENDIX NO. 12

PROJECT NO :90831

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 1 - AIR CONTROL	1501	252.0	2.595	.210	.374	.468
	1502	254.5	2.626	.198	.395	.415
	1503	253.7	2.627	.196	.413	.493
	1504	247.0	2.767	.229	.387	.482
	1505	232.9	2.740	.274	.411	.480
	1506	244.8	2.386	.178	.368	.438
	1507	265.1	2.633	.249	.354	.519
	1508	262.4	2.700	.179	.396	.455
	1509	221.4	2.589	.229	.387	.499
	1510	237.4	2.834	.215	.442	.483
	1511	249.4	2.496	.227	.335	.444
	1512	207.6	3.022	.236	.434	.523
	1513	205.4	2.542	.225	.493	.530
	1514	222.8	2.799	.220	.364	.566
	1515	256.2	2.714	.171	.390	.407

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 1 - AIR CONTROL	1501	.006	.023	.757	.040	.245
	1502	.007	.021	.619	.041	.381
	1503	.005	.020	.649	.031	.250
	1504	.006	.026	.736	.033	.167
	1505	.005	.030	.758	.028	.219
	1506	.007	.029	.656	.042	.221
	1507	.005	.025	.699	.042	.189
	1508	.005	.024	.708	.027	.185
	1509	.006	.024	.680	.033	.252
	1510	.008	.023	.716	.030	.303
	1511	.005	.023	.706	.034	.334
	1512	.006	.026	.824	.041	.302
	1513	.007	.023	.762	.037	.392
	1514	.008	.030	.686	.043	.274
	1515	.007	.020	.627	.017	.232

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1501	.721	.007	.090
	1502	.758	.006	.068
	1503	.738	.007	.073
	1504	.785	.007	.079
	1505	.819	.007	.064
	1506	.808	.009	.079
	1507	.728	.006	.051
	1508	.738	.006	.072
	1509	.825	.006	.071
	1510	.845	.006	.094
	1511	.781	.006	.073
	1512	.920	.007	.125
	1513	.957	.009	.099
	1514	.900	.007	.066
	1515	.740	.010	.065

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	242.3	2.633	.208	.407	.488
	2502	219.5	2.736	.221	.373	.544
	2503	232.3	2.425	.257	.400	.520
	2504	243.7	2.831	.252	.450	.569
	2505	216.8	2.709	.220	.406	.537
	2506	249.0	2.940	.226	.352	.506
	2507	256.6	2.660	.240	.351	.599
	2508	289.2	2.760	.235	.382	.439
	2509	245.4	2.575	.224	.405	.520
	2510	263.8	2.924	.282	.433	.643
	2511	230.9	2.638	.295	.373	.565
	2512	236.8	2.494	.267	.385	.497
	2513	236.1	2.657	.250	.454	.599
	2514	219.1	2.770	.244	.408	.626
	2515	240.1	2.857	.208	.379	.514

APPENDIX NO.12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	.005	.025	.682	.028	.213
	2502	.005	.032	.683	.026	.288
	2503	.005	.020	.672	.033	.233
	2504	.007	.034	.733	.032	.245
	2505	.005	.029	.764	.037	.249
	2506	.007	.023	.736	.021	.579
	2507	.007	.021	.647	.033	.225
	2508	.007	.026	.608	.029	.132
	2509	.005	.019	.654	.025	.279
	2510	.008	.026	.725	.040	.223
	2511	.008	.029	.687	.040	.408
	2512	.008	.021	.714	.028	.214
	2513	.007	.034	.735	.029	.649
	2514	.007	.022	.732	.032	.198
	2515	.006	.019	.696	.029	.231

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	.780	.007	.067
	2502	.883	.007	.057
	2503	.841	.006	.141
	2504	.754	.007	.054
	2505	.905	.008	.060
	2506	.809	.006	.090
	2507	.794	.006	.049
	2508	.671	.005	.077
	2509	.794	.006	.046
	2510	.707	.006	.088
	2511	.905	.006	.090
	2512	.848	.006	.083
	2513	.873	.006	.055
	2514	.943	.007	.037
	2515	.773	.007	.076

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	243.6	2.925	.214	.439	.755
	3502	228.0	2.562	.253	.367	.646
	3503	269.1	2.602	.211	.412	.556
	3504	229.5	2.952	.327	.439	.641
	3505	233.4	2.898	.184	.422	.592
	3506	250.2	2.420	.223	.373	.713
	3507	216.6	2.619	.274	.504	.783
	3508	250.5	2.475	.164	.353	.599
	3509	246.9	2.366	.173	.437	1.027
	3510	244.3	2.828	.248	.456	.732
	3511	214.2	2.560	.262	.408	.756
	3513	237.2	2.505	.208	.375	.667
	3514	263.4	2.946	.206	.406	.675
	3516	228.4	2.581	.261	.387	.629
	3517	202.8	2.662	.182	.396	.683

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	.006	.030	.745	.023	.269
	3502	.008	.026	.762	.041	.244
	3503	.005	.017	.626	.033	.240
	3504	.006	.028	.721	.044	.210
	3505	.005	.021	.618	.028	.258
	3506	.006	.029	.629	.045	.235
	3507	.010	.033	.670	.045	.507
	3508	.006	.021	.647	.023	.421
	3509	.007	.030	.633	.040	.185
	3510	.007	.024	.760	.040	.270
	3511	.006	.028	.679	.033	.227
	3513	.007	.024	.721	.039	.257
	3514	.005	.025	.730	.038	.329
	3516	.009	.028	.719	.033	.253
	3517	.007	.025	.749	.035	.223

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	.791	.008	.070
	3502	.859	.006	.066
	3503	.735	.006	.085
	3504	.821	.007	.106
	3505	.838	.007	.070
	3506	.758	.006	.085
	3507	.863	.007	.118
	3508	.744	.006	.083
	3509	.784	.006	.076
	3510	.783	.006	.081
	3511	.921	.006	.094
	3513	.837	.007	.120
	3514	.830	.008	.084
	3516	.846	.007	.071
	3517	.928	.005	.081

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	TERMINAL BODY WEIGHT (G)	LIVER	SPLEEN	HEART	LUNGS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	270.1	2.608	.184	.369	1.289
	4502	232.7	2.752	.245	.407	1.456
	4503	214.6	2.703	.209	.451	1.480
	4504	214.4	2.813	.235	.450	1.703
	4505	230.9	2.542	.207	.438	1.195
	4506	241.6	2.496	.238	.401	1.254
	4507	230.0	2.705	.242	.416	1.177
	4508	242.2	2.951	.215	.396	1.268
	4509	223.5	2.731	.225	.401	1.430
	4510	225.9	2.888	.251	.438	1.363
	4511	224.5	2.451	.157	.368	1.225
	4513	250.5	3.002	.244	.444	1.368
	4514	241.9	2.413	.229	.383	1.539
	4515	249.7	2.909	.220	.377	1.323
	4516	219.4	2.664	.228	.408	1.299

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS	GONADS	UTERUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	.006	.021	.637	.028	.154
	4502	.006	.034	.701	.040	.189
	4503	.005	.026	.651	.041	.231
	4504	.010	.031	.820	.044	.346
	4505	.008	.030	.634	.039	.295
	4506	.006	.019	.606	.029	.255
	4507	.009	.031	.755	.023	.637
	4508	.006	.032	.734	.031	.217
	4509	.007	.022	.699	.040	.223
	4510	.009	.026	.684	.037	.257
	4511	.005	.024	.622	.028	.394
	4513	.009	.028	.788	.030	.277
	4514	.006	.026	.653	.032	.227
	4515	.006	.026	.728	.030	.199
	4516	.008	.024	.668	.036	.212

APPENDIX NO. 12

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BODY WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN	PIT-UITARY	THYMUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	.764	.006	.045
	4502	.844	.007	.049
	4503	.888	.007	.076
	4504	.905	.007	.066
	4505	.842	.006	.070
	4506	.779	.007	.077
	4507	.844	.008	.097
	4508	.780	.007	.071
	4509	.845	.006	.071
	4510	.845	.007	.077
	4511	.872	.006	.077
	4513	.785	.008	.061
	4514	.794	.005	.111
	4515	.761	.006	.069
	4516	.861	.007	.041

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 1 - AIR CONTROL	1001	2.293	563.628	44.396	80.331
	1002	2.278	522.564	36.831	74.759
	1005	2.199	579.127	35.834	71.851
	1006	2.132	547.280	30.535	64.681
	1007	2.033	697.295	40.138	77.865
	1008	2.015	513.846	34.640	68.734
	1009	2.094	499.809	30.134	78.415
	1010	2.271	526.508	30.735	61.735
	1011	2.047	470.005	36.786	74.548
	1012	2.151	607.764	36.076	77.499
	1013	2.238	477.167	30.965	63.047
	1014	2.212	647.107	39.060	80.967
	1015	2.162	635.430	32.979	73.265
	1016	2.137	693.308	47.169	82.171
	1017	2.133	607.032	37.553	77.496

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 1 - AIR CONTROL	1001	75.578	1.186	3.336	143.262
	1002	80.773	1.356	2.436	131.914
	1005	79.354	1.191	2.897	119.054
	1006	71.857	.966	3.110	156.191
	1007	77.275	.989	2.838	148.549
	1008	77.816	.804	2.928	151.017
	1009	69.914	1.227	2.846	128.415
	1010	66.711	1.026	2.197	112.946
	1011	71.226	.987	3.356	125.305
	1012	76.104	.990	2.166	145.421
	1013	70.420	.903	2.752	125.424
	1014	73.960	1.212	3.074	151.221
	1015	76.688	.888	3.150	141.119
	1016	79.270	1.151	3.290	162.939
	1017	72.199	1.327	3.038	134.599

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	GONADS	PRO-STATE	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1001	168.338	60.314	.863	12.952
	1002	163.389	52.722	.702	15.233
	1005	173.124	54.570	.900	9.550
	1006	167.964	44.653	.769	7.974
	1007	166.749	59.518	.664	9.543
	1008	147.742	60.050	.645	8.189
	1009	151.958	64.995	.716	8.214
	1010	145.663	70.806	.480	7.926
	1011	155.936	33.219	.493	12.115
	1012	170.711	61.506	.697	8.880
	1013	151.877	75.156	.648	10.679
	1014	173.373	61.483	.705	9.855
	1015	190.333	58.788	.657	7.678
	1016	160.318	59.897	.618	13.617
	1017	172.668	71.214	.788	11.158

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 2 - CERIC OXIDE LOW DOSE	2001	2.188	584.552	38.117	68.784
	2002	2.184	683.974	49.176	76.419
	2003	2.171	667.895	37.540	92.169
	2004	2.187	642.798	32.693	74.897
	2005	2.148	519.227	42.970	71.741
	2006	2.121	570.863	38.001	72.513
	2007	2.222	533.663	47.300	74.932
	2008	2.106	579.487	29.297	66.477
	2009	2.176	454.366	31.388	62.408
	2010	2.126	739.182	45.343	85.278
	2011	2.082	455.860	34.966	67.243
	2012	2.059	474.502	29.335	70.811
	2013	2.052	520.760	34.259	75.731
	2015	2.069	529.918	40.503	76.897
	2016	2.106	639.364	33.951	73.789

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT. NO :90831

MALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 2 - CERIC OXIDE LOW DOSE	2001	78.336	1.037	2.911	140.996
	2002	72.940	1.049	2.367	152.289
	2003	94.933	.921	2.764	140.811
	2004	85.460	1.088	2.451	143.804
	2005	81.145	1.038	2.663	124.395
	2006	77.605	.934	2.603	139.415
	2007	79.163	1.053	2.763	137.309
	2008	83.286	1.121	2.939	133.666
	2009	69.347	.758	2.238	121.783
	2010	89.229	.960	2.625	167.168
	2011	81.748	1.004	2.671	132.757
	2012	80.525	1.054	3.424	126.469
	2013	88.840	1.028	3.051	135.770
	2015	84.389	1.092	2.731	142.823
	2016	91.548	.921	2.830	145.014

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	GONADS	PRO-STATE	PIT-UITARY	THYMUS
GROUP 2 - CERIC OXIDE LOW DOSE	2001	173.263	76.417	.750	8.090
	2002	159.753	61.813	.540	9.661
	2003	173.837	75.587	.553	14.786
	2004	159.076	55.601	.695	7.910
	2005	146.182	71.927	.670	7.635
	2006	169.448	47.525	.646	12.164
	2007	145.320	78.938	.779	11.791
	2008	185.945	57.787	.726	15.859
	2009	153.539	34.881	.584	8.410
	2010	157.197	77.846	.701	12.183
	2011	166.234	66.955	.648	13.016
	2012	184.216	63.137	.806	10.928
	2013	183.772	91.082	.785	10.673
	2015	144.611	57.854	.696	10.971
	2016	168.139	58.689	.931	11.491

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	2.171	631.506	33.994	77.568
	3002	1.995	657.293	41.053	84.461
	3003	2.195	630.205	35.535	65.786
	3004	2.124	549.294	29.237	70.198
	3005	2.182	664.436	39.780	74.015
	3006	1.951	711.122	45.515	75.756
	3007	2.088	546.121	45.642	71.121
	3008	2.171	686.872	50.345	75.956
	3009	2.194	544.394	37.785	79.170
	3011	2.055	636.496	42.822	79.124
	3012	2.066	561.810	50.871	66.844
	3013	2.162	605.874	43.848	71.693
	3014	2.135	561.499	43.372	77.799
	3015	2.070	630.773	39.758	72.415
	3016	2.213	562.223	34.930	70.131

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	101.750	1.027	2.220	141.133
	3002	130.627	1.088	2.947	138.045
	3003	106.105	.797	2.661	135.763
	3004	105.508	.951	1.963	133.286
	3005	118.423	1.114	2.984	152.521
	3006	152.178	.994	2.455	158.534
	3007	132.088	1.351	2.471	141.906
	3008	127.683	.889	3.008	149.655
	3009	101.869	.980	2.785	127.666
	3011	96.448	1.085	2.316	140.438
	3012	138.867	.944	2.149	141.868
	3013	127.845	.888	3.057	138.853
	3014	142.061	1.040	2.567	131.054
	3015	148.068	.720	2.676	140.000
	3016	99.458	.750	2.815	137.189

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	GONADS	PRO-STATE	PIT-UITARY	THYMUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3001	169.876	69.369	.751	10.963
	3002	178.546	46.917	.632	15.940
	3003	171.891	48.975	.661	15.125
	3004	163.041	59.605	.541	12.759
	3005	166.957	62.007	.591	15.949
	3006	184.418	59.354	.779	14.403
	3007	178.496	67.864	.704	13.362
	3008	165.592	45.924	.654	14.740
	3009	159.344	67.046	.839	9.389
	3011	157.908	50.900	.608	14.696
	3012	174.105	48.790	.712	13.166
	3013	188.807	81.452	.587	11.980
	3014	187.728	59.251	.689	12.272
	3015	168.309	50.628	.715	14.976
	3016	151.559	69.634	.624	13.737

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	2.016	451.488	39.087	67.510
	4003	2.090	618.947	46.699	76.746
	4004	2.161	433.040	31.143	65.572
	4005	2.255	571.308	56.142	66.608
	4006	2.268	573.766	31.702	68.430
	4007	2.059	473.045	38.077	76.105
	4008	2.172	521.087	38.674	72.422
	4009	2.145	470.723	36.084	64.942
	4010	2.099	707.099	51.596	73.273
	4011	2.069	618.705	42.533	76.752
	4012	2.183	507.421	33.578	73.065
	4014	2.090	529.569	40.191	71.100
	4015	2.069	621.218	34.026	63.122
	4016	1.475	1128.339	73.763	185.695

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	200.298	.893	2.907	115.972
	4003	258.708	.799	3.340	142.440
	4004	243.869	1.101	2.545	108.792
	4005	218.714	1.193	2.279	140.621
	4006	220.459	1.010	2.747	137.963
	4007	259.786	.797	2.846	117.678
	4008	199.448	1.225	2.772	126.519
	4009	176.410	1.380	2.261	124.009
	4010	213.864	.981	3.149	155.979
	4011	222.281	1.121	2.755	154.036
	4012	225.286	.843	2.579	118.049
	4014	216.124	.828	2.148	129.569
	4015	191.542	.947	2.673	141.711
	4016	317.085	1.844	4.434	248.814

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

MALES

	ANIMAL NO.	GONADS	PRO-STATE	PIT-UITARY	THYMUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4002	163.393	58.879	.650	9.177
	4003	156.124	57.512	.670	10.622
	4004	153.725	55.345	.611	7.820
	4005	171.929	64.257	.652	11.663
	4006	172.487	61.332	.626	9.480
	4007	119.378	55.415	.699	10.636
	4008	163.904	74.678	.677	9.622
	4009	174.312	49.837	.657	10.256
	4010	173.464	73.178	.838	14.531
	4011	168.391	87.675	.797	22.620
	4012	153.779	51.580	.563	9.757
	4014	173.923	57.512	.612	8.182
	4015	174.625	43.741	.609	13.678
	4016	241.017	149.017	1.329	22.508

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 1 - AIR CONTROL	1501	1.816	360.132	29.185	51.872
	1502	1.929	346.397	26.179	52.151
	1503	1.873	355.846	26.535	55.953
	1504	1.938	352.683	29.154	49.329
	1505	1.908	334.434	33.491	50.210
	1506	1.977	295.498	22.003	45.524
	1507	1.929	361.845	34.266	48.626
	1508	1.937	365.720	24.316	53.691
	1509	1.827	313.793	27.750	46.907
	1510	2.007	335.177	25.411	52.267
	1511	1.948	319.610	29.107	42.916
	1512	1.910	328.429	25.654	47.225
	1513	1.966	265.565	23.550	51.475
	1514	2.005	311.022	24.489	40.499
	1515	1.896	366.719	23.154	52.637

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 1 - AIR CONTROL	1501	64.923	.887	3.166	105.011
	1502	54.692	.975	2.836	81.649
	1503	61.345	.630	2.702	87.934
	1504	61.404	.717	3.318	93.756
	1505	58.648	.624	3.679	92.505
	1506	54.224	.865	3.576	81.234
	1507	71.280	.715	3.396	96.060
	1508	61.693	.650	3.258	95.870
	1509	60.482	.761	2.928	82.375
	1510	57.150	.917	2.765	84.654
	1511	56.879	.703	2.890	90.349
	1512	56.806	.681	2.806	89.529
	1513	55.341	.758	2.355	79.603
	1514	62.893	.903	3.332	76.209
	1515	55.063	.928	2.658	84.757

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	GONADS	UTERUS	PIT-UITARY	THYMUS
GROUP 1 - AIR CONTROL	1501	5.595	33.976	1.024	12.500
	1502	5.438	50.233	.814	9.020
	1503	4.170	33.903	.940	9.931
	1504	4.169	21.311	.862	10.010
	1505	3.381	26.677	.907	7.809
	1506	5.225	27.365	.961	9.762
	1507	5.734	26.024	.809	7.050
	1508	3.660	25.039	.769	9.757
	1509	4.012	30.542	.733	8.593
	1510	3.508	35.825	.683	11.161
	1511	4.292	42.762	.734	9.343
	1512	4.497	32.775	.733	13.560
	1513	3.871	40.946	.966	10.326
	1514	4.738	30.474	.818	7.282
	1515	2.358	31.329	1.287	8.808

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 2 - CERIC OXIDE LOW DOSE	2501	1.890	337.566	26.667	52.169
	2502	1.938	309.856	24.974	42.208
	2503	1.954	288.280	30.502	47.544
	2504	1.837	375.504	33.370	59.717
	2505	1.962	299.337	24.261	44.852
	2506	2.014	363.456	27.905	43.496
	2507	2.037	335.052	30.191	44.232
	2508	1.941	411.283	35.085	56.878
	2509	1.948	324.333	28.234	51.027
	2510	1.866	413.344	39.925	61.147
	2511	2.089	291.623	32.647	41.264
	2512	2.008	294.124	31.474	45.418
	2513	2.062	304.268	28.661	51.940
	2514	2.067	293.662	25.835	43.203
	2515	1.855	369.757	26.954	49.057

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	62.540	.635	3.185	87.460
	2502	61.610	.614	3.571	77.399
	2503	61.771	.553	2.339	79.887
	2504	75.449	.893	4.507	97.278
	2505	59.378	.550	3.211	84.404
	2506	62.562	.899	2.895	90.963
	2507	75.454	.839	2.617	81.492
	2508	65.482	1.046	3.812	90.623
	2509	65.503	.667	2.408	82.392
	2510	90.836	1.109	3.698	102.465
	2511	62.422	.886	3.212	75.969
	2512	58.566	1.001	2.525	84.213
	2513	68.623	.820	3.904	84.142
	2514	66.328	.745	2.351	77.552
	2515	66.469	.830	2.453	90.027

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	GONADS	UTERUS	PIT-UITARY	THYMUS
GROUP 2 - CERIC OXIDE LOW DOSE	2501	3.577	27.249	.852	8.624
	2502	2.905	32.611	.779	6.502
	2503	3.920	27.687	.676	16.735
	2504	4.257	32.553	.947	7.186
	2505	4.037	27.523	.872	6.626
	2506	2.651	71.549	.750	11.172
	2507	4.138	28.326	.771	6.136
	2508	4.338	19.629	.814	11.489
	2509	3.090	35.113	.749	5.749
	2510	5.611	31.511	.820	12.433
	2511	4.461	45.093	.665	9.909
	2512	3.257	25.199	.657	9.811
	2513	3.346	74.345	.689	6.305
	2514	3.430	20.997	.701	3.919
	2515	3.811	29.919	.938	9.811

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	1.928	369.606	27.075	55.446
	3502	1.959	298.213	29.454	42.675
	3503	1.977	354.224	28.730	56.095
	3504	1.885	359.363	39.841	53.475
	3505	1.957	345.580	21.921	50.281
	3506	1.897	319.241	29.468	49.236
	3507	1.869	303.478	31.728	58.373
	3508	1.863	332.743	22.008	47.504
	3509	1.936	301.756	22.056	55.785
	3510	1.913	361.213	31.626	58.181
	3511	1.973	277.952	28.434	44.349
	3513	1.985	299.345	24.887	44.786
	3514	2.186	355.032	24.840	48.948
	3516	1.932	305.072	30.849	45.756
	3517	1.881	287.028	19.617	42.743

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	95.332	.742	3.833	94.191
	3502	75.191	.904	2.981	88.719
	3503	75.670	.637	2.307	85.180
	3504	78.037	.700	3.454	87.798
	3505	70.567	.654	2.545	73.684
	3506	94.096	.849	3.864	82.920
	3507	90.690	1.188	3.858	77.689
	3508	80.515	.811	2.759	86.957
	3509	130.940	.909	3.869	80.733
	3510	93.466	.842	3.100	97.073
	3511	82.058	.669	3.077	73.746
	3513	79.748	.831	2.912	86.196
	3514	81.382	.608	3.028	88.015
	3516	74.327	1.051	3.318	84.990
	3517	73.684	.707	2.690	80.755

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	GONADS	UTERUS	PIT-UITARY	THYMUS
GROUP 3 - CERIC OXIDE INTERMEDIATE DOSE	3501	2.884	34.025	1.037	8.869
	3502	4.752	28.433	.669	7.657
	3503	4.426	32.625	.769	11.583
	3504	5.310	25.570	.881	12.891
	3505	3.352	30.761	.848	8.329
	3506	5.909	31.049	.749	11.228
	3507	5.169	58.801	.829	13.697
	3508	3.081	56.575	.789	11.218
	3509	5.062	23.554	.785	9.659
	3510	5.102	34.501	.727	10.403
	3511	3.619	24.633	.674	10.238
	3513	4.640	30.730	.821	14.307
	3514	4.538	39.661	.961	10.064
	3516	3.939	29.917	.787	8.385
	3517	3.721	24.083	.590	8.772

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	BRAIN WEIGHT (G)	LIVER	SPLEEN	HEART
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	2.063	341.493	24.091	48.279
	4502	1.965	325.954	29.059	48.143
	4503	1.905	304.514	23.517	50.761
	4504	1.940	310.876	25.928	49.691
	4505	1.944	301.903	24.640	52.058
	4506	1.883	320.287	30.536	51.514
	4507	1.942	320.340	28.682	49.228
	4508	1.890	378.148	27.566	50.794
	4509	1.888	323.252	26.642	47.458
	4510	1.908	341.876	29.665	51.887
	4511	1.957	281.196	17.987	42.207
	4513	1.966	382.503	31.027	56.612
	4514	1.920	304.063	28.906	48.281
	4515	1.901	382.115	28.880	49.553
	4516	1.890	309.259	26.508	47.354

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	LUNGS	THYROIDS/ PARA-THYROIDS	ADRENALS	KIDNEYS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	168.735	.848	2.763	83.374
	4502	172.417	.702	4.025	83.003
	4503	166.772	.530	2.924	73.386
	4504	188.196	1.103	3.438	90.619
	4505	141.975	1.008	3.601	75.360
	4506	160.913	.759	2.427	77.801
	4507	139.392	1.061	3.625	89.444
	4508	162.434	.767	4.074	94.021
	4509	169.227	.874	2.569	82.786
	4510	161.426	1.090	3.024	81.027
	4511	140.521	.598	2.718	71.334
	4513	174.262	1.155	3.596	100.407
	4514	193.958	.755	3.214	82.292
	4515	173.803	.726	3.372	95.634
	4516	150.794	.873	2.788	77.513

APPENDIX NO. 13

RELATIVE ORGAN WEIGHTS (G%)
(RELATIVE TO BRAIN WEIGHT)

PROJECT NO :90831

FEMALES

	ANIMAL NO.	GONADS	UTERUS	PIT-UITARY	THYMUS
GROUP 4 - CERIC OXIDE HIGH DOSE	4501	3.694	20.116	.814	5.865
	4502	4.702	22.341	.799	5.852
	4503	4.572	26.037	.777	8.556
	4504	4.918	38.247	.799	7.320
	4505	4.604	35.082	.772	8.333
	4506	3.733	32.661	.892	9.825
	4507	2.750	75.386	.906	11.432
	4508	3.952	27.778	.852	9.153
	4509	4.746	26.430	.667	8.422
	4510	4.340	30.398	.844	9.172
	4511	3.250	45.171	.644	8.789
	4513	3.881	35.351	1.033	7.833
	4514	4.073	28.646	.641	14.010
	4515	3.882	26.197	.810	9.100
	4516	4.164	24.603	.778	4.815

APPENDIX NO. 14

PROJECT NO. 90831

INDIVIDUAL GROSS PATHOLOGICAL FINDINGS
HEALTH SCREEN
MALES

ANIMAL NO.	ORGAN	FINDINGS
5001	Kidney	Cyst: Single, left.
5002	Lymph node pancreatic	Enlargement.
5003		No abnormal findings.
5004	Thymus	Area dark: Multiple.
5005	Thymus	Area dark: Multiple.
5006		No abnormal findings.
5007		No abnormal findings.
5008		No abnormal findings.
5009		No abnormal findings.
5010		No abnormal findings.

APPENDIX NO. 14 PROJECT NO. 90831

INDIVIDUAL GROSS PATHOLOGICAL FINDINGS
HEALTH SCREEN
FEMALES

ANIMAL NO.	ORGAN	FINDINGS
5501		No abnormal findings.
5502		No abnormal findings.
5503		No abnormal findings.
5504		No abnormal findings.
5505	Kidney	Cyst: Multiple, bilateral.
5506		No abnormal findings.
5507		No abnormal findings.
5508		No abnormal findings.
5509	Kidney	Area depressed: Pale, single, left.
5510		No abnormal findings.

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1001 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [2]	
LYMPH NODE PANCREATIC	ENLARGEMENT [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
HEART	INFILTRATION, MONONUCLEAR CELL MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [2]	2
LYMPH NODE PANCREATIC	NO ABNORMAL FINDINGS [1]	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1002 MALE
STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
HEART	INFILTRATION, MONONUCLEAR CELL FOCAL.	1
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1005 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA DEPRESSED DARK, SINGLE, RIGHT. [2]	
LYMPH NODE MANDIBULAR	ENLARGEMENT LEFT. [1]	
URINARY BLADDER	DILATATION [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
KIDNEY	NO ABNORMAL FINDINGS [2]	
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY UNILATERAL. [1]	3
URINARY BLADDER	DILATATION [3]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: #- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1006 MALE
STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE; MULTIPLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE MANDIBULAR	AREA DARK MULTIPLE, RIGHT. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
HEART	INFILTRATION, MONONUCLEAR CELL MULTIFOCAL.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1
LYMPH NODE MANDIBULAR	NO ABNORMAL FINDINGS [2]	
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
PROSTATE	PROSTATITIS ACUTE, MULTIFOCAL.	1
SPINAL CORD CERVICAL	UNAVAILABLE NOT FOUND IN WET TISSUES.	

GROSS GRADE CODE: *- NOT SUBMITTED

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1006 (cont'd) MALE
STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1007 MALE
STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
HEART	INFILTRATION, MONONUCLEAR CELL FOCAL.	1
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1008 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA DEPRESSED DARK, SINGLE, LEFT. [2]	
LIVER	AREA RAISED PALE, SINGLE, FISSURE, MEDIAN LOBE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	FIBROPLASIA FOCAL, WITH SUBACUTE INFLAMMATION. [2]	1
LIVER	VACUOLATION, HEPATOCELLULAR LOCALLY EXTENSIVE. [1]	2
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90B31

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1009 MALE
STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
HEART	INFILTRATION, MONONUCLEAR CELL FOCAL.	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1010 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [1]	2
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS BILATERAL.	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1011 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
HEART	INFILTRATION, MONONUCLEAR CELL MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1012 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	1
HEART	INFILTRATION, MONONUCLEAR CELL FOCAL.	1
PROSTATE	PROSTATITIS ACUTE, FOCAL.	1
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1013 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	3
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1014 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA RAISED PALE, FIRM, SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
EYE	FOLD/ROSETTE, RETINAL LOCALLY EXTENSIVE, UNILATERAL.	1
HEART	INFILTRATION, MONONUCLEAR CELL MULTIFOCAL.	1
LIVER	NO ABNORMAL FINDINGS [1]	
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [2]	2
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1014 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
PROSTATE	PROSTATITIS ACUTE, MULTIFOCAL.	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1015 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
ALL TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	CYST UNILATERAL.	2
	FIBROPLASIA SEGMENTAL, WITH TUBULAR BASOPHILIA AND SUBACUTE INFLAMMATION.	1
MAMMARY GLAND	NO GLANDULAR TISSUE IN SECTION	
PROSTATE	PROSTATITIS ACUTE, FOCAL.	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90B31

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1016 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	AREA DARK MULTIPLE, BILATERAL. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
LYMPH NODE MANDIBULAR	HEMORRHAGE FOCAL TO MULTIFOCAL, BILATERAL. [1]	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
PITUITARY	CYST	1
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1017 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LODE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
EYE	ATROPHY, RETINAL LOCALLY EXTENSIVE, UNILATERAL.	2
LIVER	NO ABNORMAL FINDINGS [1]	
PITUITARY	NO ABNORMAL FINDINGS PARS NERVOSA NOT PRESENT.	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2001 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [1]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2002 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA PALE SINGLE, RIGHT. [2]	
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
KIDNEY	NO ABNORMAL FINDINGS [2]	
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2002 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	INTRACELLULAR, MULTIFOCAL.	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [3]	1
	HYPERPLASIA, LYMPHOID	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2003 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	AREA DARK MULTIPLE, BILATERAL. [2]	
SPLEEN	CYST MULTIPLE, EDGE. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3] DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	HEMORRHAGE MULTIFOCAL, UNILATERAL. [2]	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2003 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
SPLEEN	CYST, CAPSULAR [1]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2004 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4]	
	DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LIVER	VACUOLATION, HEPATOCELLULAR LOCALLY EXTENSIVE. [1]	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2004 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
	MINERALIZATION VASCULAR, FOCAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	2
	HYPERPLASIA, LYMPHOID [4]	1
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [3]	2
	HYPERPLASIA, LYMPHOID [2]	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2005 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2006 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	1
	HYPERPLASIA, LYMPHOID	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2007 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LODE. [1]	
LYMPH NODE MANDIBULAR	ENLARGEMENT LEFT. [2] FOCI DARK BILATERAL. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4] DISCOLORATION PALE. [5]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	NO ABNORMAL FINDINGS [1]	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, x- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2007 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY UNILATERAL. [2]	3
	HEMORRHAGE MULTIFOCAL, BILATERAL. [3]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	2
	HYPERPLASIA, LYMPHOID [4]	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2008 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	DILATATION PELVIS, LEFT. [3]	
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	NO ABNORMAL FINDINGS [3]	
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	VACUOLATION, HEPATOCELLULAR MULTIFOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2008 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	INTRACELLULAR, MULTIFOCAL.	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. (2)	1
	HYPERPLASIA, LYMPHOID	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2009 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	RHINITIS SUPPURATIVE, LOCALLY EXTENSIVE, WITH EPITHELIAL HYPERPLASIA AND FOCAL ATROPHY.	2
	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	VACUOLATION, HEPATOCELLULAR LOCALLY EXTENSIVE. [1]	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2009 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	MULTIFOCAL. [2]	
	HYPERPLASIA, LYMPHOID	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2010 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
	HYPERPLASIA, LYMPHOID	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2011 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2012 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2013 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4] DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2] DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2013 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [4]	1
	PIGMENT ACCUMULATION MULTIFOCAL. [5]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [3]	2
	HYPERPLASIA, LYMPHOID [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2015 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE MULTIPLE, FISSURE, MEDIAN LOBE; SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LIVER	VACUOLATION, HEPATOCELLULAR MULTIFOCAL TO LOCALLY EXTENSIVE. [1]	2
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2015 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2016 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	DILATATION PELVIS, LEFT. [4]	
LIVER	AREA PALE MULTIPLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
PITUITARY	CYST SINGLE. [3]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
KIDNEY	DILATATION, PELVIS [4]	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	NO ABNORMAL FINDINGS	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90C31

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2016 (cont'd) MALE STUDY WEEK OF DEATH: 14 (DAY 92)

TISSUE	FINDING	GRADE
LIVER (cont'd)	[1]	
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
PITUITARY	CYST [3]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3001 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [4]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [5] DISCOLORATION PALE. [6]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2] DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3001 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LIVER	NO ABNORMAL FINDINGS [1]	
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, MULTIFOCAL. [4]	3
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [5]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [6]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [2]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [3]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3002 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [6]	
LYMPH NODE MANDIBULAR	FOCI DARK BILATERAL. [1]	
	ENLARGEMENT LEFT. [2]	
PROSTATE	AREA PALE MULTIPLE. [7]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [4]	
	ENLARGEMENT [5]	
LYMPH NODE PANCREATIC	AREA DARK MULTIPLE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3002 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY UNILATERAL. [2]	2
	HEMORRHAGE MULTIFOCAL TO LOCALLY EXTENSIVE, UNILATERAL. [1]	2
PROSTATE	PROSTATITIS SUBACUTE, MULTIFOCAL TO LOCALLY EXTENSIVE. [7]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	3
	HYPERPLASIA, LYMPHOID [5]	2
LYMPH NODE PANCREATIC	HEMORRHAGE MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #D- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3003 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE MANDIBULAR	AREA DARK MULTIPLE, BILATERAL. [1]	
	ENLARGEMENT BILATERAL. [2]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [6]	
	DISCOLORATION PALE. [7]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3003 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
CAVITY NASAL (cont'd)	INTRAFOLLICULAR (LEVEL III).	
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, MULTIFOCAL. [5]	3
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [2]	3
	HEMORRHAGE MULTIFOCAL, BILATERAL. [1]	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [7]	2
	HYPERPLASIA, LYMPHOID [6]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [3]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3004 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, MULTIFOCAL. [5]	3
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3004 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	MULTIFOCAL. [4]	
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION	2
	MULTIFOCAL. [2]	
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3005 MALE STUDY WEEK OF DEATH: 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, DORSAL SURFACE, VENTRAL PORTION OF RIGHT LOBE. [1]	
LUNG	AREA PALE MULTIPLE, EDGE. [4]	
URINARY BLADDER	DILATATION [5]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2] ENLARGEMENT [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LIVER	VACUOLATION, HEPATOCELLULAR	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3005 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LIVER (cont'd)	FOCAL. [1]	
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, MULTIFOCAL. [4]	3
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
URINARY BLADDER	DILATATION [5]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2
	HYPERPLASIA, LYMPHOID [3]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, x- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3006 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [4]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
TRACHEA	PIGMENT ACCUMULATION MUCOSAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [6]	2
	HYPERPLASIA, LYMPHOID [5]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [2]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [3]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3006 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [4]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [5]	
	DISCOLORATION PALE. [6]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3007 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	DILATATION PELVIS, LEFT. [6]	
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3007 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
KIDNEY	DILATATION, PELVIS [6]	3
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [5]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [3]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [4]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: #- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3000 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE, EDGE. [3]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1] ENLARGEMENT [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [3]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [1]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3008 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3009 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [1]	
URINARY BLADDER	THICKENING WALL. [4] AREA DARK MULTIPLE, MUCOSA. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [2] DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [1]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3009 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
URINARY BLADDER	HEMORRHAGE MULTIFOCAL. [5]	1
	NO CORRELATION WITH GROSS FINDING [4]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [3]	3
	HYPERPLASIA, LYMPHOID [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3011 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, CAUDATE LOBE, LEFT LOBE, VENTRAL PORTION OF RIGHT LOBE. [1]	
	AREA RAISED PALE, FIRM, SINGLE, NEAR HILUS, RIGHT PORTION OF MEDIAN LOBE, VENTRAL PORTION OF RIGHT LOBE. [2]	
LUNG	AREA PALE MULTIPLE. [8]	
LYMPH NODE MANDIBULAR	ENLARGEMENT LEFT. [4]	
STOMACH	AREA DARK MULTIPLE, MUCOSA, GLANDULAR PORTION. [3]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [6]	
	ENLARGEMENT [7]	
LYMPH NODE MEDIASTINAL	AREA DARK MULTIPLE. [5]	

ALL OTHER TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90B31

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3011 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LIVER	NECROSIS MULTIFOCAL TO LOCALLY EXTENSIVE, WITH FIBROPLASIA AND ACUTE TO SUBACUTE INFLAMMATION. [1,2]	2
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [8]	3
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [4]	4
STOMACH	NO ABNORMAL FINDINGS [3]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [6]	2
	HYPERPLASIA, LYMPHOID [7]	2
LYMPH NODE MEDIASTINAL	HEMORRHAGE	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #D- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3011 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL (cont'd)	LOCALLY EXTENSIVE. [5]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: ■- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3012 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [3]	
PROSTATE	AREA PALE MULTIPLE. [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4]	
	DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3012 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [3]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
PROSTATE	PROSTATITIS SUBACUTE, MULTIFOCAL TO LOCALLY EXTENSIVE. [6]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	3
	HYPERPLASIA, LYMPHOID [4]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	3
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3013 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [6] AREA DARK MULTIPLE. [7]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4] DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2] DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3013 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	BASE OF EPIGLOTTIS.	
LIVER	VACUOLATION, HEPATOCELLULAR MULTIFOCAL, WITH ACUTE INFLAMMATION AND NECROSIS. [1]	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL. NO CORRELATION WITH GROSS FINDING [7]	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [5]	2
	HYPERPLASIA, LYMPHOID [4]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [2] NO CORRELATION WITH GROSS FINDING [3]	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3014 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, RIGHT PORTION OF MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [6] UNCOLLAPSED [7]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [2] FOCI DARK RIGHT. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4] DISCOLORATION PALE. [5]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II,III).	1
LARYNX	METAPLASIA	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3014 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	BASE OF EPIGLOTTIS.	
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [6,7]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL. [6,7]	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [2]	2
	NO CORRELATION WITH GROSS FINDING [3]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	3
	HYPERPLASIA, LYMPHOID [4]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3015 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [8] UNCOLLAPSED [9]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [2] AREA DARK MULTIPLE, RIGHT. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [6] DISCOLORATION PALE. [7]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [4] DISCOLORATION PALE. [5]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3015 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
CAVITY NASAL (cont'd)	INTRAFOLLICULAR (LEVEL II,III).	
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [8,9]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [2]	3
	NO CORRELATION WITH GROSS FINDING [3].	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [7]	2
	HYPERPLASIA, LYMPHOID [6]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	2
	HYPERPLASIA, LYMPHOID	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3015 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL (cont'd)		
	[4]	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3016 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [4]	
THYROID	SMALL RIGHT LOBE. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [5]	
	DISCOLORATION PALE. [6]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3016 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [4]	3
THYROID	NO ABNORMAL FINDINGS [3]	
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [5]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [6]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: #- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4001 MALE STUDY WEEK OF DEATH 11 (DAY 72)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [4]	
	AREA DARK MULTIPLE. [5]	
	UNCOLLAPSED [8]	
THYMUS	AREA DARK MULTIPLE. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [6]	
	DISCOLORATION PALE. [7]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4001 (cont'd) MALE STUDY WEEK OF DEATH 11 (DAY 72)

TISSUE	FINDING	GRADE
BRONCHUS (cont'd)	INTRALUMINAL.	
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
CECUM	POSTMORTEM CHANGE	*
COLON	POSTMORTEM CHANGE	*
DUODENUM	POSTMORTEM CHANGE	*
ILEUM	POSTMORTEM CHANGE	*
JEJUNUM	POSTMORTEM CHANGE	*
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	2
LUNG	PIGMENT ACCUMULATION DIFFUSE, EXTRA- AND INTRACELLULAR, WITH CONGESTION. [4,5,8]	4
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYMUS	HEMORRHAGE	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4001 (cont'd) MALE STUDY WEEK OF DEATH 11 (DAY 72)

TISSUE	FINDING	GRADE
THYMUS (cont'd)	MULTIFOCAL TO LOCALLY EXTENSIVE. [1]	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [7]	3
	HYPERPLASIA, LYMPHOID [6]	3
LYMPH NODE MEDIASTINAL	UNAVAILABLE NOT FOUND IN WET TISSUES. [2,3]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: #- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4002 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA DEPRESSED DARK, SINGLE, LEFT. [1]	
	DILATATION PELVIS, BILATERAL. [2]	
LUNG	DISCOLORATION PALE. [3]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [4]	
	ENLARGEMENT [5]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
KIDNEY	DILATATION, PELVIS	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4002 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
KIDNEY (cont'd)	BILATERAL.	
	NO CORRELATION WITH GROSS FINDING [1]	
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [3,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [3,6]	3
LYMPH NODE MANDIBULAR	HYPERPLASIA, LYMPHOID	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYMUS	HEMORRHAGE	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4002 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
THYMUS (cont'd)	FOCAL.	
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3
	HYPERPLASIA, LYMPHOID [5]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4003 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE; NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LUNG	DISCOLORATION PALE. [4]	
	UNCOLLAPSED [5]	
LYMPH NODE MANDIBULAR	AREA DARK MULTIPLE, BILATERAL. [2]	
THYMUS	AREA DARK MULTIPLE. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [6]	
	DISCOLORATION PALE. [7]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4003 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
ADRENAL (cont'd)	LOCALLY EXTENSIVE, BILATERAL.	
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II,III).	1
COLON	PARASITE INTRALUMINAL.	1
KIDNEY	CYST UNILATERAL.	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	LARYNGITIS PROLIFERATIVE, MULTIFOCAL, WITH FOREIGN BODY.	2
	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [4,5]	4

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4003 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [4,5]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	HEMORRHAGE FOCAL, BILATERAL. [2]	1
	PIGMENT ACCUMULATION MULTIFOCAL.	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYMUS	HEMORRHAGE MULTIFOCAL. [3]	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [6]	3
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [7]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4004 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	MASS APPROXIMATELY 15X5X5 MM, PALE, FIRM, WELL DEFINED, LEFT LOBE. [1]	
LUNG	UNCOLLAPSED [5] DISCOLORATION PALE. [6]	
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [2]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [7] DISCOLORATION PALE. [6]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [3] DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4004 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
BRONCHUS (cont'd)	INTRALUMINAL.	
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION MUCOSAL.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
	NO CORRELATION WITH GROSS FINDING [1]	
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [5,6]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	HYPERPLASIA, LYMPHOID [2]	2
	PIGMENT ACCUMULATION MULTIFOCAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4004 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [7]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [8]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [3]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [4]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4005 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [1]	
	UNCOLLAPSED [2]	
URINARY BLADDER	DILATATION [5]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
	ENLARGEMENT [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	1
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4005 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [1,2]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [1,2]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
URINARY BLADDER	DILATATION [5]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	3
	HYPERPLASIA, LYMPHOID [4]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4006 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	DILATATION PELVIS, LEFT. [1]	
LUNG	DISCOLORATION PALE. [4]	
	UNCOLLAPSED [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [6]	
	DISCOLORATION PALE. [7]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	2
BRONCHUS	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4006 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
BRONCHUS (cont'd)	INTRALUMINAL.	
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
KIDNEY	DILATATION, PELVIS UNILATERAL. [1]	2
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [4,5]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [4,5]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
MUSCLE SKELETAL	INFILTRATION, MONONUCLEAR CELL LOCALLY EXTENSIVE.	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4006 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
URINARY BLADDER	DILATATION	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [7]	3
	HYPERPLASIA, LYMPHOID [6]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [2]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4007 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	UNCOLLAPSED [4]	
	DISCOLORATION PALE. [5]	
PITUITARY	CYST SINGLE. [9]	
PROSTATE	AREA PALE MULTIPLE, DORSAL PORTION. [8]	
SPLEEN	CYST MULTIPLE, EDGE. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [6]	
	DISCOLORATION PALE. [7]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90B31

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4007 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [4,5]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [4,5]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
PITUITARY	NO ABNORMAL FINDINGS [9]	
PROSTATE	PROSTATITIS	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4007 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
PROSTATE (cont'd)	SUBACUTE, MULTIFOCAL TO LOCALLY EXTENSIVE. [8]	
SPLEEN	CYST, CAPSULAR [1]	2
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [7]	3
	HYPERPLASIA, LYMPHOID [6]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [2]	3
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4008 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	1
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4008 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [5,6]	3
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [1]	2
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4008 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	
	HYPERPLASIA, LYMPHOID [2]	3
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4009 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	INTRALUMINAL AND MUCOSAL.	
	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [5,6]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
PITUITARY	NO ABNORMAL FINDINGS PARS NERVOSA NOT PRESENT.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS BILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3
	HYPERPLASIA, LYMPHOID	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4009 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)	[3]	
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4010 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	DISCOLORATION PALE. [5] UNCOLLAPSED [6]	
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [2]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [7] DISCOLORATION PALE. [8]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [3] DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4010 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
BRONCHUS (cont'd)	INTRALUMINAL AND MUCOSAL.	
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
HEART	INFILTRATION, MONONUCLEAR CELL FOCAL.	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL. NO CORRELATION WITH GROSS FINDING [1]	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [2]	2
	HEMORRHAGE	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4010 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MANDIBULAR (cont'd)	MULTIFOCAL, UNILATERAL.	
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [8]	4
	HYPERPLASIA, LYMPHOID [7]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [3]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4011 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [4]	
	UNCOLLAPSED [3]	
THYMUS	AREA DARK MULTIPLE. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
	ENLARGEMENT [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, UNILATERAL.	2
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4011 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [4,5]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [4,5]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYMUS	NO ABNORMAL FINDINGS [1]	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4011 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
THYROID (cont'd)	BILATERAL.	
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3
	HYPERPLASIA, LYMPHOID [3]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4012 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4012 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	BASE OF EPIGLOTTIS.	
	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [5,6]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
MAMMARY GLAND	NO GLANDULAR TISSUE IN SECTION	
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4012 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
THYROID (cont'd)	UNILATERAL.	
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4014 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [3]	
	UNCOLLAPSED [4]	
PROSTATE	AREA RAISED PALE, FIRM, MULTIPLE, VENTRAL PORTION. [5]	
THYMUS	SMALL [6]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
	ENLARGEMENT [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	VACUOLATION, CORTICAL LOCALLY EXTENSIVE, BILATERAL.	1
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4014 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
HEART	INFILTRATION, MONONUCLEAR CELL MULTIFOCAL.	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [3,4]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [3,4]	3
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY	2
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
PROSTATE	NO ABNORMAL FINDINGS [5]	
THYMUS	NO ABNORMAL FINDINGS [6]	
TRACHEA	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4014 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
TRACHEA (cont'd)	INTRALUMINAL AND MUCOSAL.	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [1]	2
	HYPERPLASIA, LYMPHOID [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90D31

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4015 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4015 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	MUCOSAL.	
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE. [5,6]	3
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID [3]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	3
	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4015 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL (cont'd)		
	MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4016 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	FOCI DARK BILATERAL. [1]	
	DILATATION PELVIS, LEFT. [9]	
LUNG	UNCOLLAPSED [5]	
	DISCOLORATION PALE. [6]	
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [2]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [7]	
	DISCOLORATION PALE. [0]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4016 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
BRONCHUS (cont'd)	MUCOSAL AND INTRALUMINAL.	
CAVITY NASAL	HYPERTROPHY AND/OR HYPERPLASIA, GOBLET CELL LOCALLY EXTENSIVE.	2
	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II,III).	1
KIDNEY	DILATATION, TUBULAR MULTIFOCAL, WITH TUBULAR BASOPHILIA AND INTRATUBULAR HEMORRHAGE. [1]	2
	DILATATION, PELVIS UNILATERAL. [9]	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [2]	4
PITUITARY	CYST	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4016 (cont'd) MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [7]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [8]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [3]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1501 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [2] FOCI DARK BILATERAL. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION DARK. [4]	
LYMPH NODE PANCREATIC	ENLARGEMENT [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [2]	2
	HEMORRHAGE MULTIFOCAL, UNILATERAL. [3]	2
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
LYMPH NODE MEDIASTINAL	HEMORRHAGE LOCALLY EXTENSIVE. [4]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1501 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE PANCREATIC	NO CORRELATION WITH GROSS FINDING [1]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: N- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, K- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1502 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	FOCAL CORTICAL HYPERTROPHY WITH VACUOLATION, UNILATERAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS BILATERAL.	1
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1503 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE PANCREATIC	ENLARGEMENT [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
LYMPH NODE PANCREATIC	NO ABNORMAL FINDINGS [1]	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1504 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	ATROPHY, OLFACTORY EPITHELIUM FOCAL, TURBINATE.	1
LYMPH NODE MANDIBULAR	HEMORRHAGE FOCAL.	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1505 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
	ALL EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1506 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
THYROID	ENLARGEMENT RIGHT LOBE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL. NO CORRELATION WITH GROSS FINDING [1]	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1507 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1508 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	ADHESION RIGHT TO CAPSULE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	NO ABNORMAL FINDINGS [1]	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1509 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1510 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	DILATATION PELVIS, LEFT. [2]	
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	DILATATION, PELVIS UNILATERAL. [2]	2
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1511 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LYMPH NODE MANDIBULAR	AREA DARK MULTIPLE, BILATERAL. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1
LYMPH NODE MANDIBULAR	HEMORRHAGE MULTIFOCAL, UNILATERAL. [2]	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1512 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
	ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 1 AIR CONTROL
ANIMAL NO. 1513 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	ADHESION TO CAPSULE, RIGHT. [2]	
LIVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	ADHESION, CAPSULAR FOCAL, WITH ADIPOSE TISSUE. [2]	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [3]	2
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, X- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1514 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
	ALL TISSUES WERE UNREMARKABLE	
HISTOPATHOLOGICAL FINDINGS		
	ALL EXAMINED TISSUES WERE UNREMARKABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 1 AIR CONTROL
ANIMAL NO. 1515 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA RAISED PALE, FIRM, SINGLE, FISSURE, MEDIAN LOBE. [1]	
PITUITARY	ENLARGEMENT [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LIVER	ACCESSORY HEPATIC TISSUE WITH VACUOLATION. [1]	1
PITUITARY	NO ABNORMAL FINDINGS [2]	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS BILATERAL.	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2501 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2502 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID	1
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	1
	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2503 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	CYST SINGLE, LEFT. [2]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	HYPERTROPHY AND/OR HYPERPLASIA, GOBLET CELL LOCALLY EXTENSIVE, VENTRAL MEATUS (LEVEL I).	2
KIDNEY	NO ABNORMAL FINDINGS [2]	
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
	HYPERPLASIA, LYMPHOID	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2504 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
ADRENAL	ENLARGEMENT BILATERAL. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ADRENAL	NO ABNORMAL FINDINGS [1]	
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2504 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	MULTIFOCAL. [3]	
	HYPERPLASIA, LYMPHOID	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION	2
	MULTIFOCAL. [2]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2505 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA DEPRESSED PALE, SINGLE, RIGHT. [1]	
LUNG	FOCI PALE EDGE, RIGHT APICAL LOBE, LEFT LOBE. [3]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	NO ABNORMAL FINDINGS [1]	
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [3]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2506 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
	HYPERPLASIA, LYMPHOID	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2505 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION	1
	MULTIFOCAL. [2]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2507 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	1
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
	HYPERPLASIA, LYMPHOID	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2508 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	FOCI PALE EDGE, RIGHT APICAL LOBE, LEFT LOBE. [4]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [4]	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [1]	3
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2508 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	MULTIFOCAL. [3]	
	HYPERPLASIA, LYMPHOID	1
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION	1
	MULTIFOCAL. [2]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2509 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
	HYPERPLASIA, LYMPHOID	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2510 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [1]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [1]	3
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3501 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	2
	HYPERPLASIA, LYMPHOID [4]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	3
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4009 MALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3502 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3502 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	INTRACELLULAR, MULTIFOCAL. [5]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	3
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3503 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA DEPRESSED DARK, MULTIPLE, LEFT. [2]	
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3] DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
KIDNEY	INFILTRATION, MONONUCLEAR CELL FOCAL, WITH TISSUE LOSS. [2]	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1
LUNG	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3503 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	INTRACELLULAR, MULTIFOCAL. [5]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3504 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [6]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4]	
	DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [2]	
	ENLARGEMENT [7]	
LYMPH NODE PANCREATIC	ENLARGEMENT [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3504 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [6]	3
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [3]	3
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	3
	HYPERPLASIA, LYMPHOID [4]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [7]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3
LYMPH NODE PANCREATIC	PIGMENT ACCUMULATION MULTIFOCAL.	2
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90631

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3505 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [5]	3
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3505 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3506 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [3]	4
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3
	HYPERPLASIA, LYMPHOID	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3506 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	[1]	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, x- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3507 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [7]	
LYMPH NODE MANDIBULAR	ENLARGEMENT LEFT. [2]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [5] DISCOLORATION PALE. [6]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [3] DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3507 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [7]	3
	EPITHELIAL HYPERPLASIA, ALVEOLAR FOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [2]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [6]	2
	HYPERPLASIA, LYMPHOID [5]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [3]	2
	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3508 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4] DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [2] DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	VACUOLATION, HEPATOCELLULAR	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3508 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LIVER (cont'd)	FOCAL. [1]	
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [6]	3
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	3
	HYPERPLASIA, LYMPHOID [4]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [2]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [3]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3509 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	CYST SINGLE, LEFT. [4]	
LUNG	AREA PALE MULTIPLE. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [1] DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
KIDNEY	CYST [4]	1
LARYNX	LARYNGITIS	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #D- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3509 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	SUBACUTE, WITH EPITHELIAL HYPERPLASIA AND FOREIGN BODY.	
LUNG	PIGMENT ACCUMULATION INTRA- AND EXTRACELLULAR, DIFFUSE. [3]	4
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2
	HYPERPLASIA, LYMPHOID [1]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: #- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3510 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3510 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [5]	3
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID [3]	3
	PIGMENT ACCUMULATION MULTIFOCAL. [4]	4
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3511 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA PALE SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [4]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [2] DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION MUCOSAL.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3511 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [4]	3
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	3
	HYPERPLASIA, LYMPHOID [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3513 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [4]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LUNG	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3513 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	INTRACELLULAR, MULTIFOCAL. [4]	
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	2
	HYPERPLASIA, LYMPHOID [2]	1
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [1]	3
	HYPERPLASIA, LYMPHOID	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3514 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [5]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3514 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3516 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA RAISED PALE, FIRM, SINGLE, FISSURE, MEDIAN LOBE. [1]	
LUNG	AREA PALE MULTIPLE. [2]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	ATROPHY, OLFACTORY EPITHELIUM FOCAL (LEVEL II)	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LIVER	VACUOLATION, HEPATOCELLULAR FOCAL, SUBCAPSULAR. [1]	2
LUNG	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3516 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	INTRACELLULAR, MULTIFOCAL. [2]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [3]	2
	HYPERPLASIA, LYMPHOID	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3517 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [4]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
	ENLARGEMENT [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [4]	3
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [1]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3
	HYPERPLASIA, LYMPHOID [3]	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4501 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	UNCOLLAPSED [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
	ENLARGEMENT [5]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [6]	
LYMPH NODE PANCREATIC	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	HYPERTROPHY AND/OR HYPERPLASIA, GOBLET CELL VENTRAL MEATUS (LEVEL I).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4501 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [3,4]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4501 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)	MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	
	HYPERPLASIA, LYMPHOID [5]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [6]	3
LYMPH NODE PANCREATIC	PIGMENT ACCUMULATION MULTIFOCAL. [1]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4502 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION WITH EXUDATE, MULTIFOCAL (LEVEL I,II,III,IV); INTRAFOLLICULAR (LEVEL III).	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4502 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	3
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4502 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4503 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [3]	
	UNCOLLAPSED [4]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LIVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [3,4]	4

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4503 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL. [3,4]	2
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
SPLEEN	PIGMENT ACCUMULATION MULTIFOCAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	3
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2510 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION	2
	MULTIFOCAL. [2]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2511 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	FOCI PALE LEFT LOBE, RIGHT APICAL LOBE, RIGHT CARDIAC LOBE. [2]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [2]	2
LYMPH NODE BRONCHIAL	UNAVAILABLE NOT FOUND IN WET TISSUES. [3]	
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [1]	2
	HYPERPLASIA, LYMPHOID	2
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, x- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2512 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT BILATERAL. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY BILATERAL. [1]	2
LYMPH NODE BRONCHIAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2513 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LIVER	AREA RAISED PALE, FIRM, SINGLE, FISSURE, MEDIAN LOBE. [1] AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [2]	
LYMPH NODE MANDIBULAR	FOCI DARK RIGHT. [3]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LIVER	VACUOLATION, HEPATOCELLULAR MULTIFOCAL, SUBCAPSULAR. [1,2]	2
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	HEMORRHAGE	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2513 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MANDIBULAR (cont'd)		
	FOCAL. [3]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	1
	MULTIFOCAL. [5]	
	HYPERPLASIA, LYMPHOID	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID	2
	PIGMENT ACCUMULATION	2
	MULTIFOCAL. [4]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2514 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	FOCI PALE EDGE, RIGHT APICAL LODE. [4]	
THYMUS	SMALL [3]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL. [4]	2
THYMUS	NO ABNORMAL FINDINGS [3]	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, x- NOT TABULATED #D- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2514 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE BRONCHIAL (cont'd)		
	MULTIFOCAL. [5]	
	HYPERPLASIA, LYMPHOID	1
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION MULTIFOCAL. [2]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 2 CERIC OXIDE LOW DOSE
ANIMAL NO. 2515 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LYMPH NODE MANDIBULAR	ENLARGEMENT LEFT. [1]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [1]	2
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [2]	1
	HEMORRHAGE MULTIFOCAL.	1
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14
PROJECT NO.: 90031

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

GROUP 3 CERIC OXIDE INTERMEDIATE DOSE
ANIMAL NO. 3501 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	AREA PALE MULTIPLE. [3]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [4]	
	DISCOLORATION PALE. [5]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II,III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION INTRACELLULAR, DIFFUSE. [3]	4

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4504 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
KIDNEY	AREA DEPRESSED DARK, SINGLE, RIGHT. [1]	
LUNG	UNCOLLAPSED [6]	
	DISCOLORATION PALE. [7]	
LYMPH NODE MANDIBULAR	ENLARGEMENT RIGHT. [2]	
THYMUS	AREA DARK MULTIPLE, RIGHT LOBE. [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [8]	
	DISCOLORATION PALE. [9]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4504 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	HYPERTROPHY AND/OR HYPERPLASIA, GOBLET CELL VENTRAL MEATUS (LEVEL I).	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
KIDNEY	NO ABNORMAL FINDINGS [1]	
LARYNX	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
	METAPLASIA BASE OF EPIGLOTTIS.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [6,7]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
LYMPH NODE MANDIBULAR	PLASMACYTOSIS AND/OR HISTIOCYTOSIS, MEDULLARY [2]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4504 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
THYMUS	HEMORRHAGE MULTIFOCAL. [5]	2
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [9]	2
	HYPERPLASIA, LYMPHOID [8]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3
	HYPERPLASIA, LYMPHOID [3]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4505 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4505 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	BASE OF EPIGLOTTIS.	
	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	2
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
PARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3
	HYPERPLASIA, LYMPHOID [3]	3
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4506 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [3]	
	UNCOLLAPSED [4]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION	4

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #D- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4506 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LUNG (cont'd)	EXTRA- AND INTRACELLULAR, DIFFUSE. [3,4]	
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
TRACHEA	PIGMENT ACCUMULATION MUCOSAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PENDIX NO. 14
OJECT NO.: 90831

INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS

OUP 4 CERIC OXIDE HIGH DOSE
IMAL NO. 4507 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
NG	UNCOLLAPSED [5]	
	DISCOLORATION PALE. [6]	
MPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
MPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
AVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
YE	FOLD/ROSETTE, RETINAL	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90031

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4507 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
YE (cont'd)	LOCALLY EXTENSIVE, UNILATERAL.	
ARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
UNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	1
ARATHYROID	ONE PARATHYROID UNAVAILABLE NOT PRESENT IN SECTION.	
HYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
RACHEA	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
YMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3
	HYPERPLASIA, LYMPHOID [3]	3
YMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4507 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4500 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4508 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	BASE OF EPIGLOTTIS.	
	PIGMENT ACCUMULATION MUCOSAL.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
	HYPERPLASIA, LYMPHOID MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
TRACHEA	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	3
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3
	HYPERPLASIA, LYMPHOID [1]	2

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4509 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [1]	
	UNCOLLAPSED [2]	
LYMPH NODE BRONCHIAL	DISCOLORATION PALE. [3]	
	ENLARGEMENT [4]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II, III).	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [1,2]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
	HYPERPLASIA, LYMPHOID	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90831

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4509 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
UNG (cont'd)		
	MULTIFOCAL.	
ARATHYROID	UNAVAILABLE	
	NOT PRESENT IN SECTION.	
RACHEA	PIGMENT ACCUMULATION	1
	INTRALUMINAL AND MUCOSAL.	
YMPH NODE BRONCHIAL	PIGMENT ACCUMULATION	3
	MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	
	HYPERPLASIA, LYMPHOID	3
	[4]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
OJECT NO.: 90831

OUP 4 CERIC OXIDE HIGH DOSE
IMAL NO. 4510 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
DNEY	ADHESION TO CAPSULE, RIGHT. [1]	
	DILATATION PELVIS, RIGHT. [8]	
ING	UNCOLLAPSED [6]	
	DISCOLORATION PALE. [7]	
MPH NODE BRONCHIAL	ENLARGEMENT [4]	
	DISCOLORATION [5]	
MPH NODE MEDIASTINAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
ONCHUS	PIGMENT ACCUMULATION	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90031

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4510 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
RONCHUS (cont'd)	MUCOSAL AND INTRALUMINAL.	
AVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
IDNEY	DILATATION, PELVIS UNILATERAL. [8] NO CORRELATION WITH GROSS FINDING [1]	1
ARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
IVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
UNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [6,7]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
YMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
ARATHYROID	ONE PARATHYROID UNAVAILABLE	

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4510 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
PARATHYROID (cont'd)	NOT PRESENT IN SECTION.	
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [5]	4
	HYPERPLASIA, LYMPHOID [4]	4
LYMPH NODE MEDIASTINAL	PIGMENT ACCUMULATION MULTIFOCAL. [3]	4
	HYPERPLASIA, LYMPHOID [2]	4

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4511 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [4]	
	UNCOLLAPSED [5]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
LYMPH NODE MEDIASTINAL	DISCOLORATION PALE. [1]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II,III).	1
EYE	FOLD/ROSETTE, RETINAL FOCAL, UNILATERAL.	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90831

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4511 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
ARYNX	PIGMENT ACCUMULATION MUCOSAL.	1
IVER	PIGMENT ACCUMULATION INTRACELLULAR, SINUSOIDAL, MULTIFOCAL.	1
UNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [4,5]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
RACHEA	PIGMENT ACCUMULATION INTRALUMINAL AND MUCOSAL.	1
YMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	3
	HYPERPLASIA, LYMPHOID [2]	3
YMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID NO CORRELATION WITH GROSS FINDING [1]	1

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4513 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL II,III).	1
KIDNEY	CYST	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, N- NOT TABULATED *B- BENIGN, *M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4513 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
KIDNEY (cont'd)	UNILATERAL.	
LARYNX	METAPLASIA BASE OF EPIGLOTTIS.	1
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
LYMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [4]	4
	HYPERPLASIA, LYMPHOID [3]	3
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION	3

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4513 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL (cont'd)		
	MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	
ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE		

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4514 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
LUNG	DISCOLORATION PALE. [5]	
	UNCOLLAPSED [6]	
LYMPH NODE BRONCHIAL	ENLARGEMENT [3]	
	DISCOLORATION PALE. [4]	
LYMPH NODE MEDIASTINAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
BRONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
CAVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
LARYNX	METAPLASIA	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO.14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90831

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4514 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LARYNX (cont'd)	BASE OF EPIGLOTTIS.	
	PIGMENT ACCUMULATION INTRAFOLLICULAR.	1
LUNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [5,6]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL TO LOCALLY EXTENSIVE.	2
PARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
THYROID	CYST, ULTIMOBRANCHIAL/THYROGLOSSAL REMNANTS UNILATERAL.	1
TRACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
LYMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL. [4]	2
	HYPERPLASIA, LYMPHOID [3]	2
LYMPH NODE MEDIASTINAL	HYPERPLASIA, LYMPHOID [1]	2
	PIGMENT ACCUMULATION	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
PROJECT NO.: 90031

GROUP 4 CERIC OXIDE HIGH DOSE
ANIMAL NO. 4514 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
LYMPH NODE MEDIASTINAL (cont'd)		
	MULTIFOCAL. [2]	

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90831

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4515 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
UNG	DISCOLORATION PALE. [3]	
	UNCOLLAPSED [4]	
YMPH NODE BRONCHIAL	ENLARGEMENT [1]	
	DISCOLORATION PALE. [2]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
RONCHUS	PIGMENT ACCUMULATION INTRALUMINAL.	1
AVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1
UNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [3,4]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
	HYPERPLASIA, LYMPHOID	2

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90831

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4515 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
UNG (cont'd)	MULTIFOCAL.	
YMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
ARATHYROID	UNAVAILABLE NOT PRESENT IN SECTION.	
RACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
YMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [2]	3
	HYPERPLASIA, LYMPHOID [1]	4

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90031

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4516 FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
GROSS PATHOLOGICAL FINDINGS		
IVER	AREA PALE SINGLE, NEAR HILUS, VENTRAL PORTION OF RIGHT LOBE. [1]	
UNG	DISCOLORATION PALE. [4]	
	UNCOLLAPSED [5]	
HYMUS	SMALL [6]	
YMPH NODE BRONCHIAL	ENLARGEMENT [2]	
	DISCOLORATION PALE. [3]	
ALL OTHER TISSUES WERE UNREMARKABLE		
HISTOPATHOLOGICAL FINDINGS		
RONCHUS	PIGMENT ACCUMULATION MUCOSAL AND INTRALUMINAL.	1
AVITY NASAL	PIGMENT ACCUMULATION INTRAFOLLICULAR (LEVEL III).	1

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

PPENDIX NO. 14 INDIVIDUAL GROSS AND HISTOPATHOLOGICAL FINDINGS
ROJECT NO.: 90831

ROUP 4 CERIC OXIDE HIGH DOSE
NIMAL NO. 4516 (cont'd) FEMALE STUDY WEEK OF DEATH 14 (DAY 92)

TISSUE	FINDING	GRADE
IVER	VACUOLATION, HEPATOCELLULAR FOCAL. [1]	1
JNG	PIGMENT ACCUMULATION EXTRA- AND INTRACELLULAR, DIFFUSE. [4,5]	4
	EPITHELIAL HYPERPLASIA, ALVEOLAR MULTIFOCAL.	2
YMPH NODE MANDIBULAR	PIGMENT ACCUMULATION MULTIFOCAL.	1
HYMUS	NO ABNORMAL FINDINGS [6]	
RACHEA	PIGMENT ACCUMULATION INTRALUMINAL.	1
YMPH NODE BRONCHIAL	PIGMENT ACCUMULATION MULTIFOCAL TO LOCALLY EXTENSIVE. [3]	3
	HYPERPLASIA, LYMPHOID [2]	3

ALL OTHER EXAMINED TISSUES WERE UNREMARKABLE

GROSS GRADE CODE: *- NOT SUBMITTED
HISTO GRADE CODE: 1- SLIGHT, 2- MILD, 3- MODERATE, 4- SEVERE, P- PRESENT, *- NOT TABULATED #B- BENIGN, #M- MALIGNANT

APPENDIX NO. 15

PROJECT NO. 90831

PMI Feeds, Inc.
1401 S. Hanley Road
St. Louis, MO 63144

(314) 768-4100
(314) 768-4765 Fax

TO RICHMOND, IN

CC DAN HOPKINS, IW
RICHMOND, IN

LAB NO 214031 ENTERED 07/19/93 REPORTED 07/28/93 RHI 5002

CERTIFIED RODENT DIET CHECKERS
LOT NUMBER JUL 17 93 2B

ASSAY	ANALYSIS	UNITS
PROTEIN (N X 6.25)	21.8	%
FAT (ACID HYDRO.)	5.82	%
FIBER (CRUDE)	4.21	%
ARSENIC	0.425	PPM
CADMIUM	0.150	PPM
CALCIUM	0.835	%
LEAD	0.219	PPM
MERCURY	LESS THAN 0.05 PPM	
PHOSPHORUS	0.706	%
SELENIUM	0.250	PPM

ORGANOPHOSPHATE PEST

	(PPM)		(PPM)
DIAZINON	LESS THAN 0.02	PARATHION	LESS THAN 0.02
DISULFOTON	LESS THAN 0.02	THIMET	LESS THAN 0.02
ETHION	LESS THAN 0.02	THIODAN	LESS THAN 0.02
MALATHION	0.09	TRITHION	LESS THAN 0.02
METHYL PARATHION	LESS THAN 0.02		

PESTICIDE & PCB

	(PPM)		(PPM)
ALDRIN	LESS THAN 0.02	ENDRIN	LESS THAN 0.02
ALPHA-BHC	LESS THAN 0.02	HCB	LESS THAN 0.02
BETA-BHC	LESS THAN 0.02	HEPTACHLOR	LESS THAN 0.02
DELTA-BHC	LESS THAN 0.02	HEPTACHLOR EPOXIDE	LESS THAN 0.02
CHLORDANE	LESS THAN 0.02	LINDANE	LESS THAN 0.02
DDE	LESS THAN 0.02	METHOXYCHLOR	LESS THAN 0.02
DDT..(TOTAL)	LESS THAN 0.02	MIREX	LESS THAN 0.02

APPENDIX NO. 15

PMI Feeds, Inc.
1401 S. Hanley Road
St. Louis, MO 63144

(314) 768-4100
(314) 768-4765 Fax

PROJECT NO. 90831

RT LAB NUMBER 216021

CERTIFIED RODENT DIET CHECKERS
LOT NUMBER JUL 17 93 2B

PESTICIDE & PCB (CONTINUED)
DIELDRIN..... LESS THAN 0.02 PCB..... LESS THAN 0.15

AFLATOXIN
TOTAL:LESS THAN 5 PPB

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
(1) FOR ASSAY METHODOLOGY - MICHAEL J. MURPHY 314-982-3562
(2) FOR NUTRITIONAL INTERPRETATION-DR DAN HOPKINS 314-768-4576
(3) ALL OTHER QUESTIONS-RICHMOND, IN., MANUFACTURING PLANT 317-962-9561

RESULTS ARE
SUITABLE FOR USE ON ANIMALS

REVIEWED BY: 24 09 93
Christian Beaudry

APPENDIX NO. 15

PMI Feeds, Inc.
1401 S. Hanley Road
St. Louis, MO 63144

(314) 768-4100
(314) 768-4767 F

PROJECT NO. 90831

TO RICHMOND, IN

CC DAN HOPKINS, 1W
RICHMOND, IN

LAB NO 315926 ENTERED 07/29/93 REPORTED 08/10/93 RHI 5002

CERTIFIED RODENT DIET CHECKERS
LOT NUMBER JUL 27 93 2B

ASSAY	ANALYSIS	UNITS
PROTEIN (N X 6.25)	21.5	%
FAT (ACID HYDRO.)	5.73	%
FIBER (CRUDE)	4.75	%
ARSENIC	0.265	PPM
CADMIUM	0.124	PPM
CALCIUM	0.811	%
LEAD	0.263	PPM
MERCURY	LESS THAN 0.05	PPM
PHOSPHORUS	0.690	%
SELENIUM	0.281	PPM

ORGANOPHOSPHATE PEST

	(PPM)		(PPM)
DIAZINON.....	LESS THAN 0.02	PARATHION.....	LESS THAN 0.02
DISULFOTON.....	LESS THAN 0.02	THIMET.....	LESS THAN 0.02
ETHION.....	LESS THAN 0.02	THIODAN.....	LESS THAN 0.02
MALATHION.....	0.04	TRITHION.....	LESS THAN 0.02
METHYL PARATHION...	LESS THAN 0.02		

PESTICIDE & PCB

	(PPM)		(PPM)
ALDRIN.....	LESS THAN 0.02	ENDRIN.....	LESS THAN 0.02
ALPHA-BHC.....	LESS THAN 0.02	HCB.....	LESS THAN 0.02
BETA-.....	LESS THAN 0.02	HEPTACHLOR.....	LESS THAN 0.02
DELTA-.....	LESS THAN 0.02	HEPTACHLOR EPOXIDE.	LESS THAN 0.02
CHLORDANE.....	LESS THAN 0.02	LINDANE.....	LESS THAN 0.02
DDE.....	LESS THAN 0.02	METHOXYCHLOR.....	LESS THAN 0.02
DDT..(TOT/.....	LESS THAN 0.02	MIREX.....	LESS THAN 0.02

APPENDIX NO. 15

PMI Feeds, Inc.
1401 S. Hanley Road
St. Louis, MO 63144
5926
(314) 768-4100
DIET CHECKER'S Fax

PROJECT NO. 90831

LOT NUMBER JUL 27 93 2B

PESTICIDE & PCB (CONTINUED)

DIELDRIN..... LESS THAN 0.02 PCB..... LESS THAN 0.15

AFLATOXIN

TOTAL:LESS THAN 5 PPB

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
(1) FOR ASSAY METHODOLOGY - MICHAEL J. MURPHY 314-982-3562
(2) FOR NUTRITIONAL INTERPRETATION-DR DAN HOPKINS 314-768-4576
(3) ALL OTHER QUESTIONS-RICHMOND, IN., MANUFACTURING PLANT 317-962-9561

RESULTS ARE
SUITABLE FOR USE ON ANIMALS

REVIEWED BY: 21-01-94
Christian Beaudry

PMI Feeds, Inc.
1401 S. Hanley Road
St. Louis, MO 63144

(314) 768-4100
(314) 768-4765 Fax

PROJECT NO. 90831

TO RICHMOND, IN

CC RICHMOND, IN
DAN HOPKINS, IW

LAB NO 324600 ENTERED 09/17/93 REPORTED 09/23/93 RHI 5002

CERTIFIED RODENT DIET CHECKERS
LOT NUMBER SEP 15 93 1B

ASSAY	ANALYSIS	UNITS
PROTEIN (N X 6.25)	21.6	%
FAT (ACID HYDRO.)	5.74	%
FIBER (CRUDE)	4.22	%
ARSENIC	0.374	PPM
CADMIUM	0.131	PPM
CALCIUM	0.747	%
LEAD	0.235	PPM
MERCURY	LESS THAN 0.05 PPM	
PHOSPHORUS	0.640	%
SELENIUM	0.239	PPM

ORGANOPHOSPHATE PEST

	(PPM)		(PPM)
DIAZINON.....	LESS THAN 0.02	PARATHION.....	LESS THAN 0.02
DISULFOTON.....	LESS THAN 0.02	THIMET.....	LESS THAN 0.02
ETHION.....	LESS THAN 0.02	THIODAN.....	LESS THAN 0.02
MALATHION.....	0.03	TRITHION.....	LESS THAN 0.02
METHYL PARATHION...	LESS THAN 0.02		

PESTICIDE & PCB

	(PPM)		(PPM)
ALDRIN.....	LESS THAN 0.02	ENDRIN.....	LESS THAN 0.02
ALPHA-BHC.....	LESS THAN 0.02	HCB.....	LESS THAN 0.02
BETA-BHC.....	LESS THAN 0.02	HEPTACHLOR.....	LESS THAN 0.02
DELTA-BHC.....	LESS THAN 0.02	HEPTACHLOR EPOXIDE.	LESS THAN 0.02
CHLORDANE.....	LESS THAN 0.02	LINDANE.....	LESS THAN 0.02
DDE.....	LESS THAN 0.02	METHOXYCHLOR.....	LESS THAN 0.02
DDT..(TOTAL).....	LESS THAN 0.02	MIREX.....	LESS THAN 0.02

APPENDIX NO. 15

PMI Feeds, Inc.
1401 S. Hanley Road
St. Louis, MO 63144

(314) 768-4100
(314) 768-4765 Fax

PROJECT NO. 90831

CERTIFIED RODENT DIET CHECKERS
LOT NUMBER SEP 16 93 1B

PESTICIDE & PCB (CONTINUED)
DIELDRIN..... LESS THAN 0.02 PCB..... LESS THAN 0.15

AFLATOXIN
TOTAL:LESS THAN 5 PPB

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:
(1) FOR ASSAY METHODOLOGY - MICHAEL J. MURPHY 314-982-2562
(2) FOR NUTRITIONAL INTERPRETATION-DR DAN HOPKINS 314-768-4576
(3) ALL OTHER QUESTIONS-RICHMOND, IN., MANUFACTURING PLANT 317-962-9561

RESULTS ARE
SUITABLE FOR USE ON ANIMALS

REVIEWED BY: 31-01-94
Christian Beaudry

APPENDIX NO. 16

PROJECT NO. 90831

Les Laboratoires
ECO•CNFS

Bio Recherche Lab. Ltd.
87 Senneville
Senneville Qc.
H9X 3R3

Date: September 9, 1993
Date received: September 3, 1993
Project number: 305533

Attention: Mr. Christian Beaudry

Certificate of analysis

Parameters	Samples			
	Bldg 2 room 2-157 tank	Bldg 2 room 2-157 membrane	Bldg 2 room 2-157 U.V.	Bldg 2 oom 2-157 return
Total bacterial count/ml				
20 C, 72 hres	142	14	4240	14
35 C, 48 hres	155	17	2940	12
Total Colif./100ml	<2	<2	<2	<2
Fecal colif./100ml	0	0	0	0
Pseudomonas aer./ 100ml	0	0	0	0

France Lafleur
France Lafleur
microbiologiste

REVIEWED BY: 21-09-93
Christian Beaudry

1325 rue Newton
Boucherville
Québec
J4B 5H2
Téléphone:
514.655.9510
Fax:
514.655.7426

✓121 Boul. Hymus
Pointe Claire
Québec
H9R 1E6
Telephone:
[illegible]
Fax:
[illegible]

APPENDIX NO. 16

Les Laboratoires
ECO•CNFS

PROJECT NO. 90831

Bio Recherche Lab. Ltd.
87 Senneville
Senneville Qc.
H9X 3R3

Date: September 13, 1993
Date received: September 10, 1993
Project number: 305 761

Attention: Mr. Christian Beaudry

Certificate of analysis

Parameters	Samples
	Bldg 2 room 157 U.V.
Total bacterial count/ml	
20 C, 72 hres	L.A.
35 C, 48 hres	24
Total Colif./100ml	<2
Fecal colif./100ml	0
Pseudomonas aer./ 100 ml	0

L.A.: Laboratory accident

France Lafleur
microbiologiste

REVIEWED BY: 21-9-93
Christian Beaudry

1325 rue Newton
Boucherville
Québec
J4B 5H2
Téléphone:
514.655.9510
Fax:
514.655.7426

121 Boul. Hymus
Pointe Claire
Québec
H9R 1E6
Telephone
[illegible]
Fax.
[illegible]

APPENDIX NO. 16

Les Laboratoires
ECO•CNFS

PROJECT NO. 90831

Bio Recherche Lab. Ltd.
87 Senneville
Senneville Qc.
H9X 3R3

Date: September 20, 1993
Date received: September 15, 1993
Project number: 305898

Attention: Mr. Christian Beaudry

Certificate of analysis

Parameters	Samples Bldg 2 room 157 U.V.
Total bacterial count/ml	
20 C, 72 hres	7
35 C, 48 hres	7
Total Colif./100ml	-
Fecal colif./100ml	-
Pseudomonas aer./ 100 ml	-

1325 rue Newton
Boucherville
Québec
J4B 5H2
Téléphone:
514.655.9510
Fax:
514.655.7426

121 Boul. Hymus
Pointe Claire
Québec
H9R 1E6
Téléphone:
514 697-3421
Fax:
514 697-2060

France Lafleur
France Lafleur
microbiologiste

REVIEWED BY: 22-09-93
Christian Beaudry

APPENDIX NO. 16

MEMORANDUM

PROJECT NO. 90831

DESTINATAIRE/TO: G. Lulham, C. Perkin

cc: Water file
G. Goldsmith
Q.A. Units

EXPÉDITEUR/FROM: C. Beaudry

DATE/DATE: September 21, 1993

OBJECT/SUBJECT: Microbiological water analysis result

Results from microbiological analysis performed on September 3, 10 and 15, 1993 have been reviewed. Water from all buildings is considered suitable for use on animals. Certificates of analysis are kept in the appropriate binder and can be consulted upon request.

Thank you

23 09 93

APPENDIX NO. 16

MEMORANDUM

PROJECT NO. 90831

DESTINATAIRE/TO: Water file

cc: G. Goldsmith
Q.A. Unit

EXPÉDITEUR/FROM: C. Beaudry

DATE/DATE: September 23, 1993

OBJECT/SUBJECT: Microbiological water analysis result - Sep. 3, 10, 15, 1993

The certificates of analysis for water samples taken on Sep. 3,10 and 15, 1993 were reviewed and they indicate that:

- The first sample collected on September 3 from Building 2 U.V. light was contaminated. A second sample has been collected on September 10 and unfortunately the ECO-CNFS LAB. mentioned a laboratory accident. A third sample has been performed on September 15 and the result was within the acceptable range. The high bacterial count reported for the first sampling was caused by contamination during sampling procedure.

Thank you

23-09-93

APPENDIX NO. 16

PROJECT NO. 90831

Les Laboratoires
ECO•CNFS

Bio Recherche Lab. Ltd.
87 Senneville
Senneville Qc.
H9X 3R3

Date: January 11, 1994
Date received: December 02, 1993
Analysed: December 03, 1993
Project number: 308 643
Revised: March 14, 1994

Attention: Ghislaine Morin

Certificate of analysis

Parameters	Samples			
	Bldg 2 room 157 tank	Bgdg 2 room 157 membrane	Bldg 2 room 157 U.V.	Bldg 2 room 157 return
Total bacterial count/ml				
20 C, 72 hres	670	800	0	970
35 C, 48 hres	490	1700	0	1020
Total Colif./100 ml	<2	<2	<2	<2
Fecal colif./100ml	0	0	0	0
Pseudomonas aer./ 100 ml	0	0	0	0

France Lafleur
microbiologiste

RESULTS ARE
SUITABLE FOR USE ON ANIMALS

REVIEWED BY: 23-03-94
Christian Beaudry

1325 rue Newton
Boucherville
Québec
J4B 5H2
Téléphone:
514.655.9510
Fax:
514.655.7426

121 Boul. Hymus
Pointe Claire
Québec
H9R 1E6
Téléphone:
514.697.3241
Fax:
514.697.2090

APPENDIX NO. 16

PROJECT NO. 90831

Les Laboratoires
ECO•CNFS

Bio Recherche Lab. Ltd.
87 Senneville
Senneville Qc.
H9X 3R3

Date: January 11, 1994
Date received: December 09, 1993
Project number: 308 882

Attention: Mr. Christian Beaudry

Certificate of analysis

Parameters	Samples		
	Bldg 2 room 157 membrane	Bldg 2 room 157 return	Bldg 2 room 157 tank
Total bacterial count/ml			
20 C, 72 hres	131	268	75
35 C, 48 hres	147	239	64
Total Colif./100ml	<2	<2	<2
Fecal colif./100ml	0	0	0
Pseudomonas aer./ 100 ml	0	0	0

France Lafleur
microbiologiste

REVIEWED BY: Christian Beaudry 26-01-94

1325 rue Newton
Boucherville
Québec
J4B 5H2
Téléphone:
514.655.9510
Fax:
514.655.7426

121 Boul. Hymus
Pointe Claire
Québec
H9R 1E6
Telephone:
514.697.3420
Fax:
514.697.2093

BIO APPENDIX NO. 16 PROJECT NO. 90831

MEMORANDUM

DESTINATAIRE/TO: G. Lulham, C. Perkin ✓

cc: Water file
G. Goldsmith
Q.A. Unit

EXPÉDITEUR/FROM: C. Beaudry

DATE/DATE: January 21, 1994

OBJECT/SUBJECT: Microbiological water analysis result, December 1993

Results from microbiological analysis performed on December 03 and 09, 1993 have been reviewed. Water from all buildings was considered suitable for use on animals. Certificates of analysis are kept in the appropriate binder and can be consulted upon request.

Thank you

28-1-94

MEMORANDUM

PROJECT NO. 90831

DESTINATAIRE/TO: Water file

cc: C. Beaudry
G. Goldsmith
Q.A. Unit

EXPÉDITEUR/FROM: G. Morin

DATE/DATE: January 21, 1994

OBJECT/SUBJECT: Microbiological water analysis result December 1993

The microbiological water analysis of sampling performed on December ~~05~~ 02 Ⓐ and 09, 1993 were reviewed and indicated that:

-The first sample collected in Building No. 2 on December ~~03~~ 02 Ⓑ, 1993 from the membrane, the return line and the tank were contaminated. The membrane has been cleaned and disinfected with formaldehyde. A second samples have been collected on December 09, 1993 and the results were within the acceptable range.

G Morin 21.01.94

28-01-94

Ⓐ Wrong entry G Morin 23.3.94

Ⓑ wrong entry 30.03.94

APPENDIX NO. 16

PROJECT NO. 90831

Laboratoires
ECO•CNFS Inc.

CERTIFICATE OF ANALYSIS

CLIENT	: BIO RECHERCHES LAB LTD	PROJECT NUMBER	:308643
ATTENTION	: GHYSLAINE MORIN	DATE OF RECEPTION	:3 DÉCEMBRE 1993
ADRESS	: 87 SENNEVILLE, QUÉ.	SAMPLING DATE	:2 DÉCEMBRE 1993
	: H9X 3R3	PURCHASE ORDER	:
	:		
COMMENTS	:		

LABORATORY NUMBERS	WATER SAMPLES (mg/L)		
	12	13	14
IDENTIFICATION	BUILD 5 TANK	BUIL 2 TANK	BUIL D3 END OF LINE
Appearance	Clear & Bright	Clear & Bright	Clear & Bright
Alkalinity in CaCO3	1.9	2.6	22
Chlorides	<0.5	<0.5	4.8
Conductivity (µmhos/cm)	-	-	-
Colors (TCV)	<3	<3	<3
Dissolved solids	73	18	102
Fluorides	<0.05	<0.05	<0.05
Nitrates in N	0.72	<0.05	0.52
Nitrites in N	<0.05	<0.05	<0.05
Odor	Odorless	Odorless	Odorless
Phenols	<0.002	<0.002	<0.002
Sulfides	<0.05	<0.05	<0.05
Sulphates	2.6	<0.5	27
Arsenic	<0.001	<0.001	<0.001
Cadmium	<0.0003	<0.0003	<0.0003
Calcium	0.06	0.03	15.9
Chromium	<0.001	<0.001	<0.001
Copper	0.03	0.02	0.06
Iron	0.02	0.04	0.05
Manganese	<0.01	<0.01	<0.01
Mercury	<0.0002	<0.0002	<0.0002
pH	5.7	6.0	7.0
Lead	0.001	0.001	<0.001
Selenium	<0.001	<0.001	<0.001
Zinc	0.03	<0.01	<0.01

Any sample pertaining to this report will be kept 30 days after report date.

REVIEWED BY: 4-4-94
Christian Beaudry

Chemist : Micheline
Micheline Godin
84-032
Québec

Date : 29 Mars 1994

APPENDIX NO. 16

Laboratoires
Eco•CNFS Inc.

PROJECT NO. 90831

ANALYSIS CERTIFICAT

CLIENT	: BIO RESEARCH LTD.	PROJECT #	: 308643
RESPONSABLE	: GHISLAINE MORIN	RECEPTION DATE	: 3/12/93
ADRESS	: 87 SENNEVILLE	SAMPLING DATE	: 02/12/93
	: SENNEVILLE, QUEBEC	P.O. #	: ——
	: H9X 3R3		
REMARK	:		

	WATER SAMPLE (mg/L)	
LABORATORY NUMBER	1	2
IDENTIFICATION	BUILD TANK #5	BUILD TANK #2
Organochlorinated Pesticide		
Lindane	< 0.00001	< 0.00001
Heptachlor	< 0.00001	< 0.00001
Aldrin	< 0.00001	< 0.00001
Toxaphene	< 0.0001	< 0.0001
Endrin	< 0.00001	< 0.00001
4,4'-DDT	< 0.00001	< 0.00001
Methoxychlor	< 0.00001	< 0.00001
Polychlorinated biphenyls	< 0.0001	< 0.0001
Phenoxy Acids		
2,4-D	< 0.0001	< 0.0001
2,4,5-TP	< 0.0001	< 0.0001

QUALITY CONTROL	Recovery	Recovery
RECOVERY STANDARD	%	%
Nonachlorobiphenyl	72	108
2,4,6-Tribromophenol	95	85

REVIEWED BY: 4-4-94
Christian Beaudry

MARTIN DEA
92-012

All samples will be kept 30 days after the emission of the certificat.

Supervisor : Yves Aubert Chemist :

Date : 03/25/94

LABORATOIRES ECO-CNFS INC. 121 BOUL HYMUS, POINTE CLAIRE (QUÉBEC) H9R 1E6. TÉLÉPHONE: (514)697-3400 - TÉLÉCOPIEUR: (514)697-2090

APPENDIX NO. 16

MEMORANDUM

PROJECT NO. 90831

DESTINATAIRE/TO: Water file

cc: C. Beaudry
G. Goldsmith
Q.A. Unit

EXPÉDITEUR/FROM: G. Morin

DATE/DATE: March 31, 1994

OBJECT/SUBJECT: Chemical water analysis result, December 1993

The chemical analysis of water sampling performed on December 02, 1993 were reviewed and indicated that:

-The sample collected in Building No. 2, 5 and ultra pure water indicated a PH value slightly below the acceptable range. However the water is considered acceptable for use of animals since this parameter is not generally considered health related. the Animal Resources Manager will take action only if the PH results are excessive and could result in health problems. No related clinical signs on animals using this water have been observed since the sampling.

Thank you

G Morin 31-03-94

31-03-94

APPENDIX NO. 16

MEMORANDUM

PROJECT NO. 90831

DESTINATAIRE/TO: G. Lulham, C. Perkin

cc: Water file
G. Goldsmith
Q.A. Unit

EXPÉDITEUR/FROM: C. Beaudry

DATE/DATE: March 31, 1994

OBJECT/SUBJECT: Chemical water analysis result, December 1993

Results from chemical analysis of water sampling performed on December 02, 1993 have been reviewed. Water from buildings 2, 3, 5 and ultra pure water is considered suitable for use on animals. Certificates of analysis are kept in the appropriate binder and can be consulted upon request.

Thank you

31 03 94

APPENDIX NO. 17 PROJECT NO. 90831

RHONE-POULENC CHIMIE
SIEGE SOCIAL : 25, QUAI PAUL UMER 92408 COURBEVOIE CEDEX
TEL. (1) 47.68.12.34 SOCIETE ANONYME AU CAPITAL DE 2402500000 DE FRS
NANTERRE B642014526

PRODUCT ..... : OPALINE BROYEE

CUSTOMER ..... : RHONE POULENC INC. C/O SILVEY SHIPPING CO
BLDG. 75, SUITE 211
ADDRESS ..... : NORTH HANGAR ROAD, JFK INT'L AIRPORT
JAMAICA, NY 11430
U.S.A.

ORDER NR ..... : 287998 WEIGHT : 200,000 KG
EXPEDITION NR : 287998/00001
BRANCH OFFICE ORDER REFERENCE : 25903
CLIENT ORDER REFERENCE ..... : 125903

CERTIFICATE OF ANALYSIS

BATCH : 9019101 WEIGHT : 200,000 KG

DETERMINATIONS	UNITS		RESULTS
LOSS ON IGNITION	%/TEL	<	0.50
* FE2O3	PPM/TEL	<	100.0
> 63 MIC. (250 MESH)	%/TEL	=	2.10
* PR6O11	PPM/OT	<	25.0
* ND2O3	PPM/OT	<	25.0

PRODUCT QUALITY MANAGER

RHONE-POULENC CHIMIE - LA ROCHELLE
SEPTEMBER 14 , 1992
ENVOI : J.GLEBA/SHELTON
) : STATISTICAL QUALITY CONTROL CERTIF : 92/ 3376

RECEIVED
SEP 24 1992
RHONE-POULENC INC.

16 SEP. 1992

APPENDIX NO. 17

OPALINE UNGROUND

TECHNICAL DATA SHEET

Formula : CeO_2 C.A.S.: 1306-38-3

"AS IS" BASIS			RARE EARTH OXIDE BASIS		
Buff agglomerates 0.1 to 5 mm			CeO_2.....%	99.95	min
LOI (1000°C).....%	1	max	Pr_6O_{11}.....ppm	25	max
Total REO.....%	99	min	Nd_2O_3.....ppm	25	max
Fe_2O_3.....ppm	75	max			

Lot Size : 500 kg

PACKAGING : 50 kg plastic drum.

SAFETY : Material Safety Data Sheet is available which describes the safety precautions to be used with the product.

514009/6

RHÔNE-POULENC
RHÔNE-POULENC BASIC CHEMICALS CO.
FINE INORGANIC CHEMICALS
ONE CORPORATE DRIVE, BOX 881
SHELTON, CT 06484
TEL: (203) 925-3685
TELEX: 4750055
FAX: (203) 925-8182

APPENDIX NO. 18

BIO-RESEARCH LABORATORIES LTD.

CONFIDENTIAL

PROTOCOL

A 13-WEEK INHALATION TOXICITY AND NEUROTOXICITY STUDY BY NOSE-ONLY EXPOSURE OF A DRY POWDER AEROSOL OF CERIC OXIDE IN THE ALBINO RAT

All phases of the study performed at Bio-Research Laboratories will comply with the EPA TSCA Good Laboratory Practice Standards (40 CFR Part 792), Japanese MHW Good Laboratory Practice Regulations (Notification No. 313 and subsequent revised rule Notification No. 870) and OECD guidelines (No. 413). All procedures conducted at these laboratories will be in accordance with Bio-Research's Standard Operating Procedures.

For: Rhône-Poulenc Inc.
PO Box 12014
2 T.W. Alexander Drive
Research Triangle Park, NC
U.S.A.

Project No.: 90831

Date: August 6, 1993

Page 1 of 19 Pages

MONTRÉAL
85 Senneville Rd., Senneville, Quebec H9X 3R3, Canada
Tel: (514) 630-8200 Cable: BIOCAN Fax: (514) 457-5865

PROTOCOL

PURPOSE	To investigate the potential toxicity of a powder aerosol of ceric oxide (CeO_2) during daily inhalation administration to the rat for a minimum of 13 consecutive weeks.
PROJECT NO.	90831
PROTOCOL DATE	August 6, 1993
SPONSOR	Rhône-Poulenc Inc. PO Box 12014 2 T.W. Alexander Drive Research Triangle Park, NC U.S.A.
TESTING FACILITY	Bio-Research Laboratories Ltd. 87 Senneville Road Senneville, Quebec Canada H9X 3R3
TEST ARTICLE	Ceric oxide
ROUTE OF ADMINISTRATION	Nose-only inhalation
GROUPS AND TREATMENT	One air control and 3 treated groups each consisting of 15 males and 15 females. (Total number of animals: 70 males and 70 females including 10/sex for a health screen examination) plus an appropriate number of spares.
DURATION OF TREATMENT	13 weeks minimum
STUDY DIRECTOR	A. Viau, B.Sc.

BEHAVIORAL TOXICOLOGIST

P. Beyrouty, B.Sc.

PATHOLOGISTS

P. Tellier, D.V.M., Dip.Path., M.Sc.
Diplomate A.C.V.P.
Vice President, Pathology

B. Broxup, B.V.Sc., D.V.Sc., M.R.C.V.S.
Director, Scientific Development

R. Stejskal, M.S.Dr., Ph.D.
Associate Scientific Director, Pathology

N. Hamelin, D.V.M., Dip.Path., M.Sc.
Senior Pathologist

W. Evering, D.V.M., Ph.D.
M. Chagnon, D.V.M., Dip.Path., M.Sc.
Staff Pathologists

PARTICIPATING SCIENTISTS

G.W. Lulham, M.Sc.
Director, Toxicology

C. Banks, B.Sc.
Scientific Director, Inhalation Toxicology

Y. Deschamps, Ph.D.
Director, Clinical Laboratories

A. Provencher, D.V.M., Dip.Clin.Path.
Staff Scientist, Clinical Laboratories

P. Burnett, B.Sc.
Manager, Analytical Chemistry

K. Robinson, B.Sc.
Scientific Director,
Reproductive Toxicology

QUALITY ASSURANCE MANAGEMENT

P. Sidney, B.Sc.
Director, Quality Assurance and Support Services

A. Gagné, B.Sc.
Manager, Quality Assurance

CLINICAL VETERINARIAN AND ANIMAL RESOURCES MANAGER	C. Beaudry, D.V.M.
CLINICAL VETERINARIAN	S. Faubert, D.V.M.
PROPOSED TREATMENT STARTING DATE	To be determined *
PROPOSED TREATMENT COMPLETION DATE	To be determined *
TARGET DATE FOR COMPLETION OF AUDITED DRAFT REPORT	As per contract

TEST SYSTEM

Species	*Rattus norvegicus*
Strain	Sprague-Dawley CD (Crl: CD^{R}(SD)BR)
Source	Charles River Canada Inc. St. Constant, Quebec, Canada
Age	Approximately 7 weeks at the onset of treatment
Weight	Males approximately 250-300 g and females approximately 150-200 g at the onset of treatment
Acclimation Period	*Circa* 2 weeks

Actual age, weight, acclimation period and number of animals received to be documented in the final report.

REASON FOR CHOICE OF TEST SYSTEM

The rat is a standard species for use in inhalation toxicity and neurotoxicity studies.

* A detailed study schedule relating to all critical phases of this study will be issued prior to the commencement of dosing.

RATIONALE FOR STUDY CONDUCT

The requirements for, and use of animals in, this research are the responsibility of the Sponsor, in that the research does not unnecessarily duplicate previous animal experiments and is being conducted in the absence of acceptable non-animal alternatives to accomplish its objective.

TEST ARTICLE

Identity	Ceric oxide (CeO_2)
Supplier	Sponsor

The test article will be characterized by the Sponsor. All data relevant to such analyses will be retained by the Sponsor who will provide a test article Certificate of Analysis for inclusion in the study report.

Details of purity, stability, storage conditions and handling precautions will be supplied by the Sponsor. These documents will be retained in the Pharmacy Department of Bio-Research Laboratories Ltd.

With the exception of an archive sample, all test article remaining at study termination will be returned to the Sponsor.

REASON FOR CHOICE OF ROUTE OF ADMINISTRATION

The inhalation route has been selected since this is a possible route of exposure in humans.

ABSORPTION OF TEST ARTICLE

It is not the intention of this study to investigate the absorption of the test article.

HANDLING OF TEST ARTICLE

The test article will be stored at room temperature and out of direct light. Each container of test article will be labeled with the project number, identity of the contents, a unique identification number, a lot number, an expiration date, storage conditions and handling precautions, as appropriate. A log book will be maintained indicating where and when individual test article containers are used.

Samples of test material (5 g) will be returned to the Sponsor, both before and after the treatment period, in order to assess the stability of the test article during treatment.

ANIMAL MANAGEMENT

On arrival, all animals will be subjected to a general physical examination by a qualified member of the veterinary staff to ensure "normal" health status 1.

Animals will be housed individually in stainless-steel wire-mesh bottomed cages, equipped with an automatic watering valve. All cages will be clearly labeled with a color-coded cage card indicating project, group and animal numbers, sex and dosage level.

Each animal will be uniquely identified using the AIMS tail tattoo system, with the exception of health screen animals which will be identified by means of a standard system of ear notching.

The animal room environment and photoperiod will be controlled (targeted conditions: 12-15 air changes/hour, temperature 22 ± 3°C, humidity 50 ± 20%, 12 hours light and 12 hours dark).

DIET

All animals will have access to a standard certified commercial laboratory diet (PMI Certified Rodent Chow 5002: PMI Feeds, Inc.) except during treatment, urinalysis, prior to bleeding and necropsy. Animals will also be provided with tap water ad libitum (except during exposure) which has been softened, purified by reverse osmosis and sterilized by ultraviolet light.

Maximum allowable concentrations of contaminants in the diet (e.g., heavy metals, aflatoxin, organophosphate, chlorinated hydrocarbons, PCBs) are controlled and routinely analyzed by the manufacturers.

Periodic analysis of the water is subcontracted to management authorized analytical laboratories which are audited by the Quality Assurance Department of Bio-Research Laboratories Ltd. The analytical results are retained in the archives of Bio-Research Laboratories Ltd.

It is considered that there are no known contaminants in the dietary materials that could influence the toxicity of the test article.

ACCLIMATION AND RANDOMIZATION

An acclimation period of approximately 2 weeks will be allowed between animal receipt and the start of treatment in order to acclimate the rats to the laboratory environment.

Before the assignment of animals to treatment groups, 10 male and 10 female rats will be selected from the total population using computer generated random numbers for the provision of blood samples, urine samples

and gross pathology examination for health-screen purposes. The results of these investigations will be available prior to the commencement of treatment.

Approximately 1 week before treatment initiation, all rats will be weighed and assigned to treatment groups using a computer-based randomization procedure which ensures homogeneity of group means and variances for body weight. Males and females will be processed separately. Rats in poor health or at the extremes of the body weight range will not be assigned to treatment groups.

Where relevant, any animals considered unacceptable for use in the study will normally be replaced from additional animals included with the batch of animals ordered for the study.

Animals will be randomized into the following groups:

Group/ Identification	Target Exposure Level (mg/L)	Animal No. Males	Animal No. Females
1 Air control	0	1001-1015	1501-1515
2 Low dose	0.01	2001-2015	2501-2515
3 Intermediate dose	0.1	3001-3015	3501-3515
4 High dose	1.0	4001-4015	4501-4515

Approximately 2 weeks after the start of treatment, all spares remaining unassigned to groups will be discarded from the study.

Reason for Dose Level Selection

The dose levels will be selected according to the proposed human exposure, existing toxicity data and any limitations imposed by the exposure apparatus and procedure as well as the stability of the experimental atmosphere.

TREATMENT

1. Experimental Design

The air control group (Group 1) will be restrained and handled in the same manner as the test groups. The air control rats will be exposed to filtered conditioned air only, using a system identical to that of the test groups. The 3 levels of exposure to the test article will be achieved by varying the rate of test article introduction into the exposure chamber.

2. Description of Inhalation Exposure Equipment

Standard stainless-steel cylindrical "flow-through" nose-only inhalation chambers (chamber volume approximately 127 L) will be utilized in this experiment. The body of each chamber has 60 separate ports in three separate rows into which can be inserted the conical front section of a polycarbonate restraint cone. The top section of the inhalation chamber has an opening for inlet air into which the test article can be introduced. The bottom section of the chamber has a corresponding air extraction port and a drain valve for cleaning. The chamber is mounted on a transport cart such that the chamber can be easily rotated. The chambers will be operated under slight negative pressure to prevent outward leakage of the test atmospheres.

The cones which serve to restrain individual rats are custom-molded polycarbonate tubes of three different sizes which can accommodate weanling rats, young adults and adult rats. One end of the cone is tapered to approximately fit the shape of the rat's head and the diameter of the cylindrical portion of the cone is such that it is difficult for the rat to turn in the cone. The back portion of the cone is sealed with a plastic cap. The cone containing the rat is fastened to the inhalation chamber by means of a bracket with the nose portion of the cone protruding through a gasket into the chamber. This permits the rat to inhale the test or control atmospheres within the inhalation chamber without otherwise coming in contact with the atmosphere.

During the acclimation period, the rats will be conditioned to the laboratory setting and restraint cones. The rats will be acclimated to the restraint cones over a period of at least 3 days.

The flow rate through the inhalation chamber will be set at a level determined in preliminary work to be adequate to maintain a chamber environment of 20-24°C, 30-70% relative humidity and at least 19% O_2 (prior to test article introduction) with the present animal load. A Sihi low-pressure vacuum pump will be used to exhaust the inhalation chamber at the required flow rate and draw the contaminated air through a purifying system.

The inhalation chamber and test article generation system for the test groups will be contained within separate ventilated walk-in fumehoods to prevent possible contamination of the room air with trace amounts of the test article.

3. Duration of Exposure

The rats will be subjected to "nose-only" exposure for six hours a day, 5 days each week for a minimum of 13 weeks. Rats will be exposed up to the day preceding scheduled necropsy. For each test

group, time zero will be defined as that point in time at which approximately 95% of the desired concentration of test article has been established within the chamber. Flow rate through the chamber will be calculated to yield a t_{95} (the time required to build up 95% of the target concentration) of no more than approximately 5 minutes. The t_{95} and t_{05} (the time to decay to 5% of the established concentration) will be calculated and reported.

During exposure, aerosol will be actively generated for 360 minutes (for the duration of the t_{95} plus 355 minutes). Following 360 minutes of continuous operation, aerosol generation will be stopped, and the chamber concentration allowed to decay for the calculated t_{05}. The rats will then be removed from the exposure chamber and will be returned to their home cages.

4. Atmosphere Generation System

The test atmospheres will be established using a fluid energy air mill supplied with conditioned and filtered compressed air. Chamber concentration will be controlled by varying the rate of test article introduction into the chamber.

MONITORING OF EXPERIMENTAL ATMOSPHERES

1. Prestudy Chamber Atmosphere Validation

Prior to the start of treatment, a target chamber aerosol concentration for each dose level will be established and the gravimetric concentrations of each atmosphere determined from open-face glass fiber filter samples collected at a representative animal breathing point.

Analysis of the aerosol particle size distribution will be performed for each dose level using an Andersen 1 ACFM Cascade Impactor.

The homogeneity of chamber atmosphere distribution will be evaluated for the low and high dose test article chambers. Three ports will be sampled in sequence on the top and bottom animal levels of the chamber in duplicate. The overall mean of each run with the standard deviation will be determined.

2. Chamber Concentrations

Chamber concentrations of aerosol will be measured hourly each day from the animal breathing zone using a gravimetric method. Should the weight of any sample vary by 20% or more from samples previously obtained on this study, the sampling will be repeated immediately. Each test atmosphere will be continually monitored throughout the exposure period by a precalibrated real-time aerosol monitor (RAM) to provide instantaneous qualitative feedback on temporal atmosphere

concentration stability. Filters from the first day of treatment, and monthly thereafter will be forwarded to the Sponsor for chemical analysis.

Nominal chamber concentrations will be calculated from the airflow through the chamber and the quantities of test compound used.

3. Particle Size Analysis

Analysis of the aerosol particle size distribution at a representative animal breathing point in each of the test atmospheres will be performed weekly using an Andersen 1ACFM cascade impactor operated at a flow rate of 28.3 LPM (Liters Per Minute). Sampling durations will be selected to collect approximately 10 mg of test article. The method used will consist of classification into a series of size ranges followed by gravimetric analysis.

From the deposit collected at each stage, the mass median aerodynamic diameter and its geometric standard deviation (MMAD ± GSD) will be calculated.

4. Chamber Conditions

Chamber airflow, temperature and humidity will be recorded hourly during the exposure period.

OBSERVATIONS

Dated and signed records of activities relating to the day-to-day running and maintenance of the study within the animal room as well as the activities relating to the observations and examinations outlined in this protocol will be recorded in the Project Log Book.

1. Clinical Examination

All animals will be examined within the cage twice daily for mortality and morbidity. Also, each animal will be examined before and after exposure for signs of reaction to treatment. In addition, animals will be examined hourly during exposure for any overt signs of reaction to treatment. A complete examination for clinical signs will be performed weekly. Additional examinations may be performed if considered necessary. Mortalities and observed clinical signs will be individually recorded.

Moribund animals will be sacrificed for humane reasons at the discretion of the attending clinical veterinarian and/or study director (in consultation with the Sponsor, if possible), blood samples will be obtained, and a detailed internal and external gross examination will be performed. Any animal not considered able to

survive will be sampled for blood, killed and subjected to post mortem examination.

2. Body Weight

Body weight will be measured for each animal weekly, commencing the day of randomization and extending throughout the treatment period. In addition, each animal will be weighed on the days of behavioral testing and immediately before sacrifice at necropsy.

3. Food Consumption

Individual food consumption will be measured weekly commencing the day of randomization and extending throughout the treatment period.

4. Functional Observational Battery (FOB)

All animals will be tested prior to commencement of treatment, on Day 1 (post-dosing) and once during each of Weeks 4, 8 and 13. Testing will be performed by the same trained technicians, wherever possible, who will be blind to the animal's treatment.

4.1 Qualitative

Observations in Home Cage

body position
tremors, twitches, convulsions
bizarre/stereotypic behavior

Removal from Home Cage

ease of removal
vocalization

Observations in Arena

rearing
ataxic, hypotonic and impaired gait
overall gait incapacity
bizarre/stereotypic behavior
palpebral closure
tremors, twitches, convulsions
piloerection
respiratory rate/pattern
locomotor activity level
arousal
grooming
defecation
urination
olfactory response

Handling Observations

lacrimation
pupil size
salivation
urinary staining
diarrhea
body and abdominal tones
extensor thrust
corneal reflex
pinna reflex
toe and tail pinch
visual placing

On Surface	On Top of Box
auricular startle air righting reflex	positional passivity

4.2 Quantitative

4.2.1 Grip Strength

Before the start of testing and following completion of testing on each day, the Chatillon strain gauges will be checked using calibration weights and the readings recorded.

Forelimb

The dial on the gauge will be set to "0". The rat will be held by the body and/or tail and allowed to grip the mesh, and then will be pulled slowly and steadily until it releases its grip. Maximum strain will be recorded two times alternating with hindlimb grip testing.

Hindlimb

The dial on the gauge will be set to "0". The rat will be alloved to set its hindpaws against the mesh and will be pulled backward by the base of the tail until it releases its grip. The maximum strain will be recorded two times alternating with forelimb grip testing.

4.2.2 Hindlimb Splay

Landing foot spread will be measured using inking of the hind feet. Hindlimb splay will be recorded twice. The ink will be wiped off the feet after testing using a paper towel dampened with water.

4.2.3 Body Temperature

The rectal probe will be gently inserted, the reading allowed to stabilize and the temperature then recorded.

The functional observational battery will be performed with equipment built for this purpose. The arena is a 2' square of plexiglass placed on a raised platform. The tests will be conducted in the room housing the animals, where temperature, humidity and photoperiod are monitored. Odors in the room will be minimized by maintaining adequate air changes and cleaning of equipment, as necessary.

5. Motor Activity

Following the FOB assessments the animals will be transferred to a testing room where activity levels will be measured individually in figure 8 enclosures. Animals will be tested prior to commencement of treatment, and during Weeks 4, 8 and 13. Animals from the control and treated groups will be balanced across enclosures, where possible, using a preassigned distribution. The sessions will be of 1-hour duration and activity counts will be recorded by a microcomputer in 6 successive 10-minute intervals.

In the testing room, temperature and humidity will be monitored and a background sound level of approximately 70 dBA and an illumination of approximately 1000-1200 Lux maintained throughout testing. Light levels in the testing room will be measured before the start of testing and following completion of testing on each day. The sound level will be recorded on a continuous basis throughout testing on each day.

In addition to the "diagnostic" function in the system, a check of each beam will be made by manually "breaking" each beam a predetermined number of times and verifying that the "breaks" were properly recorded. These checks will be made at least prior to the start of testing and at the completion of testing on each day.

6. Laboratory Investigations

Prior to commencement of treatment, laboratory investigations (hematology, clinical biochemistry and urinalysis) will be performed on the 10 male and 10 female "health screen" animals.

Hematology and biochemistry will be performed in Week 6 and on all surviving animals at study termination (at necropsy). Food will be removed overnight from animals to be sampled for hematology and biochemistry. Blood samples will be collected from the tail vein in Week 6 and from the abdominal aorta at necropsy.

Urine samples will be collected in Weeks 6 and 13 (after the final FOB assessment) from individual animals placed in metabolism cages overnight (approximately 16-hour collection period) during which time they will be deprived of food.

6.1 Hematology (using EDTA or Citrate* as anticoagulant)

Parameters examined:

red blood cell count
hemoglobin
hematocrit
erythrocyte indices (calculated: MCV, MCH, MCHC and RDW)
platelet count
mean platelet volume (MPV)
white blood cell count (total and differential)
prothrombin time (PT)*
blood cell morphology

Bone marrow smears will be prepared as described in TERMINAL PROCEDURES, Section 3. Tissue Preservation.

6.2 Clinical Biochemistry (using no anticoagulant)

Parameters examined:

alkaline phosphatase (ALP)
alanine amino-transferase (ALT)
aspartate amino-transferase (AST)
total bilirubin
cholesterol
triglycerides
glucose
blood urea nitrogen (BUN)
creatinine
total protein
albumin
globulin (calculated)
A/G ratio (calculated)
sodium
chloride
potassium
calcium
inorganic phosphorus

6.3 Urinalysis

Parameters examined:

color and appearance
pH
glucose
ketones
blood (hemoglobin)
volume
specific gravity
bile pigment (bilirubin)
urobilinogen
protein
nitrite
microscopy of centrifuged deposit

TERMINAL PROCEDURES

1. Gross Pathology

Prior to commencement of treatment, 10 male and 10 female "health screen" animals will be sacrificed by exsanguination from the abdominal aorta following anesthesia by intraperitoneal injection of

sodium pentobarbital and blood sample collection. These animals will be subjected to external and internal gross examination. Tissues will not normally be preserved.

In order to avoid autolytic change, a complete necropsy will be conducted immediately on any animal sacrificed during the study or at its termination. If an animal is found dead, necropsy will be completed as soon as possible after the time of death and, if necessary, the carcass will be stored in a refrigerator (circa 4°C) prior to necropsy. All necropsies performed during regular working hours will be conducted under the supervision of a pathologist.

All animals found dead or sacrificed for humane reasons during the study will be subjected to necropsy and tissue samples will be preserved. Animals sacrificed for humane reasons will also have blood samples collected.

All preterminally and terminally sacrificed animals will be killed by exsanguination following anesthesia by intraperitoneal injection of sodium pentobarbital. All animals will be fasted overnight before scheduled sacrifice.

Terminal body weight will be recorded at time of necropsy.

For all animals, necropsy will consist of an external examination, including identification of all clinically recorded lesions, as well as a detailed internal examination.

2. Organ Weight Assessment

For each animal sacrificed at study termination, the following organs will be dissected free of fat and weighed:

adrenals
brain
heart
kidneys
liver
lungs
ovaries/testes
pituitary
prostate
spleen
thymus
thyroid lobes and parathyroids (lobes weighed together)
uterus

Paired organs will be weighed together.

Organ weights relative to both body and brain weights will be calculated.

3. Tissue Preservation

On completion of the necropsy of each animal, the following tissues and organs will be retained. Neutral buffered 10% formalin will be used for fixation and preservation unless otherwise indicated.

abnormalities
animal identification ▪
adrenals
aorta (thoracic)
bone and marrow (sternum) **
brain (3 levels)
bronchi
cecum
colon
duodenum
epididymides *
esophagus
eyes *
heart (including section of aorta)
ileum
jejunum
kidneys
larynx
liver (sample of 2 lobes)
lungs (all lobes) ++
lymph nodes (bronchial, mandibular and mesenteric)
mammary gland (inguinal) +
nasal cavities and sinuses (4 levels) **
optic nerves *+
ovaries
pancreas
pharynx
pituitary
prostate
rectum ▪
salivary gland (submandibular)
sciatic nerve
seminal vesicles
skeletal muscle
skin (inguinal)
spinal cord (cervical)
spleen
stomach
testes *
thymus
thyroid lobes (and parathyroids) +
tissue masses (and drainage lymph nodes)
tongue
trachea
urinary bladder
uterus (and cervix)
vagina

* Fixed in Zenker's fluid (sacrificed animals only).
** Decalcified prior to sectioning.
\+ Examined histopathologically only if present in routine sections of eyes (optic nerves), thyroid lobes (parathyroids), or skin (mammary gland).
++ Lungs will be infused with neutral buffered 10% formalin (sacrificed animals only).
▪ Retained but not processed.

For all <u>sacrificed</u> animals, three femoral bone marrow smears will be prepared and stained with May-Grünwald-Giemsa but only evaluated if hematology or pathology findings dictate (additional cost).

Additional tissue samples may be taken at the discretion of the supervising pathologist to elucidate abnormal findings.

4. <u>Histopathology</u>

Tissues listed above from animals in Groups 1 and 4, all animals that die prematurely, and respiratory tissues (nasal cavities and sinuses, pharynx, pharynx, trachea and lungs) and gross lesions from animals in Groups 2 and 3 will be prepared for histopathological examination by embedding in paraffin wax, sectioning and staining with hematoxylin and eosin. These tissues will be examined microscopically.

STATISTICS

Numerical data obtained during the conduct of the study will be subjected to calculation of group mean values and standard deviation. The data will be analyzed for homogeneity of variance using Bartlett's test (FOB count data may be transformed before analysis).

Homogeneous data will be analyzed using Analysis of Variance and the significance of differences between the control and treated groups will be assessed using Dunnett's 't' test. Heterogeneous data will be analyzed using Kruskal-Wallis test and the significance of differences between the control and treated groups will be assessed using Dunn's test.

Motor activity counts will be analyzed using repeat measures analysis and graphical presentation of the data will be made.

Where appropriate, frequency data will be analyzed by comparing the control group to the tested groups using Fisher's exact probability test.

Further statistical evaluation can be undertaken after consultation with the Sponsor and may involve additional costs and a reporting time longer than that specified in the study contract.

ANIMAL CARE AND USE COMMITTEE APPROVAL

The protocol and any amendment(s) or procedures involving the care and use of animals in this study will be reviewed and approved by Bio-Research's Animal Care and Use Committee (ACUC) prior to conduct. During the study, the care and use of animals will be conducted in accordance with the regulations of the USDA Animal Welfare Act, (relevant sections of 9 CFR Parts 2 and 3) and the Canadian Council on Animal Care (CCAC).

QUALITY ASSURANCE

The Quality Assurance Department of Bio-Research Laboratories Ltd. will undertake and document inspections and audits of critical phases of the study performed at Bio-Research Laboratories Ltd. during its conduct and audit the study report. Data audits will be conducted according to MIL-STANDARD 105D, where appropriate.

Authorized designates of the Sponsor may inspect their study during regular working hours for quality assurance purposes.

COMMUNICATION

As necessary during the study, the study director will take appropriate action, in consultation with the clinical veterinarian and Sponsor (if

possible), to minimize discomfort and pain to animals, provided such action will not interfere with the objectives or outcome of the study.

Untoward changes or events occurring during the study will be communicated to the Sponsor by telephone or telefax. Agreed upon changes in study conduct or design will be documented in protocol amendments. Before such changes are implemented, their cost and effect upon study or report timing will be agreed upon with the Sponsor and will be confirmed in writing (telefax and/or letter) as soon as practical.

Copies of each protocol amendment will be sent to the Sponsor whose formal approval will be indicated by the return of 1 signed copy to Bio-Research Laboratories Ltd.

FINAL REPORT

A complete detailed audited draft report will be submitted to the Sponsor within the time frame specified in the contract. Subsequent to any modifications or corrections (agreed upon by the Sponsor and Bio-Research Laboratories Ltd.), 2 copies of a final version of the report will be issued.

ARCHIVES

All raw data, samples of test and control articles, specimens and documents generated at Bio-Research Laboratories Ltd. during this study, together with the original copy of the protocol (including amendments, if any) and the final report, will be retained in the scientific archives of Bio-Research Laboratories Ltd.

Such materials will remain archived at Bio-Research Laboratories Ltd. for a minimum of 5 years, after which the Sponsor will be contacted for transfer or disposal approval. Should the Sponsor request return of any or all of these specimens or materials, such shipment and the insurance thereof will be at the Sponsor's expense. Details of storage of such materials and/or their return to the Sponsor will be as per contract.

This protocol has been verified and approved by:

6 August 1993
Date

for: A. Viau, B.Sc.
Study Director
Senior Research Scientist,
Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

6 August 1993
Date

C. Banks, B.Sc.
Scientific Director, Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

August 6, 1993
Date

Keith Robinson

K. Robinson, B.Sc.
Scientific Director, Reproductive Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

6 August, 1993
Date

G.W. Lulham, M.Sc.
Director, Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

13 August 1993
Date

J. Rieth, Ph.D., D.A.B.T.
Rhône-Poulenc Inc.

APPENDIX NO. 18

PROTOCOL AMENDMENT NO. 1

PROJECT NO. 90831

PROTOCOL DATE August 6, 1993

PROJECT TITLE A 13-Week Inhalation Toxicity and Neurotoxicity Study by Nose-Only Exposure of a Dry Powder Aerosol of Ceric Oxide in the Albino Rat

SPONSOR
Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

TESTING FACILITY
Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

AMENDMENT DATE October 19, 1993

AMENDMENTS

1. Page 1 of 19 pages,

Amended to read:

Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

Reason for amendment:

Change of address at Sponsor request.

2. Page 2 of 19 pages, SPONSOR

Amended to read:

Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

Reason for amendment:

Change of address at Sponsor request.

3. Page 4 of 19 pages,

Amended to read:

PROPOSED TREATMENT STARTING DATE	September 13, 1993 *
PROPOSED TREATMENT COMPLETION DATE	December 19, 1993 *
TARGET DATE FOR COMPLETION OF AUDITED DRAFT REPORT	April, 1994

Reason for amendment:

Clarification.

4. Page 5 of 19 pages, TEST ARTICLE, first sentence

Amended to read:

The test article (CAS Number 1306-38-3) will be characterized by the Sponsor.

Reason for amendment:

Clarification.

5. Page 6 of 19 pages, ANIMAL MANAGEMENT, first paragraph

Amended to read:

On arrival, all animals will be subjected to a general physical examination by a qualified member of the veterinary staff to ensure "normal" health status.

Reason for amendment:

Typographical error.

6. Page 7 of 19 pages, ACCLIMATION AND RANDOMIZATION, fourth paragraph

Amended to read:

Animals will be randomized into the following groups:

Group/ Identification	Target Exposure Level (mg/L)	Animal No. Males	Animal No. Females
1 Air control	0	1001-1015	1501-1515
2 Low dose	0.005	2001-2015	2501-2515
3 Intermediate dose	0.05	3001-3015	3501-3515
4 High dose	0.5	4001-4015	4501-4515

Reason for amendment:

At Sponsor request and based on a TLV of 5 mg/m^3 for respirable nuisance dusts.

7. Page 7 of 19 pages, Reason for Dose Level Selection

Amended to read:

The dose levels will be selected according to the proposed human exposure (TLV of 5 mg/m^3 for respirable nuisance dusts), existing toxicity data and any limitations imposed by the exposure apparatus and procedure as well as the stability of the experimental atmosphere.

Reason for amendment:

Additional information for dose level selection.

8. Page 8 of 19 pages, Duration of Exposure, first paragraph, third sentence and second paragraph

Amended to read:

For each test group, time zero, the time at which animals will be placed on the chamber, will be defined as that point in time at which approximately 95% of the desired concentration of test article has been established within the chamber. Flow rate through the chamber will be calculated to yield a t_{95} (the time required to build up 95% of the target concentration) of no more than approximately 5 minutes. The t_{95} and t_{05} (the time to decay to 5% of the established concentration) will be calculated and reported.

During exposure, aerosol will be actively generated for 365 minutes (for the duration of the t_{95} plus 360 minutes). Following 365 minutes of continuous operation, aerosol generation will be stopped, and the chamber concentration allowed to decay for the calculated t_{05}. The rats will be removed from the exposure chamber when the generator is stopped and will be returned to their home cages.

Reason for amendment:

Actual procedures to be used during treatment.

9. Page 9 of 19 pages, Atmosphere Generation System, first sentence

Amended to read:

The test atmospheres will be established using a fluid energy air mill supplied with conditioned and filtered compressed air and fed by a linear track system.

Reason for amendment:

Clarification.

10. Page 9 of 19 pages, Chamber Concentrations, first paragraph, last sentence

Amended to read:

Filters from the second day of treatment of males and females, and monthly thereafter will be forwarded to the Sponsor for chemical analysis.

Reason for amendment:

At Sponsor request.

11. Page 10 of 19 pages, Particle Size Analysis, second sentence

Amended to read:

Sampling durations will be selected to collect approximately 10 mg of test article, if possible.

Reason for amendment:

Collection may be less than 10 mg due to the limitation imposed by the new target chamber concentrations.

12. Page 14 of 19 pages,

Add the following:

7. Ophthalmology

Funduscopic (indirect ophthalmoscopy) and biomicroscopic (slit lamp) examinations will be performed on all animals prior to commencement of treatment and during the last week of treament on animals in the high dose and control groups. If changes in the eye are detected, animals in the low and intermediate will also be examined (additional cost).

Reason for amendment:

Observations to be performed on the study.

13. Page 16 of 19 pages, Histopathology, first sentence

Amended to read:

Tissues listed above from animals in Groups 1 and 4, all animals that die prematurely, and respiratory tissues (nasal cavities and sinuses, pharynx, larynx, trachea and lungs) and gross lesions from animals in Groups 2 and 3 will be prepared for histopathological examination by embedding in paraffin wax, sectioning and staining with hematoxylin and eosin.

Reason for amendment:

Typographical error.

14. Page 18 of 19 pages, ARCHIVES, first paragraph

Amended to read:

All raw data, samples of test article (except test article and gravimetric samples sent to the Sponsor), specimens and documents generated at Bio-Research Laboratories Ltd. during this study, together with the original copy of the protocol (including amendments, if any) and the final report, will be retained in the scientific archives of Bio-Research Laboratories Ltd.

Reason for amendment:

Clarification.

This protocol amendment has been verified and approved by:

A. Viau, B.Sc.
Senior Research Scientist,
Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

October 19, 1993
Date

J. Rieth, Ph.D., D.A.B.T.
Rhône-Poulenc

19 October 1993
Date

APPENDIX NO. 18

PROTOCOL AMENDMENT NO. 2

PROJECT NO. 90831

PROTOCOL DATE August 6, 1993

PROJECT TITLE A 13-Week Inhalation Toxicity and Neurotoxicity Study by Nose-Only Exposure of a Dry Powder Aerosol of Ceric Oxide in the Albino Rat

SPONSOR Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

TESTING FACILITY Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

AMENDMENT DATE December 9, 1993

AMENDMENTS

1. Page 16 of 19 pages, 3. Tissue Preservation

   Add the following:

   Femur *

   Reason for amendment:

   At Sponsor request.

2. Point No. 13, protocol amendment no. 1

   Amended to read:

   Tissues listed above from animals in Groups 1 and 4, all animals that die prematurely, and respiratory tissues (nasal cavities and sinuses, pharynx, larynx, trachea, lungs and bronchi) and gross lesions from animals in Groups 2 and 3 will be prepared

for histopathological examination by embedding in paraffin wax, sectioning and staining with hematoxylin and eosin.

Reason for amendment:

Clarification.

This protocol amendment has been verified and approved by:

December 9, 1993
Date

A. Viau, B.Sc.
Senior Research Scientist,
Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

13 April 1994
Date

J. Rieth, Ph.D., D.A.B.T.
Rhône-Poulenc

APPENDIX NO. 18

PROTOCOL AMENDMENT NO. 3

PROJECT NO. 90831

PROTOCOL DATE August 6, 1993

PROJECT TITLE A 13-Week Inhalation Toxicity and Neurotoxicity Study by Nose-Only Exposure of a Dry Powder Aerosol of Ceric Oxide in the Albino Rat

SPONSOR Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

TESTING FACILITY Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

AMENDMENT DATE April 13, 1994

AMENDMENTS

1. Page 3 of 19 pages, PARTICIPATING SCIENTISTS

   Add the following:

   C.J. Perkin, B.Sc., D.A.B.T.
   Director, Scientific Operations
   Toxicology Division

   P. Blouin, D.V.M., Ph.D., Diplomate A.C.V.O.
   Ophthalmologist

   Reason for amendment:

   Omitted from the protocol.

2. Page 8 of 19 pages, 2. Description of Inhalation Exposure Equipment, first paragraph, first and second sentences

Amended to read:

Standard stainless-steel cylindrical "flow-through" nose-only inhalation chambers (chamber volume approximately 80.6 L) will be utilized in this experiment. The body of each chamber has 40 separate ports in two separate rows into which can be inserted the conical front section of a polycarbonate restraint cone.

Reason for amendment:

Actual chamber size used on the study.

3. Point No. 13, protocol amendment no. 1

Amended to read:

Tissues listed above from animals in Groups 1 and 4, all animals that die prematurely, and respiratory tissues (nasal cavities and sinuses, pharynx, larynx, trachea, lungs and bronchi) and gross lesions from animals in Groups 2 and 3 will be prepared for histopathological examination by embedding in paraffin wax, sectioning and staining with hematoxylin and eosin.

Reason for amendment:

Clarification.

This protocol amendment has been verified and approved by:

A. Viau, B.Sc.
Senior Research Scientist,
Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

April 13, 1994
Date

J. Rieth, Ph.D., D.A.B.T.
Rhône-Poulenc

13 April 1994
Date

PROTOCOL AMENDMENT NO. 4

PROJECT NO. 90831

PROTOCOL DATE August 6, 1993

PROJECT TITLE A 13-Week Inhalation Toxicity and Neurotoxicity Study by Nose-Only Exposure of a Dry Powder Aerosol of Ceric Oxide in the Albino Rat

SPONSOR
Rhône-Poulenc Canada Inc.
2000 Argentia Road
Plaza 3, Suite 400
Mississauga, Ontario
Canada L5N 1V9

TESTING FACILITY
Bio-Research Laboratories Ltd.
87 Senneville Road
Senneville, Quebec
Canada H9X 3R3

AMENDMENT DATE June 7, 1994

AMENDMENTS

1. Page 5 of 19 pages, TEST ARTICLE, third paragraph

Amended to read:

With the exception of an archive sample, all test article remaining following completion of studies with CeO_2 will be returned to the Sponsor.

Reason for amendment:

Clarification.

2. Page 17 of 19 pages, STATISTICS fourth paragraph

Amended to read:

Where appropriate, frequency data, gross pathology and histopathology findings will be analyzed by comparing the control group to the tested groups using Fisher's exact probability test.

Reason for amendment:

Additional statisitical analysis performed at the Sponsor's request.

This protocol amendment has been verified and approved by:

June 7, 1994
Date

A. Viau, B.Sc.
Senior Research Scientist,
Inhalation Toxicology
Toxicology Division
Bio-Research Laboratories Ltd.

10 June 1994
Date

J. Rieth, Ph.D., D.A.B.T.
Rhône-Poulenc

APPENDIX NO. 19

RHÔNE-POULENC

RHÔNE-POULENC BASIC CHEMICALS CO.
FINE INORGANIC CHEMICALS
6213 HIGHWAY 332 EAST
FREEPORT, TX 77541
TEL: (409) 233-7871
FAX: (409) 233-4682

MAY - 9 1994
J. P. RIETH

May 2, 1994

Dr. Joseph P. Rieth
Toxicology Dept.
Rhone-Poulenc
P.O. Box 12014, 2 Alexander Dr.
Research Triangle Park, NC 27709

Dear Joe:

We have completed analysis of sixty (60) filters from Bio-Research project no. 90831. The filters were extracted with nitric acid according to our basic procedure #LAB-0121 which was modified to fit this project. A copy of the modified procedure is attached. The extract solution from each filter was analyzed by Inductively Coupled Plasma - Atomic Emission Spectroscopy (ICP-AES) for Cerium Oxide content. The readings were mathematically adjusted to express the results as milligrams of Cerium Oxide per filter. The results are reported in attachment #2.

Bio-Research sent us ten test filters for validation of our procedures. Results from those filters indicated that we were able to extract and measure the Cerium Oxide. See Attachment #1 for details. You will notice a consistent difference between our results and the weights reported by Bio-Research amounting to an average of -4%. We are not certain what causes the difference but speculate that it reflects; (1) an incomplete extraction of Cerium Oxide from the filters or (2) when the filter samples were being taken, some other particulate matter was present in the air.

Instrument readings were recorded on log sheets which are stored in our laboratory files for a minimum of three years. In the event this is not compatible with your document retention requirements, copies of the log sheets are attached.

Since we did not know what statistical treatments you needed, we are reporting our findings simply as milligrams of Cerium Oxide per filter. Also, the data is stored on a floppy disk using Microsoft Word For Windows. If it will be easier for you to use the data from a disk, let us know and we will send a copy.

APPENDIX NO. 19

PROJECT NO. 90831

CEINHALDOC

The extract solutions will be stored in our lab until June 1, 1994. If you see a need to retain them longer, please let us know before that date.

We hope these results are adequate for your needs. If we can answer any questions or be of additional service, please feel free to let us know.

Sincerely,

John D. Edwards

John D. Edwards
Laboratory Supervisor

APPENDIX NO. 19

PROJECT NO. 90831

Attachment #1

VALIDATION SAMPLES

Sample No.	Wt Cerium Oxide*(mg)	Cerium Oxide by ICP-AES (mg)	Difference (mg)	Difference %
1	2.12	1.96	-0.16	7.5
2	1.78	1.72	-0.06	3.4
3	1.97	1.82	-0.15	7.6
4	1.77	1.76	-0.01	0.6
5	2.09	1.99	-0.10	4.8
6	1.95	1.89	-0.06	3.1
7	1.99	1.90	-0.09	4.5
8	2.05	2.03	-0.02	1.0
9	2.15	2.07	-0.08	3.7
10	2.19	2.10	-0.09	4.1
Average				4.0
Standard Deviation				2.3

* - As reported by Bio-Research

APPENDIX NO. 19

PROJECT NO. 90831

Attachment #2

ANALYSIS OF CERIUM OXIDE COLLECTED ON FILTERS DURING BIO-RESEARCH PROJECT NO. 90831

Label On Vial			Filter Analysis By ICP-AES
Day	Group	Sample Number	CeO_2 (mg)
2	1	1	0.01
		3	0.01
		5	0.01
	2	5	1.85
		7	0.98
		9	1.61
	3	1	2.98
		3	2.03
		5	1.83
	4	1	2.13
		3	1.78
		5	2.19
9	1	1	0.02
		3	0.01
		5	0.01
	2	3	1.70
		5	1.56
		7	1.34
	3	1	2.08
		3	1.90
		5	1.83
	4	5	1.98
		7	1.89
		9	2.21
31	1	1	0.02
		3	0.01
		5	0.03
	2	1	1.79
		3	1.79
		9	2.41
	3	1	1.62
		3	1.84
		5	2.91
	4	1	2.25
		5	1.77
		7	1.78

APPENDIX NO. 19

PROJECT NO. 90831

Label On Vial			Filter Analysis By ICP-AES
Day	Group	Sample Number	CeO_2 (mg)
51	1	1	0.01
		3	0.01
		5	0.01
	2	1	2.22
		3	1.70
		5	1.99
	3	3	1.97
		5	2.33
		7	1.56
	4	1	2.05
		3	1.87
		5	1.57
86	1	1	0.05
		3	0.01
		5	0.01
	2	3	1.84
		7	1.54
		8	1.98
	3	1	1.64
		3	1.89
		5	1.87
	4	1	2.11
		5	1.96
		8	1.95
Reagent Blank			<0.01

APPENDIX NO. 19

PROJECT NO. 90831

DOCUMENT: LAB-0.0

	RHONE-POULENC FREEPORT PLANT 6213 HIGHWAY 332 EAST FREEPORT, TX 77541 METHOD FOR DISSOLUTION OF CERIUM OXIDE FROM FILTER DISCS	

1. SCOPE

1.1 As part of Bio-Research Project No. 90831 (Bio-Research Laboratories, Ltd, Senneville, Quebec, Canada), filter discs impregnated with Cerium Oxide were sent to the Freeport Lab for confirmation of Cerium content.

1.2 Since cerium is constantly present in the Freeport laboratory, every effort was made to reduce the risk of contamination. This included the use of a remote hood with new and dedicated glassware.

2. PRINCIPLE

2.1 The CeO_2 from the filter discs are dissolved with nitric acid using a procedure based on Analytical Method #LAB-0121.

2.2 The nitric acid solution is then analyzed by ICP using the basic procedure described in Analytical Method #LAB-0501.

3. EQUIPMENT

3.1 See Analytical Methods #LAB-0121 and #LAB-0501.

4. REAGENTS

4.1 See Analytical Methods #LAB-0121 and #LAB-0501.

5. SAFETY

5.1 See Analytical Methods #LAB-0121 and #LAB-0501.

6. PROCEDURE

6.1 Place filter disc with sample into a 150 mL beaker. Carefully examine the glass container which stored the filter disc for residue. Rinse any residue into the beaker using DI water.

6.2 Add 20 to 30 mL DI water and place teflon coated stir bar into the beaker.

6.3 Place beaker on a magnetic stirrer and begin mixing.

6.4 While mixing add the following:

- ~5 mL concentrated HNO3
- 3 to 4 drops dilute HF solution (prepared by diluting 1 mL 50% HF to 10 mL using DI water).
- 3 to 4 drops dilute H_2O_2 solution (prepared by diluting 1 mL 50% H_2O_2 to 10 mL using DI water).
- 10 to 20 mL DI water.

6.5 Digest the mixture on a hot plate with continuous stirring using high heat for 45 to 60 minutes. Maintain the volume in the beaker to 20 to 30 mL by adding DI water.

6.6 Filter the mixture through Whatman #5 or #42 filter paper into a 100 mL volumetric flask. Rinse the beaker with DI water thoroughly to get complete transfer. Then rinse the residue on the filter paper several times with warm DI water.

6.7 Fill to the mark with DI water. Mix and analyze by ICP for CeO_2 content.

7. CALCULATIONS

7.1 Use the following formula:

$$\text{mg } CeO_2 \text{ on filter disc} = \frac{X}{10}$$

Where X = the direct CeO_2 reading from the ICP in mg/L.

8. STATISTICS

8.1 See validation statistics in a separate report.

9. COMMENTS

9.1 None

10. REFERENCES

10.1 Analytical Methods #LAB-0121 and #LAB-0501.

APPENDIX NO. 19

PROJECT NO. 90831

ABS Quality Evaluations, Inc.
Quality Assurance Certification

Issue Date: **16 DECEMBER 1992**
Expire Date: **15 DECEMBER 1995**

Certificate No.: 30081.3

ISO 9000

CERTIFICATE OF COMPLIANCE

This is to certify that the Quality Management System of:

RHONE-POULENC BASIC CHEMICALS CO.
6213 HIGHWAY 332 EAST
FREEPORT, TEXAS 77541

has been assessed by ABS Quality Evaluations, Inc. (ABS QE) and found to be in compliance with the following quality standards:

ISO 9002

The Quality Management System is applicable to:

MANUFACTURE OF SEPARATED RARE EARTH PRODUCTS, ISOCYANATE RESINS, AND AGRICULTURAL INTERMEDIATE CHEMICALS

on behalf of
ABS Quality Evaluations, Inc.

ACCREDITED BY THE DUTCH COUNCIL FOR CERTIFICATION

REGISTRAR ACCREDITATION BOARD

Validity is subject to the organization and procedures being audited twice annually and the Company reporting in the interim any major changes to quality standard elements to ABS Quality Evaluations, Inc. in writing.